Id,Name,Type,VectorableProperty
28811,ASATadjBMI,Phenotype,ASATadjBMI
29283,High-density lipoprotein cholesterol,Phenotype,High-density lipoprotein cholesterol
29770,type 2 diabetes mellitus,Phenotype,type 2 diabetes mellitus
30011,vatAsatRatio,Phenotype,vatAsatRatio
30581,HOMAIRadjBMI,Phenotype,HOMAIRadjBMI
30798,HOMAIR_hm3,Phenotype,HOMAIR_hm3
30953,VATadjBMI,Phenotype,VATadjBMI
31179,FastingGlucose_MAGIC,Phenotype,FastingGlucose_MAGIC
31589,HbA1c_MAGIC,Phenotype,HbA1c_MAGIC
31936,GFATadjBMI,Phenotype,GFATadjBMI
32551,Schizophrenia,Phenotype,Schizophrenia
32786,WHRadjBMI,Phenotype,WHRadjBMI
33361,Coronary Artery Disease,Phenotype,Coronary Artery Disease
34630,low-density lipoprotein cholesterol,Phenotype,low-density lipoprotein cholesterol
34905,BMI,Phenotype,BMI
35037,IFCadjBMI,Phenotype,IFCadjBMI
36695,FastingInsulin_MAGIC,Phenotype,FastingInsulin_MAGIC
37155,HbA1c_hm3,Phenotype,HbA1c_hm3
37369,type 1 diabetes mellitus,Phenotype,type 1 diabetes mellitus
38543,ISIadjBMI,Phenotype,ISIadjBMI
40312,Hip circumference adjusted for BMI,Phenotype,Hip circumference adjusted for BMI
40313,Waist circumference,Phenotype,Waist circumference
40314,Waist-hip ratio,Phenotype,Waist-hip ratio
40315,Body mass index,Phenotype,Body mass index
40316,Hip circumference,Phenotype,Hip circumference
40317,Response to Homoharringtonine (cytotoxicity),Phenotype,Response to Homoharringtonine (cytotoxicity)
40318,Thrombomodulin levels in ischemic stroke,Phenotype,Thrombomodulin levels in ischemic stroke
40319,Creatinine levels in ischemic stroke,Phenotype,Creatinine levels in ischemic stroke
40320,Prothrombin fragments F1+2 levels in ischemic stroke,Phenotype,Prothrombin fragments F1+2 levels in ischemic stroke
40321,Clozapine-induced cytotoxicity,Phenotype,Clozapine-induced cytotoxicity
40322,Waist circumference adjusted for body mass index,Phenotype,Waist circumference adjusted for body mass index
40323,Trans fatty acid levels,Phenotype,Trans fatty acid levels
40324,Response to inhaled glucocorticoid treatment in asthma (change in FEV1),Phenotype,Response to inhaled glucocorticoid treatment in asthma (change in FEV1)
40325,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide),Phenotype,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)
40326,Subcortical brain region volumes,Phenotype,Subcortical brain region volumes
40327,Bipolar disorder,Phenotype,Bipolar disorder
40328,Cutaneous psoriasis,Phenotype,Cutaneous psoriasis
40329,Psoriasis vulgaris,Phenotype,Psoriasis vulgaris
40330,Psoriatic arthritis,Phenotype,Psoriatic arthritis
40331,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Phenotype,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)
40332,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Phenotype,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)
40333,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Phenotype,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)
40334,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Phenotype,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)
40335,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Phenotype,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)
40336,Delta-5 desaturase activity,Phenotype,Delta-5 desaturase activity
40337,Waist-to-hip ratio adjusted for body mass index,Phenotype,Waist-to-hip ratio adjusted for body mass index
40338,Verbal declarative memory,Phenotype,Verbal declarative memory
40339,Peanut allergy,Phenotype,Peanut allergy
40340,Egg allergy,Phenotype,Egg allergy
40341,QT interval,Phenotype,QT interval
40342,Celiac disease,Phenotype,Celiac disease
40343,Beta-2 microglubulin plasma levels,Phenotype,Beta-2 microglubulin plasma levels
40344,Rheumatoid arthritis,Phenotype,Rheumatoid arthritis
40345,Asymmetrical dimethylarginine levels,Phenotype,Asymmetrical dimethylarginine levels
40346,Symmetrical dimethylarginine levels,Phenotype,Symmetrical dimethylarginine levels
40347,Serum dimethylarginine levels (asymmetric/symetric ratio),Phenotype,Serum dimethylarginine levels (asymmetric/symetric ratio)
40348,Lipid metabolism phenotypes,Phenotype,Lipid metabolism phenotypes
40349,Type 2 diabetes,Phenotype,Type 2 diabetes
40350,Complement C3 and C4 levels,Phenotype,Complement C3 and C4 levels
40351,Metabolite levels,Phenotype,Metabolite levels
40352,Systemic lupus erythematosus and Systemic sclerosis,Phenotype,Systemic lupus erythematosus and Systemic sclerosis
40353,Colorectal cancer,Phenotype,Colorectal cancer
40354,Alzheimer's disease (APOE e4 interaction),Phenotype,Alzheimer's disease (APOE e4 interaction)
40355,Alzheimer's disease in APOE e4+ carriers,Phenotype,Alzheimer's disease in APOE e4+ carriers
40356,Antibody level in response to infection,Phenotype,Antibody level in response to infection
40357,Maximal oxygen uptake response,Phenotype,Maximal oxygen uptake response
40358,HDL Cholesterol in HIV-infection,Phenotype,HDL Cholesterol in HIV-infection
40359,Magnesium levels,Phenotype,Magnesium levels
40360,Cutaneous lupus erythematosus,Phenotype,Cutaneous lupus erythematosus
40361,Vein graft stenosis in coronary artery bypass grafting,Phenotype,Vein graft stenosis in coronary artery bypass grafting
40362,Sasang constitutional medicine type (So-Eum),Phenotype,Sasang constitutional medicine type (So-Eum)
40363,Psoriasis,Phenotype,Psoriasis
40364,Diisocyanate-induced asthma,Phenotype,Diisocyanate-induced asthma
40365,Type 1 diabetes and autoimmune thyroid diseases,Phenotype,Type 1 diabetes and autoimmune thyroid diseases
40366,Leishmaniasis (visceral),Phenotype,Leishmaniasis (visceral)
40367,Breast cancer (estrogen-receptor negative-- progesterone-receptor negative-- and human epidermal growth factor-receptor negative),Phenotype,Breast cancer (estrogen-receptor negative-- progesterone-receptor negative-- and human epidermal growth factor-receptor negative)
40368,Brugada syndrome,Phenotype,Brugada syndrome
40369,Obesity (early onset extreme),Phenotype,Obesity (early onset extreme)
40370,Gray matter volume (schizophrenia interaction),Phenotype,Gray matter volume (schizophrenia interaction)
40371,Chronic hepatitis C infection,Phenotype,Chronic hepatitis C infection
40372,Ulcerative colitis,Phenotype,Ulcerative colitis
40373,Plasma plasminogen levels,Phenotype,Plasma plasminogen levels
40374,Mammographic density,Phenotype,Mammographic density
40375,Thiazide-induced adverse metabolic effects in hypertensive patients,Phenotype,Thiazide-induced adverse metabolic effects in hypertensive patients
40376,Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab),Phenotype,Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)
40377,Sickle cell anemia (haemolysis),Phenotype,Sickle cell anemia (haemolysis)
40378,Red blood cell traits,Phenotype,Red blood cell traits
40379,Stroke (ischemic),Phenotype,Stroke (ischemic)
40380,Febrile seizures (MMR vaccine-related),Phenotype,Febrile seizures (MMR vaccine-related)
40381,Rheumatoid arthritis (ACPA-negative),Phenotype,Rheumatoid arthritis (ACPA-negative)
40382,Multiple cancers (lung cancer-- gastric cancer-- and squamous cell carcinoma),Phenotype,Multiple cancers (lung cancer-- gastric cancer-- and squamous cell carcinoma)
40383,Very long-chain saturated fatty acid levels (fatty acid 20:0),Phenotype,Very long-chain saturated fatty acid levels (fatty acid 20:0)
40384,Heschl's gyrus morphology,Phenotype,Heschl's gyrus morphology
40385,Crohn's disease,Phenotype,Crohn's disease
40386,Age-related nuclear cataracts,Phenotype,Age-related nuclear cataracts
40387,Pulmonary function in asthmatics,Phenotype,Pulmonary function in asthmatics
40388,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine),Phenotype,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)
40389,Schizophrenia (inflammation and infection response interaction),Phenotype,Schizophrenia (inflammation and infection response interaction)
40390,Nonsyndromic cleft lip with or without cleft palate,Phenotype,Nonsyndromic cleft lip with or without cleft palate
40391,Number of pregnancies,Phenotype,Number of pregnancies
40392,Spontaneous preterm birth (preterm birth),Phenotype,Spontaneous preterm birth (preterm birth)
40393,Psychotic symptoms and prion disease,Phenotype,Psychotic symptoms and prion disease
40394,Behavioral disturbance or psychiatric symptoms in prion disease,Phenotype,Behavioral disturbance or psychiatric symptoms in prion disease
40395,Response to serotonin reuptake inhibitors in major depressive disorder,Phenotype,Response to serotonin reuptake inhibitors in major depressive disorder
40396,Prostate cancer,Phenotype,Prostate cancer
40397,Serum total protein levels,Phenotype,Serum total protein levels
40398,Dental caries,Phenotype,Dental caries
40399,Iron status biomarkers (ferritin levels),Phenotype,Iron status biomarkers (ferritin levels)
40400,Iron status biomarkers (transferrin saturation),Phenotype,Iron status biomarkers (transferrin saturation)
40401,Iron status biomarkers (iron levels),Phenotype,Iron status biomarkers (iron levels)
40402,Iron status biomarkers (transferrin levels),Phenotype,Iron status biomarkers (transferrin levels)
40403,Vogt-Koyanagi-Harada syndrome,Phenotype,Vogt-Koyanagi-Harada syndrome
40404,Nasopharyngeal carcinoma (SNP x SNP interaction),Phenotype,Nasopharyngeal carcinoma (SNP x SNP interaction)
40405,Gastritis,Phenotype,Gastritis
40406,Platelet count,Phenotype,Platelet count
40407,Melanoma,Phenotype,Melanoma
40408,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure),Phenotype,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)
40409,Response to abacavir-containing treatment in HIV-1 infection (virologic failure),Phenotype,Response to abacavir-containing treatment in HIV-1 infection (virologic failure)
40410,Sleep time,Phenotype,Sleep time
40411,Sleep quality,Phenotype,Sleep quality
40412,Sleep duration,Phenotype,Sleep duration
40413,Allergic sensitization,Phenotype,Allergic sensitization
40414,Pancreatic cancer,Phenotype,Pancreatic cancer
40415,Cardiac Troponin-T levels,Phenotype,Cardiac Troponin-T levels
40416,Multiple sclerosis,Phenotype,Multiple sclerosis
40417,Body mass index (change over time),Phenotype,Body mass index (change over time)
40418,Hodgkin's lymphoma,Phenotype,Hodgkin's lymphoma
40419,Follicular lymphoma,Phenotype,Follicular lymphoma
40420,Red wine liking,Phenotype,Red wine liking
40421,White wine liking,Phenotype,White wine liking
40422,Chronic hepatitis B infection,Phenotype,Chronic hepatitis B infection
40423,Number of children (6+ vs. 0 or 1),Phenotype,Number of children (6+ vs. 0 or 1)
40424,Number of children,Phenotype,Number of children
40425,Survival in microsatellite instability low/stable colorectal cancer,Phenotype,Survival in microsatellite instability low/stable colorectal cancer
40426,Survival in rectal cancer,Phenotype,Survival in rectal cancer
40427,Sitting height ratio,Phenotype,Sitting height ratio
40428,Information processing speed,Phenotype,Information processing speed
40429,Polychlorinated biphenyl levels,Phenotype,Polychlorinated biphenyl levels
40430,Myeloproliferative neoplasms,Phenotype,Myeloproliferative neoplasms
40431,Blood pressure,Phenotype,Blood pressure
40432,Food antigen IgG levels,Phenotype,Food antigen IgG levels
40433,Diffuse large B cell lymphoma,Phenotype,Diffuse large B cell lymphoma
40434,Plasma plasminogen activator levels,Phenotype,Plasma plasminogen activator levels
40435,Hepatitis,Phenotype,Hepatitis
40436,Bladder cancer (smoking interaction),Phenotype,Bladder cancer (smoking interaction)
40437,Telomere length,Phenotype,Telomere length
40438,Carotid intima media thickness,Phenotype,Carotid intima media thickness
40439,Cytomegalovirus antibody response,Phenotype,Cytomegalovirus antibody response
40440,Sarcoidosis,Phenotype,Sarcoidosis
40441,Menarche (age at onset),Phenotype,Menarche (age at onset)
40442,Lipoprotein (a) - cholesterol levels,Phenotype,Lipoprotein (a) - cholesterol levels
40443,Urate levels in lean individuals,Phenotype,Urate levels in lean individuals
40444,Urate levels in overweight individuals,Phenotype,Urate levels in overweight individuals
40445,ADAMTS13 activity,Phenotype,ADAMTS13 activity
40446,Recalcitrant atopic dermatitis,Phenotype,Recalcitrant atopic dermatitis
40447,Serum IgE levels,Phenotype,Serum IgE levels
40448,Chronic obstructive pulmonary disease-related biomarkers,Phenotype,Chronic obstructive pulmonary disease-related biomarkers
40449,Cataracts in type 2 diabetes,Phenotype,Cataracts in type 2 diabetes
40450,Coronary heart disease,Phenotype,Coronary heart disease
40451,Alcohol dependence,Phenotype,Alcohol dependence
40452,Facial pigmentation,Phenotype,Facial pigmentation
40453,Behavioural disinhibition (generation interaction),Phenotype,Behavioural disinhibition (generation interaction)
40454,Lipid traits,Phenotype,Lipid traits
40455,Acne (severe),Phenotype,Acne (severe)
40456,Anger,Phenotype,Anger
40457,Adiponectin levels,Phenotype,Adiponectin levels
40458,Chronic lymphocytic leukemia,Phenotype,Chronic lymphocytic leukemia
40459,Preschool internalizing problems,Phenotype,Preschool internalizing problems
40460,Glycated hemoglobin levels,Phenotype,Glycated hemoglobin levels
40461,Endometrial cancer,Phenotype,Endometrial cancer
40462,Antinuclear antibody levels,Phenotype,Antinuclear antibody levels
40463,Interferon alpha levels in systemic lupus erythematosus,Phenotype,Interferon alpha levels in systemic lupus erythematosus
40464,Thyroid peroxidase antibody positivity,Phenotype,Thyroid peroxidase antibody positivity
40465,Immune response to measles-mumps-rubella vaccine,Phenotype,Immune response to measles-mumps-rubella vaccine
40466,Systemic lupus erythematosus,Phenotype,Systemic lupus erythematosus
40467,General cognitive ability,Phenotype,General cognitive ability
40468,Enteric fever,Phenotype,Enteric fever
40469,Parkinson's disease,Phenotype,Parkinson's disease
40470,Breast cancer (menopausal hormone therapy interaction),Phenotype,Breast cancer (menopausal hormone therapy interaction)
40471,Political ideology,Phenotype,Political ideology
40472,Serum uric acid levels,Phenotype,Serum uric acid levels
40473,Birth weight,Phenotype,Birth weight
40474,HDL cholesterol,Phenotype,HDL cholesterol
40475,Bronchopulmonary dysplasia,Phenotype,Bronchopulmonary dysplasia
40476,Puberty onset (genital enlargement),Phenotype,Puberty onset (genital enlargement)
40477,Puberty onset (breast development),Phenotype,Puberty onset (breast development)
40478,Puberty onset,Phenotype,Puberty onset
40479,Response to statins (LDL cholesterol change),Phenotype,Response to statins (LDL cholesterol change)
40480,Tourette's syndrome or obsessive-compulsive disorder,Phenotype,Tourette's syndrome or obsessive-compulsive disorder
40481,Chemerin levels,Phenotype,Chemerin levels
40482,Hypospadias,Phenotype,Hypospadias
40483,Breastfeeding duration,Phenotype,Breastfeeding duration
40484,Hyperopia,Phenotype,Hyperopia
40485,Myopia,Phenotype,Myopia
40486,Iron status biomarkers,Phenotype,Iron status biomarkers
40487,Serum thyroid-stimulating hormone levels,Phenotype,Serum thyroid-stimulating hormone levels
40488,Bone mineral density,Phenotype,Bone mineral density
40489,Vitiligo,Phenotype,Vitiligo
40490,Vertical cup-disc ratio,Phenotype,Vertical cup-disc ratio
40491,Bipolar disorder (body mass index interaction),Phenotype,Bipolar disorder (body mass index interaction)
40492,Kidney function decline traits,Phenotype,Kidney function decline traits
40493,Airway responsiveness in chronic obstructive pulmonary disease,Phenotype,Airway responsiveness in chronic obstructive pulmonary disease
40494,Cognitive function,Phenotype,Cognitive function
40495,Cervical artery dissection,Phenotype,Cervical artery dissection
40496,Non-alcoholic fatty liver disease histology (other),Phenotype,Non-alcoholic fatty liver disease histology (other)
40497,Multiple myeloma,Phenotype,Multiple myeloma
40498,Alzheimer's disease,Phenotype,Alzheimer's disease
40499,Educational attainment,Phenotype,Educational attainment
40500,Acute anterior uveitis (with or without ankylosing spondylitis),Phenotype,Acute anterior uveitis (with or without ankylosing spondylitis)
40501,Acute anterior uveitis in ankylosing spondylitis,Phenotype,Acute anterior uveitis in ankylosing spondylitis
40502,Refractive astigmatism,Phenotype,Refractive astigmatism
40503,Social autistic-like traits,Phenotype,Social autistic-like traits
40504,Lung Cancer (DNA repair capacity),Phenotype,Lung Cancer (DNA repair capacity)
40505,Fibrinogen,Phenotype,Fibrinogen
40506,Systolic blood pressure (alcohol consumption interaction),Phenotype,Systolic blood pressure (alcohol consumption interaction)
40507,Autoimmune hepatitis type-1,Phenotype,Autoimmune hepatitis type-1
40508,Mitochondrial DNA levels,Phenotype,Mitochondrial DNA levels
40509,Breast cancer,Phenotype,Breast cancer
40510,Breast cancer (early onset),Phenotype,Breast cancer (early onset)
40511,Plasma homocysteine levels (post-methionine load test),Phenotype,Plasma homocysteine levels (post-methionine load test)
40512,Cholesterol,Phenotype,Cholesterol
40513,Central corneal thickness,Phenotype,Central corneal thickness
40514,Periodontal disease-related phenotype (Socransky),Phenotype,Periodontal disease-related phenotype (Socransky)
40515,Response to inhaled corticosteroid treatment in asthma (change in FEV1),Phenotype,Response to inhaled corticosteroid treatment in asthma (change in FEV1)
40516,Response to antipsychotic therapy (extrapyramidal side effects),Phenotype,Response to antipsychotic therapy (extrapyramidal side effects)
40517,Fetal hemoglobin levels in sickle cell anemia,Phenotype,Fetal hemoglobin levels in sickle cell anemia
40518,Methotrexate pharmacokinetics (acute lymphoblastic leukemia),Phenotype,Methotrexate pharmacokinetics (acute lymphoblastic leukemia)
40519,Glaucoma,Phenotype,Glaucoma
40520,Ossification of the posterior longitudinal ligament of the spine,Phenotype,Ossification of the posterior longitudinal ligament of the spine
40521,Schizophrenia or bipolar disorder,Phenotype,Schizophrenia or bipolar disorder
40522,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection,Phenotype,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection
40523,Diabetic retinopathy in type 2 diabetes,Phenotype,Diabetic retinopathy in type 2 diabetes
40524,Asthma and hay fever,Phenotype,Asthma and hay fever
40525,Cervical cancer,Phenotype,Cervical cancer
40526,Tuberculosis,Phenotype,Tuberculosis
40527,Laryngeal squamous cell carcinoma,Phenotype,Laryngeal squamous cell carcinoma
40528,Breast cancer (survival),Phenotype,Breast cancer (survival)
40529,Electroencephalogram traits,Phenotype,Electroencephalogram traits
40530,Obesity-related traits,Phenotype,Obesity-related traits
40531,Illicit drug use,Phenotype,Illicit drug use
40532,Non-substance related behavioral disinhibition,Phenotype,Non-substance related behavioral disinhibition
40533,Asthma (sex interaction),Phenotype,Asthma (sex interaction)
40534,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced),Phenotype,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)
40535,Lupus nephritis in systemic lupus erythematosus,Phenotype,Lupus nephritis in systemic lupus erythematosus
40536,Bone mineral density (paediatric-- upper limb),Phenotype,Bone mineral density (paediatric-- upper limb)
40537,Bone mineral density (paediatric-- skull),Phenotype,Bone mineral density (paediatric-- skull)
40538,Bone mineral density (paediatric-- total body less head),Phenotype,Bone mineral density (paediatric-- total body less head)
40539,Reading disability or specific language impairment (pleiotropy),Phenotype,Reading disability or specific language impairment (pleiotropy)
40540,Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy),Phenotype,Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy)
40541,Colorectal cancer (calcium intake interaction),Phenotype,Colorectal cancer (calcium intake interaction)
40542,Psychosis (atypical),Phenotype,Psychosis (atypical)
40543,Height adjusted BMI,Phenotype,Height adjusted BMI
40544,Response to cytadine analogues (cytosine arabinoside),Phenotype,Response to cytadine analogues (cytosine arabinoside)
40545,Barrett's esophagus,Phenotype,Barrett's esophagus
40546,Neuroblastoma,Phenotype,Neuroblastoma
40547,C-reactive protein,Phenotype,C-reactive protein
40548,AIDS progression,Phenotype,AIDS progression
40549,Smoking quantity,Phenotype,Smoking quantity
40550,Smoking initiation,Phenotype,Smoking initiation
40551,C-reactive protein levels,Phenotype,C-reactive protein levels
40552,Hypertension,Phenotype,Hypertension
40553,Birth length,Phenotype,Birth length
40554,Infant length,Phenotype,Infant length
40555,Systolic blood pressure,Phenotype,Systolic blood pressure
40556,Diastolic blood pressure,Phenotype,Diastolic blood pressure
40557,Alzheimer's disease (age of onset),Phenotype,Alzheimer's disease (age of onset)
40558,Age-related hearing impairment (SNP x SNP interaction),Phenotype,Age-related hearing impairment (SNP x SNP interaction)
40559,Age-related hearing impairment,Phenotype,Age-related hearing impairment
40560,IgE levels,Phenotype,IgE levels
40561,IgA nephropathy,Phenotype,IgA nephropathy
40562,Thyroid peroxidase antibody levels,Phenotype,Thyroid peroxidase antibody levels
40563,Response to taxane treatment (paclitaxel),Phenotype,Response to taxane treatment (paclitaxel)
40564,Response to antipsychotic treatment,Phenotype,Response to antipsychotic treatment
40565,Myopia (pathological),Phenotype,Myopia (pathological)
40566,Resting heart rate,Phenotype,Resting heart rate
40567,Asthma,Phenotype,Asthma
40568,Amyotrophic lateral sclerosis,Phenotype,Amyotrophic lateral sclerosis
40569,Narcolepsy (onset before 2009 H1N1 influenza pandemic),Phenotype,Narcolepsy (onset before 2009 H1N1 influenza pandemic)
40570,Narcolepsy (age of onset),Phenotype,Narcolepsy (age of onset)
40571,IgE levels in asthmatics (D.f. specific),Phenotype,IgE levels in asthmatics (D.f. specific)
40572,Hepatitis B vaccine response,Phenotype,Hepatitis B vaccine response
40573,Lung function (forced vital capacity),Phenotype,Lung function (forced vital capacity)
40574,Endometriosis,Phenotype,Endometriosis
40575,Mammographic density (dense area),Phenotype,Mammographic density (dense area)
40576,Mammographic density (non-dense area),Phenotype,Mammographic density (non-dense area)
40577,Overweight status,Phenotype,Overweight status
40578,Educational attainment (years of education),Phenotype,Educational attainment (years of education)
40579,Educational attainment (college completion),Phenotype,Educational attainment (college completion)
40580,Nonsyndromic cleft lip with cleft palate,Phenotype,Nonsyndromic cleft lip with cleft palate
40581,Post bronchodilator FEV1/FVC ratio,Phenotype,Post bronchodilator FEV1/FVC ratio
40582,Antithyroid drug-induced agranulocytosis,Phenotype,Antithyroid drug-induced agranulocytosis
40583,Hematocrit,Phenotype,Hematocrit
40584,Mean corpuscular hemoglobin concentration,Phenotype,Mean corpuscular hemoglobin concentration
40585,Presence of antiphospholipid antibodies,Phenotype,Presence of antiphospholipid antibodies
40586,Eosinophil counts,Phenotype,Eosinophil counts
40587,Loneliness (multivariate analysis),Phenotype,Loneliness (multivariate analysis)
40588,Loneliness,Phenotype,Loneliness
40589,Loneliness (linear analysis),Phenotype,Loneliness (linear analysis)
40590,Inflammatory bowel disease,Phenotype,Inflammatory bowel disease
40591,Drug-induced liver injury,Phenotype,Drug-induced liver injury
40592,Spherical equivalent (joint analysis main effects and education interaction),Phenotype,Spherical equivalent (joint analysis main effects and education interaction)
40593,Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder,Phenotype,Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder
40594,Aggressiveness in attention deficit hyperactivity disorder,Phenotype,Aggressiveness in attention deficit hyperactivity disorder
40595,Diastolic blood pressure response to hydrochlorothiazide in hypertension,Phenotype,Diastolic blood pressure response to hydrochlorothiazide in hypertension
40596,Systolic blood pressure response to hydrochlorothiazide in hypertension,Phenotype,Systolic blood pressure response to hydrochlorothiazide in hypertension
40597,Lung cancer,Phenotype,Lung cancer
40598,Smoking status (current vs former),Phenotype,Smoking status (current vs former)
40599,Bone mineral density (Ward's triangle area),Phenotype,Bone mineral density (Ward's triangle area)
40600,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia,Phenotype,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
40601,Eosinophil percentage of white cells,Phenotype,Eosinophil percentage of white cells
40602,Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50),Phenotype,Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50)
40603,Glaucoma (primary open-angle),Phenotype,Glaucoma (primary open-angle)
40604,Mean corpuscular volume,Phenotype,Mean corpuscular volume
40605,Midgestational circulating levels of PCBs (fetal genetic effect),Phenotype,Midgestational circulating levels of PCBs (fetal genetic effect)
40606,Midgestational circulating levels of PBDEs,Phenotype,Midgestational circulating levels of PBDEs
40607,Midgestational circulating levels of PBDEs (fetal genetic effect),Phenotype,Midgestational circulating levels of PBDEs (fetal genetic effect)
40608,Midgestational circulating levels of PCBs,Phenotype,Midgestational circulating levels of PCBs
40609,Cerebrospinal P-tau181p levels,Phenotype,Cerebrospinal P-tau181p levels
40610,C-reactive protein levels or HDL-cholesterol levels (pleiotropy),Phenotype,C-reactive protein levels or HDL-cholesterol levels (pleiotropy)
40611,C-reactive protein levels or LDL-cholesterol levels (pleiotropy),Phenotype,C-reactive protein levels or LDL-cholesterol levels (pleiotropy)
40612,C-reactive protein levels or total cholesterol levels (pleiotropy),Phenotype,C-reactive protein levels or total cholesterol levels (pleiotropy)
40613,Cerebrospinal fluid AB1-42 levels,Phenotype,Cerebrospinal fluid AB1-42 levels
40614,C-reactive protein levels or triglyceride levels (pleiotropy),Phenotype,C-reactive protein levels or triglyceride levels (pleiotropy)
40615,Red blood cell count,Phenotype,Red blood cell count
40616,Hemoglobin levels,Phenotype,Hemoglobin levels
40617,Ischemic stroke,Phenotype,Ischemic stroke
40618,Small vessel stroke,Phenotype,Small vessel stroke
40619,Caffeine metabolism (plasma 1--7-dimethylxanthine (paraxanthine) level),Phenotype,Caffeine metabolism (plasma 1--7-dimethylxanthine (paraxanthine) level)
40620,Neuroticism,Phenotype,Neuroticism
40621,Non-response to antidepressants and depression,Phenotype,Non-response to antidepressants and depression
40622,Response to citalopram or escitalopram in depression,Phenotype,Response to citalopram or escitalopram in depression
40623,Non-response to citalopram or escitalopram and depression,Phenotype,Non-response to citalopram or escitalopram and depression
40624,Gout,Phenotype,Gout
40625,Renal underexcretion gout,Phenotype,Renal underexcretion gout
40626,Core binding factor acute myeloid leukemia,Phenotype,Core binding factor acute myeloid leukemia
40627,Sleep traits (multi-trait analysis),Phenotype,Sleep traits (multi-trait analysis)
40628,Insomnia,Phenotype,Insomnia
40629,Monocyte count,Phenotype,Monocyte count
40630,Mathematical ability,Phenotype,Mathematical ability
40631,Cerebrospinal T-tau levels,Phenotype,Cerebrospinal T-tau levels
40632,Chronic inflammatory diseases (ankylosing spondylitis-- Crohn's disease-- psoriasis-- primary sclerosing cholangitis-- ulcerative colitis) (pleiotropy),Phenotype,Chronic inflammatory diseases (ankylosing spondylitis-- Crohn's disease-- psoriasis-- primary sclerosing cholangitis-- ulcerative colitis) (pleiotropy)
40633,Mean corpuscular hemoglobin,Phenotype,Mean corpuscular hemoglobin
40634,Optic cup area,Phenotype,Optic cup area
40635,Granulocyte percentage of myeloid white cells,Phenotype,Granulocyte percentage of myeloid white cells
40636,Pulse pressure,Phenotype,Pulse pressure
40637,Post bronchodilator FEV1,Phenotype,Post bronchodilator FEV1
40638,Cholesterol-- total,Phenotype,Cholesterol-- total
40639,Body fat percentage,Phenotype,Body fat percentage
40640,Height,Phenotype,Height
40641,Bortezomib-induced peripheral neuropathy in multiple myeloma,Phenotype,Bortezomib-induced peripheral neuropathy in multiple myeloma
40642,Monocyte percentage of white cells,Phenotype,Monocyte percentage of white cells
40643,Migraine,Phenotype,Migraine
40644,Hypothyroidism,Phenotype,Hypothyroidism
40645,Breast size,Phenotype,Breast size
40646,Monobrow,Phenotype,Monobrow
40647,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase,Phenotype,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase
40648,Antineutrophil cytoplasmic antibody-associated vasculitis,Phenotype,Antineutrophil cytoplasmic antibody-associated vasculitis
40649,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction),Phenotype,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)
40650,White blood cell count,Phenotype,White blood cell count
40651,Male-pattern baldness,Phenotype,Male-pattern baldness
40652,Plateletcrit,Phenotype,Plateletcrit
40653,Venous thromboembolism adjusted for sickle cell variant rs77121243-T,Phenotype,Venous thromboembolism adjusted for sickle cell variant rs77121243-T
40654,Carotid plaque burden,Phenotype,Carotid plaque burden
40655,Clopidogrel active metabolite levels,Phenotype,Clopidogrel active metabolite levels
40656,Tonsillectomy,Phenotype,Tonsillectomy
40657,Age at voice drop,Phenotype,Age at voice drop
40658,Optic disc area,Phenotype,Optic disc area
40659,Sepsis in extremely premature infants,Phenotype,Sepsis in extremely premature infants
40660,Allergy,Phenotype,Allergy
40661,Photic sneeze reflex,Phenotype,Photic sneeze reflex
40662,Childhood ear infection,Phenotype,Childhood ear infection
40663,Chin dimples,Phenotype,Chin dimples
40664,Prostate-specific antigen levels,Phenotype,Prostate-specific antigen levels
40665,Nose size,Phenotype,Nose size
40666,Joint mobility (Beighton score),Phenotype,Joint mobility (Beighton score)
40667,Prostate-specific antigen levels (conditioned on lead SNPs),Phenotype,Prostate-specific antigen levels (conditioned on lead SNPs)
40668,Response to paliperidone in schizophrenia (positive Marder score),Phenotype,Response to paliperidone in schizophrenia (positive Marder score)
40670,Response to paliperidone in schizophrenia (negative Marder score),Phenotype,Response to paliperidone in schizophrenia (negative Marder score)
40673,Parental longevity (mother's age at death),Phenotype,Parental longevity (mother's age at death)
40674,Parental longevity (combined parental age at death),Phenotype,Parental longevity (combined parental age at death)
40675,Cannabis dependence symptom count,Phenotype,Cannabis dependence symptom count
40676,Anti-thyroid drug induced agranulocytosis,Phenotype,Anti-thyroid drug induced agranulocytosis
40677,Non-chemotherapy drug induced agranulocytosis,Phenotype,Non-chemotherapy drug induced agranulocytosis
40678,Celiac disease and Rheumatoid arthritis,Phenotype,Celiac disease and Rheumatoid arthritis
40679,Liver fibrosis severity in HIV/hepatitis C co-infection,Phenotype,Liver fibrosis severity in HIV/hepatitis C co-infection
40680,Collagenous colitis,Phenotype,Collagenous colitis
40681,Migraine without aura,Phenotype,Migraine without aura
40682,Endometrial endometrioid carcinoma,Phenotype,Endometrial endometrioid carcinoma
40683,Response to antidepressants and depression,Phenotype,Response to antidepressants and depression
40684,Posterior cortical atrophy and Alzheimer's disease,Phenotype,Posterior cortical atrophy and Alzheimer's disease
40685,Cancer (pleiotropy),Phenotype,Cancer (pleiotropy)
40686,Cancer,Phenotype,Cancer
40687,HDL cholesterol levels,Phenotype,HDL cholesterol levels
40688,Platelet distribution width,Phenotype,Platelet distribution width
40689,Eosinophil percentage of granulocytes,Phenotype,Eosinophil percentage of granulocytes
40690,Atrial fibrillation,Phenotype,Atrial fibrillation
40691,White blood cell count (basophil),Phenotype,White blood cell count (basophil)
40692,Reticulocyte fraction of red cells,Phenotype,Reticulocyte fraction of red cells
40693,Sum basophil neutrophil counts,Phenotype,Sum basophil neutrophil counts
40694,Isovolumetric relaxation time,Phenotype,Isovolumetric relaxation time
40695,Aortic root size,Phenotype,Aortic root size
40696,Left atrial antero-posterior diameter,Phenotype,Left atrial antero-posterior diameter
40697,Left ventricle wall thickness,Phenotype,Left ventricle wall thickness
40698,Red cell distribution width,Phenotype,Red cell distribution width
40699,Left ventricular fractional shortening,Phenotype,Left ventricular fractional shortening
40700,Essential tremor,Phenotype,Essential tremor
40701,Liver injury in anti-tuberculosis drug treatment,Phenotype,Liver injury in anti-tuberculosis drug treatment
40702,Daytime sleep phenotypes,Phenotype,Daytime sleep phenotypes
40704,Night sleep phenotypes,Phenotype,Night sleep phenotypes
40705,High light scatter reticulocyte count,Phenotype,High light scatter reticulocyte count
40706,Response to paliperidone in schizophrenia (CGI-S score),Phenotype,Response to paliperidone in schizophrenia (CGI-S score)
40708,Gut microbiota (beta diversity),Phenotype,Gut microbiota (beta diversity)
40709,Sum neutrophil eosinophil counts,Phenotype,Sum neutrophil eosinophil counts
40710,Exhaled nitric oxide output,Phenotype,Exhaled nitric oxide output
40711,Exhaled nitric oxide levels,Phenotype,Exhaled nitric oxide levels
40712,Body mass index (change over time) in cancer or chronic obstructive pulmonary disease,Phenotype,Body mass index (change over time) in cancer or chronic obstructive pulmonary disease
40713,Body mass index (change over time) in lung cancer,Phenotype,Body mass index (change over time) in lung cancer
40714,Body mass index (change over time) in cancer,Phenotype,Body mass index (change over time) in cancer
40715,Granulocyte count,Phenotype,Granulocyte count
40716,Skin pigmentation,Phenotype,Skin pigmentation
40717,Age-related diseases-- mortality and associated endophenotypes,Phenotype,Age-related diseases-- mortality and associated endophenotypes
40718,Age-related diseases and mortality,Phenotype,Age-related diseases and mortality
40719,Incident atrial fibrillation,Phenotype,Incident atrial fibrillation
40720,Age-related disease endophenotypes,Phenotype,Age-related disease endophenotypes
40721,Hemoglobin concentration,Phenotype,Hemoglobin concentration
40722,Prevalent atrial fibrillation,Phenotype,Prevalent atrial fibrillation
40728,Response to paliperidone in schizophrenia (PANSS score),Phenotype,Response to paliperidone in schizophrenia (PANSS score)
40729,Immune response to measles vaccine (measles-induced IFN gamma),Phenotype,Immune response to measles vaccine (measles-induced IFN gamma)
40730,Gut microbiota (bacterial taxa),Phenotype,Gut microbiota (bacterial taxa)
40731,Gut microbiota (functional units),Phenotype,Gut microbiota (functional units)
40732,Systemic sclerosis,Phenotype,Systemic sclerosis
40733,RR interval (tricyclic/tetracyclic antidepressant use interaction),Phenotype,RR interval (tricyclic/tetracyclic antidepressant use interaction)
40734,High light scatter reticulocyte percentage of red cells,Phenotype,High light scatter reticulocyte percentage of red cells
40735,Total cholesterol levels,Phenotype,Total cholesterol levels
40736,LDL cholesterol levels,Phenotype,LDL cholesterol levels
40737,Triglyceride levels,Phenotype,Triglyceride levels
40738,Sum eosinophil basophil counts,Phenotype,Sum eosinophil basophil counts
40739,Otitis media,Phenotype,Otitis media
40740,Otitis media (recurrent),Phenotype,Otitis media (recurrent)
40741,Hepcidin/ferritin ratio,Phenotype,Hepcidin/ferritin ratio
40742,Lung function (FVC),Phenotype,Lung function (FVC)
40743,Myeloid white cell count,Phenotype,Myeloid white cell count
40744,Lung function (FEV1),Phenotype,Lung function (FEV1)
40745,Lung function (FEV1/FVC),Phenotype,Lung function (FEV1/FVC)
40746,Chronic obstructive pulmonary disease,Phenotype,Chronic obstructive pulmonary disease
40747,Lymphocyte count,Phenotype,Lymphocyte count
40748,Reticulocyte count,Phenotype,Reticulocyte count
40749,Pre-treatment pain in head and neck squamous cell carcinoma,Phenotype,Pre-treatment pain in head and neck squamous cell carcinoma
40750,Neutrophil percentage of granulocytes,Phenotype,Neutrophil percentage of granulocytes
40751,QRS duration,Phenotype,QRS duration
40752,QRS complex (Cornell),Phenotype,QRS complex (Cornell)
40753,QRS complex (Sokolow-Lyon),Phenotype,QRS complex (Sokolow-Lyon)
40754,Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes,Phenotype,Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes
40755,QRS complex (12-leadsum),Phenotype,QRS complex (12-leadsum)
40756,Response to platinum-based neoadjuvant chemotherapy in cervical cancer,Phenotype,Response to platinum-based neoadjuvant chemotherapy in cervical cancer
40757,Immature fraction of reticulocytes,Phenotype,Immature fraction of reticulocytes
40758,HIV progression (CD4 and viral load),Phenotype,HIV progression (CD4 and viral load)
40759,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive),Phenotype,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)
40760,Acute-on-chronic liver failure in hepatitis B,Phenotype,Acute-on-chronic liver failure in hepatitis B
40761,Neutrophil count,Phenotype,Neutrophil count
40762,LDL cholesterol,Phenotype,LDL cholesterol
40763,Response to fenofibrate (HDL cholesterol levels),Phenotype,Response to fenofibrate (HDL cholesterol levels)
40764,Parental extreme longevity (95 years and older),Phenotype,Parental extreme longevity (95 years and older)
40765,middle facial morphology traits (quantitative measurement),Phenotype,middle facial morphology traits (quantitative measurement)
40766,facial morphology traits (multivariate analysis),Phenotype,facial morphology traits (multivariate analysis)
40767,Pathological gambling,Phenotype,Pathological gambling
40768,Gestational age at birth (maternal effect),Phenotype,Gestational age at birth (maternal effect)
40769,Gestational age at birth in labor-initiated deliveries (child effect),Phenotype,Gestational age at birth in labor-initiated deliveries (child effect)
40770,Gestational age at birth in labor-initiated deliveries (maternal effect),Phenotype,Gestational age at birth in labor-initiated deliveries (maternal effect)
40771,EGFR mutation-positive lung adenocarcinoma,Phenotype,EGFR mutation-positive lung adenocarcinoma
40772,Alcohol consumption (heavy vs. light/non-drinkers),Phenotype,Alcohol consumption (heavy vs. light/non-drinkers)
40773,Extraversion,Phenotype,Extraversion
40774,Positive affect,Phenotype,Positive affect
40775,Depression,Phenotype,Depression
40776,Subjective well-being,Phenotype,Subjective well-being
40777,Life satisfaction,Phenotype,Life satisfaction
40778,Systemic juvenile idiopathic arthritis,Phenotype,Systemic juvenile idiopathic arthritis
40779,JT interval (sulfonylurea treatment interaction),Phenotype,JT interval (sulfonylurea treatment interaction)
40780,QRS interval (sulfonylurea treatment interaction),Phenotype,QRS interval (sulfonylurea treatment interaction)
40781,Bone mineral density (spine),Phenotype,Bone mineral density (spine)
40782,Age at first birth,Phenotype,Age at first birth
40783,Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder,Phenotype,Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder
40784,Bipolar disorder or attention deficit hyperactivity disorder,Phenotype,Bipolar disorder or attention deficit hyperactivity disorder
40785,Excessive daytime sleepiness,Phenotype,Excessive daytime sleepiness
40786,Childhood body mass index,Phenotype,Childhood body mass index
40787,Membranous nephropathy,Phenotype,Membranous nephropathy
40788,Triglycerides,Phenotype,Triglycerides
40789,Stroke,Phenotype,Stroke
40790,Gastroesophageal reflux disease,Phenotype,Gastroesophageal reflux disease
40791,Severity of facial solar lentigines,Phenotype,Severity of facial solar lentigines
40792,Subcutaneous adipose tissue,Phenotype,Subcutaneous adipose tissue
40793,Visceral adipose tissue adjusted for BMI,Phenotype,Visceral adipose tissue adjusted for BMI
40794,Visceral adipose tissue/subcutaneous adipose tissue ratio,Phenotype,Visceral adipose tissue/subcutaneous adipose tissue ratio
40795,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,Phenotype,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
40796,Coronary artery disease,Phenotype,Coronary artery disease
40797,Subcutaneous adipose tissue attenuation (Hounsfield unit scale),Phenotype,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
40798,Visceral adipose tissue attenuation (Hounslow unit scale),Phenotype,Visceral adipose tissue attenuation (Hounslow unit scale)
40799,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time),Phenotype,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
40800,Developmental language disorder,Phenotype,Developmental language disorder
40801,Developmental language disorder (linguistic errors),Phenotype,Developmental language disorder (linguistic errors)
40802,Breast cancer (estrogen-receptor negative),Phenotype,Breast cancer (estrogen-receptor negative)
40803,Protein C levels,Phenotype,Protein C levels
40804,B-cell malignancies (chronic lymphocytic leukemia-- Hodgkin lymphoma or multiple myeloma) (pleiotropy),Phenotype,B-cell malignancies (chronic lymphocytic leukemia-- Hodgkin lymphoma or multiple myeloma) (pleiotropy)
40805,Takotsubo syndrome,Phenotype,Takotsubo syndrome
40806,Plasma t-tau levels,Phenotype,Plasma t-tau levels
40807,Fibrinogen levels,Phenotype,Fibrinogen levels
40808,Methadone dose in opioid dependence,Phenotype,Methadone dose in opioid dependence
40809,Basophil percentage of white cells,Phenotype,Basophil percentage of white cells
40810,Lymphocyte percentage of white cells,Phenotype,Lymphocyte percentage of white cells
40811,Neutrophil percentage of white cells,Phenotype,Neutrophil percentage of white cells
40812,Pediatric bone mineral density (spine),Phenotype,Pediatric bone mineral density (spine)
40813,Pediatric bone mineral content (femoral neck),Phenotype,Pediatric bone mineral content (femoral neck)
40814,Pediatric bone mineral density (femoral neck),Phenotype,Pediatric bone mineral density (femoral neck)
40815,Pediatric bone mineral density (hip),Phenotype,Pediatric bone mineral density (hip)
40816,Pediatric bone mineral content (radius),Phenotype,Pediatric bone mineral content (radius)
40817,Pediatric bone mineral content (spine),Phenotype,Pediatric bone mineral content (spine)
40818,Basophil percentage of granulocytes,Phenotype,Basophil percentage of granulocytes
40819,Mean platelet volume,Phenotype,Mean platelet volume
40820,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),Phenotype,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
40821,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),Phenotype,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
40822,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),Phenotype,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
40823,Longevity,Phenotype,Longevity
40824,Parental longevity (father's age at death),Phenotype,Parental longevity (father's age at death)
40825,Microalbuminuria in type 1 diabetes,Phenotype,Microalbuminuria in type 1 diabetes
40826,Dental caries (decayed-- missing and filled teeth),Phenotype,Dental caries (decayed-- missing and filled teeth)
40827,Dental caries (decayed and filled deciduous tooth surfaces),Phenotype,Dental caries (decayed and filled deciduous tooth surfaces)
40828,Dental caries (decayed-- missing and filled tooth surfaces),Phenotype,Dental caries (decayed-- missing and filled tooth surfaces)
40829,Blood protein levels,Phenotype,Blood protein levels
40830,Resistant hypertension,Phenotype,Resistant hypertension
40831,Heel bone mineral density,Phenotype,Heel bone mineral density
40837,Epigenetic age acceleration in alcohol use disorder,Phenotype,Epigenetic age acceleration in alcohol use disorder
40838,Phenylephrine infusion rate during anesthesia,Phenotype,Phenylephrine infusion rate during anesthesia
40839,High density lipoprotein cholesterol levels,Phenotype,High density lipoprotein cholesterol levels
40840,Low density lipoprotein cholesterol levels,Phenotype,Low density lipoprotein cholesterol levels
40841,Plasma anti-thyroglobulin and anti-thyroid peroxidase levels (bivariate analysis),Phenotype,Plasma anti-thyroglobulin and anti-thyroid peroxidase levels (bivariate analysis)
40842,Plasma anti-thyroglobulin levels,Phenotype,Plasma anti-thyroglobulin levels
40843,Plasma anti-thyroid peroxidase levels,Phenotype,Plasma anti-thyroid peroxidase levels
40844,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),Phenotype,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
40845,Adolescent idiopathic scoliosis,Phenotype,Adolescent idiopathic scoliosis
40846,Waist-to-hip ratio adjusted for BMI,Phenotype,Waist-to-hip ratio adjusted for BMI
40847,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),Phenotype,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
40848,Stress sensitivity (neuroticism score x major depressive disorder status interaction),Phenotype,Stress sensitivity (neuroticism score x major depressive disorder status interaction)
40849,Peripheral artery disease,Phenotype,Peripheral artery disease
40850,Minimum ankle–brachial index,Phenotype,Minimum ankle–brachial index
40851,Age-related cognitive decline (memory) (slope of z-scores),Phenotype,Age-related cognitive decline (memory) (slope of z-scores)
40852,Age-related cognitive decline (visuospatial skill) (slope of z-scores),Phenotype,Age-related cognitive decline (visuospatial skill) (slope of z-scores)
40853,Age-related cognitive decline (attention/processing speed) (slope of z-scores),Phenotype,Age-related cognitive decline (attention/processing speed) (slope of z-scores)
40854,Age-related cognitive decline (language) (slope of z-scores),Phenotype,Age-related cognitive decline (language) (slope of z-scores)
40855,End-stage kidney disease,Phenotype,End-stage kidney disease
40856,Mild to moderate chronic kidney disease,Phenotype,Mild to moderate chronic kidney disease
40857,Predicted visceral adipose tissue,Phenotype,Predicted visceral adipose tissue
40858,Mosaic loss of chromosome Y (Y chromosome dosage),Phenotype,Mosaic loss of chromosome Y (Y chromosome dosage)
40859,Serum platinum levels after completion of cisplatin chemotherapy,Phenotype,Serum platinum levels after completion of cisplatin chemotherapy
40860,T wave morphology restitution during exercise (MTAG),Phenotype,T wave morphology restitution during exercise (MTAG)
40861,T wave morphology restitution during exercise,Phenotype,T wave morphology restitution during exercise
40862,Microalbuminuria,Phenotype,Microalbuminuria
40863,Urinary albumin-to-creatinine ratio,Phenotype,Urinary albumin-to-creatinine ratio
40864,Basal metabolic rate,Phenotype,Basal metabolic rate
40865,Post-traumatic stress disorder,Phenotype,Post-traumatic stress disorder
40866,Metabolic syndrome,Phenotype,Metabolic syndrome
40881,Skin aging measurement,Phenotype,Skin aging measurement
40882,Asthma (childhood onset),Phenotype,Asthma (childhood onset)
40883,Asthma and attention deficit hyperactivity disorder,Phenotype,Asthma and attention deficit hyperactivity disorder
40884,Asthma and major depressive disorder,Phenotype,Asthma and major depressive disorder
40885,Corneal resistance factor,Phenotype,Corneal resistance factor
40886,Corneal hysteresis,Phenotype,Corneal hysteresis
40887,Cytokine levels,Phenotype,Cytokine levels
40888,Cytokine network levels (multivariate analysis),Phenotype,Cytokine network levels (multivariate analysis)
40889,Rate of ventricular enlargement,Phenotype,Rate of ventricular enlargement
40890,Response to ketamine in bipolar disorder or major depression (antidepressant effects),Phenotype,Response to ketamine in bipolar disorder or major depression (antidepressant effects)
40891,Red vs. brown/black hair color,Phenotype,Red vs. brown/black hair color
40892,Blond vs. brown/black hair color,Phenotype,Blond vs. brown/black hair color
40893,Childhood steroid-sensitive nephrotic syndrome,Phenotype,Childhood steroid-sensitive nephrotic syndrome
40894,Longevity (age >90th survival percentile),Phenotype,Longevity (age >90th survival percentile)
40895,Gut microbiota relative abundance (bacterial taxa),Phenotype,Gut microbiota relative abundance (bacterial taxa)
40896,Parental longevity (father's age at death or father's attained age),Phenotype,Parental longevity (father's age at death or father's attained age)
40897,Asthma (time to onset),Phenotype,Asthma (time to onset)
40898,Cognitive performance (processing speed),Phenotype,Cognitive performance (processing speed)
40899,Parental longevity (mother's age at death or mother's attained age),Phenotype,Parental longevity (mother's age at death or mother's attained age)
40900,Working memory,Phenotype,Working memory
40901,Lung adenocarcinoma,Phenotype,Lung adenocarcinoma
40902,Non-small cell lung cancer,Phenotype,Non-small cell lung cancer
40903,High chromosomal aberration frequency (chromosome type),Phenotype,High chromosomal aberration frequency (chromosome type)
40904,Chromosomal aberration frequency (chromosome type),Phenotype,Chromosomal aberration frequency (chromosome type)
40905,High chromosomal aberration frequency (total),Phenotype,High chromosomal aberration frequency (total)
40906,High chromosomal aberration frequency (chromatid type),Phenotype,High chromosomal aberration frequency (chromatid type)
40932,Gestational age at birth (child effect),Phenotype,Gestational age at birth (child effect)
40934,Pulmonary arterial hypertension,Phenotype,Pulmonary arterial hypertension
40935,Right planum temporale grey matter volume,Phenotype,Right planum temporale grey matter volume
40936,Urinary sodium excretion,Phenotype,Urinary sodium excretion
40937,Urinary potassium excretion,Phenotype,Urinary potassium excretion
40938,Non-lobar intracerebral hemorrhage (MTAG),Phenotype,Non-lobar intracerebral hemorrhage (MTAG)
40939,Emotional recognition,Phenotype,Emotional recognition
40940,Face memory,Phenotype,Face memory
40941,Abstraction and mental flexibility,Phenotype,Abstraction and mental flexibility
40942,Spatial memory,Phenotype,Spatial memory
40943,Joint damage in rheumatoid arthritis,Phenotype,Joint damage in rheumatoid arthritis
40951,White coat effect (clinic systolic blood pressure minus ambulatory systolic blood pressure),Phenotype,White coat effect (clinic systolic blood pressure minus ambulatory systolic blood pressure)
40952,White coat effect (clinic diastolic blood pressure minus ambulatory diastolic blood pressure),Phenotype,White coat effect (clinic diastolic blood pressure minus ambulatory diastolic blood pressure)
40953,Maximum retinal arteriolar tortuosity,Phenotype,Maximum retinal arteriolar tortuosity
40954,Uveal melanoma,Phenotype,Uveal melanoma
40956,Uveal melanoma with any chromosomal aberration,Phenotype,Uveal melanoma with any chromosomal aberration
40957,Hydrolysed wheat protein allergy,Phenotype,Hydrolysed wheat protein allergy
40958,Recurrence of mild malaria attacks,Phenotype,Recurrence of mild malaria attacks
40959,Body fat percentage variance,Phenotype,Body fat percentage variance
40960,Body mass index variance,Phenotype,Body mass index variance
40961,Waist circumference variance,Phenotype,Waist circumference variance
40962,Basal metabolic rate variance,Phenotype,Basal metabolic rate variance
40963,Hip circumference variance,Phenotype,Hip circumference variance
40964,Heel bone mineral density variance,Phenotype,Heel bone mineral density variance
40965,Chronic lymphocytic leukemia or multiple sclerosis,Phenotype,Chronic lymphocytic leukemia or multiple sclerosis
40966,Marginal zone lymphoma or rheumatoid arthritis,Phenotype,Marginal zone lymphoma or rheumatoid arthritis
40967,Marginal zone lymphoma or systemic lupus erythematosus,Phenotype,Marginal zone lymphoma or systemic lupus erythematosus
40968,Prepulse inhibition of the startle response,Phenotype,Prepulse inhibition of the startle response
40969,Degraded stimulus continuous performance test score,Phenotype,Degraded stimulus continuous performance test score
40970,Spatial processing,Phenotype,Spatial processing
40971,California verbal learning test score,Phenotype,California verbal learning test score
40972,Antisaccade task score,Phenotype,Antisaccade task score
40973,Neuroblastoma or malignant cutaneous melanoma,Phenotype,Neuroblastoma or malignant cutaneous melanoma
40990,Suicide,Phenotype,Suicide
40991,Numerical cognitive ability,Phenotype,Numerical cognitive ability
40992,Figural/spatial cognitive ability,Phenotype,Figural/spatial cognitive ability
40993,Tendinopathy,Phenotype,Tendinopathy
40994,Ankle-brachial index,Phenotype,Ankle-brachial index
40995,Peripheral artery disease (borderline),Phenotype,Peripheral artery disease (borderline)
41004,Number of decayed-- missing and filled tooth surfaces or use of dentures,Phenotype,Number of decayed-- missing and filled tooth surfaces or use of dentures
41005,Dentures,Phenotype,Dentures
41006,Nicotine dependence symptom count,Phenotype,Nicotine dependence symptom count
41030,White matter microstructure (radial diusivities),Phenotype,White matter microstructure (radial diusivities)
41031,Spontaneous adipocyte lipolysis,Phenotype,Spontaneous adipocyte lipolysis
41032,Stimulated adipocyte lipolysis,Phenotype,Stimulated adipocyte lipolysis
41033,Cortical surface area,Phenotype,Cortical surface area
41034,White matter microstructure (mode of anisotropy),Phenotype,White matter microstructure (mode of anisotropy)
41035,Modic changes,Phenotype,Modic changes
41036,Frequency of relapse in mepolizumab-treated eosinophilic granulomatosis with polyangiitis,Phenotype,Frequency of relapse in mepolizumab-treated eosinophilic granulomatosis with polyangiitis
41037,Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis,Phenotype,Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis
41052,Pelvic organ prolapse,Phenotype,Pelvic organ prolapse
41053,Follicle stimulating hormone levels,Phenotype,Follicle stimulating hormone levels
41054,Follicle stimulating hormone in healthy women,Phenotype,Follicle stimulating hormone in healthy women
41055,Luteinizing hormone levels in healthy women,Phenotype,Luteinizing hormone levels in healthy women
41056,White matter microstructure (fractional anisotropy),Phenotype,White matter microstructure (fractional anisotropy)
41057,White matter microstructure (axial diusivities),Phenotype,White matter microstructure (axial diusivities)
41058,Behcet's disease,Phenotype,Behcet's disease
41062,Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia,Phenotype,Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
41063,DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia,Phenotype,DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia
41064,Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia,Phenotype,Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
41065,Breast cancer (estrogen-receptor positive),Phenotype,Breast cancer (estrogen-receptor positive)
41074,Lean mass index,Phenotype,Lean mass index
41076,Cortical thickness,Phenotype,Cortical thickness
41077,Ocular sarcoidosis,Phenotype,Ocular sarcoidosis
41078,Brown vs. black hair color,Phenotype,Brown vs. black hair color
41079,Factor VIII levels,Phenotype,Factor VIII levels
41080,vWF levels,Phenotype,vWF levels
41081,Automobile speeding propensity,Phenotype,Automobile speeding propensity
41082,Alcohol consumption (drinks per week),Phenotype,Alcohol consumption (drinks per week)
41083,Fat-free mass,Phenotype,Fat-free mass
41084,Smoking status (ever vs never smokers),Phenotype,Smoking status (ever vs never smokers)
41085,Risk-taking tendency (4-domain principal component model),Phenotype,Risk-taking tendency (4-domain principal component model)
41086,General risk tolerance (MTAG),Phenotype,General risk tolerance (MTAG)
41087,Brain region volumes,Phenotype,Brain region volumes
41088,Vertical cup-disc ratio (adjusted for vertical disc diameter),Phenotype,Vertical cup-disc ratio (adjusted for vertical disc diameter)
41089,Vertical cup-disc ratio (multi-trait analysis),Phenotype,Vertical cup-disc ratio (multi-trait analysis)
41090,Intraocular pressure,Phenotype,Intraocular pressure
41091,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),Phenotype,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
41092,Gut microbiota (alpha diversity),Phenotype,Gut microbiota (alpha diversity)
41093,Accommodative esotropia,Phenotype,Accommodative esotropia
41094,Amblyopia,Phenotype,Amblyopia
41104,Early cardiac repolarization,Phenotype,Early cardiac repolarization
41106,Moderate-to-late spontaneous preterm birth,Phenotype,Moderate-to-late spontaneous preterm birth
41107,Spontaneous preterm birth with premature rupture of membranes,Phenotype,Spontaneous preterm birth with premature rupture of membranes
41108,Spontaneous preterm birth without premature rupture of membranes,Phenotype,Spontaneous preterm birth without premature rupture of membranes
41109,Uterine fibroids,Phenotype,Uterine fibroids
41110,Subpleural-predominant interstitial lung abnormalities,Phenotype,Subpleural-predominant interstitial lung abnormalities
41111,Interstitial lung abnormalities,Phenotype,Interstitial lung abnormalities
41112,Adventurousness,Phenotype,Adventurousness
41113,Thoracic aortic calcification levels,Phenotype,Thoracic aortic calcification levels
41114,Cocaine use disorder x household tobacco use interaction,Phenotype,Cocaine use disorder x household tobacco use interaction
41116,Apolipoprotein B levels,Phenotype,Apolipoprotein B levels
41117,OTU97_108 (Phascolarctobacterium) abundance,Phenotype,OTU97_108 (Phascolarctobacterium) abundance
41119,OTU97_117 (Ruminococcus) abundance,Phenotype,OTU97_117 (Ruminococcus) abundance
41120,OTU97_101 (Sutterella) abundance,Phenotype,OTU97_101 (Sutterella) abundance
41122,OTU97_17 (Parabacteroides) abundance,Phenotype,OTU97_17 (Parabacteroides) abundance
41125,OTU97_150 (Bacteroides) abundance,Phenotype,OTU97_150 (Bacteroides) abundance
41127,OTU97_126 (Prevotella) abundance,Phenotype,OTU97_126 (Prevotella) abundance
41129,Age at adiposity rebound,Phenotype,Age at adiposity rebound
41130,C_Clostridia abundance,Phenotype,C_Clostridia abundance
41132,F_Lachnospiraceae abundance,Phenotype,F_Lachnospiraceae abundance
41134,Heart failure,Phenotype,Heart failure
41135,OTU97_23 (Faecalibacterium) abundance,Phenotype,OTU97_23 (Faecalibacterium) abundance
41137,G_Bacteroidetes abundance,Phenotype,G_Bacteroidetes abundance
41139,G_Barnesiella abundance,Phenotype,G_Barnesiella abundance
41141,OTU97_51 (Barnesiella) abundance,Phenotype,OTU97_51 (Barnesiella) abundance
41142,OTU97_354 (Alloprevotella) abundance,Phenotype,OTU97_354 (Alloprevotella) abundance
41144,OTU97_39 (Proteobacteria) abundance,Phenotype,OTU97_39 (Proteobacteria) abundance
41147,OTU99_34 (Holdemanella) abundance,Phenotype,OTU99_34 (Holdemanella) abundance
41150,OTU99_40 (Proteobacteria) abundance,Phenotype,OTU99_40 (Proteobacteria) abundance
41151,OTU99_45 (Faecalibacterium) abundance,Phenotype,OTU99_45 (Faecalibacterium) abundance
41153,OTU99_54 (Holdemanella) abundance,Phenotype,OTU99_54 (Holdemanella) abundance
41155,Type 2 diabetes (adjusted for BMI),Phenotype,Type 2 diabetes (adjusted for BMI)
41156,G_Parasutterella abundance,Phenotype,G_Parasutterella abundance
41158,Anxiety,Phenotype,Anxiety
41159,G_Ruminococcus abundance,Phenotype,G_Ruminococcus abundance
41161,O_Clostridiales abundance,Phenotype,O_Clostridiales abundance
41162,G_Prevotella abundance,Phenotype,G_Prevotella abundance
41164,G_Sutterella abundance,Phenotype,G_Sutterella abundance
41166,OTU99_2 (Bacteroides) prevalence,Phenotype,OTU99_2 (Bacteroides) prevalence
41168,OTU99_23 (Faecalibacterium) prevalence,Phenotype,OTU99_23 (Faecalibacterium) prevalence
41170,OTU99_40 (Proteobacteria) prevalence,Phenotype,OTU99_40 (Proteobacteria) prevalence
41172,OTU99_45 (Faecalibacterium) prevalence,Phenotype,OTU99_45 (Faecalibacterium) prevalence
41174,OTU99_39 (Alphaproteobacteria) prevalence,Phenotype,OTU99_39 (Alphaproteobacteria) prevalence
41176,OTU99_558 (Bacteroidales) prevalence,Phenotype,OTU99_558 (Bacteroidales) prevalence
41178,OTU99_47 (Prevotella) prevalence,Phenotype,OTU99_47 (Prevotella) prevalence
41180,TestASV_12 (Bacteroides) prevalence,Phenotype,TestASV_12 (Bacteroides) prevalence
41182,TestASV_14 (Lachnospiraceae) prevalence,Phenotype,TestASV_14 (Lachnospiraceae) prevalence
41184,OTU99_65 (Sutterellaceae) prevalence,Phenotype,OTU99_65 (Sutterellaceae) prevalence
41186,Gamma glutamyl transferase levels in excessive alcohol consumption,Phenotype,Gamma glutamyl transferase levels in excessive alcohol consumption
41187,Alanine aminotransferase levels in excessive alcohol consumption,Phenotype,Alanine aminotransferase levels in excessive alcohol consumption
41188,Erectile dysfunction,Phenotype,Erectile dysfunction
41189,Gamma glutamyl transferase levels in low alcohol consumption,Phenotype,Gamma glutamyl transferase levels in low alcohol consumption
41190,Hepatitis C (spontaneous viral clearance),Phenotype,Hepatitis C (spontaneous viral clearance)
41191,Number of sexual partners,Phenotype,Number of sexual partners
41192,TestASV_15 (Bacteroides) prevalence,Phenotype,TestASV_15 (Bacteroides) prevalence
41194,Crohn's disease (time to progression),Phenotype,Crohn's disease (time to progression)
41195,Crohn's disease (time to first abdominal surgery),Phenotype,Crohn's disease (time to first abdominal surgery)
41196,Intracranial volume,Phenotype,Intracranial volume
41197,Attention deficit hyperactivity disorder or intracranial volume (pleiotropy),Phenotype,Attention deficit hyperactivity disorder or intracranial volume (pleiotropy)
41205,Peak expiratory flow,Phenotype,Peak expiratory flow
41206,Hemoglobin,Phenotype,Hemoglobin
41212,FEV1,Phenotype,FEV1
41213,Serum urea levels,Phenotype,Serum urea levels
41214,Morningness,Phenotype,Morningness
41223,Crohn's disease or systemic sclerosis,Phenotype,Crohn's disease or systemic sclerosis
41228,Autism spectrum disorder,Phenotype,Autism spectrum disorder
41230,Autism and major depressive disorder (MTAG),Phenotype,Autism and major depressive disorder (MTAG)
41231,Autism and schizophrenia (MTAG),Phenotype,Autism and schizophrenia (MTAG)
41232,Autism and educational attainment (MTAG),Phenotype,Autism and educational attainment (MTAG)
41233,Thiopurine-induced myelosuppression in inflammatory bowel disease,Phenotype,Thiopurine-induced myelosuppression in inflammatory bowel disease
41250,Daytime nap,Phenotype,Daytime nap
41251,Ease of getting up in the morning,Phenotype,Ease of getting up in the morning
41255,Snoring,Phenotype,Snoring
41260,IgG N-glycosylation phenotypes (multivariate analysis),Phenotype,IgG N-glycosylation phenotypes (multivariate analysis)
41261,Intracranial aneurysm,Phenotype,Intracranial aneurysm
41262,Insomnia symptoms (never/rarely vs. sometimes/usually),Phenotype,Insomnia symptoms (never/rarely vs. sometimes/usually)
41263,Triiodothyronine levels,Phenotype,Triiodothyronine levels
41264,Creativity,Phenotype,Creativity
41265,Calcific aortic valve stenosis,Phenotype,Calcific aortic valve stenosis
41272,Tourette syndrome,Phenotype,Tourette syndrome
41301,Carotid intima media thickness x smoking interaction,Phenotype,Carotid intima media thickness x smoking interaction
41302,Bladder cancer,Phenotype,Bladder cancer
41303,Polycystic ovary syndrome,Phenotype,Polycystic ovary syndrome
41317,Alzheimer's disease (late onset),Phenotype,Alzheimer's disease (late onset)
41322,Insomnia symptoms (never/rarely vs. usually),Phenotype,Insomnia symptoms (never/rarely vs. usually)
41323,Weight gain in amisulpride-treated first-episode psychosis,Phenotype,Weight gain in amisulpride-treated first-episode psychosis
41324,Endometriosis or migraine,Phenotype,Endometriosis or migraine
41325,Adverse response to inhaled corticosteroid treatment x age interaction in asthma,Phenotype,Adverse response to inhaled corticosteroid treatment x age interaction in asthma
41326,Venous thromboembolism,Phenotype,Venous thromboembolism
41328,Trauma exposure in major depressive disorder-negative individuals,Phenotype,Trauma exposure in major depressive disorder-negative individuals
41329,Trauma exposure,Phenotype,Trauma exposure
41330,Trauma exposure in major depressive disorder,Phenotype,Trauma exposure in major depressive disorder
41331,Postoperative acute renal failure after cardiac surgery,Phenotype,Postoperative acute renal failure after cardiac surgery
41332,Spontaneous coronary artery dissection,Phenotype,Spontaneous coronary artery dissection
41346,Attention deficit hyperactivity disorder,Phenotype,Attention deficit hyperactivity disorder
41347,Attention deficit hyperactivity disorder (persistent),Phenotype,Attention deficit hyperactivity disorder (persistent)
41348,Attention deficit hyperactivity disorder (childhood),Phenotype,Attention deficit hyperactivity disorder (childhood)
41349,Lactate dehydrogenase levels,Phenotype,Lactate dehydrogenase levels
41355,Major depressive disorder in trauma exposed individuals,Phenotype,Major depressive disorder in trauma exposed individuals
41356,Major depressive disorder in trauma-unexposed individuals,Phenotype,Major depressive disorder in trauma-unexposed individuals
41357,Major depressive disorder,Phenotype,Major depressive disorder
41358,Drug-induced liver injury (flucloxacillin),Phenotype,Drug-induced liver injury (flucloxacillin)
41359,Recurrence of Clostridium difficile infection x bezlotuxumab treatment interaction (2df test),Phenotype,Recurrence of Clostridium difficile infection x bezlotuxumab treatment interaction (2df test)
41361,Chronic rhinosinusitis,Phenotype,Chronic rhinosinusitis
41362,Nasal polyps,Phenotype,Nasal polyps
41363,Obese vs. thin,Phenotype,Obese vs. thin
41364,Obesity (extreme),Phenotype,Obesity (extreme)
41398,Essential hypertension (time to event),Phenotype,Essential hypertension (time to event)
41399,Hyperlipidemia (time to event),Phenotype,Hyperlipidemia (time to event)
41400,Asthma (time to event),Phenotype,Asthma (time to event)
41401,Cataract (time to event),Phenotype,Cataract (time to event)
41417,Chronotype (sMEQ score),Phenotype,Chronotype (sMEQ score)
41418,Evening vs. morning chronotype (sMEQ score),Phenotype,Evening vs. morning chronotype (sMEQ score)
41419,Evening vs. morning chronotype (self-assessed),Phenotype,Evening vs. morning chronotype (self-assessed)
41426,Brain amyloid deposition (PET imaging),Phenotype,Brain amyloid deposition (PET imaging)
41427,Gut microbiota (bacterial taxa-- hurdle binary method),Phenotype,Gut microbiota (bacterial taxa-- hurdle binary method)
41428,Depressive symptoms x herpes simplex 1 infection interaction,Phenotype,Depressive symptoms x herpes simplex 1 infection interaction
41429,Depression x herpes simplex 1 infection interaction,Phenotype,Depression x herpes simplex 1 infection interaction
41430,Idiopathic membranous nephropathy,Phenotype,Idiopathic membranous nephropathy
41431,Immunoglobulin A,Phenotype,Immunoglobulin A
41432,Hepatocellular carcinoma,Phenotype,Hepatocellular carcinoma
41433,Caudate nucleus volume,Phenotype,Caudate nucleus volume
41434,Lipoprotein-associated phospholipase A2 activity change in response to statin therapy,Phenotype,Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
41435,Lipoprotein-associated phospholipase A2 activity and mass,Phenotype,Lipoprotein-associated phospholipase A2 activity and mass
41436,Response to hepatitis C treatment,Phenotype,Response to hepatitis C treatment
41437,Hepatitis C induced liver cirrhosis,Phenotype,Hepatitis C induced liver cirrhosis
41438,Menopause (age at onset),Phenotype,Menopause (age at onset)
41439,Waist circumference and related phenotypes,Phenotype,Waist circumference and related phenotypes
41440,Infantile hypertrophic pyloric stenosis,Phenotype,Infantile hypertrophic pyloric stenosis
41441,Menarche and menopause (age at onset),Phenotype,Menarche and menopause (age at onset)
41442,Bone mineral density (hip),Phenotype,Bone mineral density (hip)
41443,Response to citalopram treatment,Phenotype,Response to citalopram treatment
41444,Primary biliary cholangitis,Phenotype,Primary biliary cholangitis
41445,Warfarin maintenance dose,Phenotype,Warfarin maintenance dose
41446,Nasopharyngeal carcinoma,Phenotype,Nasopharyngeal carcinoma
41447,Type 1 diabetes,Phenotype,Type 1 diabetes
41448,Inflammatory bowel disease (early onset),Phenotype,Inflammatory bowel disease (early onset)
41449,Lumiracoxib-related liver injury,Phenotype,Lumiracoxib-related liver injury
41450,Bipolar disorder or major depressive disorder,Phenotype,Bipolar disorder or major depressive disorder
41451,Response to statin therapy,Phenotype,Response to statin therapy
41452,Pulmonary function,Phenotype,Pulmonary function
41453,Malaria,Phenotype,Malaria
41454,Heart rate,Phenotype,Heart rate
41455,HIV-1 control,Phenotype,HIV-1 control
41456,Monocyte early outgrowth colony forming units,Phenotype,Monocyte early outgrowth colony forming units
41457,Major depressive disorder (broad),Phenotype,Major depressive disorder (broad)
41458,Platelet aggregation,Phenotype,Platelet aggregation
41459,Renal cell carcinoma,Phenotype,Renal cell carcinoma
41460,Electrocardiographic traits,Phenotype,Electrocardiographic traits
41461,Calcium levels,Phenotype,Calcium levels
41462,Response to treatment for acute lymphoblastic leukemia,Phenotype,Response to treatment for acute lymphoblastic leukemia
41463,Smoking behavior,Phenotype,Smoking behavior
41464,Age-related macular degeneration,Phenotype,Age-related macular degeneration
41465,Dupuytren's disease,Phenotype,Dupuytren's disease
41466,Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN),Phenotype,Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)
41467,Bipolar disorder and schizophrenia,Phenotype,Bipolar disorder and schizophrenia
41468,Renal function-related traits (BUN),Phenotype,Renal function-related traits (BUN)
41469,Renal function-related traits (sCR),Phenotype,Renal function-related traits (sCR)
41470,Renal function-related traits (eGRFcrea),Phenotype,Renal function-related traits (eGRFcrea)
41471,Renal function-related traits (urea),Phenotype,Renal function-related traits (urea)
41472,Lentiform nucleus volume,Phenotype,Lentiform nucleus volume
41473,End-stage coagulation,Phenotype,End-stage coagulation
41474,Pit-and-Fissure caries,Phenotype,Pit-and-Fissure caries
41475,Circulating vasoactive peptide levels,Phenotype,Circulating vasoactive peptide levels
41476,Refractive error,Phenotype,Refractive error
41477,Blood trace element (Se levels),Phenotype,Blood trace element (Se levels)
41478,Blood trace element (Cu levels),Phenotype,Blood trace element (Cu levels)
41479,Acute lymphoblastic leukemia (childhood),Phenotype,Acute lymphoblastic leukemia (childhood)
41480,Obesity,Phenotype,Obesity
41481,Uric acid levels,Phenotype,Uric acid levels
41482,Hematological parameters,Phenotype,Hematological parameters
41483,Ovarian reserve,Phenotype,Ovarian reserve
41484,Apolipoprotein A1 levels,Phenotype,Apolipoprotein A1 levels
41485,Cognitive performance,Phenotype,Cognitive performance
41486,Ileal carcinoids,Phenotype,Ileal carcinoids
41487,Ankylosing spondylitis,Phenotype,Ankylosing spondylitis
41488,Protein quantitative trait loci,Phenotype,Protein quantitative trait loci
41489,IgE grass sensitization,Phenotype,IgE grass sensitization
41490,Allergic rhinitis,Phenotype,Allergic rhinitis
41491,Pubertal anthropometrics,Phenotype,Pubertal anthropometrics
41492,Attention deficit hyperactivity disorder and conduct disorder,Phenotype,Attention deficit hyperactivity disorder and conduct disorder
41493,Response to TNF antagonist treatment,Phenotype,Response to TNF antagonist treatment
41494,Response to anti-TNF alpha therapy in inflammatory bowel disease,Phenotype,Response to anti-TNF alpha therapy in inflammatory bowel disease
41495,Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction),Phenotype,Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction)
41496,Conduct disorder (maternal expressed emotions interaction),Phenotype,Conduct disorder (maternal expressed emotions interaction)
41497,Black vs. blond hair color,Phenotype,Black vs. blond hair color
41498,Black vs. red hair color,Phenotype,Black vs. red hair color
41499,Cardiovascular disease risk factors,Phenotype,Cardiovascular disease risk factors
41500,Interstitial lung disease,Phenotype,Interstitial lung disease
41501,Hematology traits,Phenotype,Hematology traits
41502,Relative hand skill in reading disability,Phenotype,Relative hand skill in reading disability
41503,Hematological and biochemical traits,Phenotype,Hematological and biochemical traits
41504,Response to dabigatran etexilate treatment,Phenotype,Response to dabigatran etexilate treatment
41505,Ulcerative colitis or Crohn's disease,Phenotype,Ulcerative colitis or Crohn's disease
41506,Immune response to anthrax vaccine,Phenotype,Immune response to anthrax vaccine
41507,Activated partial thromboplastin time,Phenotype,Activated partial thromboplastin time
41508,Electroencephalographic traits in alcoholism,Phenotype,Electroencephalographic traits in alcoholism
41509,Basal cell carcinoma,Phenotype,Basal cell carcinoma
41510,Depression (quantitative trait),Phenotype,Depression (quantitative trait)
41511,Response to antipsychotic treatment in schizophrenia (working memory),Phenotype,Response to antipsychotic treatment in schizophrenia (working memory)
41512,Response to antipsychotic treatment in schizophrenia (reasoning),Phenotype,Response to antipsychotic treatment in schizophrenia (reasoning)
41513,Renal sinus fat,Phenotype,Renal sinus fat
41514,Airflow obstruction,Phenotype,Airflow obstruction
41515,Femoral neck bone geometry,Phenotype,Femoral neck bone geometry
41516,Nodular sclerosis Hodgkin lymphoma,Phenotype,Nodular sclerosis Hodgkin lymphoma
41517,Clozapine-induced agranulocytosis,Phenotype,Clozapine-induced agranulocytosis
41518,Homocysteine levels,Phenotype,Homocysteine levels
41519,Axial length,Phenotype,Axial length
41520,Body mass index in non-asthmatics,Phenotype,Body mass index in non-asthmatics
41521,Metabolite levels (HVA),Phenotype,Metabolite levels (HVA)
41522,Metabolite levels (5-HIAA),Phenotype,Metabolite levels (5-HIAA)
41523,Metabolite levels (HVA-5-HIAA Factor score),Phenotype,Metabolite levels (HVA-5-HIAA Factor score)
41524,Metabolite levels (HVA/5-HIAA ratio),Phenotype,Metabolite levels (HVA/5-HIAA ratio)
41525,Metabolite levels (HVA/MHPG ratio),Phenotype,Metabolite levels (HVA/MHPG ratio)
41526,Metabolite levels (MHPG),Phenotype,Metabolite levels (MHPG)
41527,Metabolite levels (5-HIAA/ MHPG Ratio),Phenotype,Metabolite levels (5-HIAA/ MHPG Ratio)
41528,Response to fenofibrate (adiponectin levels),Phenotype,Response to fenofibrate (adiponectin levels)
41529,Obsessive-compulsive disorder,Phenotype,Obsessive-compulsive disorder
41530,Breast cancer (male),Phenotype,Breast cancer (male)
41531,Orofacial clefts,Phenotype,Orofacial clefts
41532,Disc degeneration (lumbar),Phenotype,Disc degeneration (lumbar)
41533,Partial epilepsies,Phenotype,Partial epilepsies
41534,Non-obstructive azoospermia,Phenotype,Non-obstructive azoospermia
41535,HPV seropositivity,Phenotype,HPV seropositivity
41536,Progressive supranuclear palsy,Phenotype,Progressive supranuclear palsy
41537,Aging,Phenotype,Aging
41538,Neonatal lupus,Phenotype,Neonatal lupus
41539,Autism,Phenotype,Autism
41540,Chronic kidney disease and serum creatinine levels,Phenotype,Chronic kidney disease and serum creatinine levels
41541,Testicular germ cell tumor,Phenotype,Testicular germ cell tumor
41542,PR interval,Phenotype,PR interval
41543,Breast Cancer in BRCA1 mutation carriers,Phenotype,Breast Cancer in BRCA1 mutation carriers
41544,Response to fenofibrate,Phenotype,Response to fenofibrate
41545,Sunburns,Phenotype,Sunburns
41546,Hair color,Phenotype,Hair color
41547,Non-melanoma skin cancer,Phenotype,Non-melanoma skin cancer
41548,Tanning,Phenotype,Tanning
41549,Periodontal microbiota,Phenotype,Periodontal microbiota
41550,Caffeine consumption,Phenotype,Caffeine consumption
41551,Circulating myeloperoxidase levels (serum),Phenotype,Circulating myeloperoxidase levels (serum)
41552,Dengue shock syndrome,Phenotype,Dengue shock syndrome
41553,Liver enzyme levels (alkaline phosphatase),Phenotype,Liver enzyme levels (alkaline phosphatase)
41554,Liver enzyme levels (gamma-glutamyl transferase),Phenotype,Liver enzyme levels (gamma-glutamyl transferase)
41555,White blood cell types,Phenotype,White blood cell types
41556,Brain connectivity,Phenotype,Brain connectivity
41557,Sex hormone-binding globulin levels,Phenotype,Sex hormone-binding globulin levels
41558,Hepatocellular carcinoma in hepatitis B infection,Phenotype,Hepatocellular carcinoma in hepatitis B infection
41559,Periodontitis,Phenotype,Periodontitis
41560,QT interval (drug interaction),Phenotype,QT interval (drug interaction)
41561,Attention deficit hyperactivity disorder (combined symptoms),Phenotype,Attention deficit hyperactivity disorder (combined symptoms)
41562,Attention deficit hyperactivity disorder (inattention symptoms),Phenotype,Attention deficit hyperactivity disorder (inattention symptoms)
41563,HbA2 levels,Phenotype,HbA2 levels
41564,Atopic dermatitis,Phenotype,Atopic dermatitis
41565,Venous thromboembolism (SNP x SNP interaction),Phenotype,Venous thromboembolism (SNP x SNP interaction)
41566,Response to amphetamines,Phenotype,Response to amphetamines
41567,Urate levels,Phenotype,Urate levels
41568,Adiposity,Phenotype,Adiposity
41569,Lung cancer (asbestos exposure interaction),Phenotype,Lung cancer (asbestos exposure interaction)
41570,Cannabis use (initiation),Phenotype,Cannabis use (initiation)
41571,Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs),Phenotype,Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
41572,Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide),Phenotype,Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)
41573,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs),Phenotype,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
41574,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel),Phenotype,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
41575,Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel),Phenotype,Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
41576,Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin),Phenotype,Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)
41577,Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin),Phenotype,Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
41578,Preeclampsia,Phenotype,Preeclampsia
41579,Type 2 diabetes (dietary heme iron intake interaction),Phenotype,Type 2 diabetes (dietary heme iron intake interaction)
41580,Palmitic acid (16:0) levels,Phenotype,Palmitic acid (16:0) levels
41581,Palmitoleic acid (16:1n-7) levels,Phenotype,Palmitoleic acid (16:1n-7) levels
41582,Oleic acid (18:1n-9) levels,Phenotype,Oleic acid (18:1n-9) levels
41583,Visceral fat,Phenotype,Visceral fat
41584,Age-related macular degeneration (choroidal neovascularisation),Phenotype,Age-related macular degeneration (choroidal neovascularisation)
41585,Age-related macular degeneration (geographic atrophy),Phenotype,Age-related macular degeneration (geographic atrophy)
41586,Esophageal cancer (squamous cell),Phenotype,Esophageal cancer (squamous cell)
41587,Lifetime average cigarettes per day in chronic obstructive pulmonary disease,Phenotype,Lifetime average cigarettes per day in chronic obstructive pulmonary disease
41588,Sexual dysfunction (female),Phenotype,Sexual dysfunction (female)
41589,Age at smoking initiation in chronic obstructive pulmonary disease,Phenotype,Age at smoking initiation in chronic obstructive pulmonary disease
41590,Capecitabine sensitivity,Phenotype,Capecitabine sensitivity
41591,Esophageal cancer,Phenotype,Esophageal cancer
41592,Aspirin exacerbated respiratory disease in asthmatics,Phenotype,Aspirin exacerbated respiratory disease in asthmatics
41593,Cystic fibrosis severity,Phenotype,Cystic fibrosis severity
41594,Hypertension (SNP x SNP interaction),Phenotype,Hypertension (SNP x SNP interaction)
41595,Scoliosis,Phenotype,Scoliosis
41596,Response to anti-depressant treatment in major depressive disorder,Phenotype,Response to anti-depressant treatment in major depressive disorder
41597,Adverse response to carbamazepine,Phenotype,Adverse response to carbamazepine
41598,Gambling,Phenotype,Gambling
41599,Molar-incisor hypomineralization,Phenotype,Molar-incisor hypomineralization
41600,Epstein-Barr virus immune response (EBNA-1),Phenotype,Epstein-Barr virus immune response (EBNA-1)
41601,Myasthenia gravis,Phenotype,Myasthenia gravis
41602,Anxiety in major depressive disorder,Phenotype,Anxiety in major depressive disorder
41603,Anxiety and major depressive disorder,Phenotype,Anxiety and major depressive disorder
41604,Multiple sclerosis (OCB status),Phenotype,Multiple sclerosis (OCB status)
41605,Femoral neck bone mineral density,Phenotype,Femoral neck bone mineral density
41606,Lumbar spine bone mineral density,Phenotype,Lumbar spine bone mineral density
41607,Alcohol and nicotine co-dependence,Phenotype,Alcohol and nicotine co-dependence
41608,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),Phenotype,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
41609,C-reactive protein and white blood cell count,Phenotype,C-reactive protein and white blood cell count
41610,Thyroid hormone levels,Phenotype,Thyroid hormone levels
41611,Retinopathy in non-diabetics,Phenotype,Retinopathy in non-diabetics
41612,Alzheimer's disease (cognitive decline),Phenotype,Alzheimer's disease (cognitive decline)
41613,Periodontitis (Mean PAL),Phenotype,Periodontitis (Mean PAL)
41614,Periodontitis (PAL4Q3),Phenotype,Periodontitis (PAL4Q3)
41615,Periodontitis (CDC/AAP),Phenotype,Periodontitis (CDC/AAP)
41616,Response to tocilizumab in rheumatoid arthritis,Phenotype,Response to tocilizumab in rheumatoid arthritis
41617,Thyroid function,Phenotype,Thyroid function
41618,Thyroid peroxidase autoantibody levels in type 1 diabetes,Phenotype,Thyroid peroxidase autoantibody levels in type 1 diabetes
41619,Bilirubin levels,Phenotype,Bilirubin levels
41620,Autism spectrum disorder-- attention deficit-hyperactivity disorder-- bipolar disorder-- major depressive disorder-- and schizophrenia (combined),Phenotype,Autism spectrum disorder-- attention deficit-hyperactivity disorder-- bipolar disorder-- major depressive disorder-- and schizophrenia (combined)
41621,Electrocardiographic conduction measures,Phenotype,Electrocardiographic conduction measures
41622,Economic and political preferences,Phenotype,Economic and political preferences
41623,Economic and political preferences (environmentalism),Phenotype,Economic and political preferences (environmentalism)
41624,Crohn's disease and celiac disease,Phenotype,Crohn's disease and celiac disease
41625,Response to angiotensin II receptor blocker therapy,Phenotype,Response to angiotensin II receptor blocker therapy
41626,Economic and political preferences (immigration/crime),Phenotype,Economic and political preferences (immigration/crime)
41627,Nephropathy,Phenotype,Nephropathy
41628,White matter integrity,Phenotype,White matter integrity
41629,Hepatitis B (viral clearance),Phenotype,Hepatitis B (viral clearance)
41630,Dietary macronutrient intake,Phenotype,Dietary macronutrient intake
41631,Haptoglobin levels,Phenotype,Haptoglobin levels
41632,Restless legs syndrome,Phenotype,Restless legs syndrome
41633,Drug-induced liver injury (amoxicillin-clavulanate),Phenotype,Drug-induced liver injury (amoxicillin-clavulanate)
41634,Dialysis-related mortality,Phenotype,Dialysis-related mortality
41635,Antipsychotic drug-induced QTc interval prolongation,Phenotype,Antipsychotic drug-induced QTc interval prolongation
41636,Metabolic traits,Phenotype,Metabolic traits
41637,Immune reponse to smallpox (secreted IL-2),Phenotype,Immune reponse to smallpox (secreted IL-2)
41638,Immune reponse to smallpox (secreted IL-10),Phenotype,Immune reponse to smallpox (secreted IL-10)
41639,Immune reponse to smallpox (secreted IL-12p40),Phenotype,Immune reponse to smallpox (secreted IL-12p40)
41640,Immune response to smallpox vaccine (IL-6),Phenotype,Immune response to smallpox vaccine (IL-6)
41641,Immune reponse to smallpox (secreted IFN-alpha),Phenotype,Immune reponse to smallpox (secreted IFN-alpha)
41642,Response to mTOR inhibitor (everolimus),Phenotype,Response to mTOR inhibitor (everolimus)
41643,Response to mTOR inhibitor (rapamycin),Phenotype,Response to mTOR inhibitor (rapamycin)
41644,Primary tooth development (number of teeth),Phenotype,Primary tooth development (number of teeth)
41645,Primary tooth development (time to first tooth eruption),Phenotype,Primary tooth development (time to first tooth eruption)
41646,Coronary artery calcification,Phenotype,Coronary artery calcification
41647,Response to gemcitabine in pancreatic cancer,Phenotype,Response to gemcitabine in pancreatic cancer
41648,Crohn's disease and psoriasis,Phenotype,Crohn's disease and psoriasis
41649,Treatment response for severe sepsis,Phenotype,Treatment response for severe sepsis
41650,Osteoarthritis,Phenotype,Osteoarthritis
41651,Phospholipid levels (plasma),Phenotype,Phospholipid levels (plasma)
41652,Sphingolipid levels,Phenotype,Sphingolipid levels
41653,Response to TNF-alpha inhibitors in rheumatoid arthritis,Phenotype,Response to TNF-alpha inhibitors in rheumatoid arthritis
41654,Lp (a) levels,Phenotype,Lp (a) levels
41655,Paget's disease,Phenotype,Paget's disease
41656,Weight loss (gastric bypass surgery),Phenotype,Weight loss (gastric bypass surgery)
41657,Sexual dimorphism in anthropometric traits,Phenotype,Sexual dimorphism in anthropometric traits
41658,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU),Phenotype,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
41659,Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel),Phenotype,Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)
41660,Kawasaki disease,Phenotype,Kawasaki disease
41661,vWF and FVIII levels,Phenotype,vWF and FVIII levels
41662,Alopecia areata,Phenotype,Alopecia areata
41663,Hepatitis B,Phenotype,Hepatitis B
41664,Nevirapine-induced rash,Phenotype,Nevirapine-induced rash
41665,HIV-1 viral setpoint,Phenotype,HIV-1 viral setpoint
41666,Graves' disease,Phenotype,Graves' disease
41667,Multiple myeloma (IgH translocation),Phenotype,Multiple myeloma (IgH translocation)
41668,HIV-1 susceptibility,Phenotype,HIV-1 susceptibility
41669,Bulimia nervosa,Phenotype,Bulimia nervosa
41670,Anorexia nervosa,Phenotype,Anorexia nervosa
41671,Eating disorders,Phenotype,Eating disorders
41672,Metabolite levels (Pyroglutamine),Phenotype,Metabolite levels (Pyroglutamine)
41673,Metabolite levels  (X-11787),Phenotype,Metabolite levels  (X-11787)
41674,Metabolite levels (Dihydroxy docosatrienoic acid),Phenotype,Metabolite levels (Dihydroxy docosatrienoic acid)
41675,Tetralogy of Fallot,Phenotype,Tetralogy of Fallot
41676,D-dimer levels,Phenotype,D-dimer levels
41677,Erectile dysfunction in type 1 diabetes,Phenotype,Erectile dysfunction in type 1 diabetes
41678,Corneal astigmatism,Phenotype,Corneal astigmatism
41679,Homeostasis model assessment of beta-cell function (dietary factor interaction),Phenotype,Homeostasis model assessment of beta-cell function (dietary factor interaction)
41680,Fasting insulin (dietary factor interaction),Phenotype,Fasting insulin (dietary factor interaction)
41681,Homeostasis model assessment of insulin resistance (dietary factor interaction),Phenotype,Homeostasis model assessment of insulin resistance (dietary factor interaction)
41682,Liver enzyme levels (alanine transaminase),Phenotype,Liver enzyme levels (alanine transaminase)
41683,Insulin resistance/response,Phenotype,Insulin resistance/response
41684,Orthostatic hypotension,Phenotype,Orthostatic hypotension
41685,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Phenotype,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)
41686,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Phenotype,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)
41687,Fasting blood insulin (BMI interaction),Phenotype,Fasting blood insulin (BMI interaction)
41688,Fasting blood glucose (BMI interaction),Phenotype,Fasting blood glucose (BMI interaction)
41689,Fasting blood insulin,Phenotype,Fasting blood insulin
41690,Fasting blood glucose,Phenotype,Fasting blood glucose
41691,Retinal vascular caliber,Phenotype,Retinal vascular caliber
41692,IgG glycosylation,Phenotype,IgG glycosylation
41693,Hemostatic factors and hematological phenotypes,Phenotype,Hemostatic factors and hematological phenotypes
41694,Arthritis (juvenile idiopathic),Phenotype,Arthritis (juvenile idiopathic)
41695,Brain structure (hippocampal volume),Phenotype,Brain structure (hippocampal volume)
41696,Corneal structure,Phenotype,Corneal structure
41697,Crohn's disease (time to surgery),Phenotype,Crohn's disease (time to surgery)
41698,F-cell distribution,Phenotype,F-cell distribution
41699,Select biomarker traits,Phenotype,Select biomarker traits
41700,Skin sensitivity to sun,Phenotype,Skin sensitivity to sun
41701,Red vs non-red hair color,Phenotype,Red vs non-red hair color
41702,Freckles,Phenotype,Freckles
41703,Blond vs. brown hair color,Phenotype,Blond vs. brown hair color
41704,Diabetes (gestational),Phenotype,Diabetes (gestational)
41705,Metabolic syndrome (bivariate traits),Phenotype,Metabolic syndrome (bivariate traits)
41706,HDL Cholesterol - Triglycerides (HDLC-TG),Phenotype,HDL Cholesterol - Triglycerides (HDLC-TG)
41707,Other erythrocyte phenotypes,Phenotype,Other erythrocyte phenotypes
41708,Prostate cancer (SNP x SNP interaction),Phenotype,Prostate cancer (SNP x SNP interaction)
41709,Anthropometric traits,Phenotype,Anthropometric traits
41710,Non-alcoholic fatty liver disease histology (AST),Phenotype,Non-alcoholic fatty liver disease histology (AST)
41711,RR interval (heart rate),Phenotype,RR interval (heart rate)
41712,Alcoholism (alcohol use disorder factor score),Phenotype,Alcoholism (alcohol use disorder factor score)
41713,Alcoholism (alcohol dependence factor score),Phenotype,Alcoholism (alcohol dependence factor score)
41714,Alzheimer's disease biomarkers,Phenotype,Alzheimer's disease biomarkers
41715,F-cell distribution in sickle cell anaemia,Phenotype,F-cell distribution in sickle cell anaemia
41716,Freckling,Phenotype,Freckling
41717,Common traits (Other),Phenotype,Common traits (Other)
41718,Eye color,Phenotype,Eye color
41719,Biomedical quantitative traits,Phenotype,Biomedical quantitative traits
41720,Liver enzyme levels,Phenotype,Liver enzyme levels
41721,Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction),Phenotype,Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction)
41722,Quantitative traits,Phenotype,Quantitative traits
41723,Type 2 diabetes nephropathy,Phenotype,Type 2 diabetes nephropathy
41724,Optic disc parameters,Phenotype,Optic disc parameters
41725,Inattentive symptoms,Phenotype,Inattentive symptoms
41726,Hyperactive-impulsive symptoms,Phenotype,Hyperactive-impulsive symptoms
41727,Age-related macular degeneration (smoking status interaction),Phenotype,Age-related macular degeneration (smoking status interaction)
41728,Age-related macular degeneration (extreme sampling),Phenotype,Age-related macular degeneration (extreme sampling)
41729,Brain structure,Phenotype,Brain structure
41730,Attention deficit hyperactivity disorder (time to onset),Phenotype,Attention deficit hyperactivity disorder (time to onset)
41731,Beta thalassemia/hemoglobin E disease,Phenotype,Beta thalassemia/hemoglobin E disease
41732,Response to interferon beta therapy,Phenotype,Response to interferon beta therapy
41733,Panic disorder,Phenotype,Panic disorder
41734,Folate pathway vitamin levels,Phenotype,Folate pathway vitamin levels
41736,Cognitive test performance,Phenotype,Cognitive test performance
41737,Echocardiographic traits,Phenotype,Echocardiographic traits
41738,Optic nerve measurement (rim area),Phenotype,Optic nerve measurement (rim area)
41739,Smooth-surface caries,Phenotype,Smooth-surface caries
41740,Carotenoid and tocopherol levels,Phenotype,Carotenoid and tocopherol levels
41741,Insulin-like growth factors,Phenotype,Insulin-like growth factors
41742,Thyroid stimulating hormone levels,Phenotype,Thyroid stimulating hormone levels
41743,Major CVD,Phenotype,Major CVD
41744,Leprosy,Phenotype,Leprosy
41745,Hip geometry,Phenotype,Hip geometry
41746,Tonometry,Phenotype,Tonometry
41747,Lymphoma,Phenotype,Lymphoma
41748,Myocardial infarction (early onset),Phenotype,Myocardial infarction (early onset)
41749,Brain lesion load,Phenotype,Brain lesion load
41750,Multiple sclerosis (severity),Phenotype,Multiple sclerosis (severity)
41751,Normalized brain volume,Phenotype,Normalized brain volume
41752,Weight,Phenotype,Weight
41753,Morbidity-free survival,Phenotype,Morbidity-free survival
41754,Hearing impairment,Phenotype,Hearing impairment
41755,Cardiovascular risk factors,Phenotype,Cardiovascular risk factors
41756,Cardiac structure and function,Phenotype,Cardiac structure and function
41757,Osteosarcoma,Phenotype,Osteosarcoma
41758,Pulmonary function (smoking interaction),Phenotype,Pulmonary function (smoking interaction)
41759,Diabetic retinopathy,Phenotype,Diabetic retinopathy
41760,Biochemical measures,Phenotype,Biochemical measures
41761,Sudden cardiac arrest,Phenotype,Sudden cardiac arrest
41762,Orofacial clefts (maternal alcohol consumption interaction),Phenotype,Orofacial clefts (maternal alcohol consumption interaction)
41763,Alcohol consumption (transferrin glycosylation),Phenotype,Alcohol consumption (transferrin glycosylation)
41764,Body mass in chronic obstructive pulmonary disease,Phenotype,Body mass in chronic obstructive pulmonary disease
41765,Cardiac hypertrophy,Phenotype,Cardiac hypertrophy
41766,Vitiligo (non-segmental),Phenotype,Vitiligo (non-segmental)
41767,Chronic kidney disease,Phenotype,Chronic kidney disease
41768,Radiation response,Phenotype,Radiation response
41769,Hoarding,Phenotype,Hoarding
41770,Anti-cyclic Citrullinated Peptide Antibody,Phenotype,Anti-cyclic Citrullinated Peptide Antibody
41771,Systolic blood pressure in sickle cell anemia,Phenotype,Systolic blood pressure in sickle cell anemia
41772,Hepatitis C induced liver fibrosis,Phenotype,Hepatitis C induced liver fibrosis
41773,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy),Phenotype,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)
41774,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy),Phenotype,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)
41775,Sjögren's syndrome,Phenotype,Sjögren's syndrome
41776,Electrodermal activity,Phenotype,Electrodermal activity
41777,Bone properties (heel),Phenotype,Bone properties (heel)
41778,Serum metabolite levels,Phenotype,Serum metabolite levels
41779,Esophageal squamous cell carcinoma,Phenotype,Esophageal squamous cell carcinoma
41780,Urinary uromodulin levels,Phenotype,Urinary uromodulin levels
41781,Bipolar disorder with mood-incongruent psychosis,Phenotype,Bipolar disorder with mood-incongruent psychosis
41782,Hashimoto thyroiditis versus Graves' disease,Phenotype,Hashimoto thyroiditis versus Graves' disease
41783,Marginal zone lymphoma,Phenotype,Marginal zone lymphoma
41784,Sensory disturbances after bilateral sagittal split ramus osteotomy,Phenotype,Sensory disturbances after bilateral sagittal split ramus osteotomy
41785,Amyotrophic lateral sclerosis (sporadic),Phenotype,Amyotrophic lateral sclerosis (sporadic)
41786,Social communication problems,Phenotype,Social communication problems
41787,Schizophrenia-- schizoaffective disorder or bipolar disorder,Phenotype,Schizophrenia-- schizoaffective disorder or bipolar disorder
41788,Large artery stroke,Phenotype,Large artery stroke
41789,Coronary artery disease or ischemic stroke,Phenotype,Coronary artery disease or ischemic stroke
41790,Coronary artery disease or large artery stroke,Phenotype,Coronary artery disease or large artery stroke
41791,PR interval in Tripanosoma cruzi seropositivity,Phenotype,PR interval in Tripanosoma cruzi seropositivity
41792,QT interval in Tripanosoma cruzi seropositivity,Phenotype,QT interval in Tripanosoma cruzi seropositivity
41793,Ejection fraction in Tripanosoma cruzi seropositivity,Phenotype,Ejection fraction in Tripanosoma cruzi seropositivity
41794,Self-reported allergy,Phenotype,Self-reported allergy
41795,Aortic-valve calcification,Phenotype,Aortic-valve calcification
41796,Narcolepsy,Phenotype,Narcolepsy
41797,Body mass index  (smoking years interaction),Phenotype,Body mass index  (smoking years interaction)
41798,Thyroid volume,Phenotype,Thyroid volume
41799,Epilepsy (remission after treatment),Phenotype,Epilepsy (remission after treatment)
41800,Migraine - clinic-based,Phenotype,Migraine - clinic-based
41801,Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer,Phenotype,Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
41802,Job-related exhaustion,Phenotype,Job-related exhaustion
41803,Body mass index (SNP x SNP interaction),Phenotype,Body mass index (SNP x SNP interaction)
41804,Vascular endothelial growth factor levels,Phenotype,Vascular endothelial growth factor levels
41805,Response to platinum-based agents,Phenotype,Response to platinum-based agents
41806,Eosinophilic esophagitis (pediatric),Phenotype,Eosinophilic esophagitis (pediatric)
41807,Wegener's granulomatosis,Phenotype,Wegener's granulomatosis
41808,Hepcidin levels,Phenotype,Hepcidin levels
41809,Creatinine levels,Phenotype,Creatinine levels
41810,Digit length ratio,Phenotype,Digit length ratio
41811,Personality dimensions,Phenotype,Personality dimensions
41812,Knee osteoarthritis,Phenotype,Knee osteoarthritis
41813,QRS duration in Tripanosoma cruzi seropositivity,Phenotype,QRS duration in Tripanosoma cruzi seropositivity
41814,Chagas cardiomyopathy in Tripanosoma cruzi seropositivity,Phenotype,Chagas cardiomyopathy in Tripanosoma cruzi seropositivity
41815,Antibody status in Tripanosoma cruzi seropositivity,Phenotype,Antibody status in Tripanosoma cruzi seropositivity
41816,Parasitemia in Tripanosoma cruzi seropositivity,Phenotype,Parasitemia in Tripanosoma cruzi seropositivity
41817,Blood pressure measurement (high sodium and potassium intervention),Phenotype,Blood pressure measurement (high sodium and potassium intervention)
41818,Blood pressure measurement (low sodium intervention),Phenotype,Blood pressure measurement (low sodium intervention)
41819,Blood pressure measurement (high sodium intervention),Phenotype,Blood pressure measurement (high sodium intervention)
41820,Chronic myeloid leukemia,Phenotype,Chronic myeloid leukemia
41821,Glycemic traits,Phenotype,Glycemic traits
41822,Migraine with aura,Phenotype,Migraine with aura
41823,Word reading,Phenotype,Word reading
41824,Reading and spelling,Phenotype,Reading and spelling
41825,Non-word repetition,Phenotype,Non-word repetition
41826,Phosphorus levels,Phenotype,Phosphorus levels
41827,Response to platinum-based chemotherapy (carboplatin),Phenotype,Response to platinum-based chemotherapy (carboplatin)
41828,Response to platinum-based chemotherapy (cisplatin),Phenotype,Response to platinum-based chemotherapy (cisplatin)
41829,Response to antidepressants,Phenotype,Response to antidepressants
41830,Inflammatory skin disease,Phenotype,Inflammatory skin disease
41831,Blood pressure (smoking interaction),Phenotype,Blood pressure (smoking interaction)
41832,Response to Dalcetrapib treatment in acute coronary syndrome,Phenotype,Response to Dalcetrapib treatment in acute coronary syndrome
41833,Congenital left-sided heart lesions,Phenotype,Congenital left-sided heart lesions
41834,Epithelial ovarian cancer,Phenotype,Epithelial ovarian cancer
41835,Allergic rhinitis in non-asthmatics,Phenotype,Allergic rhinitis in non-asthmatics
41836,Red blood cell fatty acid levels,Phenotype,Red blood cell fatty acid levels
41837,Frontotemporal dementia,Phenotype,Frontotemporal dementia
41838,L-arginine levels,Phenotype,L-arginine levels
41839,Shingles,Phenotype,Shingles
41840,Glucose homeostasis traits,Phenotype,Glucose homeostasis traits
41841,Glaucoma (high intraocular pressure),Phenotype,Glaucoma (high intraocular pressure)
41842,White matter microstructure (global fractional anisotropy),Phenotype,White matter microstructure (global fractional anisotropy)
41843,Conduct disorder (symptom count),Phenotype,Conduct disorder (symptom count)
41844,Renal function and chronic kidney disease,Phenotype,Renal function and chronic kidney disease
41845,Asthma (corticosteroid response),Phenotype,Asthma (corticosteroid response)
41846,Esophageal adenocarcinoma,Phenotype,Esophageal adenocarcinoma
41847,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined),Phenotype,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
41848,Response to radiotherapy in cancer (late toxicity),Phenotype,Response to radiotherapy in cancer (late toxicity)
41849,Autism spectrum disorder-related traits,Phenotype,Autism spectrum disorder-related traits
41850,CD4:CD8 lymphocyte ratio,Phenotype,CD4:CD8 lymphocyte ratio
41851,CD8-positive T-lymphocyte count,Phenotype,CD8-positive T-lymphocyte count
41852,Fasting plasma glucose,Phenotype,Fasting plasma glucose
41853,Longevity (90 years and older),Phenotype,Longevity (90 years and older)
41854,Age-related cataracts,Phenotype,Age-related cataracts
41855,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Phenotype,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)
41856,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Phenotype,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)
41857,Sepsis from pneumonia (survival),Phenotype,Sepsis from pneumonia (survival)
41858,White matter hyperintensity volume (adjusted for hypertension),Phenotype,White matter hyperintensity volume (adjusted for hypertension)
41859,Parkinson's disease progression (composite),Phenotype,Parkinson's disease progression (composite)
41860,Response to selenium supplementation (change in plasma selenium concentration),Phenotype,Response to selenium supplementation (change in plasma selenium concentration)
41870,Nonalcoholic fatty liver disease,Phenotype,Nonalcoholic fatty liver disease
41871,Percent liver fat,Phenotype,Percent liver fat
41872,Liver fibrosis and steatohepatitis severity (MRI cT1 measure),Phenotype,Liver fibrosis and steatohepatitis severity (MRI cT1 measure)
41873,Problematic alcohol use (MTAG),Phenotype,Problematic alcohol use (MTAG)
41874,Diffuse plaques (SNP x SNP interaction),Phenotype,Diffuse plaques (SNP x SNP interaction)
41875,Schizophrenia (MTAG),Phenotype,Schizophrenia (MTAG)
41876,Bipolar disorder (MTAG),Phenotype,Bipolar disorder (MTAG)
41877,Homeostasis model assessment of insulin resistance,Phenotype,Homeostasis model assessment of insulin resistance
41878,Fasting glucose,Phenotype,Fasting glucose
41879,Parental lifespan,Phenotype,Parental lifespan
41880,Caffeine consumption from coffee,Phenotype,Caffeine consumption from coffee
41881,Caffeine consumption from tea,Phenotype,Caffeine consumption from tea
41882,Caffeine consumption from coffee or tea,Phenotype,Caffeine consumption from coffee or tea
41883,Septic shock,Phenotype,Septic shock
41884,Autism spectrum disorder (MTAG),Phenotype,Autism spectrum disorder (MTAG)
41885,Depressive symptoms (MTAG),Phenotype,Depressive symptoms (MTAG)
41896,White matter hyperintensity volume,Phenotype,White matter hyperintensity volume
41908,Help-seeking from a GP,Phenotype,Help-seeking from a GP
41909,Help-seeking from a psychiatrist,Phenotype,Help-seeking from a psychiatrist
41910,Help-seeking from a GP (without major depressive disorder symptoms),Phenotype,Help-seeking from a GP (without major depressive disorder symptoms)
41911,Major depressive disorder (lifetime),Phenotype,Major depressive disorder (lifetime)
41912,Alcohol use disorder,Phenotype,Alcohol use disorder
41913,Response to antiepileptic mood-stabilizing treatment in bipolar disorder,Phenotype,Response to antiepileptic mood-stabilizing treatment in bipolar disorder
41914,Gut microbiota (bacterial taxa-- rank normal transformation method),Phenotype,Gut microbiota (bacterial taxa-- rank normal transformation method)
41915,Parent of origin effect on receptive language ability (paternal),Phenotype,Parent of origin effect on receptive language ability (paternal)
41916,Parent of origin effect on receptive language ability (maternal),Phenotype,Parent of origin effect on receptive language ability (maternal)
41917,Preeclampsia (maternal genotype effect),Phenotype,Preeclampsia (maternal genotype effect)
41919,Triglyceride levels in HIV infection,Phenotype,Triglyceride levels in HIV infection
41920,Macrovascular complications in type 2 diabetes,Phenotype,Macrovascular complications in type 2 diabetes
41924,Neuritic plaques (SNP x SNP interaction),Phenotype,Neuritic plaques (SNP x SNP interaction)
41925,Problematic alcohol use,Phenotype,Problematic alcohol use
41942,Alcohol consumption (drinks per week) (MTAG),Phenotype,Alcohol consumption (drinks per week) (MTAG)
41943,Attention deficit hyperactivity disorder (MTAG),Phenotype,Attention deficit hyperactivity disorder (MTAG)
41944,Depressive symptoms,Phenotype,Depressive symptoms
41946,Rate of cognitive decline in Alzheimer's disease,Phenotype,Rate of cognitive decline in Alzheimer's disease
41975,LDL cholesterol levels in HIV infection,Phenotype,LDL cholesterol levels in HIV infection
41976,Peak hip bone mineral content,Phenotype,Peak hip bone mineral content
41978,CV-A6-associated hand-- foot-- and mouth disease (severe vs mild),Phenotype,CV-A6-associated hand-- foot-- and mouth disease (severe vs mild)
41979,Migraine with aura and/or diastolic blood pressure,Phenotype,Migraine with aura and/or diastolic blood pressure
41980,Migraine with aura and/or systolic blood pressure,Phenotype,Migraine with aura and/or systolic blood pressure
41981,Migraine with aura and/or pulse pressure,Phenotype,Migraine with aura and/or pulse pressure
41982,Migraine without aura and/or diastolic blood pressure,Phenotype,Migraine without aura and/or diastolic blood pressure
41983,Migraine without aura and/or systolic blood pressure,Phenotype,Migraine without aura and/or systolic blood pressure
41984,Migraine without aura and/or pulse pressure,Phenotype,Migraine without aura and/or pulse pressure
41985,Migraine and/or diastolic blood pressure,Phenotype,Migraine and/or diastolic blood pressure
41986,Migraine and/or pulse pressure,Phenotype,Migraine and/or pulse pressure
41987,Migraine and/or systolic blood pressure,Phenotype,Migraine and/or systolic blood pressure
41988,Deliberate self-harm,Phenotype,Deliberate self-harm
41989,Thrombosis in response to liver transplant,Phenotype,Thrombosis in response to liver transplant
41990,Autoimmune thyroid disease,Phenotype,Autoimmune thyroid disease
41991,Cognitive function in depression,Phenotype,Cognitive function in depression
41993,Tumor necrosis factor beta levels,Phenotype,Tumor necrosis factor beta levels
41994,Rheumatic heart disease,Phenotype,Rheumatic heart disease
41995,Response to radiotherapy in nasopharyngeal carcinoma (acute oral mucositis),Phenotype,Response to radiotherapy in nasopharyngeal carcinoma (acute oral mucositis)
42020,Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms),Phenotype,Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
42021,Estrogen level change in anastrozole-treated breast cancer,Phenotype,Estrogen level change in anastrozole-treated breast cancer
42024,Sepsis (hospital admission),Phenotype,Sepsis (hospital admission)
42025,Sepsis (90-day mortality),Phenotype,Sepsis (90-day mortality)
42026,L-selectin levels,Phenotype,L-selectin levels
42029,Cardiovascular death or myocardial infarction in response to clopidogrel treatment,Phenotype,Cardiovascular death or myocardial infarction in response to clopidogrel treatment
42030,Cardiovascular death-- myocardial infarction or stroke in response to clopidogrel treatment,Phenotype,Cardiovascular death-- myocardial infarction or stroke in response to clopidogrel treatment
42031,Stent thrombosis in response to clopidogrel treatment,Phenotype,Stent thrombosis in response to clopidogrel treatment
42033,Platelet reactivity in response to clopidogrel treatment,Phenotype,Platelet reactivity in response to clopidogrel treatment
42034,Nontraumatic osteonecrosis of the femoral head,Phenotype,Nontraumatic osteonecrosis of the femoral head
42035,White matter hyperintensity volume x hypertension interaction (2df),Phenotype,White matter hyperintensity volume x hypertension interaction (2df)
42036,HDL cholesterol levels in HIV infection,Phenotype,HDL cholesterol levels in HIV infection
42037,Periventricular white matter hyperintensities,Phenotype,Periventricular white matter hyperintensities
42038,Total PHF-tau (SNP x SNP interaction),Phenotype,Total PHF-tau (SNP x SNP interaction)
42039,Autoimmune traits,Phenotype,Autoimmune traits
42042,Cardiovascular disease,Phenotype,Cardiovascular disease
42045,Tumor necrosis factor levels,Phenotype,Tumor necrosis factor levels
42047,Pancreatic beta-cell glucose sensitivity,Phenotype,Pancreatic beta-cell glucose sensitivity
42048,Myocardial fractal dimension (slice 5),Phenotype,Myocardial fractal dimension (slice 5)
42049,Myocardial fractal dimension (slice 7),Phenotype,Myocardial fractal dimension (slice 7)
42050,Myocardial fractal dimension (slice 6),Phenotype,Myocardial fractal dimension (slice 6)
42051,Myocardial fractal dimension (slice 4),Phenotype,Myocardial fractal dimension (slice 4)
42052,Myocardial fractal dimension (slice 8),Phenotype,Myocardial fractal dimension (slice 8)
42053,Shoulder impingement syndrome,Phenotype,Shoulder impingement syndrome
42060,Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer,Phenotype,Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer
42061,Leukoderma in response to rhododendrol,Phenotype,Leukoderma in response to rhododendrol
42072,Eczema,Phenotype,Eczema
42075,Mastocytosis,Phenotype,Mastocytosis
42076,Systemic mastocytosis,Phenotype,Systemic mastocytosis
42077,Cutaneous mastocytosis,Phenotype,Cutaneous mastocytosis
42078,Facial morphology traits (59 NSCL/P endophenotypic segments),Phenotype,Facial morphology traits (59 NSCL/P endophenotypic segments)
42090,Residual cognitive resilience,Phenotype,Residual cognitive resilience
42091,Combined resilience (covariance of educational attainment with residual cognitive resilience),Phenotype,Combined resilience (covariance of educational attainment with residual cognitive resilience)
42092,Vaginal microbiome composition (Shannon diversity index),Phenotype,Vaginal microbiome composition (Shannon diversity index)
42112,Gastric cancer,Phenotype,Gastric cancer
42113,Neonatal white matter microstructure,Phenotype,Neonatal white matter microstructure
42114,Adult onset asthma or type 2 diabetes,Phenotype,Adult onset asthma or type 2 diabetes
42115,Adult onset asthma and/or BMI,Phenotype,Adult onset asthma and/or BMI
42116,Nonatopic asthma and/or BMI,Phenotype,Nonatopic asthma and/or BMI
42117,Asthma (adult onset),Phenotype,Asthma (adult onset)
42120,Aging traits (healthspan-- parental lifespan or longevity) (multivariate analysis),Phenotype,Aging traits (healthspan-- parental lifespan or longevity) (multivariate analysis)
42121,Electrocardiographic traits (multivariate),Phenotype,Electrocardiographic traits (multivariate)
42122,Brain morphology (MOSTest),Phenotype,Brain morphology (MOSTest)
42123,Motor fluctuations in levodopa treated Parkinson's disease,Phenotype,Motor fluctuations in levodopa treated Parkinson's disease
42124,Levodopa-induced dyskinesia in levodopa treated Parkinson's disease,Phenotype,Levodopa-induced dyskinesia in levodopa treated Parkinson's disease
42125,Response to esketamine in treatment resistant depression,Phenotype,Response to esketamine in treatment resistant depression
42126,Response to esketamine (responder status) in treatment resistant depression,Phenotype,Response to esketamine (responder status) in treatment resistant depression
42129,Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG levels,Phenotype,Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG levels
42132,Cortical thickness (MOSTest),Phenotype,Cortical thickness (MOSTest)
42133,Subcortical volume (MOSTest),Phenotype,Subcortical volume (MOSTest)
42136,Arterial stiffness (brachial-femoral pulse wave velocity),Phenotype,Arterial stiffness (brachial-femoral pulse wave velocity)
42137,Total carotid plaque area (excess vs minimal atherosclerosis),Phenotype,Total carotid plaque area (excess vs minimal atherosclerosis)
42138,circulating leptin levels adjusted for BMI,Phenotype,circulating leptin levels adjusted for BMI
42139,circulating leptin levels,Phenotype,circulating leptin levels
42140,Glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia,Phenotype,Glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia
42164,Percent mammographic density,Phenotype,Percent mammographic density
42165,Cerebrospinal fluid t-tau:AB1-42 ratio,Phenotype,Cerebrospinal fluid t-tau:AB1-42 ratio
42166,Restless legs syndrome in migraine without aura,Phenotype,Restless legs syndrome in migraine without aura
42168,Deep white matter hyperintensities,Phenotype,Deep white matter hyperintensities
42173,Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism,Phenotype,Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism
42178,Respiratory diseases,Phenotype,Respiratory diseases
42205,Age at menopause,Phenotype,Age at menopause
42218,Neuroblastoma (pediatric),Phenotype,Neuroblastoma (pediatric)
42224,Allergic disease (asthma-- hay fever and/or eczema) (age of onset),Phenotype,Allergic disease (asthma-- hay fever and/or eczema) (age of onset)
42225,Allergic disease (asthma-- hay fever and/or eczema) (multivariate analysis),Phenotype,Allergic disease (asthma-- hay fever and/or eczema) (multivariate analysis)
42242,Brain morphology (min-P),Phenotype,Brain morphology (min-P)
42243,Cortical surface area (MOSTest),Phenotype,Cortical surface area (MOSTest)
42273,Cortical surface area (min-P),Phenotype,Cortical surface area (min-P)
42274,Subcortical volume (min-P),Phenotype,Subcortical volume (min-P)
42275,Cortical thickness (min-P),Phenotype,Cortical thickness (min-P)
42280,Oral cavity cancer,Phenotype,Oral cavity cancer
42281,Oropharynx cancer,Phenotype,Oropharynx cancer
42282,Head and neck squamous cell carcinoma,Phenotype,Head and neck squamous cell carcinoma
42283,Ceramide levels (C24:0),Phenotype,Ceramide levels (C24:0)
42284,Ceramide levels (C22:0),Phenotype,Ceramide levels (C22:0)
42285,Waist-to-hip ratio adjusted for BMI in non-smokers,Phenotype,Waist-to-hip ratio adjusted for BMI in non-smokers
42286,Body fat mass,Phenotype,Body fat mass
42287,Skin aging (microtopography measurement),Phenotype,Skin aging (microtopography measurement)
42288,Dehydroepiandrosterone sulphate levels,Phenotype,Dehydroepiandrosterone sulphate levels
42289,Chronic periodontitis (mean interproximal clinical attachment level),Phenotype,Chronic periodontitis (mean interproximal clinical attachment level)
42290,Barrett's esophagus  or Esophageal adenocarcinoma,Phenotype,Barrett's esophagus  or Esophageal adenocarcinoma
42291,Survival in pancreatic cancer,Phenotype,Survival in pancreatic cancer
42292,Glomerular filtration rate,Phenotype,Glomerular filtration rate
42293,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),Phenotype,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
42294,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,Phenotype,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
42295,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,Phenotype,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes
42296,Body mass index (joint analysis main effects and physical activity interaction),Phenotype,Body mass index (joint analysis main effects and physical activity interaction)
42297,Modified Stumvoll Insulin Sensitivity Index (BMI interaction),Phenotype,Modified Stumvoll Insulin Sensitivity Index (BMI interaction)
42298,Psychosis proneness (hypomanic personality scale),Phenotype,Psychosis proneness (hypomanic personality scale)
42299,Psychosis proneness (perceptual aberration scale),Phenotype,Psychosis proneness (perceptual aberration scale)
42300,Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale),Phenotype,Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale)
42301,Acute graft versus host disease in bone marrow transplantation (recipient effect),Phenotype,Acute graft versus host disease in bone marrow transplantation (recipient effect)
42302,Acute graft versus host disease in bone marrow transplantation (donor effect),Phenotype,Acute graft versus host disease in bone marrow transplantation (donor effect)
42303,Response to statins (HDL cholesterol change),Phenotype,Response to statins (HDL cholesterol change)
42304,Early onset atrial fibrillation,Phenotype,Early onset atrial fibrillation
42305,Alcoholic chronic pancreatitis,Phenotype,Alcoholic chronic pancreatitis
42306,Left ventricular obstructive tract defect (inherited effect),Phenotype,Left ventricular obstructive tract defect (inherited effect)
42307,Left ventricular obstructive tract defect (maternal effect),Phenotype,Left ventricular obstructive tract defect (maternal effect)
42308,Congenital heart disease (inherited effect),Phenotype,Congenital heart disease (inherited effect)
42309,Congenital heart disease (maternal effect),Phenotype,Congenital heart disease (maternal effect)
42310,Conotruncal heart defects (maternal effects),Phenotype,Conotruncal heart defects (maternal effects)
42311,Appendicular lean mass,Phenotype,Appendicular lean mass
42312,Lean body mass,Phenotype,Lean body mass
42313,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),Phenotype,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
42314,Plantar warts,Phenotype,Plantar warts
42315,Bacterial meningitis,Phenotype,Bacterial meningitis
42316,Fear of minor pain,Phenotype,Fear of minor pain
42317,Fear of medical pain (dental),Phenotype,Fear of medical pain (dental)
42318,Fear of pain,Phenotype,Fear of pain
42319,IgG galactosylation phenotypes (multivariate analysis),Phenotype,IgG galactosylation phenotypes (multivariate analysis)
42320,Rubella,Phenotype,Rubella
42321,Mononucleosis,Phenotype,Mononucleosis
42322,Insomnia complaints,Phenotype,Insomnia complaints
42323,Peripheral arterial disease (traffic-related air pollution interaction),Phenotype,Peripheral arterial disease (traffic-related air pollution interaction)
42324,Facial morphology (factor 16),Phenotype,Facial morphology (factor 16)
42325,Facial morphology (factor 17-- height of vermillion upper lip),Phenotype,Facial morphology (factor 17-- height of vermillion upper lip)
42326,Facial morphology (factor 15-- philtrum width),Phenotype,Facial morphology (factor 15-- philtrum width)
42327,Autism spectrum disorder or schizophrenia,Phenotype,Autism spectrum disorder or schizophrenia
42328,Urinary tract infection frequency,Phenotype,Urinary tract infection frequency
42329,Chronic sinus infection,Phenotype,Chronic sinus infection
42330,Number of common colds,Phenotype,Number of common colds
42331,Hepatitis A,Phenotype,Hepatitis A
42332,Rheumatic fever,Phenotype,Rheumatic fever
42333,Pneumonia,Phenotype,Pneumonia
42334,Scarlet fever,Phenotype,Scarlet fever
42335,Small cell lung carcinoma,Phenotype,Small cell lung carcinoma
42336,Squamous cell lung carcinoma,Phenotype,Squamous cell lung carcinoma
42337,Facial morphology (factor 12-- vertical position of sublabial sulcus relative to central midface),Phenotype,Facial morphology (factor 12-- vertical position of sublabial sulcus relative to central midface)
42338,Facial morphology (factor 4-- facial height related to vertical position of gnathion),Phenotype,Facial morphology (factor 4-- facial height related to vertical position of gnathion)
42339,Facial morphology (factor 9-- facial height related to vertical position of nasion),Phenotype,Facial morphology (factor 9-- facial height related to vertical position of nasion)
42340,Facial morphology (factor 7-- width of cartilaginous portion of nose),Phenotype,Facial morphology (factor 7-- width of cartilaginous portion of nose)
42341,Facial morphology (factor 8-- orbital inclination due to vertical and horizontal position of exocanthion),Phenotype,Facial morphology (factor 8-- orbital inclination due to vertical and horizontal position of exocanthion)
42342,Facial morphology (factor 6-- height of vermillion lower lip),Phenotype,Facial morphology (factor 6-- height of vermillion lower lip)
42343,Facial morphology (factor 11-- projection of the nose),Phenotype,Facial morphology (factor 11-- projection of the nose)
42344,Obstetric antiphospholipid syndrome,Phenotype,Obstetric antiphospholipid syndrome
42345,Chickenpox,Phenotype,Chickenpox
42346,Cold sores,Phenotype,Cold sores
42347,Mumps,Phenotype,Mumps
42348,Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms,Phenotype,Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms
42349,Lipoprotein (a) levels,Phenotype,Lipoprotein (a) levels
42350,Lung cancer in ever smokers,Phenotype,Lung cancer in ever smokers
42351,Lung cancer in never smokers,Phenotype,Lung cancer in never smokers
42352,Facial morphology (factor 2-- vertical position of orbits relative to midface),Phenotype,Facial morphology (factor 2-- vertical position of orbits relative to midface)
42353,Facial morphology (factor 18),Phenotype,Facial morphology (factor 18)
42354,Facial morphology (factor 19),Phenotype,Facial morphology (factor 19)
42355,Trunk fat mass,Phenotype,Trunk fat mass
42356,Verbal memory performance (immediate recall change),Phenotype,Verbal memory performance (immediate recall change)
42357,Verbal memory performance (residualized delayed recall level),Phenotype,Verbal memory performance (residualized delayed recall level)
42358,Hepatocellular carcinoma in hepatitis C infection,Phenotype,Hepatocellular carcinoma in hepatitis C infection
42359,Strep throat,Phenotype,Strep throat
42360,Subjective well-being (MTAG),Phenotype,Subjective well-being (MTAG)
42361,Neuroticism (MTAG),Phenotype,Neuroticism (MTAG)
42362,Cerebral blood flow,Phenotype,Cerebral blood flow
42363,Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous),Phenotype,Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous)
42364,Red blood cell density in sickle cell anemia,Phenotype,Red blood cell density in sickle cell anemia
42365,Heart rate variability traits (SDNN),Phenotype,Heart rate variability traits (SDNN)
42366,Heart rate variability traits (RMSSD),Phenotype,Heart rate variability traits (RMSSD)
42367,Heart rate variability traits (pvRSA/HF),Phenotype,Heart rate variability traits (pvRSA/HF)
42368,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment),Phenotype,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)
42369,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment),Phenotype,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)
42370,Monocyte chemoattractant protein-1 levels,Phenotype,Monocyte chemoattractant protein-1 levels
42371,Interleukin-12p70 levels,Phenotype,Interleukin-12p70 levels
42372,RANTES levels,Phenotype,RANTES levels
42373,Platelet-derived growth factor BB levels,Phenotype,Platelet-derived growth factor BB levels
42374,Stem cell factor levels,Phenotype,Stem cell factor levels
42375,Macrophage inflammatory protein 1b levels,Phenotype,Macrophage inflammatory protein 1b levels
42376,Prudent dietary pattern,Phenotype,Prudent dietary pattern
42377,Western dietary pattern,Phenotype,Western dietary pattern
42378,Primary vesicoureteric reflux,Phenotype,Primary vesicoureteric reflux
42379,Anti-saccade response,Phenotype,Anti-saccade response
42380,Pursuit maintenance gain,Phenotype,Pursuit maintenance gain
42381,Initial pursuit acceleration in psychotic disorders,Phenotype,Initial pursuit acceleration in psychotic disorders
42382,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications,Phenotype,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications
42383,Macrophage inflammatory protein 1a levels,Phenotype,Macrophage inflammatory protein 1a levels
42384,Monokine induced by gamma interferon levels,Phenotype,Monokine induced by gamma interferon levels
42385,Macrophage colony stimulating factor levels,Phenotype,Macrophage colony stimulating factor levels
42386,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),Phenotype,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
42387,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),Phenotype,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
42388,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),Phenotype,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
42389,Post bronchodilator FEV1/FVC ratio in COPD,Phenotype,Post bronchodilator FEV1/FVC ratio in COPD
42390,ACPA-positive rheumatoid arthritis (smoking interaction),Phenotype,ACPA-positive rheumatoid arthritis (smoking interaction)
42391,Milk allergy (maternal genetic effects),Phenotype,Milk allergy (maternal genetic effects)
42392,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction),Phenotype,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction)
42393,Limited cutaneous systemic scleroderma,Phenotype,Limited cutaneous systemic scleroderma
42394,Blood osmolality (transformed sodium),Phenotype,Blood osmolality (transformed sodium)
42395,Neuritic plaques or neurofibrillary tangles (pleiotropy),Phenotype,Neuritic plaques or neurofibrillary tangles (pleiotropy)
42396,Initial pursuit acceleration,Phenotype,Initial pursuit acceleration
42397,Cleft palate,Phenotype,Cleft palate
42398,Primary sclerosing cholangitis,Phenotype,Primary sclerosing cholangitis
42399,Multiple system atrophy,Phenotype,Multiple system atrophy
42400,Ovarian disease with few adhesions,Phenotype,Ovarian disease with few adhesions
42401,Deep ovarian and/or rectovaginal disease with dense adhesions,Phenotype,Deep ovarian and/or rectovaginal disease with dense adhesions
42402,Opioid dependence,Phenotype,Opioid dependence
42403,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),Phenotype,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
42404,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease,Phenotype,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease
42405,Diarrhoea in darapladib-treated cardiovascular disease (time to event),Phenotype,Diarrhoea in darapladib-treated cardiovascular disease (time to event)
42406,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction),Phenotype,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)
42407,Lipoprotein phospholipase A2 activity in cardiovascular disease,Phenotype,Lipoprotein phospholipase A2 activity in cardiovascular disease
42408,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event),Phenotype,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)
42409,GLP-1 levels in response to oral glucose tolerance test (fasting),Phenotype,GLP-1 levels in response to oral glucose tolerance test (fasting)
42410,GIP levels in response to oral glucose tolerance test (120 minutes),Phenotype,GIP levels in response to oral glucose tolerance test (120 minutes)
42411,Nicotine dependence,Phenotype,Nicotine dependence
42412,Mean arterial pressure,Phenotype,Mean arterial pressure
42415,Obsessive-compulsive disorder or autism spectrum disorder,Phenotype,Obsessive-compulsive disorder or autism spectrum disorder
42416,Huntington's disease progression,Phenotype,Huntington's disease progression
42417,Immunoglobulin A vasculitis,Phenotype,Immunoglobulin A vasculitis
42418,Intelligence (MTAG),Phenotype,Intelligence (MTAG)
42419,Adult asthma,Phenotype,Adult asthma
42420,Coenzyme Q10 levels,Phenotype,Coenzyme Q10 levels
42421,Plasma kynurenine levels in major depressive disorder,Phenotype,Plasma kynurenine levels in major depressive disorder
42422,Follicle stimulating hormone levels in polycystic ovary syndrome,Phenotype,Follicle stimulating hormone levels in polycystic ovary syndrome
42423,Testosterone levels in polycystic ovary syndrome,Phenotype,Testosterone levels in polycystic ovary syndrome
42424,Sarcoidosis (non-Lofgren's syndrome),Phenotype,Sarcoidosis (non-Lofgren's syndrome)
42425,Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations),Phenotype,Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations)
42426,Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome),Phenotype,Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)
42427,Thrombin-activatable fibrinolysis inhibitor activation peptide,Phenotype,Thrombin-activatable fibrinolysis inhibitor activation peptide
42428,Sarcoidosis (Lofgren's syndrome),Phenotype,Sarcoidosis (Lofgren's syndrome)
42429,Epstein-Barr virus copy number in lymphoblastoid cell lines,Phenotype,Epstein-Barr virus copy number in lymphoblastoid cell lines
42430,Serum uric acid levels in response to allopurinol in gout,Phenotype,Serum uric acid levels in response to allopurinol in gout
42431,Lower body strength,Phenotype,Lower body strength
42432,Brain volume in infants (white matter),Phenotype,Brain volume in infants (white matter)
42433,Brain volume in infants (cerebrospinal fluid),Phenotype,Brain volume in infants (cerebrospinal fluid)
42434,Brain volume in infants (grey matter),Phenotype,Brain volume in infants (grey matter)
42435,Opioid requirements during laparoscopic-assisted colectomy,Phenotype,Opioid requirements during laparoscopic-assisted colectomy
42436,Total cholesterol levels in HDL,Phenotype,Total cholesterol levels in HDL
42437,Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer,Phenotype,Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer
42438,Recurrent major depressive disorder,Phenotype,Recurrent major depressive disorder
42439,Disease progression in age-related macular degeneration,Phenotype,Disease progression in age-related macular degeneration
42440,Disease progression to choroidal neovascularization form in age-related macular degeneration,Phenotype,Disease progression to choroidal neovascularization form in age-related macular degeneration
42441,Disease progression in age-related macular degeneration (adjusted for baseline),Phenotype,Disease progression in age-related macular degeneration (adjusted for baseline)
42442,Coronary artery disease (myocardial infarction-- percutaneous transluminal coronary angioplasty-- coronary artery bypass grafting-- angina or chromic ischemic heart disease),Phenotype,Coronary artery disease (myocardial infarction-- percutaneous transluminal coronary angioplasty-- coronary artery bypass grafting-- angina or chromic ischemic heart disease)
42443,Forced expiratory volume in 1 second (environmental tobacco smoke interaction),Phenotype,Forced expiratory volume in 1 second (environmental tobacco smoke interaction)
42444,Response to metformin (IC50),Phenotype,Response to metformin (IC50)
42445,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction),Phenotype,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)
42446,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),Phenotype,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)
42447,Nevirapine-induced hypersensitivity in HIV,Phenotype,Nevirapine-induced hypersensitivity in HIV
42448,Itch intensity from mosquito bite,Phenotype,Itch intensity from mosquito bite
42449,Itch intensity from mosquito bite adjusted by bite size,Phenotype,Itch intensity from mosquito bite adjusted by bite size
42450,Tenofovir clearance in HIV infection,Phenotype,Tenofovir clearance in HIV infection
42451,Blood pressure traits (multi-trait analysis),Phenotype,Blood pressure traits (multi-trait analysis)
42452,Waist circumference adjusted for BMI (adjusted for smoking behaviour),Phenotype,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
42453,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),Phenotype,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
42454,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),Phenotype,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
42455,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),Phenotype,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
42456,Body mass index (adult),Phenotype,Body mass index (adult)
42457,Intelligence,Phenotype,Intelligence
42458,Mosquito bite size,Phenotype,Mosquito bite size
42459,Perceived unattractiveness to mosquitoes,Phenotype,Perceived unattractiveness to mosquitoes
42460,BMI (adjusted for smoking behaviour),Phenotype,BMI (adjusted for smoking behaviour)
42461,Body mass index (joint analysis main effects and smoking interaction),Phenotype,Body mass index (joint analysis main effects and smoking interaction)
42462,Pre bronchodilator FEV1/FVC ratio in never-smokers,Phenotype,Pre bronchodilator FEV1/FVC ratio in never-smokers
42463,Late-onset Alzheimer's disease,Phenotype,Late-onset Alzheimer's disease
42464,Dermatomyositis,Phenotype,Dermatomyositis
42465,Hip minimal joint space width,Phenotype,Hip minimal joint space width
42466,Insulin levels,Phenotype,Insulin levels
42467,Insulin levels adjusted for BMI,Phenotype,Insulin levels adjusted for BMI
42468,Insulin disposition index,Phenotype,Insulin disposition index
42469,Incremental insulin,Phenotype,Incremental insulin
42470,Corrected insulin response,Phenotype,Corrected insulin response
42471,Corrected insulin response adjusted for insulin sensitivity index,Phenotype,Corrected insulin response adjusted for insulin sensitivity index
42472,Bipolar disorder lithium response (continuous) or schizophrenia,Phenotype,Bipolar disorder lithium response (continuous) or schizophrenia
42473,Bipolar disorder lithium response (categorical) or schizophrenia,Phenotype,Bipolar disorder lithium response (categorical) or schizophrenia
42474,Response to mepolizumab in severe asthma,Phenotype,Response to mepolizumab in severe asthma
42475,Moyamoya disease,Phenotype,Moyamoya disease
42476,Alcohol dependence symptom count,Phenotype,Alcohol dependence symptom count
42477,Selective IgA deficiency,Phenotype,Selective IgA deficiency
42478,Thiopurine S-methyltransferase activity,Phenotype,Thiopurine S-methyltransferase activity
42479,Oral cavity and pharyngeal cancer,Phenotype,Oral cavity and pharyngeal cancer
42480,Mortality in sepsis,Phenotype,Mortality in sepsis
42481,Food addiction,Phenotype,Food addiction
42482,Depression in response to interferon-based therapy in chronic hepatitis C,Phenotype,Depression in response to interferon-based therapy in chronic hepatitis C
42483,Inhibitory control,Phenotype,Inhibitory control
42484,Dementia with Lewy bodies,Phenotype,Dementia with Lewy bodies
42485,Chronic rhinosinusitis with nasal polyps,Phenotype,Chronic rhinosinusitis with nasal polyps
42486,Sulfasalazine-induced agranulocytosis,Phenotype,Sulfasalazine-induced agranulocytosis
42487,Heart rate response to exercise,Phenotype,Heart rate response to exercise
42488,Heart rate response to recovery post exercise,Phenotype,Heart rate response to recovery post exercise
42489,Systemic sclerosis (anti-centromere-positive),Phenotype,Systemic sclerosis (anti-centromere-positive)
42490,Diffuse cutaneous systemic sclerosis,Phenotype,Diffuse cutaneous systemic sclerosis
42491,Systemic sclerosis (anti-topoisomerase-positive),Phenotype,Systemic sclerosis (anti-topoisomerase-positive)
42492,Total body bone mineral density,Phenotype,Total body bone mineral density
42493,Epstein Barr virus nuclear antigen 1 IgG levels,Phenotype,Epstein Barr virus nuclear antigen 1 IgG levels
42494,Epstein Barr virus nuclear antigen 1 IgG seropositivity,Phenotype,Epstein Barr virus nuclear antigen 1 IgG seropositivity
42495,Epstein-Barr virus immune response (multivariate analysis),Phenotype,Epstein-Barr virus immune response (multivariate analysis)
42496,Giant cell arteritis,Phenotype,Giant cell arteritis
42497,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
42498,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
42499,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
42500,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
42501,Total body bone mineral density (age 30-45),Phenotype,Total body bone mineral density (age 30-45)
42502,Total body bone mineral density (age 45-60),Phenotype,Total body bone mineral density (age 45-60)
42503,Total body bone mineral density (age over 60),Phenotype,Total body bone mineral density (age over 60)
42504,Alzheimer's disease or family history of Alzheimer's disease,Phenotype,Alzheimer's disease or family history of Alzheimer's disease
42505,Stimulated C-peptide levels in type I diabetes,Phenotype,Stimulated C-peptide levels in type I diabetes
42506,Random C-peptide levels in type I diabetes,Phenotype,Random C-peptide levels in type I diabetes
42507,C-peptide levels in type I diabetes,Phenotype,C-peptide levels in type I diabetes
42508,Low tan response,Phenotype,Low tan response
42509,Neuromyelitis optica,Phenotype,Neuromyelitis optica
42510,Neuromyelitis optica (AQP4-IgG-positive),Phenotype,Neuromyelitis optica (AQP4-IgG-positive)
42511,Spherical equivalent or myopia (age of diagnosis),Phenotype,Spherical equivalent or myopia (age of diagnosis)
42512,Myopia (age of diagnosis),Phenotype,Myopia (age of diagnosis)
42513,Allergic disease (asthma-- hay fever or eczema),Phenotype,Allergic disease (asthma-- hay fever or eczema)
42514,Thyroid autoantibody positivity (anti-thyroglobulin (TgAb) and/or anti-thyroid peroxidase  (TPOAb) levels),Phenotype,Thyroid autoantibody positivity (anti-thyroglobulin (TgAb) and/or anti-thyroid peroxidase  (TPOAb) levels)
42515,Optic disc size,Phenotype,Optic disc size
42516,Bone mineral density (total hip),Phenotype,Bone mineral density (total hip)
42517,Menstruation quality of life impact (loss of concentration),Phenotype,Menstruation quality of life impact (loss of concentration)
42518,Vaginal discharge (itching),Phenotype,Vaginal discharge (itching)
42534,Exacerbations requiring hospitalisation in asthma,Phenotype,Exacerbations requiring hospitalisation in asthma
42535,Cannabis use (age at onset),Phenotype,Cannabis use (age at onset)
42536,Reaction time,Phenotype,Reaction time
42537,Coronary artery disease in diabetes,Phenotype,Coronary artery disease in diabetes
42538,Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease,Phenotype,Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease
42539,Executive function in ADHD,Phenotype,Executive function in ADHD
42541,Spherical equivalent,Phenotype,Spherical equivalent
42542,Optic nerve head parameters (multi-trait analysis),Phenotype,Optic nerve head parameters (multi-trait analysis)
42543,Cognitive decline (age-related),Phenotype,Cognitive decline (age-related)
42546,Behavioural changes in frontotemporal lobe dementia,Phenotype,Behavioural changes in frontotemporal lobe dementia
42547,Anti-chlamydia trachomatis IgG seropositivity,Phenotype,Anti-chlamydia trachomatis IgG seropositivity
42548,Blood glucose levels,Phenotype,Blood glucose levels
42549,Myocardial infarction,Phenotype,Myocardial infarction
42550,Coffee consumption,Phenotype,Coffee consumption
42551,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Phenotype,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect)
42552,Cervical cancer (MTAG),Phenotype,Cervical cancer (MTAG)
42553,Gynecologic disease (multivariate analysis),Phenotype,Gynecologic disease (multivariate analysis)
42555,Atopic asthma,Phenotype,Atopic asthma
42557,Dermatomyositis or juvenile dermatomyositis,Phenotype,Dermatomyositis or juvenile dermatomyositis
42558,Polymyositis,Phenotype,Polymyositis
42559,Idiopathic inflammatory myopathy,Phenotype,Idiopathic inflammatory myopathy
42560,Age at loss of ambulation in Duchenne muscular dystrophy,Phenotype,Age at loss of ambulation in Duchenne muscular dystrophy
42561,Non-glioblastoma glioma,Phenotype,Non-glioblastoma glioma
42562,Glioma,Phenotype,Glioma
42563,Worry,Phenotype,Worry
42564,Rosacea symptom severity,Phenotype,Rosacea symptom severity
42565,Obstructive sleep apnea trait (apnea hypopnea index-- change over time),Phenotype,Obstructive sleep apnea trait (apnea hypopnea index-- change over time)
42566,Delta-5 desaturase activity response to n3-polyunsaturated fat supplement,Phenotype,Delta-5 desaturase activity response to n3-polyunsaturated fat supplement
42567,End stage renal disease x APOL1 genotype interaction,Phenotype,End stage renal disease x APOL1 genotype interaction
42568,Menstruation quality of life impact (dysmenorrhea),Phenotype,Menstruation quality of life impact (dysmenorrhea)
42569,Menstruation quality of life impact (acne),Phenotype,Menstruation quality of life impact (acne)
42570,Menstruation quality of life impact (fever),Phenotype,Menstruation quality of life impact (fever)
42571,Blood protein levels in cardiovascular risk,Phenotype,Blood protein levels in cardiovascular risk
42572,Serum polyunsaturated fatty acid concentration x Mediterranean diet adherence interaction in metabolic syndrome,Phenotype,Serum polyunsaturated fatty acid concentration x Mediterranean diet adherence interaction in metabolic syndrome
42573,Longitudinal brain connectivity change (Louvain modularity),Phenotype,Longitudinal brain connectivity change (Louvain modularity)
42574,Serum 25-Hydroxyvitamin D levels,Phenotype,Serum 25-Hydroxyvitamin D levels
42575,Nonatopic asthma,Phenotype,Nonatopic asthma
42576,Response to ketogenic dietary therapies in epilepsy,Phenotype,Response to ketogenic dietary therapies in epilepsy
42577,Depressed affect,Phenotype,Depressed affect
42579,Response to (pegylated) interferon in HBeAg-negative hepatitis B,Phenotype,Response to (pegylated) interferon in HBeAg-negative hepatitis B
42580,Response to (pegylated) interferon in HBeAG-positive hepatitis B,Phenotype,Response to (pegylated) interferon in HBeAG-positive hepatitis B
42581,Intrinsic epigenetic age acceleration,Phenotype,Intrinsic epigenetic age acceleration
42582,Total body bone mineral density (MTAG),Phenotype,Total body bone mineral density (MTAG)
42583,Heel bone mineral density (MTAG),Phenotype,Heel bone mineral density (MTAG)
42584,Gynecologic disease,Phenotype,Gynecologic disease
42585,Ovarian cancer (MTAG),Phenotype,Ovarian cancer (MTAG)
42586,Alcohol-associated liver disease in light drinkers,Phenotype,Alcohol-associated liver disease in light drinkers
42588,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 2),Phenotype,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 2)
42590,Rapidly progressive Alzheimer's disease (typical) (case-control set 2),Phenotype,Rapidly progressive Alzheimer's disease (typical) (case-control set 2)
42592,Rapidly progressive Alzheimer's disease (pathologically-confirmed vs typical) (case-control set 3),Phenotype,Rapidly progressive Alzheimer's disease (pathologically-confirmed vs typical) (case-control set 3)
42595,Rapidly progressive Alzheimer's disease (typical) (case-control set 1),Phenotype,Rapidly progressive Alzheimer's disease (typical) (case-control set 1)
42597,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 1),Phenotype,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 1)
42598,Rapidly progressive Alzheimer's disease (clinical) (case-control set 3),Phenotype,Rapidly progressive Alzheimer's disease (clinical) (case-control set 3)
42601,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 3),Phenotype,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 3)
42602,Prostate cancer (early onset),Phenotype,Prostate cancer (early onset)
42603,Diabetes mellitus,Phenotype,Diabetes mellitus
42604,Non-del(5q) myelodysplastic syndromes,Phenotype,Non-del(5q) myelodysplastic syndromes
42605,Bone mineral content,Phenotype,Bone mineral content
42606,Maternal nondisjunction of chromosome 21 (mothers vs fathers),Phenotype,Maternal nondisjunction of chromosome 21 (mothers vs fathers)
42607,Maternal nondisjunction of chromosome 21 (MI error vs fathers),Phenotype,Maternal nondisjunction of chromosome 21 (MI error vs fathers)
42608,Cryptosporidiosis,Phenotype,Cryptosporidiosis
42609,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Phenotype,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome
42610,Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Phenotype,Serum docosahexaenoic fatty acid concentration in metabolic syndrome
42611,Severe aplastic anemia,Phenotype,Severe aplastic anemia
42612,Uterine fibroids (MTAG),Phenotype,Uterine fibroids (MTAG)
42613,Endometrial cancer (MTAG),Phenotype,Endometrial cancer (MTAG)
42614,Ovarian cancer,Phenotype,Ovarian cancer
42615,Red blood cell traits (multivariate analysis),Phenotype,Red blood cell traits (multivariate analysis)
42635,NASH resolution in nonalcoholic steatohepatitis,Phenotype,NASH resolution in nonalcoholic steatohepatitis
42636,Cutaneous squamous cell carcinoma,Phenotype,Cutaneous squamous cell carcinoma
42637,Response to statins (LDL cholesterol percent change),Phenotype,Response to statins (LDL cholesterol percent change)
42638,Low density lipoprotein cholesterol levels (on statin treatment),Phenotype,Low density lipoprotein cholesterol levels (on statin treatment)
42639,Alcohol-associated liver disease in non drinkers,Phenotype,Alcohol-associated liver disease in non drinkers
42678,Maximum cranial length,Phenotype,Maximum cranial length
42679,Prostate cancer (advanced),Phenotype,Prostate cancer (advanced)
42680,Cerebellum growth,Phenotype,Cerebellum growth
42681,Cardioembolic stroke (CCSp classification),Phenotype,Cardioembolic stroke (CCSp classification)
42682,Cardioembolic stroke (TOAST classification),Phenotype,Cardioembolic stroke (TOAST classification)
42683,Cardioembolic stroke (CCS and TOAST classification),Phenotype,Cardioembolic stroke (CCS and TOAST classification)
42684,Cardioembolic stroke (CCS or TOAST classification),Phenotype,Cardioembolic stroke (CCS or TOAST classification)
42685,Cardioembolic stroke (CCSc classification),Phenotype,Cardioembolic stroke (CCSc classification)
42686,Lipoprotein (a) levels in response to niacin in statin-treated individuals,Phenotype,Lipoprotein (a) levels in response to niacin in statin-treated individuals
42687,HDL cholesterol change in response to niacin in statin-treated individuals,Phenotype,HDL cholesterol change in response to niacin in statin-treated individuals
42688,Gastrointestinal infection,Phenotype,Gastrointestinal infection
42689,Glycosuria in pregnancy (maternal genotype effect),Phenotype,Glycosuria in pregnancy (maternal genotype effect)
42690,Glycosuria in pregnancy (offspring genotype effect),Phenotype,Glycosuria in pregnancy (offspring genotype effect)
42691,Glycosuria in pregnancy (maternal and offspring genotype effect),Phenotype,Glycosuria in pregnancy (maternal and offspring genotype effect)
42692,Neck pain or shoulder pain,Phenotype,Neck pain or shoulder pain
42693,Hallux valgus,Phenotype,Hallux valgus
42694,Gout (normal type),Phenotype,Gout (normal type)
42696,Externalizing behaviour score,Phenotype,Externalizing behaviour score
42697,Parkinson's disease or first degree relation to individual with Parkinson's disease,Phenotype,Parkinson's disease or first degree relation to individual with Parkinson's disease
42698,Occipital lobe volume,Phenotype,Occipital lobe volume
42699,Lung function in never smokers (high FEV1 vs average FEV1),Phenotype,Lung function in never smokers (high FEV1 vs average FEV1)
42700,Lung function in never smokers (low FEV1 vs average FEV1),Phenotype,Lung function in never smokers (low FEV1 vs average FEV1)
42701,Smoking status (heavy vs never),Phenotype,Smoking status (heavy vs never)
42702,Lung function (low FEV1 vs high FEV1),Phenotype,Lung function (low FEV1 vs high FEV1)
42703,Lung function in never smokers (low FEV1 vs high FEV1),Phenotype,Lung function in never smokers (low FEV1 vs high FEV1)
42704,Lung function (low FEV1 vs high FEV1) x smoking interaction,Phenotype,Lung function (low FEV1 vs high FEV1) x smoking interaction
42705,Cerebrospinal fluid sTREM-2 levels,Phenotype,Cerebrospinal fluid sTREM-2 levels
42725,HDL cholesterol levels x long total sleep time interaction (2df test),Phenotype,HDL cholesterol levels x long total sleep time interaction (2df test)
42726,Idiopathic pulmonary fibrosis,Phenotype,Idiopathic pulmonary fibrosis
42727,Hospital contact for infections,Phenotype,Hospital contact for infections
42748,TestASV_38 (Ruminococcus) abundance,Phenotype,TestASV_38 (Ruminococcus) abundance
42749,OTU97_31 (Prevotella) prevalence,Phenotype,OTU97_31 (Prevotella) prevalence
42751,OTU97_2 (Bacteroides) prevalence,Phenotype,OTU97_2 (Bacteroides) prevalence
42752,OTU97_21 (Parasutterella) prevalence,Phenotype,OTU97_21 (Parasutterella) prevalence
42754,OTU97_354 (Alloprevotella) prevalence,Phenotype,OTU97_354 (Alloprevotella) prevalence
42756,OTU97_38 (Alphaproteobacteria) prevalence,Phenotype,OTU97_38 (Alphaproteobacteria) prevalence
42758,OTU99_124 (Paraprevotella) prevalence,Phenotype,OTU99_124 (Paraprevotella) prevalence
42760,OTU99_132 (Bacteroidales) prevalence,Phenotype,OTU99_132 (Bacteroidales) prevalence
42763,Urinary metabolite levels in chronic kidney disease,Phenotype,Urinary metabolite levels in chronic kidney disease
42764,Fish- and plant-related diet,Phenotype,Fish- and plant-related diet
42765,Oily fish consumption,Phenotype,Oily fish consumption
42766,Non-oily fish consumption,Phenotype,Non-oily fish consumption
42767,Lamb consumption,Phenotype,Lamb consumption
42768,Beef consumption,Phenotype,Beef consumption
42769,HDL cholesterol levels x short total sleep time interaction (2df test),Phenotype,HDL cholesterol levels x short total sleep time interaction (2df test)
42770,Kidney stones,Phenotype,Kidney stones
42792,Trunk fat mass adjusted for trunk lean mass,Phenotype,Trunk fat mass adjusted for trunk lean mass
42793,Femoral neck bone mineral density and trunk fat mass adjusted by trunk lean mass,Phenotype,Femoral neck bone mineral density and trunk fat mass adjusted by trunk lean mass
42794,Serum alkaline phosphatase levels,Phenotype,Serum alkaline phosphatase levels
42797,Hemoglobin A1c levels,Phenotype,Hemoglobin A1c levels
42800,Parkinson's disease (age of onset),Phenotype,Parkinson's disease (age of onset)
42801,Birth weight (MTAG),Phenotype,Birth weight (MTAG)
42802,Birth length (MTAG),Phenotype,Birth length (MTAG)
42803,Infant head circumference (MTAG),Phenotype,Infant head circumference (MTAG)
42804,Skin pigmentation (conditioned on rs1426654 and rs35397),Phenotype,Skin pigmentation (conditioned on rs1426654 and rs35397)
42813,Facial morphology,Phenotype,Facial morphology
42814,Serum metabolite levels (CMS),Phenotype,Serum metabolite levels (CMS)
42815,Café-au-lait macule number in neurofibromatosis type1,Phenotype,Café-au-lait macule number in neurofibromatosis type1
42816,Basophil count,Phenotype,Basophil count
42820,Household income (MTAG),Phenotype,Household income (MTAG)
42821,Excessive sweating,Phenotype,Excessive sweating
42823,Self-reported risk-taking behaviour,Phenotype,Self-reported risk-taking behaviour
42826,Mucinous adenocarcinoma in colorectal cancer,Phenotype,Mucinous adenocarcinoma in colorectal cancer
42827,Cerebrospinal fluid α-synuclein levels,Phenotype,Cerebrospinal fluid α-synuclein levels
42831,Cleft lip with or without cleft palate x maternal periconceptional vitamin use interaction (parent of origin effect),Phenotype,Cleft lip with or without cleft palate x maternal periconceptional vitamin use interaction (parent of origin effect)
42832,Type 1 diabetes in high risk HLA genotype individuals (time to event),Phenotype,Type 1 diabetes in high risk HLA genotype individuals (time to event)
42833,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event),Phenotype,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)
42834,White matter microstructure (mean diusivities),Phenotype,White matter microstructure (mean diusivities)
42835,Leukocyte telomere length,Phenotype,Leukocyte telomere length
42836,Serum cancer antigen 125 (CA 125) levels,Phenotype,Serum cancer antigen 125 (CA 125) levels
42837,Osteoarthritis of the hand,Phenotype,Osteoarthritis of the hand
42838,Household income,Phenotype,Household income
42839,Osteoporosis-related phenotypes (MTAG),Phenotype,Osteoporosis-related phenotypes (MTAG)
42840,Urinary calcium excretion,Phenotype,Urinary calcium excretion
42841,Urinary magnesium excretion,Phenotype,Urinary magnesium excretion
42842,Urinary volume,Phenotype,Urinary volume
42847,Hay fever and/or eczema,Phenotype,Hay fever and/or eczema
42862,Insulin-related traits (multivariate analysis),Phenotype,Insulin-related traits (multivariate analysis)
42897,Clozapine-induced myocarditis in schizophrenia,Phenotype,Clozapine-induced myocarditis in schizophrenia
42941,TestASV_33 (Paraprevotella) prevalence,Phenotype,TestASV_33 (Paraprevotella) prevalence
42943,TestASV_30 (Paraprevotella) prevalence,Phenotype,TestASV_30 (Paraprevotella) prevalence
42945,TestASV_48 (Sutterella) abundance,Phenotype,TestASV_48 (Sutterella) abundance
42947,TestASV_42 (Alphaproteobacteria) abundance,Phenotype,TestASV_42 (Alphaproteobacteria) abundance
42948,TestASV_39 (Bacteroides) abundance,Phenotype,TestASV_39 (Bacteroides) abundance
42950,TestASV_44 (Parasutterella) abundance,Phenotype,TestASV_44 (Parasutterella) abundance
42952,TestASV_46 (Sutterella) abundance,Phenotype,TestASV_46 (Sutterella) abundance
42954,Bipolar disorder or body mass index,Phenotype,Bipolar disorder or body mass index
42955,OTU97_58 (Sutterellaceae) prevalence,Phenotype,OTU97_58 (Sutterellaceae) prevalence
42956,OTU97_6 (Sutterella) prevalence,Phenotype,OTU97_6 (Sutterella) prevalence
42958,OTU97_39 (Proteobacteria) prevalence,Phenotype,OTU97_39 (Proteobacteria) prevalence
42959,OTU97_51 (Barnesiella) prevalence,Phenotype,OTU97_51 (Barnesiella) prevalence
42961,TestASV_6 (Subdoligranulum) prevalence,Phenotype,TestASV_6 (Subdoligranulum) prevalence
42963,TestASV_47 (Parasutterella) prevalence,Phenotype,TestASV_47 (Parasutterella) prevalence
42964,Low HDL-cholesterol levels,Phenotype,Low HDL-cholesterol levels
42965,Graft survival time in renal transplantation (donor effect),Phenotype,Graft survival time in renal transplantation (donor effect)
42966,Graft survival time in renal transplantation (donor effect) x APOL1 genotype interaction,Phenotype,Graft survival time in renal transplantation (donor effect) x APOL1 genotype interaction
42967,Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker,Phenotype,Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker
42968,Fruit consumption,Phenotype,Fruit consumption
42969,Fractures,Phenotype,Fractures
42970,TestASV_2 (Bacteroides) abundance,Phenotype,TestASV_2 (Bacteroides) abundance
42972,TestASV_20 (Phascolarctobacterium) abundance,Phenotype,TestASV_20 (Phascolarctobacterium) abundance
42974,TestASV_21 (Ruminococcaceae) abundance,Phenotype,TestASV_21 (Ruminococcaceae) abundance
42976,TestASV_24 (Bacteroides) abundance,Phenotype,TestASV_24 (Bacteroides) abundance
42977,OTU97_80 (Ruminococcus) prevalence,Phenotype,OTU97_80 (Ruminococcus) prevalence
42979,OTU99_106 (Barnesiella) prevalence,Phenotype,OTU99_106 (Barnesiella) prevalence
42981,OTU99_108 (Cytophagales) prevalence,Phenotype,OTU99_108 (Cytophagales) prevalence
42983,OTU97_95 (Cytophagales) prevalence,Phenotype,OTU97_95 (Cytophagales) prevalence
42984,Survival in breast cancer (estrogen-receptor positive),Phenotype,Survival in breast cancer (estrogen-receptor positive)
42985,Suicidal or self-harm ideation,Phenotype,Suicidal or self-harm ideation
42986,Compulsion score in obsessive compulsive disorder,Phenotype,Compulsion score in obsessive compulsive disorder
42987,Meat-related diet,Phenotype,Meat-related diet
42988,Pork consumption,Phenotype,Pork consumption
42989,Coronary artery disease in type 1 diabetes,Phenotype,Coronary artery disease in type 1 diabetes
42990,TestASV_10 (Parabacteroides) abundance,Phenotype,TestASV_10 (Parabacteroides) abundance
42992,OTU99_92 (Ruminococcus) abundance,Phenotype,OTU99_92 (Ruminococcus) abundance
42994,TestASV_16 (Bacteroides) abundance,Phenotype,TestASV_16 (Bacteroides) abundance
42996,OTU99_84 (Prevotella) abundance,Phenotype,OTU99_84 (Prevotella) abundance
42998,G_Coprococcus prevalence,Phenotype,G_Coprococcus prevalence
43001,G_Parasutterella prevalence,Phenotype,G_Parasutterella prevalence
43003,G_Prevotella prevalence,Phenotype,G_Prevotella prevalence
43004,G_Bacteroidales prevalence,Phenotype,G_Bacteroidales prevalence
43006,G_Catenibacterium prevalence,Phenotype,G_Catenibacterium prevalence
43008,OTU97_137 (Catenibacterium) prevalence,Phenotype,OTU97_137 (Catenibacterium) prevalence
43009,OTU97_138 (Oscillibacter) prevalence,Phenotype,OTU97_138 (Oscillibacter) prevalence
43011,OTU97_150 (Bacteroides) prevalence,Phenotype,OTU97_150 (Bacteroides) prevalence
43013,OTU97_16 (Faecalibacterium) prevalence,Phenotype,OTU97_16 (Faecalibacterium) prevalence
43015,OTU97_13 (Subdoligranulum) prevalence,Phenotype,OTU97_13 (Subdoligranulum) prevalence
43017,Lung function,Phenotype,Lung function
43018,Hypertriglyceridemia,Phenotype,Hypertriglyceridemia
43019,Urinary metabolite modules (eigenmetabolites) in chronic kidney disease,Phenotype,Urinary metabolite modules (eigenmetabolites) in chronic kidney disease
43020,Serum immune biomarker levels,Phenotype,Serum immune biomarker levels
43021,Cerebrospinal fluid immune biomarker levels,Phenotype,Cerebrospinal fluid immune biomarker levels
43022,Epilepsy,Phenotype,Epilepsy
43023,Juvenile myoclonic epilepsy,Phenotype,Juvenile myoclonic epilepsy
43024,Focal epilepsy (with hippocampal sclerosis),Phenotype,Focal epilepsy (with hippocampal sclerosis)
43025,Generalized epilepsy,Phenotype,Generalized epilepsy
43026,Taste perception (total score including phenylthiocarbamide) in obesity with metabolic syndrome,Phenotype,Taste perception (total score including phenylthiocarbamide) in obesity with metabolic syndrome
43027,Aspartate aminotransferase levels in low alcohol consumption,Phenotype,Aspartate aminotransferase levels in low alcohol consumption
43028,Blood metabolite levels,Phenotype,Blood metabolite levels
43029,Youthful appearance (self-reported),Phenotype,Youthful appearance (self-reported)
43030,White matter hyperintensities,Phenotype,White matter hyperintensities
43031,White matter integrity (fractional anisotropy),Phenotype,White matter integrity (fractional anisotropy)
43032,White matter integrity (mean diffusivity),Phenotype,White matter integrity (mean diffusivity)
43033,Cutaneous malignant melanoma,Phenotype,Cutaneous malignant melanoma
43034,Cutaneous melanoma or hair colour,Phenotype,Cutaneous melanoma or hair colour
43035,Nevus count or cutaneous melanoma,Phenotype,Nevus count or cutaneous melanoma
43038,Neuropathologic traits (pleiotropy),Phenotype,Neuropathologic traits (pleiotropy)
43039,Microscopic brain infarct,Phenotype,Microscopic brain infarct
43040,Macroscopic brain infarct,Phenotype,Macroscopic brain infarct
43043,Neuritic plaque,Phenotype,Neuritic plaque
43046,Diffuse plaques,Phenotype,Diffuse plaques
43048,Neurofibrillary tangles,Phenotype,Neurofibrillary tangles
43049,COVID-19 (critical illness vs population),Phenotype,COVID-19 (critical illness vs population)
43051,JT interval,Phenotype,JT interval
43052,Sleep (1/2-day periodicity),Phenotype,Sleep (1/2-day periodicity)
43053,Sleep activity levels,Phenotype,Sleep activity levels
43054,Sleep start time,Phenotype,Sleep start time
43055,LDL cholesterol levels x short total sleep time interaction (2df test),Phenotype,LDL cholesterol levels x short total sleep time interaction (2df test)
43056,Triglyceride levels x long total sleep time interaction (2df test),Phenotype,Triglyceride levels x long total sleep time interaction (2df test)
43057,Triglyceride levels x short total sleep time interaction (2df test),Phenotype,Triglyceride levels x short total sleep time interaction (2df test)
43058,LDL cholesterol levels x short total sleep time interaction (1df test),Phenotype,LDL cholesterol levels x short total sleep time interaction (1df test)
43059,LDL cholesterol levels x loop diuretics use interaction,Phenotype,LDL cholesterol levels x loop diuretics use interaction
43060,Triglyceride levels x loop diuretics use interaction,Phenotype,Triglyceride levels x loop diuretics use interaction
43061,Brainstem volume,Phenotype,Brainstem volume
43062,Putamen volume,Phenotype,Putamen volume
43063,Cortical surface area (visual PC2),Phenotype,Cortical surface area (visual PC2)
43064,Cortical surface area (global PC1),Phenotype,Cortical surface area (global PC1)
43065,Response to lamotrigine and valproic acid in genetic generalized epilepsy,Phenotype,Response to lamotrigine and valproic acid in genetic generalized epilepsy
43066,Leisure sedentary behaviour (television watching),Phenotype,Leisure sedentary behaviour (television watching)
43067,Bone mineral density (hip) and hip bone size,Phenotype,Bone mineral density (hip) and hip bone size
43068,Leisure sedentary behaviour (computer use),Phenotype,Leisure sedentary behaviour (computer use)
43069,Complement factor H binding to malondialdehyde,Phenotype,Complement factor H binding to malondialdehyde
43070,LDL cholesterol levels x long total sleep time interaction (2df test),Phenotype,LDL cholesterol levels x long total sleep time interaction (2df test)
43071,Circulating leptin levels in high cardiovascular risk,Phenotype,Circulating leptin levels in high cardiovascular risk
43111,MHC class I polypeptide-related sequence A levels,Phenotype,MHC class I polypeptide-related sequence A levels
43112,CCL19 levels,Phenotype,CCL19 levels
43113,Protein level change in low calorie diet obesity intervention,Phenotype,Protein level change in low calorie diet obesity intervention
43114,Protein levels in obesity,Phenotype,Protein levels in obesity
43137,High myopia,Phenotype,High myopia
43138,Retinal detachment or retinal break,Phenotype,Retinal detachment or retinal break
43139,Cataracts (operation),Phenotype,Cataracts (operation)
43140,Buruli ulcer (age at onset),Phenotype,Buruli ulcer (age at onset)
43141,Hip bone size,Phenotype,Hip bone size
43142,Primary biliary cirrhosis,Phenotype,Primary biliary cirrhosis
43143,Adipose morphology,Phenotype,Adipose morphology
43144,Vascular endothelial growth factor levels in major depressive disorder,Phenotype,Vascular endothelial growth factor levels in major depressive disorder
43145,Glaucoma (multi-trait analysis),Phenotype,Glaucoma (multi-trait analysis)
43146,Relative fat intake,Phenotype,Relative fat intake
43147,Relative carbohydrate intake,Phenotype,Relative carbohydrate intake
43148,Relative sugar intake,Phenotype,Relative sugar intake
43149,Carotid intima media thickness (mean),Phenotype,Carotid intima media thickness (mean)
43150,Carotid intima media thickness (mean-maximum),Phenotype,Carotid intima media thickness (mean-maximum)
43151,Ebbinghaus illusion (underestimation),Phenotype,Ebbinghaus illusion (underestimation)
43152,Ebbinghaus illusion (overestimation),Phenotype,Ebbinghaus illusion (overestimation)
43153,OTU97_86 (Phascolarctobacterium) abundance,Phenotype,OTU97_86 (Phascolarctobacterium) abundance
43155,TPE interval (resting),Phenotype,TPE interval (resting)
43156,OTU99_116 (Sutterella) abundance,Phenotype,OTU99_116 (Sutterella) abundance
43158,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies),Phenotype,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies)
43159,Pepsinogen I/II ratio,Phenotype,Pepsinogen I/II ratio
43160,Eosinophilic esophagitis,Phenotype,Eosinophilic esophagitis
43161,Lifetime smoking index,Phenotype,Lifetime smoking index
43166,OTU99_23 (Faecalibacterium) abundance,Phenotype,OTU99_23 (Faecalibacterium) abundance
43168,OTU99_132 (Bacteroidales) abundance,Phenotype,OTU99_132 (Bacteroidales) abundance
43170,OTU99_137 (Ruminococcus) abundance,Phenotype,OTU99_137 (Ruminococcus) abundance
43171,OTU99_150 (Prevotella) abundance,Phenotype,OTU99_150 (Prevotella) abundance
43172,Childhood obesity,Phenotype,Childhood obesity
43173,Proliferative diabetic retinopathy,Phenotype,Proliferative diabetic retinopathy
43174,Bipolar I disorder,Phenotype,Bipolar I disorder
43175,Age-related hearing impairment (high frequency),Phenotype,Age-related hearing impairment (high frequency)
43179,Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive),Phenotype,Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive)
43180,Eosinophilic granulomatosis with polyangiitis (ANCA negative),Phenotype,Eosinophilic granulomatosis with polyangiitis (ANCA negative)
43181,Eosinophilic granulomatosis with polyangiitis,Phenotype,Eosinophilic granulomatosis with polyangiitis
43182,Smoking status (current vs never),Phenotype,Smoking status (current vs never)
43185,BMI in adult survivors of childhood acute lymphoblastic leukemia,Phenotype,BMI in adult survivors of childhood acute lymphoblastic leukemia
43186,Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders),Phenotype,Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)
43187,Response to antidepressants (non-treatment-resistant vs treatment-resistant depression),Phenotype,Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)
43188,Mastocytosis (KIT D816V positive),Phenotype,Mastocytosis (KIT D816V positive)
43189,Fasting insulin,Phenotype,Fasting insulin
43190,Plasma free amino acid levels (adjusted for twenty other PFAAs),Phenotype,Plasma free amino acid levels (adjusted for twenty other PFAAs)
43191,Eye color (brightness),Phenotype,Eye color (brightness)
43192,Plasma free amino acid levels (adjusted for one other PFAA),Phenotype,Plasma free amino acid levels (adjusted for one other PFAA)
43193,Skin-- hair and eye pigmentation (multivariate analysis),Phenotype,Skin-- hair and eye pigmentation (multivariate analysis)
43194,Plasma free amino acid levels,Phenotype,Plasma free amino acid levels
43195,Body fat distribution (arm fat ratio),Phenotype,Body fat distribution (arm fat ratio)
43196,Glucagon levels in response to oral glucose tolerance test (30 minutes),Phenotype,Glucagon levels in response to oral glucose tolerance test (30 minutes)
43197,Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-30 minutes),Phenotype,Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-30 minutes)
43198,Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-120 minutes),Phenotype,Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-120 minutes)
43199,Glucagon levels in response to oral glucose tolerance test (fasting),Phenotype,Glucagon levels in response to oral glucose tolerance test (fasting)
43200,Glucagon levels in response to oral glucose tolerance test (120 minutes),Phenotype,Glucagon levels in response to oral glucose tolerance test (120 minutes)
43201,Body fat distribution (leg fat ratio),Phenotype,Body fat distribution (leg fat ratio)
43202,HDL cholesterol x physical activity interaction (2df test),Phenotype,HDL cholesterol x physical activity interaction (2df test)
43203,LDL cholesterol x physical activity interaction (2df test),Phenotype,LDL cholesterol x physical activity interaction (2df test)
43204,Triglycerides x physical activity interaction (2df test),Phenotype,Triglycerides x physical activity interaction (2df test)
43205,Body fat distribution (trunk fat ratio),Phenotype,Body fat distribution (trunk fat ratio)
43206,Staphylococcus aureus nasal carriage (intermittent),Phenotype,Staphylococcus aureus nasal carriage (intermittent)
43207,Pediatric autoimmune diseases,Phenotype,Pediatric autoimmune diseases
43208,Postoperative atrial fibrillation in coronary artery bypass grafting surgery,Phenotype,Postoperative atrial fibrillation in coronary artery bypass grafting surgery
43209,Rotator cuff tears,Phenotype,Rotator cuff tears
43210,Influenza A (H1N1) infection,Phenotype,Influenza A (H1N1) infection
43211,Mild influenza (H1N1) infection,Phenotype,Mild influenza (H1N1) infection
43212,Severe influenza A (H1N1) infection,Phenotype,Severe influenza A (H1N1) infection
43213,Urinary metabolites,Phenotype,Urinary metabolites
43214,Bone mineral density (hip) and age at menarche,Phenotype,Bone mineral density (hip) and age at menarche
43215,Scalp hair shape,Phenotype,Scalp hair shape
43216,Eyebrow thickness,Phenotype,Eyebrow thickness
43217,Monobrow thickness,Phenotype,Monobrow thickness
43218,Beard thickness,Phenotype,Beard thickness
43219,Hair greying,Phenotype,Hair greying
43220,Gut microbiome composition (winter),Phenotype,Gut microbiome composition (winter)
43221,Gut microbiome composition (summer),Phenotype,Gut microbiome composition (summer)
43222,Thrombosis,Phenotype,Thrombosis
43223,Squamous cell carcinoma,Phenotype,Squamous cell carcinoma
43224,Low high density lipoprotein cholesterol levels,Phenotype,Low high density lipoprotein cholesterol levels
43225,Advanced age-related macular degeneration,Phenotype,Advanced age-related macular degeneration
43226,Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging),Phenotype,Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)
43227,Cognitive decline rate in late mild cognitive impairment,Phenotype,Cognitive decline rate in late mild cognitive impairment
43228,Glomerular filtration rate in non diabetics (creatinine),Phenotype,Glomerular filtration rate in non diabetics (creatinine)
43229,Glomerular filtration rate in diabetics (creatinine),Phenotype,Glomerular filtration rate in diabetics (creatinine)
43230,Glomerular filtration rate (creatinine),Phenotype,Glomerular filtration rate (creatinine)
43231,Myositis,Phenotype,Myositis
43232,Parkinson disease and lewy body pathology,Phenotype,Parkinson disease and lewy body pathology
43233,Oligoclonal band status in multiple sclerosis,Phenotype,Oligoclonal band status in multiple sclerosis
43234,Immunoglobulin G index levels in multiple sclerosis,Phenotype,Immunoglobulin G index levels in multiple sclerosis
43235,Motion sickness,Phenotype,Motion sickness
43236,Depressive symptoms (SSRI exposure interaction),Phenotype,Depressive symptoms (SSRI exposure interaction)
43237,Exudative age-related macular degeneration,Phenotype,Exudative age-related macular degeneration
43238,Takayasu arteritis,Phenotype,Takayasu arteritis
43239,Adenocarcinoma,Phenotype,Adenocarcinoma
43240,Ischemic stroke (cardioembolic),Phenotype,Ischemic stroke (cardioembolic)
43241,Ischemic stroke (undetermined subtype),Phenotype,Ischemic stroke (undetermined subtype)
43242,Cerebral amyloid deposition (PET imaging),Phenotype,Cerebral amyloid deposition (PET imaging)
43243,antipsychotic drug dosage in schizophrenia or schizoaffective disorder,Phenotype,antipsychotic drug dosage in schizophrenia or schizoaffective disorder
43244,Alzheimer disease and age of onset,Phenotype,Alzheimer disease and age of onset
43245,Morning vs. evening chronotype,Phenotype,Morning vs. evening chronotype
43246,Chronotype,Phenotype,Chronotype
43247,Obstructive sleep apnea (average oxygen saturation during sleep),Phenotype,Obstructive sleep apnea (average oxygen saturation during sleep)
43248,Obstructive sleep apnea trait (average respiratory event duration),Phenotype,Obstructive sleep apnea trait (average respiratory event duration)
43249,Post bronchodilator FEV1 in COPD,Phenotype,Post bronchodilator FEV1 in COPD
43250,Gut microbiome composition (summer and winter),Phenotype,Gut microbiome composition (summer and winter)
43251,Bone mineral density (femoral neck),Phenotype,Bone mineral density (femoral neck)
43252,Entorhinal cortical volume,Phenotype,Entorhinal cortical volume
43253,Total ventricular volume,Phenotype,Total ventricular volume
43254,Entorhinal cortical volume (Alzheimer's disease interaction),Phenotype,Entorhinal cortical volume (Alzheimer's disease interaction)
43255,Body mass index (age interaction),Phenotype,Body mass index (age interaction)
43256,Exploratory eye movement dysfunction in schizophrenia (mean eye scanning length),Phenotype,Exploratory eye movement dysfunction in schizophrenia (mean eye scanning length)
43257,Exploratory eye movement dysfunction in schizophrenia (number of eye fixations),Phenotype,Exploratory eye movement dysfunction in schizophrenia (number of eye fixations)
43258,Exploratory eye movement dysfunction in schizophrenia (responsive search score),Phenotype,Exploratory eye movement dysfunction in schizophrenia (responsive search score)
43259,Early childhood aggressive behavior,Phenotype,Early childhood aggressive behavior
43260,Childhood and early adolescence aggressive behavior,Phenotype,Childhood and early adolescence aggressive behavior
43261,Exploratory eye movement dysfunction in schizophrenia (cognitive search score),Phenotype,Exploratory eye movement dysfunction in schizophrenia (cognitive search score)
43262,Systolic blood pressure (cigarette smoking interaction),Phenotype,Systolic blood pressure (cigarette smoking interaction)
43263,Response to anti-TNF therapy in rheumatoid arthritis,Phenotype,Response to anti-TNF therapy in rheumatoid arthritis
43264,Manic episodes in bipolar disorder,Phenotype,Manic episodes in bipolar disorder
43265,Depressive episodes in bipolar disorder,Phenotype,Depressive episodes in bipolar disorder
43266,Depressive and manic episodes in bipolar disorder,Phenotype,Depressive and manic episodes in bipolar disorder
43267,Glucocorticoid-induced osteonecrosis,Phenotype,Glucocorticoid-induced osteonecrosis
43268,Incident coronary heart disease,Phenotype,Incident coronary heart disease
43269,Incident myocardial infarction,Phenotype,Incident myocardial infarction
43270,Urinary albumin-to-creatinine ratio in non-diabetics,Phenotype,Urinary albumin-to-creatinine ratio in non-diabetics
43271,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab),Phenotype,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)
43272,Emphysema imaging phenotypes,Phenotype,Emphysema imaging phenotypes
43273,Percentage gas trapping,Phenotype,Percentage gas trapping
43274,Hippocampal sclerosis,Phenotype,Hippocampal sclerosis
43275,Cerebral amyloid angiopathy,Phenotype,Cerebral amyloid angiopathy
43276,Narcolepsy with cataplexy,Phenotype,Narcolepsy with cataplexy
43277,3-hydroxypropylmercapturic acid levels in smokers,Phenotype,3-hydroxypropylmercapturic acid levels in smokers
43278,Asparaginase hypersensitivity in acute lymphoblastic leukemia,Phenotype,Asparaginase hypersensitivity in acute lymphoblastic leukemia
43279,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,Phenotype,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
43280,Multiple myeloma and monoclonal gammopathy,Phenotype,Multiple myeloma and monoclonal gammopathy
43281,Sex hormone levels,Phenotype,Sex hormone levels
43282,Response to simvastatin treatment (PCSK9 protein level change),Phenotype,Response to simvastatin treatment (PCSK9 protein level change)
43283,Yu-Zhi constitution type in type 2 diabetes,Phenotype,Yu-Zhi constitution type in type 2 diabetes
43284,Multiple myeloma (survival),Phenotype,Multiple myeloma (survival)
43285,Colorectal or endometrial cancer,Phenotype,Colorectal or endometrial cancer
43286,Glomerular filtration rate in chronic kidney disease,Phenotype,Glomerular filtration rate in chronic kidney disease
43287,Proteinuria in chronic kidney disease,Phenotype,Proteinuria in chronic kidney disease
43288,Dementia and core Alzheimer's disease neuropathologic changes,Phenotype,Dementia and core Alzheimer's disease neuropathologic changes
43289,Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis,Phenotype,Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis
43290,Skin colour saturation,Phenotype,Skin colour saturation
43291,Perceived skin darkness,Phenotype,Perceived skin darkness
43292,Forced expiratory volume in 1 second (occupational environmental exposures interaction),Phenotype,Forced expiratory volume in 1 second (occupational environmental exposures interaction)
43293,Classic bladder exstrophy,Phenotype,Classic bladder exstrophy
43294,Response to zileuton treatment in asthma (FEV1 change interaction),Phenotype,Response to zileuton treatment in asthma (FEV1 change interaction)
43295,Bone mineral accretion in asthma (oral corticosteroid dose interaction),Phenotype,Bone mineral accretion in asthma (oral corticosteroid dose interaction)
43296,Erythema nodosum in inflammatory bowel disease,Phenotype,Erythema nodosum in inflammatory bowel disease
43297,Peak creatinine levels in vancomycin therapy,Phenotype,Peak creatinine levels in vancomycin therapy
43298,Epilepsy and lamotrigine-induced maculopapular eruptions,Phenotype,Epilepsy and lamotrigine-induced maculopapular eruptions
43299,Blond vs non-blond hair color,Phenotype,Blond vs non-blond hair color
43300,Brown vs. non-brown hair color,Phenotype,Brown vs. non-brown hair color
43301,Light vs. dark hair color,Phenotype,Light vs. dark hair color
43302,Black vs. non-black hair color,Phenotype,Black vs. non-black hair color
43303,Trichloroethylene-induced hypersensitivity syndrome,Phenotype,Trichloroethylene-induced hypersensitivity syndrome
43304,Attention function in attention deficit hyperactive disorder,Phenotype,Attention function in attention deficit hyperactive disorder
43305,Postprandial triglyceride response to high fat diet meal,Phenotype,Postprandial triglyceride response to high fat diet meal
43306,Left superior temporal gyrus thickness (schizophrenia interaction),Phenotype,Left superior temporal gyrus thickness (schizophrenia interaction)
43307,Diabetic kidney disease,Phenotype,Diabetic kidney disease
43308,Mitral valve prolapse,Phenotype,Mitral valve prolapse
43309,Antipsychotic drug-induced weight gain,Phenotype,Antipsychotic drug-induced weight gain
43310,Antipsychotic drug-induced weight gain (time interaction),Phenotype,Antipsychotic drug-induced weight gain (time interaction)
43311,White matter lesion progression (adjusted for white matter lesion burden at baseline),Phenotype,White matter lesion progression (adjusted for white matter lesion burden at baseline)
43312,Eating disorder in bipolar disorder,Phenotype,Eating disorder in bipolar disorder
43313,Bipolar disorder and eating disorder,Phenotype,Bipolar disorder and eating disorder
43314,Lung disease severity in cystic fibrosis,Phenotype,Lung disease severity in cystic fibrosis
43315,Staphylococcus aureus infection,Phenotype,Staphylococcus aureus infection
43316,Skin and soft tissue Staphylococcus aureus infection,Phenotype,Skin and soft tissue Staphylococcus aureus infection
43317,Soluble receptor for advanced glycation end-product levels,Phenotype,Soluble receptor for advanced glycation end-product levels
43318,Ear morphology,Phenotype,Ear morphology
43319,Lobe size,Phenotype,Lobe size
43320,Lobe attachment,Phenotype,Lobe attachment
43321,Cerebrospinal fluid clusterin levels,Phenotype,Cerebrospinal fluid clusterin levels
43322,Plasma clusterin levels,Phenotype,Plasma clusterin levels
43323,Response to Pazopanib in cancer (hepatotoxicity),Phenotype,Response to Pazopanib in cancer (hepatotoxicity)
43324,Cardiovascular disease in hypertension (calcium channel blocker interaction),Phenotype,Cardiovascular disease in hypertension (calcium channel blocker interaction)
43325,Atopic march,Phenotype,Atopic march
43326,Setpoint viral load in HIV-1 infection,Phenotype,Setpoint viral load in HIV-1 infection
43327,Pelvic organ prolapse (moderate/severe),Phenotype,Pelvic organ prolapse (moderate/severe)
43328,Late-onset myasthenia gravis,Phenotype,Late-onset myasthenia gravis
43329,LDL peak particle diameter (total fat intake interaction),Phenotype,LDL peak particle diameter (total fat intake interaction)
43330,Dysphagia,Phenotype,Dysphagia
43331,Plasma homocysteine levels,Phenotype,Plasma homocysteine levels
43332,Non-cardia gastric cancer,Phenotype,Non-cardia gastric cancer
43333,Thionamide-induced agranulocytosis in Graves' disease,Phenotype,Thionamide-induced agranulocytosis in Graves' disease
43334,Response to lithium treatment in bipolar disorder (dichotomous phenotype),Phenotype,Response to lithium treatment in bipolar disorder (dichotomous phenotype)
43335,Survival in colorectal cancer (distant metastatic),Phenotype,Survival in colorectal cancer (distant metastatic)
43336,Sense of smell,Phenotype,Sense of smell
43337,Osteoarthritis (hip),Phenotype,Osteoarthritis (hip)
43338,Tetanus toxoid IgG concentrations post childhood immunization,Phenotype,Tetanus toxoid IgG concentrations post childhood immunization
43340,Lipoprotein (a) levels in coronary artery disease (percutaneous coronary intervention),Phenotype,Lipoprotein (a) levels in coronary artery disease (percutaneous coronary intervention)
43341,Osteoarthritis of the hip or knee,Phenotype,Osteoarthritis of the hip or knee
43342,3-Indolepropionic acid to L-Valine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to L-Valine ratio in coronary artery disease
43344,3-Indolepropionic acid levels in coronary artery disease,Phenotype,3-Indolepropionic acid levels in coronary artery disease
43346,L-Histidine to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Histidine to 3-Indolepropionic acid ratio in coronary artery disease
43348,3-Indolepropionic acid to LysoPC 16:0 ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to LysoPC 16:0 ratio in coronary artery disease
43349,3-Indolepropionic acid to LysoPC 18:1 ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to LysoPC 18:1 ratio in coronary artery disease
43350,L-Thyroxine to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Thyroxine to 3-Indolepropionic acid ratio in coronary artery disease
43351,Hydrocinnamic acid levels in coronary artery disease,Phenotype,Hydrocinnamic acid levels in coronary artery disease
43352,3-Indolepropionic acid to Trimethylamine N-oxide ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Trimethylamine N-oxide ratio in coronary artery disease
43353,3-Indolepropionic acid to Sarcosine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Sarcosine ratio in coronary artery disease
43354,3-Indolepropionic acid to L-Lysine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to L-Lysine ratio in coronary artery disease
43355,L-Glutamic acid to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Glutamic acid to 3-Indolepropionic acid ratio in coronary artery disease
43356,3-Indolepropionic acid to Adenine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Adenine ratio in coronary artery disease
43357,3-Indolepropionic acid to L-Methionine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to L-Methionine ratio in coronary artery disease
43358,L-Phenylalanine to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Phenylalanine to 3-Indolepropionic acid ratio in coronary artery disease
43359,3-Indolepropionic acid to L-Tyrosine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to L-Tyrosine ratio in coronary artery disease
43360,3-Indolepropionic acid to Phenylpyruvic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Phenylpyruvic acid ratio in coronary artery disease
43361,3-Indolepropionic acid to L-Ornithine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to L-Ornithine ratio in coronary artery disease
43362,L-Glutamine to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Glutamine to 3-Indolepropionic acid ratio in coronary artery disease
43363,3-Indolepropionic acid to Taurocholic acid sodium salt hydrate ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Taurocholic acid sodium salt hydrate ratio in coronary artery disease
43364,Asp-phe to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,Asp-phe to 3-Indolepropionic acid ratio in coronary artery disease
43366,3-Indolepropionic acid to 3--3'--5-Triiodo-L-thyronine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 3--3'--5-Triiodo-L-thyronine ratio in coronary artery disease
43367,D-Arabinose to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,D-Arabinose to 3-Indolepropionic acid ratio in coronary artery disease
43368,L-Threonine to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Threonine to 3-Indolepropionic acid ratio in coronary artery disease
43369,3-Indolepropionic acid to N6-Acetyl-L-lysine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to N6-Acetyl-L-lysine ratio in coronary artery disease
43370,L-Aspartic acid to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Aspartic acid to 3-Indolepropionic acid ratio in coronary artery disease
43371,3-Indolepropionic acid to Uric acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Uric acid ratio in coronary artery disease
43372,3-Indolepropionic acid to D-Fructose ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to D-Fructose ratio in coronary artery disease
43373,L-Tryptophan to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Tryptophan to 3-Indolepropionic acid ratio in coronary artery disease
43374,3-Indolepropionic acid to Choline ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Choline ratio in coronary artery disease
43375,3-Indolepropionic acid to Uridine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Uridine ratio in coronary artery disease
43376,L-Serine to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Serine to 3-Indolepropionic acid ratio in coronary artery disease
43377,3-Indolepropionic acid to S-(5-Adenosy) -L-homocysteine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to S-(5-Adenosy) -L-homocysteine ratio in coronary artery disease
43378,3-Indolepropionic acid to D-2-Aminobutyric acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to D-2-Aminobutyric acid ratio in coronary artery disease
43379,3-Indolepropionic acid to LysoPC 16:1 ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to LysoPC 16:1 ratio in coronary artery disease
43380,3-Indolepropionic acid to Hippuric acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Hippuric acid ratio in coronary artery disease
43381,3-Indolepropionic acid to Pipecolinic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Pipecolinic acid ratio in coronary artery disease
43382,L-Citrulline to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Citrulline to 3-Indolepropionic acid ratio in coronary artery disease
43383,Response to treatment in irritable bowel syndrome (symptom severity),Phenotype,Response to treatment in irritable bowel syndrome (symptom severity)
43385,Asthma (moderate or severe),Phenotype,Asthma (moderate or severe)
43387,Protein quantitative trait loci (liver),Phenotype,Protein quantitative trait loci (liver)
43388,Circulating fibroblast growth factor 23 levels,Phenotype,Circulating fibroblast growth factor 23 levels
43390,Amygdala volume change rate x age interaction (1df),Phenotype,Amygdala volume change rate x age interaction (1df)
43392,Cerebellum cortex volume change rate x age interaction (1df),Phenotype,Cerebellum cortex volume change rate x age interaction (1df)
43394,Lateral ventricle volume change rate x age interaction (1df),Phenotype,Lateral ventricle volume change rate x age interaction (1df)
43396,Cerebellum white matter volume change rate x age interaction (1df),Phenotype,Cerebellum white matter volume change rate x age interaction (1df)
43398,Cerebral white matter volume change rate x age interaction (1df),Phenotype,Cerebral white matter volume change rate x age interaction (1df)
43401,Cortex volume change rate x age interaction (1df),Phenotype,Cortex volume change rate x age interaction (1df)
43403,Brain surface area change rate x age interaction (1df),Phenotype,Brain surface area change rate x age interaction (1df)
43405,Thalamus volume change rate x age interaction (1df),Phenotype,Thalamus volume change rate x age interaction (1df)
43407,Thalamus volume change rate,Phenotype,Thalamus volume change rate
43409,Total brain volume change rate,Phenotype,Total brain volume change rate
43410,Putamen volume change rate,Phenotype,Putamen volume change rate
43412,Pallidum volume change rate x age interaction (1df),Phenotype,Pallidum volume change rate x age interaction (1df)
43414,Putamen volume change rate x age interaction (1df),Phenotype,Putamen volume change rate x age interaction (1df)
43416,Gut microbiota alpha diversity (Shannon index),Phenotype,Gut microbiota alpha diversity (Shannon index)
43417,Carbamazepine-induced serious cutaneous adverse reaction,Phenotype,Carbamazepine-induced serious cutaneous adverse reaction
43421,Total amyloid (SNP x SNP interaction),Phenotype,Total amyloid (SNP x SNP interaction)
43422,Neurofibrillary tangles (SNP x SNP interaction),Phenotype,Neurofibrillary tangles (SNP x SNP interaction)
43444,Mean spheric corpuscular volume,Phenotype,Mean spheric corpuscular volume
43451,Corneal endothelial cell size variation coefficient,Phenotype,Corneal endothelial cell size variation coefficient
43452,Impulsivity (non-planning),Phenotype,Impulsivity (non-planning)
43453,Lack of premeditation,Phenotype,Lack of premeditation
43454,Negative urgency,Phenotype,Negative urgency
43455,Sweet beverage consumption,Phenotype,Sweet beverage consumption
43456,Sugar-sweetened beverage consumption,Phenotype,Sugar-sweetened beverage consumption
43457,Artificially sweetened beverage consumption,Phenotype,Artificially sweetened beverage consumption
43458,Pure non-grapefruit juice consumption,Phenotype,Pure non-grapefruit juice consumption
43459,Tea consumption,Phenotype,Tea consumption
43460,Grapefruit juice consumption,Phenotype,Grapefruit juice consumption
43461,Lack of perseverance,Phenotype,Lack of perseverance
43462,Impulsivity (attentional),Phenotype,Impulsivity (attentional)
43463,Aspartate aminotransferase levels in non-alcoholic fatty liver disease,Phenotype,Aspartate aminotransferase levels in non-alcoholic fatty liver disease
43464,Alanine aminotransferase levels in non-alcoholic fatty liver disease,Phenotype,Alanine aminotransferase levels in non-alcoholic fatty liver disease
43465,Priapism in sickle cell disease,Phenotype,Priapism in sickle cell disease
43466,Cerebellum white matter volume change rate x age interaction (2df),Phenotype,Cerebellum white matter volume change rate x age interaction (2df)
43468,Cerebral white matter volume change rate x age interaction (2df),Phenotype,Cerebral white matter volume change rate x age interaction (2df)
43469,Cortical thickness change rate x age interaction (2df),Phenotype,Cortical thickness change rate x age interaction (2df)
43471,Short-term memory (digit-span task),Phenotype,Short-term memory (digit-span task)
43472,Rapid automised naming of digits,Phenotype,Rapid automised naming of digits
43473,Rapid automised naming of pictures,Phenotype,Rapid automised naming of pictures
43493,Post-traumatic stress disorder (re-experiencing symptoms),Phenotype,Post-traumatic stress disorder (re-experiencing symptoms)
43494,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event),Phenotype,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event)
43499,Percentage of invited food questionnaires completed,Phenotype,Percentage of invited food questionnaires completed
43500,Acceptance of an invitation to participate in a mental health questionnaire,Phenotype,Acceptance of an invitation to participate in a mental health questionnaire
43501,Blood cell traits (multivariate analysis),Phenotype,Blood cell traits (multivariate analysis)
43502,Emphysema annual change measurement in smokers (adjusted lung density),Phenotype,Emphysema annual change measurement in smokers (adjusted lung density)
43503,Emphysema annual change measurement in smokers (percent low attenuation area),Phenotype,Emphysema annual change measurement in smokers (percent low attenuation area)
43504,Bitter non-alcoholic beverage consumption,Phenotype,Bitter non-alcoholic beverage consumption
43505,Bitter alcoholic beverage consumption,Phenotype,Bitter alcoholic beverage consumption
43509,Estimated glomerular filtration rate,Phenotype,Estimated glomerular filtration rate
43510,Response to treatment in irritable bowel syndrome (pain frequency),Phenotype,Response to treatment in irritable bowel syndrome (pain frequency)
43513,Response to treatment in irritable bowel syndrome (pain severity),Phenotype,Response to treatment in irritable bowel syndrome (pain severity)
43518,3-Indolepropionic acid to L-Pipecolic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to L-Pipecolic acid ratio in coronary artery disease
43519,3-Indolepropionic acid to 3-Hydroxybutyrate ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 3-Hydroxybutyrate ratio in coronary artery disease
43520,3-Indolepropionic acid to (S)-(-)-2-Hydroxyisocaproic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to (S)-(-)-2-Hydroxyisocaproic acid ratio in coronary artery disease
43521,3-Indolepropionic acid to Creatinine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Creatinine ratio in coronary artery disease
43522,L-Pyroglutamic acid to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Pyroglutamic acid to 3-Indolepropionic acid ratio in coronary artery disease
43523,3-Indolepropionic acid to gamma-Linolenic acid (C18:3n6) ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to gamma-Linolenic acid (C18:3n6) ratio in coronary artery disease
43524,3-Indolepropionic acid to N--N-Dimethylglycine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to N--N-Dimethylglycine ratio in coronary artery disease
43525,3-Indolepropionic acid to SubericAcid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to SubericAcid ratio in coronary artery disease
43526,3-Indolepropionic acid to 2-(dimethylamino) guanosine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 2-(dimethylamino) guanosine ratio in coronary artery disease
43527,3-Indolepropionic acid to LysoPC 14:0 ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to LysoPC 14:0 ratio in coronary artery disease
43528,3-Indolepropionic acid to 4-Hydroxybenzaldehyde ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 4-Hydroxybenzaldehyde ratio in coronary artery disease
43529,3-Indolepropionic acid to Azelaic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Azelaic acid ratio in coronary artery disease
43530,3-Indolepropionic acid to cis-5--8--11--14--17-Eicosapentaenoic acid (C20:5n3) ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to cis-5--8--11--14--17-Eicosapentaenoic acid (C20:5n3) ratio in coronary artery disease
43531,3-Indolepropionic acid to Hypoxanthine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Hypoxanthine ratio in coronary artery disease
43532,L-Proline to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Proline to 3-Indolepropionic acid ratio in coronary artery disease
43533,D-Trehalose to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,D-Trehalose to 3-Indolepropionic acid ratio in coronary artery disease
43534,3-Indolepropionic acid to Methylmalonic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Methylmalonic acid ratio in coronary artery disease
43535,3-Indolepropionic acid to alpha-Linolenic acid (C18:3n3) ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to alpha-Linolenic acid (C18:3n3) ratio in coronary artery disease
43536,3-Indolepropionic acid to S-Sulfo-L-cysteine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to S-Sulfo-L-cysteine ratio in coronary artery disease
43537,3-Indolepropionic acid to LysoPC 20:0 ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to LysoPC 20:0 ratio in coronary artery disease
43538,3-Indolepropionic acid to beta-Pseudouridine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to beta-Pseudouridine ratio in coronary artery disease
43539,Dulcitol to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,Dulcitol to 3-Indolepropionic acid ratio in coronary artery disease
43540,3-Indolepropionic acid to 4-Nitrophenol ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 4-Nitrophenol ratio in coronary artery disease
43541,3-Indolepropionic acid to Indole-5-carboxylic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Indole-5-carboxylic acid ratio in coronary artery disease
43542,Pantothenate to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,Pantothenate to 3-Indolepropionic acid ratio in coronary artery disease
43543,3-Indolepropionic acid to L-Saccharopine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to L-Saccharopine ratio in coronary artery disease
43544,3-Indolepropionic acid to 5-oxoproline ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 5-oxoproline ratio in coronary artery disease
43545,L-Asparagine Anhydrous to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Asparagine Anhydrous to 3-Indolepropionic acid ratio in coronary artery disease
43546,3-Indolepropionic acid to Kinurenine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Kinurenine ratio in coronary artery disease
43547,3-Indolepropionic acid to LysoPC 18:0 ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to LysoPC 18:0 ratio in coronary artery disease
43548,3-Indolepropionic acid to L-2-Aminobutyric acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to L-2-Aminobutyric acid ratio in coronary artery disease
43549,3-Indolepropionic acid to 2-Picolinic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 2-Picolinic acid ratio in coronary artery disease
43550,3-Indolepropionic acid to 2-Methylsuccinic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 2-Methylsuccinic acid ratio in coronary artery disease
43551,3-Indolepropionic acid to LysoPC 20:2 ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to LysoPC 20:2 ratio in coronary artery disease
43552,3-Indolepropionic acid to 4-Guanidinobutyric acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 4-Guanidinobutyric acid ratio in coronary artery disease
43553,3-Indolepropionic acid to Isonicotinamide ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Isonicotinamide ratio in coronary artery disease
43554,5-Methyluridine to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,5-Methyluridine to 3-Indolepropionic acid ratio in coronary artery disease
43555,3-Indolepropionic acid to N-acetylglycine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to N-acetylglycine ratio in coronary artery disease
43556,3-Indolepropionic acid to N-Acetyl-L-tyrosine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to N-Acetyl-L-tyrosine ratio in coronary artery disease
43557,L-Cystine to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,L-Cystine to 3-Indolepropionic acid ratio in coronary artery disease
43558,3-Indolepropionic acid to Cyclic AMP ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Cyclic AMP ratio in coronary artery disease
43559,3-Indolepropionic acid to L-Carnitine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to L-Carnitine ratio in coronary artery disease
43560,3-Indolepropionic acid to 1--4-dihydro-1-Methyl-4-oxo-3-pyridinecarboxamide ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 1--4-dihydro-1-Methyl-4-oxo-3-pyridinecarboxamide ratio in coronary artery disease
43561,3-Indolepropionic acid to Creatine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Creatine ratio in coronary artery disease
43562,3-Indolepropionic acid to Dodecanedioic aicd ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Dodecanedioic aicd ratio in coronary artery disease
43563,3-Indolepropionic acid to LysoPC 20:1 ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to LysoPC 20:1 ratio in coronary artery disease
43564,3-Indolepropionic acid to L-Arginine ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to L-Arginine ratio in coronary artery disease
43565,3-Indolepropionic acid to Kynurenic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Kynurenic acid ratio in coronary artery disease
43566,3-Indolepropionic acid to 2-Hydroxyisocaproic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 2-Hydroxyisocaproic acid ratio in coronary artery disease
43567,3-Indolepropionic acid to 4-Pyridoxic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to 4-Pyridoxic acid ratio in coronary artery disease
43568,3-Indolepropionic acid to Lauric acid/Dodecanoic acid (C12:0) ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Lauric acid/Dodecanoic acid (C12:0) ratio in coronary artery disease
43569,3-Indolepropionic acid to Homovanillic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Homovanillic acid ratio in coronary artery disease
43570,N-acetyl-l-leucine to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,N-acetyl-l-leucine to 3-Indolepropionic acid ratio in coronary artery disease
43571,3-Indolepropionic acid to Myoinositol ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Myoinositol ratio in coronary artery disease
43572,3-Indolepropionic acid to Urocanic acid ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Urocanic acid ratio in coronary artery disease
43573,Riboflavin to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,Riboflavin to 3-Indolepropionic acid ratio in coronary artery disease
43574,3-Indolepropionic acid to Maltose ratio in coronary artery disease,Phenotype,3-Indolepropionic acid to Maltose ratio in coronary artery disease
43575,D-Malic acid to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,D-Malic acid to 3-Indolepropionic acid ratio in coronary artery disease
43576,D-Sucrose to 3-Indolepropionic acid ratio in coronary artery disease,Phenotype,D-Sucrose to 3-Indolepropionic acid ratio in coronary artery disease
43577,Caudate volume change rate,Phenotype,Caudate volume change rate
43580,Lateral ventricle volume change rate,Phenotype,Lateral ventricle volume change rate
43582,Pallidum volume change rate,Phenotype,Pallidum volume change rate
43585,Cortex volume change rate,Phenotype,Cortex volume change rate
43587,Cortical thickness change rate,Phenotype,Cortical thickness change rate
43589,Thalamus volume change rate x age interaction (2df),Phenotype,Thalamus volume change rate x age interaction (2df)
43591,Lateral ventricle volume change rate x age interaction (2df),Phenotype,Lateral ventricle volume change rate x age interaction (2df)
43592,Pallidum volume change rate x age interaction (2df),Phenotype,Pallidum volume change rate x age interaction (2df)
43595,Putamen volume change rate x age interaction (2df),Phenotype,Putamen volume change rate x age interaction (2df)
43597,Mortality in COVID-19,Phenotype,Mortality in COVID-19
43610,Alanine aminotransferase levels,Phenotype,Alanine aminotransferase levels
43611,Corneal curvature,Phenotype,Corneal curvature
43614,Gut microbiota relative abundance (Sutterella),Phenotype,Gut microbiota relative abundance (Sutterella)
43615,Gut microbiota relative abundance (Faecalibacterium),Phenotype,Gut microbiota relative abundance (Faecalibacterium)
43616,Gut microbiota relative abundance (Oscillospira),Phenotype,Gut microbiota relative abundance (Oscillospira)
43617,Gut microbiota relative abundance (Eubacterium belonging to family Erysipelotrichaceae),Phenotype,Gut microbiota relative abundance (Eubacterium belonging to family Erysipelotrichaceae)
43618,Gut microbiota alpha diversity (Chao1 index),Phenotype,Gut microbiota alpha diversity (Chao1 index)
43619,Gut microbiota relative abundance (Ruminococcus belonging to family Lachnospiraceae),Phenotype,Gut microbiota relative abundance (Ruminococcus belonging to family Lachnospiraceae)
43622,Cognitive function (generalized correlation coefficient),Phenotype,Cognitive function (generalized correlation coefficient)
43623,Body mass index and systolic blood pressure (bivariate analysis),Phenotype,Body mass index and systolic blood pressure (bivariate analysis)
43624,Body mass index and diastolic blood pressure (bivariate analysis),Phenotype,Body mass index and diastolic blood pressure (bivariate analysis)
43625,Systolic blood pressure and diastolic blood pressure (bivariate analysis),Phenotype,Systolic blood pressure and diastolic blood pressure (bivariate analysis)
43626,Mean reticulocyte volume,Phenotype,Mean reticulocyte volume
43629,Gut microbiota relative abundance (Prevotella),Phenotype,Gut microbiota relative abundance (Prevotella)
43630,Gut microbiota relative abundance (Streptococcus),Phenotype,Gut microbiota relative abundance (Streptococcus)
43632,Atorvastatin-induced myopathy,Phenotype,Atorvastatin-induced myopathy
43633,Self-rated health,Phenotype,Self-rated health
43634,Bone mineral density or leg lean mass (pleiotropy),Phenotype,Bone mineral density or leg lean mass (pleiotropy)
43635,Leg lean mass,Phenotype,Leg lean mass
43636,Anorectal malformation,Phenotype,Anorectal malformation
43638,Iron status biomarkers (total iron binding capacity),Phenotype,Iron status biomarkers (total iron binding capacity)
43660,First fracture in long-term childhood cancer survivors (time to event),Phenotype,First fracture in long-term childhood cancer survivors (time to event)
43661,Cortical volume,Phenotype,Cortical volume
43662,Helicobacter pylori OMP antibody levels,Phenotype,Helicobacter pylori OMP antibody levels
43663,Chlamydia trachomatis PorB antibody levels,Phenotype,Chlamydia trachomatis PorB antibody levels
43664,Epstein-Barr virus EA-D antibody levels,Phenotype,Epstein-Barr virus EA-D antibody levels
43665,Epstein-Barr virus VCA p18 antibody levels,Phenotype,Epstein-Barr virus VCA p18 antibody levels
43666,Epstein-Barr virus ZEBRA antibody levels,Phenotype,Epstein-Barr virus ZEBRA antibody levels
43667,Merkel cell polyomavirus VP1 antibody levels,Phenotype,Merkel cell polyomavirus VP1 antibody levels
43668,Anti-human herpes virus 6 IE1A IgG seropositivity,Phenotype,Anti-human herpes virus 6 IE1A IgG seropositivity
43669,Human herpes virus 6 IE1A antibody levels,Phenotype,Human herpes virus 6 IE1A antibody levels
43670,Varicella zoster virus glycoproteins E and I antibody levels,Phenotype,Varicella zoster virus glycoproteins E and I antibody levels
43671,Helicobacter pylori UREA antibody levels,Phenotype,Helicobacter pylori UREA antibody levels
43672,Anti-polyomavirus 2 IgG seropositivity,Phenotype,Anti-polyomavirus 2 IgG seropositivity
43673,Polyomavirus 2  JC VP1 antibody levels,Phenotype,Polyomavirus 2  JC VP1 antibody levels
43674,Epstein-Barr virus EBNA-1 antibody levels,Phenotype,Epstein-Barr virus EBNA-1 antibody levels
43675,Anti-Merkel cell polyomavirus IgG seropositivity,Phenotype,Anti-Merkel cell polyomavirus IgG seropositivity
43676,Human herpes virus 7 U14 antibody levels,Phenotype,Human herpes virus 7 U14 antibody levels
43677,Anti-varicella zoster virus IgG seropositivity,Phenotype,Anti-varicella zoster virus IgG seropositivity
43678,Opioid use disorder,Phenotype,Opioid use disorder
43679,Gut microbiota relative abundance (unclassified genus belonging to family Lachnospiraceae),Phenotype,Gut microbiota relative abundance (unclassified genus belonging to family Lachnospiraceae)
43680,Gut microbiota relative abundance (Blautia),Phenotype,Gut microbiota relative abundance (Blautia)
43681,Gut microbiota relative abundance (unclassified genus belonging to family Ruminococcaceae),Phenotype,Gut microbiota relative abundance (unclassified genus belonging to family Ruminococcaceae)
43682,Gut microbiota relative abundance (Dorea),Phenotype,Gut microbiota relative abundance (Dorea)
43700,Urolithiasis,Phenotype,Urolithiasis
43701,Arrhythmia,Phenotype,Arrhythmia
43709,Simvastatin-induced myopathy,Phenotype,Simvastatin-induced myopathy
43721,Chronic kidney disease x type 2 diabetes interaction,Phenotype,Chronic kidney disease x type 2 diabetes interaction
43722,Obsessive-compulsive traits,Phenotype,Obsessive-compulsive traits
43723,Interleukin-6 levels,Phenotype,Interleukin-6 levels
43728,Mitochondrial DNA copy number,Phenotype,Mitochondrial DNA copy number
43729,Mitochondrial DNA copy number (white blood cells),Phenotype,Mitochondrial DNA copy number (white blood cells)
43730,Factor VII activity,Phenotype,Factor VII activity
43741,Lean nonalcoholic fatty liver disease,Phenotype,Lean nonalcoholic fatty liver disease
43742,Nonsyndromic cleft palate,Phenotype,Nonsyndromic cleft palate
43752,Differentiated thyroid cancer,Phenotype,Differentiated thyroid cancer
43753,Aspartate aminotransferase levels,Phenotype,Aspartate aminotransferase levels
43757,Beta-2-microglobulin levels,Phenotype,Beta-2-microglobulin levels
43758,C-C motif chemokine 22 levels,Phenotype,C-C motif chemokine 22 levels
43760,C-C motif chemokine 17 levels,Phenotype,C-C motif chemokine 17 levels
43762,Ubiquitin-conjugating enzyme E2 G2 levels,Phenotype,Ubiquitin-conjugating enzyme E2 G2 levels
43767,Ubiquitin carboxyl-terminal hydrolase 25 levels,Phenotype,Ubiquitin carboxyl-terminal hydrolase 25 levels
43775,Post-traumatic stress disorder (MTAG),Phenotype,Post-traumatic stress disorder (MTAG)
43777,Non-HDL cholesterol levels,Phenotype,Non-HDL cholesterol levels
43802,Tryptase beta-2 levels,Phenotype,Tryptase beta-2 levels
43815,GDNF family receptor alpha-1 levels,Phenotype,GDNF family receptor alpha-1 levels
43817,Heparin cofactor 2 levels,Phenotype,Heparin cofactor 2 levels
43820,Thrombospondin-2 levels,Phenotype,Thrombospondin-2 levels
43853,Hazardous alcohol drinking,Phenotype,Hazardous alcohol drinking
43860,Rectal cancer,Phenotype,Rectal cancer
43863,Colorectal cancer vs inflammatory bowel disease,Phenotype,Colorectal cancer vs inflammatory bowel disease
43866,Colorectal cancer vs inflammatory bowel disease or controls,Phenotype,Colorectal cancer vs inflammatory bowel disease or controls
43870,Right colon cancer,Phenotype,Right colon cancer
43872,Left colon cancer,Phenotype,Left colon cancer
43880,HDL cholesterol levels in type 2 diabetes,Phenotype,HDL cholesterol levels in type 2 diabetes
43881,Total cholesterol levels in chylomicrons and extremely large VLDL,Phenotype,Total cholesterol levels in chylomicrons and extremely large VLDL
43883,Cholesteryl esters to total lipids ratio in medium VLDL,Phenotype,Cholesteryl esters to total lipids ratio in medium VLDL
43884,Free cholesterol to total lipids ratio in medium VLDL,Phenotype,Free cholesterol to total lipids ratio in medium VLDL
43886,Free cholesterol in medium VLDL,Phenotype,Free cholesterol in medium VLDL
43888,Cholesterol esters in medium VLDL,Phenotype,Cholesterol esters in medium VLDL
43889,Total cholesterol levels in small HDL,Phenotype,Total cholesterol levels in small HDL
43890,Total cholesterol to total lipids ratio in small HDL,Phenotype,Total cholesterol to total lipids ratio in small HDL
43892,Ratio of saturated fatty acids to total fatty acids,Phenotype,Ratio of saturated fatty acids to total fatty acids
43893,Saturated fatty acids,Phenotype,Saturated fatty acids
43897,Serum total triglyceride levels,Phenotype,Serum total triglyceride levels
43898,Free cholesterol to total lipids ratio in small LDL,Phenotype,Free cholesterol to total lipids ratio in small LDL
43900,Concentration of small LDL particles,Phenotype,Concentration of small LDL particles
43902,Total lipids in small LDL,Phenotype,Total lipids in small LDL
43906,Ischemic stroke (large artery atherosclerosis),Phenotype,Ischemic stroke (large artery atherosclerosis)
43907,Ischemic stroke (small-vessel),Phenotype,Ischemic stroke (small-vessel)
43908,Apolipoprotein A-I levels,Phenotype,Apolipoprotein A-I levels
43910,Systolic blood pressure (BMI adjusted),Phenotype,Systolic blood pressure (BMI adjusted)
43913,Systolic blood pressure (BMI unadjusted),Phenotype,Systolic blood pressure (BMI unadjusted)
43916,Total cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,Phenotype,Total cholesterol to total lipids ratio in chylomicrons and extremely large VLDL
43918,Cholesteryl ester levels in chylomicrons and extremely large VLDL,Phenotype,Cholesteryl ester levels in chylomicrons and extremely large VLDL
43919,Triglycerides to total lipids ratio in very small VLDL,Phenotype,Triglycerides to total lipids ratio in very small VLDL
43920,Triglycerides in very small VLDL,Phenotype,Triglycerides in very small VLDL
43921,Phospholipids in very small VLDL,Phenotype,Phospholipids in very small VLDL
43931,Serum total cholesterol levels,Phenotype,Serum total cholesterol levels
43933,Polyunsaturated fatty acids,Phenotype,Polyunsaturated fatty acids
43934,Remnant cholesterol (non-HDL-- non-LDL -cholesterol),Phenotype,Remnant cholesterol (non-HDL-- non-LDL -cholesterol)
43936,Ratio of polyunsaturated fatty acids to total fatty acids,Phenotype,Ratio of polyunsaturated fatty acids to total fatty acids
43938,Pyruvate levels,Phenotype,Pyruvate levels
43940,Phenylalanine levels,Phenotype,Phenylalanine levels
43943,Cholesterol esters in small LDL,Phenotype,Cholesterol esters in small LDL
43945,Total cholesterol to total lipids ratio in small LDL,Phenotype,Total cholesterol to total lipids ratio in small LDL
43947,Total Cholesterol in small LDL,Phenotype,Total Cholesterol in small LDL
43948,Hashimoto thyroiditis,Phenotype,Hashimoto thyroiditis
43950,Ratio of apolipoprotein B to apolipoprotein A1 levels,Phenotype,Ratio of apolipoprotein B to apolipoprotein A1 levels
43951,Diastolic blood pressure (BMI unadjusted),Phenotype,Diastolic blood pressure (BMI unadjusted)
43956,Coronary artery disease or von Willebrand factor levels (pleiotropy),Phenotype,Coronary artery disease or von Willebrand factor levels (pleiotropy)
43957,Coronary artery disease or factor XI levels (pleiotropy),Phenotype,Coronary artery disease or factor XI levels (pleiotropy)
43964,Unstable angina pectoris,Phenotype,Unstable angina pectoris
43966,acne vulgaris,Phenotype,acne vulgaris
43967,Breast cancer subtype (triple negative vs luminal A-like),Phenotype,Breast cancer subtype (triple negative vs luminal A-like)
43968,Serum albumin levels,Phenotype,Serum albumin levels
43973,Ratio of triglycerides to phosphoglycerides,Phenotype,Ratio of triglycerides to phosphoglycerides
43975,Triglycerides to total lipids ratio in small VLDL,Phenotype,Triglycerides to total lipids ratio in small VLDL
43977,Triglycerides in small VLDL,Phenotype,Triglycerides in small VLDL
43978,Acute radiotoxicity in head and neck cancer,Phenotype,Acute radiotoxicity in head and neck cancer
43980,Acute radiotoxicity in lung cancer,Phenotype,Acute radiotoxicity in lung cancer
43991,Phospholipids in very large VLDL,Phenotype,Phospholipids in very large VLDL
43996,Neovascular age-related macular degeneration,Phenotype,Neovascular age-related macular degeneration
44000,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL,Phenotype,Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL
44001,Free cholesterol levels in chylomicrons and extremely large VLDL,Phenotype,Free cholesterol levels in chylomicrons and extremely large VLDL
44002,Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,Phenotype,Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL
44003,Total lipid levels in chylomicrons and extremely large VLDL,Phenotype,Total lipid levels in chylomicrons and extremely large VLDL
44004,Phospholipid levels in chylomicrons and extremely large VLDL,Phenotype,Phospholipid levels in chylomicrons and extremely large VLDL
44005,Phospholipids to total lipids ratio in medium LDL,Phenotype,Phospholipids to total lipids ratio in medium LDL
44007,Concentration of chylomicrons and extremely large VLDL particles,Phenotype,Concentration of chylomicrons and extremely large VLDL particles
44008,Cholesterol esters in small HDL,Phenotype,Cholesterol esters in small HDL
44009,Cholesteryl esters to total lipids ratio in small HDL,Phenotype,Cholesteryl esters to total lipids ratio in small HDL
44010,Free cholesterol to total lipids ratio in small HDL,Phenotype,Free cholesterol to total lipids ratio in small HDL
44011,Free cholesterol in small HDL,Phenotype,Free cholesterol in small HDL
44014,Total lipids in small HDL,Phenotype,Total lipids in small HDL
44016,Waist-hip index,Phenotype,Waist-hip index
44017,Phospholipids to total lipids ratio in small LDL,Phenotype,Phospholipids to total lipids ratio in small LDL
44018,Phospholipids in small LDL,Phenotype,Phospholipids in small LDL
44019,Triglycerides in small LDL,Phenotype,Triglycerides in small LDL
44023,3-Hydroxybutyrate levels,Phenotype,3-Hydroxybutyrate levels
44024,Conjugated linoleic acid,Phenotype,Conjugated linoleic acid
44029,Diastolic blood pressure (BMI adjusted),Phenotype,Diastolic blood pressure (BMI adjusted)
44032,Nonalcoholic fatty liver disease (imputed),Phenotype,Nonalcoholic fatty liver disease (imputed)
44037,Uterine prolapse,Phenotype,Uterine prolapse
44038,Uveitis,Phenotype,Uveitis
44040,Coronary artery disease or fibrinogen levels (pleiotropy),Phenotype,Coronary artery disease or fibrinogen levels (pleiotropy)
44051,Varicose veins,Phenotype,Varicose veins
44068,Dry eye disease,Phenotype,Dry eye disease
44085,Phospholipids to total lipids ratio in very large HDL,Phenotype,Phospholipids to total lipids ratio in very large HDL
44086,Phospholipids in very large HDL,Phenotype,Phospholipids in very large HDL
44092,Severe COVID-19 infection (severe vs non-severe),Phenotype,Severe COVID-19 infection (severe vs non-severe)
44094,Free cholesterol to total lipids ratio in very small VLDL,Phenotype,Free cholesterol to total lipids ratio in very small VLDL
44096,Free cholesterol in very small VLDL,Phenotype,Free cholesterol in very small VLDL
44097,Concentration of very small VLDL particles,Phenotype,Concentration of very small VLDL particles
44098,Total lipids in very small VLDL,Phenotype,Total lipids in very small VLDL
44099,Total fatty acids,Phenotype,Total fatty acids
44100,Total phosphoglycerides levels,Phenotype,Total phosphoglycerides levels
44103,Tyrosine levels,Phenotype,Tyrosine levels
44105,Estimated degree of unsaturation,Phenotype,Estimated degree of unsaturation
44106,Total cholines levels,Phenotype,Total cholines levels
44108,Cholesterol esters in very small VLDL,Phenotype,Cholesterol esters in very small VLDL
44110,Total cholesterol to total lipids ratio in very small VLDL,Phenotype,Total cholesterol to total lipids ratio in very small VLDL
44111,Cholesteryl esters to total lipids ratio in very small VLDL,Phenotype,Cholesteryl esters to total lipids ratio in very small VLDL
44112,Triglycerides to total lipids ratio in very large VLDL,Phenotype,Triglycerides to total lipids ratio in very large VLDL
44113,Triglycerides in very large VLDL,Phenotype,Triglycerides in very large VLDL
44114,Total cholesterol in very small VLDL,Phenotype,Total cholesterol in very small VLDL
44115,Triglycerides to total lipids ratio in medium LDL,Phenotype,Triglycerides to total lipids ratio in medium LDL
44117,Triglycerides in medium LDL,Phenotype,Triglycerides in medium LDL
44118,Monounsaturated fatty acids (16:1-- 18:1) levels,Phenotype,Monounsaturated fatty acids (16:1-- 18:1) levels
44119,Ratio of monounsaturated fatty acids to total fatty acids,Phenotype,Ratio of monounsaturated fatty acids to total fatty acids
44122,Triglycerides to total lipids ratio in medium VLDL,Phenotype,Triglycerides to total lipids ratio in medium VLDL
44123,Phospholipids to total lipids ratio in medium VLDL,Phenotype,Phospholipids to total lipids ratio in medium VLDL
44124,Triglycerides in medium VLDL,Phenotype,Triglycerides in medium VLDL
44125,Phosphatidylcholine and other choline levels,Phenotype,Phosphatidylcholine and other choline levels
44126,Phospholipids in medium VLDL,Phenotype,Phospholipids in medium VLDL
44127,Cholesteryl esters to total lipids ratio in small LDL,Phenotype,Cholesteryl esters to total lipids ratio in small LDL
44128,Free cholesterol in small LDL,Phenotype,Free cholesterol in small LDL
44129,Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL,Phenotype,Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL
44131,Triglyceride levels in chylomicrons and extremely large VLDL,Phenotype,Triglyceride levels in chylomicrons and extremely large VLDL
44133,Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL,Phenotype,Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL
44134,Acetate levels,Phenotype,Acetate levels
44136,Total cholesterol in small VLDL,Phenotype,Total cholesterol in small VLDL
44137,Alanine levels,Phenotype,Alanine levels
44142,Omega-3 fatty acids levels,Phenotype,Omega-3 fatty acids levels
44143,Ratio of omega-3 fatty acids to total fatty acids,Phenotype,Ratio of omega-3 fatty acids to total fatty acids
44144,Omega-6 fatty acids levels,Phenotype,Omega-6 fatty acids levels
44146,Mean arterial pressure (BMI adjusted),Phenotype,Mean arterial pressure (BMI adjusted)
44147,Coronary artery disease or factor VII levels (pleiotropy),Phenotype,Coronary artery disease or factor VII levels (pleiotropy)
44148,Coronary artery disease or tissue plasminogen activator levels (pleiotropy),Phenotype,Coronary artery disease or tissue plasminogen activator levels (pleiotropy)
44161,Total cholesterol in very large VLDL,Phenotype,Total cholesterol in very large VLDL
44162,Cholesterol esters in very large VLDL,Phenotype,Cholesterol esters in very large VLDL
44163,Total cholesterol to total lipids ratio in very large VLDL,Phenotype,Total cholesterol to total lipids ratio in very large VLDL
44164,Cholesteryl esters to total lipids ratio in very large VLDL,Phenotype,Cholesteryl esters to total lipids ratio in very large VLDL
44165,Free cholesterol in very large VLDL,Phenotype,Free cholesterol in very large VLDL
44183,Angina,Phenotype,Angina
44186,Ratio of omega-6 fatty acids to total fatty acids,Phenotype,Ratio of omega-6 fatty acids to total fatty acids
44187,Glucose levels,Phenotype,Glucose levels
44188,Retinal venular tortuosity,Phenotype,Retinal venular tortuosity
44190,Retinal venular width,Phenotype,Retinal venular width
44202,Electrocardiogram morphology (amplitude at temporal datapoints),Phenotype,Electrocardiogram morphology (amplitude at temporal datapoints)
44203,Urine heptanoylglutamine levels in chronic kidney disease,Phenotype,Urine heptanoylglutamine levels in chronic kidney disease
44204,Plasma hexanoylglutamine levels in chronic kidney disease,Phenotype,Plasma hexanoylglutamine levels in chronic kidney disease
44206,Urine gamma-CEHC sulfate levels in chronic kidney disease,Phenotype,Urine gamma-CEHC sulfate levels in chronic kidney disease
44207,Plasma butyrylcarnitine (C4) levels in chronic kidney disease,Phenotype,Plasma butyrylcarnitine (C4) levels in chronic kidney disease
44208,Plasma carotene diol (1) levels in chronic kidney disease,Phenotype,Plasma carotene diol (1) levels in chronic kidney disease
44210,Plasma carotene diol (2) levels in chronic kidney disease,Phenotype,Plasma carotene diol (2) levels in chronic kidney disease
44211,Plasma carotene diol (3) levels in chronic kidney disease,Phenotype,Plasma carotene diol (3) levels in chronic kidney disease
44212,Plasma cerotoylcarnitine (C26)* levels in chronic kidney disease,Phenotype,Plasma cerotoylcarnitine (C26)* levels in chronic kidney disease
44213,Plasma ethylmalonate levels in chronic kidney disease,Phenotype,Plasma ethylmalonate levels in chronic kidney disease
44215,Urine ethylmalonate levels in chronic kidney disease,Phenotype,Urine ethylmalonate levels in chronic kidney disease
44216,Plasma ferulic acid 4-sulfate levels in chronic kidney disease,Phenotype,Plasma ferulic acid 4-sulfate levels in chronic kidney disease
44217,Urine ferulic acid 4-sulfate levels in chronic kidney disease,Phenotype,Urine ferulic acid 4-sulfate levels in chronic kidney disease
44218,Plasma furaneol sulfate levels in chronic kidney disease,Phenotype,Plasma furaneol sulfate levels in chronic kidney disease
44219,Urine furaneol sulfate levels in chronic kidney disease,Phenotype,Urine furaneol sulfate levels in chronic kidney disease
44220,Urine hexanoylglutamine levels in chronic kidney disease,Phenotype,Urine hexanoylglutamine levels in chronic kidney disease
44221,Plasma ergothioneine levels in chronic kidney disease,Phenotype,Plasma ergothioneine levels in chronic kidney disease
44223,Autoimmune neurological syndromes with anti-GAD65 autoantibodies,Phenotype,Autoimmune neurological syndromes with anti-GAD65 autoantibodies
44230,Vertex-wise cortical thickness,Phenotype,Vertex-wise cortical thickness
44231,Urinary uromodulin levels (raw),Phenotype,Urinary uromodulin levels (raw)
44240,Urinary uromodulin levels (indexed to creatinine),Phenotype,Urinary uromodulin levels (indexed to creatinine)
44244,Fasting plasma glucose change,Phenotype,Fasting plasma glucose change
44247,COVID-19 (critical illness vs population or mild symptoms),Phenotype,COVID-19 (critical illness vs population or mild symptoms)
44251,Estimated glomerular filtration rate (creatinine),Phenotype,Estimated glomerular filtration rate (creatinine)
44253,Predicted developmental stuttering,Phenotype,Predicted developmental stuttering
44263,Vaginal microbiome MetaCyc pathway (P163-PWY|L-lysine fermentation to acetate and butanoate),Phenotype,Vaginal microbiome MetaCyc pathway (P163-PWY|L-lysine fermentation to acetate and butanoate)
44266,Vaginal microbiome MetaCyc pathway (P562-PWY|myo-inositol degradation I),Phenotype,Vaginal microbiome MetaCyc pathway (P562-PWY|myo-inositol degradation I)
44270,Vaginal microbiome MetaCyc pathway (POLYAMSYN-PWY|superpathway of polyamine biosynthesis I),Phenotype,Vaginal microbiome MetaCyc pathway (POLYAMSYN-PWY|superpathway of polyamine biosynthesis I)
44272,Vaginal microbiome MetaCyc pathway (PPGPPMET-PWY|ppGpp biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PPGPPMET-PWY|ppGpp biosynthesis)
44274,Vaginal microbiome MetaCyc pathway (P381-PWY|adenosylcobalamin biosynthesis II (late cobalt incorporation)),Phenotype,Vaginal microbiome MetaCyc pathway (P381-PWY|adenosylcobalamin biosynthesis II (late cobalt incorporation))
44278,Vaginal microbiome MetaCyc pathway (P164-PWY|purine nucleobases degradation I (anaerobic)),Phenotype,Vaginal microbiome MetaCyc pathway (P164-PWY|purine nucleobases degradation I (anaerobic))
44281,Vaginal microbiome MetaCyc pathway (P221-PWY|octane oxidation),Phenotype,Vaginal microbiome MetaCyc pathway (P221-PWY|octane oxidation)
44284,Vertex-wise cortical surface area,Phenotype,Vertex-wise cortical surface area
44285,Vertex-wise sulcal depth,Phenotype,Vertex-wise sulcal depth
44295,Orofacial cleft x maternal vitamin supplementation interaction (2df),Phenotype,Orofacial cleft x maternal vitamin supplementation interaction (2df)
44298,Plasma ascorbic acid 2-sulfate levels in chronic kidney disease,Phenotype,Plasma ascorbic acid 2-sulfate levels in chronic kidney disease
44300,Plasma ascorbic acid 3-sulfate* levels in chronic kidney disease,Phenotype,Plasma ascorbic acid 3-sulfate* levels in chronic kidney disease
44302,Urine azelate (C9-DC) levels in chronic kidney disease,Phenotype,Urine azelate (C9-DC) levels in chronic kidney disease
44303,Plasma 5-methylthioadenosine (MTA) levels in chronic kidney disease,Phenotype,Plasma 5-methylthioadenosine (MTA) levels in chronic kidney disease
44305,Plasma acisoga levels in chronic kidney disease,Phenotype,Plasma acisoga levels in chronic kidney disease
44306,Urine glutamine conjugate of C10H16O2 (2)* levels in chronic kidney disease,Phenotype,Urine glutamine conjugate of C10H16O2 (2)* levels in chronic kidney disease
44307,Urine glutamine conjugate of C8H12O2 (3)* levels in chronic kidney disease,Phenotype,Urine glutamine conjugate of C8H12O2 (3)* levels in chronic kidney disease
44309,Urine glutamine conjugate of C8H12O4 (1)* levels in chronic kidney disease,Phenotype,Urine glutamine conjugate of C8H12O4 (1)* levels in chronic kidney disease
44310,Urine glutamine conjugate of C9H16O2 (1)* levels in chronic kidney disease,Phenotype,Urine glutamine conjugate of C9H16O2 (1)* levels in chronic kidney disease
44311,Plasma glutarylcarnitine (C5-DC) levels in chronic kidney disease,Phenotype,Plasma glutarylcarnitine (C5-DC) levels in chronic kidney disease
44312,Urine glutarylcarnitine (C5-DC) levels in chronic kidney disease,Phenotype,Urine glutarylcarnitine (C5-DC) levels in chronic kidney disease
44313,Urine alpha-CEHC sulfate levels in chronic kidney disease,Phenotype,Urine alpha-CEHC sulfate levels in chronic kidney disease
44314,Plasma arachidonoylcarnitine (C20:4) levels in chronic kidney disease,Phenotype,Plasma arachidonoylcarnitine (C20:4) levels in chronic kidney disease
44315,Plasma argininate* levels in chronic kidney disease,Phenotype,Plasma argininate* levels in chronic kidney disease
44316,Urine argininate* levels in chronic kidney disease,Phenotype,Urine argininate* levels in chronic kidney disease
44317,Urine acisoga levels in chronic kidney disease,Phenotype,Urine acisoga levels in chronic kidney disease
44318,Urine adenosine 3'--5'-cyclic monophosphate (cAMP) levels in chronic kidney disease,Phenotype,Urine adenosine 3'--5'-cyclic monophosphate (cAMP) levels in chronic kidney disease
44320,Urine adenosine levels in chronic kidney disease,Phenotype,Urine adenosine levels in chronic kidney disease
44321,Plasma adipoylcarnitine (C6-DC) levels in chronic kidney disease,Phenotype,Plasma adipoylcarnitine (C6-DC) levels in chronic kidney disease
44322,Urine adipoylcarnitine (C6-DC) levels in chronic kidney disease,Phenotype,Urine adipoylcarnitine (C6-DC) levels in chronic kidney disease
44351,Vaginal microbiome MetaCyc pathway (PWY-5121|superpathway of geranylgeranyl diphosphate biosynthesis II (via MEP)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5121|superpathway of geranylgeranyl diphosphate biosynthesis II (via MEP))
44353,Vaginal microbiome MetaCyc pathway (PWY-5177|glutaryl-CoA degradation),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5177|glutaryl-CoA degradation)
44356,Vaginal microbiome MetaCyc pathway (PWY-5182|toluene degradation II (aerobic) (via 4-methylcatechol)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5182|toluene degradation II (aerobic) (via 4-methylcatechol))
44360,Vaginal microbiome MetaCyc pathway (PWY-5180|toluene degradation I (aerobic) (via o-cresol)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5180|toluene degradation I (aerobic) (via o-cresol))
44369,Urine 3-formylindole levels in chronic kidney disease,Phenotype,Urine 3-formylindole levels in chronic kidney disease
44371,Urine 3-hydroxycinnamate sulfate levels in chronic kidney disease,Phenotype,Urine 3-hydroxycinnamate sulfate levels in chronic kidney disease
44372,Plasma 3-hydroxydecanoylcarnitine levels in chronic kidney disease,Phenotype,Plasma 3-hydroxydecanoylcarnitine levels in chronic kidney disease
44374,Urine 3-hydroxydodecanedioate* levels in chronic kidney disease,Phenotype,Urine 3-hydroxydodecanedioate* levels in chronic kidney disease
44376,Plasma 3-hydroxyhexanoate levels in chronic kidney disease,Phenotype,Plasma 3-hydroxyhexanoate levels in chronic kidney disease
44378,Urine 3-hydroxyindolin-2-one sulfate levels in chronic kidney disease,Phenotype,Urine 3-hydroxyindolin-2-one sulfate levels in chronic kidney disease
44380,Plasma 3-hydroxyoctanoylcarnitine (1) levels in chronic kidney disease,Phenotype,Plasma 3-hydroxyoctanoylcarnitine (1) levels in chronic kidney disease
44381,Plasma 3-hydroxyoctanoylcarnitine (2) levels in chronic kidney disease,Phenotype,Plasma 3-hydroxyoctanoylcarnitine (2) levels in chronic kidney disease
44382,Urine 3-hydroxysebacate levels in chronic kidney disease,Phenotype,Urine 3-hydroxysebacate levels in chronic kidney disease
44384,Urine 21-hydroxypregnenolone disulfate levels in chronic kidney disease,Phenotype,Urine 21-hydroxypregnenolone disulfate levels in chronic kidney disease
44385,Urine 3-(3-hydroxyphenyl)propionate levels in chronic kidney disease,Phenotype,Urine 3-(3-hydroxyphenyl)propionate levels in chronic kidney disease
44386,Plasma 3-decenoylcarnitine levels in chronic kidney disease,Phenotype,Plasma 3-decenoylcarnitine levels in chronic kidney disease
44388,Urine 4-hydroxycinnamate sulfate levels in chronic kidney disease,Phenotype,Urine 4-hydroxycinnamate sulfate levels in chronic kidney disease
44389,Urine 4-hydroxyphenylacetylglutamine levels in chronic kidney disease,Phenotype,Urine 4-hydroxyphenylacetylglutamine levels in chronic kidney disease
44391,Urine 4-hydroxyphenylpyruvate levels in chronic kidney disease,Phenotype,Urine 4-hydroxyphenylpyruvate levels in chronic kidney disease
44392,Urine 4-methylhexanoylglutamine levels in chronic kidney disease,Phenotype,Urine 4-methylhexanoylglutamine levels in chronic kidney disease
44394,Urine 5-hydroxyindole sulfate levels in chronic kidney disease,Phenotype,Urine 5-hydroxyindole sulfate levels in chronic kidney disease
44436,Vaginal microbiome MetaCyc pathway (P124-PWY|Bifidobacterium shunt),Phenotype,Vaginal microbiome MetaCyc pathway (P124-PWY|Bifidobacterium shunt)
44438,Vaginal microbiome MetaCyc pathway (NAD-BIOSYNTHESIS-II|NAD salvage pathway II),Phenotype,Vaginal microbiome MetaCyc pathway (NAD-BIOSYNTHESIS-II|NAD salvage pathway II)
44441,Vaginal microbiome MetaCyc pathway (METH-ACETATE-PWY|methanogenesis from acetate),Phenotype,Vaginal microbiome MetaCyc pathway (METH-ACETATE-PWY|methanogenesis from acetate)
44446,Vaginal microbiome MetaCyc pathway (P125-PWY|superpathway of (R--R)-butanediol biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (P125-PWY|superpathway of (R--R)-butanediol biosynthesis)
44456,Urine 2-hydroxysebacate levels in chronic kidney disease,Phenotype,Urine 2-hydroxysebacate levels in chronic kidney disease
44457,Plasma 2--3-dihydroxy-5-methylthio-4-pentenoate (DMTPA)* levels in chronic kidney disease,Phenotype,Plasma 2--3-dihydroxy-5-methylthio-4-pentenoate (DMTPA)* levels in chronic kidney disease
44458,Plasma phenylacetylglutamate levels in chronic kidney disease,Phenotype,Plasma phenylacetylglutamate levels in chronic kidney disease
44460,Urine phenylacetylglutamate levels in chronic kidney disease,Phenotype,Urine phenylacetylglutamate levels in chronic kidney disease
44461,Plasma phenyllactate (PLA) levels in chronic kidney disease,Phenotype,Plasma phenyllactate (PLA) levels in chronic kidney disease
44463,Urine phenyllactate (PLA) levels in chronic kidney disease,Phenotype,Urine phenyllactate (PLA) levels in chronic kidney disease
44464,Plasma picolinate levels in chronic kidney disease,Phenotype,Plasma picolinate levels in chronic kidney disease
44465,Plasma 1--2-dipalmitoyl-GPC (16:0/16:0) levels in chronic kidney disease,Phenotype,Plasma 1--2-dipalmitoyl-GPC (16:0/16:0) levels in chronic kidney disease
44466,Urine pterin levels in chronic kidney disease,Phenotype,Urine pterin levels in chronic kidney disease
44467,Urine pyridoxal levels in chronic kidney disease,Phenotype,Urine pyridoxal levels in chronic kidney disease
44468,Plasma S-adenosylhomocysteine (SAH) levels in chronic kidney disease,Phenotype,Plasma S-adenosylhomocysteine (SAH) levels in chronic kidney disease
44469,Urine S-adenosylhomocysteine (SAH) levels in chronic kidney disease,Phenotype,Urine S-adenosylhomocysteine (SAH) levels in chronic kidney disease
44471,Urine sebacate (C10-DC) levels in chronic kidney disease,Phenotype,Urine sebacate (C10-DC) levels in chronic kidney disease
44473,Urine picolinate levels in chronic kidney disease,Phenotype,Urine picolinate levels in chronic kidney disease
44474,Plasma picolinoylglycine levels in chronic kidney disease,Phenotype,Plasma picolinoylglycine levels in chronic kidney disease
44475,Plasma pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels in chronic kidney disease,Phenotype,Plasma pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels in chronic kidney disease
44476,Urine pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels in chronic kidney disease,Phenotype,Urine pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels in chronic kidney disease
44477,Urine pregnenediol disulfate (C21H34O8S2)* levels in chronic kidney disease,Phenotype,Urine pregnenediol disulfate (C21H34O8S2)* levels in chronic kidney disease
44478,Urine prolylglycine levels in chronic kidney disease,Phenotype,Urine prolylglycine levels in chronic kidney disease
44480,Plasma propionylcarnitine (C3) levels in chronic kidney disease,Phenotype,Plasma propionylcarnitine (C3) levels in chronic kidney disease
44481,Plasma stearoylcarnitine (C18) levels in chronic kidney disease,Phenotype,Plasma stearoylcarnitine (C18) levels in chronic kidney disease
44482,Urine suberate (C8-DC) levels in chronic kidney disease,Phenotype,Urine suberate (C8-DC) levels in chronic kidney disease
44484,Plasma suberoylcarnitine (C8-DC) levels in chronic kidney disease,Phenotype,Plasma suberoylcarnitine (C8-DC) levels in chronic kidney disease
44493,Fasting plasma glucose in prediabetes,Phenotype,Fasting plasma glucose in prediabetes
44495,Body mass index in prediabetes,Phenotype,Body mass index in prediabetes
44503,Vaginal microbiome MetaCyc pathway (PWY-1861|formaldehyde assimilation II (RuMP Cycle)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-1861|formaldehyde assimilation II (RuMP Cycle))
44505,Vaginal microbiome MetaCyc pathway (PWY-4984|urea cycle),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-4984|urea cycle)
44507,Vaginal microbiome MetaCyc pathway (PROTOCATECHUATE-ORTHO-CLEAVAGE-PWY|protocatechuate degradation II (ortho-cleavage pathway)),Phenotype,Vaginal microbiome MetaCyc pathway (PROTOCATECHUATE-ORTHO-CLEAVAGE-PWY|protocatechuate degradation II (ortho-cleavage pathway))
44509,Vaginal microbiome MetaCyc pathway (PWY-1622|formaldehyde assimilation I (serine pathway)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-1622|formaldehyde assimilation I (serine pathway))
44529,Breast cancer or lung cancer (pleiotropy),Phenotype,Breast cancer or lung cancer (pleiotropy)
44532,Lung cancer or head/neck cancer (pleiotropy),Phenotype,Lung cancer or head/neck cancer (pleiotropy)
44534,Breast cancer or ovarian cancer (pleiotropy),Phenotype,Breast cancer or ovarian cancer (pleiotropy)
44536,Retinal arteriolar tortuosity,Phenotype,Retinal arteriolar tortuosity
44542,Urine nicotinamide riboside levels in chronic kidney disease,Phenotype,Urine nicotinamide riboside levels in chronic kidney disease
44543,Plasma oleoylcarnitine (C18:1) levels in chronic kidney disease,Phenotype,Plasma oleoylcarnitine (C18:1) levels in chronic kidney disease
44544,Plasma palmitoylcarnitine (C16) levels in chronic kidney disease,Phenotype,Plasma palmitoylcarnitine (C16) levels in chronic kidney disease
44545,Plasma X-11381 levels in chronic kidney disease,Phenotype,Plasma X-11381 levels in chronic kidney disease
44546,Plasma X-11470 levels in chronic kidney disease,Phenotype,Plasma X-11470 levels in chronic kidney disease
44548,Urine X-11470 levels in chronic kidney disease,Phenotype,Urine X-11470 levels in chronic kidney disease
44549,Plasma X-11478 levels in chronic kidney disease,Phenotype,Plasma X-11478 levels in chronic kidney disease
44550,Urine X-12097 levels in chronic kidney disease,Phenotype,Urine X-12097 levels in chronic kidney disease
44552,Plasma X-12100 levels in chronic kidney disease,Phenotype,Plasma X-12100 levels in chronic kidney disease
44554,Urine X-12100 levels in chronic kidney disease,Phenotype,Urine X-12100 levels in chronic kidney disease
44556,Urine X-12124 levels in chronic kidney disease,Phenotype,Urine X-12124 levels in chronic kidney disease
44558,Plasma X-12689 levels in chronic kidney disease,Phenotype,Plasma X-12689 levels in chronic kidney disease
44560,Urine X-12704 levels in chronic kidney disease,Phenotype,Urine X-12704 levels in chronic kidney disease
44561,Urine X-12707 levels in chronic kidney disease,Phenotype,Urine X-12707 levels in chronic kidney disease
44580,Central serous chorioretinopathy,Phenotype,Central serous chorioretinopathy
44591,Vaginal microbiome MetaCyc pathway (FASYN-INITIAL-PWY|superpathway of fatty acid biosynthesis initiation (E. coli)),Phenotype,Vaginal microbiome MetaCyc pathway (FASYN-INITIAL-PWY|superpathway of fatty acid biosynthesis initiation (E. coli))
44594,Vaginal microbiome MetaCyc pathway (FUC-RHAMCAT-PWY|superpathway of fucose and rhamnose degradation),Phenotype,Vaginal microbiome MetaCyc pathway (FUC-RHAMCAT-PWY|superpathway of fucose and rhamnose degradation)
44596,Vaginal microbiome MetaCyc pathway (CENTFERM-PWY|pyruvate fermentation to butanoate),Phenotype,Vaginal microbiome MetaCyc pathway (CENTFERM-PWY|pyruvate fermentation to butanoate)
44601,Vaginal microbiome MetaCyc pathway (ENTBACSYN-PWY|enterobactin biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (ENTBACSYN-PWY|enterobactin biosynthesis)
44604,Vaginal microbiome MetaCyc pathway (FUCCAT-PWY|fucose degradation),Phenotype,Vaginal microbiome MetaCyc pathway (FUCCAT-PWY|fucose degradation)
44609,Vaginal microbiome MetaCyc pathway (FAO-PWY|fatty acid beta;-oxidation I),Phenotype,Vaginal microbiome MetaCyc pathway (FAO-PWY|fatty acid beta;-oxidation I)
44627,Plasma 1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)* levels in chronic kidney disease,Phenotype,Plasma 1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)* levels in chronic kidney disease
44628,Plasma 1-methylnicotinamide levels in chronic kidney disease,Phenotype,Plasma 1-methylnicotinamide levels in chronic kidney disease
44629,Age at menarche,Phenotype,Age at menarche
44630,Urine diacetylspermidine* levels in chronic kidney disease,Phenotype,Urine diacetylspermidine* levels in chronic kidney disease
44631,Plasma dihomo-linolenoylcarnitine (C20:3n3 or 6)* levels in chronic kidney disease,Phenotype,Plasma dihomo-linolenoylcarnitine (C20:3n3 or 6)* levels in chronic kidney disease
44632,Plasma dihomo-linoleoylcarnitine (C20:2)* levels in chronic kidney disease,Phenotype,Plasma dihomo-linoleoylcarnitine (C20:2)* levels in chronic kidney disease
44633,Urine dihydroferulic acid sulfate levels in chronic kidney disease,Phenotype,Urine dihydroferulic acid sulfate levels in chronic kidney disease
44634,Urine isoxanthopterin levels in chronic kidney disease,Phenotype,Urine isoxanthopterin levels in chronic kidney disease
44635,Plasma kynurenine levels in chronic kidney disease,Phenotype,Plasma kynurenine levels in chronic kidney disease
44636,Urine kynurenine levels in chronic kidney disease,Phenotype,Urine kynurenine levels in chronic kidney disease
44638,Plasma levulinoylcarnitine levels in chronic kidney disease,Phenotype,Plasma levulinoylcarnitine levels in chronic kidney disease
44639,Plasma linolenoylcarnitine (C18:3)* levels in chronic kidney disease,Phenotype,Plasma linolenoylcarnitine (C18:3)* levels in chronic kidney disease
44640,Plasma linoleoylcarnitine (C18:2)* levels in chronic kidney disease,Phenotype,Plasma linoleoylcarnitine (C18:2)* levels in chronic kidney disease
44641,Plasma lysine levels in chronic kidney disease,Phenotype,Plasma lysine levels in chronic kidney disease
44642,Urine cyclo(leu-asp)* levels in chronic kidney disease,Phenotype,Urine cyclo(leu-asp)* levels in chronic kidney disease
44643,Plasma cys-gly-- oxidized levels in chronic kidney disease,Phenotype,Plasma cys-gly-- oxidized levels in chronic kidney disease
44645,Plasma cysteinylglycine disulfide* levels in chronic kidney disease,Phenotype,Plasma cysteinylglycine disulfide* levels in chronic kidney disease
44647,Urine cysteinylglycine disulfide* levels in chronic kidney disease,Phenotype,Urine cysteinylglycine disulfide* levels in chronic kidney disease
44648,Plasma cysteinylglycine levels in chronic kidney disease,Phenotype,Plasma cysteinylglycine levels in chronic kidney disease
44649,Urine cysteinylglycine levels in chronic kidney disease,Phenotype,Urine cysteinylglycine levels in chronic kidney disease
44650,Urine glucuronide of C10H18O2 (10)* levels in chronic kidney disease,Phenotype,Urine glucuronide of C10H18O2 (10)* levels in chronic kidney disease
44652,Plasma imidazole lactate levels in chronic kidney disease,Phenotype,Plasma imidazole lactate levels in chronic kidney disease
44654,Urine imidazole lactate levels in chronic kidney disease,Phenotype,Urine imidazole lactate levels in chronic kidney disease
44655,Plasma indoleacetoylcarnitine* levels in chronic kidney disease,Phenotype,Plasma indoleacetoylcarnitine* levels in chronic kidney disease
44656,Urine indoleacetoylcarnitine* levels in chronic kidney disease,Phenotype,Urine indoleacetoylcarnitine* levels in chronic kidney disease
44657,Plasma indoleacetylglutamine levels in chronic kidney disease,Phenotype,Plasma indoleacetylglutamine levels in chronic kidney disease
44658,Urine indoleacetylglutamine levels in chronic kidney disease,Phenotype,Urine indoleacetylglutamine levels in chronic kidney disease
44659,Urine indoleacetylglycine levels in chronic kidney disease,Phenotype,Urine indoleacetylglycine levels in chronic kidney disease
44660,Urine indolelactate levels in chronic kidney disease,Phenotype,Urine indolelactate levels in chronic kidney disease
44661,Plasma indolepropionate levels in chronic kidney disease,Phenotype,Plasma indolepropionate levels in chronic kidney disease
44662,Plasma isobutyrylcarnitine (C4) levels in chronic kidney disease,Phenotype,Plasma isobutyrylcarnitine (C4) levels in chronic kidney disease
44663,Urine isobutyrylcarnitine (C4) levels in chronic kidney disease,Phenotype,Urine isobutyrylcarnitine (C4) levels in chronic kidney disease
44664,Urine isocaproylglutamine levels in chronic kidney disease,Phenotype,Urine isocaproylglutamine levels in chronic kidney disease
44665,Plasma 1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6)* levels in chronic kidney disease,Phenotype,Plasma 1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6)* levels in chronic kidney disease
44666,Total bilirubin levels,Phenotype,Total bilirubin levels
44671,Chronic sputum production,Phenotype,Chronic sputum production
44684,Vaginal microbiome MetaCyc pathway (ARG+POLYAMINE-SYN|superpathway of arginine and polyamine biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (ARG+POLYAMINE-SYN|superpathway of arginine and polyamine biosynthesis)
44686,Vaginal microbiome MetaCyc pathway (CATECHOL-ORTHO-CLEAVAGE-PWY|catechol degradation to beta;-ketoadipate),Phenotype,Vaginal microbiome MetaCyc pathway (CATECHOL-ORTHO-CLEAVAGE-PWY|catechol degradation to beta;-ketoadipate)
44691,Vaginal microbiome MetaCyc pathway (ALL-CHORISMATE-PWY|superpathway of chorismate metabolism),Phenotype,Vaginal microbiome MetaCyc pathway (ALL-CHORISMATE-PWY|superpathway of chorismate metabolism)
44698,Triglycerides (54:7)B levels,Phenotype,Triglycerides (54:7)B levels
44701,Phosphatidylcholines (42:5) levels,Phenotype,Phosphatidylcholines (42:5) levels
44703,Fornix volume,Phenotype,Fornix volume
44705,Brain age (difference between predicted and chronological age),Phenotype,Brain age (difference between predicted and chronological age)
44706,Plasma methylsuccinoylcarnitine levels in chronic kidney disease,Phenotype,Plasma methylsuccinoylcarnitine levels in chronic kidney disease
44708,Urine methylsuccinoylcarnitine levels in chronic kidney disease,Phenotype,Urine methylsuccinoylcarnitine levels in chronic kidney disease
44709,Urine myo-inositol levels in chronic kidney disease,Phenotype,Urine myo-inositol levels in chronic kidney disease
44710,Urine N-lactoyl leucine levels in chronic kidney disease,Phenotype,Urine N-lactoyl leucine levels in chronic kidney disease
44712,Urine N-lactoyl phenylalanine levels in chronic kidney disease,Phenotype,Urine N-lactoyl phenylalanine levels in chronic kidney disease
44713,Urine N-lactoyl tyrosine levels in chronic kidney disease,Phenotype,Urine N-lactoyl tyrosine levels in chronic kidney disease
44715,Urine N-lactoyl valine levels in chronic kidney disease,Phenotype,Urine N-lactoyl valine levels in chronic kidney disease
44716,Urine N-octanoylglutamine levels in chronic kidney disease,Phenotype,Urine N-octanoylglutamine levels in chronic kidney disease
44717,Urine suberoylcarnitine (C8-DC) levels in chronic kidney disease,Phenotype,Urine suberoylcarnitine (C8-DC) levels in chronic kidney disease
44718,Plasma maltol sulfate levels in chronic kidney disease,Phenotype,Plasma maltol sulfate levels in chronic kidney disease
44719,Urine maltol sulfate levels in chronic kidney disease,Phenotype,Urine maltol sulfate levels in chronic kidney disease
44720,Plasma N-acetyl-isoputreanine levels in chronic kidney disease,Phenotype,Plasma N-acetyl-isoputreanine levels in chronic kidney disease
44721,Urine N-acetyl-met-phe levels in chronic kidney disease,Phenotype,Urine N-acetyl-met-phe levels in chronic kidney disease
44722,Plasma N-acetylcarnosine levels in chronic kidney disease,Phenotype,Plasma N-acetylcarnosine levels in chronic kidney disease
44724,Urine N-acetylcarnosine levels in chronic kidney disease,Phenotype,Urine N-acetylcarnosine levels in chronic kidney disease
44725,Plasma N-acetylphenylalanine levels in chronic kidney disease,Phenotype,Plasma N-acetylphenylalanine levels in chronic kidney disease
44726,Plasma N-acetyltryptophan levels in chronic kidney disease,Phenotype,Plasma N-acetyltryptophan levels in chronic kidney disease
44728,Plasma N-acetylglucosamine/N-acetylgalactosamine levels in chronic kidney disease,Phenotype,Plasma N-acetylglucosamine/N-acetylgalactosamine levels in chronic kidney disease
44730,Urine N-acetylglucosamine/N-acetylgalactosamine levels in chronic kidney disease,Phenotype,Urine N-acetylglucosamine/N-acetylgalactosamine levels in chronic kidney disease
44731,Plasma N-acetylglucosaminylasparagine levels in chronic kidney disease,Phenotype,Plasma N-acetylglucosaminylasparagine levels in chronic kidney disease
44732,Urine N-acetylglucosaminylasparagine levels in chronic kidney disease,Phenotype,Urine N-acetylglucosaminylasparagine levels in chronic kidney disease
44733,Plasma N-acetylkynurenine (2) levels in chronic kidney disease,Phenotype,Plasma N-acetylkynurenine (2) levels in chronic kidney disease
44741,Phosphatidylcholines (38:2) levels,Phenotype,Phosphatidylcholines (38:2) levels
44752,Urine X-21829 levels in chronic kidney disease,Phenotype,Urine X-21829 levels in chronic kidney disease
44753,Urine X-21841 levels in chronic kidney disease,Phenotype,Urine X-21841 levels in chronic kidney disease
44754,Urine X-23518 levels in chronic kidney disease,Phenotype,Urine X-23518 levels in chronic kidney disease
44755,Plasma X-24422 levels in chronic kidney disease,Phenotype,Plasma X-24422 levels in chronic kidney disease
44756,Urine X-24470 levels in chronic kidney disease,Phenotype,Urine X-24470 levels in chronic kidney disease
44760,Urine X-17328 levels in chronic kidney disease,Phenotype,Urine X-17328 levels in chronic kidney disease
44761,Urine X-17674 levels in chronic kidney disease,Phenotype,Urine X-17674 levels in chronic kidney disease
44762,Urine X-18888 levels in chronic kidney disease,Phenotype,Urine X-18888 levels in chronic kidney disease
44763,Urine X-13837 levels in chronic kidney disease,Phenotype,Urine X-13837 levels in chronic kidney disease
44764,Plasma X-13846 levels in chronic kidney disease,Phenotype,Plasma X-13846 levels in chronic kidney disease
44765,Urine X-13846 levels in chronic kidney disease,Phenotype,Urine X-13846 levels in chronic kidney disease
44766,Plasma X-13866 levels in chronic kidney disease,Phenotype,Plasma X-13866 levels in chronic kidney disease
44768,Urine X-13866 levels in chronic kidney disease,Phenotype,Urine X-13866 levels in chronic kidney disease
44769,Urine X-13874 levels in chronic kidney disease,Phenotype,Urine X-13874 levels in chronic kidney disease
44770,Urine X-15806 levels in chronic kidney disease,Phenotype,Urine X-15806 levels in chronic kidney disease
44771,Plasma X-17304 levels in chronic kidney disease,Phenotype,Plasma X-17304 levels in chronic kidney disease
44772,Plasma X-17323 levels in chronic kidney disease,Phenotype,Plasma X-17323 levels in chronic kidney disease
44773,Urine X-17323 levels in chronic kidney disease,Phenotype,Urine X-17323 levels in chronic kidney disease
44774,Plasma X-19141 levels in chronic kidney disease,Phenotype,Plasma X-19141 levels in chronic kidney disease
44775,Urine X-24515 levels in chronic kidney disease,Phenotype,Urine X-24515 levels in chronic kidney disease
44776,Plasma X-24556 levels in chronic kidney disease,Phenotype,Plasma X-24556 levels in chronic kidney disease
44777,Urine X-12714 levels in chronic kidney disease,Phenotype,Urine X-12714 levels in chronic kidney disease
44778,Plasma X-12798 levels in chronic kidney disease,Phenotype,Plasma X-12798 levels in chronic kidney disease
44780,Plasma X-12822 levels in chronic kidney disease,Phenotype,Plasma X-12822 levels in chronic kidney disease
44781,Urine X-12822 levels in chronic kidney disease,Phenotype,Urine X-12822 levels in chronic kidney disease
44783,Urine X-12839 levels in chronic kidney disease,Phenotype,Urine X-12839 levels in chronic kidney disease
44784,Plasma X-13684 levels in chronic kidney disease,Phenotype,Plasma X-13684 levels in chronic kidney disease
44786,Urine X-13684 levels in chronic kidney disease,Phenotype,Urine X-13684 levels in chronic kidney disease
44787,Urine X-23787 levels in chronic kidney disease,Phenotype,Urine X-23787 levels in chronic kidney disease
44789,Plasma X-23983 levels in chronic kidney disease,Phenotype,Plasma X-23983 levels in chronic kidney disease
44791,Urine X-24339 levels in chronic kidney disease,Phenotype,Urine X-24339 levels in chronic kidney disease
44793,Urine X-24345 levels in chronic kidney disease,Phenotype,Urine X-24345 levels in chronic kidney disease
44798,Cardiovascular delta age (difference between ECG-predicted and chronological age),Phenotype,Cardiovascular delta age (difference between ECG-predicted and chronological age)
44806,Blood urea nitrogen levels,Phenotype,Blood urea nitrogen levels
44810,Vaginal microbiome MetaCyc pathway (GLUCOSE1PMETAB-PWY|glucose and glucose-1-phosphate degradation),Phenotype,Vaginal microbiome MetaCyc pathway (GLUCOSE1PMETAB-PWY|glucose and glucose-1-phosphate degradation)
44812,Vaginal microbiome MetaCyc pathway (GLUCUROCAT-PWY|superpathway of beta;-D-glucuronide and D-glucuronate degradation),Phenotype,Vaginal microbiome MetaCyc pathway (GLUCUROCAT-PWY|superpathway of beta;-D-glucuronide and D-glucuronate degradation)
44814,Vaginal microbiome MetaCyc pathway (HISDEG-PWY|L-histidine degradation I),Phenotype,Vaginal microbiome MetaCyc pathway (HISDEG-PWY|L-histidine degradation I)
44818,Vaginal microbiome MetaCyc pathway (GALACT-GLUCUROCAT-PWY|superpathway of hexuronide and hexuronate degradation),Phenotype,Vaginal microbiome MetaCyc pathway (GALACT-GLUCUROCAT-PWY|superpathway of hexuronide and hexuronate degradation)
44819,Vaginal microbiome MetaCyc pathway (KDO-NAGLIPASYN-PWY|superpathway of (Kdo)2-lipid A biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (KDO-NAGLIPASYN-PWY|superpathway of (Kdo)2-lipid A biosynthesis)
44823,Vaginal microbiome MetaCyc pathway (PWY-5265|peptidoglycan biosynthesis II (staphylococci)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5265|peptidoglycan biosynthesis II (staphylococci))
44826,Ascending thoracic aortic diameter,Phenotype,Ascending thoracic aortic diameter
44831,Rheumatoid arthritis or multiple sclerosis,Phenotype,Rheumatoid arthritis or multiple sclerosis
44834,Rheumatoid arthritis or irritable bowel disease,Phenotype,Rheumatoid arthritis or irritable bowel disease
44847,Rheumatoid arthritis or type 1 diabetes,Phenotype,Rheumatoid arthritis or type 1 diabetes
44862,Orange juice liking,Phenotype,Orange juice liking
44864,Oranges liking,Phenotype,Oranges liking
44865,Plum liking,Phenotype,Plum liking
44869,F-meat liking (derived food-liking factor),Phenotype,F-meat liking (derived food-liking factor)
44870,Milky sweets liking,Phenotype,Milky sweets liking
44872,F-oily fish liking (derived food-liking factor),Phenotype,F-oily fish liking (derived food-liking factor)
44874,Liver liking,Phenotype,Liver liking
44875,Salad dressing liking,Phenotype,Salad dressing liking
44877,Salami liking,Phenotype,Salami liking
44878,Mackerel liking,Phenotype,Mackerel liking
44880,Porridge liking,Phenotype,Porridge liking
44881,Raw carrot liking,Phenotype,Raw carrot liking
44882,Red meat liking,Phenotype,Red meat liking
44883,F-acquired taste liking (derived food-liking factor),Phenotype,F-acquired taste liking (derived food-liking factor)
44885,F-fatty food liking (derived food-liking factor),Phenotype,F-fatty food liking (derived food-liking factor)
44886,F-fish liking (derived food-liking factor),Phenotype,F-fish liking (derived food-liking factor)
44887,F-chocolate/coffee liking (derived food-liking factor),Phenotype,F-chocolate/coffee liking (derived food-liking factor)
44889,F-coffee/alcohol liking (derived food-liking factor),Phenotype,F-coffee/alcohol liking (derived food-liking factor)
44890,F-cooking vegetables liking (derived food-liking factor),Phenotype,F-cooking vegetables liking (derived food-liking factor)
44892,Coriander liking,Phenotype,Coriander liking
44894,Crisps liking,Phenotype,Crisps liking
44896,Coffee difference liking,Phenotype,Coffee difference liking
44898,Coffee max liking,Phenotype,Coffee max liking
44899,F-cooking flavour liking (derived food-liking factor),Phenotype,F-cooking flavour liking (derived food-liking factor)
44901,Croissant liking,Phenotype,Croissant liking
44903,Curry liking,Phenotype,Curry liking
44904,F-deep fried food liking (derived food-liking factor),Phenotype,F-deep fried food liking (derived food-liking factor)
44907,Fruit liking,Phenotype,Fruit liking
44908,Dried fruit liking,Phenotype,Dried fruit liking
44909,F-fatty/salty food liking (derived food-liking factor),Phenotype,F-fatty/salty food liking (derived food-liking factor)
44910,Capers liking,Phenotype,Capers liking
44911,F-capsicum liking (derived food-liking factor),Phenotype,F-capsicum liking (derived food-liking factor)
44912,F-cheese liking (derived food-liking factor),Phenotype,F-cheese liking (derived food-liking factor)
44980,F-fruit liking (derived food-liking factor),Phenotype,F-fruit liking (derived food-liking factor)
44981,Fruit juice liking,Phenotype,Fruit juice liking
44982,Globe artichoke liking,Phenotype,Globe artichoke liking
44983,Serum uromodulin concentration,Phenotype,Serum uromodulin concentration
45048,Small intestine neuroendocrine tumor,Phenotype,Small intestine neuroendocrine tumor
45092,F-vegetarian liking (derived food-liking factor),Phenotype,F-vegetarian liking (derived food-liking factor)
45093,White bread liking,Phenotype,White bread liking
45095,F-whole food liking (derived food-liking factor),Phenotype,F-whole food liking (derived food-liking factor)
45097,Whole grain cereal liking,Phenotype,Whole grain cereal liking
45098,F-strong vegetable liking (derived food-liking factor),Phenotype,F-strong vegetable liking (derived food-liking factor)
45099,Smoked fish liking,Phenotype,Smoked fish liking
45100,F-sodas liking (derived food-liking factor),Phenotype,F-sodas liking (derived food-liking factor)
45101,Soft cheese liking,Phenotype,Soft cheese liking
45103,Soy sauce liking,Phenotype,Soy sauce liking
45105,Soya milk liking,Phenotype,Soya milk liking
45107,Spicy food liking,Phenotype,Spicy food liking
45109,Strawberries liking,Phenotype,Strawberries liking
45111,F-sweet food liking (derived food-liking factor),Phenotype,F-sweet food liking (derived food-liking factor)
45113,Tea difference liking,Phenotype,Tea difference liking
45114,Tea with sugar liking,Phenotype,Tea with sugar liking
45117,F-strong flavour liking (derived food-liking factor),Phenotype,F-strong flavour liking (derived food-liking factor)
45120,Alcohol liking,Phenotype,Alcohol liking
45122,Aniseed liking,Phenotype,Aniseed liking
45125,Apple juice liking,Phenotype,Apple juice liking
45133,Longitudinal peak diastolic strain rate,Phenotype,Longitudinal peak diastolic strain rate
45134,Radial peak diastolic strain rate,Phenotype,Radial peak diastolic strain rate
45168,Phosphatidylethanolamine (36:2) levels,Phenotype,Phosphatidylethanolamine (36:2) levels
45174,Plasma X-25244 levels in chronic kidney disease,Phenotype,Plasma X-25244 levels in chronic kidney disease
45175,Plasma X-25371 levels in chronic kidney disease,Phenotype,Plasma X-25371 levels in chronic kidney disease
45177,Plasma xanthurenate levels in chronic kidney disease,Phenotype,Plasma xanthurenate levels in chronic kidney disease
45178,Plasma ximenoylcarnitine (C26:1)* levels in chronic kidney disease,Phenotype,Plasma ximenoylcarnitine (C26:1)* levels in chronic kidney disease
45189,Vaginal microbiome beta diversity (Unweighted Unifrac),Phenotype,Vaginal microbiome beta diversity (Unweighted Unifrac)
45191,Vaginal microbiome beta diversity (Bray-curtis Dissimilarity),Phenotype,Vaginal microbiome beta diversity (Bray-curtis Dissimilarity)
45193,Vaginal microbiome dominance (s_Lactobacillus iners),Phenotype,Vaginal microbiome dominance (s_Lactobacillus iners)
45195,Vaginal microbiome MetaCyc pathway (1CMET2-PWY|N10-formyl-tetrahydrofolate biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (1CMET2-PWY|N10-formyl-tetrahydrofolate biosynthesis)
45199,Descending thoracic aortic diameter,Phenotype,Descending thoracic aortic diameter
45206,Malignant vs benign glioma,Phenotype,Malignant vs benign glioma
45230,Haddock liking,Phenotype,Haddock liking
45231,F-healthy food liking (derived food-liking factor),Phenotype,F-healthy food liking (derived food-liking factor)
45232,F-healthy breakfast food liking (derived food-liking factor),Phenotype,F-healthy breakfast food liking (derived food-liking factor)
45233,Goat cheese liking,Phenotype,Goat cheese liking
45240,Herring liking,Phenotype,Herring liking
45245,F-highly palatable foods liking (derived food-liking factor),Phenotype,F-highly palatable foods liking (derived food-liking factor)
45246,Kiwi liking,Phenotype,Kiwi liking
45248,Lager liking,Phenotype,Lager liking
45250,Horseradish liking,Phenotype,Horseradish liking
45252,Honey liking,Phenotype,Honey liking
45253,F-bitter food liking (derived food-liking factor),Phenotype,F-bitter food liking (derived food-liking factor)
45254,Broad bean liking,Phenotype,Broad bean liking
45258,Beans liking,Phenotype,Beans liking
45260,Beef/steak liking,Phenotype,Beef/steak liking
45261,Beetroot liking,Phenotype,Beetroot liking
45263,F-caffeinated/sweet liking (derived food-liking factor),Phenotype,F-caffeinated/sweet liking (derived food-liking factor)
45264,F-cake/biscuits liking (derived food-liking factor),Phenotype,F-cake/biscuits liking (derived food-liking factor)
45265,Avocado liking,Phenotype,Avocado liking
45268,Baked/steamed fish liking,Phenotype,Baked/steamed fish liking
45269,Butternut squash liking,Phenotype,Butternut squash liking
45274,Obstructive heart defect,Phenotype,Obstructive heart defect
45276,Obstructive heart defect (maternal genotype effect),Phenotype,Obstructive heart defect (maternal genotype effect)
45283,Hormone-sensitive cancer,Phenotype,Hormone-sensitive cancer
45295,Vaginal microbiome MetaCyc pathway (PWY-6507|4-deoxy-L-threo-hex-4-enopyranuronate degradation),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6507|4-deoxy-L-threo-hex-4-enopyranuronate degradation)
45296,Vaginal microbiome MetaCyc pathway (PWY-6519|8-amino-7-oxononanoate biosynthesis I),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6519|8-amino-7-oxononanoate biosynthesis I)
45299,Vaginal microbiome MetaCyc pathway (PWY-6383|mono-trans-- poly-cis decaprenyl phosphate biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6383|mono-trans-- poly-cis decaprenyl phosphate biosynthesis)
45301,Vaginal microbiome MetaCyc pathway (PWY-6562|norspermidine biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6562|norspermidine biosynthesis)
45303,Vaginal microbiome relative abundance (f_Mycoplasmataceae),Phenotype,Vaginal microbiome relative abundance (f_Mycoplasmataceae)
45306,Vaginal microbiome relative abundance (o_Bacteroidales),Phenotype,Vaginal microbiome relative abundance (o_Bacteroidales)
45307,Vaginal microbiome relative abundance (g_Dialister),Phenotype,Vaginal microbiome relative abundance (g_Dialister)
45311,Vaginal microbiome relative abundance (g_Megasphaera),Phenotype,Vaginal microbiome relative abundance (g_Megasphaera)
45313,Vaginal microbiome relative abundance (g_Anaerococcus),Phenotype,Vaginal microbiome relative abundance (g_Anaerococcus)
45315,Vaginal microbiome relative abundance (o_Campylobacterales),Phenotype,Vaginal microbiome relative abundance (o_Campylobacterales)
45318,Vaginal microbiome relative abundance (g_Peptoniphilus),Phenotype,Vaginal microbiome relative abundance (g_Peptoniphilus)
45321,Vaginal microbiome relative abundance (g_Prevotella),Phenotype,Vaginal microbiome relative abundance (g_Prevotella)
45322,Vaginal microbiome relative abundance (g_Streptococcus),Phenotype,Vaginal microbiome relative abundance (g_Streptococcus)
45324,Vaginal microbiome relative abundance (p_Proteobacteria),Phenotype,Vaginal microbiome relative abundance (p_Proteobacteria)
45326,Medication use (vasodilators used in cardiac diseases),Phenotype,Medication use (vasodilators used in cardiac diseases)
45329,Medication use (antihypertensives),Phenotype,Medication use (antihypertensives)
45331,Medication use (antithrombotic agents),Phenotype,Medication use (antithrombotic agents)
45334,Medication use (beta blocking agents),Phenotype,Medication use (beta blocking agents)
45340,Medication use (diuretics),Phenotype,Medication use (diuretics)
45345,Actinic keratosis,Phenotype,Actinic keratosis
45377,Vaginal microbiome MetaCyc pathway (PWY-6708|ubiquinol-8 biosynthesis (prokaryotic)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6708|ubiquinol-8 biosynthesis (prokaryotic))
45378,Vaginal microbiome MetaCyc pathway (PWY-6749|CMP-legionaminate biosynthesis I),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6749|CMP-legionaminate biosynthesis I)
45381,Vaginal microbiome MetaCyc pathway (PWY-6590|superpathway of Clostridium acetobutylicum acidogenic fermentation),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6590|superpathway of Clostridium acetobutylicum acidogenic fermentation)
45382,Vaginal microbiome MetaCyc pathway (PWY-6608|guanosine nucleotides degradation III),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6608|guanosine nucleotides degradation III)
45404,Vaginal microbiome MetaCyc pathway (PWY-6609|adenine and adenosine salvage III),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6609|adenine and adenosine salvage III)
45405,Vaginal microbiome relative abundance (s_Lactobacillus crispatus),Phenotype,Vaginal microbiome relative abundance (s_Lactobacillus crispatus)
45407,Vaginal microbiome relative abundance (s_Lactobacillus jensenii),Phenotype,Vaginal microbiome relative abundance (s_Lactobacillus jensenii)
45410,Vaginal microbiome relative abundance (s_Dialister micraerophilus),Phenotype,Vaginal microbiome relative abundance (s_Dialister micraerophilus)
45411,Vaginal microbiome relative abundance (s_Dialister propionicifaciens),Phenotype,Vaginal microbiome relative abundance (s_Dialister propionicifaciens)
45413,Vaginal microbiome relative abundance (s_Aerococcus christensenii),Phenotype,Vaginal microbiome relative abundance (s_Aerococcus christensenii)
45420,Vaginal microbiome relative abundance (s_Lactobacillus reuteri),Phenotype,Vaginal microbiome relative abundance (s_Lactobacillus reuteri)
45425,Facial skin hydration,Phenotype,Facial skin hydration
45428,Facial wrinkles,Phenotype,Facial wrinkles
45430,Serum creatinine levels,Phenotype,Serum creatinine levels
45441,Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease),Phenotype,Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease)
45442,Medication use (drugs used in diabetes),Phenotype,Medication use (drugs used in diabetes)
45444,BMI at 8 months old,Phenotype,BMI at 8 months old
45446,BMI at 1 year old,Phenotype,BMI at 1 year old
45452,BMI at 2 years old,Phenotype,BMI at 2 years old
45453,BMI at 3 years old,Phenotype,BMI at 3 years old
45454,BMI at 7 years old,Phenotype,BMI at 7 years old
45455,BMI at 1.5 years old,Phenotype,BMI at 1.5 years old
45456,BMI at 8 years old,Phenotype,BMI at 8 years old
45457,Medication use (immunosuppressants),Phenotype,Medication use (immunosuppressants)
45460,Medication use (anti-inflammatory and antirheumatic products-- non-steroids),Phenotype,Medication use (anti-inflammatory and antirheumatic products-- non-steroids)
45461,Medication use (drugs affecting bone structure and mineralization),Phenotype,Medication use (drugs affecting bone structure and mineralization)
45463,Medication use (salicylic acid and derivatives),Phenotype,Medication use (salicylic acid and derivatives)
45466,Medication use (anilides),Phenotype,Medication use (anilides)
45467,Medication use (antimigraine preparations),Phenotype,Medication use (antimigraine preparations)
45470,Medication use (thyroid preparations),Phenotype,Medication use (thyroid preparations)
45473,Executive function (longitudinal),Phenotype,Executive function (longitudinal)
45475,Executive function,Phenotype,Executive function
45480,Cognitive performance (visuoconstruction) (longitudinal),Phenotype,Cognitive performance (visuoconstruction) (longitudinal)
45484,Cognitive performance (visuoconstruction),Phenotype,Cognitive performance (visuoconstruction)
45495,Vaginal microbiome MetaCyc pathway (PWY-5507|adenosylcobalamin biosynthesis I (early cobalt insertion)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5507|adenosylcobalamin biosynthesis I (early cobalt insertion))
45497,Vaginal microbiome MetaCyc pathway (PWY-5856|ubiquinol-9 biosynthesis (prokaryotic)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5856|ubiquinol-9 biosynthesis (prokaryotic))
45499,Vaginal microbiome MetaCyc pathway (PWY-5857|ubiquinol-10 biosynthesis (prokaryotic)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5857|ubiquinol-10 biosynthesis (prokaryotic))
45500,Vaginal microbiome MetaCyc pathway (PWY-5415|catechol degradation I (meta-cleavage pathway)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5415|catechol degradation I (meta-cleavage pathway))
45506,Vaginal microbiome MetaCyc pathway (PWY-5705|allantoin degradation to glyoxylate III),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5705|allantoin degradation to glyoxylate III)
45510,Vaginal microbiome MetaCyc pathway (PWY-5741|ethylmalonyl-CoA pathway),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5741|ethylmalonyl-CoA pathway)
45513,Vaginal microbiome MetaCyc pathway (PWY-5860|superpathway of demethylmenaquinol-6 biosynthesis I),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5860|superpathway of demethylmenaquinol-6 biosynthesis I)
45514,Vaginal microbiome MetaCyc pathway (PWY-5861|superpathway of demethylmenaquinol-8 biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5861|superpathway of demethylmenaquinol-8 biosynthesis)
45515,Vaginal microbiome MetaCyc pathway (PWY-5845|superpathway of menaquinol-9 biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5845|superpathway of menaquinol-9 biosynthesis)
45517,Vaginal microbiome MetaCyc pathway (PWY-5850|superpathway of menaquinol-6 biosynthesis I),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5850|superpathway of menaquinol-6 biosynthesis I)
45518,Vaginal microbiome MetaCyc pathway (PWY-5855|ubiquinol-7 biosynthesis (prokaryotic)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5855|ubiquinol-7 biosynthesis (prokaryotic))
45519,Vaginal microbiome MetaCyc pathway (PWY-5862|superpathway of demethylmenaquinol-9 biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5862|superpathway of demethylmenaquinol-9 biosynthesis)
45520,Estimated glomerular filtration rate (cystatin c),Phenotype,Estimated glomerular filtration rate (cystatin c)
45522,Vaginal microbiome MetaCyc pathway (PWY0-1241|ADP-L-glycero-beta;-D-manno-heptose biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY0-1241|ADP-L-glycero-beta;-D-manno-heptose biosynthesis)
45524,Vaginal microbiome MetaCyc pathway (PWY0-1261|anhydromuropeptides recycling),Phenotype,Vaginal microbiome MetaCyc pathway (PWY0-1261|anhydromuropeptides recycling)
45525,Vaginal microbiome MetaCyc pathway (PWY0-1298|superpathway of pyrimidine deoxyribonucleosides degradation),Phenotype,Vaginal microbiome MetaCyc pathway (PWY0-1298|superpathway of pyrimidine deoxyribonucleosides degradation)
45526,Vaginal microbiome MetaCyc pathway (PWY0-1533|methylphosphonate degradation I),Phenotype,Vaginal microbiome MetaCyc pathway (PWY0-1533|methylphosphonate degradation I)
45527,Vaginal microbiome MetaCyc pathway (PWY0-162|superpathway of pyrimidine ribonucleotides de novo biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY0-162|superpathway of pyrimidine ribonucleotides de novo biosynthesis)
45529,Vaginal microbiome MetaCyc pathway (PWY0-166|superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis (E. coli)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY0-166|superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis (E. coli))
45534,Vaginal microbiome MetaCyc pathway (PWY0-1479|tRNA processing),Phenotype,Vaginal microbiome MetaCyc pathway (PWY0-1479|tRNA processing)
45549,Vaginal microbiome relative abundance (s_Megasphaera genomosp type 1),Phenotype,Vaginal microbiome relative abundance (s_Megasphaera genomosp type 1)
45552,Vaginal microbiome relative abundance (s_Prevotella bivia),Phenotype,Vaginal microbiome relative abundance (s_Prevotella bivia)
45553,Vaginal microbiome relative abundance (s_Peptoniphilus vaginalis),Phenotype,Vaginal microbiome relative abundance (s_Peptoniphilus vaginalis)
45555,Vaginal microbiome relative abundance (pleiotropy),Phenotype,Vaginal microbiome relative abundance (pleiotropy)
45557,BMI at 6 months old,Phenotype,BMI at 6 months old
45565,BMI at birth,Phenotype,BMI at birth
45566,BMI at 3 months old,Phenotype,BMI at 3 months old
45567,Myalgic encephalomyelitis / chronic fatigue syndrome,Phenotype,Myalgic encephalomyelitis / chronic fatigue syndrome
45569,Log white blood cell count in acute lymphoblastic leukemia,Phenotype,Log white blood cell count in acute lymphoblastic leukemia
45571,Spline residuals of log white blood cell count in acute lymphoblastic leukemia,Phenotype,Spline residuals of log white blood cell count in acute lymphoblastic leukemia
45574,Cognitive performance (attention) (longitudinal),Phenotype,Cognitive performance (attention) (longitudinal)
45578,Medication use (HMG CoA reductase inhibitors),Phenotype,Medication use (HMG CoA reductase inhibitors)
45592,Breast cancer x TP53 mutation interaction,Phenotype,Breast cancer x TP53 mutation interaction
45594,Breast cancer x TP53 gain of function mutation interaction,Phenotype,Breast cancer x TP53 gain of function mutation interaction
45604,Depression (age of onset),Phenotype,Depression (age of onset)
45607,Vaginal microbiome MetaCyc pathway (PWY-7159|chlorophyllide a biosynthesis III (aerobic-- light independent)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7159|chlorophyllide a biosynthesis III (aerobic-- light independent))
45608,Vaginal microbiome MetaCyc pathway (PWY-7013|L-1--2-propanediol degradation),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7013|L-1--2-propanediol degradation)
45610,Vaginal microbiome MetaCyc pathway (PWY-7094|fatty acid salvage),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7094|fatty acid salvage)
45611,Vaginal microbiome MetaCyc pathway (TEICHOICACID-PWY|teichoic acid (poly-glycerol) biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (TEICHOICACID-PWY|teichoic acid (poly-glycerol) biosynthesis)
45612,Vaginal microbiome MetaCyc pathway (RUMP-PWY|formaldehyde oxidation I),Phenotype,Vaginal microbiome MetaCyc pathway (RUMP-PWY|formaldehyde oxidation I)
45614,Vaginal microbiome MetaCyc pathway (PYRIDOXSYN-PWY|pyridoxal 5'-phosphate biosynthesis I),Phenotype,Vaginal microbiome MetaCyc pathway (PYRIDOXSYN-PWY|pyridoxal 5'-phosphate biosynthesis I)
45616,Cutaneous melanoma (MTAG),Phenotype,Cutaneous melanoma (MTAG)
45623,Medication use (agents acting on the renin-angiotensin system),Phenotype,Medication use (agents acting on the renin-angiotensin system)
45654,Regional cortical thickness (medialorbitofrontal),Phenotype,Regional cortical thickness (medialorbitofrontal)
45655,Regional cortical thickness (parahippocampal),Phenotype,Regional cortical thickness (parahippocampal)
45656,Regional cortical thickness (inferiorparietal),Phenotype,Regional cortical thickness (inferiorparietal)
45658,Regional cortical thickness (lingual),Phenotype,Regional cortical thickness (lingual)
45659,Regional cortical thickness (lateraloccipital),Phenotype,Regional cortical thickness (lateraloccipital)
45660,Vaginal microbiome MetaCyc pathway (PWY-6151|S-adenosyl-L-methionine cycle I),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6151|S-adenosyl-L-methionine cycle I)
45662,Vaginal microbiome MetaCyc pathway (PWY-621|sucrose degradation III (sucrose invertase)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-621|sucrose degradation III (sucrose invertase))
45663,Vaginal microbiome MetaCyc pathway (PWY-6123|inosine-5'-phosphate biosynthesis I),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6123|inosine-5'-phosphate biosynthesis I)
45665,Vaginal microbiome MetaCyc pathway (PWY-6125|superpathway of guanosine nucleotides de novo biosynthesis II),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6125|superpathway of guanosine nucleotides de novo biosynthesis II)
45666,Vaginal microbiome MetaCyc pathway (PWY-6700|queuosine biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6700|queuosine biosynthesis)
45667,Vaginal microbiome MetaCyc pathway (PWY-6277|superpathway of 5-aminoimidazole ribonucleotide biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-6277|superpathway of 5-aminoimidazole ribonucleotide biosynthesis)
45669,Vaginal microbiome MetaCyc pathway (PWY-5863|superpathway of phylloquinol biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5863|superpathway of phylloquinol biosynthesis)
45671,Vaginal microbiome MetaCyc pathway (PWY-5896|superpathway of menaquinol-10 biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5896|superpathway of menaquinol-10 biosynthesis)
45672,Vaginal microbiome MetaCyc pathway (PWY-5897|superpathway of menaquinol-11 biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5897|superpathway of menaquinol-11 biosynthesis)
45673,Vaginal microbiome MetaCyc pathway (PWY-5899|superpathway of menaquinol-13 biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5899|superpathway of menaquinol-13 biosynthesis)
45674,Vaginal microbiome MetaCyc pathway (PWY490-3|nitrate reduction VI (assimilatory)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY490-3|nitrate reduction VI (assimilatory))
45676,Vaginal microbiome MetaCyc pathway (PYRIDNUCSAL-PWY|NAD salvage pathway I),Phenotype,Vaginal microbiome MetaCyc pathway (PYRIDNUCSAL-PWY|NAD salvage pathway I)
45677,Vaginal microbiome MetaCyc pathway (PYRIDNUCSYN-PWY|NAD biosynthesis I (from aspartate)),Phenotype,Vaginal microbiome MetaCyc pathway (PYRIDNUCSYN-PWY|NAD biosynthesis I (from aspartate))
45678,Vaginal microbiome MetaCyc pathway (PWY0-321|phenylacetate degradation I (aerobic)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY0-321|phenylacetate degradation I (aerobic))
45690,Vaginal microbiome MetaCyc pathway (PWY0-42|2-methylcitrate cycle I),Phenotype,Vaginal microbiome MetaCyc pathway (PWY0-42|2-methylcitrate cycle I)
45692,Vaginal microbiome MetaCyc pathway (PWY0-862|(5Z)-dodec-5-enoate biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY0-862|(5Z)-dodec-5-enoate biosynthesis)
45694,Vaginal microbiome MetaCyc pathway (PWY1G-0|mycothiol biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY1G-0|mycothiol biosynthesis)
45697,Pseudouridine levels,Phenotype,Pseudouridine levels
45699,Medication use (calcium channel blockers),Phenotype,Medication use (calcium channel blockers)
45705,High-density lipoprotein mediated cholesterol efflux capacity,Phenotype,High-density lipoprotein mediated cholesterol efflux capacity
45706,White matter lesions (Fazekas score),Phenotype,White matter lesions (Fazekas score)
45709,Left hippocampal volume,Phenotype,Left hippocampal volume
45712,Global cognition (Mini Mental State Examination) (longitudinal),Phenotype,Global cognition (Mini Mental State Examination) (longitudinal)
45723,Facial wrinkles (under eye),Phenotype,Facial wrinkles (under eye)
45726,Sib-shared facial trait 757; Facial segment 37; 3D morphology of the philtrium,Phenotype,Sib-shared facial trait 757; Facial segment 37; 3D morphology of the philtrium
45728,Sib-shared facial trait 782; Facial segment 40; 3D morphology of the nose sides,Phenotype,Sib-shared facial trait 782; Facial segment 40; 3D morphology of the nose sides
45730,Sib-shared facial trait 788; Facial segment 42; 3D morphology of the nose sides,Phenotype,Sib-shared facial trait 788; Facial segment 42; 3D morphology of the nose sides
45731,Sib-shared facial trait 823; Facial segment 44; 3D morphology of the nose apex,Phenotype,Sib-shared facial trait 823; Facial segment 44; 3D morphology of the nose apex
45733,Sib-shared facial trait 835; Facial segment 45; 3D morphology of the nose alae,Phenotype,Sib-shared facial trait 835; Facial segment 45; 3D morphology of the nose alae
45735,Sib-shared facial trait 869; Facial segment 50; 3D morphology of the cheeks,Phenotype,Sib-shared facial trait 869; Facial segment 50; 3D morphology of the cheeks
45737,Inosine levels,Phenotype,Inosine levels
45738,Isobutyrylcarnitine (c4) levels,Phenotype,Isobutyrylcarnitine (c4) levels
45739,Ornithine levels (Metabolon platform),Phenotype,Ornithine levels (Metabolon platform)
45741,Regional cortical thickness (frontalpole),Phenotype,Regional cortical thickness (frontalpole)
45743,Regional cortical thickness (insula),Phenotype,Regional cortical thickness (insula)
45744,Vaginal microbiome MetaCyc pathway (PWY-5837|1--4-dihydroxy-2-naphthoate biosynthesis I),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5837|1--4-dihydroxy-2-naphthoate biosynthesis I)
45746,Vaginal microbiome MetaCyc pathway (PWY-5838|superpathway of menaquinol-8 biosynthesis I),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5838|superpathway of menaquinol-8 biosynthesis I)
45750,Vaginal microbiome MetaCyc pathway (PWY-5840|superpathway of menaquinol-7 biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5840|superpathway of menaquinol-7 biosynthesis)
45755,Vaginal microbiome MetaCyc pathway (PWY-5747|2-methylcitrate cycle II),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5747|2-methylcitrate cycle II)
45757,Vaginal microbiome MetaCyc pathway (PWY-5695|urate biosynthesis/inosine 5'-phosphate degradation),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-5695|urate biosynthesis/inosine 5'-phosphate degradation)
45763,Vaginal microbiome MetaCyc pathway (PWY-7539|6-hydroxymethyl-dihydropterin diphosphate biosynthesis III (Chlamydia)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7539|6-hydroxymethyl-dihydropterin diphosphate biosynthesis III (Chlamydia))
45765,Vaginal microbiome MetaCyc pathway (PWY-7664|oleate biosynthesis IV (anaerobic)),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7664|oleate biosynthesis IV (anaerobic))
45767,Vaginal microbiome MetaCyc pathway (PWY-7373|superpathway of demethylmenaquinol-6 biosynthesis II),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7373|superpathway of demethylmenaquinol-6 biosynthesis II)
45776,Medication use (adrenergics-- inhalants),Phenotype,Medication use (adrenergics-- inhalants)
45779,Cognitive performance (language ability) (longitudinal),Phenotype,Cognitive performance (language ability) (longitudinal)
45782,Medication use (antihistamines for systemic use),Phenotype,Medication use (antihistamines for systemic use)
45783,Medication use (antiglaucoma preparations and miotics),Phenotype,Medication use (antiglaucoma preparations and miotics)
45784,Cognitive function (delayed memory) (longitudinal),Phenotype,Cognitive function (delayed memory) (longitudinal)
45786,Cognitive function (delayed memory),Phenotype,Cognitive function (delayed memory)
45790,Cognitive function (immediate memory),Phenotype,Cognitive function (immediate memory)
45795,Medication use (glucocorticoids),Phenotype,Medication use (glucocorticoids)
45806,Regional cortical thickness (entorhinal),Phenotype,Regional cortical thickness (entorhinal)
45807,Regional cortical thickness (fusiform),Phenotype,Regional cortical thickness (fusiform)
45808,Regional cortical thickness (caudalmiddlefrontal),Phenotype,Regional cortical thickness (caudalmiddlefrontal)
45810,Global cortical thickness (GlobalMeanMean),Phenotype,Global cortical thickness (GlobalMeanMean)
45812,Tyrosine levels (Biocrates platform),Phenotype,Tyrosine levels (Biocrates platform)
45814,Threonine levels (Metabolon platform),Phenotype,Threonine levels (Metabolon platform)
45816,Oleoylcarnitine levels (Metabolon platform),Phenotype,Oleoylcarnitine levels (Metabolon platform)
45818,1-palmitoleoylglycerophosphocholine levels (Metabolon platform),Phenotype,1-palmitoleoylglycerophosphocholine levels (Metabolon platform)
45820,X-11469 levels,Phenotype,X-11469 levels
45822,X-12798 levels,Phenotype,X-12798 levels
45823,X-13435 levels,Phenotype,X-13435 levels
45825,X-14086 levels,Phenotype,X-14086 levels
45827,Sib-shared facial trait 891; Facial segment 52; 3D morphology of the outer cheeks,Phenotype,Sib-shared facial trait 891; Facial segment 52; 3D morphology of the outer cheeks
45829,Sib-shared facial trait 920; Facial segment 56; 3D morphology of the middle forehead,Phenotype,Sib-shared facial trait 920; Facial segment 56; 3D morphology of the middle forehead
45831,Sib-shared facial trait 1000; Facial segment 60; 3D morphology of the eye sockets,Phenotype,Sib-shared facial trait 1000; Facial segment 60; 3D morphology of the eye sockets
45833,Elevated alanine aminotransferase and aspartate aminotransferase levels in acute lymphoblastic leukemia,Phenotype,Elevated alanine aminotransferase and aspartate aminotransferase levels in acute lymphoblastic leukemia
45850,Vaginal microbiome MetaCyc pathway (PWY-7328|superpathway of UDP-glucose-derived O-antigen building blocks biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7328|superpathway of UDP-glucose-derived O-antigen building blocks biosynthesis)
45852,Vaginal microbiome MetaCyc pathway (PWY-7237|myo--- chiro- and scillo-inositol degradation),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7237|myo--- chiro- and scillo-inositol degradation)
45854,Vaginal microbiome MetaCyc pathway (PWY-7242|D-fructuronate degradation),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7242|D-fructuronate degradation)
45855,Vaginal microbiome MetaCyc pathway (PWY-7219|adenosine ribonucleotides de novo biosynthesis),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7219|adenosine ribonucleotides de novo biosynthesis)
45857,Vaginal microbiome MetaCyc pathway (PWY-7220|adenosine deoxyribonucleotides de novo biosynthesis II),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7220|adenosine deoxyribonucleotides de novo biosynthesis II)
45859,Vaginal microbiome MetaCyc pathway (PWY-7222|guanosine deoxyribonucleotides de novo biosynthesis II),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7222|guanosine deoxyribonucleotides de novo biosynthesis II)
45860,Vaginal microbiome MetaCyc pathway (PWY-7371|1--4-dihydroxy-6-naphthoate biosynthesis II),Phenotype,Vaginal microbiome MetaCyc pathway (PWY-7371|1--4-dihydroxy-6-naphthoate biosynthesis II)
45864,Vaginal microbiome MetaCyc pathway (UBISYN-PWY|superpathway of ubiquinol-8 biosynthesis (prokaryotic)),Phenotype,Vaginal microbiome MetaCyc pathway (UBISYN-PWY|superpathway of ubiquinol-8 biosynthesis (prokaryotic))
45865,Vaginal microbiome presence (c_Actinobacteria),Phenotype,Vaginal microbiome presence (c_Actinobacteria)
45868,Vaginal microbiome presence (s_Dialister micraerophilus),Phenotype,Vaginal microbiome presence (s_Dialister micraerophilus)
45869,Vaginal microbiome presence (s_Lactobacillus mulieris),Phenotype,Vaginal microbiome presence (s_Lactobacillus mulieris)
45871,Vaginal microbiome presence (f_Mycoplasmataceae),Phenotype,Vaginal microbiome presence (f_Mycoplasmataceae)
45872,Vaginal microbiome presence (g_Dialister),Phenotype,Vaginal microbiome presence (g_Dialister)
45873,Vaginal microbiome presence (g_Megasphaera),Phenotype,Vaginal microbiome presence (g_Megasphaera)
45874,Vaginal microbiome presence (p_Proteobacteria),Phenotype,Vaginal microbiome presence (p_Proteobacteria)
45875,Vaginal microbiome presence (s_Aerococcus christensenii),Phenotype,Vaginal microbiome presence (s_Aerococcus christensenii)
45877,Vaginal microbiome relative abundance (f_Lachnospiraceae),Phenotype,Vaginal microbiome relative abundance (f_Lachnospiraceae)
45881,Vaginal microbiome relative abundance (c_Gammaproteobacteria),Phenotype,Vaginal microbiome relative abundance (c_Gammaproteobacteria)
45882,Vaginal microbiome relative abundance (f_Aerococcaceae),Phenotype,Vaginal microbiome relative abundance (f_Aerococcaceae)
45883,Facial skin elasticity,Phenotype,Facial skin elasticity
45886,Facial skin melanin,Phenotype,Facial skin melanin
45888,Facial skin gloss,Phenotype,Facial skin gloss
45894,Biological age (PhenoAge),Phenotype,Biological age (PhenoAge)
45903,Global cognition (Mini Mental State Examination),Phenotype,Global cognition (Mini Mental State Examination)
45908,Cognitive function (immediate memory) (longitudinal),Phenotype,Cognitive function (immediate memory) (longitudinal)
45926,Regional cortical thickness (superiorfrontal),Phenotype,Regional cortical thickness (superiorfrontal)
45927,Sib-shared facial trait 524; Facial segment 18; 3D morphology of the philtrium,Phenotype,Sib-shared facial trait 524; Facial segment 18; 3D morphology of the philtrium
45929,Sib-shared facial trait 528; Facial segment 18; 3D morphology of the philtrium,Phenotype,Sib-shared facial trait 528; Facial segment 18; 3D morphology of the philtrium
45931,Sib-shared facial trait 232; Facial segment 5; 3D morphology of the nose,Phenotype,Sib-shared facial trait 232; Facial segment 5; 3D morphology of the nose
45933,Sib-shared facial trait 25; Facial segment 1; 3D morphology of the full face,Phenotype,Sib-shared facial trait 25; Facial segment 1; 3D morphology of the full face
45935,Sib-shared facial trait 247; Facial segment 6; 3D morphology of the lower face,Phenotype,Sib-shared facial trait 247; Facial segment 6; 3D morphology of the lower face
45937,Sib-shared facial trait 263; Facial segment 6; 3D morphology of the lower face,Phenotype,Sib-shared facial trait 263; Facial segment 6; 3D morphology of the lower face
45939,Sib-shared facial trait 283; Facial segment 7; 3D morphology of the upper face,Phenotype,Sib-shared facial trait 283; Facial segment 7; 3D morphology of the upper face
45941,Sib-shared facial trait 347; Facial segment 9; 3D morphology of the upper lip,Phenotype,Sib-shared facial trait 347; Facial segment 9; 3D morphology of the upper lip
45943,Sib-shared facial trait 159; Facial segment 3; 3D morphology of the upper and lower face-- excluding the nose,Phenotype,Sib-shared facial trait 159; Facial segment 3; 3D morphology of the upper and lower face-- excluding the nose
45945,Sib-shared facial trait 84; Facial segment 1; 3D morphology of the full face,Phenotype,Sib-shared facial trait 84; Facial segment 1; 3D morphology of the full face
45947,Sib-shared facial trait 290; Facial segment 7; 3D morphology of the upper face,Phenotype,Sib-shared facial trait 290; Facial segment 7; 3D morphology of the upper face
45949,Regional cortical thickness (superiorparietal),Phenotype,Regional cortical thickness (superiorparietal)
45950,Sib-shared facial trait 531; Facial segment 19; 3D morphology of the upper vermillion,Phenotype,Sib-shared facial trait 531; Facial segment 19; 3D morphology of the upper vermillion
45953,Regional cortical thickness (rostralanteriorcingulate),Phenotype,Regional cortical thickness (rostralanteriorcingulate)
45955,Regional cortical thickness (rostralmiddlefrontal),Phenotype,Regional cortical thickness (rostralmiddlefrontal)
45956,Regional cortical thickness (superiortemporal),Phenotype,Regional cortical thickness (superiortemporal)
45958,Regional cortical thickness (supramarginal),Phenotype,Regional cortical thickness (supramarginal)
45959,Regional cortical thickness (precentral),Phenotype,Regional cortical thickness (precentral)
45960,Regional cortical thickness (precuneus),Phenotype,Regional cortical thickness (precuneus)
45961,Acid sphingomyelinase-like phosphodiesterase 3a levels,Phenotype,Acid sphingomyelinase-like phosphodiesterase 3a levels
45963,Vascular endothelial growth factor A-- isoform 121 levels,Phenotype,Vascular endothelial growth factor A-- isoform 121 levels
45964,alpha-2-macroglobulin receptor-associated protein levels,Phenotype,alpha-2-macroglobulin receptor-associated protein levels
45976,Oxaliplatin-induced peripheral sensory neuropathy in colon cancer,Phenotype,Oxaliplatin-induced peripheral sensory neuropathy in colon cancer
45978,Time to recovery from peripheral sensory neuropathy in colon cancer,Phenotype,Time to recovery from peripheral sensory neuropathy in colon cancer
45981,Oxaliplatin-induced allergic reactions in colon cancer,Phenotype,Oxaliplatin-induced allergic reactions in colon cancer
45989,Intracranial germ cell tumors,Phenotype,Intracranial germ cell tumors
45998,Advanced glycosylation end product-specific receptor-- soluble levels,Phenotype,Advanced glycosylation end product-specific receptor-- soluble levels
46000,Complement factor B levels,Phenotype,Complement factor B levels
46002,Cation-independent mannose-6-phosphate receptor levels,Phenotype,Cation-independent mannose-6-phosphate receptor levels
46009,Plasminogen levels,Phenotype,Plasminogen levels
46014,ICD10 K44: Diaphragmatic hernia,Phenotype,ICD10 K44: Diaphragmatic hernia
46016,Time to colon cancer recurrence,Phenotype,Time to colon cancer recurrence
46024,Retinoic acid receptor responder protein 2 levels,Phenotype,Retinoic acid receptor responder protein 2 levels
46041,Stem Cell Growth Factor-alpha levels,Phenotype,Stem Cell Growth Factor-alpha levels
46043,Brain-specific serine protease 4 levels,Phenotype,Brain-specific serine protease 4 levels
46046,Complement C4 levels,Phenotype,Complement C4 levels
46069,CD109 antigen levels,Phenotype,CD109 antigen levels
46083,Glycine levels,Phenotype,Glycine levels
46085,Glycoprotein acetyls (mainly a1-acid glycoprotein),Phenotype,Glycoprotein acetyls (mainly a1-acid glycoprotein)
46086,Mean diameter of VLDL particles,Phenotype,Mean diameter of VLDL particles
46091,Decenoylcarnitine levels,Phenotype,Decenoylcarnitine levels
46093,Decanoylcarnitine levels,Phenotype,Decanoylcarnitine levels
46095,Butyrylcarnitine levels,Phenotype,Butyrylcarnitine levels
46096,Sarcosine levels,Phenotype,Sarcosine levels
46098,Dodecanoylcarnitine levels,Phenotype,Dodecanoylcarnitine levels
46101,Octanoylcarnitine levels,Phenotype,Octanoylcarnitine levels
46102,Propionylcarnitine levels,Phenotype,Propionylcarnitine levels
46103,Dodecenoylcarnitine levels,Phenotype,Dodecenoylcarnitine levels
46104,Tetradecenoylcarnitine levels,Phenotype,Tetradecenoylcarnitine levels
46105,QTc interval,Phenotype,QTc interval
46120,F-savour/caloric food liking (derived food-liking factor),Phenotype,F-savour/caloric food liking (derived food-liking factor)
46121,F-seafood liking (derived food-liking factor),Phenotype,F-seafood liking (derived food-liking factor)
46136,F-savoury food liking (derived food-liking factor),Phenotype,F-savoury food liking (derived food-liking factor)
46138,Salmon liking,Phenotype,Salmon liking
46139,Sardines liking,Phenotype,Sardines liking
46146,F-sharp flavour liking (derived food-liking factor),Phenotype,F-sharp flavour liking (derived food-liking factor)
46147,F-small fish liking (derived food-liking factor),Phenotype,F-small fish liking (derived food-liking factor)
46150,Shellfish liking,Phenotype,Shellfish liking
46175,Oral corticosteroid burst in asthma,Phenotype,Oral corticosteroid burst in asthma
46184,Asthma exacerbations in inhaled corticosteroid treatment,Phenotype,Asthma exacerbations in inhaled corticosteroid treatment
46193,Germline telomere length in neuroblastoma,Phenotype,Germline telomere length in neuroblastoma
46195,Serum uromodulin levels (antibody-based assay),Phenotype,Serum uromodulin levels (antibody-based assay)
46197,Serum uromodulin levels (aptamer-based assay),Phenotype,Serum uromodulin levels (aptamer-based assay)
46209,COVID-19 (hospitalized vs population),Phenotype,COVID-19 (hospitalized vs population)
46210,SARS-CoV-2 infection,Phenotype,SARS-CoV-2 infection
46212,Environmental pollutants exposure (AC50 low),Phenotype,Environmental pollutants exposure (AC50 low)
46215,Environmental pollutants exposure (AC50 high),Phenotype,Environmental pollutants exposure (AC50 high)
46218,Cadmium chloride levels,Phenotype,Cadmium chloride levels
46219,Chlorpyrifos levels,Phenotype,Chlorpyrifos levels
46220,Di-n-butyl phthalate levels,Phenotype,Di-n-butyl phthalate levels
46221,Diazinon levels,Phenotype,Diazinon levels
46222,Nickel levels,Phenotype,Nickel levels
46223,Pentachlorophenol levels,Phenotype,Pentachlorophenol levels
46224,Parathion levels,Phenotype,Parathion levels
46226,Ideal cardiovascular health score (clinical and behavioral),Phenotype,Ideal cardiovascular health score (clinical and behavioral)
46228,Ideal cardiovascular health (clinical and behavioral),Phenotype,Ideal cardiovascular health (clinical and behavioral)
46229,alpha-Aminoadipic acid levels,Phenotype,alpha-Aminoadipic acid levels
46233,Environmental pollutants exposure (POD high),Phenotype,Environmental pollutants exposure (POD high)
46234,Environmental pollutants exposure (POD low),Phenotype,Environmental pollutants exposure (POD low)
46240,Environmental pollutants exposure (Expo high),Phenotype,Environmental pollutants exposure (Expo high)
46241,Endrin levels,Phenotype,Endrin levels
46242,Ethion levels,Phenotype,Ethion levels
46243,Endosulfan levels,Phenotype,Endosulfan levels
46248,Heptachlor levels,Phenotype,Heptachlor levels
46250,Environmental pollutants exposure (Expo low),Phenotype,Environmental pollutants exposure (Expo low)
46253,Lithium clearance,Phenotype,Lithium clearance
46255,Heptachlor epoxide levels,Phenotype,Heptachlor epoxide levels
46256,Mercuric chloride levels,Phenotype,Mercuric chloride levels
46257,Methoxychlor levels,Phenotype,Methoxychlor levels
46258,Mercuric chloride-2 levels,Phenotype,Mercuric chloride-2 levels
46259,Cardioembolic stroke (MTAG),Phenotype,Cardioembolic stroke (MTAG)
46262,2--4--5-trichlorophenol levels,Phenotype,2--4--5-trichlorophenol levels
46265,Aldrin levels,Phenotype,Aldrin levels
46266,Azinphos methyl levels,Phenotype,Azinphos methyl levels
46268,DDT metabolite (DDD p-p') levels,Phenotype,DDT metabolite (DDD p-p') levels
46269,DDT metabolite (DDT o-p') levels,Phenotype,DDT metabolite (DDT o-p') levels
46270,DDT metabolite (DDT p-p') levels,Phenotype,DDT metabolite (DDT p-p') levels
46273,4--6-dinitro-o-cresol levels,Phenotype,4--6-dinitro-o-cresol levels
46274,2--4--5-trichlorophenol-2 levels,Phenotype,2--4--5-trichlorophenol-2 levels
46278,Cobalt levels,Phenotype,Cobalt levels
46280,Disulfoton levels,Phenotype,Disulfoton levels
46281,Dieldrin levels,Phenotype,Dieldrin levels
46282,Dicofol levels,Phenotype,Dicofol levels
46289,Potassium chromate levels,Phenotype,Potassium chromate levels
46290,Atrial fibrillation (MTAG),Phenotype,Atrial fibrillation (MTAG)
46294,Environmental pollutants exposure (RfD high),Phenotype,Environmental pollutants exposure (RfD high)
46295,Environmental pollutants exposure (RfD low),Phenotype,Environmental pollutants exposure (RfD low)
46311,A body shape index,Phenotype,A body shape index
46313,Sex hormone-binding globulin levels adjusted for BMI,Phenotype,Sex hormone-binding globulin levels adjusted for BMI
46314,Coffee consumption (cups per day),Phenotype,Coffee consumption (cups per day)
46315,Gastroesophageal reflux disease-- peptic ulcer disease and/or corresponding medications and treatment,Phenotype,Gastroesophageal reflux disease-- peptic ulcer disease and/or corresponding medications and treatment
46316,Irritable bowel syndrome,Phenotype,Irritable bowel syndrome
46317,Mouth ulcers,Phenotype,Mouth ulcers
46325,Total testosterone levels,Phenotype,Total testosterone levels
46328,Digit length ratio (right hand),Phenotype,Digit length ratio (right hand)
46329,Digit length ratio (left hand),Phenotype,Digit length ratio (left hand)
46330,Cerebrospinal fluid p-Tau181p:AB1-42 ratio,Phenotype,Cerebrospinal fluid p-Tau181p:AB1-42 ratio
46331,Adult body size,Phenotype,Adult body size
46332,IgM levels,Phenotype,IgM levels
46333,IgG levels,Phenotype,IgG levels
46334,Diverticular disease,Phenotype,Diverticular disease
46335,Anti-sp100 seropositivity in primary biliary cholangitis,Phenotype,Anti-sp100 seropositivity in primary biliary cholangitis
46336,Cognitive function in longevity,Phenotype,Cognitive function in longevity
46337,Systolic blood pressure (baseline),Phenotype,Systolic blood pressure (baseline)
46338,Systolic blood pressure change trajectory,Phenotype,Systolic blood pressure change trajectory
46339,Autoimmune pulmonary alveolar proteinosis,Phenotype,Autoimmune pulmonary alveolar proteinosis
46341,Well-being spectrum (multivariate analysis),Phenotype,Well-being spectrum (multivariate analysis)
46342,Triiodothyronine levels and thyroxine levels,Phenotype,Triiodothyronine levels and thyroxine levels
46343,Carpal tunnel syndrome,Phenotype,Carpal tunnel syndrome
46344,Hand grip strength,Phenotype,Hand grip strength
46345,Cognitive impairment test score,Phenotype,Cognitive impairment test score
46347,Diastolic blood pressure change trajectory,Phenotype,Diastolic blood pressure change trajectory
46348,Academic attainment (maths),Phenotype,Academic attainment (maths)
46349,Cirrhosis (alcohol related),Phenotype,Cirrhosis (alcohol related)
46351,Diastolic blood pressure (long-term average),Phenotype,Diastolic blood pressure (long-term average)
46352,Academic attainment (science),Phenotype,Academic attainment (science)
46354,Metabolically unhealthy in obesity,Phenotype,Metabolically unhealthy in obesity
46355,Metabolically unhealthy in normal weight,Phenotype,Metabolically unhealthy in normal weight
46356,Cutaneous leishmaniasis,Phenotype,Cutaneous leishmaniasis
46366,joint destruction in rheumatoid arthritis (rapid vs slow),Phenotype,joint destruction in rheumatoid arthritis (rapid vs slow)
46367,Hypertrophic cardiomyopathy,Phenotype,Hypertrophic cardiomyopathy
46368,Lack of behavioral control,Phenotype,Lack of behavioral control
46369,Frontal fibrosing alopecia,Phenotype,Frontal fibrosing alopecia
46371,Alcohol use disorder (consumption score),Phenotype,Alcohol use disorder (consumption score)
46372,Serum urate levels in chronic kidney disease,Phenotype,Serum urate levels in chronic kidney disease
46375,Ferritin levels,Phenotype,Ferritin levels
46376,Declining hemoglobin trajectory in blood donors,Phenotype,Declining hemoglobin trajectory in blood donors
46385,BRCA1/2-negative high-risk breast cancer,Phenotype,BRCA1/2-negative high-risk breast cancer
46386,Hip shape (DXA scan),Phenotype,Hip shape (DXA scan)
46387,Addison's disease,Phenotype,Addison's disease
46390,Vesicoureteral reflux,Phenotype,Vesicoureteral reflux
46391,Early age-related macular degeneration,Phenotype,Early age-related macular degeneration
46393,Facial pigmentation measurement (UV light),Phenotype,Facial pigmentation measurement (UV light)
46394,Facial pigmentation measurement (polar light),Phenotype,Facial pigmentation measurement (polar light)
46395,Response to tofacitinib treatment in rheumatoid arthritis (herpes zoster)(time to event),Phenotype,Response to tofacitinib treatment in rheumatoid arthritis (herpes zoster)(time to event)
46396,Response to tofacitinib treatment in psoriasis (herpes zoster)(time to event),Phenotype,Response to tofacitinib treatment in psoriasis (herpes zoster)(time to event)
46397,Response to tofacitinib treatment in rheumatoid arthritis (herpes zoster),Phenotype,Response to tofacitinib treatment in rheumatoid arthritis (herpes zoster)
46398,Response to tofacitinib treatment in psoriasis (herpes zoster),Phenotype,Response to tofacitinib treatment in psoriasis (herpes zoster)
46399,Response to tofacitinib treatment (herpes zoster)(time to event),Phenotype,Response to tofacitinib treatment (herpes zoster)(time to event)
46400,Response to tofacitinib treatment (herpes zoster),Phenotype,Response to tofacitinib treatment (herpes zoster)
46401,Ulna and radius bone mineral density,Phenotype,Ulna and radius bone mineral density
46402,Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma,Phenotype,Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma
46404,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,Phenotype,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
46405,Carbamazepine metabolism (carbamazepine-10--11-diol to carbamazepine ratio) in epilepsy,Phenotype,Carbamazepine metabolism (carbamazepine-10--11-diol to carbamazepine ratio) in epilepsy
46406,Asthma with severe exacerbations,Phenotype,Asthma with severe exacerbations
46407,Diverticulitis,Phenotype,Diverticulitis
46408,Bipolar disorder or ulcerative colitis (MTAG),Phenotype,Bipolar disorder or ulcerative colitis (MTAG)
46411,Bipolar disorder or inflammatory bowel disease (MTAG),Phenotype,Bipolar disorder or inflammatory bowel disease (MTAG)
46413,2-hydroxyadipate levels,Phenotype,2-hydroxyadipate levels
46415,Eukaryotic elongation factor 2 kinase levels,Phenotype,Eukaryotic elongation factor 2 kinase levels
46417,Tapasin levels,Phenotype,Tapasin levels
46419,Proteasome subunit beta type-1 levels,Phenotype,Proteasome subunit beta type-1 levels
46421,NAD-dependent protein deacylase sirtuin-5-- mitochondrial levels,Phenotype,NAD-dependent protein deacylase sirtuin-5-- mitochondrial levels
46426,Chloride intracellular channel protein 5 levels,Phenotype,Chloride intracellular channel protein 5 levels
46428,Integrin beta-2 levels,Phenotype,Integrin beta-2 levels
46429,Histone deacetylase complex subunit SAP30 levels,Phenotype,Histone deacetylase complex subunit SAP30 levels
46438,Migraine with aura (age at onset),Phenotype,Migraine with aura (age at onset)
46440,Interleukin-17B (analyte X3499.77) levels,Phenotype,Interleukin-17B (analyte X3499.77) levels
46444,Epididymis-specific alpha-mannosidase levels,Phenotype,Epididymis-specific alpha-mannosidase levels
46445,Triggering receptor expressed on myeloid cells 1 levels,Phenotype,Triggering receptor expressed on myeloid cells 1 levels
46447,Cation-independent mannose-6-phosphate receptor (analyte X3676.15) levels,Phenotype,Cation-independent mannose-6-phosphate receptor (analyte X3676.15) levels
46448,Membrane frizzled-related protein levels,Phenotype,Membrane frizzled-related protein levels
46451,Butyrophilin subfamily 2 member A1 levels,Phenotype,Butyrophilin subfamily 2 member A1 levels
46453,N-acetylglucosamine-6-sulfatase (analyte X3616.3) levels,Phenotype,N-acetylglucosamine-6-sulfatase (analyte X3616.3) levels
46456,Lymphocyte antigen 86 levels,Phenotype,Lymphocyte antigen 86 levels
46460,SLAM family member 5 (analyte X3642.4) levels,Phenotype,SLAM family member 5 (analyte X3642.4) levels
46462,Thrombospondin-2 (analyte X3339.33) levels,Phenotype,Thrombospondin-2 (analyte X3339.33) levels
46464,Tryptase beta-2 (analyte X3403.1) levels,Phenotype,Tryptase beta-2 (analyte X3403.1) levels
46466,Granzyme A (analyte X3440.7) levels,Phenotype,Granzyme A (analyte X3440.7) levels
46468,Severe coronary stenosis (family history of CAD interaction),Phenotype,Severe coronary stenosis (family history of CAD interaction)
46469,Severe coronary stenosis,Phenotype,Severe coronary stenosis
46471,Lung adenocarcinoma (conditioned on cigarettes per day),Phenotype,Lung adenocarcinoma (conditioned on cigarettes per day)
46472,Squamous cell lung carcinoma (conditioned on cigarettes per day),Phenotype,Squamous cell lung carcinoma (conditioned on cigarettes per day)
46473,Lung cancer (conditioned on cigarettes per day),Phenotype,Lung cancer (conditioned on cigarettes per day)
46475,Methazolamide-induced Stevens-Johnson syndrome / toxic epidermal necrolysis,Phenotype,Methazolamide-induced Stevens-Johnson syndrome / toxic epidermal necrolysis
46486,FAD-linked sulfhydryl oxidase ALR levels,Phenotype,FAD-linked sulfhydryl oxidase ALR levels
46488,Otoraplin levels,Phenotype,Otoraplin levels
46490,Neuregulin-1-- sensory and motor neuron-derived factor isoform levels,Phenotype,Neuregulin-1-- sensory and motor neuron-derived factor isoform levels
46491,5'-Nucleotidase (analyte X15452.5) levels,Phenotype,5'-Nucleotidase (analyte X15452.5) levels
46493,T-cell surface glycoprotein CD8 alpha chain (analyte X15462.28) levels,Phenotype,T-cell surface glycoprotein CD8 alpha chain (analyte X15462.28) levels
46494,Collagen alpha-1(IX) chain (analyte X15466.30) levels,Phenotype,Collagen alpha-1(IX) chain (analyte X15466.30) levels
46496,Low-density lipoprotein receptor-related protein 11 (analyte X15472.16) levels,Phenotype,Low-density lipoprotein receptor-related protein 11 (analyte X15472.16) levels
46498,Vascular non-inflammatory molecule 2 (analyte X15480.2) levels,Phenotype,Vascular non-inflammatory molecule 2 (analyte X15480.2) levels
46500,Cation-independent mannose-6-phosphate receptor (analyte X16057.6) levels,Phenotype,Cation-independent mannose-6-phosphate receptor (analyte X16057.6) levels
46502,Nidogen-2 (analyte X16060.99) levels,Phenotype,Nidogen-2 (analyte X16060.99) levels
46504,Triggering receptor expressed on myeloid cells 2 (analyte X16300.4) levels,Phenotype,Triggering receptor expressed on myeloid cells 2 (analyte X16300.4) levels
46505,Syndecan-3 levels,Phenotype,Syndecan-3 levels
46507,Ephrin type-A receptor 7 (analyte X15580.2) levels,Phenotype,Ephrin type-A receptor 7 (analyte X15580.2) levels
46509,Myelin-oligodendrocyte glycoprotein levels,Phenotype,Myelin-oligodendrocyte glycoprotein levels
46510,Prostasin (analyte X15513.108) levels,Phenotype,Prostasin (analyte X15513.108) levels
46512,M.tuberculosis induced TNF-a level,Phenotype,M.tuberculosis induced TNF-a level
46514,S.typhi induced IL-10 level,Phenotype,S.typhi induced IL-10 level
46517,S.typhi induced IL-1B level,Phenotype,S.typhi induced IL-1B level
46519,S.pneumoniae induced IL-1B level,Phenotype,S.pneumoniae induced IL-1B level
46521,S.pneumoniae induced IL-6 level,Phenotype,S.pneumoniae induced IL-6 level
46523,S.pneumoniae induced TNF-a level,Phenotype,S.pneumoniae induced TNF-a level
46525,LPS induced IL-1B level,Phenotype,LPS induced IL-1B level
46527,S.enteritidis induced IFN-G level,Phenotype,S.enteritidis induced IFN-G level
46529,Protein disulfide-isomerase A3 (analyte X7832.181) levels,Phenotype,Protein disulfide-isomerase A3 (analyte X7832.181) levels
46531,S-arrestin levels,Phenotype,S-arrestin levels
46533,Double C2-like domain-containing protein beta levels,Phenotype,Double C2-like domain-containing protein beta levels
46535,Glycoprotein endo-alpha-1--2-mannosidase levels,Phenotype,Glycoprotein endo-alpha-1--2-mannosidase levels
46537,Ferritin-- mitochondrial levels,Phenotype,Ferritin-- mitochondrial levels
46538,N-acetylated-alpha-linked acidic dipeptidase 2 levels,Phenotype,N-acetylated-alpha-linked acidic dipeptidase 2 levels
46539,Chronic obstructive pulmonary disease in non-current smokers,Phenotype,Chronic obstructive pulmonary disease in non-current smokers
46540,Schizophrenia vs bipolar disorder (ordinary least squares (OLS)),Phenotype,Schizophrenia vs bipolar disorder (ordinary least squares (OLS))
46542,Schizophrenia vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS)),Phenotype,Schizophrenia vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS))
46544,Neuferricin levels,Phenotype,Neuferricin levels
46545,39S ribosomal protein L55-- mitochondrial levels,Phenotype,39S ribosomal protein L55-- mitochondrial levels
46547,P-selectin glycoprotein ligand 1:Extracellular domain levels,Phenotype,P-selectin glycoprotein ligand 1:Extracellular domain levels
46550,Collagen alpha-2(XI) chain levels,Phenotype,Collagen alpha-2(XI) chain levels
46552,Cyclic AMP-responsive element-binding protein 3-like protein 4 levels,Phenotype,Cyclic AMP-responsive element-binding protein 3-like protein 4 levels
46556,Cyclic AMP-dependent transcription factor ATF-6 beta levels,Phenotype,Cyclic AMP-dependent transcription factor ATF-6 beta levels
46558,Hepatitis A virus cellular receptor 2 (analyte X11481.25) levels,Phenotype,Hepatitis A virus cellular receptor 2 (analyte X11481.25) levels
46560,Signal peptide-- CUB and EGF-like domain-containing protein 3 levels,Phenotype,Signal peptide-- CUB and EGF-like domain-containing protein 3 levels
46562,Sphingomyelin phosphodiesterase levels,Phenotype,Sphingomyelin phosphodiesterase levels
46564,Secretagogin (analyte X10894.25) levels,Phenotype,Secretagogin (analyte X10894.25) levels
46566,N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase levels,Phenotype,N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase levels
46567,Thioredoxin domain-containing protein 5 levels,Phenotype,Thioredoxin domain-containing protein 5 levels
46569,Zymogen granule protein 16 homolog B levels,Phenotype,Zymogen granule protein 16 homolog B levels
46571,Low-density lipoprotein receptor-related protein 11 (analyte X8330.1) levels,Phenotype,Low-density lipoprotein receptor-related protein 11 (analyte X8330.1) levels
46572,Uronyl 2-sulfotransferase levels,Phenotype,Uronyl 2-sulfotransferase levels
46574,Allograft inflammatory factor 1 levels,Phenotype,Allograft inflammatory factor 1 levels
46575,Olfactomedin-like protein 3 (analyte X8660.33) levels,Phenotype,Olfactomedin-like protein 3 (analyte X8660.33) levels
46577,Dipeptidase 1 (analyte X8794.13) levels,Phenotype,Dipeptidase 1 (analyte X8794.13) levels
46579,Myeloid cell surface antigen CD33 levels,Phenotype,Myeloid cell surface antigen CD33 levels
46581,Natural cytotoxicity triggering receptor 3 levels,Phenotype,Natural cytotoxicity triggering receptor 3 levels
46582,Agouti-related protein levels,Phenotype,Agouti-related protein levels
46584,Delta-like protein 1 (analyte X8264.43) levels,Phenotype,Delta-like protein 1 (analyte X8264.43) levels
46586,Alpha-L-iduronidase levels,Phenotype,Alpha-L-iduronidase levels
46587,Lysosomal protective protein levels,Phenotype,Lysosomal protective protein levels
46588,Complement C2 levels,Phenotype,Complement C2 levels
46590,WAP-- kazal-- immunoglobulin-- kunitz and NTR domain-containing protein 1 levels,Phenotype,WAP-- kazal-- immunoglobulin-- kunitz and NTR domain-containing protein 1 levels
46592,melanoma-derived growth regulatory protein levels,Phenotype,melanoma-derived growth regulatory protein levels
46594,NKG2D ligand 3 levels,Phenotype,NKG2D ligand 3 levels
46598,Inguinal hernia,Phenotype,Inguinal hernia
46600,Bipolar disorder or Crohn's disease (MTAG),Phenotype,Bipolar disorder or Crohn's disease (MTAG)
46606,Intestinal permeability measurement,Phenotype,Intestinal permeability measurement
46607,Creutzfeldt-Jakob disease (sporadic),Phenotype,Creutzfeldt-Jakob disease (sporadic)
46608,Schizophrenia vs autism spectrum disorder (ordinary least squares (OLS)),Phenotype,Schizophrenia vs autism spectrum disorder (ordinary least squares (OLS))
46609,Diphosphomevalonate decarboxylase (analyte X19748.3) levels,Phenotype,Diphosphomevalonate decarboxylase (analyte X19748.3) levels
46611,Acylpyruvase FAHD1-- mitochondrial levels,Phenotype,Acylpyruvase FAHD1-- mitochondrial levels
46613,Charged multivesicular body protein 1a levels,Phenotype,Charged multivesicular body protein 1a levels
46614,Hydroxyacylglutathione hydrolase-- mitochondrial levels,Phenotype,Hydroxyacylglutathione hydrolase-- mitochondrial levels
46616,Enoyl-CoA delta isomerase 1-- mitochondrial levels,Phenotype,Enoyl-CoA delta isomerase 1-- mitochondrial levels
46618,Retinoic acid early transcript 1L protein (analyte X20526.3) levels,Phenotype,Retinoic acid early transcript 1L protein (analyte X20526.3) levels
46620,Nuclear apoptosis-inducing factor 1 levels,Phenotype,Nuclear apoptosis-inducing factor 1 levels
46622,Desmoglein-2 (analyte X20517.1) levels,Phenotype,Desmoglein-2 (analyte X20517.1) levels
46623,Gastric intrinsic factor levels,Phenotype,Gastric intrinsic factor levels
46625,Tripeptidyl-peptidase 1 levels,Phenotype,Tripeptidyl-peptidase 1 levels
46627,Butyrophilin subfamily 3 member A3 (analyte X17692.2) levels,Phenotype,Butyrophilin subfamily 3 member A3 (analyte X17692.2) levels
46629,Microtubule-associated proteins 1A/1B light chain 3A levels,Phenotype,Microtubule-associated proteins 1A/1B light chain 3A levels
46630,Succinate-semialdehyde dehydrogenase-- mitochondrial levels,Phenotype,Succinate-semialdehyde dehydrogenase-- mitochondrial levels
46632,Phosphomannomutase 2 levels,Phenotype,Phosphomannomutase 2 levels
46634,Valacyclovir hydrolase levels,Phenotype,Valacyclovir hydrolase levels
46636,Glycerol-3-phosphate phosphatase levels,Phenotype,Glycerol-3-phosphate phosphatase levels
46637,Promotilin levels,Phenotype,Promotilin levels
46639,Triggering receptor expressed on myeloid cells 2 (analyte X5635.66) levels,Phenotype,Triggering receptor expressed on myeloid cells 2 (analyte X5635.66) levels
46640,Chymotrypsinogen B2 levels,Phenotype,Chymotrypsinogen B2 levels
46643,Endophilin-A3 (analyte X23029.3) levels,Phenotype,Endophilin-A3 (analyte X23029.3) levels
46644,AN1-type zinc finger protein 2B levels,Phenotype,AN1-type zinc finger protein 2B levels
46645,Vasorin levels,Phenotype,Vasorin levels
46646,Cysteine-rich secretory protein LCCL domain-containing 2 levels,Phenotype,Cysteine-rich secretory protein LCCL domain-containing 2 levels
46648,Tenascin-X levels,Phenotype,Tenascin-X levels
46650,Trem-like transcript 2 protein levels,Phenotype,Trem-like transcript 2 protein levels
46651,Colipase levels,Phenotype,Colipase levels
46653,T-cell surface glycoprotein CD8 alpha chain (analyte X5992.50) levels,Phenotype,T-cell surface glycoprotein CD8 alpha chain (analyte X5992.50) levels
46654,Paraneoplastic antigen Ma2 levels,Phenotype,Paraneoplastic antigen Ma2 levels
46661,Glutathione S-transferase A2 levels,Phenotype,Glutathione S-transferase A2 levels
46685,Suicide attempt severity in mood disorders,Phenotype,Suicide attempt severity in mood disorders
46686,Suicidality in mood disorders,Phenotype,Suicidality in mood disorders
46691,Serpin B9 levels,Phenotype,Serpin B9 levels
46693,Alpha-L-fucoside fucohydrolase levels,Phenotype,Alpha-L-fucoside fucohydrolase levels
46694,L-dopachrome tautomerase levels,Phenotype,L-dopachrome tautomerase levels
46695,Shadow of prion protein levels,Phenotype,Shadow of prion protein levels
46697,Killer cell immunoglobulin-like receptor 2DS2 levels,Phenotype,Killer cell immunoglobulin-like receptor 2DS2 levels
46699,Apolipoprotein M (analyte X10445.20) levels,Phenotype,Apolipoprotein M (analyte X10445.20) levels
46701,Interleukin-18 receptor accessory protein (analyte X10457.3) levels,Phenotype,Interleukin-18 receptor accessory protein (analyte X10457.3) levels
46703,Splicing factor U2AF 65 kDa subunit levels,Phenotype,Splicing factor U2AF 65 kDa subunit levels
46705,Rac GTPase-activating protein 1 levels,Phenotype,Rac GTPase-activating protein 1 levels
46708,Plexin domain-containing protein 2:Extracellular domain levels,Phenotype,Plexin domain-containing protein 2:Extracellular domain levels
46710,Retinoic acid early transcript 1L protein (analyte X10589.7) levels,Phenotype,Retinoic acid early transcript 1L protein (analyte X10589.7) levels
46712,Protein Mdm4 levels,Phenotype,Protein Mdm4 levels
46714,N-acetylglucosamine-1-phosphotransferase subunit gamma levels,Phenotype,N-acetylglucosamine-1-phosphotransferase subunit gamma levels
46716,Leukocyte elastase inhibitor levels,Phenotype,Leukocyte elastase inhibitor levels
46721,Immunoglobulin D levels,Phenotype,Immunoglobulin D levels
46722,Neuropeptide W levels,Phenotype,Neuropeptide W levels
46724,Protein FAM110A (analyte X22371.46) levels,Phenotype,Protein FAM110A (analyte X22371.46) levels
46726,Acid sphingomyelinase-like phosphodiesterase 3a (analyte X4771.10) levels,Phenotype,Acid sphingomyelinase-like phosphodiesterase 3a (analyte X4771.10) levels
46727,CD83 antigen levels,Phenotype,CD83 antigen levels
46729,MHC class I polypeptide-related sequence B levels,Phenotype,MHC class I polypeptide-related sequence B levels
46734,Reticulon-4 receptor levels,Phenotype,Reticulon-4 receptor levels
46735,Platelet-activating factor acetylhydrolase levels,Phenotype,Platelet-activating factor acetylhydrolase levels
46737,Lactoylglutathione lyase levels,Phenotype,Lactoylglutathione lyase levels
46739,Peptidyl-prolyl cis-trans isomerase-like 1 levels,Phenotype,Peptidyl-prolyl cis-trans isomerase-like 1 levels
46740,Unconventional myosin-VI levels,Phenotype,Unconventional myosin-VI levels
46742,Complement C4b levels,Phenotype,Complement C4b levels
46745,Ras association domain-containing protein 2 levels,Phenotype,Ras association domain-containing protein 2 levels
46747,Delta-like protein 1 (analyte X5349.69) levels,Phenotype,Delta-like protein 1 (analyte X5349.69) levels
46751,Bipolar disorder vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS)),Phenotype,Bipolar disorder vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS))
46752,Anorexia nervosa vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS)),Phenotype,Anorexia nervosa vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS))
46753,Autism spectrum disorder vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS)),Phenotype,Autism spectrum disorder vs Tourette's syndrome and other tic disorders (ordinary least squares (OLS))
46754,ADHD vs anorexia nervosa (ordinary least squares (OLS)),Phenotype,ADHD vs anorexia nervosa (ordinary least squares (OLS))
46756,Ultradistal forearm bone mineral density,Phenotype,Ultradistal forearm bone mineral density
46757,Laminin-2 levels,Phenotype,Laminin-2 levels
46759,C4a anaphylatoxin levels,Phenotype,C4a anaphylatoxin levels
46763,Interleukin-17B (analyte X14022.17) levels,Phenotype,Interleukin-17B (analyte X14022.17) levels
46764,Fibroblast growth factor 7 (analyte X14031.18) levels,Phenotype,Fibroblast growth factor 7 (analyte X14031.18) levels
46765,Interleukin-15 receptor subunit alpha (analyte X14054.17) levels,Phenotype,Interleukin-15 receptor subunit alpha (analyte X14054.17) levels
46766,Acid sphingomyelinase-like phosphodiesterase 3a (analyte X14086.11) levels,Phenotype,Acid sphingomyelinase-like phosphodiesterase 3a (analyte X14086.11) levels
46768,Thrombospondin-2 (analyte X14111.15) levels,Phenotype,Thrombospondin-2 (analyte X14111.15) levels
46770,Tumor necrosis factor receptor superfamily member 10D levels,Phenotype,Tumor necrosis factor receptor superfamily member 10D levels
46772,Apolipoprotein M (analyte X14125.5) levels,Phenotype,Apolipoprotein M (analyte X14125.5) levels
46774,Interleukin-36 alpha levels,Phenotype,Interleukin-36 alpha levels
46777,Homeobox protein SIX6 levels,Phenotype,Homeobox protein SIX6 levels
46778,Uncharacterized metallophosphoesterase CSTP1 levels,Phenotype,Uncharacterized metallophosphoesterase CSTP1 levels
46780,Adhesion G-protein coupled receptor G1 levels,Phenotype,Adhesion G-protein coupled receptor G1 levels
46782,Tryptase beta-2 (analyte X14696.45) levels,Phenotype,Tryptase beta-2 (analyte X14696.45) levels
46784,Secretagogin (analyte X15305.7) levels,Phenotype,Secretagogin (analyte X15305.7) levels
46786,Thioredoxin-like protein 4B levels,Phenotype,Thioredoxin-like protein 4B levels
46787,Prolyl endopeptidase levels,Phenotype,Prolyl endopeptidase levels
46789,Ras-related protein Rab-14 levels,Phenotype,Ras-related protein Rab-14 levels
46790,Stromal cell-derived factor 2-like protein 1 levels,Phenotype,Stromal cell-derived factor 2-like protein 1 levels
46793,Protein G6b:Isoform A-- Extracellular domain levels,Phenotype,Protein G6b:Isoform A-- Extracellular domain levels
46797,IGF-like family receptor 1 levels,Phenotype,IGF-like family receptor 1 levels
46799,Protein-methionine sulfoxide oxidase MICAL1 levels,Phenotype,Protein-methionine sulfoxide oxidase MICAL1 levels
46800,Nodal modulator 2 levels,Phenotype,Nodal modulator 2 levels
46802,HLA class II histocompatibility antigen-- DQ alpha 2 chain levels,Phenotype,HLA class II histocompatibility antigen-- DQ alpha 2 chain levels
46806,DnaJ homolog subfamily B member 11 levels,Phenotype,DnaJ homolog subfamily B member 11 levels
46808,C->U-editing enzyme APOBEC-2 levels,Phenotype,C->U-editing enzyme APOBEC-2 levels
46809,Inactive pancreatic lipase-related protein 1 levels,Phenotype,Inactive pancreatic lipase-related protein 1 levels
46811,Low-density lipoprotein receptor-related protein 11 (analyte X6713.4) levels,Phenotype,Low-density lipoprotein receptor-related protein 11 (analyte X6713.4) levels
46813,Hemoglobin subunit zeta levels,Phenotype,Hemoglobin subunit zeta levels
46815,GDNF family receptor alpha-like levels,Phenotype,GDNF family receptor alpha-like levels
46817,Procollagen-lysine--2-oxoglutarate 5-dioxygenase 2 levels,Phenotype,Procollagen-lysine--2-oxoglutarate 5-dioxygenase 2 levels
46818,Hepatitis A virus cellular receptor 2 (analyte X7152.5) levels,Phenotype,Hepatitis A virus cellular receptor 2 (analyte X7152.5) levels
46819,GDH/6PGL endoplasmic bifunctional protein levels,Phenotype,GDH/6PGL endoplasmic bifunctional protein levels
46822,Liver carboxylesterase 1 (analyte X7182.1) levels,Phenotype,Liver carboxylesterase 1 (analyte X7182.1) levels
46823,Leucine-rich repeat and fibronectin type-III domain-containing protein 2 levels,Phenotype,Leucine-rich repeat and fibronectin type-III domain-containing protein 2 levels
46825,Tuberoinfundibular peptide of 39 residues levels,Phenotype,Tuberoinfundibular peptide of 39 residues levels
46826,Cadherin-1 (analyte X2501.51) levels,Phenotype,Cadherin-1 (analyte X2501.51) levels
46828,NADP-dependent malic enzyme levels,Phenotype,NADP-dependent malic enzyme levels
46840,Sun-seeking behavior,Phenotype,Sun-seeking behavior
46841,Crohn's disease vs rheumatoid arthritis (ordinary least squares (OLS)),Phenotype,Crohn's disease vs rheumatoid arthritis (ordinary least squares (OLS))
46842,Acetyl-CoA acetyltransferase-- cytosolic levels,Phenotype,Acetyl-CoA acetyltransferase-- cytosolic levels
46844,MAM domain-containing glycosylphosphatidylinositol anchor protein 1 levels,Phenotype,MAM domain-containing glycosylphosphatidylinositol anchor protein 1 levels
46846,Killer cell immunoglobulin-like receptor 2DL3 levels,Phenotype,Killer cell immunoglobulin-like receptor 2DL3 levels
46848,Lysosome-associated membrane glycoprotein 1 levels,Phenotype,Lysosome-associated membrane glycoprotein 1 levels
46849,Ribonuclease T2 levels,Phenotype,Ribonuclease T2 levels
46851,GMP reductase 1 levels,Phenotype,GMP reductase 1 levels
46853,Daily alcohol intake x rs671 interaction (2df),Phenotype,Daily alcohol intake x rs671 interaction (2df)
46854,Alcohol drinking status x rs671 interaction (2df),Phenotype,Alcohol drinking status x rs671 interaction (2df)
46855,Butyrophilin subfamily 3 member A2 levels,Phenotype,Butyrophilin subfamily 3 member A2 levels
46861,Transcription initiation factor IIA subunit 2 levels,Phenotype,Transcription initiation factor IIA subunit 2 levels
46862,Butyrophilin subfamily 3 member A3 (analyte X22950.6) levels,Phenotype,Butyrophilin subfamily 3 member A3 (analyte X22950.6) levels
46866,NKG2D ligand 2 (analyte X22583.47) levels,Phenotype,NKG2D ligand 2 (analyte X22583.47) levels
46867,Butyrophilin subfamily 2 member A2 levels,Phenotype,Butyrophilin subfamily 2 member A2 levels
46871,N-acetylgalactosamine-6-sulfatase levels,Phenotype,N-acetylgalactosamine-6-sulfatase levels
46873,Glutamate carboxypeptidase 2 (analyte X5478.50) levels,Phenotype,Glutamate carboxypeptidase 2 (analyte X5478.50) levels
46875,Clinical depression,Phenotype,Clinical depression
46883,Angiostatin levels,Phenotype,Angiostatin levels
46884,Heat shock 70 kDa protein 1A (analyte X4124.24) levels,Phenotype,Heat shock 70 kDa protein 1A (analyte X4124.24) levels
46886,Methyltransferase-like protein 24 levels,Phenotype,Methyltransferase-like protein 24 levels
46888,Desmoglein-2 (analyte X9484.75) levels,Phenotype,Desmoglein-2 (analyte X9484.75) levels
46891,72 kDa type IV collagenase levels,Phenotype,72 kDa type IV collagenase levels
46893,Cysteine-rich secretory protein 2 levels,Phenotype,Cysteine-rich secretory protein 2 levels
46896,Peptidyl-prolyl cis-trans isomerase FKBP7 levels,Phenotype,Peptidyl-prolyl cis-trans isomerase FKBP7 levels
46900,Fibroblast growth factor 7 (analyte X4487.1) levels,Phenotype,Fibroblast growth factor 7 (analyte X4487.1) levels
46901,Interleukin-34 levels,Phenotype,Interleukin-34 levels
46903,Carbohydrate sulfotransferase 6 levels,Phenotype,Carbohydrate sulfotransferase 6 levels
46905,Ribosyldihydronicotinamide dehydrogenase [quinone] levels,Phenotype,Ribosyldihydronicotinamide dehydrogenase [quinone] levels
46907,WAP four-disulfide core domain protein 1 levels,Phenotype,WAP four-disulfide core domain protein 1 levels
46909,Protein eyes shut homolog levels,Phenotype,Protein eyes shut homolog levels
46911,Tryptase beta-1 levels,Phenotype,Tryptase beta-1 levels
46912,NAD(P)H dehydrogenase [quinone] 1 levels,Phenotype,NAD(P)H dehydrogenase [quinone] 1 levels
46915,HLA-C levels,Phenotype,HLA-C levels
46921,Crohn's disease vs ulcerative colitis (ordinary least squares (OLS)),Phenotype,Crohn's disease vs ulcerative colitis (ordinary least squares (OLS))
46922,Major depressive disorder vs ADHD (ordinary least squares (OLS)),Phenotype,Major depressive disorder vs ADHD (ordinary least squares (OLS))
46924,Psoriasis or type 2 diabetes (trans-disease meta-analysis),Phenotype,Psoriasis or type 2 diabetes (trans-disease meta-analysis)
46925,Psoriasis or type 2 diabetes (trans-disease meta-analysis)(opposite effect),Phenotype,Psoriasis or type 2 diabetes (trans-disease meta-analysis)(opposite effect)
46926,Childhood aggressive behavior,Phenotype,Childhood aggressive behavior
46930,Stomatin-like protein 2-- mitochondrial levels,Phenotype,Stomatin-like protein 2-- mitochondrial levels
46932,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 levels,Phenotype,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 levels
46934,Tolloid-like protein 1 levels,Phenotype,Tolloid-like protein 1 levels
46936,UPF0705 protein C11orf49 (analyte X23767.1) levels,Phenotype,UPF0705 protein C11orf49 (analyte X23767.1) levels
46937,Aspartate aminotransferase-- mitochondrial (analyte X23903.3) levels,Phenotype,Aspartate aminotransferase-- mitochondrial (analyte X23903.3) levels
46939,SH2 domain-containing adapter protein D levels,Phenotype,SH2 domain-containing adapter protein D levels
46941,Prosaposin levels,Phenotype,Prosaposin levels
46942,Adhesion G protein-coupled receptor F5 levels,Phenotype,Adhesion G protein-coupled receptor F5 levels
46944,Prenylcysteine oxidase 1 levels,Phenotype,Prenylcysteine oxidase 1 levels
46946,Leukocyte immunoglobulin-like receptor subfamily B member 4 levels,Phenotype,Leukocyte immunoglobulin-like receptor subfamily B member 4 levels
46968,Symptomatic extra- and intra-cranial atherosclerotic stenosis,Phenotype,Symptomatic extra- and intra-cranial atherosclerotic stenosis
46971,Phosphatidylcholine-O_18:0_[M+H]1+/Lysophosphatidylethanolamine_21:0_[M+H]1+ levels,Phenotype,Phosphatidylcholine-O_18:0_[M+H]1+/Lysophosphatidylethanolamine_21:0_[M+H]1+ levels
46973,Phosphatidylcholine-O_32:1_[M+H]1+/Phosphatidylcholine-P_32:0_[M+H]1+/Phosphatidylethanolamine-O_35:1_[M+H]1+ levels,Phenotype,Phosphatidylcholine-O_32:1_[M+H]1+/Phosphatidylcholine-P_32:0_[M+H]1+/Phosphatidylethanolamine-O_35:1_[M+H]1+ levels
46975,Gamma glutamyl transferase levels,Phenotype,Gamma glutamyl transferase levels
46978,Phosphatidylcholine(36:3)_[M+H]1+/Phosphatidylethanolamine(39:3)_[M+H]1+/Phosphatidate(41:4)_[M+NH4]1+ levels,Phenotype,Phosphatidylcholine(36:3)_[M+H]1+/Phosphatidylethanolamine(39:3)_[M+H]1+/Phosphatidate(41:4)_[M+NH4]1+ levels
46980,Node-level brain connectivity (multivariate analysis),Phenotype,Node-level brain connectivity (multivariate analysis)
46984,Serum urate levels,Phenotype,Serum urate levels
47023,Phosphatidylcholine_38:3_[M+H]1+/Phosphatidylethanolamine_41:3_[M+H]1+/Phosphatidate_43:4_[M+NH4]1+ levels,Phenotype,Phosphatidylcholine_38:3_[M+H]1+/Phosphatidylethanolamine_41:3_[M+H]1+/Phosphatidate_43:4_[M+NH4]1+ levels
47030,Phosphatidylcholine_38:5_[M+H]1+/Phosphatidylethanolamine_41:5_[M+H]1+/Phosphatidate_43:6_[M+NH4]1+ levels,Phenotype,Phosphatidylcholine_38:5_[M+H]1+/Phosphatidylethanolamine_41:5_[M+H]1+/Phosphatidate_43:6_[M+NH4]1+ levels
47056,Serum phosphate levels,Phenotype,Serum phosphate levels
47084,Gut bacterial pathway abundance (GLYCOCAT.PWY..glycogen.degradation.I..bacterial.),Phenotype,Gut bacterial pathway abundance (GLYCOCAT.PWY..glycogen.degradation.I..bacterial.)
47086,Gut bacterial pathway abundance (PWY.5088..L.glutamate.degradation.VIII..to.propanoate.),Phenotype,Gut bacterial pathway abundance (PWY.5088..L.glutamate.degradation.VIII..to.propanoate.)
47120,Phosphatidylcholine(38:3)_[M+H]1+/Phosphatidylethanolamine(41:3)_[M+H]1+/Phosphatidate(43:4)_[M+NH4]1+ levels,Phenotype,Phosphatidylcholine(38:3)_[M+H]1+/Phosphatidylethanolamine(41:3)_[M+H]1+/Phosphatidate(43:4)_[M+NH4]1+ levels
47128,White blood cell count (neutrophil),Phenotype,White blood cell count (neutrophil)
47131,Phosphatidylcholine(38:3)_[M+OAc]1-/Phosphatidylserine(42:2)_[M-H]1- levels,Phenotype,Phosphatidylcholine(38:3)_[M+OAc]1-/Phosphatidylserine(42:2)_[M-H]1- levels
47142,Phosphatidylethanolamine(40:2)_[M-H]1- levels,Phenotype,Phosphatidylethanolamine(40:2)_[M-H]1- levels
47161,Phosphatidylcholine_40:6_[M+H]1+/Phosphatidylethanolamine_43:6_[M+H]1+ levels,Phenotype,Phosphatidylcholine_40:6_[M+H]1+/Phosphatidylethanolamine_43:6_[M+H]1+ levels
47176,Insulin-like growth factor 1 levels,Phenotype,Insulin-like growth factor 1 levels
47177,Phosphatidylcholine(38:2)_[M+H]1+/Phosphatidylethanolamine(41:2)_[M+H]1+ levels,Phenotype,Phosphatidylcholine(38:2)_[M+H]1+/Phosphatidylethanolamine(41:2)_[M+H]1+ levels
47178,Heel bone mineral density T score,Phenotype,Heel bone mineral density T score
47180,Direct bilirubin levels,Phenotype,Direct bilirubin levels
47182,12-lead ECG morphology phenotype,Phenotype,12-lead ECG morphology phenotype
47188,Depressive symptoms x dependent stressful life events interaction (1df test),Phenotype,Depressive symptoms x dependent stressful life events interaction (1df test)
47190,Depressive symptoms x independent stressful life events interaction (2df test),Phenotype,Depressive symptoms x independent stressful life events interaction (2df test)
47192,Depressive symptoms x dependent stressful life events interaction (2df test),Phenotype,Depressive symptoms x dependent stressful life events interaction (2df test)
47193,Depressive symptoms x stressful life events interaction (1df test),Phenotype,Depressive symptoms x stressful life events interaction (1df test)
47194,Depressive symptoms x stressful life events interaction (2df test),Phenotype,Depressive symptoms x stressful life events interaction (2df test)
47195,Depressive symptoms x independent stressful life events interaction (1df test),Phenotype,Depressive symptoms x independent stressful life events interaction (1df test)
47211,Edge-level brain connectivity (multivariate analysis),Phenotype,Edge-level brain connectivity (multivariate analysis)
47215,Schizophrenia or breast cancer (pleiotropy),Phenotype,Schizophrenia or breast cancer (pleiotropy)
47216,Schizophrenia or ER positive breast cancer (pleiotropy),Phenotype,Schizophrenia or ER positive breast cancer (pleiotropy)
47221,White blood cell count (lymphocyte),Phenotype,White blood cell count (lymphocyte)
47224,White blood cell count (monocyte),Phenotype,White blood cell count (monocyte)
47247,Phosphatidylcholine_37:3_[M+OAc]1-/Phosphatidylserine_41:2_[M-H]1- levels,Phenotype,Phosphatidylcholine_37:3_[M+OAc]1-/Phosphatidylserine_41:2_[M-H]1- levels
47248,Phosphatidylcholine-O_34:3_[M+H]1+/Phosphatidylcholine-P_34:2_[M+H]1+/Phosphatidylethanolamine-P_37:2_[M+H]1+ levels,Phenotype,Phosphatidylcholine-O_34:3_[M+H]1+/Phosphatidylcholine-P_34:2_[M+H]1+/Phosphatidylethanolamine-P_37:2_[M+H]1+ levels
47249,Phosphatidylcholine-O_34:1_[M+H]1+/Phosphatidylcholine-P_34:0_[M+H]1+/Phosphatidylethanolamine-O_37:1_[M+H]1+ levels,Phenotype,Phosphatidylcholine-O_34:1_[M+H]1+/Phosphatidylcholine-P_34:0_[M+H]1+/Phosphatidylethanolamine-O_37:1_[M+H]1+ levels
47252,Lung function (FVC) and body mass index,Phenotype,Lung function (FVC) and body mass index
47258,Mean sphered cell volume,Phenotype,Mean sphered cell volume
47268,Phosphatidylcholine(40:6)_[M+H]1+/Phosphatidylethanolamine(43:6)_[M+H]1+ levels,Phenotype,Phosphatidylcholine(40:6)_[M+H]1+/Phosphatidylethanolamine(43:6)_[M+H]1+ levels
47270,Phosphatidylethanolamine_38:3_[M-H]1- levels,Phenotype,Phosphatidylethanolamine_38:3_[M-H]1- levels
47277,Risky substance use,Phenotype,Risky substance use
47279,Phosphatidylcholine_36:3_[M+H]1+/Phosphatidylethanolamine_39:3_[M+H]1+/Phosphatidate_41:4_[M+NH4]1+ levels,Phenotype,Phosphatidylcholine_36:3_[M+H]1+/Phosphatidylethanolamine_39:3_[M+H]1+/Phosphatidate_41:4_[M+NH4]1+ levels
47280,Phosphatidylcholine-O(34:3)_[M+H]1+/Phosphatidylethanolamine-P(37:2)_[M+H]1+ levels,Phenotype,Phosphatidylcholine-O(34:3)_[M+H]1+/Phosphatidylethanolamine-P(37:2)_[M+H]1+ levels
47303,Lung function (FEV1) and body mass index,Phenotype,Lung function (FEV1) and body mass index
47305,Cystatin C levels,Phenotype,Cystatin C levels
47312,Phosphatidylcholine(38:6)_[M+H]1+/Phosphatidylethanolamine(41:6)_[M+H]1+ levels,Phenotype,Phosphatidylcholine(38:6)_[M+H]1+/Phosphatidylethanolamine(41:6)_[M+H]1+ levels
47357,Cholesteryl ester(20:3)_[M+NH4]1+ levels,Phenotype,Cholesteryl ester(20:3)_[M+NH4]1+ levels
47397,Early-onset myasthenia gravis,Phenotype,Early-onset myasthenia gravis
47399,Diacylglycerol_38:5_[M+H-H2O]1+ levels,Phenotype,Diacylglycerol_38:5_[M+H-H2O]1+ levels
47413,Phosphatidylcholine_38:2_[M+H]1+/Phosphatidylethanolamine_41:2_[M+H]1+ levels,Phenotype,Phosphatidylcholine_38:2_[M+H]1+/Phosphatidylethanolamine_41:2_[M+H]1+ levels
47416,Go reaction time variability,Phenotype,Go reaction time variability
47443,Cholesteryl ester_18:3_[M+NH4]1+ levels,Phenotype,Cholesteryl ester_18:3_[M+NH4]1+ levels
47444,Cholesteryl ester_20:3_[M+NH4]1+ levels,Phenotype,Cholesteryl ester_20:3_[M+NH4]1+ levels
47446,Cholesteryl ester_22:6_[M+NH4]1+ levels,Phenotype,Cholesteryl ester_22:6_[M+NH4]1+ levels
47447,Phosphatidylethanolamine_38:5_[M-H]1- levels,Phenotype,Phosphatidylethanolamine_38:5_[M-H]1- levels
47458,Fatty acid(20:3)_[M-H]1- levels,Phenotype,Fatty acid(20:3)_[M-H]1- levels
47475,Acute myeloid leukemia or myelodysplastic syndrome (pleiotropy),Phenotype,Acute myeloid leukemia or myelodysplastic syndrome (pleiotropy)
47493,Externalizing behaviour (multivariate analysis),Phenotype,Externalizing behaviour (multivariate analysis)
47502,Osteoarthritis of the hip or knee (with total joint replacement),Phenotype,Osteoarthritis of the hip or knee (with total joint replacement)
47523,Body mass index and bone mineral density (pleiotropy),Phenotype,Body mass index and bone mineral density (pleiotropy)
47553,Kidney cancer,Phenotype,Kidney cancer
47561,Response to erlotinib,Phenotype,Response to erlotinib
47563,Response to trametinib,Phenotype,Response to trametinib
47566,Response to arsenic trioxide,Phenotype,Response to arsenic trioxide
47569,Response to vemurafenib,Phenotype,Response to vemurafenib
47571,Response to paclitaxel and epirubicin,Phenotype,Response to paclitaxel and epirubicin
47574,Response to vinblastine,Phenotype,Response to vinblastine
47576,Hydroxycholesterol_[M+H-2H2O]1+ levels,Phenotype,Hydroxycholesterol_[M+H-2H2O]1+ levels
47578,Lysophosphatidylcholine_16:0_[M+H]1+/Lysophosphatidylethanolamine_19:0_[M+H]1+ levels,Phenotype,Lysophosphatidylcholine_16:0_[M+H]1+/Lysophosphatidylethanolamine_19:0_[M+H]1+ levels
47586,Phosphatidylcholine_32:0_[M+H]1+/Phosphatidylethanolamine_35:0_[M+H]1+/Phosphatidate_37:1_[M+NH4]1+ levels,Phenotype,Phosphatidylcholine_32:0_[M+H]1+/Phosphatidylethanolamine_35:0_[M+H]1+/Phosphatidate_37:1_[M+NH4]1+ levels
47610,Clear cell renal cell carcinoma,Phenotype,Clear cell renal cell carcinoma
47617,Osteoarthritis (with total hip replacement),Phenotype,Osteoarthritis (with total hip replacement)
47621,Finger osteoarthritis,Phenotype,Finger osteoarthritis
47625,Change in high-sensitivity cardiac troponin I concentration,Phenotype,Change in high-sensitivity cardiac troponin I concentration
47627,High-sensitivity cardiac troponin I concentration,Phenotype,High-sensitivity cardiac troponin I concentration
47641,Phosphatidylinositol(40:6)_[M-H]1- levels,Phenotype,Phosphatidylinositol(40:6)_[M-H]1- levels
47652,Delayed neurodevelopment,Phenotype,Delayed neurodevelopment
47683,Sleepwalking,Phenotype,Sleepwalking
47688,Idiopathic achalasia,Phenotype,Idiopathic achalasia
47692,Phosphatidylcholine_34:2_[M+H]1+/Phosphatidylethanolamine_37:2_[M+H]1+/Phosphatidate_39:3_[M+NH4]1+ levels,Phenotype,Phosphatidylcholine_34:2_[M+H]1+/Phosphatidylethanolamine_37:2_[M+H]1+/Phosphatidate_39:3_[M+NH4]1+ levels
47693,Phosphatidylcholine_34:1_[M+H]1+/Phosphatidylethanolamine_37:1_[M+H]1+/Phosphatidate_39:2_[M+NH4]1+ levels,Phenotype,Phosphatidylcholine_34:1_[M+H]1+/Phosphatidylethanolamine_37:1_[M+H]1+/Phosphatidate_39:2_[M+NH4]1+ levels
47694,Phosphatidylcholine_34:0_[M+H]1+/Phosphatidylethanolamine_37:0_[M+H]1+/Phosphatidate_39:1_[M+NH4]1+ levels,Phenotype,Phosphatidylcholine_34:0_[M+H]1+/Phosphatidylethanolamine_37:0_[M+H]1+/Phosphatidate_39:1_[M+NH4]1+ levels
47706,Physical activity,Phenotype,Physical activity
47709,Suicide attempt,Phenotype,Suicide attempt
47713,Cardiorespiratory fitness (vo2 max),Phenotype,Cardiorespiratory fitness (vo2 max)
47716,Vitamin D-binding protein levels (adjusted for GC haplotype),Phenotype,Vitamin D-binding protein levels (adjusted for GC haplotype)
47720,Lysophosphatidylethanolamine_18:0_[M-H]1- levels,Phenotype,Lysophosphatidylethanolamine_18:0_[M-H]1- levels
47721,Lysophosphatidylethanolamine_20:0_[M-H]1- levels,Phenotype,Lysophosphatidylethanolamine_20:0_[M-H]1- levels
47722,Phosphatidylcholine_35:2_[M+H]1+/Phosphatidylethanolamine_38:2_[M+H]1+/Phosphatidate_40:3_[M+NH4]1+ levels,Phenotype,Phosphatidylcholine_35:2_[M+H]1+/Phosphatidylethanolamine_38:2_[M+H]1+/Phosphatidate_40:3_[M+NH4]1+ levels
47723,Phosphatidylcholine_34:3_[M+H]1+/Phosphatidylethanolamine_37:3_[M+H]1+/Phosphatidate_39:4_[M+NH4]1+ levels,Phenotype,Phosphatidylcholine_34:3_[M+H]1+/Phosphatidylethanolamine_37:3_[M+H]1+/Phosphatidate_39:4_[M+NH4]1+ levels
47743,Human papilloma virus 16 negative oropharyngeal cancer,Phenotype,Human papilloma virus 16 negative oropharyngeal cancer
47745,Human papilloma virus 16 positive oropharyngeal cancer,Phenotype,Human papilloma virus 16 positive oropharyngeal cancer
47749,Oropharynx cancer and human papilloma virus 16 negative oropharyngeal cancer,Phenotype,Oropharynx cancer and human papilloma virus 16 negative oropharyngeal cancer
47759,Breast cancer and/or colorectal cancer,Phenotype,Breast cancer and/or colorectal cancer
47760,Educational attainment (MTAG),Phenotype,Educational attainment (MTAG)
47761,Pre-treatment viral load in HIV-1 infection,Phenotype,Pre-treatment viral load in HIV-1 infection
47762,Velopharyngeal dysfunction,Phenotype,Velopharyngeal dysfunction
47763,Cognitive empathy,Phenotype,Cognitive empathy
47768,Anorexia nervosa-- attention-deficit/hyperactivity disorder-- autism spectrum disorder-- bipolar disorder-- major depression-- obsessive-compulsive disorder-- schizophrenia-- or Tourette syndrome (pleiotropy),Phenotype,Anorexia nervosa-- attention-deficit/hyperactivity disorder-- autism spectrum disorder-- bipolar disorder-- major depression-- obsessive-compulsive disorder-- schizophrenia-- or Tourette syndrome (pleiotropy)
47769,Hypertrophic cardiomyopathy (sarcomere positive),Phenotype,Hypertrophic cardiomyopathy (sarcomere positive)
47770,Hypertrophic cardiomyopathy (sarcomere negative),Phenotype,Hypertrophic cardiomyopathy (sarcomere negative)
47771,Self-reported math ability (MTAG),Phenotype,Self-reported math ability (MTAG)
47772,T cell lymphocyte profile difference,Phenotype,T cell lymphocyte profile difference
47773,Childhood body fatness,Phenotype,Childhood body fatness
47774,Self-reported math ability,Phenotype,Self-reported math ability
47775,Aerodigestive squamous cell cancer (pleiotropy),Phenotype,Aerodigestive squamous cell cancer (pleiotropy)
47776,Shigella-associated diarrhea,Phenotype,Shigella-associated diarrhea
47777,Systolic blood pressure (education interaction),Phenotype,Systolic blood pressure (education interaction)
47778,Diastolic blood pressure (education interaction),Phenotype,Diastolic blood pressure (education interaction)
47779,Adverse response to benznidazole in Chagas disease,Phenotype,Adverse response to benznidazole in Chagas disease
47780,BMI x environmental factors (including physical activity) interaction,Phenotype,BMI x environmental factors (including physical activity) interaction
47781,BMI x  environmental factors (excluding physical activity) interaction,Phenotype,BMI x  environmental factors (excluding physical activity) interaction
47782,Fever in mesalamine-treated irritable bowel disease,Phenotype,Fever in mesalamine-treated irritable bowel disease
47783,Fever and diarrhea in mesalamine-treated irritable bowel disease,Phenotype,Fever and diarrhea in mesalamine-treated irritable bowel disease
47784,Macular thickness,Phenotype,Macular thickness
47785,Childhood onset ulcerative colitis,Phenotype,Childhood onset ulcerative colitis
47786,Fulminant type 1 diabetes,Phenotype,Fulminant type 1 diabetes
47787,Facial morphology traits (63 three-dimensional facial segments),Phenotype,Facial morphology traits (63 three-dimensional facial segments)
47788,B cell lymphocyte profile difference,Phenotype,B cell lymphocyte profile difference
47789,Cognitive performance (MTAG),Phenotype,Cognitive performance (MTAG)
47790,Sum of carotid plaque area,Phenotype,Sum of carotid plaque area
47791,Carotid plaque maximum area,Phenotype,Carotid plaque maximum area
47792,Mean area of carotid plaque,Phenotype,Mean area of carotid plaque
47793,Maximum stenosis,Phenotype,Maximum stenosis
47794,Mean degree of stenosis,Phenotype,Mean degree of stenosis
47795,Adiponectin levels x Mediterranean diet adherence interaction,Phenotype,Adiponectin levels x Mediterranean diet adherence interaction
47796,Post-traumatic stress disorder (mental health questionnaire or predicted),Phenotype,Post-traumatic stress disorder (mental health questionnaire or predicted)
47799,Generalized anxiety disorder (phenotype risk score),Phenotype,Generalized anxiety disorder (phenotype risk score)
47801,Post-traumatic stress disorder (phenotype risk score),Phenotype,Post-traumatic stress disorder (phenotype risk score)
47803,Autoimmune traits (pleiotropy),Phenotype,Autoimmune traits (pleiotropy)
47804,Left-handedness,Phenotype,Left-handedness
47805,Breast cancer in BRCA2 mutation carriers,Phenotype,Breast cancer in BRCA2 mutation carriers
47806,Extranodal natural killer T-cell lymphoma (nasal type),Phenotype,Extranodal natural killer T-cell lymphoma (nasal type)
47807,Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event),Phenotype,Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event)
47808,Cellular nuclear factor (erythroid-derived 2)-like 2 levels,Phenotype,Cellular nuclear factor (erythroid-derived 2)-like 2 levels
47809,Heart rate in heart failure with reduced ejection fraction,Phenotype,Heart rate in heart failure with reduced ejection fraction
47810,Sero-negative rheumatoid arthritis,Phenotype,Sero-negative rheumatoid arthritis
47811,Carotid plaque,Phenotype,Carotid plaque
47812,Sum of stenosis,Phenotype,Sum of stenosis
47813,Urinary albumin excretion,Phenotype,Urinary albumin excretion
47814,Poor prognosis in Crohn's disease,Phenotype,Poor prognosis in Crohn's disease
47815,Macular telangiectasia type 2,Phenotype,Macular telangiectasia type 2
47816,Cannabis smoking or cigarette smoking or schizophrenia,Phenotype,Cannabis smoking or cigarette smoking or schizophrenia
47819,Hypo-HDL-cholesterolemia,Phenotype,Hypo-HDL-cholesterolemia
47820,BMI at 5 years old,Phenotype,BMI at 5 years old
47821,Adult hearing difficulty,Phenotype,Adult hearing difficulty
47822,Alzheimer's disease with memory domain impairment,Phenotype,Alzheimer's disease with memory domain impairment
47823,Alzheimer's disease with visuospatial domain impairment,Phenotype,Alzheimer's disease with visuospatial domain impairment
47824,Alzheimer's disease with multiple cognitive domain impairments,Phenotype,Alzheimer's disease with multiple cognitive domain impairments
47825,Alzheimer's disease with no specific cognitive domain impairment,Phenotype,Alzheimer's disease with no specific cognitive domain impairment
47826,Health literacy,Phenotype,Health literacy
47827,Response to cognitive-behavioural therapy in anxiety disorder,Phenotype,Response to cognitive-behavioural therapy in anxiety disorder
47828,Response to cognitive-behavioural therapy in major depressive disorder,Phenotype,Response to cognitive-behavioural therapy in major depressive disorder
47829,Aromatic antiseizure medication-induced Stevens-Johnson syndrome or toxic epidermal necrolysis in HLA-B*15:02 non-carriers,Phenotype,Aromatic antiseizure medication-induced Stevens-Johnson syndrome or toxic epidermal necrolysis in HLA-B*15:02 non-carriers
47831,Candidemia,Phenotype,Candidemia
47832,Response to hepatitis B vaccine,Phenotype,Response to hepatitis B vaccine
47833,Sensitivity to environmental stress and adversity,Phenotype,Sensitivity to environmental stress and adversity
47834,Sleep (number of episodes),Phenotype,Sleep (number of episodes)
47841,Peginterferon alfa-2a treatment response in chronic hepatitis B infection,Phenotype,Peginterferon alfa-2a treatment response in chronic hepatitis B infection
47867,Major depressive episode treated with electroconvulsive therapy,Phenotype,Major depressive episode treated with electroconvulsive therapy
47868,Major depressive disorder and major depressive episode treated with electroconvulsive therapy,Phenotype,Major depressive disorder and major depressive episode treated with electroconvulsive therapy
47869,Carotenoid levels,Phenotype,Carotenoid levels
47870,Lipid or lipoprotein levels,Phenotype,Lipid or lipoprotein levels
47871,IgA levels,Phenotype,IgA levels
47872,Composite immunoglobulin trait (IgA/IgG),Phenotype,Composite immunoglobulin trait (IgA/IgG)
47873,Composite immunoglobulin trait (IgA/IgM),Phenotype,Composite immunoglobulin trait (IgA/IgM)
47874,Composite immunoglobulin trait (IgA x IgG x IgM),Phenotype,Composite immunoglobulin trait (IgA x IgG x IgM)
47875,Left ventricular mass to end-diastolic volume ratio,Phenotype,Left ventricular mass to end-diastolic volume ratio
47876,Left ventricular global circumferential strain,Phenotype,Left ventricular global circumferential strain
47877,Dilated cardiomyopathy (MTAG),Phenotype,Dilated cardiomyopathy (MTAG)
47878,Left ventricular global radial strain,Phenotype,Left ventricular global radial strain
47879,Left ventricular global longitudinal strain,Phenotype,Left ventricular global longitudinal strain
47880,Hypertrophic cardiomyopathy (MTAG),Phenotype,Hypertrophic cardiomyopathy (MTAG)
47881,Sleep duration (short sleep),Phenotype,Sleep duration (short sleep)
47882,Sleep duration (long sleep),Phenotype,Sleep duration (long sleep)
47892,Latent autoimmune diabetes,Phenotype,Latent autoimmune diabetes
47893,Latent autoimmune diabetes vs. type 2 diabetes,Phenotype,Latent autoimmune diabetes vs. type 2 diabetes
47894,Latent autoimmune diabetes vs. type 1 diabetes,Phenotype,Latent autoimmune diabetes vs. type 1 diabetes
47895,Seasonality and depression,Phenotype,Seasonality and depression
47898,HDL cholesterol and triglyceride levels (pleiotropy),Phenotype,HDL cholesterol and triglyceride levels (pleiotropy)
47899,Delayed reward discounting,Phenotype,Delayed reward discounting
47900,Plasma renin activity levels,Phenotype,Plasma renin activity levels
47901,Diffusing capacity of the lung for carbon monoxide traits,Phenotype,Diffusing capacity of the lung for carbon monoxide traits
47902,Upper eyelid sagging severity,Phenotype,Upper eyelid sagging severity
47903,Initial alcohol sensitivity,Phenotype,Initial alcohol sensitivity
47915,Waist-to-hip ratio adjusted for BMI (additive genetic model),Phenotype,Waist-to-hip ratio adjusted for BMI (additive genetic model)
47916,Morning person,Phenotype,Morning person
47917,Smoking behaviour (cigarettes smoked per day),Phenotype,Smoking behaviour (cigarettes smoked per day)
47918,Smoking cessation,Phenotype,Smoking cessation
47919,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer,Phenotype,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer
47920,Age of smoking initiation (MTAG),Phenotype,Age of smoking initiation (MTAG)
47921,Smoking initiation (ever regular vs never regular) (MTAG),Phenotype,Smoking initiation (ever regular vs never regular) (MTAG)
47922,Thyroglobulin plasma levels,Phenotype,Thyroglobulin plasma levels
47923,Postoperative survival time in hepatocellular carcinoma,Phenotype,Postoperative survival time in hepatocellular carcinoma
47924,Chronic obstructive pulmonary disease or resting heart rate (pleiotropy),Phenotype,Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)
47925,Lumbar spine bone mineral density (trabecular),Phenotype,Lumbar spine bone mineral density (trabecular)
47926,Lumbar spine bone mineral density (integral),Phenotype,Lumbar spine bone mineral density (integral)
47927,Depression in smokers,Phenotype,Depression in smokers
47928,Cerebral amyloid angiopathy in APOEe4 non-carrier Alzheimer’s disease,Phenotype,Cerebral amyloid angiopathy in APOEe4 non-carrier Alzheimer’s disease
47929,Cerebral amyloid angiopathy x sex interaction in Alzheimer’s disease,Phenotype,Cerebral amyloid angiopathy x sex interaction in Alzheimer’s disease
47930,Cerebral amyloid angiopathy x APOEe4 status interaction in Alzheimer’s disease,Phenotype,Cerebral amyloid angiopathy x APOEe4 status interaction in Alzheimer’s disease
47931,Cerebral amyloid angiopathy in Alzheimer’s disease,Phenotype,Cerebral amyloid angiopathy in Alzheimer’s disease
47962,Major adverse cardiovascular events in response to aspirin and clopidogrel treatment,Phenotype,Major adverse cardiovascular events in response to aspirin and clopidogrel treatment
47976,Lymphocyte-to-monocyte ratio,Phenotype,Lymphocyte-to-monocyte ratio
47979,Neutrophil-to-lymphocyte ratio,Phenotype,Neutrophil-to-lymphocyte ratio
47985,Platelet-to-lymphocyte ratio,Phenotype,Platelet-to-lymphocyte ratio
47992,Corneal resistance factor (MTAG),Phenotype,Corneal resistance factor (MTAG)
47995,Central corneal thickness (MTAG),Phenotype,Central corneal thickness (MTAG)
47999,Kawasaki disease or immunoglobulin A vasculitis (pleiotropy),Phenotype,Kawasaki disease or immunoglobulin A vasculitis (pleiotropy)
48047,Liver stiffness changes at sustained virological response following antiviral therapy in HCV infection,Phenotype,Liver stiffness changes at sustained virological response following antiviral therapy in HCV infection
48068,Intracerebral hemorrhage stroke,Phenotype,Intracerebral hemorrhage stroke
48070,Subcortical intracerebral hemorrhage,Phenotype,Subcortical intracerebral hemorrhage
48072,Triglyceride to HDL cholesterol ratio,Phenotype,Triglyceride to HDL cholesterol ratio
48074,Sensation seeking (measured by UPPS at 28 years),Phenotype,Sensation seeking (measured by UPPS at 28 years)
48086,Trunk lean mass,Phenotype,Trunk lean mass
48087,Gynoid fat mass,Phenotype,Gynoid fat mass
48089,Android bone mass,Phenotype,Android bone mass
48091,Right unilateral cleft lip,Phenotype,Right unilateral cleft lip
48092,Left unilateral cleft lip,Phenotype,Left unilateral cleft lip
48093,Right unilateral cleft lip and palate,Phenotype,Right unilateral cleft lip and palate
48094,Left unilateral cleft lip and palate,Phenotype,Left unilateral cleft lip and palate
48095,Idiopathic central precocious puberty,Phenotype,Idiopathic central precocious puberty
48098,Frailty index,Phenotype,Frailty index
48099,Nasal protrusion,Phenotype,Nasal protrusion
48101,Neuroticism conditioned on cognitive performance (multi-trait conditioning and joint analysis),Phenotype,Neuroticism conditioned on cognitive performance (multi-trait conditioning and joint analysis)
48104,Thoracic aortic aneurysms,Phenotype,Thoracic aortic aneurysms
48106,Neuroticism conditioned on Townsend deprivation index (multi-trait conditioning and joint analysis),Phenotype,Neuroticism conditioned on Townsend deprivation index (multi-trait conditioning and joint analysis)
48113,Neuroticism conditioned on average household income before tax (multi-trait conditioning and joint analysis),Phenotype,Neuroticism conditioned on average household income before tax (multi-trait conditioning and joint analysis)
48114,Neuroticism conditioned on educational attainment (multi-trait conditioning and joint analysis),Phenotype,Neuroticism conditioned on educational attainment (multi-trait conditioning and joint analysis)
48115,Neuroticism conditioned on highest math class (multi-trait conditioning and joint analysis),Phenotype,Neuroticism conditioned on highest math class (multi-trait conditioning and joint analysis)
48120,Neuroticism conditioned on self-rated math ability (multi-trait conditioning and joint analysis),Phenotype,Neuroticism conditioned on self-rated math ability (multi-trait conditioning and joint analysis)
48121,Childhood asthma x sex interaction,Phenotype,Childhood asthma x sex interaction
48123,Recurrence-free survival in non-muscle-invasive bladder cancer,Phenotype,Recurrence-free survival in non-muscle-invasive bladder cancer
48125,Progression-free survival in non-muscle-invasive bladder cancer,Phenotype,Progression-free survival in non-muscle-invasive bladder cancer
48128,Hearing function,Phenotype,Hearing function
48131,Hearing function (left/right asymmetry),Phenotype,Hearing function (left/right asymmetry)
48161,Opioid dependence (time to event),Phenotype,Opioid dependence (time to event)
48162,HTLV-1 associated myelopathy,Phenotype,HTLV-1 associated myelopathy
48169,Wheat-dependent exercise-induced anaphylaxis,Phenotype,Wheat-dependent exercise-induced anaphylaxis
48171,Complement factor H-like 1 protein levels,Phenotype,Complement factor H-like 1 protein levels
48174,Complement factor H measurement,Phenotype,Complement factor H measurement
48177,Complement factor H-related protein 1 levels,Phenotype,Complement factor H-related protein 1 levels
48180,Complement factor H-related protein 3 levels,Phenotype,Complement factor H-related protein 3 levels
48183,Complement factor H-related protein 2 levels,Phenotype,Complement factor H-related protein 2 levels
48193,Pulmonary mycobacterium avium complex disease,Phenotype,Pulmonary mycobacterium avium complex disease
48208,Complement factor H-related protein 4 levels,Phenotype,Complement factor H-related protein 4 levels
48218,Complement factor H-related protein 5 levels,Phenotype,Complement factor H-related protein 5 levels
48224,Switch to non-stimulant treatment in ADHD,Phenotype,Switch to non-stimulant treatment in ADHD
48231,Tinnitus (chronic-- bothersome),Phenotype,Tinnitus (chronic-- bothersome)
48233,Total cerebellar volume (excluding Crus I vermis),Phenotype,Total cerebellar volume (excluding Crus I vermis)
48238,Body fat percentage or coronary artery disease (MTAG),Phenotype,Body fat percentage or coronary artery disease (MTAG)
48239,Body fat percentage or heart failure (MTAG),Phenotype,Body fat percentage or heart failure (MTAG)
48265,Warfarin dose variability,Phenotype,Warfarin dose variability
48276,Progesterone levels,Phenotype,Progesterone levels
48294,Testosterone to estradiol ratio,Phenotype,Testosterone to estradiol ratio
48296,Schizophrenia-- bipolar disorder or recurrent major depressive disorder,Phenotype,Schizophrenia-- bipolar disorder or recurrent major depressive disorder
48297,Schizophrenia-- bipolar disorder or recurrent major depressive disorder x sex interaction (3df),Phenotype,Schizophrenia-- bipolar disorder or recurrent major depressive disorder x sex interaction (3df)
48298,Schizophrenia-- bipolar disorder or major depressive disorder,Phenotype,Schizophrenia-- bipolar disorder or major depressive disorder
48299,Schizophrenia-- bipolar disorder or major depressive disorder x sex interaction (3df),Phenotype,Schizophrenia-- bipolar disorder or major depressive disorder x sex interaction (3df)
48300,Response to antipsychotic treatment in schizophrenia,Phenotype,Response to antipsychotic treatment in schizophrenia
48308,Lipoprotein-associated phospholipase A2 mass,Phenotype,Lipoprotein-associated phospholipase A2 mass
48310,Bisphosphonate-related osteonecrosis of the jaw,Phenotype,Bisphosphonate-related osteonecrosis of the jaw
48314,Language functional connectivity,Phenotype,Language functional connectivity
48329,Schizophrenia x sex interaction,Phenotype,Schizophrenia x sex interaction
48330,Bipolar disorder x sex interaction,Phenotype,Bipolar disorder x sex interaction
48331,Major depressive disorder x sex interaction,Phenotype,Major depressive disorder x sex interaction
48338,Lipoprotein-associated phospholipase A2 activity,Phenotype,Lipoprotein-associated phospholipase A2 activity
48359,Vertigo,Phenotype,Vertigo
48421,Copper levels,Phenotype,Copper levels
48433,Negative urgency (measured by UPPS at 28 years),Phenotype,Negative urgency (measured by UPPS at 28 years)
48437,Sensation seeking (measured by UPPS at 26 years),Phenotype,Sensation seeking (measured by UPPS at 26 years)
48460,Metabolic biomarkers (multivariate analysis),Phenotype,Metabolic biomarkers (multivariate analysis)
48465,Cognitive processing speed,Phenotype,Cognitive processing speed
48468,Cognitive processing accuracy,Phenotype,Cognitive processing accuracy
48471,DNA methylation-estimated plasminogen activator inhibitor-1 levels,Phenotype,DNA methylation-estimated plasminogen activator inhibitor-1 levels
48472,DNA methylation PhenoAge acceleration,Phenotype,DNA methylation PhenoAge acceleration
48473,Hemorrhagic fever with renal syndrome,Phenotype,Hemorrhagic fever with renal syndrome
48476,Hemorrhagic fever with renal syndrome (severe vs mild),Phenotype,Hemorrhagic fever with renal syndrome (severe vs mild)
48483,Random glucose levels,Phenotype,Random glucose levels
48485,Systolic blood pressure (MTAG),Phenotype,Systolic blood pressure (MTAG)
48492,DNA methylation GrimAge acceleration,Phenotype,DNA methylation GrimAge acceleration
48493,Non-albumin protein levels,Phenotype,Non-albumin protein levels
48494,Lipoprotein A levels (UKB data field 30790),Phenotype,Lipoprotein A levels (UKB data field 30790)
48502,Alkaline phosphatase (UKB data field 30610),Phenotype,Alkaline phosphatase (UKB data field 30610)
48504,Ocular disease,Phenotype,Ocular disease
48506,Severe insulin-resistant type 2 diabetes,Phenotype,Severe insulin-resistant type 2 diabetes
48507,Severe insulin-deficient type 2 diabetes,Phenotype,Severe insulin-deficient type 2 diabetes
48508,Mild obesity-related type 2 diabetes,Phenotype,Mild obesity-related type 2 diabetes
48509,Mild age-related type 2 diabetes,Phenotype,Mild age-related type 2 diabetes
48510,Severe autoimmune type 2 diabetes,Phenotype,Severe autoimmune type 2 diabetes
48518,Response to levetiracetam in focal epilepsy,Phenotype,Response to levetiracetam in focal epilepsy
48520,Response to phenytoin in focal epilepsy,Phenotype,Response to phenytoin in focal epilepsy
48523,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node1),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node1)
48524,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node25),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node25)
48526,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node26),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node26)
48528,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node27),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node27)
48530,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node29),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node29)
48532,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node42),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node42)
48534,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node2),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node2)
48535,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node3),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node3)
48537,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node5),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node5)
48538,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node17),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node17)
48539,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node9),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node9)
48541,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node11),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node11)
48542,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node14),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node14)
48543,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node20),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node20)
48544,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node21),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net25_Node21)
48545,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node44),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node44)
48546,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node48),Phenotype,Brain rsFMRI measurement (amplitude of low frequency fluctations) (Net100_Node48)
48548,DNA methylation Hannum age acceleration,Phenotype,DNA methylation Hannum age acceleration
48549,Wellbeing index,Phenotype,Wellbeing index
48551,Childhood maltreatment,Phenotype,Childhood maltreatment
48577,Testosterone levels,Phenotype,Testosterone levels
48580,Type 2 diabetes or polycystic ovary syndrome (pleiotropy),Phenotype,Type 2 diabetes or polycystic ovary syndrome (pleiotropy)
48581,Type 2 diabetes (adjusted for BMI) or polycystic ovary syndrome (pleiotropy),Phenotype,Type 2 diabetes (adjusted for BMI) or polycystic ovary syndrome (pleiotropy)
48583,Fasting insulin (adjusted for BMI) or polycystic ovary syndrome (pleiotropy),Phenotype,Fasting insulin (adjusted for BMI) or polycystic ovary syndrome (pleiotropy)
48585,HbA1c or polycystic ovary syndrome (pleiotropy),Phenotype,HbA1c or polycystic ovary syndrome (pleiotropy)
48594,Stimulant dependence,Phenotype,Stimulant dependence
48597,Ascending aorta diameter,Phenotype,Ascending aorta diameter
48599,Neonatal abstinence syndrome,Phenotype,Neonatal abstinence syndrome
48603,Bisoprolol clearance in non-ST elevation acute coronary syndrome,Phenotype,Bisoprolol clearance in non-ST elevation acute coronary syndrome
48608,Epigenetic age acceleration (Hannum) in childhood cancer survivors,Phenotype,Epigenetic age acceleration (Hannum) in childhood cancer survivors
48640,Response to levetiracetam in epilepsy,Phenotype,Response to levetiracetam in epilepsy
48642,Clostridioides difficle infection,Phenotype,Clostridioides difficle infection
48669,Primary dental caries (decayed and filled teeth),Phenotype,Primary dental caries (decayed and filled teeth)
48671,Permanent dental caries (decayed and filled teeth),Phenotype,Permanent dental caries (decayed and filled teeth)
48679,Albuminuria,Phenotype,Albuminuria
48680,Dyslipidemia,Phenotype,Dyslipidemia
48682,Osteoporosis,Phenotype,Osteoporosis
48685,Carotid artery intima-media thickness in type 2 diabetes,Phenotype,Carotid artery intima-media thickness in type 2 diabetes
48687,Coronary artery calcification in type 2 diabetes (excluding prevalent cardiovascular disease),Phenotype,Coronary artery calcification in type 2 diabetes (excluding prevalent cardiovascular disease)
48690,Femur bone mineral density x serum urate levels interaction,Phenotype,Femur bone mineral density x serum urate levels interaction
48691,Aspartate aminotransferase to alanine aminotransferase ratio,Phenotype,Aspartate aminotransferase to alanine aminotransferase ratio
48692,Mean platelet volume during first trimester of pregnancy,Phenotype,Mean platelet volume during first trimester of pregnancy
48705,Total protein levels x insomnia interaction,Phenotype,Total protein levels x insomnia interaction
48707,Mean platelet volume during the postpartum period,Phenotype,Mean platelet volume during the postpartum period
48710,Mean platelet volume at delivery,Phenotype,Mean platelet volume at delivery
48714,Fasting total lipids in very small VLDL,Phenotype,Fasting total lipids in very small VLDL
48715,Fasting very small VLDL particle concentration,Phenotype,Fasting very small VLDL particle concentration
48716,Fasting phospholipid levels in very large HDL,Phenotype,Fasting phospholipid levels in very large HDL
48717,Fasting total cholesterol in very small VLDL,Phenotype,Fasting total cholesterol in very small VLDL
48718,Fasting cholesterol esters in very small VLDL,Phenotype,Fasting cholesterol esters in very small VLDL
48719,Fasting total cholesterol in very large HDL,Phenotype,Fasting total cholesterol in very large HDL
48720,Fasting cholesterol esters in very large HDL,Phenotype,Fasting cholesterol esters in very large HDL
48721,Parkinson's disease motor subtype (tremor dominant vs postural instability/gait difficulty),Phenotype,Parkinson's disease motor subtype (tremor dominant vs postural instability/gait difficulty)
48722,Parkinson's disease motor subtype (tremor to postural instability/gait difficulty score ratio),Phenotype,Parkinson's disease motor subtype (tremor to postural instability/gait difficulty score ratio)
48723,Fasting tyrosine,Phenotype,Fasting tyrosine
48727,Fasting free cholesterol in very large HDL,Phenotype,Fasting free cholesterol in very large HDL
48728,Fasting total lipids in very large HDL,Phenotype,Fasting total lipids in very large HDL
48729,Fasting very large HDL particle concentration,Phenotype,Fasting very large HDL particle concentration
48730,Coprococcus comes,Phenotype,Coprococcus comes
48732,Chronic widespread musculoskeletal pain,Phenotype,Chronic widespread musculoskeletal pain
48733,Progression free survival in epithelial ovarian cancer treated with carboplatin and paclitaxel,Phenotype,Progression free survival in epithelial ovarian cancer treated with carboplatin and paclitaxel
48734,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,Phenotype,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
48735,Progression free survival in serous epithelial ovarian cancer,Phenotype,Progression free survival in serous epithelial ovarian cancer
48736,Pancreas volume,Phenotype,Pancreas volume
48737,Kidney volume,Phenotype,Kidney volume
48738,Visceral adipose tissue volume,Phenotype,Visceral adipose tissue volume
48739,Abdominal subcutaneous adipose tissue volume,Phenotype,Abdominal subcutaneous adipose tissue volume
48740,Liver iron content,Phenotype,Liver iron content
48741,Lung volume,Phenotype,Lung volume
48742,Pancreas fat,Phenotype,Pancreas fat
48743,JC polyomavirus VP1 antibody levels,Phenotype,JC polyomavirus VP1 antibody levels
48747,Human polyomavirus 6 VP1 antibody levels,Phenotype,Human polyomavirus 6 VP1 antibody levels
48749,Anti-JC polyomavirus IgG seropositivity,Phenotype,Anti-JC polyomavirus IgG seropositivity
48751,COVID-19 (severe respiratory symptoms vs population),Phenotype,COVID-19 (severe respiratory symptoms vs population)
48753,COVID-19 (covid respiratory support vs population),Phenotype,COVID-19 (covid respiratory support vs population)
48756,Mean platelet volume during third trimester of pregnancy,Phenotype,Mean platelet volume during third trimester of pregnancy
48769,Postprandial total cholesterol in very large HDL,Phenotype,Postprandial total cholesterol in very large HDL
48770,Postprandial cholesterol esters in very large HDL,Phenotype,Postprandial cholesterol esters in very large HDL
48771,Postprandial free cholesterol in very large HDL,Phenotype,Postprandial free cholesterol in very large HDL
48772,Postprandial cholesterol esters in small VLDL,Phenotype,Postprandial cholesterol esters in small VLDL
48773,Postprandial total cholesterol in very small VLDL,Phenotype,Postprandial total cholesterol in very small VLDL
48774,Postprandial cholesterol esters in very small VLDL,Phenotype,Postprandial cholesterol esters in very small VLDL
48775,Postprandial total lipids in very small VLDL,Phenotype,Postprandial total lipids in very small VLDL
48776,Postprandial very small VLDL particle concentration,Phenotype,Postprandial very small VLDL particle concentration
48777,Postprandial total lipids in very large HDL,Phenotype,Postprandial total lipids in very large HDL
48778,Postprandial very large HDL particle concentration,Phenotype,Postprandial very large HDL particle concentration
48779,Postprandial phospholipid levels in very large HDL,Phenotype,Postprandial phospholipid levels in very large HDL
48780,Postprandial tyrosine,Phenotype,Postprandial tyrosine
48785,25(OH)D3 levels in prediabetes,Phenotype,25(OH)D3 levels in prediabetes
48854,Hearing function (0.5 kHz),Phenotype,Hearing function (0.5 kHz)
48856,Hearing function (1 kHz),Phenotype,Hearing function (1 kHz)
48858,Hearing function (4 kHz),Phenotype,Hearing function (4 kHz)
48860,Hearing function (8 kHz),Phenotype,Hearing function (8 kHz)
48864,Accelerated cognitive decline,Phenotype,Accelerated cognitive decline
48868,Decaffeinated coffee consumption or major depression disorder,Phenotype,Decaffeinated coffee consumption or major depression disorder
48870,Decaffeinated coffee consumption and/or neuroticism,Phenotype,Decaffeinated coffee consumption and/or neuroticism
48878,Cholesteryl ester levels in large HDL,Phenotype,Cholesteryl ester levels in large HDL
48882,Free cholesterol levels in large HDL,Phenotype,Free cholesterol levels in large HDL
48885,Concentration of large HDL particles,Phenotype,Concentration of large HDL particles
48887,Gestational diabetes,Phenotype,Gestational diabetes
48890,Phospholipids to total lipids ratio in large HDL,Phenotype,Phospholipids to total lipids ratio in large HDL
48892,Triglyceride levels in large HDL,Phenotype,Triglyceride levels in large HDL
48898,Alanine aminotransferase levels x vegetarianism interaction,Phenotype,Alanine aminotransferase levels x vegetarianism interaction
48900,Albumin levels x vegetarianism interaction,Phenotype,Albumin levels x vegetarianism interaction
48903,Alkaline phosphatase levels x vegetarianism interaction,Phenotype,Alkaline phosphatase levels x vegetarianism interaction
48905,Apolipoprotein B levels x vegetarianism interaction,Phenotype,Apolipoprotein B levels x vegetarianism interaction
48907,Free cholesterol levels in large LDL,Phenotype,Free cholesterol levels in large LDL
48910,Aspartate aminotransferase levels x vegetarianism interaction,Phenotype,Aspartate aminotransferase levels x vegetarianism interaction
48912,C reactive protein levels x vegetarianism interaction,Phenotype,C reactive protein levels x vegetarianism interaction
48915,Calcium levels x vegetarianism interaction,Phenotype,Calcium levels x vegetarianism interaction
48917,Cholesterol levels x vegetarianism interaction,Phenotype,Cholesterol levels x vegetarianism interaction
48920,HbA1c levels (adjusted for BMI) x vegetarianism interaction,Phenotype,HbA1c levels (adjusted for BMI) x vegetarianism interaction
48923,Cystatin C levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Cystatin C levels (adjusted for BMI) x vegetarianism interaction
48926,Gamma glutamyltransferase levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Gamma glutamyltransferase levels (adjusted for BMI) x vegetarianism interaction
48929,Insulin-like growth factor 1 levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Insulin-like growth factor 1 levels (adjusted for BMI) x vegetarianism interaction
48931,Direct low density lipoprotein cholesterol levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Direct low density lipoprotein cholesterol levels (adjusted for BMI) x vegetarianism interaction
48933,Concentration of large LDL particles,Phenotype,Concentration of large LDL particles
48938,Cholesterol levels in large VLDL,Phenotype,Cholesterol levels in large VLDL
48947,Hip index,Phenotype,Hip index
48948,Phospholipid levels in large VLDL,Phenotype,Phospholipid levels in large VLDL
48949,Concentration of large VLDL particles,Phenotype,Concentration of large VLDL particles
48950,Ribosyldihydronicotinamide dehydrogenase [quinone] levels (NQO2.9754.33.3),Phenotype,Ribosyldihydronicotinamide dehydrogenase [quinone] levels (NQO2.9754.33.3)
48954,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 levels (ENPP5.6556.5.3),Phenotype,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 levels (ENPP5.6556.5.3)
48958,Cholesteryl ester levels in HDL,Phenotype,Cholesteryl ester levels in HDL
48961,Carotid Intima-media thickness (mean of the maximum cIMT),Phenotype,Carotid Intima-media thickness (mean of the maximum cIMT)
48969,Fractalkine levels (CX3CL1.2827.23.2),Phenotype,Fractalkine levels (CX3CL1.2827.23.2)
48975,Ubiquitin-like protein ISG15 levels (ISG15.14151.4.3),Phenotype,Ubiquitin-like protein ISG15 levels (ISG15.14151.4.3)
48977,UDP-N-acetylhexosamine pyrophosphorylase levels (UAP1.13580.2.3),Phenotype,UDP-N-acetylhexosamine pyrophosphorylase levels (UAP1.13580.2.3)
48978,Phospholipid levels in HDL,Phenotype,Phospholipid levels in HDL
48981,Ubiquitin carboxyl-terminal hydrolase 25 levels (USP25.9215.117.3),Phenotype,Ubiquitin carboxyl-terminal hydrolase 25 levels (USP25.9215.117.3)
48995,Concentration of HDL particles,Phenotype,Concentration of HDL particles
48996,Cholesterol levels in IDL,Phenotype,Cholesterol levels in IDL
49000,Phospholipid levels in IDL,Phenotype,Phospholipid levels in IDL
49002,Melanocyte protein PMEL levels (PMEL.6472.40.3),Phenotype,Melanocyte protein PMEL levels (PMEL.6472.40.3)
49004,NAD(P)H dehydrogenase [quinone] 1 levels (NQO1.9837.60.3),Phenotype,NAD(P)H dehydrogenase [quinone] 1 levels (NQO1.9837.60.3)
49007,Natural cytotoxicity triggering receptor 3 levels (NCR3.3003.29.2),Phenotype,Natural cytotoxicity triggering receptor 3 levels (NCR3.3003.29.2)
49009,MHC class I polypeptide-related sequence B levels (MICB.5102.55.3),Phenotype,MHC class I polypeptide-related sequence B levels (MICB.5102.55.3)
49016,Vesicle-fusing ATPase levels (NSF.13992.12.3),Phenotype,Vesicle-fusing ATPase levels (NSF.13992.12.3)
49018,Zinc fingers and homeoboxes protein 3 levels (ZHX3.10036.201.3),Phenotype,Zinc fingers and homeoboxes protein 3 levels (ZHX3.10036.201.3)
49020,N-acetylated-alpha-linked acidic dipeptidase 2 levels (NAALAD2.7986.98.3),Phenotype,N-acetylated-alpha-linked acidic dipeptidase 2 levels (NAALAD2.7986.98.3)
49021,N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase levels (NAGPA.11208.15.3),Phenotype,N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase levels (NAGPA.11208.15.3)
49022,Cyclic AMP-dependent transcription factor ATF-6 alpha levels (ATF6.11277.23.3),Phenotype,Cyclic AMP-dependent transcription factor ATF-6 alpha levels (ATF6.11277.23.3)
49023,Polypeptide N-acetylgalactosaminyltransferase 1 levels (GALNT1.7090.17.3),Phenotype,Polypeptide N-acetylgalactosaminyltransferase 1 levels (GALNT1.7090.17.3)
49027,Glycoprotein endo-alpha-1--2-mannosidase levels (MANEA.8014.359.3),Phenotype,Glycoprotein endo-alpha-1--2-mannosidase levels (MANEA.8014.359.3)
49031,Carotid intima media thickness (maximum),Phenotype,Carotid intima media thickness (maximum)
49033,Glutathione S-transferase A1 levels (GSTA1.12446.49.3),Phenotype,Glutathione S-transferase A1 levels (GSTA1.12446.49.3)
49035,Glycine N-methyltransferase levels (GNMT.14006.36.3),Phenotype,Glycine N-methyltransferase levels (GNMT.14006.36.3)
49040,Free cholesterol to total lipids ratio in IDL,Phenotype,Free cholesterol to total lipids ratio in IDL
49053,Cholesterol to total lipids ratio in large HDL,Phenotype,Cholesterol to total lipids ratio in large HDL
49058,Phospholipid levels in large HDL,Phenotype,Phospholipid levels in large HDL
49071,Cholesterol to total lipids ratio in large LDL,Phenotype,Cholesterol to total lipids ratio in large LDL
49074,Albumin levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Albumin levels (adjusted for BMI) x vegetarianism interaction
49075,Total lipid levels in large LDL,Phenotype,Total lipid levels in large LDL
49077,Free cholesterol to total lipids ratio in large LDL,Phenotype,Free cholesterol to total lipids ratio in large LDL
49079,Estimated glomerular filtration rate x vegetarianism interaction,Phenotype,Estimated glomerular filtration rate x vegetarianism interaction
49080,Urea levels x vegetarianism interaction,Phenotype,Urea levels x vegetarianism interaction
49082,Vitamin D levels x vegetarianism interaction,Phenotype,Vitamin D levels x vegetarianism interaction
49084,Triglycerides to total lipids ratio in large LDL,Phenotype,Triglycerides to total lipids ratio in large LDL
49087,Total lipid levels in large VLDL,Phenotype,Total lipid levels in large VLDL
49088,Free cholesterol to total lipids ratio in large VLDL,Phenotype,Free cholesterol to total lipids ratio in large VLDL
49092,Cholesteryl esters to total lipids ratio in large HDL,Phenotype,Cholesteryl esters to total lipids ratio in large HDL
49102,HbA1c levels x vegetarianism interaction,Phenotype,HbA1c levels x vegetarianism interaction
49107,Direct low density lipoprotein cholesterol levels x vegetarianism interaction,Phenotype,Direct low density lipoprotein cholesterol levels x vegetarianism interaction
49108,Phosphate levels x vegetarianism interaction,Phenotype,Phosphate levels x vegetarianism interaction
49110,Testosterone levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Testosterone levels (adjusted for BMI) x vegetarianism interaction
49113,Total bilirubin levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Total bilirubin levels (adjusted for BMI) x vegetarianism interaction
49116,Lipoprotein A levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Lipoprotein A levels (adjusted for BMI) x vegetarianism interaction
49119,Phosphate levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Phosphate levels (adjusted for BMI) x vegetarianism interaction
49120,Phospholipid levels in large LDL,Phenotype,Phospholipid levels in large LDL
49121,Cholesterol to total lipids ratio in large VLDL,Phenotype,Cholesterol to total lipids ratio in large VLDL
49131,Total lipid levels in large HDL,Phenotype,Total lipid levels in large HDL
49132,Insomnia or psoriasis (pleiotropy),Phenotype,Insomnia or psoriasis (pleiotropy)
49158,Cholesteryl ester levels in large LDL,Phenotype,Cholesteryl ester levels in large LDL
49160,Cholesteryl esters to total lipids ratio in large LDL,Phenotype,Cholesteryl esters to total lipids ratio in large LDL
49173,Free cholesterol levels in large VLDL,Phenotype,Free cholesterol levels in large VLDL
49175,Cholesterol levels in large HDL,Phenotype,Cholesterol levels in large HDL
49176,Free cholesterol to total lipids ratio in large HDL,Phenotype,Free cholesterol to total lipids ratio in large HDL
49193,Cholesterol levels in large LDL,Phenotype,Cholesterol levels in large LDL
49194,Triglycerides to total lipids ratio in large HDL,Phenotype,Triglycerides to total lipids ratio in large HDL
49196,Cholesterol levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Cholesterol levels (adjusted for BMI) x vegetarianism interaction
49197,Aspartate aminotransferase levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Aspartate aminotransferase levels (adjusted for BMI) x vegetarianism interaction
49199,C reactive protein levels (adjusted for BMI) x vegetarianism interaction,Phenotype,C reactive protein levels (adjusted for BMI) x vegetarianism interaction
49201,Calcium levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Calcium levels (adjusted for BMI) x vegetarianism interaction
49202,Phospholipids to total lipids ratio in large LDL,Phenotype,Phospholipids to total lipids ratio in large LDL
49208,Estimated glomerular filtration rate (adjusted for BMI) x vegetarianism interaction,Phenotype,Estimated glomerular filtration rate (adjusted for BMI) x vegetarianism interaction
49209,Urea levels (adjusted for BMI) x vegetarianism interaction,Phenotype,Urea levels (adjusted for BMI) x vegetarianism interaction
49211,Cholesteryl esters to total lipids ratio in large VLDL,Phenotype,Cholesteryl esters to total lipids ratio in large VLDL
49239,Testosterone levels x vegetarianism interaction,Phenotype,Testosterone levels x vegetarianism interaction
49240,Total bilirubin levels x vegetarianism interaction,Phenotype,Total bilirubin levels x vegetarianism interaction
49241,Triglyceride levels x vegetarianism interaction,Phenotype,Triglyceride levels x vegetarianism interaction
49246,Triglyceride levels in large LDL,Phenotype,Triglyceride levels in large LDL
49247,Cholesteryl ester levels in large VLDL,Phenotype,Cholesteryl ester levels in large VLDL
49248,Free cholesterol levels in LDL,Phenotype,Free cholesterol levels in LDL
49249,Pediatric dental caries (decayed-- missing and filled teeth >5),Phenotype,Pediatric dental caries (decayed-- missing and filled teeth >5)
49251,Cholesteryl ester levels in medium HDL,Phenotype,Cholesteryl ester levels in medium HDL
49254,Cholesterol to total lipids ratio in medium HDL,Phenotype,Cholesterol to total lipids ratio in medium HDL
49255,Total lipid levels in medium HDL,Phenotype,Total lipid levels in medium HDL
49260,Depression severity  x hours spent watching television interaction,Phenotype,Depression severity  x hours spent watching television interaction
49263,Cigarette consumption x playing computer games interaction,Phenotype,Cigarette consumption x playing computer games interaction
49264,Alcohol consumption x playing computer games interaction,Phenotype,Alcohol consumption x playing computer games interaction
49267,Anxiety severity x hours spent watching television interaction,Phenotype,Anxiety severity x hours spent watching television interaction
49271,Cholesterol levels in medium LDL,Phenotype,Cholesterol levels in medium LDL
49272,Cholesterol to total lipids ratio in medium LDL,Phenotype,Cholesterol to total lipids ratio in medium LDL
49277,Phospholipid levels in medium LDL,Phenotype,Phospholipid levels in medium LDL
49282,Testosterone levels in premenopausal women,Phenotype,Testosterone levels in premenopausal women
49284,Omega-3 fatty acid levels,Phenotype,Omega-3 fatty acid levels
49287,Ferritin levels (FTH1.FTL.3031.66.1),Phenotype,Ferritin levels (FTH1.FTL.3031.66.1)
49288,ER membrane protein complex subunit 4 levels (EMC4.13516.46.3),Phenotype,ER membrane protein complex subunit 4 levels (EMC4.13516.46.3)
49290,Carotid intima media thickness (minimum),Phenotype,Carotid intima media thickness (minimum)
49291,Cholesteryl esters to total lipids ratio in IDL,Phenotype,Cholesteryl esters to total lipids ratio in IDL
49293,Chronic elevation of alanine aminotransferase (cALT) levels,Phenotype,Chronic elevation of alanine aminotransferase (cALT) levels
49295,Triglyceride levels in IDL,Phenotype,Triglyceride levels in IDL
49300,Mitogen-activated protein kinase 13 levels (MAPK13.5006.71.1),Phenotype,Mitogen-activated protein kinase 13 levels (MAPK13.5006.71.1)
49308,Osteocalcin levels (BGLAP.11067.13.3),Phenotype,Osteocalcin levels (BGLAP.11067.13.3)
49310,NmrA-like family domain-containing protein 1 levels (NMRAL1.13988.67.3),Phenotype,NmrA-like family domain-containing protein 1 levels (NMRAL1.13988.67.3)
49312,Neural cell adhesion molecule 2 levels (NCAM2.6507.16.3),Phenotype,Neural cell adhesion molecule 2 levels (NCAM2.6507.16.3)
49314,Neuropeptide W levels (NPW.9986.14.3),Phenotype,Neuropeptide W levels (NPW.9986.14.3)
49316,Neutrophil collagenase levels (MMP8.2954.56.2),Phenotype,Neutrophil collagenase levels (MMP8.2954.56.2)
49320,SPARC-like protein 1 levels (SPARCL1.4467.49.2),Phenotype,SPARC-like protein 1 levels (SPARCL1.4467.49.2)
49321,Granulysin levels (GNLY.3195.50.2),Phenotype,Granulysin levels (GNLY.3195.50.2)
49323,Gremlin-1 levels (GREM1.4449.67.3),Phenotype,Gremlin-1 levels (GREM1.4449.67.3)
49328,Stromal membrane-associated protein 1 levels (SMAP1.11649.3.3),Phenotype,Stromal membrane-associated protein 1 levels (SMAP1.11649.3.3)
49330,Killer cell immunoglobulin-like receptor 2DS2 levels (KIR2DS2.10428.1.3),Phenotype,Killer cell immunoglobulin-like receptor 2DS2 levels (KIR2DS2.10428.1.3)
49334,Triglyceride levels in HDL,Phenotype,Triglyceride levels in HDL
49336,Average diameter for HDL particles,Phenotype,Average diameter for HDL particles
49338,Free cholesterol levels in IDL,Phenotype,Free cholesterol levels in IDL
49339,Phospholipids to total lipids ratio in IDL,Phenotype,Phospholipids to total lipids ratio in IDL
49344,Vascular endothelial growth factor A levels (VEGFA.2597.8.3),Phenotype,Vascular endothelial growth factor A levels (VEGFA.2597.8.3)
49345,Vascular endothelial growth factor A-- isoform 121 levels (VEGFA.14032.2.3),Phenotype,Vascular endothelial growth factor A-- isoform 121 levels (VEGFA.14032.2.3)
49348,Promotilin levels (MLN.5631.83.3),Phenotype,Promotilin levels (MLN.5631.83.3)
49351,T-cell surface protein tactile levels (CD96.9735.44.3),Phenotype,T-cell surface protein tactile levels (CD96.9735.44.3)
49353,Tapasin levels (TAPBP.12378.71.3),Phenotype,Tapasin levels (TAPBP.12378.71.3)
49355,Tapasin-related protein levels (TAPBPL.6364.7.3),Phenotype,Tapasin-related protein levels (TAPBPL.6364.7.3)
49356,HLA class II histocompatibility antigen-- DQ alpha 2 chain levels (HLA.DQA2.7757.5.3),Phenotype,HLA class II histocompatibility antigen-- DQ alpha 2 chain levels (HLA.DQA2.7757.5.3)
49362,Tenascin-X levels (TNXB.5698.60.3),Phenotype,Tenascin-X levels (TNXB.5698.60.3)
49368,Cholesterol to total lipids ratio in IDL,Phenotype,Cholesterol to total lipids ratio in IDL
49374,Total lipid levels in IDL,Phenotype,Total lipid levels in IDL
49375,Concentration of IDL particles,Phenotype,Concentration of IDL particles
49377,Triglycerides to total lipids ratio in IDL,Phenotype,Triglycerides to total lipids ratio in IDL
49378,Thioredoxin domain-containing protein 5 levels (TXNDC5.11212.7.3),Phenotype,Thioredoxin domain-containing protein 5 levels (TXNDC5.11212.7.3)
49379,Thrombospondin-2 levels (THBS2.3339.33.1),Phenotype,Thrombospondin-2 levels (THBS2.3339.33.1)
49383,Inactive pancreatic lipase-related protein 1 levels (PNLIPRP1.6627.25.3),Phenotype,Inactive pancreatic lipase-related protein 1 levels (PNLIPRP1.6627.25.3)
49385,Inducible T-cell costimulator levels (ICOS.14084.191.3),Phenotype,Inducible T-cell costimulator levels (ICOS.14084.191.3)
49387,Total lipid levels in HDL,Phenotype,Total lipid levels in HDL
49391,Cholesteryl ester levels in IDL,Phenotype,Cholesteryl ester levels in IDL
49392,radiation-induced toxicity (physician-rated acute dysphagia),Phenotype,radiation-induced toxicity (physician-rated acute dysphagia)
49394,radiation-induced toxicity (patient-rated acute xerostomia),Phenotype,radiation-induced toxicity (patient-rated acute xerostomia)
49395,radiation-induced toxicity (physician-rated acute xerostomia),Phenotype,radiation-induced toxicity (physician-rated acute xerostomia)
49398,radiation-induced toxicity (patient-rated acute sticky saliva),Phenotype,radiation-induced toxicity (patient-rated acute sticky saliva)
49400,radiation-induced toxicity (standardized total average toxicity_patient),Phenotype,radiation-induced toxicity (standardized total average toxicity_patient)
49402,Free cholesterol levels in small HDL,Phenotype,Free cholesterol levels in small HDL
49404,Phospholipids to total lipids ratio in small HDL,Phenotype,Phospholipids to total lipids ratio in small HDL
49410,Cholesterol levels in small LDL,Phenotype,Cholesterol levels in small LDL
49411,Primary open angle glaucoma (multi-trait analysis),Phenotype,Primary open angle glaucoma (multi-trait analysis)
49422,Cholesterol to total lipids ratio in small LDL,Phenotype,Cholesterol to total lipids ratio in small LDL
49424,Cholesteryl ester levels in small VLDL,Phenotype,Cholesteryl ester levels in small VLDL
49426,Cholesterol to total lipids ratio in small VLDL,Phenotype,Cholesterol to total lipids ratio in small VLDL
49429,Annual frequency of asthma exacerbations in non-smokers,Phenotype,Annual frequency of asthma exacerbations in non-smokers
49431,Annual frequency of asthma exacerbations in smokers,Phenotype,Annual frequency of asthma exacerbations in smokers
49433,Cholesteryl esters to total lipids ratio in small VLDL,Phenotype,Cholesteryl esters to total lipids ratio in small VLDL
49436,Saturated fatty acid levels,Phenotype,Saturated fatty acid levels
49440,Total lipid levels in lipoprotein particles,Phenotype,Total lipid levels in lipoprotein particles
49441,Total concentration of lipoprotein particles,Phenotype,Total concentration of lipoprotein particles
49442,Total fatty acid levels,Phenotype,Total fatty acid levels
49443,Anti-hepatitis E antibody seropositivity,Phenotype,Anti-hepatitis E antibody seropositivity
49446,Free cholesterol levels in VLDL,Phenotype,Free cholesterol levels in VLDL
49447,Total lipid levels in VLDL,Phenotype,Total lipid levels in VLDL
49448,Triglyceride levels in VLDL,Phenotype,Triglyceride levels in VLDL
49449,Cholesterol levels in very large HDL,Phenotype,Cholesterol levels in very large HDL
49453,Cholesteryl ester levels in very large HDL,Phenotype,Cholesteryl ester levels in very large HDL
49454,Cholesteryl esters to total lipids ratio in very large HDL,Phenotype,Cholesteryl esters to total lipids ratio in very large HDL
49459,Free cholesterol levels in very large HDL,Phenotype,Free cholesterol levels in very large HDL
49462,Free cholesterol to total lipids ratio in very large HDL,Phenotype,Free cholesterol to total lipids ratio in very large HDL
49463,Total lipid levels in very large HDL,Phenotype,Total lipid levels in very large HDL
49464,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; all treatment preparations),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; all treatment preparations)
49466,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFNβ-1b subcutaneous),Phenotype,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFNβ-1b subcutaneous)
49469,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFNβ-1a subcutaneous and intramuscular),Phenotype,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFNβ-1a subcutaneous and intramuscular)
49472,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFNβ-1a subcutaneous),Phenotype,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFNβ-1a subcutaneous)
49474,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; all treatment preparations),Phenotype,Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; all treatment preparations)
49479,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFNβ-1b subcutaneous),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFNβ-1b subcutaneous)
49481,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFNβ-1a subcutaneous and intramuscular),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFNβ-1a subcutaneous and intramuscular)
49483,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFNβ-1a subcutaneous),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFNβ-1a subcutaneous)
49485,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; all treatment preparations),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; all treatment preparations)
49486,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFNβ-1b subcutaneous),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFNβ-1b subcutaneous)
49488,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFNβ-1a subcutaneous and intramuscular),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFNβ-1a subcutaneous and intramuscular)
49490,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFNβ-1a subcutaneous),Phenotype,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFNβ-1a subcutaneous)
49492,Phospholipid levels in very large HDL,Phenotype,Phospholipid levels in very large HDL
49499,Triglycerides to total lipids ratio in very large HDL,Phenotype,Triglycerides to total lipids ratio in very large HDL
49500,Cholesterol levels in very large VLDL,Phenotype,Cholesterol levels in very large VLDL
49501,Cholesterol to total lipids ratio in very large VLDL,Phenotype,Cholesterol to total lipids ratio in very large VLDL
49506,Whole brain restricted isotropic diffusion (multivariate analysis),Phenotype,Whole brain restricted isotropic diffusion (multivariate analysis)
49509,Cholesteryl ester levels in very large VLDL,Phenotype,Cholesteryl ester levels in very large VLDL
49512,Concentration of medium HDL particles,Phenotype,Concentration of medium HDL particles
49514,Hunner-type interstitial cystitis,Phenotype,Hunner-type interstitial cystitis
49515,Psycho-cardiometabolic multimorbidity (multivariate analysis),Phenotype,Psycho-cardiometabolic multimorbidity (multivariate analysis)
49522,Total lipid levels in small HDL,Phenotype,Total lipid levels in small HDL
49523,Concentration of small HDL particles,Phenotype,Concentration of small HDL particles
49526,Free cholesterol levels in small LDL,Phenotype,Free cholesterol levels in small LDL
49529,Phospholipid levels in small LDL,Phenotype,Phospholipid levels in small LDL
49530,Extraintestinal manifestations in inflammatory bowel disease (ankylosing spondylitis and sacroiliitis),Phenotype,Extraintestinal manifestations in inflammatory bowel disease (ankylosing spondylitis and sacroiliitis)
49533,Extraintestinal manifestations in inflammatory bowel disease (ocular manifestations),Phenotype,Extraintestinal manifestations in inflammatory bowel disease (ocular manifestations)
49536,Extraintestinal manifestations in inflammatory bowel disease (primary sclerosing cholangitis),Phenotype,Extraintestinal manifestations in inflammatory bowel disease (primary sclerosing cholangitis)
49542,Extraintestinal manifestations in inflammatory bowel disease (any of 6 phenotypes),Phenotype,Extraintestinal manifestations in inflammatory bowel disease (any of 6 phenotypes)
49544,Free cholesterol levels in small VLDL,Phenotype,Free cholesterol levels in small VLDL
49545,Phospholipids to total lipids ratio in small VLDL,Phenotype,Phospholipids to total lipids ratio in small VLDL
49547,Sphingomyelin levels,Phenotype,Sphingomyelin levels
49549,Total triglycerides levels,Phenotype,Total triglycerides levels
49550,Tanner 3 to Tanner 4 pubertal stage transition (joint longitudinal BMI and survival model),Phenotype,Tanner 3 to Tanner 4 pubertal stage transition (joint longitudinal BMI and survival model)
49553,Tanner 2 to Tanner 4 pubertal stage transition (joint longitudinal BMI and survival model),Phenotype,Tanner 2 to Tanner 4 pubertal stage transition (joint longitudinal BMI and survival model)
49557,Phospholipid levels in VLDL,Phenotype,Phospholipid levels in VLDL
49558,Concentration of VLDL particles,Phenotype,Concentration of VLDL particles
49562,Triglyceride levels in small HDL,Phenotype,Triglyceride levels in small HDL
49565,Triglyceride levels in small LDL,Phenotype,Triglyceride levels in small LDL
49567,Free cholesterol to total lipids ratio in small VLDL,Phenotype,Free cholesterol to total lipids ratio in small VLDL
49570,Cardiorespiratory fitness,Phenotype,Cardiorespiratory fitness
49573,Phospholipid levels in small VLDL,Phenotype,Phospholipid levels in small VLDL
49574,Total phospholipid levels in lipoprotein particles,Phenotype,Total phospholipid levels in lipoprotein particles
49576,Cholesterol to total lipids ratio in very large HDL,Phenotype,Cholesterol to total lipids ratio in very large HDL
49579,High general stress,Phenotype,High general stress
49583,Concentration of very large HDL particles,Phenotype,Concentration of very large HDL particles
49587,Triglyceride levels in very large HDL,Phenotype,Triglyceride levels in very large HDL
49598,Acetoacetate levels,Phenotype,Acetoacetate levels
49602,Acetone levels,Phenotype,Acetone levels
49605,Clinical LDL cholesterol levels,Phenotype,Clinical LDL cholesterol levels
49608,Potassium levels,Phenotype,Potassium levels
49613,Glycoprotein acetyls levels,Phenotype,Glycoprotein acetyls levels
49623,Cholesterol levels in medium HDL,Phenotype,Cholesterol levels in medium HDL
49624,Polyunsaturated fatty acid levels,Phenotype,Polyunsaturated fatty acid levels
49633,Alpha-hydroxyisovalerate levels in elite athletes,Phenotype,Alpha-hydroxyisovalerate levels in elite athletes
49638,Argininate levels in elite athletes,Phenotype,Argininate levels in elite athletes
49640,Beta-citrylglutamate levels in elite athletes,Phenotype,Beta-citrylglutamate levels in elite athletes
49643,Betaine levels in elite athletes,Phenotype,Betaine levels in elite athletes
49646,1-methylhistidine levels in elite athletes,Phenotype,1-methylhistidine levels in elite athletes
49649,Periodontal pocket (adjusted for age-- sex and smoking status),Phenotype,Periodontal pocket (adjusted for age-- sex and smoking status)
49651,Periodontal pocket (adjusted for age-- sex-- smoking status  and plaque),Phenotype,Periodontal pocket (adjusted for age-- sex-- smoking status  and plaque)
49652,Perfluorooctanesulfonic acid (PFOS) levels in elite athletes,Phenotype,Perfluorooctanesulfonic acid (PFOS) levels in elite athletes
49654,Ursodeoxycholate levels in elite athletes,Phenotype,Ursodeoxycholate levels in elite athletes
49658,Tyrosine levels in elite athletes,Phenotype,Tyrosine levels in elite athletes
49660,N-methylpipecolate levels in elite athletes,Phenotype,N-methylpipecolate levels in elite athletes
49662,Methyl glucopyranoside (alpha + beta) levels in elite athletes,Phenotype,Methyl glucopyranoside (alpha + beta) levels in elite athletes
49664,Tryptophan betaine levels in elite athletes,Phenotype,Tryptophan betaine levels in elite athletes
49666,Tryptophan levels in elite athletes,Phenotype,Tryptophan levels in elite athletes
49667,N-(2-furoyl)glycine levels in elite athletes,Phenotype,N-(2-furoyl)glycine levels in elite athletes
49669,Tartronate (hydroxymalonate) levels in elite athletes,Phenotype,Tartronate (hydroxymalonate) levels in elite athletes
49672,Bilirubin (Z--Z) levels in elite athletes,Phenotype,Bilirubin (Z--Z) levels in elite athletes
49674,Gulonate levels in elite athletes,Phenotype,Gulonate levels in elite athletes
49676,Ribonate levels in elite athletes,Phenotype,Ribonate levels in elite athletes
49678,Xylose levels in elite athletes,Phenotype,Xylose levels in elite athletes
49680,Alpha-ketoglutarate levels in elite athletes,Phenotype,Alpha-ketoglutarate levels in elite athletes
49682,1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4) levels in elite athletes,Phenotype,1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4) levels in elite athletes
49684,Galactonate levels in elite athletes,Phenotype,Galactonate levels in elite athletes
49686,Tyramine O-sulfate levels in elite athletes,Phenotype,Tyramine O-sulfate levels in elite athletes
49688,Urea levels in elite athletes,Phenotype,Urea levels in elite athletes
49690,1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1) levels in elite athletes,Phenotype,1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1) levels in elite athletes
49692,1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) levels in elite athletes,Phenotype,1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) levels in elite athletes
49694,1-palmitoyl-2-oleoyl-GPC (16:0/18:1) levels in elite athletes,Phenotype,1-palmitoyl-2-oleoyl-GPC (16:0/18:1) levels in elite athletes
49696,1-palmitoyl-2-oleoyl-GPE (16:0/18:1) levels in elite athletes,Phenotype,1-palmitoyl-2-oleoyl-GPE (16:0/18:1) levels in elite athletes
49703,5-oxoproline levels in elite athletes,Phenotype,5-oxoproline levels in elite athletes
49705,1-stearoyl-GPC (18:0) levels in elite athletes,Phenotype,1-stearoyl-GPC (18:0) levels in elite athletes
49709,1-stearoyl-GPE (18:0) levels in elite athletes,Phenotype,1-stearoyl-GPE (18:0) levels in elite athletes
49710,1-palmitoyl-GPI (16:0) levels in elite athletes,Phenotype,1-palmitoyl-GPI (16:0) levels in elite athletes
49712,1-stearoyl-2-linoleoyl-GPC (18:0/18:2) levels in elite athletes,Phenotype,1-stearoyl-2-linoleoyl-GPC (18:0/18:2) levels in elite athletes
49714,1-stearoyl-2-linoleoyl-GPI (18:0/18:2) levels in elite athletes,Phenotype,1-stearoyl-2-linoleoyl-GPI (18:0/18:2) levels in elite athletes
49716,1-stearoyl-2-oleoyl-GPI (18:0/18:1) levels in elite athletes,Phenotype,1-stearoyl-2-oleoyl-GPI (18:0/18:1) levels in elite athletes
49718,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels in elite athletes,Phenotype,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels in elite athletes
49721,1-palmitoyl-2-stearoyl-GPC (16:0/18:0) levels in elite athletes,Phenotype,1-palmitoyl-2-stearoyl-GPC (16:0/18:0) levels in elite athletes
49722,1-palmitoyl-GPC (16:0) levels in elite athletes,Phenotype,1-palmitoyl-GPC (16:0) levels in elite athletes
49723,1-palmitoyl-GPE (16:0) levels in elite athletes,Phenotype,1-palmitoyl-GPE (16:0) levels in elite athletes
49725,5-HETE levels in elite athletes,Phenotype,5-HETE levels in elite athletes
49727,Cysteine levels in elite athletes,Phenotype,Cysteine levels in elite athletes
49733,Cystathionine levels in elite athletes,Phenotype,Cystathionine levels in elite athletes
49735,5-HEPE levels in elite athletes,Phenotype,5-HEPE levels in elite athletes
49737,4-HDoHE levels in elite athletes,Phenotype,4-HDoHE levels in elite athletes
49739,Cortisone levels in elite athletes,Phenotype,Cortisone levels in elite athletes
49741,3-hydroxyoctanoate levels in elite athletes,Phenotype,3-hydroxyoctanoate levels in elite athletes
49743,Chenodeoxycholate levels in elite athletes,Phenotype,Chenodeoxycholate levels in elite athletes
49749,Dehydroisoandrosterone sulfate (DHEA-S) levels in elite athletes,Phenotype,Dehydroisoandrosterone sulfate (DHEA-S) levels in elite athletes
49751,Deoxycholate levels in elite athletes,Phenotype,Deoxycholate levels in elite athletes
49754,Dihomo-linoleate (20:2n6) levels in elite athletes,Phenotype,Dihomo-linoleate (20:2n6) levels in elite athletes
49756,5alpha-pregnan-3beta--20beta-diol monosulfate (1) levels in elite athletes,Phenotype,5alpha-pregnan-3beta--20beta-diol monosulfate (1) levels in elite athletes
49758,Dimethylglycine levels in elite athletes,Phenotype,Dimethylglycine levels in elite athletes
49760,5alpha-pregnan-3(alpha or beta)--20beta-diol disulfate levels in elite athletes,Phenotype,5alpha-pregnan-3(alpha or beta)--20beta-diol disulfate levels in elite athletes
49762,5alpha-pregnan-3beta-ol--20-one sulfate levels in elite athletes,Phenotype,5alpha-pregnan-3beta-ol--20-one sulfate levels in elite athletes
49764,Adipoylcarnitine (C6-DC) levels in elite athletes,Phenotype,Adipoylcarnitine (C6-DC) levels in elite athletes
49766,Andro steroid monosulfate C19H28O6S (1) levels in elite athletes,Phenotype,Andro steroid monosulfate C19H28O6S (1) levels in elite athletes
49768,5alpha-pregnan-3beta--20alpha-diol monosulfate (2) levels in elite athletes,Phenotype,5alpha-pregnan-3beta--20alpha-diol monosulfate (2) levels in elite athletes
49771,Atopic dermatitis (moderate to severe),Phenotype,Atopic dermatitis (moderate to severe)
49775,Glutamine levels,Phenotype,Glutamine levels
49778,Docosahexaenoic acid levels,Phenotype,Docosahexaenoic acid levels
49780,Histidine levels,Phenotype,Histidine levels
49782,Isoleucine levels,Phenotype,Isoleucine levels
49783,Lactate levels,Phenotype,Lactate levels
49784,Linoleic acid levels,Phenotype,Linoleic acid levels
49791,Total free cholesterol levels,Phenotype,Total free cholesterol levels
49792,4-hydroxyphenylpyruvate levels in elite athletes,Phenotype,4-hydroxyphenylpyruvate levels in elite athletes
49794,2-oxoarginine levels in elite athletes,Phenotype,2-oxoarginine levels in elite athletes
49796,3-hydroxy-2-ethylpropionate levels in elite athletes,Phenotype,3-hydroxy-2-ethylpropionate levels in elite athletes
49800,3-methylglutaconate levels in elite athletes,Phenotype,3-methylglutaconate levels in elite athletes
49805,2-hydroxy-3-methylvalerate levels in elite athletes,Phenotype,2-hydroxy-3-methylvalerate levels in elite athletes
49807,1-methylimidazoleacetate levels in elite athletes,Phenotype,1-methylimidazoleacetate levels in elite athletes
49809,5-bromotryptophan levels in elite athletes,Phenotype,5-bromotryptophan levels in elite athletes
49812,2-hydroxybutyrate/2-hydroxyisobutyrate levels in elite athletes,Phenotype,2-hydroxybutyrate/2-hydroxyisobutyrate levels in elite athletes
49814,2-methylbutyrylcarnitine (C5) levels in elite athletes,Phenotype,2-methylbutyrylcarnitine (C5) levels in elite athletes
49817,2-methylbutyrylglycine levels in elite athletes,Phenotype,2-methylbutyrylglycine levels in elite athletes
49821,Taurolithocholate 3-sulfate levels in elite athletes,Phenotype,Taurolithocholate 3-sulfate levels in elite athletes
49823,Tetradecanedioate levels in elite athletes,Phenotype,Tetradecanedioate levels in elite athletes
49825,Theobromine levels in elite athletes,Phenotype,Theobromine levels in elite athletes
49827,Cinnamoylglycine levels in elite athletes,Phenotype,Cinnamoylglycine levels in elite athletes
49829,5-acetylamino-6-amino-3-methyluracil levels in elite athletes,Phenotype,5-acetylamino-6-amino-3-methyluracil levels in elite athletes
49831,5-acetylamino-6-formylamino-3-methyluracil levels in elite athletes,Phenotype,5-acetylamino-6-formylamino-3-methyluracil levels in elite athletes
49834,6-hydroxyindole sulfate levels in elite athletes,Phenotype,6-hydroxyindole sulfate levels in elite athletes
49836,Acesulfame levels in elite athletes,Phenotype,Acesulfame levels in elite athletes
49838,Gluconate levels in elite athletes,Phenotype,Gluconate levels in elite athletes
49841,Stearoylcarnitine (C18) levels in elite athletes,Phenotype,Stearoylcarnitine (C18) levels in elite athletes
49842,Dihydroferulic acid levels in elite athletes,Phenotype,Dihydroferulic acid levels in elite athletes
49844,Taurochenodeoxycholate levels in elite athletes,Phenotype,Taurochenodeoxycholate levels in elite athletes
49848,S-methylmethionine levels in elite athletes,Phenotype,S-methylmethionine levels in elite athletes
49850,1--3--7-trimethylurate levels in elite athletes,Phenotype,1--3--7-trimethylurate levels in elite athletes
49852,1--5-anhydroglucitol (1--5-AG) levels in elite athletes,Phenotype,1--5-anhydroglucitol (1--5-AG) levels in elite athletes
49854,1--7-dimethylurate levels in elite athletes,Phenotype,1--7-dimethylurate levels in elite athletes
49856,Spermidine levels in elite athletes,Phenotype,Spermidine levels in elite athletes
49858,Tiglylcarnitine (C5:1-DC) levels in elite athletes,Phenotype,Tiglylcarnitine (C5:1-DC) levels in elite athletes
49860,N-formylphenylalanine levels in elite athletes,Phenotype,N-formylphenylalanine levels in elite athletes
49862,N-trimethyl 5-aminovalerate levels in elite athletes,Phenotype,N-trimethyl 5-aminovalerate levels in elite athletes
49864,N-acetyltryptophan levels in elite athletes,Phenotype,N-acetyltryptophan levels in elite athletes
49865,N-acetylproline levels in elite athletes,Phenotype,N-acetylproline levels in elite athletes
49868,3-ureidopropionate levels in elite athletes,Phenotype,3-ureidopropionate levels in elite athletes
49870,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels in elite athletes,Phenotype,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels in elite athletes
49872,1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6) levels in elite athletes,Phenotype,1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6) levels in elite athletes
49874,1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels in elite athletes,Phenotype,1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels in elite athletes
49876,1-palmitoleoyl-GPC (16:1) levels in elite athletes,Phenotype,1-palmitoleoyl-GPC (16:1) levels in elite athletes
49878,1-palmitoleoylglycerol (16:1) levels in elite athletes,Phenotype,1-palmitoleoylglycerol (16:1) levels in elite athletes
49880,1-oleoyl-GPE (18:1) levels in elite athletes,Phenotype,1-oleoyl-GPE (18:1) levels in elite athletes
49881,1-oleoyl-GPI (18:1) levels in elite athletes,Phenotype,1-oleoyl-GPI (18:1) levels in elite athletes
49885,Carnitine levels in elite athletes,Phenotype,Carnitine levels in elite athletes
49887,Biliverdin levels in elite athletes,Phenotype,Biliverdin levels in elite athletes
49889,2-aminooctanoate levels in elite athletes,Phenotype,2-aminooctanoate levels in elite athletes
49891,Arginine levels in elite athletes,Phenotype,Arginine levels in elite athletes
49893,Aspartate levels in elite athletes,Phenotype,Aspartate levels in elite athletes
49895,2-hydroxyadipate levels in elite athletes,Phenotype,2-hydroxyadipate levels in elite athletes
49897,Caffeic acid sulfate levels in elite athletes,Phenotype,Caffeic acid sulfate levels in elite athletes
49899,21-hydroxypregnenolone disulfate levels in elite athletes,Phenotype,21-hydroxypregnenolone disulfate levels in elite athletes
49901,3-hydroxy-3-methylglutarate levels in elite athletes,Phenotype,3-hydroxy-3-methylglutarate levels in elite athletes
49903,2-hydroxyoctanoate levels in elite athletes,Phenotype,2-hydroxyoctanoate levels in elite athletes
49904,2-linoleoylglycerol (18:2) levels in elite athletes,Phenotype,2-linoleoylglycerol (18:2) levels in elite athletes
49906,2-oleoylglycerol (18:1) levels in elite athletes,Phenotype,2-oleoylglycerol (18:1) levels in elite athletes
49908,2-palmitoleoyl-GPC (16:1) levels in elite athletes,Phenotype,2-palmitoleoyl-GPC (16:1) levels in elite athletes
49911,3-hydroxyhexanoate levels in elite athletes,Phenotype,3-hydroxyhexanoate levels in elite athletes
49913,3-hydroxymyristate levels in elite athletes,Phenotype,3-hydroxymyristate levels in elite athletes
49915,Gamma glutamyl transpeptidase,Phenotype,Gamma glutamyl transpeptidase
49928,Citrate levels,Phenotype,Citrate levels
49946,Leucine levels,Phenotype,Leucine levels
49948,Total esterified cholesterol levels,Phenotype,Total esterified cholesterol levels
49956,Dopamine 3-O-sulfate levels in elite athletes,Phenotype,Dopamine 3-O-sulfate levels in elite athletes
49958,Isobutyrylcarnitine (C4) levels in elite athletes,Phenotype,Isobutyrylcarnitine (C4) levels in elite athletes
49960,4-hydroxychlorothalonil levels in elite athletes,Phenotype,4-hydroxychlorothalonil levels in elite athletes
49962,4-methylcatechol sulfate levels in elite athletes,Phenotype,4-methylcatechol sulfate levels in elite athletes
49965,Stachydrine levels in elite athletes,Phenotype,Stachydrine levels in elite athletes
49967,3-hydroxyhippurate levels in elite athletes,Phenotype,3-hydroxyhippurate levels in elite athletes
49969,3-methoxycatechol sulfate (2) levels in elite athletes,Phenotype,3-methoxycatechol sulfate (2) levels in elite athletes
49971,3-methyl catechol sulfate (1) levels in elite athletes,Phenotype,3-methyl catechol sulfate (1) levels in elite athletes
49973,4-acetylphenol sulfate levels in elite athletes,Phenotype,4-acetylphenol sulfate levels in elite athletes
49975,4-allylphenol sulfate levels in elite athletes,Phenotype,4-allylphenol sulfate levels in elite athletes
49978,Guanidinosuccinate levels in elite athletes,Phenotype,Guanidinosuccinate levels in elite athletes
49980,Imidazole lactate levels in elite athletes,Phenotype,Imidazole lactate levels in elite athletes
49982,Imidazole propionate levels in elite athletes,Phenotype,Imidazole propionate levels in elite athletes
49987,Thioproline levels in elite athletes,Phenotype,Thioproline levels in elite athletes
49989,1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) levels in elite athletes,Phenotype,1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) levels in elite athletes
49990,1-(1-enyl-palmitoyl)-GPC (P-16:0) levels in elite athletes,Phenotype,1-(1-enyl-palmitoyl)-GPC (P-16:0) levels in elite athletes
49992,1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4) levels in elite athletes,Phenotype,1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4) levels in elite athletes
49993,3-(4-hydroxyphenyl)lactate levels in elite athletes,Phenotype,3-(4-hydroxyphenyl)lactate levels in elite athletes
49995,3-aminoisobutyrate levels in elite athletes,Phenotype,3-aminoisobutyrate levels in elite athletes
49997,3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF) levels in elite athletes,Phenotype,3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF) levels in elite athletes
49999,1-(1-enyl-stearoyl)-GPE (P-18:0) levels in elite athletes,Phenotype,1-(1-enyl-stearoyl)-GPE (P-18:0) levels in elite athletes
50001,1-arachidonoyl-GPA (20:4) levels in elite athletes,Phenotype,1-arachidonoyl-GPA (20:4) levels in elite athletes
50005,1-linoleoyl-GPC (18:2) levels in elite athletes,Phenotype,1-linoleoyl-GPC (18:2) levels in elite athletes
50007,1-arachidonoyl-GPI (20:4) levels in elite athletes,Phenotype,1-arachidonoyl-GPI (20:4) levels in elite athletes
50009,1-dihomo-linolenylglycerol (20:3) levels in elite athletes,Phenotype,1-dihomo-linolenylglycerol (20:3) levels in elite athletes
50012,1-lignoceroyl-GPC (24:0) levels in elite athletes,Phenotype,1-lignoceroyl-GPC (24:0) levels in elite athletes
50014,1-linolenoyl-GPC (18:3) levels in elite athletes,Phenotype,1-linolenoyl-GPC (18:3) levels in elite athletes
50016,12--13-DiHOME levels in elite athletes,Phenotype,12--13-DiHOME levels in elite athletes
50018,14-HDoHE/17-HDoHE levels in elite athletes,Phenotype,14-HDoHE/17-HDoHE levels in elite athletes
50022,1-stearoyl-GPG (18:0) levels in elite athletes,Phenotype,1-stearoyl-GPG (18:0) levels in elite athletes
50024,Adrenate (22:4n6) levels in elite athletes,Phenotype,Adrenate (22:4n6) levels in elite athletes
50026,Arabinose levels in elite athletes,Phenotype,Arabinose levels in elite athletes
50027,2-aminoheptanoate levels in elite athletes,Phenotype,2-aminoheptanoate levels in elite athletes
50029,15-methylpalmitate levels in elite athletes,Phenotype,15-methylpalmitate levels in elite athletes
50031,1--2-dipalmitoyl-GPE (16:0/16:0) levels in elite athletes,Phenotype,1--2-dipalmitoyl-GPE (16:0/16:0) levels in elite athletes
50035,10-undecenoate (11:1n1) levels in elite athletes,Phenotype,10-undecenoate (11:1n1) levels in elite athletes
50042,Erythronate levels in elite athletes,Phenotype,Erythronate levels in elite athletes
50043,Eicosapentaenoate (EPA; 20:5n3) levels in elite athletes,Phenotype,Eicosapentaenoate (EPA; 20:5n3) levels in elite athletes
50044,Androstenediol (3beta--17beta) monosulfate (1) levels in elite athletes,Phenotype,Androstenediol (3beta--17beta) monosulfate (1) levels in elite athletes
50046,Gamma-glutamylglutamate levels in elite athletes,Phenotype,Gamma-glutamylglutamate levels in elite athletes
50048,Dodecanedioate levels in elite athletes,Phenotype,Dodecanedioate levels in elite athletes
50052,Androstenediol (3alpha-- 17alpha) monosulfate (3) levels in elite athletes,Phenotype,Androstenediol (3alpha-- 17alpha) monosulfate (3) levels in elite athletes
50054,Azelate (nonanedioate) levels in elite athletes,Phenotype,Azelate (nonanedioate) levels in elite athletes
50056,Behenoyl sphingomyelin (d18:1/22:0) levels in elite athletes,Phenotype,Behenoyl sphingomyelin (d18:1/22:0) levels in elite athletes
50058,Arachidonoylcarnitine (C20:4) levels in elite athletes,Phenotype,Arachidonoylcarnitine (C20:4) levels in elite athletes
50061,Gamma-glutamylisoleucine levels in elite athletes,Phenotype,Gamma-glutamylisoleucine levels in elite athletes
50063,Gamma-glutamylleucine levels in elite athletes,Phenotype,Gamma-glutamylleucine levels in elite athletes
50065,Ceramide (d18:1/14:0-- d16:1/16:0) levels in elite athletes,Phenotype,Ceramide (d18:1/14:0-- d16:1/16:0) levels in elite athletes
50067,Ceramide (d18:1/20:0-- d16:1/22:0-- d20:1/18:0) levels in elite athletes,Phenotype,Ceramide (d18:1/20:0-- d16:1/22:0-- d20:1/18:0) levels in elite athletes
50069,Ceramide (d16:1/24:1-- d18:1/22:1) levels in elite athletes,Phenotype,Ceramide (d16:1/24:1-- d18:1/22:1) levels in elite athletes
50071,Gamma-glutamyltyrosine levels in elite athletes,Phenotype,Gamma-glutamyltyrosine levels in elite athletes
50073,Glutamine levels in elite athletes,Phenotype,Glutamine levels in elite athletes
50075,Glycerate levels in elite athletes,Phenotype,Glycerate levels in elite athletes
50077,Free cholesterol to total lipids ratio in very large VLDL,Phenotype,Free cholesterol to total lipids ratio in very large VLDL
50078,Total lipid levels in very large VLDL,Phenotype,Total lipid levels in very large VLDL
50079,Concentration of very large VLDL particles,Phenotype,Concentration of very large VLDL particles
50084,Phospholipids to total lipids ratio in very large VLDL,Phenotype,Phospholipids to total lipids ratio in very large VLDL
50086,Phospholipid levels in very large VLDL,Phenotype,Phospholipid levels in very large VLDL
50087,Triglyceride levels in very large VLDL,Phenotype,Triglyceride levels in very large VLDL
50094,Cholesterol to total lipids ratio in very small VLDL,Phenotype,Cholesterol to total lipids ratio in very small VLDL
50095,Ascending aorta maximum area,Phenotype,Ascending aorta maximum area
50096,Peripheral artery disease in non diabetes,Phenotype,Peripheral artery disease in non diabetes
50097,Ascending aorta minimum area,Phenotype,Ascending aorta minimum area
50101,Whole brain restricted directional diffusion (multivariate analysis),Phenotype,Whole brain restricted directional diffusion (multivariate analysis)
50105,Cholesteryl ester levels in very small VLDL,Phenotype,Cholesteryl ester levels in very small VLDL
50113,Gastric polyp,Phenotype,Gastric polyp
50117,Hepatic cancer,Phenotype,Hepatic cancer
50122,Triglyceride levels in very small VLDL,Phenotype,Triglyceride levels in very small VLDL
50127,Cholesterol levels in chylomicrons and extremely large VLDL,Phenotype,Cholesterol levels in chylomicrons and extremely large VLDL
50145,Free cholesterol levels in very large VLDL,Phenotype,Free cholesterol levels in very large VLDL
50157,Free cholesterol levels in very small VLDL,Phenotype,Free cholesterol levels in very small VLDL
50161,Cirrhosis,Phenotype,Cirrhosis
50162,Angina pectoris,Phenotype,Angina pectoris
50166,Chronic sinusitis,Phenotype,Chronic sinusitis
50168,Autoimmune hepatitis,Phenotype,Autoimmune hepatitis
50171,Cytomegalovirus infection after allogeneic hematopoietic cell transplantation (recipients),Phenotype,Cytomegalovirus infection after allogeneic hematopoietic cell transplantation (recipients)
50173,Cytomegalovirus high-level reactivation after allogeneic hematopoietic cell transplantation (donors),Phenotype,Cytomegalovirus high-level reactivation after allogeneic hematopoietic cell transplantation (donors)
50175,Phospholipids to total lipids ratio in very small VLDL,Phenotype,Phospholipids to total lipids ratio in very small VLDL
50177,Phospholipid levels in very small VLDL,Phenotype,Phospholipid levels in very small VLDL
50178,Facial morphology (segment 7),Phenotype,Facial morphology (segment 7)
50179,Facial morphology (segment 9),Phenotype,Facial morphology (segment 9)
50180,Facial morphology (segment 21),Phenotype,Facial morphology (segment 21)
50182,Facial morphology (segment 22),Phenotype,Facial morphology (segment 22)
50184,Facial morphology (segment 53),Phenotype,Facial morphology (segment 53)
50186,Facial morphology (segment 59),Phenotype,Facial morphology (segment 59)
50188,Facial morphology (segment 2),Phenotype,Facial morphology (segment 2)
50190,Atrial fibrillation/atrial flutter,Phenotype,Atrial fibrillation/atrial flutter
50196,Facial morphology (segment 62),Phenotype,Facial morphology (segment 62)
50198,Whole brain free water diffusion (multivariate analysis),Phenotype,Whole brain free water diffusion (multivariate analysis)
50212,Peripheral artery disease in ever smokers,Phenotype,Peripheral artery disease in ever smokers
50214,Facial morphology (segment 11),Phenotype,Facial morphology (segment 11)
50216,Facial morphology (segment 19),Phenotype,Facial morphology (segment 19)
50218,Facial morphology (segment 23),Phenotype,Facial morphology (segment 23)
50220,Facial morphology (segment 28),Phenotype,Facial morphology (segment 28)
50221,Facial morphology (segment 1),Phenotype,Facial morphology (segment 1)
50227,Substance dependence,Phenotype,Substance dependence
50233,Retinitis pigmentosa,Phenotype,Retinitis pigmentosa
50235,Pulmonary tuberculosis,Phenotype,Pulmonary tuberculosis
50237,Pollinosis,Phenotype,Pollinosis
50240,Stable angina pectoris,Phenotype,Stable angina pectoris
50254,Cholesterol levels in very small VLDL,Phenotype,Cholesterol levels in very small VLDL
50256,Total lipid levels in very small VLDL,Phenotype,Total lipid levels in very small VLDL
50257,Nephrotic syndrome,Phenotype,Nephrotic syndrome
50264,Iritis,Phenotype,Iritis
50275,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL,Phenotype,Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL
50296,Neuropathic pain,Phenotype,Neuropathic pain
50301,Brain-specific serine protease 4 levels (PRSS22.4534.10.2),Phenotype,Brain-specific serine protease 4 levels (PRSS22.4534.10.2)
50303,Beta-defensin 119 levels (DEFB119.13455.10.3),Phenotype,Beta-defensin 119 levels (DEFB119.13455.10.3)
50306,C-C motif chemokine 17 levels (CCL17.3519.3.2),Phenotype,C-C motif chemokine 17 levels (CCL17.3519.3.2)
50308,C-C motif chemokine 19 levels (CCL19.4922.13.1),Phenotype,C-C motif chemokine 19 levels (CCL19.4922.13.1)
50309,C-C motif chemokine 21 levels (CCL21.2516.57.3),Phenotype,C-C motif chemokine 21 levels (CCL21.2516.57.3)
50311,C-C motif chemokine 22 levels (CCL22.3508.78.3),Phenotype,C-C motif chemokine 22 levels (CCL22.3508.78.3)
50321,Acid sphingomyelinase-like phosphodiesterase 3a levels (SMPDL3A.14086.11.3),Phenotype,Acid sphingomyelinase-like phosphodiesterase 3a levels (SMPDL3A.14086.11.3)
50323,Adhesion G protein-coupled receptor F5 levels (ADGRF5.6409.57.3),Phenotype,Adhesion G protein-coupled receptor F5 levels (ADGRF5.6409.57.3)
50326,Advanced glycosylation end product-specific receptor-- soluble levels (AGER.4125.52.2),Phenotype,Advanced glycosylation end product-specific receptor-- soluble levels (AGER.4125.52.2)
50327,Agouti-related protein levels (AGRP.2813.11.2),Phenotype,Agouti-related protein levels (AGRP.2813.11.2)
50329,alpha-2-macroglobulin receptor-associated protein levels (LRPAP1.3640.14.3),Phenotype,alpha-2-macroglobulin receptor-associated protein levels (LRPAP1.3640.14.3)
50333,Amelogenin-- X isoform levels (AMELX.8578.45.3),Phenotype,Amelogenin-- X isoform levels (AMELX.8578.45.3)
50335,Angiostatin levels (PLG.3710.49.2),Phenotype,Angiostatin levels (PLG.3710.49.2)
50337,Cerebellin-1 levels (CBLN1.9313.27.3),Phenotype,Cerebellin-1 levels (CBLN1.9313.27.3)
50342,Chloride intracellular channel protein 5 levels (CLIC5.12475.48.3),Phenotype,Chloride intracellular channel protein 5 levels (CLIC5.12475.48.3)
50344,Chymotrypsinogen B levels (CTRB1.5671.1.3),Phenotype,Chymotrypsinogen B levels (CTRB1.5671.1.3)
50347,ATP-dependent RNA helicase DHX8 levels (DHX8.11601.26.3),Phenotype,ATP-dependent RNA helicase DHX8 levels (DHX8.11601.26.3)
50348,Colipase levels (CLPS.5749.53.3),Phenotype,Colipase levels (CLPS.5749.53.3)
50352,Apolipoprotein L1 levels (APOL1.9506.10.3),Phenotype,Apolipoprotein L1 levels (APOL1.9506.10.3)
50353,Apolipoprotein M levels (APOM.10445.20.3),Phenotype,Apolipoprotein M levels (APOM.10445.20.3)
50355,cAMP-specific 3'--5'-cyclic phosphodiesterase 4D levels (PDE4D.5255.22.3),Phenotype,cAMP-specific 3'--5'-cyclic phosphodiesterase 4D levels (PDE4D.5255.22.3)
50359,Cation-independent mannose-6-phosphate receptor levels (IGF2R.3676.15.3),Phenotype,Cation-independent mannose-6-phosphate receptor levels (IGF2R.3676.15.3)
50362,CD109 antigen levels (CD109.3290.50.2),Phenotype,CD109 antigen levels (CD109.3290.50.2)
50364,Carboxypeptidase B levels (CPB1.6356.3.3),Phenotype,Carboxypeptidase B levels (CPB1.6356.3.3)
50367,Intracerebral hemorrhage,Phenotype,Intracerebral hemorrhage
50371,Iron deficiency anemia,Phenotype,Iron deficiency anemia
50373,Juvenile rheumatoid arthritis,Phenotype,Juvenile rheumatoid arthritis
50378,Streptacidiphilus abundance in stool,Phenotype,Streptacidiphilus abundance in stool
50380,Treponema D abundance in stool,Phenotype,Treponema D abundance in stool
50382,Treponemataceae abundance in stool,Phenotype,Treponemataceae abundance in stool
50384,RUG472 sp900319345 abundance in stool,Phenotype,RUG472 sp900319345 abundance in stool
50386,RUG472 abundance in stool,Phenotype,RUG472 abundance in stool
50387,Succinivibrio abundance in stool,Phenotype,Succinivibrio abundance in stool
50389,UBA1066 sp900317515 abundance in stool,Phenotype,UBA1066 sp900317515 abundance in stool
50391,UBA11471 sp000434215 abundance in stool,Phenotype,UBA11471 sp000434215 abundance in stool
50393,UBA11471 abundance in stool,Phenotype,UBA11471 abundance in stool
50394,UBA1206 sp000433115 abundance in stool,Phenotype,UBA1206 sp000433115 abundance in stool
50396,UBA1448 sp002329405 abundance in stool,Phenotype,UBA1448 sp002329405 abundance in stool
50398,UBA1448 abundance in stool,Phenotype,UBA1448 abundance in stool
50399,UBA1777 sp900319835 abundance in stool,Phenotype,UBA1777 sp900319835 abundance in stool
50400,UBA2922 sp900313925 abundance in stool,Phenotype,UBA2922 sp900313925 abundance in stool
50402,UBA6398 sp002451695 abundance in stool,Phenotype,UBA6398 sp002451695 abundance in stool
50404,UBA7182 sp002491115 abundance in stool,Phenotype,UBA7182 sp002491115 abundance in stool
50407,Acidobacteriales abundance in stool,Phenotype,Acidobacteriales abundance in stool
50409,Agathobacter sp000434275 abundance in stool,Phenotype,Agathobacter sp000434275 abundance in stool
50411,Anaeromassilibacillus sp001305115 abundance in stool,Phenotype,Anaeromassilibacillus sp001305115 abundance in stool
50413,UBA7748 sp900314535 abundance in stool,Phenotype,UBA7748 sp900314535 abundance in stool
50415,UBA8517 abundance in stool,Phenotype,UBA8517 abundance in stool
50417,Achromobacter abundance in stool,Phenotype,Achromobacter abundance in stool
50419,Borreliaceae abundance in stool,Phenotype,Borreliaceae abundance in stool
50421,Borreliales abundance in stool,Phenotype,Borreliales abundance in stool
50424,Neuropathic bladder,Phenotype,Neuropathic bladder
50426,Malignant lymphoma,Phenotype,Malignant lymphoma
50429,Meniere's disease,Phenotype,Meniere's disease
50431,Bacillus AY abundance in stool,Phenotype,Bacillus AY abundance in stool
50433,Bifidobacterium angulatum abundance in stool,Phenotype,Bifidobacterium angulatum abundance in stool
50435,CAG-349 abundance in stool,Phenotype,CAG-349 abundance in stool
50437,CAG-448 sp000433415 abundance in stool,Phenotype,CAG-448 sp000433415 abundance in stool
50439,CAG-170 sp003516765 abundance in stool,Phenotype,CAG-170 sp003516765 abundance in stool
50441,CAG-177 sp002438685 abundance in stool,Phenotype,CAG-177 sp002438685 abundance in stool
50443,CAG-177 sp002451755 abundance in stool,Phenotype,CAG-177 sp002451755 abundance in stool
50444,CAG-177 sp003514385 abundance in stool,Phenotype,CAG-177 sp003514385 abundance in stool
50445,CAG-177 sp003538135 abundance in stool,Phenotype,CAG-177 sp003538135 abundance in stool
50446,CAG-177 abundance in stool,Phenotype,CAG-177 abundance in stool
50447,CAG-180 sp000432435 abundance in stool,Phenotype,CAG-180 sp000432435 abundance in stool
50448,CAG-269 sp001915995 abundance in stool,Phenotype,CAG-269 sp001915995 abundance in stool
50450,CAG-81 sp000435795 abundance in stool,Phenotype,CAG-81 sp000435795 abundance in stool
50452,CAG-841 sp002479075 abundance in stool,Phenotype,CAG-841 sp002479075 abundance in stool
50454,CAG-882 sp003486385 abundance in stool,Phenotype,CAG-882 sp003486385 abundance in stool
50460,CAG-977 abundance in stool,Phenotype,CAG-977 abundance in stool
50462,Clostridium tertium abundance in stool,Phenotype,Clostridium tertium abundance in stool
50464,Desulfovibrio piger abundance in stool,Phenotype,Desulfovibrio piger abundance in stool
50467,Cholesterol to total lipids ratio in small HDL,Phenotype,Cholesterol to total lipids ratio in small HDL
50469,Cholesteryl ester levels in small HDL,Phenotype,Cholesteryl ester levels in small HDL
50470,Phospholipid levels in small HDL,Phenotype,Phospholipid levels in small HDL
50471,Triglycerides to total lipids ratio in small HDL,Phenotype,Triglycerides to total lipids ratio in small HDL
50472,Total lipid levels in small LDL,Phenotype,Total lipid levels in small LDL
50473,Triglycerides to total lipids ratio in small LDL,Phenotype,Triglycerides to total lipids ratio in small LDL
50475,Total lipid levels in small VLDL,Phenotype,Total lipid levels in small VLDL
50476,Triglyceride levels in small VLDL,Phenotype,Triglyceride levels in small VLDL
50479,Resilience score,Phenotype,Resilience score
50481,VLDL cholesterol levels,Phenotype,VLDL cholesterol levels
50482,Valine levels,Phenotype,Valine levels
50489,Saliva microbiota abundance (Order Actinomycetales),Phenotype,Saliva microbiota abundance (Order Actinomycetales)
50492,Total concentration of branched-chain amino acids (leucine + isoleucine + valine),Phenotype,Total concentration of branched-chain amino acids (leucine + isoleucine + valine)
50495,Cholesteryl ester levels in VLDL,Phenotype,Cholesteryl ester levels in VLDL
50510,Cholesteryl ester levels in small LDL,Phenotype,Cholesteryl ester levels in small LDL
50511,Cholesterol levels in small VLDL,Phenotype,Cholesterol levels in small VLDL
50512,Pulmonary tuberculosis resistance,Phenotype,Pulmonary tuberculosis resistance
50514,Concentration of small VLDL particles,Phenotype,Concentration of small VLDL particles
50516,Anti-hepatitis E antibody levels,Phenotype,Anti-hepatitis E antibody levels
50523,Degree of unsaturation,Phenotype,Degree of unsaturation
50531,Average diameter for VLDL particles,Phenotype,Average diameter for VLDL particles
50537,Lignoceroylcarnitine (C24) levels in elite athletes,Phenotype,Lignoceroylcarnitine (C24) levels in elite athletes
50540,Maleate levels in elite athletes,Phenotype,Maleate levels in elite athletes
50542,Linoleoylcarnitine (C18:2) levels in elite athletes,Phenotype,Linoleoylcarnitine (C18:2) levels in elite athletes
50543,Mannose levels in elite athletes,Phenotype,Mannose levels in elite athletes
50547,Linoleoyl ethanolamide levels in elite athletes,Phenotype,Linoleoyl ethanolamide levels in elite athletes
50550,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels in elite athletes,Phenotype,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels in elite athletes
50552,Tonsillitis,Phenotype,Tonsillitis
50557,N-acetylmethionine levels in elite athletes,Phenotype,N-acetylmethionine levels in elite athletes
50559,N-acetyltaurine levels in elite athletes,Phenotype,N-acetyltaurine levels in elite athletes
50561,Palmitoyl dihydrosphingomyelin (d18:0/16:0) levels in elite athletes,Phenotype,Palmitoyl dihydrosphingomyelin (d18:0/16:0) levels in elite athletes
50563,Palmitoyl ethanolamide levels in elite athletes,Phenotype,Palmitoyl ethanolamide levels in elite athletes
50564,Palmitoyl-oleoyl-glycerol (16:0/18:1) [1] levels in elite athletes,Phenotype,Palmitoyl-oleoyl-glycerol (16:0/18:1) [1] levels in elite athletes
50567,Viral variant GAG242N carrier status in HIV infection,Phenotype,Viral variant GAG242N carrier status in HIV infection
50569,Cerebrospinal fluid metabolite X-24728 levels,Phenotype,Cerebrospinal fluid metabolite X-24728 levels
50570,Cerebrospinal fluid metabolite X-25948 levels,Phenotype,Cerebrospinal fluid metabolite X-25948 levels
50572,Cerebrospinal fluid adenine levels,Phenotype,Cerebrospinal fluid adenine levels
50574,Oleoylcarnitine (C18:1) levels in elite athletes,Phenotype,Oleoylcarnitine (C18:1) levels in elite athletes
50575,Sphingomyelin (d18:2/23:0-- d18:1/23:1-- d17:1/24:1) levels in elite athletes,Phenotype,Sphingomyelin (d18:2/23:0-- d18:1/23:1-- d17:1/24:1) levels in elite athletes
50577,Sphingomyelin (d18:2/24:1-- d18:1/24:2) levels in elite athletes,Phenotype,Sphingomyelin (d18:2/24:1-- d18:1/24:2) levels in elite athletes
50582,Brain 2-hydroxystearate levels,Phenotype,Brain 2-hydroxystearate levels
50584,Sphingomyelin (d18:2/24:2) levels in elite athletes,Phenotype,Sphingomyelin (d18:2/24:2) levels in elite athletes
50586,Sphingosine 1-phosphate levels in elite athletes,Phenotype,Sphingosine 1-phosphate levels in elite athletes
50587,Stearoylcholine levels in elite athletes,Phenotype,Stearoylcholine levels in elite athletes
50590,Chronic heart failure,Phenotype,Chronic heart failure
50595,Bronchiectasis,Phenotype,Bronchiectasis
50601,Dihydroorotate levels in elite athletes,Phenotype,Dihydroorotate levels in elite athletes
50603,Pro-hydroxy-pro levels in elite athletes,Phenotype,Pro-hydroxy-pro levels in elite athletes
50605,Pyridoxate levels in elite athletes,Phenotype,Pyridoxate levels in elite athletes
50608,Pipecolate levels in elite athletes,Phenotype,Pipecolate levels in elite athletes
50610,2'-O-methyluridine levels in elite athletes,Phenotype,2'-O-methyluridine levels in elite athletes
50612,N1-methylinosine levels in elite athletes,Phenotype,N1-methylinosine levels in elite athletes
50614,N6-carbamoylthreonyladenosine levels in elite athletes,Phenotype,N6-carbamoylthreonyladenosine levels in elite athletes
50615,Orotidine levels in elite athletes,Phenotype,Orotidine levels in elite athletes
50618,Pyruvate levels in elite athletes,Phenotype,Pyruvate levels in elite athletes
50621,Cataracts,Phenotype,Cataracts
50625,Phenylacetylglutamate levels in elite athletes,Phenotype,Phenylacetylglutamate levels in elite athletes
50627,Valylglutamine levels in elite athletes,Phenotype,Valylglutamine levels in elite athletes
50629,Valylglycine levels in elite athletes,Phenotype,Valylglycine levels in elite athletes
50631,1--2--3-benzenetriol sulfate (2) levels in elite athletes,Phenotype,1--2--3-benzenetriol sulfate (2) levels in elite athletes
50633,2--3-dihydroxyisovalerate levels in elite athletes,Phenotype,2--3-dihydroxyisovalerate levels in elite athletes
50634,3-(3-hydroxyphenyl)propionate sulfate levels in elite athletes,Phenotype,3-(3-hydroxyphenyl)propionate sulfate levels in elite athletes
50637,Esophageal varix,Phenotype,Esophageal varix
50639,Bell's palsy,Phenotype,Bell's palsy
50645,Homostachydrine levels in elite athletes,Phenotype,Homostachydrine levels in elite athletes
50648,HWESASXX levels in elite athletes,Phenotype,HWESASXX levels in elite athletes
50650,Hypoxanthine levels in elite athletes,Phenotype,Hypoxanthine levels in elite athletes
50652,Glycolithocholate sulfate levels in elite athletes,Phenotype,Glycolithocholate sulfate levels in elite athletes
50654,Glycosyl ceramide (d18:1/23:1-- d17:1/24:1) levels in elite athletes,Phenotype,Glycosyl ceramide (d18:1/23:1-- d17:1/24:1) levels in elite athletes
50657,Inosine levels in elite athletes,Phenotype,Inosine levels in elite athletes
50662,Chiro-inositol levels in elite athletes,Phenotype,Chiro-inositol levels in elite athletes
50665,Eicosenoate (20:1) levels in elite athletes,Phenotype,Eicosenoate (20:1) levels in elite athletes
50666,Etiocholanolone glucuronide levels in elite athletes,Phenotype,Etiocholanolone glucuronide levels in elite athletes
50669,Dihomo-linolenoylcarnitine (20:3n3 or 6) levels in elite athletes,Phenotype,Dihomo-linolenoylcarnitine (20:3n3 or 6) levels in elite athletes
50671,Dihomo-linoleoylcarnitine (C20:2) levels in elite athletes,Phenotype,Dihomo-linoleoylcarnitine (C20:2) levels in elite athletes
50672,Docosadienoate (22:2n6) levels in elite athletes,Phenotype,Docosadienoate (22:2n6) levels in elite athletes
50677,Leucine levels in elite athletes,Phenotype,Leucine levels in elite athletes
50686,Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) levels in elite athletes,Phenotype,Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) levels in elite athletes
50688,Kynurenine levels in elite athletes,Phenotype,Kynurenine levels in elite athletes
50691,Glycosyl ceramide (d18:2/24:1-- d18:1/24:2) levels in elite athletes,Phenotype,Glycosyl ceramide (d18:2/24:1-- d18:1/24:2) levels in elite athletes
50692,Isoleucine levels in elite athletes,Phenotype,Isoleucine levels in elite athletes
50694,Lactosyl-N-behenoyl-sphingosine (d18:1/22:0) levels in elite athletes,Phenotype,Lactosyl-N-behenoyl-sphingosine (d18:1/22:0) levels in elite athletes
50697,N-acetyl-beta-alanine levels in elite athletes,Phenotype,N-acetyl-beta-alanine levels in elite athletes
50699,N-palmitoyltaurine levels in elite athletes,Phenotype,N-palmitoyltaurine levels in elite athletes
50703,N-acetylarginine levels in elite athletes,Phenotype,N-acetylarginine levels in elite athletes
50705,Margaroylcarnitine levels in elite athletes,Phenotype,Margaroylcarnitine levels in elite athletes
50707,Methionine sulfoxide levels in elite athletes,Phenotype,Methionine sulfoxide levels in elite athletes
50709,Myristoylcarnitine (C14) levels in elite athletes,Phenotype,Myristoylcarnitine (C14) levels in elite athletes
50710,Octanoylcarnitine (C8) levels in elite athletes,Phenotype,Octanoylcarnitine (C8) levels in elite athletes
50713,Oleoyl ethanolamide levels in elite athletes,Phenotype,Oleoyl ethanolamide levels in elite athletes
50715,N-palmitoyl-sphingadienine (d18:2/16:0) levels in elite athletes,Phenotype,N-palmitoyl-sphingadienine (d18:2/16:0) levels in elite athletes
50717,Sphingomyelin (d18:1/25:0-- d19:0/24:1-- d20:1/23:0-- d19:1/24:0) levels in elite athletes,Phenotype,Sphingomyelin (d18:1/25:0-- d19:0/24:1-- d20:1/23:0-- d19:1/24:0) levels in elite athletes
50720,Sphingomyelin (d18:2/21:0-- d16:2/23:0) levels in elite athletes,Phenotype,Sphingomyelin (d18:2/21:0-- d16:2/23:0) levels in elite athletes
50722,Nonadecanoate (19:0) levels in elite athletes,Phenotype,Nonadecanoate (19:0) levels in elite athletes
50723,Sphingomyelin (d18:1/20:2-- d18:2/20:1-- d16:1/22:2) levels in elite athletes,Phenotype,Sphingomyelin (d18:1/20:2-- d18:2/20:1-- d16:1/22:2) levels in elite athletes
50725,Octadecanedioate levels in elite athletes,Phenotype,Octadecanedioate levels in elite athletes
50727,Sebacate (decanedioate) levels in elite athletes,Phenotype,Sebacate (decanedioate) levels in elite athletes
50729,Pregnanediol-3-glucuronide levels in elite athletes,Phenotype,Pregnanediol-3-glucuronide levels in elite athletes
50731,Pregnanolone/allopregnanolone sulfate levels in elite athletes,Phenotype,Pregnanolone/allopregnanolone sulfate levels in elite athletes
50733,Pregnen-diol disulfate C21H34O8S2 levels in elite athletes,Phenotype,Pregnen-diol disulfate C21H34O8S2 levels in elite athletes
50735,Sphingomyelin (d18:1/22:1-- d18:2/22:0-- d16:1/24:1) levels in elite athletes,Phenotype,Sphingomyelin (d18:1/22:1-- d18:2/22:0-- d16:1/24:1) levels in elite athletes
50737,Brain 2-hydroxyglutarate levels,Phenotype,Brain 2-hydroxyglutarate levels
50739,Cerebrospinal fluid imidazole lactate levels,Phenotype,Cerebrospinal fluid imidazole lactate levels
50740,Cerebrospinal fluid xanthosine levels,Phenotype,Cerebrospinal fluid xanthosine levels
50742,Cerebrospinal fluid phenyllactate (PLA) levels,Phenotype,Cerebrospinal fluid phenyllactate (PLA) levels
50744,Phenylacetate levels in elite athletes,Phenotype,Phenylacetate levels in elite athletes
50746,Phenyllactate (PLA) levels in elite athletes,Phenotype,Phenyllactate (PLA) levels in elite athletes
50748,Phenol sulfate levels in elite athletes,Phenotype,Phenol sulfate levels in elite athletes
50750,Cerebrospinal fluid ethylmalonate levels,Phenotype,Cerebrospinal fluid ethylmalonate levels
50752,Cerebrospinal fluid 5-methylthioadenosine (MTA) levels,Phenotype,Cerebrospinal fluid 5-methylthioadenosine (MTA) levels
50754,Cerebrospinal fluid 3-(4-hydroxyphenyl)lactate levels,Phenotype,Cerebrospinal fluid 3-(4-hydroxyphenyl)lactate levels
50756,Cerebrospinal fluid inosine levels,Phenotype,Cerebrospinal fluid inosine levels
50757,Cerebrospinal fluid methylmalonate (MMA) levels,Phenotype,Cerebrospinal fluid methylmalonate (MMA) levels
50761,Cerebrospinal fluid isobutyrylcarnitine (C4) levels,Phenotype,Cerebrospinal fluid isobutyrylcarnitine (C4) levels
50762,Leucylalanine levels in elite athletes,Phenotype,Leucylalanine levels in elite athletes
50764,Serine levels in elite athletes,Phenotype,Serine levels in elite athletes
50767,Gamma-glutamyltryptophan levels in elite athletes,Phenotype,Gamma-glutamyltryptophan levels in elite athletes
50769,Quinate levels in elite athletes,Phenotype,Quinate levels in elite athletes
50770,4-hydroxyphenylacetylglutamine levels in elite athletes,Phenotype,4-hydroxyphenylacetylglutamine levels in elite athletes
50771,Chronic glomerulonephritis,Phenotype,Chronic glomerulonephritis
50773,Chronic renal failure,Phenotype,Chronic renal failure
50775,Chronic bronchitis,Phenotype,Chronic bronchitis
50778,Colon polyp,Phenotype,Colon polyp
50780,Cystitis,Phenotype,Cystitis
50782,Cholelithiasis,Phenotype,Cholelithiasis
50784,Hearing loss-- difficulty in hearing,Phenotype,Hearing loss-- difficulty in hearing
50787,Hyperthyroidism,Phenotype,Hyperthyroidism
50791,Goiter,Phenotype,Goiter
50801,Body mass index in physically active individuals,Phenotype,Body mass index in physically active individuals
50802,Waist circumference adjusted for BMI in active individuals,Phenotype,Waist circumference adjusted for BMI in active individuals
50803,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction),Phenotype,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction)
50804,Sporadic neuroblastoma,Phenotype,Sporadic neuroblastoma
50805,Body mass index in physically inactive individuals,Phenotype,Body mass index in physically inactive individuals
50806,Waist circumference adjusted for BMI in inactive individuals,Phenotype,Waist circumference adjusted for BMI in inactive individuals
50807,Waist-to-hip ratio adjusted for BMI in active individuals,Phenotype,Waist-to-hip ratio adjusted for BMI in active individuals
50808,Foot ulcer in diabetes and neuropathy,Phenotype,Foot ulcer in diabetes and neuropathy
50809,Foot ulcer and neuropathy in diabetes,Phenotype,Foot ulcer and neuropathy in diabetes
50810,Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer,Phenotype,Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer
50811,Psychosis proneness (perceptual aberration scale and revised physical anhedonia scale),Phenotype,Psychosis proneness (perceptual aberration scale and revised physical anhedonia scale)
50812,Ankylosing spondylitis (SNP x SNP interaction),Phenotype,Ankylosing spondylitis (SNP x SNP interaction)
50813,Plasma trimethylamine N-oxide levels,Phenotype,Plasma trimethylamine N-oxide levels
50814,Obstructive sleep apnea trait (apnea hypopnea index),Phenotype,Obstructive sleep apnea trait (apnea hypopnea index)
50815,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin,Phenotype,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin
50816,Diastolic blood pressure x sodium interaction (1df test),Phenotype,Diastolic blood pressure x sodium interaction (1df test)
50817,Diastolic blood pressure x sodium interaction (2df test),Phenotype,Diastolic blood pressure x sodium interaction (2df test)
50818,Colonoscopy-negative controls vs population controls,Phenotype,Colonoscopy-negative controls vs population controls
50819,Paclitaxel disposition in epithelial ovarian cancer,Phenotype,Paclitaxel disposition in epithelial ovarian cancer
50820,Carboplatin disposition in epthelial ovarian cancer,Phenotype,Carboplatin disposition in epthelial ovarian cancer
50821,Hepatocyte growth factor levels,Phenotype,Hepatocyte growth factor levels
50822,Interleukin-1-receptor antagonist levels,Phenotype,Interleukin-1-receptor antagonist levels
50823,Interferon gamma levels,Phenotype,Interferon gamma levels
50824,Interleukin-1-beta levels,Phenotype,Interleukin-1-beta levels
50825,Interleukin-2 receptor antagonist levels,Phenotype,Interleukin-2 receptor antagonist levels
50826,Interleukin-4 levels,Phenotype,Interleukin-4 levels
50827,Interleukin-2 levels,Phenotype,Interleukin-2 levels
50828,Stromal-cell-derived factor 1 alpha levels,Phenotype,Stromal-cell-derived factor 1 alpha levels
50829,Tumor necrosis factor alpha levels,Phenotype,Tumor necrosis factor alpha levels
50830,Stem cell growth factor beta levels,Phenotype,Stem cell growth factor beta levels
50831,Idiopathic osteonecrosis of the femoral head,Phenotype,Idiopathic osteonecrosis of the femoral head
50832,Glioblastoma,Phenotype,Glioblastoma
50833,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan),Phenotype,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
50834,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan),Phenotype,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)
50835,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),Phenotype,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
50836,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),Phenotype,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
50837,Lobe attachment (rater-scored or self-reported),Phenotype,Lobe attachment (rater-scored or self-reported)
50838,Iris color (L* coordinate),Phenotype,Iris color (L* coordinate)
50839,Iris color (a* coordinate),Phenotype,Iris color (a* coordinate)
50840,Cognitive ability (MTAG),Phenotype,Cognitive ability (MTAG)
50841,Cognitive ability,Phenotype,Cognitive ability
50842,Lobe attachment (rater scored),Phenotype,Lobe attachment (rater scored)
50843,P wave terminal force,Phenotype,P wave terminal force
50844,Caudate volume in trauma-exposed individuals,Phenotype,Caudate volume in trauma-exposed individuals
50845,Nucleus accumbens volume in trauma-exposed individuals,Phenotype,Nucleus accumbens volume in trauma-exposed individuals
50846,Cardiometabolic and hematological traits,Phenotype,Cardiometabolic and hematological traits
50847,Branched-chain amino acid levels (Isoleucine),Phenotype,Branched-chain amino acid levels (Isoleucine)
50848,Branched-chain amino acid levels (Valine),Phenotype,Branched-chain amino acid levels (Valine)
50849,High altitude adaptation,Phenotype,High altitude adaptation
50850,Common carotid intima-media thickness in HIV negative individuals,Phenotype,Common carotid intima-media thickness in HIV negative individuals
50851,Common carotid intima-media thickness,Phenotype,Common carotid intima-media thickness
50852,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1),Phenotype,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)
50853,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes,Phenotype,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes
50854,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes,Phenotype,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes
50855,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes,Phenotype,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes
50856,Low vWF levels,Phenotype,Low vWF levels
50857,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy,Phenotype,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy
50858,Response to radiotherapy in prostate cancer (toxicity-- urinary frequency),Phenotype,Response to radiotherapy in prostate cancer (toxicity-- urinary frequency)
50859,Objective response to lithium treatment in bipolar disorder,Phenotype,Objective response to lithium treatment in bipolar disorder
50860,Interleukin-10 levels,Phenotype,Interleukin-10 levels
50861,Fibroblast growth factor basic levels,Phenotype,Fibroblast growth factor basic levels
50862,Growth-regulated protein alpha levels,Phenotype,Growth-regulated protein alpha levels
50863,Eotaxin levels,Phenotype,Eotaxin levels
50864,Rheumatoid arthritis (ACPA-positive),Phenotype,Rheumatoid arthritis (ACPA-positive)
50865,Waist-to-hip ratio adjusted for BMI (age <50),Phenotype,Waist-to-hip ratio adjusted for BMI (age <50)
50866,Waist-to-hip ratio adjusted for BMI (age >50),Phenotype,Waist-to-hip ratio adjusted for BMI (age >50)
50867,Body mass index (age <50),Phenotype,Body mass index (age <50)
50868,Body mass index (age>50),Phenotype,Body mass index (age>50)
50869,Interferon gamma-induced protein 10 levels,Phenotype,Interferon gamma-induced protein 10 levels
50870,Macrophage Migration Inhibitory Factor levels,Phenotype,Macrophage Migration Inhibitory Factor levels
50871,Interleukin-18 levels,Phenotype,Interleukin-18 levels
50872,Interleukin-17 levels,Phenotype,Interleukin-17 levels
50873,Immunoglobulin light chain (AL) amyloidosis,Phenotype,Immunoglobulin light chain (AL) amyloidosis
50874,TRAIL levels,Phenotype,TRAIL levels
50875,Plasma thyroid-stimulating hormone levels,Phenotype,Plasma thyroid-stimulating hormone levels
50876,Heart rate response to beta blockers (atenolol add-on therapy),Phenotype,Heart rate response to beta blockers (atenolol add-on therapy)
50877,Heart rate response to beta blockers,Phenotype,Heart rate response to beta blockers
50878,Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test),Phenotype,Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)
50879,Waist-to-hip ratio adjusted for BMI x sex interaction,Phenotype,Waist-to-hip ratio adjusted for BMI x sex interaction
50880,Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular),Phenotype,Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)
50881,Yeast infection,Phenotype,Yeast infection
50882,Myringotomy,Phenotype,Myringotomy
50883,Measles,Phenotype,Measles
50884,Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis),Phenotype,Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis)
50885,Neuroblastoma (1p deletion),Phenotype,Neuroblastoma (1p deletion)
50886,Neuroblastoma (MYCN amplification),Phenotype,Neuroblastoma (MYCN amplification)
50887,Borderline personality disorder,Phenotype,Borderline personality disorder
50888,Facial morphology (factor 22),Phenotype,Facial morphology (factor 22)
50889,Facial morphology (factor 23),Phenotype,Facial morphology (factor 23)
50890,Facial morphology (factor 14-- intercanthal width),Phenotype,Facial morphology (factor 14-- intercanthal width)
50891,Facial morphology (factor 21-- depth of nasal alae),Phenotype,Facial morphology (factor 21-- depth of nasal alae)
50892,Prevalent type 2 diabetes,Phenotype,Prevalent type 2 diabetes
50893,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),Phenotype,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)
50894,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks),Phenotype,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)
50895,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks),Phenotype,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)
50896,Waist circumference adjusted for BMI (smoking interaction),Phenotype,Waist circumference adjusted for BMI (smoking interaction)
50897,Energy expenditure (24h),Phenotype,Energy expenditure (24h)
50898,Bone ultrasound measurement (velocity of sound),Phenotype,Bone ultrasound measurement (velocity of sound)
50899,Bone ultrasound measurement (broadband ultrasound attenuation),Phenotype,Bone ultrasound measurement (broadband ultrasound attenuation)
50900,Waist circumference adjusted for BMI in non-smokers,Phenotype,Waist circumference adjusted for BMI in non-smokers
50901,Peak insulin response,Phenotype,Peak insulin response
50902,Acute insulin response,Phenotype,Acute insulin response
50903,Insulin secretion rate,Phenotype,Insulin secretion rate
50904,BMI in non-smokers,Phenotype,BMI in non-smokers
50905,Waist circumference adjusted for BMI in smokers,Phenotype,Waist circumference adjusted for BMI in smokers
50906,BMI in smokers,Phenotype,BMI in smokers
50907,Interleukin-9 levels,Phenotype,Interleukin-9 levels
50908,Interleukin-13 levels,Phenotype,Interleukin-13 levels
50909,Alcohol consumption over the past year,Phenotype,Alcohol consumption over the past year
50910,Severe malaria (adjusted for sickle cell variant rs334),Phenotype,Severe malaria (adjusted for sickle cell variant rs334)
50911,Mixed cellularity Hodgkin lymphoma,Phenotype,Mixed cellularity Hodgkin lymphoma
50912,Severe malaria,Phenotype,Severe malaria
50913,Colorectal adenoma (advanced),Phenotype,Colorectal adenoma (advanced)
50914,Interleukin-8 levels,Phenotype,Interleukin-8 levels
50915,Interleukin-7 levels,Phenotype,Interleukin-7 levels
50916,Interleukin-5 levels,Phenotype,Interleukin-5 levels
50917,CTACK levels,Phenotype,CTACK levels
50918,beta-nerve growth factor levels,Phenotype,beta-nerve growth factor levels
50919,Diastolic blood pressure (cigarette smoking interaction),Phenotype,Diastolic blood pressure (cigarette smoking interaction)
50920,Major depression and alcohol dependence,Phenotype,Major depression and alcohol dependence
50921,Facial emotion recognition (angry faces),Phenotype,Facial emotion recognition (angry faces)
50922,Facial emotion recognition (fearful faces),Phenotype,Facial emotion recognition (fearful faces)
50923,Alcohol consumption (max-drinks),Phenotype,Alcohol consumption (max-drinks)
50924,Response to alcohol consumption (flushing response),Phenotype,Response to alcohol consumption (flushing response)
50925,Body mass index x sex x age interaction (4df test),Phenotype,Body mass index x sex x age interaction (4df test)
50926,Peanut allergy (parent-of-origin effect),Phenotype,Peanut allergy (parent-of-origin effect)
50927,Peanut allergy (maternal genetic effects),Phenotype,Peanut allergy (maternal genetic effects)
50928,Idiopathic dilated cardiomyopathy,Phenotype,Idiopathic dilated cardiomyopathy
50929,Heart rate response to recovery post exercise (20 sec),Phenotype,Heart rate response to recovery post exercise (20 sec)
50930,Decline in glucose metabolism in posterior cingulate cortex,Phenotype,Decline in glucose metabolism in posterior cingulate cortex
50931,Caudate activity during reward,Phenotype,Caudate activity during reward
50932,Creatine kinase levels,Phenotype,Creatine kinase levels
50933,Response to haloperidol in schizophrenia,Phenotype,Response to haloperidol in schizophrenia
50934,Irritable mood,Phenotype,Irritable mood
50935,Feeling miserable,Phenotype,Feeling miserable
50936,Systemic lupus erythematosus or rheumatoid arthritis,Phenotype,Systemic lupus erythematosus or rheumatoid arthritis
50937,Carotid artery external diameter,Phenotype,Carotid artery external diameter
50938,Carotid artery internal diameter,Phenotype,Carotid artery internal diameter
50939,Antipsychotic drug-induced QTc interval change in schizophrenia,Phenotype,Antipsychotic drug-induced QTc interval change in schizophrenia
50940,Thiopurine-induced alopecia in inflammatory bowel disease,Phenotype,Thiopurine-induced alopecia in inflammatory bowel disease
50941,Virologic severity in Herpes simplex virus type 2 infection,Phenotype,Virologic severity in Herpes simplex virus type 2 infection
50942,Plantar fascial disorders,Phenotype,Plantar fascial disorders
50943,Serum metabolite concentrations in chronic kidney disease,Phenotype,Serum metabolite concentrations in chronic kidney disease
50944,Serum metabolite ratios in chronic kidney disease,Phenotype,Serum metabolite ratios in chronic kidney disease
50945,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma,Phenotype,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma
50946,Family history of Alzheimer's disease,Phenotype,Family history of Alzheimer's disease
50947,Fractional excretion of metabolites in chronic kidney disease,Phenotype,Fractional excretion of metabolites in chronic kidney disease
50948,Asthma or allergic disease (pleiotropy),Phenotype,Asthma or allergic disease (pleiotropy)
50949,Erosive tooth wear (severe vs non-severe),Phenotype,Erosive tooth wear (severe vs non-severe)
50950,Nonsyndromic cleft lip,Phenotype,Nonsyndromic cleft lip
50952,Keratinocyte cancer (MTAG),Phenotype,Keratinocyte cancer (MTAG)
50953,17-hydroxyprogesterone (17-OHP) levels,Phenotype,17-hydroxyprogesterone (17-OHP) levels
50954,DHEAS levels,Phenotype,DHEAS levels
50955,Smoking initiation (ever regular vs never regular),Phenotype,Smoking initiation (ever regular vs never regular)
50956,Lysophosphatidylcholine levels,Phenotype,Lysophosphatidylcholine levels
50957,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia,Phenotype,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia
50958,Suicide attempts in major depressive disorder,Phenotype,Suicide attempts in major depressive disorder
50959,Mood instability,Phenotype,Mood instability
50960,Maximum habitual alcohol consumption,Phenotype,Maximum habitual alcohol consumption
50968,Phosphatidylcholine-ether levels,Phenotype,Phosphatidylcholine-ether levels
50970,Balding type 1,Phenotype,Balding type 1
50999,Alzheimer's disease in hypertension,Phenotype,Alzheimer's disease in hypertension
51003,Smoking behaviour (cigarette pack-years),Phenotype,Smoking behaviour (cigarette pack-years)
51004,Subscapular skin fold thickness,Phenotype,Subscapular skin fold thickness
51006,Cholesteryl ester levels,Phenotype,Cholesteryl ester levels
51011,PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia,Phenotype,PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia
51024,Chronic central serous retinopathy,Phenotype,Chronic central serous retinopathy
51025,Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded),Phenotype,Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded)
51026,Benign prostatic hyperplasia and lower urinary tract symptoms,Phenotype,Benign prostatic hyperplasia and lower urinary tract symptoms
51027,Fasting glucose change (long-term),Phenotype,Fasting glucose change (long-term)
51028,Fasting glucose change (short-term),Phenotype,Fasting glucose change (short-term)
51034,Decreased fine motor function in Charcot-Marie-Tooth disease 1A (eating with utensils),Phenotype,Decreased fine motor function in Charcot-Marie-Tooth disease 1A (eating with utensils)
51035,Walking difficulty in Charcot-Marie-Tooth disease 1A,Phenotype,Walking difficulty in Charcot-Marie-Tooth disease 1A
51038,Diabetic retinopathy (all NPDR and PDR),Phenotype,Diabetic retinopathy (all NPDR and PDR)
51039,Proliferative diabetic retinopathy (vs no DR),Phenotype,Proliferative diabetic retinopathy (vs no DR)
51040,Free thyroxine concentration,Phenotype,Free thyroxine concentration
51041,Nevus count,Phenotype,Nevus count
51042,Infant-- child and juvenile death (proportion of children died <15 years),Phenotype,Infant-- child and juvenile death (proportion of children died <15 years)
51043,Brain glucose metabolism (fluorodeoxyglucose uptake),Phenotype,Brain glucose metabolism (fluorodeoxyglucose uptake)
51044,Suicidality (suicidal ideation/attempts),Phenotype,Suicidality (suicidal ideation/attempts)
51045,Vitiligo (late onset),Phenotype,Vitiligo (late onset)
51046,Vitiligo (early onset),Phenotype,Vitiligo (early onset)
51047,Suicide attempts in schizophrenia,Phenotype,Suicide attempts in schizophrenia
51048,Suicide attempts in bipolar disorder or schizophrenia,Phenotype,Suicide attempts in bipolar disorder or schizophrenia
51049,Estradiol levels,Phenotype,Estradiol levels
51050,Albumin-globulin ratio,Phenotype,Albumin-globulin ratio
51051,Feeling worry,Phenotype,Feeling worry
51052,Feeling hurt,Phenotype,Feeling hurt
51053,Feeling nervous,Phenotype,Feeling nervous
51054,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),Phenotype,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)
51055,Plasma trimethyllysine levels,Phenotype,Plasma trimethyllysine levels
51056,Urinary haptoglobin levels in type 2 diabetes,Phenotype,Urinary haptoglobin levels in type 2 diabetes
51057,Plasma haptoglobin levels in type 2 diabetes,Phenotype,Plasma haptoglobin levels in type 2 diabetes
51058,Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome,Phenotype,Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome
51059,Serum bilirubin levels x sex interaction in metabolic syndrome,Phenotype,Serum bilirubin levels x sex interaction in metabolic syndrome
51060,Cisplatin-induced ototoxicity,Phenotype,Cisplatin-induced ototoxicity
51064,LDL cholesterol levels in current drinkers,Phenotype,LDL cholesterol levels in current drinkers
51065,Response to interferon treatment in hepatitis C virus genotype 3,Phenotype,Response to interferon treatment in hepatitis C virus genotype 3
51066,Response to direct-acting antiviral treatment in hepatitis C virus genotype 3,Phenotype,Response to direct-acting antiviral treatment in hepatitis C virus genotype 3
51067,Thiopurine-induced leukopenia in inflammatory bowel disease,Phenotype,Thiopurine-induced leukopenia in inflammatory bowel disease
51068,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,Phenotype,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
51069,Neurociticism,Phenotype,Neurociticism
51070,Autoimmune hepatitis in primary sclerosing cholangitis,Phenotype,Autoimmune hepatitis in primary sclerosing cholangitis
51071,Liver transplant-free survival in primary sclerosing cholangitis (time to event),Phenotype,Liver transplant-free survival in primary sclerosing cholangitis (time to event)
51072,Feeling tense,Phenotype,Feeling tense
51073,Persistent hepatitis B virus infection,Phenotype,Persistent hepatitis B virus infection
51074,Breast milk fatty acid composition (maternal genotype effect),Phenotype,Breast milk fatty acid composition (maternal genotype effect)
51075,Breast milk fatty acid composition (infant genotype effect),Phenotype,Breast milk fatty acid composition (infant genotype effect)
51076,Aortic valve stenosis,Phenotype,Aortic valve stenosis
51077,Age at first sexual intercourse,Phenotype,Age at first sexual intercourse
51078,Empathy quotient,Phenotype,Empathy quotient
51079,Nicotine withdrawal,Phenotype,Nicotine withdrawal
51080,Coronary artery aneurysm in Kawasaki disease,Phenotype,Coronary artery aneurysm in Kawasaki disease
51081,Normal facial asymmetry (angle of surface orientation score),Phenotype,Normal facial asymmetry (angle of surface orientation score)
51082,Fast beta electroencephalogram,Phenotype,Fast beta electroencephalogram
51083,Cerebrospinal fluid biomarker levels,Phenotype,Cerebrospinal fluid biomarker levels
51084,Possible neuropathic pain in post total joint replacement surgery for osteoarthritis,Phenotype,Possible neuropathic pain in post total joint replacement surgery for osteoarthritis
51085,Moderate to vigorous physical activity levels,Phenotype,Moderate to vigorous physical activity levels
51086,Vigorous physical activity,Phenotype,Vigorous physical activity
51087,Strenuous sports or other exercises,Phenotype,Strenuous sports or other exercises
51088,Blood sugar levels,Phenotype,Blood sugar levels
51089,Alanine transaminase levels,Phenotype,Alanine transaminase levels
51090,Sodium levels,Phenotype,Sodium levels
51091,Chloride levels,Phenotype,Chloride levels
51092,Osteoarthritis (self-reported),Phenotype,Osteoarthritis (self-reported)
51093,Broad depression or major depressive disorder (self-reported),Phenotype,Broad depression or major depressive disorder (self-reported)
51094,Broad depression or schizophrenia,Phenotype,Broad depression or schizophrenia
51095,Angiotensin-converting enzyme inhibitor intolerance,Phenotype,Angiotensin-converting enzyme inhibitor intolerance
51096,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),Phenotype,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
51097,Cortisol levels (saliva),Phenotype,Cortisol levels (saliva)
51098,Feeling fed-up,Phenotype,Feeling fed-up
51099,Feeling guilty,Phenotype,Feeling guilty
51100,Experiencing mood swings,Phenotype,Experiencing mood swings
51101,Worry too long after an embarrassing experience,Phenotype,Worry too long after an embarrassing experience
51102,Smoking behaviour (maximum cigarettes in a 24 hour period),Phenotype,Smoking behaviour (maximum cigarettes in a 24 hour period)
51103,Surgical necrotising enterocolitis in extremely premature birth,Phenotype,Surgical necrotising enterocolitis in extremely premature birth
51104,Nonobstructive coronary artery disease,Phenotype,Nonobstructive coronary artery disease
51105,Barrett's esophagus x pack-years of smoking exposure interaction,Phenotype,Barrett's esophagus x pack-years of smoking exposure interaction
51106,Multiple sclerosis and systolic blood pressure (pleiotropy),Phenotype,Multiple sclerosis and systolic blood pressure (pleiotropy)
51107,Multiple sclerosis and body mass index (pleiotropy),Phenotype,Multiple sclerosis and body mass index (pleiotropy)
51108,Multiple sclerosis and waist-to-hip-ratio (pleiotropy),Phenotype,Multiple sclerosis and waist-to-hip-ratio (pleiotropy)
51109,Multiple sclerosis and type 2 diabetes (pleiotropy),Phenotype,Multiple sclerosis and type 2 diabetes (pleiotropy)
51110,Type 2 diabetes (age of onset),Phenotype,Type 2 diabetes (age of onset)
51111,Cough in response to angiotensin-converting enzyme inhibitor drugs,Phenotype,Cough in response to angiotensin-converting enzyme inhibitor drugs
51112,Liver disease severity in Alagille syndrome,Phenotype,Liver disease severity in Alagille syndrome
51113,Ankle injury,Phenotype,Ankle injury
51114,Eye morphology,Phenotype,Eye morphology
51115,Headache,Phenotype,Headache
51116,Binge eating behaviour and bipolar disorder,Phenotype,Binge eating behaviour and bipolar disorder
51117,Multiple keratinocyte cancers,Phenotype,Multiple keratinocyte cancers
51118,Gait speed in old age,Phenotype,Gait speed in old age
51127,Rostral middle frontal gyrus volume,Phenotype,Rostral middle frontal gyrus volume
51128,Superior frontal gyrus volume,Phenotype,Superior frontal gyrus volume
51129,Superior parietal cortex volume,Phenotype,Superior parietal cortex volume
51130,Pericalcarine cortex volume,Phenotype,Pericalcarine cortex volume
51131,Lateral orbital frontal cortex volume,Phenotype,Lateral orbital frontal cortex volume
51132,Middle temporal gyrus volume,Phenotype,Middle temporal gyrus volume
51133,Parahippocampal gyrus volume,Phenotype,Parahippocampal gyrus volume
51134,Precuneus cortex volume,Phenotype,Precuneus cortex volume
51135,Pars triangularis volume,Phenotype,Pars triangularis volume
51136,Paracentral lobule volume,Phenotype,Paracentral lobule volume
51137,Pars opercularis volume,Phenotype,Pars opercularis volume
51138,Medial orbital frontal cortex volume,Phenotype,Medial orbital frontal cortex volume
51139,Cortex volume,Phenotype,Cortex volume
51140,Cerebral white matter volume,Phenotype,Cerebral white matter volume
51141,Intake of sweets,Phenotype,Intake of sweets
51142,Perceived intensity of neohesperidin dihydrochalcone,Phenotype,Perceived intensity of neohesperidin dihydrochalcone
51143,Sub-cortical grey matter volume,Phenotype,Sub-cortical grey matter volume
51144,Estimated glomerular filtration rate in diabetes,Phenotype,Estimated glomerular filtration rate in diabetes
51145,Perceived intensity of sweet substances,Phenotype,Perceived intensity of sweet substances
51146,Perceived sweetness of sucrose,Phenotype,Perceived sweetness of sucrose
51147,Colorectal cancer or advanced adenoma,Phenotype,Colorectal cancer or advanced adenoma
51148,Familial lung adenocarcinoma,Phenotype,Familial lung adenocarcinoma
51149,Familial lung cancer,Phenotype,Familial lung cancer
51151,Response to antidepressants (symptom remission),Phenotype,Response to antidepressants (symptom remission)
51152,Adverse response to drug,Phenotype,Adverse response to drug
51153,Pneumococcal meningitis,Phenotype,Pneumococcal meningitis
51155,Corpus callosum central volume,Phenotype,Corpus callosum central volume
51156,Corpus callosum mid-anterior volume,Phenotype,Corpus callosum mid-anterior volume
51157,Lateral ventricle volume,Phenotype,Lateral ventricle volume
51158,Lateral ventricle temporal horn volume,Phenotype,Lateral ventricle temporal horn volume
51159,Third ventricle volume,Phenotype,Third ventricle volume
51162,Estimated glomerular filtration rate in non-diabetics,Phenotype,Estimated glomerular filtration rate in non-diabetics
51163,Familial squamous cell lung carcinoma,Phenotype,Familial squamous cell lung carcinoma
51164,Metabolite risk score for predicting weight gain,Phenotype,Metabolite risk score for predicting weight gain
51168,Caudal anterior-cingulate cortex volume,Phenotype,Caudal anterior-cingulate cortex volume
51169,Caudal middle frontal gyrus volume,Phenotype,Caudal middle frontal gyrus volume
51170,Cuneus cortex volume,Phenotype,Cuneus cortex volume
51172,Inferior parietal cortex volume,Phenotype,Inferior parietal cortex volume
51173,Isthmus-cingulate cortex volume,Phenotype,Isthmus-cingulate cortex volume
51174,Lateral occipital cortex volume,Phenotype,Lateral occipital cortex volume
51176,Systemising,Phenotype,Systemising
51177,Nucleus accumbens volume,Phenotype,Nucleus accumbens volume
51178,Choroid plexus volume,Phenotype,Choroid plexus volume
51179,Frontal pole volume,Phenotype,Frontal pole volume
51180,Temporal pole volume,Phenotype,Temporal pole volume
51181,Insular cortex volume,Phenotype,Insular cortex volume
51182,Pallidum volume,Phenotype,Pallidum volume
51183,Hippocampal volume,Phenotype,Hippocampal volume
51184,Amygdala volume,Phenotype,Amygdala volume
51185,Thalamus volume,Phenotype,Thalamus volume
51186,Cerebellum white matter volume,Phenotype,Cerebellum white matter volume
51187,Whole brain grey matter density,Phenotype,Whole brain grey matter density
51188,Intake of total sugars,Phenotype,Intake of total sugars
51189,Perceived intensity of glucose,Phenotype,Perceived intensity of glucose
51190,Superior temporal sulcus banks volume,Phenotype,Superior temporal sulcus banks volume
51194,Subjective response to placebo treatment in childhood asthma (change in cough/wheeze),Phenotype,Subjective response to placebo treatment in childhood asthma (change in cough/wheeze)
51195,Response to placebo treatment in childhood asthma (FVC change),Phenotype,Response to placebo treatment in childhood asthma (FVC change)
51196,Handedness (non-right-handed vs right-handed),Phenotype,Handedness (non-right-handed vs right-handed)
51197,Nose morphology,Phenotype,Nose morphology
51198,Upper eyelid morphology,Phenotype,Upper eyelid morphology
51199,Verbal intelligence quotient (cesarean section interaction),Phenotype,Verbal intelligence quotient (cesarean section interaction)
51200,Performance intelligence quotient (cesarean section interaction),Phenotype,Performance intelligence quotient (cesarean section interaction)
51201,Full scale intelligence quotient (cesarean section interaction),Phenotype,Full scale intelligence quotient (cesarean section interaction)
51202,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),Phenotype,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
51204,Bone mineral density (femoral neck) in inflammatory bowel disease,Phenotype,Bone mineral density (femoral neck) in inflammatory bowel disease
51205,Systolic blood pressure x alcohol consumption interaction (2df test),Phenotype,Systolic blood pressure x alcohol consumption interaction (2df test)
51206,Cerebrospinal fluid p-tau levels in normal cognition,Phenotype,Cerebrospinal fluid p-tau levels in normal cognition
51207,Logical memory (immediate recall) in normal cognition,Phenotype,Logical memory (immediate recall) in normal cognition
51208,Hippocampal volume in mild cognitive impairment,Phenotype,Hippocampal volume in mild cognitive impairment
51210,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia,Phenotype,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia
51211,Hippocampal volume in Alzheimer's disease dementia,Phenotype,Hippocampal volume in Alzheimer's disease dementia
51212,Parental longevity (mother's attained age),Phenotype,Parental longevity (mother's attained age)
51213,Parental longevity (father's attained age),Phenotype,Parental longevity (father's attained age)
51214,Pulse pressure x alcohol consumption interaction (2df test),Phenotype,Pulse pressure x alcohol consumption interaction (2df test)
51215,Mean arterial pressure x alcohol consumption interaction (2df test),Phenotype,Mean arterial pressure x alcohol consumption interaction (2df test)
51216,Diastolic blood pressure x alcohol consumption interaction (2df test),Phenotype,Diastolic blood pressure x alcohol consumption interaction (2df test)
51217,Obsessive-compulsive disorder x sex interaction,Phenotype,Obsessive-compulsive disorder x sex interaction
51219,Childhood dental caries in permanent teeth,Phenotype,Childhood dental caries in permanent teeth
51220,Parental longevity (combined parental attained age-- Martingale residuals),Phenotype,Parental longevity (combined parental attained age-- Martingale residuals)
51221,Parental longevity (both parents in top 10%),Phenotype,Parental longevity (both parents in top 10%)
51222,Cerebrospinal AB1-42 levels in normal cognition,Phenotype,Cerebrospinal AB1-42 levels in normal cognition
51223,Logical memory (delayed recall) in normal cognition,Phenotype,Logical memory (delayed recall) in normal cognition
51224,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),Phenotype,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
51225,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),Phenotype,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
51250,Fatty acid desaturase activity (serum),Phenotype,Fatty acid desaturase activity (serum)
51251,Asthma x Hispanic interaction (2df),Phenotype,Asthma x Hispanic interaction (2df)
51254,HDL cholesterol levels in current drinkers,Phenotype,HDL cholesterol levels in current drinkers
51255,Regular attendance at a gym or sports club,Phenotype,Regular attendance at a gym or sports club
51256,Regular attendance at a pub or social club,Phenotype,Regular attendance at a pub or social club
51257,Regular attendance at a religious group,Phenotype,Regular attendance at a religious group
51258,Loneliness (MTAG),Phenotype,Loneliness (MTAG)
51259,Pemphigus,Phenotype,Pemphigus
51260,Pemphigus vulgaris,Phenotype,Pemphigus vulgaris
51261,Triglyceride levels in current drinkers,Phenotype,Triglyceride levels in current drinkers
51262,Diabetic maculopathy in type 2 diabetes,Phenotype,Diabetic maculopathy in type 2 diabetes
51263,Mental health study participation (provided email address),Phenotype,Mental health study participation (provided email address)
51264,Mental health study participation (completed survey),Phenotype,Mental health study participation (completed survey)
51265,Number of alcoholic drinks required to feel an effect (long-term average),Phenotype,Number of alcoholic drinks required to feel an effect (long-term average)
51266,Alzheimer's disease or gastroesophageal reflux disease,Phenotype,Alzheimer's disease or gastroesophageal reflux disease
51268,Urea levels,Phenotype,Urea levels
51269,Diastolic blood pressure (MTAG),Phenotype,Diastolic blood pressure (MTAG)
51297,PCSK9 levels,Phenotype,PCSK9 levels
51303,body mass index x pumpkin consumption interaction,Phenotype,body mass index x pumpkin consumption interaction
51308,Seropositivity for rhinovirus b peptide (twist_47860),Phenotype,Seropositivity for rhinovirus b peptide (twist_47860)
51309,Seropositivity for enterovirus peptide (agilent_11510),Phenotype,Seropositivity for enterovirus peptide (agilent_11510)
51313,Seropositivity for enterovirus peptide (agilent_6487),Phenotype,Seropositivity for enterovirus peptide (agilent_6487)
51315,Seropositivity for enterovirus b peptide (twist_28808),Phenotype,Seropositivity for enterovirus b peptide (twist_28808)
51316,Seropositivity for enterovirus peptide (agilent_6423),Phenotype,Seropositivity for enterovirus peptide (agilent_6423)
51318,Seropositivity for escherichia coli O157:H7 str. EDL933 peptide (agilent_231281),Phenotype,Seropositivity for escherichia coli O157:H7 str. EDL933 peptide (agilent_231281)
51320,Seropositivity for human adenovirus 12 peptide (twist_43231),Phenotype,Seropositivity for human adenovirus 12 peptide (twist_43231)
51325,Seropositivity for human adenovirus 12 peptide (twist_55551),Phenotype,Seropositivity for human adenovirus 12 peptide (twist_55551)
51328,Seropositivity for human adenovirus c peptide (agilent_42),Phenotype,Seropositivity for human adenovirus c peptide (agilent_42)
51330,Seropositivity for human adenovirus c peptide (agilent_2749),Phenotype,Seropositivity for human adenovirus c peptide (agilent_2749)
51331,Seropositivity for aegilops tauschii (tausch's goatgrass) peptide (twist_22888),Phenotype,Seropositivity for aegilops tauschii (tausch's goatgrass) peptide (twist_22888)
51332,Familial combined hyperlipidemia defined by Mexico criteria,Phenotype,Familial combined hyperlipidemia defined by Mexico criteria
51334,Seropositivity for firmicutes peptide (agilent_150014),Phenotype,Seropositivity for firmicutes peptide (agilent_150014)
51336,Seropositivity for haemophilus influenzae peptide (agilent_223654),Phenotype,Seropositivity for haemophilus influenzae peptide (agilent_223654)
51338,Seropositivity for haemophilus influenzae peptide (agilent_229777),Phenotype,Seropositivity for haemophilus influenzae peptide (agilent_229777)
51342,Seropositivity for haemophilus influenzae nontypable strain 3179b peptide (agilent_223905),Phenotype,Seropositivity for haemophilus influenzae nontypable strain 3179b peptide (agilent_223905)
51344,Seropositivity for haemophilus influenzae peptide (agilent_228606),Phenotype,Seropositivity for haemophilus influenzae peptide (agilent_228606)
51345,Seropositivity for enterobacteria phage peptide (twist_92147),Phenotype,Seropositivity for enterobacteria phage peptide (twist_92147)
51347,Seropositivity for enterobacteria phage peptide (twist_65044),Phenotype,Seropositivity for enterobacteria phage peptide (twist_65044)
51349,Seropositivity for enterobacteria phage phi1 peptide (twist_87290),Phenotype,Seropositivity for enterobacteria phage phi1 peptide (twist_87290)
51352,Seropositivity for enterobacteria phage phi1 peptide (twist_60834),Phenotype,Seropositivity for enterobacteria phage phi1 peptide (twist_60834)
51353,Seropositivity for enterobacteriaceae peptide (agilent_241053),Phenotype,Seropositivity for enterobacteriaceae peptide (agilent_241053)
51355,Seropositivity for enterococcus faecalis v583 peptide (agilent_219731),Phenotype,Seropositivity for enterococcus faecalis v583 peptide (agilent_219731)
51357,Seropositivity for enterococcus faecalis v583 peptide (agilent_140151),Phenotype,Seropositivity for enterococcus faecalis v583 peptide (agilent_140151)
51359,Seropositivity for enterovirus b peptide (twist_28803),Phenotype,Seropositivity for enterovirus b peptide (twist_28803)
51361,Seropositivity for rhinovirus b peptide (twist_28813),Phenotype,Seropositivity for rhinovirus b peptide (twist_28813)
51362,Seropositivity for enterovirus peptide (agilent_4843),Phenotype,Seropositivity for enterovirus peptide (agilent_4843)
51364,Seropositivity for dorea formicigenerans (agilent_160727),Phenotype,Seropositivity for dorea formicigenerans (agilent_160727)
51365,Seropositivity for escherichia coli O157:H7 str. sakai peptide (agilent_90858),Phenotype,Seropositivity for escherichia coli O157:H7 str. sakai peptide (agilent_90858)
51369,Seropositivity for eubacterium peptide (agilent_101119),Phenotype,Seropositivity for eubacterium peptide (agilent_101119)
51371,Seropositivity for eubacterium rectale (agilent_212176),Phenotype,Seropositivity for eubacterium rectale (agilent_212176)
51372,Seropositivity for eubacterium rectale (agilent_108406),Phenotype,Seropositivity for eubacterium rectale (agilent_108406)
51373,Seropositivity for eubacterium rectale (agilent_79020),Phenotype,Seropositivity for eubacterium rectale (agilent_79020)
51375,Seropositivity for faecalibacterium prausnitzii a2-165 peptide (agilent_199016),Phenotype,Seropositivity for faecalibacterium prausnitzii a2-165 peptide (agilent_199016)
51378,Seropositivity for faecalibacterium prausnitzii a2-165 peptide (agilent_194982),Phenotype,Seropositivity for faecalibacterium prausnitzii a2-165 peptide (agilent_194982)
51381,Alzheimer's disease or gastroesophageal reflux disease and/or peptic ulcer disease,Phenotype,Alzheimer's disease or gastroesophageal reflux disease and/or peptic ulcer disease
51384,Neurofilament light chain levels,Phenotype,Neurofilament light chain levels
51389,Thyroid peroxidase antibody positivity in pregnancy,Phenotype,Thyroid peroxidase antibody positivity in pregnancy
51403,Cisplatin-induced nephrotoxicity (increased serum creatinine AKI-CTCAE),Phenotype,Cisplatin-induced nephrotoxicity (increased serum creatinine AKI-CTCAE)
51405,Cisplatin-induced nephrotoxicity (decreased eGFR),Phenotype,Cisplatin-induced nephrotoxicity (decreased eGFR)
51454,Retinal vascular fractal density,Phenotype,Retinal vascular fractal density
51459,Lysophosphatidylcholine(15:0) levels,Phenotype,Lysophosphatidylcholine(15:0) levels
51471,5alpha-pregnan-3beta--20alpha-diol monosulfate (1) levels,Phenotype,5alpha-pregnan-3beta--20alpha-diol monosulfate (1) levels
51473,Coronary artery disease (MTAG),Phenotype,Coronary artery disease (MTAG)
51477,Stroke (MTAG),Phenotype,Stroke (MTAG)
51479,Alzheimer's disease (MTAG),Phenotype,Alzheimer's disease (MTAG)
51480,Carotid intima-media thickness (MTAG),Phenotype,Carotid intima-media thickness (MTAG)
51486,Familial combined hyperlipidemia defined by Brunzell criteria,Phenotype,Familial combined hyperlipidemia defined by Brunzell criteria
51487,Acute encephalopathy with biphasic seizures and late reduced diffusion,Phenotype,Acute encephalopathy with biphasic seizures and late reduced diffusion
51489,Hair colour (natural-- before greying): Blonde (UKB data field 1747_1),Phenotype,Hair colour (natural-- before greying): Blonde (UKB data field 1747_1)
51510,Hair colour (natural-- before greying): Red (UKB data field 1747_2),Phenotype,Hair colour (natural-- before greying): Red (UKB data field 1747_2)
51528,Hair colour (natural-- before greying): Light brown (UKB data field 1747_3),Phenotype,Hair colour (natural-- before greying): Light brown (UKB data field 1747_3)
51552,Hair colour (natural-- before greying): Dark brown (UKB data field 1747_4),Phenotype,Hair colour (natural-- before greying): Dark brown (UKB data field 1747_4)
51606,Cognitive function (processing speed) x major depressive disorder interaction (1df),Phenotype,Cognitive function (processing speed) x major depressive disorder interaction (1df)
51608,Cognitive function (processing speed) x major depressive disorder interaction (2df),Phenotype,Cognitive function (processing speed) x major depressive disorder interaction (2df)
51637,Long-chain dicarboxylacylcarnitines levels (dominant genetic model),Phenotype,Long-chain dicarboxylacylcarnitines levels (dominant genetic model)
51643,Short-chain dicarboxylacylcarnitine levels (dominant genetic model),Phenotype,Short-chain dicarboxylacylcarnitine levels (dominant genetic model)
51647,Age related hearing loss-related regional glucose metabolism (Cochlear nucleus),Phenotype,Age related hearing loss-related regional glucose metabolism (Cochlear nucleus)
51652,Thyroid peroxidase antibody levels in pregnancy,Phenotype,Thyroid peroxidase antibody levels in pregnancy
51653,Age related hearing loss-related regional glucose metabolism (Inferior colliculus),Phenotype,Age related hearing loss-related regional glucose metabolism (Inferior colliculus)
51655,Free thyroxine levels within normal range in pregnancy,Phenotype,Free thyroxine levels within normal range in pregnancy
51657,Subclinical hypothyroidism in pregnancy,Phenotype,Subclinical hypothyroidism in pregnancy
51658,Isolated hypothyroxinemia  in pregnancy,Phenotype,Isolated hypothyroxinemia  in pregnancy
51660,Subclinical hyperthyroidism in pregnancy,Phenotype,Subclinical hyperthyroidism in pregnancy
51662,Overt hyperthyroidism in pregnancy,Phenotype,Overt hyperthyroidism in pregnancy
51668,Thyroid stimulating hormone levels within normal range in pregnancy,Phenotype,Thyroid stimulating hormone levels within normal range in pregnancy
51671,Vitamin D levels,Phenotype,Vitamin D levels
51681,Steroid induced osteonecrosis of the femoral head and systemic lupus erythematosus,Phenotype,Steroid induced osteonecrosis of the femoral head and systemic lupus erythematosus
51683,Bone mineral density T score in postmenopausal osteoporosis,Phenotype,Bone mineral density T score in postmenopausal osteoporosis
51685,Low hand grip strength,Phenotype,Low hand grip strength
51687,Retinal vascular fractal dimension,Phenotype,Retinal vascular fractal dimension
51707,Occupational attainment,Phenotype,Occupational attainment
51709,Lifetime smoking,Phenotype,Lifetime smoking
51717,Immunoglobulin N-glycan 10 levels,Phenotype,Immunoglobulin N-glycan 10 levels
51719,Immunoglobulin N-glycan 19 levels,Phenotype,Immunoglobulin N-glycan 19 levels
51721,lung cancer x sex interaction,Phenotype,lung cancer x sex interaction
51723,Lifetime smoking (without educational attainment),Phenotype,Lifetime smoking (without educational attainment)
51724,Granulocyte telomere length,Phenotype,Granulocyte telomere length
51726,Lymphocyte telomere length,Phenotype,Lymphocyte telomere length
51728,B-cell telomere length,Phenotype,B-cell telomere length
51731,Type ii diabetes,Phenotype,Type ii diabetes
51739,Response to gabapentin in female chronic pelvic pain,Phenotype,Response to gabapentin in female chronic pelvic pain
51743,Response to gabapentin in female chronic pelvic pain (side-effect burden),Phenotype,Response to gabapentin in female chronic pelvic pain (side-effect burden)
51751,Alzheimer's disease or peptic ulcer disease,Phenotype,Alzheimer's disease or peptic ulcer disease
51754,Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044),Phenotype,Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044)
51755,Illnesses of mother: Alzheimer's disease/dementia (UKB data field 20110_10),Phenotype,Illnesses of mother: Alzheimer's disease/dementia (UKB data field 20110_10)
51756,Hearing difficulty/problems: No (UKB data field 2247_0),Phenotype,Hearing difficulty/problems: No (UKB data field 2247_0)
51758,Hearing difficulty/problems: Yes (UKB data field 2247_1),Phenotype,Hearing difficulty/problems: Yes (UKB data field 2247_1)
51759,Hair colour (natural-- before greying): Black (UKB data field 1747_5),Phenotype,Hair colour (natural-- before greying): Black (UKB data field 1747_5)
51763,Disorders of iron metabolism (PheCode 275.1),Phenotype,Disorders of iron metabolism (PheCode 275.1)
51765,Treatment or medication use - insulin product (UKB data field 20003_1140883066),Phenotype,Treatment or medication use - insulin product (UKB data field 20003_1140883066)
51768,Treatment or medication use - sulfasalazine (UKB data field 20003_1140909702),Phenotype,Treatment or medication use - sulfasalazine (UKB data field 20003_1140909702)
51770,Treatment or medication use - atorvastatin (UKB data field 20003_1141146234),Phenotype,Treatment or medication use - atorvastatin (UKB data field 20003_1141146234)
51791,Cognitive function (executive function) x major depressive disorder interaction (1df),Phenotype,Cognitive function (executive function) x major depressive disorder interaction (1df)
51794,Cognitive function (executive function) x major depressive disorder interaction (2df),Phenotype,Cognitive function (executive function) x major depressive disorder interaction (2df)
51796,Crohn's disease or Leprosy (opposite effect),Phenotype,Crohn's disease or Leprosy (opposite effect)
51804,Seropositivity for streptococcus pneumoniae peptide (agilent_223208),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_223208)
51808,Seropositivity for streptococcus pneumoniae peptide (agilent_227833),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_227833)
51815,Seropositivity for streptococcus pneumoniae peptide (agilent_241214),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_241214)
51818,Seropositivity for streptococcus pneumoniae peptide (agilent_243228),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_243228)
51819,Seropositivity for streptococcus pneumoniae peptide (agilent_235513),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_235513)
51820,Seropositivity for streptococcus pneumoniae peptide (agilent_236127),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_236127)
51822,Seropositivity for streptococcus pneumoniae peptide (agilent_243958),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_243958)
51824,Seropositivity for streptococcus pneumoniae peptide (agilent_220951),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_220951)
51825,Seropositivity for streptococcus pneumoniae peptide (agilent_220184),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_220184)
51828,Seropositivity for streptococcus pneumoniae peptide (agilent_223641),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_223641)
51830,Seropositivity for streptococcus pneumoniae peptide (agilent_226792),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_226792)
51831,Seropositivity for streptococcus pneumoniae peptide (agilent_225587),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_225587)
51834,Seropositivity for streptococcus pneumoniae peptide (agilent_231039),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_231039)
51835,Seropositivity for streptococcus pneumoniae peptide (twist_48171),Phenotype,Seropositivity for streptococcus pneumoniae peptide (twist_48171)
51837,Seropositivity for streptococcus pneumoniae peptide (agilent_220672),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_220672)
51843,Seropositivity for streptococcus pneumoniae peptide (agilent_220944),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_220944)
51846,Seropositivity for staphylococcus aureus peptide (twist_34337),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_34337)
51850,Seropositivity for staphylococcus aureus peptide (twist_39975),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_39975)
51855,Seropositivity for staphylococcus aureus peptide (agilent_236148),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_236148)
51858,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_204518),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_204518)
51860,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_134645),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_134645)
51863,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_26654),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_26654)
51866,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_205649),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_205649)
51867,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_20117),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_20117)
51869,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_69388),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_69388)
51870,Seropositivity for staphylococcus aureus subsp. aureus MW2 peptide (agilent_236929),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MW2 peptide (agilent_236929)
51872,Seropositivity for staphylococcus aureus subsp. aureus MW2 peptide (agilent_237201),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MW2 peptide (agilent_237201)
51875,Seropositivity for staphylococcus aureus subsp. aureus strain newman peptide (agilent_239239),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus strain newman peptide (agilent_239239)
51878,Seropositivity for staphylococcus peptide (agilent_237677),Phenotype,Seropositivity for staphylococcus peptide (agilent_237677)
51880,Seropositivity for staphylococcus aureus peptide (agilent_222726),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_222726)
51883,Seropositivity for staphylococcus aureus peptide (agilent_226247),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_226247)
51884,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_217424),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_217424)
51887,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_105317),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_105317)
51889,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_188119),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_188119)
51892,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_92408),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_92408)
51893,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_81159),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_81159)
51895,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_204624),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_204624)
51896,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_15915),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_15915)
51905,Seropositivity for staphylococcus aureus peptide (agilent_241121),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_241121)
51909,Seropositivity for staphylococcus aureus peptide (agilent_222381),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_222381)
51911,Coronary vascular stenosis,Phenotype,Coronary vascular stenosis
51914,Brain vascular stenosis,Phenotype,Brain vascular stenosis
51916,Lifetime major depressive disorder (AutoComplete Impute),Phenotype,Lifetime major depressive disorder (AutoComplete Impute)
51919,Total adipose tissue,Phenotype,Total adipose tissue
51922,Sinus bradycardia,Phenotype,Sinus bradycardia
51924,Skeletal muscle mass,Phenotype,Skeletal muscle mass
51925,Seropositivity for streptococcus pyogenes peptide (agilent_241884),Phenotype,Seropositivity for streptococcus pyogenes peptide (agilent_241884)
51926,Seropositivity for streptococcus pyogenes peptide (agilent_235068),Phenotype,Seropositivity for streptococcus pyogenes peptide (agilent_235068)
51942,Seropositivity for streptococcus pyogenes peptide (agilent_221984),Phenotype,Seropositivity for streptococcus pyogenes peptide (agilent_221984)
51943,Seropositivity for streptococcus pyogenes peptide (agilent_220658),Phenotype,Seropositivity for streptococcus pyogenes peptide (agilent_220658)
51964,Seropositivity for vibrio cholerae AM-19226 peptide (agilent_188248),Phenotype,Seropositivity for vibrio cholerae AM-19226 peptide (agilent_188248)
51965,Seropositivity for vibrio vulnificus peptide (agilent_157295),Phenotype,Seropositivity for vibrio vulnificus peptide (agilent_157295)
51967,Seropositivity for neisseria meningitidis peptide (agilent_223729),Phenotype,Seropositivity for neisseria meningitidis peptide (agilent_223729)
51969,Seropositivity for gallus gallus ovomucoid precursor gallus peptide (twist_28164),Phenotype,Seropositivity for gallus gallus ovomucoid precursor gallus peptide (twist_28164)
51971,Seropositivity for gallus gallus ovomucoid precursor gallus peptide (twist_30726),Phenotype,Seropositivity for gallus gallus ovomucoid precursor gallus peptide (twist_30726)
51979,Seropositivity for gallus gallus ovomucoid precursor gallus peptide (twist_1603),Phenotype,Seropositivity for gallus gallus ovomucoid precursor gallus peptide (twist_1603)
51981,Seropositivity for staphylococcus aureus peptide (twist_2995),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_2995)
51983,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_84757),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_84757)
51993,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_187024),Phenotype,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_187024)
51995,Seropositivity for lactobacillus reuteri peptide (agilent_204160),Phenotype,Seropositivity for lactobacillus reuteri peptide (agilent_204160)
51997,Seropositivity for root peptide (agilent_156552),Phenotype,Seropositivity for root peptide (agilent_156552)
51998,Seropositivity for root peptide (agilent_184788),Phenotype,Seropositivity for root peptide (agilent_184788)
51999,Seropositivity for struthio camelus (ostrich) peptide (twist_5109),Phenotype,Seropositivity for struthio camelus (ostrich) peptide (twist_5109)
52008,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_21920),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_21920)
52011,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_23359),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_23359)
52013,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_39688),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_39688)
52016,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_180726),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_180726)
52017,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_53453),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_53453)
52019,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_80555),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_80555)
52022,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_198635),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_198635)
52023,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_205647),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_205647)
52025,Lifetime major depressive disorder (MTAG),Phenotype,Lifetime major depressive disorder (MTAG)
52026,Lifetime major depressive disorder (AutoComplete Impute and observed),Phenotype,Lifetime major depressive disorder (AutoComplete Impute and observed)
52028,Drusen,Phenotype,Drusen
52030,Forced vital capacity (FVC) (%),Phenotype,Forced vital capacity (FVC) (%)
52032,Forced expiratory volume in 1 second (FEV1) (litres),Phenotype,Forced expiratory volume in 1 second (FEV1) (litres)
52034,FEV1/FVC ratio,Phenotype,FEV1/FVC ratio
52037,Urine pH measurement,Phenotype,Urine pH measurement
52039,Lifetime major depressive disorder (SoftImpute),Phenotype,Lifetime major depressive disorder (SoftImpute)
52040,Lifetime major depressive disorder (SoftImpute and observed),Phenotype,Lifetime major depressive disorder (SoftImpute and observed)
52041,Seropositivity for streptococcus agalactiae peptide (agilent_241118),Phenotype,Seropositivity for streptococcus agalactiae peptide (agilent_241118)
52043,Seropositivity for streptococcus pneumoniae peptide (agilent_243291),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_243291)
52044,Seropositivity for streptococcus pneumoniae peptide (agilent_241401),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_241401)
52046,Seropositivity for streptococcus pneumoniae peptide (agilent_223189),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_223189)
52048,Seropositivity for streptococcus pneumoniae peptide (agilent_223825),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_223825)
52052,Seropositivity for streptococcus pneumoniae peptide (agilent_223466),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_223466)
52053,Seropositivity for streptococcus pneumoniae peptide (agilent_221413),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_221413)
52055,Seropositivity for streptococcus pneumoniae peptide (agilent_233612),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_233612)
52060,Seropositivity for staphylococcus aureus peptide (agilent_221466),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_221466)
52063,Seropositivity for staphylococcus aureus peptide (agilent_237594),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_237594)
52066,Seropositivity for staphylococcus aureus peptide (agilent_236695),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_236695)
52067,Seropositivity for staphylococcus aureus peptide (agilent_222756),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_222756)
52069,Seropositivity for influenza a virus peptide (twist_59245),Phenotype,Seropositivity for influenza a virus peptide (twist_59245)
52071,Seropositivity for lachnospiraceae peptide (agilent_193943),Phenotype,Seropositivity for lachnospiraceae peptide (agilent_193943)
52072,Seropositivity for lachnospiraceae peptide (agilent_141373),Phenotype,Seropositivity for lachnospiraceae peptide (agilent_141373)
52074,Seropositivity for lactobacillus acidophilus peptide (agilent_24672),Phenotype,Seropositivity for lactobacillus acidophilus peptide (agilent_24672)
52075,Seropositivity for lactobacillus acidophilus peptide (agilent_189058),Phenotype,Seropositivity for lactobacillus acidophilus peptide (agilent_189058)
52077,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_13363),Phenotype,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_13363)
52078,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_187025),Phenotype,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_187025)
52080,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_193278),Phenotype,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_193278)
52081,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_167634),Phenotype,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_167634)
52082,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_103772),Phenotype,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_103772)
52084,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_78561),Phenotype,Seropositivity for lactobacillus plantarum WCFS1 peptide (agilent_78561)
52085,Seropositivity for staphylococcus aureus peptide (agilent_236333),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_236333)
52086,Seropositivity for staphylococcus aureus peptide (agilent_227810),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_227810)
52088,Seropositivity for staphylococcus aureus peptide (agilent_241827),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_241827)
52089,Seropositivity for staphylococcus aureus peptide (agilent_240086),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_240086)
52091,Seropositivity for staphylococcus aureus peptide (agilent_233907),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_233907)
52092,Seropositivity for staphylococcus aureus peptide (agilent_223217),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_223217)
52104,Seropositivity for staphylococcus aureus peptide (agilent_228814),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_228814)
52105,Seropositivity for staphylococcus aureus peptide (agilent_222322),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_222322)
52108,Bone density,Phenotype,Bone density
52110,Spondylolisthesis,Phenotype,Spondylolisthesis
52113,Seropositivity for aix galericulata (mandarin duck) peptide (twist_23200),Phenotype,Seropositivity for aix galericulata (mandarin duck) peptide (twist_23200)
52117,Seropositivity for hordeum vulgare (barley) peptide (twist_15602),Phenotype,Seropositivity for hordeum vulgare (barley) peptide (twist_15602)
52121,Seropositivity for hordeum vulgare (barley) peptide (twist_7301),Phenotype,Seropositivity for hordeum vulgare (barley) peptide (twist_7301)
52122,Seropositivity for bifidobacterium longum 35624 peptide (agilent_29665),Phenotype,Seropositivity for bifidobacterium longum 35624 peptide (agilent_29665)
52124,Seropositivity for blautia obeum (agilent_133371),Phenotype,Seropositivity for blautia obeum (agilent_133371)
52126,Seropositivity for blautia producta peptide (agilent_74695),Phenotype,Seropositivity for blautia producta peptide (agilent_74695)
52127,Seropositivity for blautia producta peptide (agilent_122181),Phenotype,Seropositivity for blautia producta peptide (agilent_122181)
52129,Seropositivity for blautia producta peptide (agilent_172699),Phenotype,Seropositivity for blautia producta peptide (agilent_172699)
52131,Seropositivity for streptococcus agalactiae peptide (agilent_234887),Phenotype,Seropositivity for streptococcus agalactiae peptide (agilent_234887)
52136,Seropositivity for streptococcus pneumoniae peptide (agilent_6216),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_6216)
52140,Seropositivity for streptococcus pneumoniae peptide (twist_15509),Phenotype,Seropositivity for streptococcus pneumoniae peptide (twist_15509)
52142,Seropositivity for streptococcus peptide (agilent_235929),Phenotype,Seropositivity for streptococcus peptide (agilent_235929)
52143,Seropositivity for streptococcus peptide (agilent_223589),Phenotype,Seropositivity for streptococcus peptide (agilent_223589)
52144,Seropositivity for streptococcus pneumoniae peptide (agilent_242450),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_242450)
52146,Seropositivity for streptococcus pneumoniae peptide (agilent_229734),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_229734)
52148,Seropositivity for streptococcus pneumoniae peptide (agilent_221864),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_221864)
52152,Seropositivity for streptococcus pneumoniae peptide (agilent_229757),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_229757)
52156,Seropositivity for streptococcus pneumoniae peptide (agilent_224401),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_224401)
52158,Seropositivity for streptococcus pneumoniae peptide (agilent_231226),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_231226)
52164,Seropositivity for streptococcus pneumoniae peptide (agilent_243229),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_243229)
52166,Seropositivity for streptococcus pneumoniae peptide (agilent_226736),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_226736)
52172,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27538),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27538)
52174,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_1075),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_1075)
52176,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_318),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_318)
52177,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_32586),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_32586)
52179,Seropositivity for bacteria peptide (agilent_240518),Phenotype,Seropositivity for bacteria peptide (agilent_240518)
52181,Seropositivity for bubalus bubalis (buffalo) peptide (twist_22083),Phenotype,Seropositivity for bubalus bubalis (buffalo) peptide (twist_22083)
52183,Seropositivity for escherichia virus p1 peptide (twist_92719),Phenotype,Seropositivity for escherichia virus p1 peptide (twist_92719)
52184,Seropositivity for euarchontoglires peptide (agilent_7767),Phenotype,Seropositivity for euarchontoglires peptide (agilent_7767)
52186,Seropositivity for gallus peptide (twist_24274),Phenotype,Seropositivity for gallus peptide (twist_24274)
52187,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_52109),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_52109)
52188,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_9904),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_9904)
52190,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_212),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_212)
52192,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_46426),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_46426)
52194,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27552),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27552)
52195,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_6936),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_6936)
52197,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_8059),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_8059)
52198,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_31240),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_31240)
52199,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_129),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_129)
52201,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_35320),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_35320)
52203,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_7302),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_7302)
52205,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_32108),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_32108)
52207,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_3328),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_3328)
52210,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27540),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27540)
52211,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_321),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_321)
52213,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_34377),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_34377)
52214,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_52019),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_52019)
52216,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_7435),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_7435)
52217,Seropositivity for shigella sonnei 53g peptide (agilent_75769),Phenotype,Seropositivity for shigella sonnei 53g peptide (agilent_75769)
52218,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27904),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27904)
52219,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_54751),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_54751)
52221,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_46937),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_46937)
52223,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_43249),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_43249)
52224,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_31993),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_31993)
52225,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_56934),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_56934)
52227,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_6942),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_6942)
52229,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_4834),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_4834)
52231,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_34869),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_34869)
52233,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_52249),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_52249)
52234,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_6000),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_6000)
52235,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_7167),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_7167)
52236,Seropositivity for shigella sonnei 53g peptide (agilent_197679),Phenotype,Seropositivity for shigella sonnei 53g peptide (agilent_197679)
52237,Seropositivity for lactobacillus phage (twist_95165),Phenotype,Seropositivity for lactobacillus phage (twist_95165)
52238,Seropositivity for lactobacillus phage LFEINF peptide (twist_99693),Phenotype,Seropositivity for lactobacillus phage LFEINF peptide (twist_99693)
52239,Seropositivity for lactobacillus phage LFEINF peptide (twist_88894),Phenotype,Seropositivity for lactobacillus phage LFEINF peptide (twist_88894)
52242,Seropositivity for staphylococcus aureus subsp. aureus MW2 peptide (agilent_235512),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MW2 peptide (agilent_235512)
52244,Seropositivity for streptococcus pneumoniae peptide (twist_39967),Phenotype,Seropositivity for streptococcus pneumoniae peptide (twist_39967)
52246,Seropositivity for streptococcus pneumoniae peptide (agilent_6963),Phenotype,Seropositivity for streptococcus pneumoniae peptide (agilent_6963)
52249,Seropositivity for streptococcus pneumoniae peptide (twist_34196),Phenotype,Seropositivity for streptococcus pneumoniae peptide (twist_34196)
52251,Seropositivity for streptococcus pneumoniae peptide (twist_54623),Phenotype,Seropositivity for streptococcus pneumoniae peptide (twist_54623)
52256,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_142700),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_142700)
52258,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_171284),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_171284)
52260,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_15630),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_15630)
52263,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_16154),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_16154)
52265,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_188441),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_188441)
52270,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_79076),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_79076)
52273,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_90420),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_90420)
52276,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_62056),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_62056)
52279,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_96214),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_96214)
52280,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_49012),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_49012)
52281,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_198671),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_198671)
52283,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_217792),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_217792)
52285,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_202443),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_202443)
52286,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_24484),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_24484)
52287,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_174905),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_174905)
52288,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_171144),Phenotype,Seropositivity for staphylococcus aureus subsp. aureus MRSA252 peptide (agilent_171144)
52292,Seropositivity for haemophilus parainfluenzae T3T1 peptide (agilent_88528),Phenotype,Seropositivity for haemophilus parainfluenzae T3T1 peptide (agilent_88528)
52294,Seropositivity for human peptide (twist_18247),Phenotype,Seropositivity for human peptide (twist_18247)
52296,Seropositivity for human huntingtin peptide (twist_34234),Phenotype,Seropositivity for human huntingtin peptide (twist_34234)
52297,Seropositivity for human twist-related protein 1 peptide (twist_46270),Phenotype,Seropositivity for human twist-related protein 1 peptide (twist_46270)
52299,Seropositivity for human peptide (twist_55461),Phenotype,Seropositivity for human peptide (twist_55461)
52301,Seropositivity for ruminococcus bromii peptide (agilent_106172),Phenotype,Seropositivity for ruminococcus bromii peptide (agilent_106172)
52303,Seropositivity for ruminococcus torques (agilent_153754),Phenotype,Seropositivity for ruminococcus torques (agilent_153754)
52304,Seropositivity for secale cereale (rye) peptide (twist_23370),Phenotype,Seropositivity for secale cereale (rye) peptide (twist_23370)
52305,Seropositivity for salmonella phage felixo1 peptide (twist_85996),Phenotype,Seropositivity for salmonella phage felixo1 peptide (twist_85996)
52307,Seropositivity for shigella flexneri 2a str. 301 peptide (agilent_182601),Phenotype,Seropositivity for shigella flexneri 2a str. 301 peptide (agilent_182601)
52310,Seropositivity (peptide co-occurrence module 19: pathobion-- phages),Phenotype,Seropositivity (peptide co-occurrence module 19: pathobion-- phages)
52313,Seropositivity (peptide co-occurrence module 21: plant thionins),Phenotype,Seropositivity (peptide co-occurrence module 21: plant thionins)
52315,Seropositivity (peptide co-occurrence module 22: bacteria-- phage-- allergen),Phenotype,Seropositivity (peptide co-occurrence module 22: bacteria-- phage-- allergen)
52317,Seropositivity for haemophilus influenzae peptide (agilent_224288),Phenotype,Seropositivity for haemophilus influenzae peptide (agilent_224288)
52319,Seropositivity for haemophilus parainfluenzae T3T1 peptide (agilent_32597),Phenotype,Seropositivity for haemophilus parainfluenzae T3T1 peptide (agilent_32597)
52322,Seropositivity for root peptide (agilent_201897),Phenotype,Seropositivity for root peptide (agilent_201897)
52324,Seropositivity for triticum aestivum wheat peptide (twist_41103),Phenotype,Seropositivity for triticum aestivum wheat peptide (twist_41103)
52325,Seropositivity for triticum aestivum (common wheat) peptide (twist_14325),Phenotype,Seropositivity for triticum aestivum (common wheat) peptide (twist_14325)
52327,Seropositivity for triticum urartu (wild einkorn wheat) peptide (twist_11627),Phenotype,Seropositivity for triticum urartu (wild einkorn wheat) peptide (twist_11627)
52330,Seropositivity for triticum monococcum (einkorn wheat) peptide (twist_2100),Phenotype,Seropositivity for triticum monococcum (einkorn wheat) peptide (twist_2100)
52331,Seropositivity for triticum urartu (wild einkorn wheat) peptide (twist_12614),Phenotype,Seropositivity for triticum urartu (wild einkorn wheat) peptide (twist_12614)
52333,Seropositivity (peptide co-occurrence module 1: CMV-- (others)),Phenotype,Seropositivity (peptide co-occurrence module 1: CMV-- (others))
52335,Seropositivity (peptide co-occurrence module 5: bacteria-- phage-- autoantigens),Phenotype,Seropositivity (peptide co-occurrence module 5: bacteria-- phage-- autoantigens)
52336,Seropositivity (peptide co-occurrence module 12: H. pylori-- for phages)),Phenotype,Seropositivity (peptide co-occurrence module 12: H. pylori-- for phages))
52338,Seropositivity (peptide co-occurrence module 13: ABC transporters -- ATP-binding proteins),Phenotype,Seropositivity (peptide co-occurrence module 13: ABC transporters -- ATP-binding proteins)
52339,Seropositivity (peptide co-occurrence module 14: Enterovirus),Phenotype,Seropositivity (peptide co-occurrence module 14: Enterovirus)
52340,Seropositivity for meleagris gallopavo (turkey) peptide (twist_3824),Phenotype,Seropositivity for meleagris gallopavo (turkey) peptide (twist_3824)
52342,Seropositivity for oryza sativa (rice) peptide (twist_19685),Phenotype,Seropositivity for oryza sativa (rice) peptide (twist_19685)
52344,Seropositivity for ovis aries (sheep) peptide (twist_23154),Phenotype,Seropositivity for ovis aries (sheep) peptide (twist_23154)
52346,Seropositivity for staphylococcus aureus peptide (twist_30077),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_30077)
52347,Seropositivity for staphylococcus aureus peptide (twist_26858),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_26858)
52348,Seropositivity for staphylococcus aureus peptide (agilent_7803),Phenotype,Seropositivity for staphylococcus aureus peptide (agilent_7803)
52349,Seropositivity for staphylococcus aureus peptide (twist_42091),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_42091)
52350,Seropositivity for staphylococcus aureus clumping factor b peptide (agilent_6129),Phenotype,Seropositivity for staphylococcus aureus clumping factor b peptide (agilent_6129)
52351,Seropositivity for staphylococcaceae peptide (agilent_7434),Phenotype,Seropositivity for staphylococcaceae peptide (agilent_7434)
52352,Seropositivity for staphylococcus aureus peptide (twist_34104),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_34104)
52353,Seropositivity for staphylococcus aureus peptide (twist_26221),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_26221)
52355,Seropositivity for japanese encephalitis virus peptide (agilent_9991),Phenotype,Seropositivity for japanese encephalitis virus peptide (agilent_9991)
52356,Seropositivity for japanese encephalitis virus peptide (twist_57308),Phenotype,Seropositivity for japanese encephalitis virus peptide (twist_57308)
52357,Seropositivity for klebsiella phage peptide (twist_64561),Phenotype,Seropositivity for klebsiella phage peptide (twist_64561)
52358,Seropositivity for meleagris gallopavo (turkey) peptide (twist_1792),Phenotype,Seropositivity for meleagris gallopavo (turkey) peptide (twist_1792)
52362,Seropositivity for staphylococcus aureus peptide (twist_35030),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_35030)
52364,Seropositivity for staphylococcus aureus peptide (twist_44831),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_44831)
52365,Seropositivity for staphylococcus aureus peptide (twist_46764),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_46764)
52367,Seropositivity for staphylococcus aureus peptide (twist_38332),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_38332)
52368,Seropositivity for staphylococcus aureus peptide (twist_38683),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_38683)
52372,Seropositivity for staphylococcus aureus peptide (twist_27464),Phenotype,Seropositivity for staphylococcus aureus peptide (twist_27464)
52374,Seropositivity for staphylococcaceae peptide (agilent_4825),Phenotype,Seropositivity for staphylococcaceae peptide (agilent_4825)
52375,Seropositivity for staphylococcaceae peptide (agilent_11147),Phenotype,Seropositivity for staphylococcaceae peptide (agilent_11147)
52376,Seropositivity for staphylococcaceae peptide (agilent_1726),Phenotype,Seropositivity for staphylococcaceae peptide (agilent_1726)
52379,Seropositivity for plasmodium falciparum peptide (twist_49209),Phenotype,Seropositivity for plasmodium falciparum peptide (twist_49209)
52380,Seropositivity for human poliovirus peptide (twist_51547),Phenotype,Seropositivity for human poliovirus peptide (twist_51547)
52382,Seropositivity for porphyromonas gingivalis peptide (twist_38172),Phenotype,Seropositivity for porphyromonas gingivalis peptide (twist_38172)
52384,Seropositivity for human alphaherpesvirus 2 peptide (twist_42886),Phenotype,Seropositivity for human alphaherpesvirus 2 peptide (twist_42886)
52385,Seropositivity for human herpesvirus 1 peptide (agilent_3614),Phenotype,Seropositivity for human herpesvirus 1 peptide (agilent_3614)
52386,Seropositivity for human betaherpesvirus 5 (cytomegalovirus) peptide (twist_36146),Phenotype,Seropositivity for human betaherpesvirus 5 (cytomegalovirus) peptide (twist_36146)
52388,Seropositivity for human betaherpesvirus 5 (cytomegalovirus) peptide (twist_35647),Phenotype,Seropositivity for human betaherpesvirus 5 (cytomegalovirus) peptide (twist_35647)
52389,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_26954),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_26954)
52391,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_43798),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_43798)
52392,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_38776),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_38776)
52394,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_58154),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_58154)
52395,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_2111),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (agilent_2111)
52397,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27988),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27988)
52399,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_32572),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_32572)
52400,Seropositivity for bos taurus peptide (twist_36969),Phenotype,Seropositivity for bos taurus peptide (twist_36969)
52401,Seropositivity for bacteria peptide (agilent_8927),Phenotype,Seropositivity for bacteria peptide (agilent_8927)
52402,Seropositivity for bacteria peptide (agilent_6224),Phenotype,Seropositivity for bacteria peptide (agilent_6224)
52405,Seropositivity for lactobacillus phage LFEINF peptide (twist_64023),Phenotype,Seropositivity for lactobacillus phage LFEINF peptide (twist_64023)
52417,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_36361),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_36361)
52420,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_53018),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_53018)
52422,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27542),Phenotype,Seropositivity for human gammaherpesvirus 4 (Epstein-Barr virus) peptide (twist_27542)
52426,Seropositivity for bacteria peptide (agilent_9701),Phenotype,Seropositivity for bacteria peptide (agilent_9701)
52427,Seropositivity for human mastadenovirus peptide (agilent_9680),Phenotype,Seropositivity for human mastadenovirus peptide (agilent_9680)
52428,Seropositivity for human mastadenovirus peptide (agilent_329),Phenotype,Seropositivity for human mastadenovirus peptide (agilent_329)
52431,Seropositivity for mycobacterium tuberculosis peptide (agilent_2469),Phenotype,Seropositivity for mycobacterium tuberculosis peptide (agilent_2469)
52432,Seropositivity for mycobacterium tuberculosis peptide (twist_52112),Phenotype,Seropositivity for mycobacterium tuberculosis peptide (twist_52112)
52434,Seropositivity for mycobacterium tuberculosis peptide (agilent_10341),Phenotype,Seropositivity for mycobacterium tuberculosis peptide (agilent_10341)
52436,Seropositivity for bos taurus peptide (twist_33039),Phenotype,Seropositivity for bos taurus peptide (twist_33039)
52438,Seropositivity for bacteria peptide (agilent_240644),Phenotype,Seropositivity for bacteria peptide (agilent_240644)
52439,Seropositivity for bacteria peptide (agilent_225414),Phenotype,Seropositivity for bacteria peptide (agilent_225414)
52440,Seropositivity for bacteria peptide (agilent_220708),Phenotype,Seropositivity for bacteria peptide (agilent_220708)
52442,Seropositivity for bacteria peptide (agilent_241029),Phenotype,Seropositivity for bacteria peptide (agilent_241029)
52443,Seropositivity for lactobacillus phage phig1e peptide (twist_69609),Phenotype,Seropositivity for lactobacillus phage phig1e peptide (twist_69609)
52445,Seropositivity for lactococcus phage BIL285 peptide (twist_64633),Phenotype,Seropositivity for lactococcus phage BIL285 peptide (twist_64633)
52447,Seropositivity for listeria monocytogenes peptide (agilent_169153),Phenotype,Seropositivity for listeria monocytogenes peptide (agilent_169153)
52448,Seropositivity for listeria monocytogenes peptide (twist_41490),Phenotype,Seropositivity for listeria monocytogenes peptide (twist_41490)
52449,Seropositivity for listeria monocytogenes peptide (agilent_118201),Phenotype,Seropositivity for listeria monocytogenes peptide (agilent_118201)
52450,Seropositivity for listeria phage 2389 peptide (twist_76871),Phenotype,Seropositivity for listeria phage 2389 peptide (twist_76871)
52452,Glutamic oxaloacetic transaminase levels,Phenotype,Glutamic oxaloacetic transaminase levels
52455,COVID-19 (covid pneumonia vs population),Phenotype,COVID-19 (covid pneumonia vs population)
52457,COVID-19 (covid vs negative),Phenotype,COVID-19 (covid vs negative)
52459,COVID-19 (hospitalized covid vs population),Phenotype,COVID-19 (hospitalized covid vs population)
52467,Human milk oligosaccharide concentration (lacto-N-fucopentaose III),Phenotype,Human milk oligosaccharide concentration (lacto-N-fucopentaose III)
52470,Human milk oligosaccharide concentration (lacto-N-fucopentaose III) in non-secretors,Phenotype,Human milk oligosaccharide concentration (lacto-N-fucopentaose III) in non-secretors
52473,Platelet count during  first trimester of pregnancy,Phenotype,Platelet count during  first trimester of pregnancy
52490,Postprandial total cholesterol in HDL2,Phenotype,Postprandial total cholesterol in HDL2
52491,Postprandial total cholesterol in HDL3,Phenotype,Postprandial total cholesterol in HDL3
52492,Postprandial total cholesterol in HDL,Phenotype,Postprandial total cholesterol in HDL
52493,Postprandial apolipoprotein A-I,Phenotype,Postprandial apolipoprotein A-I
52494,Postprandial mean diameter of HDL particles,Phenotype,Postprandial mean diameter of HDL particles
52495,Low testosterone levels,Phenotype,Low testosterone levels
52496,Mean platelet volume during second trimester of pregnancy,Phenotype,Mean platelet volume during second trimester of pregnancy
52505,Motor coordination,Phenotype,Motor coordination
52506,Perceptual and visual search speed (trail making test A),Phenotype,Perceptual and visual search speed (trail making test A)
52509,Disability level (impaired activities of daily living),Phenotype,Disability level (impaired activities of daily living)
52511,Global cognition (Clinical Dementia Rating Scale Sum of Boxes),Phenotype,Global cognition (Clinical Dementia Rating Scale Sum of Boxes)
52517,Cognitive impairment level,Phenotype,Cognitive impairment level
52519,Postprandial serum total triglycerides,Phenotype,Postprandial serum total triglycerides
52521,Progression free survival in epithelial ovarian cancer,Phenotype,Progression free survival in epithelial ovarian cancer
52532,Platelet count during  third trimester of pregnancy,Phenotype,Platelet count during  third trimester of pregnancy
52535,Platelet count at delivery,Phenotype,Platelet count at delivery
52536,Platelet count during  postpartum period,Phenotype,Platelet count during  postpartum period
52545,Gestational thrombocytopenia,Phenotype,Gestational thrombocytopenia
52559,Response to buprenorphine in opioid use disorder,Phenotype,Response to buprenorphine in opioid use disorder
52561,Postprandial total cholesterol in large VLDL,Phenotype,Postprandial total cholesterol in large VLDL
52562,Postprandial mean diameter of LDL particles,Phenotype,Postprandial mean diameter of LDL particles
52563,Postprandial total cholesterol in large HDL,Phenotype,Postprandial total cholesterol in large HDL
52564,Postprandial cholesterol esters in large HDL,Phenotype,Postprandial cholesterol esters in large HDL
52565,Postprandial cholesterol esters in medium HDL,Phenotype,Postprandial cholesterol esters in medium HDL
52566,Postprandial free cholesterol in medium HDL,Phenotype,Postprandial free cholesterol in medium HDL
52567,Postprandial total lipids in medium HDL,Phenotype,Postprandial total lipids in medium HDL
52568,Postprandial medium HDL particle concentration,Phenotype,Postprandial medium HDL particle concentration
52569,Postprandial phospholipid levels in medium HDL,Phenotype,Postprandial phospholipid levels in medium HDL
52570,Postprandial triglycerides levels in medium HDL,Phenotype,Postprandial triglycerides levels in medium HDL
52571,Postprandial free cholesterol in large VLDL,Phenotype,Postprandial free cholesterol in large VLDL
52572,Postprandial total lipids in large VLDL,Phenotype,Postprandial total lipids in large VLDL
52573,Postprandial large VLDL particle concentration,Phenotype,Postprandial large VLDL particle concentration
52574,Postprandial phospholipid levels in large VLDL,Phenotype,Postprandial phospholipid levels in large VLDL
52575,Postprandial total cholesterol in medium HDL,Phenotype,Postprandial total cholesterol in medium HDL
52576,Postprandial free cholesterol in large HDL,Phenotype,Postprandial free cholesterol in large HDL
52577,Postprandial total lipids in large HDL,Phenotype,Postprandial total lipids in large HDL
52578,Postprandial large HDL particle concentration,Phenotype,Postprandial large HDL particle concentration
52579,Postprandial phospholipid levels in large HDL,Phenotype,Postprandial phospholipid levels in large HDL
52580,Postprandial triglycerides levels in large HDL,Phenotype,Postprandial triglycerides levels in large HDL
52581,Postprandial free cholesterol in medium VLDL,Phenotype,Postprandial free cholesterol in medium VLDL
52582,Anxious temperament,Phenotype,Anxious temperament
52584,Hyperthymic temperament,Phenotype,Hyperthymic temperament
52586,Platelet count during  second trimester of pregnancy,Phenotype,Platelet count during  second trimester of pregnancy
52601,Fasting total cholesterol in small VLDL,Phenotype,Fasting total cholesterol in small VLDL
52602,Fasting cholesterol esters in small VLDL,Phenotype,Fasting cholesterol esters in small VLDL
52603,Fasting triglycerides levels in small HDL,Phenotype,Fasting triglycerides levels in small HDL
52604,Conotruncal heart defects with normally related great vessels in 22q.11.2 deletion syndrome,Phenotype,Conotruncal heart defects with normally related great vessels in 22q.11.2 deletion syndrome
52606,Conotruncal heart defects with normally related great vessels (without 22q.11.2 deletion syndrome),Phenotype,Conotruncal heart defects with normally related great vessels (without 22q.11.2 deletion syndrome)
52614,Conotruncal heart defects with normally related great vessels,Phenotype,Conotruncal heart defects with normally related great vessels
52617,Liver volume,Phenotype,Liver volume
52618,Spleen volume,Phenotype,Spleen volume
52631,Postprandial triglycerides levels in chylomicrons and extremely large VLDL,Phenotype,Postprandial triglycerides levels in chylomicrons and extremely large VLDL
52633,Fasting apolipoprotein A-I,Phenotype,Fasting apolipoprotein A-I
52634,Postprandial total cholesterol in chylomicrons and extremely large VLDL,Phenotype,Postprandial total cholesterol in chylomicrons and extremely large VLDL
52635,Postprandial free cholesterol in chylomicrons and extremely large VLDL,Phenotype,Postprandial free cholesterol in chylomicrons and extremely large VLDL
52636,Postprandial total lipids in chylomicrons and extremely large VLDL,Phenotype,Postprandial total lipids in chylomicrons and extremely large VLDL
52637,Postprandial chylomicrons and extremely large VLDL particle concentration,Phenotype,Postprandial chylomicrons and extremely large VLDL particle concentration
52638,Postprandial phospholipid levels in chylomicrons and extremely large VLDL,Phenotype,Postprandial phospholipid levels in chylomicrons and extremely large VLDL
52639,Fasting total cholesterol in HDL2,Phenotype,Fasting total cholesterol in HDL2
52640,Fasting total cholesterol in HDL3,Phenotype,Fasting total cholesterol in HDL3
52641,Fasting total cholesterol in HDL,Phenotype,Fasting total cholesterol in HDL
52642,Fasting mean diameter of HDL particles,Phenotype,Fasting mean diameter of HDL particles
52643,Left atrial active emptying fraction,Phenotype,Left atrial active emptying fraction
52645,Psychosis in Alzheimer's disease,Phenotype,Psychosis in Alzheimer's disease
52654,Cluster headache,Phenotype,Cluster headache
52655,Fasting lactate,Phenotype,Fasting lactate
52657,Fasting total cholesterol in large HDL,Phenotype,Fasting total cholesterol in large HDL
52658,Fasting cholesterol esters in large HDL,Phenotype,Fasting cholesterol esters in large HDL
52659,Fasting free cholesterol in large HDL,Phenotype,Fasting free cholesterol in large HDL
52660,Fasting total lipids in large HDL,Phenotype,Fasting total lipids in large HDL
52661,Fasting large HDL particle concentration,Phenotype,Fasting large HDL particle concentration
52662,Relative brain age,Phenotype,Relative brain age
52668,Human milk oligosaccharide concentration (lacto-N-fucopentaose III) in secretors,Phenotype,Human milk oligosaccharide concentration (lacto-N-fucopentaose III) in secretors
52670,Fasting phospholipid levels in large HDL,Phenotype,Fasting phospholipid levels in large HDL
52671,Fasting triglycerides levels in large HDL,Phenotype,Fasting triglycerides levels in large HDL
52672,Fasting phospholipid levels in medium HDL,Phenotype,Fasting phospholipid levels in medium HDL
52673,Fasting triglycerides levels in medium HDL,Phenotype,Fasting triglycerides levels in medium HDL
52674,Fasting total cholesterol in medium HDL,Phenotype,Fasting total cholesterol in medium HDL
52675,Fasting cholesterol esters in medium HDL,Phenotype,Fasting cholesterol esters in medium HDL
52676,Fasting free cholesterol in medium HDL,Phenotype,Fasting free cholesterol in medium HDL
52677,Fasting total lipids in medium HDL,Phenotype,Fasting total lipids in medium HDL
52678,Fasting medium HDL particle concentration,Phenotype,Fasting medium HDL particle concentration
52679,Urgency urinary incontinence,Phenotype,Urgency urinary incontinence
52688,Oral glucose tolerance test-1h,Phenotype,Oral glucose tolerance test-1h
52690,Gestational diabetes mellitus,Phenotype,Gestational diabetes mellitus
52691,Oral glucose tolerance test-0h,Phenotype,Oral glucose tolerance test-0h
52693,Oral glucose tolerance test-2h,Phenotype,Oral glucose tolerance test-2h
52714,Glycated hemoglobin HbA1c levels,Phenotype,Glycated hemoglobin HbA1c levels
52716,hemolysis of donated blood (osmotic),Phenotype,hemolysis of donated blood (osmotic)
52717,Bullous pemphigoid,Phenotype,Bullous pemphigoid
52718,Intralaminar thalamic nuclei volume,Phenotype,Intralaminar thalamic nuclei volume
52719,Medial thalamic nuclei volume,Phenotype,Medial thalamic nuclei volume
52720,Posterior thalamic nuclei volume,Phenotype,Posterior thalamic nuclei volume
52721,Lateral thalamic nuclei volume,Phenotype,Lateral thalamic nuclei volume
52740,Hemoglobin levels in non-alcoholic fatty liver disease x mastiha supplementation interaction,Phenotype,Hemoglobin levels in non-alcoholic fatty liver disease x mastiha supplementation interaction
52741,Interleukin-10 levels in non-alcoholic fatty liver disease x mastiha supplementation interaction,Phenotype,Interleukin-10 levels in non-alcoholic fatty liver disease x mastiha supplementation interaction
52742,Heel bone mineral density x serum urate levels interaction,Phenotype,Heel bone mineral density x serum urate levels interaction
52743,Major depressive disorder (MTAG),Phenotype,Major depressive disorder (MTAG)
52748,L1-L4 bone mineral density x serum urate levels interaction,Phenotype,L1-L4 bone mineral density x serum urate levels interaction
52757,Body size (confirmatory factor analysis Factor 21),Phenotype,Body size (confirmatory factor analysis Factor 21)
52767,Basal ganglia structure,Phenotype,Basal ganglia structure
52774,FEV1 or inflammatory bowel disease (pleiotropy),Phenotype,FEV1 or inflammatory bowel disease (pleiotropy)
52777,FEV1 or irritable bowel syndrome (pleiotropy),Phenotype,FEV1 or irritable bowel syndrome (pleiotropy)
52782,FVC or peptic ulcer disease (pleiotropy),Phenotype,FVC or peptic ulcer disease (pleiotropy)
52784,FVC or inflammatory bowel disease (pleiotropy),Phenotype,FVC or inflammatory bowel disease (pleiotropy)
52786,FVC or irritable bowel syndrome (pleiotropy),Phenotype,FVC or irritable bowel syndrome (pleiotropy)
52788,FVC or gastro-oesophageal reflux disease (pleiotropy),Phenotype,FVC or gastro-oesophageal reflux disease (pleiotropy)
52790,FEV1/FVC or irritable bowel syndrome (pleiotropy),Phenotype,FEV1/FVC or irritable bowel syndrome (pleiotropy)
52801,Alkaline phosphatase levels,Phenotype,Alkaline phosphatase levels
52824,Phosphate levels,Phenotype,Phosphate levels
52833,Anxiety disorder,Phenotype,Anxiety disorder
52836,FEV1 or gastro-oesophageal reflux disease (pleiotropy),Phenotype,FEV1 or gastro-oesophageal reflux disease (pleiotropy)
52837,FEV1 or peptic ulcer disease (pleiotropy),Phenotype,FEV1 or peptic ulcer disease (pleiotropy)
52844,FEV1/FVC or peptic ulcer disease (pleiotropy),Phenotype,FEV1/FVC or peptic ulcer disease (pleiotropy)
52847,FEV1/FVC or gastro-oesophageal reflux disease (pleiotropy),Phenotype,FEV1/FVC or gastro-oesophageal reflux disease (pleiotropy)
52850,FEV1/FVC or inflammatory bowel disease (pleiotropy),Phenotype,FEV1/FVC or inflammatory bowel disease (pleiotropy)
52861,Erythrocyte sedimentation rate,Phenotype,Erythrocyte sedimentation rate
52874,Anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) IgG levels (truncated),Phenotype,Anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) IgG levels (truncated)
52875,Anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) IgG levels (peptide),Phenotype,Anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) IgG levels (peptide)
52878,Cerebrospinal fluid soluble TREM2 levels,Phenotype,Cerebrospinal fluid soluble TREM2 levels
52888,Serum potassium levels,Phenotype,Serum potassium levels
52889,Serum sodium levels,Phenotype,Serum sodium levels
52891,T4 levels,Phenotype,T4 levels
52892,Total protein levels,Phenotype,Total protein levels
52894,Myocardial infarction (PheCode 411.2),Phenotype,Myocardial infarction (PheCode 411.2)
52895,Coronary atherosclerosis (PheCode 411.4),Phenotype,Coronary atherosclerosis (PheCode 411.4)
52896,Ulcerative colitis (PheCode 555.2),Phenotype,Ulcerative colitis (PheCode 555.2)
52897,Celiac disease (PheCode 557.1),Phenotype,Celiac disease (PheCode 557.1)
52900,Platelet response to aspirin,Phenotype,Platelet response to aspirin
52916,Seropositivity for bacteroides peptide (agilent_153971),Phenotype,Seropositivity for bacteroides peptide (agilent_153971)
52918,Seropositivity for anser anser (greylag goose) peptide (twist_23199),Phenotype,Seropositivity for anser anser (greylag goose) peptide (twist_23199)
52920,Familial combined hyperlipidemia defined by Consensus criteria,Phenotype,Familial combined hyperlipidemia defined by Consensus criteria
52922,Seropositivity for klebsiella phage peptide (twist_73875),Phenotype,Seropositivity for klebsiella phage peptide (twist_73875)
52924,Familial combined hyperlipidemia defined by Dutch criteria,Phenotype,Familial combined hyperlipidemia defined by Dutch criteria
52925,Seropositivity for bacteroides peptide (agilent_161799),Phenotype,Seropositivity for bacteroides peptide (agilent_161799)
52926,Seropositivity for bacteroides peptide (agilent_170659),Phenotype,Seropositivity for bacteroides peptide (agilent_170659)
52929,Seropositivity for bacilli peptide (agilent_5601),Phenotype,Seropositivity for bacilli peptide (agilent_5601)
52930,Seropositivity for bacilli peptide (agilent_236678),Phenotype,Seropositivity for bacilli peptide (agilent_236678)
52932,Seropositivity for streptococcus phage peptide (twist_76831),Phenotype,Seropositivity for streptococcus phage peptide (twist_76831)
52934,Seropositivity for capra hircus (goat) peptide (twist_20844),Phenotype,Seropositivity for capra hircus (goat) peptide (twist_20844)
52935,Seropositivity for clostridiales peptide (agilent_205050),Phenotype,Seropositivity for clostridiales peptide (agilent_205050)
52938,Seropositivity for clostridium perfringens (agilent_61837),Phenotype,Seropositivity for clostridium perfringens (agilent_61837)
52940,Seropositivity for clostridiales peptide (agilent_68956),Phenotype,Seropositivity for clostridiales peptide (agilent_68956)
52944,Seropositivity for clostridium perfringens peptide (agilent_231580),Phenotype,Seropositivity for clostridium perfringens peptide (agilent_231580)
52946,Seropositivity for clostridium perfringens (agilent_107181),Phenotype,Seropositivity for clostridium perfringens (agilent_107181)
52947,Seropositivity for clostridium perfringens (agilent_167207),Phenotype,Seropositivity for clostridium perfringens (agilent_167207)
52949,Seropositivity for coxsackievirus peptide (twist_47443),Phenotype,Seropositivity for coxsackievirus peptide (twist_47443)
52951,Seropositivity for dorea formicigenerans (agilent_198014),Phenotype,Seropositivity for dorea formicigenerans (agilent_198014)
52953,Seropositivity for clostridiales peptide (agilent_56881),Phenotype,Seropositivity for clostridiales peptide (agilent_56881)
52955,Gallbladder cholecystitis,Phenotype,Gallbladder cholecystitis
52965,Two-hour glucose,Phenotype,Two-hour glucose
52968,Hypertension (confirmatory factor analysis Factor 12),Phenotype,Hypertension (confirmatory factor analysis Factor 12)
52977,Telangiectasia (>= grade 1) in breast cancer treated with radiotherapy,Phenotype,Telangiectasia (>= grade 1) in breast cancer treated with radiotherapy
52980,Joint pain (confirmatory factor analysis Factor 14),Phenotype,Joint pain (confirmatory factor analysis Factor 14)
52986,Coronary artery disease (confirmatory factor analysis Factor 16),Phenotype,Coronary artery disease (confirmatory factor analysis Factor 16)
52987,Chronic pain (confirmatory factor analysis Factor 18),Phenotype,Chronic pain (confirmatory factor analysis Factor 18)
52988,Bone density (confirmatory factor analysis Factor 19),Phenotype,Bone density (confirmatory factor analysis Factor 19)
53001,Fasting insulin z-score (<15th percentile),Phenotype,Fasting insulin z-score (<15th percentile)
53003,Fasting insulin z-score (<25th percentile),Phenotype,Fasting insulin z-score (<25th percentile)
53007,Fasting insulin z-score (>50th percentile),Phenotype,Fasting insulin z-score (>50th percentile)
53009,Fasting insulin z-score (>85th percentile),Phenotype,Fasting insulin z-score (>85th percentile)
53012,Placental weight (fetal genotype-- adjusted for sex and gestational age),Phenotype,Placental weight (fetal genotype-- adjusted for sex and gestational age)
53020,Dementia,Phenotype,Dementia
53026,Handedness (left-handed vs. right-handed),Phenotype,Handedness (left-handed vs. right-handed)
53046,Placental weight (fetal genotype-- adjusted for sex),Phenotype,Placental weight (fetal genotype-- adjusted for sex)
53055,Vitamin B12 levels,Phenotype,Vitamin B12 levels
53060,Intraocular pressure (confirmatory factor analysis Factor 26),Phenotype,Intraocular pressure (confirmatory factor analysis Factor 26)
53061,Age-related eyesight deterioration (confirmatory factor analysis Factor 27),Phenotype,Age-related eyesight deterioration (confirmatory factor analysis Factor 27)
53067,Diabetes (confirmatory factor analysis Factor 28),Phenotype,Diabetes (confirmatory factor analysis Factor 28)
53070,Comfortable retirement (confirmatory factor analysis Factor 29),Phenotype,Comfortable retirement (confirmatory factor analysis Factor 29)
53072,Inflammatory markers and poor diet (confirmatory factor analysis Factor 30),Phenotype,Inflammatory markers and poor diet (confirmatory factor analysis Factor 30)
53076,Endometriosis or asthma (pleiotropy),Phenotype,Endometriosis or asthma (pleiotropy)
53081,Gastrointestinal issues (confirmatory factor analysis Factor 31),Phenotype,Gastrointestinal issues (confirmatory factor analysis Factor 31)
53084,Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35),Phenotype,Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35)
53086,Cognition and processing speed (confirmatory factor analysis Factor 34),Phenotype,Cognition and processing speed (confirmatory factor analysis Factor 34)
53089,Hearing (confirmatory factor analysis Factor 32),Phenotype,Hearing (confirmatory factor analysis Factor 32)
53101,Vitamin D insufficiency,Phenotype,Vitamin D insufficiency
53105,Physical activity (confirmatory factor analysis Factor 23),Phenotype,Physical activity (confirmatory factor analysis Factor 23)
53107,Eye autorefraction and astigmatism (confirmatory factor analysis Factor 24),Phenotype,Eye autorefraction and astigmatism (confirmatory factor analysis Factor 24)
53123,Esophageal atresia with or without tracheoesophageal fistula,Phenotype,Esophageal atresia with or without tracheoesophageal fistula
53125,Vascular dementia,Phenotype,Vascular dementia
53129,Urbanicity (confirmatory factor analysis Factor 4),Phenotype,Urbanicity (confirmatory factor analysis Factor 4)
53131,Occupation and workplace environment (confirmatory factor analysis Factor 5),Phenotype,Occupation and workplace environment (confirmatory factor analysis Factor 5)
53133,Smoking and associated risk behaviours (confirmatory factor analysis Factor 6),Phenotype,Smoking and associated risk behaviours (confirmatory factor analysis Factor 6)
53136,BMI and adiposity (confirmatory factor analysis Factor 7),Phenotype,BMI and adiposity (confirmatory factor analysis Factor 7)
53148,Trauma (confirmatory factor analysis Factor 9),Phenotype,Trauma (confirmatory factor analysis Factor 9)
53149,Educational attainment (confirmatory factor analysis Factor 10),Phenotype,Educational attainment (confirmatory factor analysis Factor 10)
53151,Respiratory disease (confirmatory factor analysis Factor 11),Phenotype,Respiratory disease (confirmatory factor analysis Factor 11)
53172,Amyloid beta standardized uptake value ratio (adjusted for APOE E4 count),Phenotype,Amyloid beta standardized uptake value ratio (adjusted for APOE E4 count)
53195,Alcohol consumption x experiences in childhood (felt loved by family member) interaction,Phenotype,Alcohol consumption x experiences in childhood (felt loved by family member) interaction
53197,Alcohol consumption x traumatic event in childhood (felt hated by family member) interaction,Phenotype,Alcohol consumption x traumatic event in childhood (felt hated by family member) interaction
53200,Smoking x experiences in childhood (felt loved by family member) interaction,Phenotype,Smoking x experiences in childhood (felt loved by family member) interaction
53202,Smoking x traumatic event in childhood (felt hated by family member) interaction,Phenotype,Smoking x traumatic event in childhood (felt hated by family member) interaction
53203,Smoking x traumatic event in childhood (sexually molested) interaction,Phenotype,Smoking x traumatic event in childhood (sexually molested) interaction
53207,Reduction in HbA1c levels in response to sulfonylureas treatment in type 2 diabetes,Phenotype,Reduction in HbA1c levels in response to sulfonylureas treatment in type 2 diabetes
53210,Physical activity (Total log acceleration 12am-2am),Phenotype,Physical activity (Total log acceleration 12am-2am)
53211,Physical activity (Total log acceleration 2am-4am),Phenotype,Physical activity (Total log acceleration 2am-4am)
53212,Physical activity (Total log acceleration 10pm-12am),Phenotype,Physical activity (Total log acceleration 10pm-12am)
53213,Major depressive disorder or stress-related disorder,Phenotype,Major depressive disorder or stress-related disorder
53267,Thrombin generation parameter (endogenous thrombin potential),Phenotype,Thrombin generation parameter (endogenous thrombin potential)
53269,Bevacizumab-induced composite toxicity (either hypertension or proteinuria),Phenotype,Bevacizumab-induced composite toxicity (either hypertension or proteinuria)
53272,Sociability score,Phenotype,Sociability score
53273,Phospholipids in IDL,Phenotype,Phospholipids in IDL
53276,Bipolar disorder or glomerular filtration rate estimated from creatine (MTAG),Phenotype,Bipolar disorder or glomerular filtration rate estimated from creatine (MTAG)
53277,Bipolar disorder or glomerular filtration rate estimated from cystatin (MTAG),Phenotype,Bipolar disorder or glomerular filtration rate estimated from cystatin (MTAG)
53280,Bipolar disorder or urinary albumin-to-creatinine ratio (MTAG),Phenotype,Bipolar disorder or urinary albumin-to-creatinine ratio (MTAG)
53282,Major depressive disorder or blood urea nitrogen levels (MTAG),Phenotype,Major depressive disorder or blood urea nitrogen levels (MTAG)
53283,Triglyceride levels in LDL,Phenotype,Triglyceride levels in LDL
53284,Mean diameter of LDL particles,Phenotype,Mean diameter of LDL particles
53289,Stable warfarin dose,Phenotype,Stable warfarin dose
53301,Triglycerides to total lipids ratio in large VLDL,Phenotype,Triglycerides to total lipids ratio in large VLDL
53302,Phospholipids in large VLDL,Phenotype,Phospholipids in large VLDL
53303,Phospholipids to total lipids ratio in large VLDL,Phenotype,Phospholipids to total lipids ratio in large VLDL
53304,Triglycerides in large VLDL,Phenotype,Triglycerides in large VLDL
53308,Cholesteryl esters to total lipids ratio in medium LDL,Phenotype,Cholesteryl esters to total lipids ratio in medium LDL
53309,Free cholesterol in medium LDL,Phenotype,Free cholesterol in medium LDL
53310,Cholesterol esters in medium LDL,Phenotype,Cholesterol esters in medium LDL
53311,Concentration of medium LDL particles,Phenotype,Concentration of medium LDL particles
53319,STAMBP protein levels,Phenotype,STAMBP protein levels
53321,LTA protein levels,Phenotype,LTA protein levels
53323,MMP10 protein levels,Phenotype,MMP10 protein levels
53325,CXCL8 protein levels,Phenotype,CXCL8 protein levels
53327,SULT1A1 protein levels,Phenotype,SULT1A1 protein levels
53330,SIRT2 protein levels,Phenotype,SIRT2 protein levels
53331,VEGFA protein levels,Phenotype,VEGFA protein levels
53332,BMI x meat diet interaction,Phenotype,BMI x meat diet interaction
53333,HDL-C x sedentary time interaction,Phenotype,HDL-C x sedentary time interaction
53341,Left atrial diameter,Phenotype,Left atrial diameter
53344,High-sensitivity cardiac troponin T levels,Phenotype,High-sensitivity cardiac troponin T levels
53354,High-density lipoprotein 3 cholesterol levels,Phenotype,High-density lipoprotein 3 cholesterol levels
53355,Clonal hematopoiesis (mutational barcode method),Phenotype,Clonal hematopoiesis (mutational barcode method)
53370,NT5E protein levels,Phenotype,NT5E protein levels
53373,TXLNA protein levels,Phenotype,TXLNA protein levels
53374,MSLN protein levels,Phenotype,MSLN protein levels
53376,MICA-MICB heterodimer protein levels,Phenotype,MICA-MICB heterodimer protein levels
53384,RSPO3 protein levels,Phenotype,RSPO3 protein levels
53386,Raynaud's syndrome,Phenotype,Raynaud's syndrome
53398,Acute myeloid leukemia (normal cytogenetics),Phenotype,Acute myeloid leukemia (normal cytogenetics)
53399,Seroconversion induced by one dose of COVID-19 vaccine,Phenotype,Seroconversion induced by one dose of COVID-19 vaccine
53400,Seroconversion induced by two doses of COVID-19 vaccine,Phenotype,Seroconversion induced by two doses of COVID-19 vaccine
53417,Total lipid levels in medium LDL,Phenotype,Total lipid levels in medium LDL
53423,ASCVD risk score (Systematic Coronary Risk Evaluation 2-Older People-Lipid scores),Phenotype,ASCVD risk score (Systematic Coronary Risk Evaluation 2-Older People-Lipid scores)
53434,Parkinson's disease (age of onset) x smoking interaction,Phenotype,Parkinson's disease (age of onset) x smoking interaction
53438,Phospholipids in medium LDL,Phenotype,Phospholipids in medium LDL
53449,GLO1 protein levels,Phenotype,GLO1 protein levels
53456,HAVCR1 protein levels,Phenotype,HAVCR1 protein levels
53458,CBLIF protein levels,Phenotype,CBLIF protein levels
53460,CA5A protein levels,Phenotype,CA5A protein levels
53462,THBS2 protein levels,Phenotype,THBS2 protein levels
53464,Type 2 diabetes mellitus adjusted for BMI or coronary artery disease (pleiotropy),Phenotype,Type 2 diabetes mellitus adjusted for BMI or coronary artery disease (pleiotropy)
53498,Education attainment or attention deficit hyperactivity disorder,Phenotype,Education attainment or attention deficit hyperactivity disorder
53500,Education attainment or autism spectrum disorders,Phenotype,Education attainment or autism spectrum disorders
53501,Education attainment or alcohol use disorders,Phenotype,Education attainment or alcohol use disorders
53502,Education attainment or bipolar disorder,Phenotype,Education attainment or bipolar disorder
53503,Education attainment or cannabis use disorder,Phenotype,Education attainment or cannabis use disorder
53504,Education attainment or tourette’s syndrome,Phenotype,Education attainment or tourette’s syndrome
53508,Type 2 diabetes mellitus or coronary artery disease (pleiotropy),Phenotype,Type 2 diabetes mellitus or coronary artery disease (pleiotropy)
53523,High-sensitivity cardiac troponin T levels (MTAG),Phenotype,High-sensitivity cardiac troponin T levels (MTAG)
53525,High-sensitivity cardiac troponin I concentration (MTAG),Phenotype,High-sensitivity cardiac troponin I concentration (MTAG)
53526,Serum aluminum levels,Phenotype,Serum aluminum levels
53528,Serum arsenic levels,Phenotype,Serum arsenic levels
53530,Serum barium levels,Phenotype,Serum barium levels
53535,Serum calcium levels,Phenotype,Serum calcium levels
53540,Total cholesterol in HDL3,Phenotype,Total cholesterol in HDL3
53541,Cholesterol esters in IDL,Phenotype,Cholesterol esters in IDL
53542,Total cholesterol to total lipids ratio in IDL,Phenotype,Total cholesterol to total lipids ratio in IDL
53546,Free cholesterol in IDL,Phenotype,Free cholesterol in IDL
53548,Free cholesterol in large HDL,Phenotype,Free cholesterol in large HDL
53553,Phospholipids in large LDL,Phenotype,Phospholipids in large LDL
53562,Triglycerides in large LDL,Phenotype,Triglycerides in large LDL
53563,Total cholesterol in HDL2,Phenotype,Total cholesterol in HDL2
53569,Total Cholesterol in IDL,Phenotype,Total Cholesterol in IDL
53570,Total cholesterol in large HDL,Phenotype,Total cholesterol in large HDL
53573,Triglycerides in large HDL,Phenotype,Triglycerides in large HDL
53574,Phospholipids in large HDL,Phenotype,Phospholipids in large HDL
53576,Intestinal Behcet's disease,Phenotype,Intestinal Behcet's disease
53579,Cholesterol esters in large VLDL,Phenotype,Cholesterol esters in large VLDL
53580,Total cholesterol to total lipids ratio in large VLDL,Phenotype,Total cholesterol to total lipids ratio in large VLDL
53581,Free cholesterol in large VLDL,Phenotype,Free cholesterol in large VLDL
53586,Triglycerides to total lipids ratio in medium HDL,Phenotype,Triglycerides to total lipids ratio in medium HDL
53587,Phospholipids to total lipids ratio in medium HDL,Phenotype,Phospholipids to total lipids ratio in medium HDL
53588,Phospholipids in medium HDL,Phenotype,Phospholipids in medium HDL
53591,Triglycerides in medium HDL,Phenotype,Triglycerides in medium HDL
53598,Rectum and left colon stage I/II/IV colorectal cancer (metastasis vs no metastasis),Phenotype,Rectum and left colon stage I/II/IV colorectal cancer (metastasis vs no metastasis)
53600,Triglycerides in IDL,Phenotype,Triglycerides in IDL
53603,Major depressive disorder or glomerular filtration rate estimated from creatine (MTAG),Phenotype,Major depressive disorder or glomerular filtration rate estimated from creatine (MTAG)
53608,Major depressive disorder or glomerular filtration rate estimated from cystatin (MTAG),Phenotype,Major depressive disorder or glomerular filtration rate estimated from cystatin (MTAG)
53628,Total lipids in large VLDL,Phenotype,Total lipids in large VLDL
53629,Total cholesterol to total lipids ratio in medium LDL,Phenotype,Total cholesterol to total lipids ratio in medium LDL
53630,Total cholesterol in medium LDL,Phenotype,Total cholesterol in medium LDL
53635,Free cholesterol levels,Phenotype,Free cholesterol levels
53637,Glycoprotein acetylation,Phenotype,Glycoprotein acetylation
53647,Total lipids in large HDL,Phenotype,Total lipids in large HDL
53648,Mosaic loss of chromosome X,Phenotype,Mosaic loss of chromosome X
53673,Total Cholesterol in large VLDL,Phenotype,Total Cholesterol in large VLDL
53675,Free cholesterol to total lipids ratio in medium HDL,Phenotype,Free cholesterol to total lipids ratio in medium HDL
53676,Total lipids in medium HDL,Phenotype,Total lipids in medium HDL
53677,Free cholesterol in medium HDL,Phenotype,Free cholesterol in medium HDL
53690,Total lipids in IDL,Phenotype,Total lipids in IDL
53693,Cholesterol esters in large HDL,Phenotype,Cholesterol esters in large HDL
53694,Total cholesterol to total lipids ratio in large HDL,Phenotype,Total cholesterol to total lipids ratio in large HDL
53711,Cholesterol esters in large LDL,Phenotype,Cholesterol esters in large LDL
53712,Free cholesterol in large LDL,Phenotype,Free cholesterol in large LDL
53713,Total lipids in large LDL,Phenotype,Total lipids in large LDL
53717,Mean diameter of HDL particles,Phenotype,Mean diameter of HDL particles
53719,Total cholesterol levels in LDL,Phenotype,Total cholesterol levels in LDL
53720,Ratio of 18:2 linoleic acid to total fatty acids,Phenotype,Ratio of 18:2 linoleic acid to total fatty acids
53722,Linoleic acid (18:2) levels,Phenotype,Linoleic acid (18:2) levels
53730,Total cholesterol in large LDL,Phenotype,Total cholesterol in large LDL
53731,Total cholesterol to total lipids ratio in large LDL,Phenotype,Total cholesterol to total lipids ratio in large LDL
53740,Total cholesterol levels in medium HDL,Phenotype,Total cholesterol levels in medium HDL
53741,Total cholesterol to total lipids ratio in medium HDL,Phenotype,Total cholesterol to total lipids ratio in medium HDL
53744,Cholesterol esters in medium HDL,Phenotype,Cholesterol esters in medium HDL
53745,Cholesteryl esters to total lipids ratio in medium HDL,Phenotype,Cholesteryl esters to total lipids ratio in medium HDL
53747,Plasma factor V levels (parent of origin effect) x rs75463553 interaction,Phenotype,Plasma factor V levels (parent of origin effect) x rs75463553 interaction
53751,Free cholesterol to total lipids ratio in medium LDL,Phenotype,Free cholesterol to total lipids ratio in medium LDL
53752,Coronary artery disease or factor VIII levels (pleiotropy),Phenotype,Coronary artery disease or factor VIII levels (pleiotropy)
53760,Skeletal age,Phenotype,Skeletal age
53764,Free cholesterol in very large HDL,Phenotype,Free cholesterol in very large HDL
53765,Total lipids in very large HDL,Phenotype,Total lipids in very large HDL
53776,Urticaria,Phenotype,Urticaria
53782,Phospholipids in small VLDL,Phenotype,Phospholipids in small VLDL
53783,Acute radiotoxicity in cancer (adjusted for clinical covariates),Phenotype,Acute radiotoxicity in cancer (adjusted for clinical covariates)
53785,Acute radiotoxicity in prostate cancer,Phenotype,Acute radiotoxicity in prostate cancer
53791,Total lipids in very large VLDL,Phenotype,Total lipids in very large VLDL
53793,Coronary artery disease or plasminogen activator inhibitor 1 levels (pleiotropy),Phenotype,Coronary artery disease or plasminogen activator inhibitor 1 levels (pleiotropy)
53796,Ischemic stroke or factor VII levels (pleiotropy),Phenotype,Ischemic stroke or factor VII levels (pleiotropy)
53797,Ischemic stroke or factor VIII levels (pleiotropy),Phenotype,Ischemic stroke or factor VIII levels (pleiotropy)
53798,Ischemic stroke or von Willebrand factor levels (pleiotropy),Phenotype,Ischemic stroke or von Willebrand factor levels (pleiotropy)
53800,Free cholesterol in small VLDL,Phenotype,Free cholesterol in small VLDL
53801,Total lipids in small VLDL,Phenotype,Total lipids in small VLDL
53802,Melanoma x citrus consumption interaction (2df),Phenotype,Melanoma x citrus consumption interaction (2df)
53804,Total cholesterol levels in very large HDL,Phenotype,Total cholesterol levels in very large HDL
53806,Total cholesterol to total lipids ratio in very large HDL,Phenotype,Total cholesterol to total lipids ratio in very large HDL
53807,Cholesterol esters in very large HDL,Phenotype,Cholesterol esters in very large HDL
53828,Fibrinogen levels or plasminogen activator inhibitor 1 levels (pleiotropy),Phenotype,Fibrinogen levels or plasminogen activator inhibitor 1 levels (pleiotropy)
53831,Fibrinogen levels or factor VII levels or factor XI levels or tissue plasminogen activator levels (pleiotropy),Phenotype,Fibrinogen levels or factor VII levels or factor XI levels or tissue plasminogen activator levels (pleiotropy)
53832,Fibrinogen levels or tissue plasminogen activator levels (pleiotropy),Phenotype,Fibrinogen levels or tissue plasminogen activator levels (pleiotropy)
53833,Venous thromboembolism or factor VII levels (pleiotropy),Phenotype,Venous thromboembolism or factor VII levels (pleiotropy)
53837,Cholesterol esters in small VLDL,Phenotype,Cholesterol esters in small VLDL
53838,Age of onset of type 1 diabetes,Phenotype,Age of onset of type 1 diabetes
53839,Ischemic stroke or factor XI levels (pleiotropy),Phenotype,Ischemic stroke or factor XI levels (pleiotropy)
53840,Ischemic stroke or fibrinogen levels (pleiotropy),Phenotype,Ischemic stroke or fibrinogen levels (pleiotropy)
53842,Ischemic stroke or tissue plasminogen activator levels (pleiotropy),Phenotype,Ischemic stroke or tissue plasminogen activator levels (pleiotropy)
53843,Ischemic stroke or plasminogen activator inhibitor 1 levels (pleiotropy),Phenotype,Ischemic stroke or plasminogen activator inhibitor 1 levels (pleiotropy)
53844,Factor VIII levels or von Willebrand factor levels (pleiotropy),Phenotype,Factor VIII levels or von Willebrand factor levels (pleiotropy)
53846,Fibrinogen levels or factor VII levels (pleiotropy),Phenotype,Fibrinogen levels or factor VII levels (pleiotropy)
53855,Acute radiotoxicity in cancer,Phenotype,Acute radiotoxicity in cancer
53860,Triglycerides in very large HDL,Phenotype,Triglycerides in very large HDL
53881,Total bone mineral density x gut microbiota (genus Dialister) interaction,Phenotype,Total bone mineral density x gut microbiota (genus Dialister) interaction
53883,Femur total bone mineral density x gut microbiota (genus Lactococcus) interaction,Phenotype,Femur total bone mineral density x gut microbiota (genus Lactococcus) interaction
53903,Total cholesterol to total lipids ratio in small VLDL,Phenotype,Total cholesterol to total lipids ratio in small VLDL
53908,Total cholesterol levels in VLDL,Phenotype,Total cholesterol levels in VLDL
53912,gp41 C34 peptide-- HIV levels,Phenotype,gp41 C34 peptide-- HIV levels
53915,Granzyme A levels,Phenotype,Granzyme A levels
53920,Plasma titanium levels,Phenotype,Plasma titanium levels
53922,Plasma vanadium levels,Phenotype,Plasma vanadium levels
53927,Phosphatidylcholine diacyl C40:6 levels,Phenotype,Phosphatidylcholine diacyl C40:6 levels
53928,Phosphatidylcholine diacyl C42:5 levels,Phenotype,Phosphatidylcholine diacyl C42:5 levels
53930,Phosphatidylcholine acyl-alkyl C34:1 levels,Phenotype,Phosphatidylcholine acyl-alkyl C34:1 levels
53931,Phosphatidylcholine acyl-alkyl C34:3 levels,Phenotype,Phosphatidylcholine acyl-alkyl C34:3 levels
53932,Phosphatidylcholine diacyl C36:3 levels,Phenotype,Phosphatidylcholine diacyl C36:3 levels
53933,Phosphatidylcholine diacyl C36:4 levels,Phenotype,Phosphatidylcholine diacyl C36:4 levels
53934,Phosphatidylcholine acyl-alkyl C38:5 levels,Phenotype,Phosphatidylcholine acyl-alkyl C38:5 levels
53935,Phosphatidylcholine acyl-alkyl C38:6 levels,Phenotype,Phosphatidylcholine acyl-alkyl C38:6 levels
53936,Phosphatidylcholine acyl-alkyl C42:1 levels,Phenotype,Phosphatidylcholine acyl-alkyl C42:1 levels
53937,Phosphatidylcholine diacyl C38:3 levels,Phenotype,Phosphatidylcholine diacyl C38:3 levels
53938,Phosphatidylcholine diacyl C38:4 levels,Phenotype,Phosphatidylcholine diacyl C38:4 levels
53939,Phosphatidylcholine diacyl C38:5 levels,Phenotype,Phosphatidylcholine diacyl C38:5 levels
53940,Phosphatidylcholine diacyl C38:6 levels,Phenotype,Phosphatidylcholine diacyl C38:6 levels
53941,Phosphatidylcholine acyl-alkyl C42:3 levels,Phenotype,Phosphatidylcholine acyl-alkyl C42:3 levels
53943,Phosphatidylcholine acyl-alkyl C42:5 levels,Phenotype,Phosphatidylcholine acyl-alkyl C42:5 levels
53945,Phosphatidylcholine acyl-alkyl C36:3 levels,Phenotype,Phosphatidylcholine acyl-alkyl C36:3 levels
53946,Phosphatidylcholine acyl-alkyl C36:4 levels,Phenotype,Phosphatidylcholine acyl-alkyl C36:4 levels
53947,Phosphatidylcholine acyl-alkyl C36:5 levels,Phenotype,Phosphatidylcholine acyl-alkyl C36:5 levels
53948,Phosphatidylcholine acyl-alkyl C32:2 levels,Phenotype,Phosphatidylcholine acyl-alkyl C32:2 levels
53949,Phosphatidylcholine diacyl C42:6 levels,Phenotype,Phosphatidylcholine diacyl C42:6 levels
53950,Phosphatidylcholine acyl-alkyl C34:2 levels,Phenotype,Phosphatidylcholine acyl-alkyl C34:2 levels
53951,Phosphatidylcholine acyl-alkyl C32:1 levels,Phenotype,Phosphatidylcholine acyl-alkyl C32:1 levels
53952,Alkylphosphatidylcholine (O-18:1/18:2) levels,Phenotype,Alkylphosphatidylcholine (O-18:1/18:2) levels
53954,Alkenylphosphatidylcholine (P-16:0/20:5) levels,Phenotype,Alkenylphosphatidylcholine (P-16:0/20:5) levels
53956,Alkylphosphatidylcholine (O-16:0/22:6) levels,Phenotype,Alkylphosphatidylcholine (O-16:0/22:6) levels
53959,Alkenylphosphatidylethanolamine (P-20:1/20:4) levels,Phenotype,Alkenylphosphatidylethanolamine (P-20:1/20:4) levels
53961,Phosphatidylglycerol (36:1) levels,Phenotype,Phosphatidylglycerol (36:1) levels
53963,Phosphatidylinositol (18:0_20:3) (b) levels,Phenotype,Phosphatidylinositol (18:0_20:3) (b) levels
53964,Phosphatidylinositol (18:0_22:4) levels,Phenotype,Phosphatidylinositol (18:0_22:4) levels
53965,Alkenylphosphatidylethanolamine (P-19:0/20:4) (a) levels,Phenotype,Alkenylphosphatidylethanolamine (P-19:0/20:4) (a) levels
53967,Phosphatidylinositol (18:0_18:1) levels,Phenotype,Phosphatidylinositol (18:0_18:1) levels
53972,Alkenylphosphatidylethanolamine (P-18:1/20:5) (b) levels,Phenotype,Alkenylphosphatidylethanolamine (P-18:1/20:5) (b) levels
53974,Diacylglycerol (18:1_20:3) levels,Phenotype,Diacylglycerol (18:1_20:3) levels
53976,Dehydrocholesteryl ester (16:0) levels,Phenotype,Dehydrocholesteryl ester (16:0) levels
53978,Dehydrocholesteryl ester (18:1) levels,Phenotype,Dehydrocholesteryl ester (18:1) levels
53980,C-C motif chemokine 19 levels,Phenotype,C-C motif chemokine 19 levels
53985,Plasma manganese levels,Phenotype,Plasma manganese levels
53987,Plasma rubidium levels,Phenotype,Plasma rubidium levels
53989,Plasma selenium levels,Phenotype,Plasma selenium levels
53991,Plasma nickel levels,Phenotype,Plasma nickel levels
53993,Plasma lead levels,Phenotype,Plasma lead levels
53998,Revision surgery after total joint arthroplasty,Phenotype,Revision surgery after total joint arthroplasty
54000,Revision surgery due to aseptic loosening after total hip arthroplasty,Phenotype,Revision surgery due to aseptic loosening after total hip arthroplasty
54012,Sphingomyeline C18:0 levels,Phenotype,Sphingomyeline C18:0 levels
54013,Tetradecadienylcarnitine levels,Phenotype,Tetradecadienylcarnitine levels
54014,Tetradecanoylcarnitine levels,Phenotype,Tetradecanoylcarnitine levels
54016,Threonine levels,Phenotype,Threonine levels
54019,Pimelylcarnitine levels,Phenotype,Pimelylcarnitine levels
54022,Sphingomyeline C16:0 levels,Phenotype,Sphingomyeline C16:0 levels
54024,Tryptophan levels,Phenotype,Tryptophan levels
54026,Number of clonal hematopoiesis mutations,Phenotype,Number of clonal hematopoiesis mutations
54028,Phosphatidylinositol (18:0_22:5) (n6) levels,Phenotype,Phosphatidylinositol (18:0_22:5) (n6) levels
54029,Phosphatidylinositol (34:1) levels,Phenotype,Phosphatidylinositol (34:1) levels
54030,Acylcarnitine (12:0) levels,Phenotype,Acylcarnitine (12:0) levels
54037,Acylcarnitine (16:0) levels,Phenotype,Acylcarnitine (16:0) levels
54045,Acylcarnitine (16:1) levels,Phenotype,Acylcarnitine (16:1) levels
54047,Acylcarnitine (17:0) (a) levels,Phenotype,Acylcarnitine (17:0) (a) levels
54048,Acylcarnitine (17:0) (b) levels,Phenotype,Acylcarnitine (17:0) (b) levels
54049,Acylcarnitine (18:0) levels,Phenotype,Acylcarnitine (18:0) levels
54054,Acylcarnitine (14:0) levels,Phenotype,Acylcarnitine (14:0) levels
54055,Acylcarnitine (15:0) (a) levels,Phenotype,Acylcarnitine (15:0) (a) levels
54056,Acylcarnitine (15:0) (b) levels,Phenotype,Acylcarnitine (15:0) (b) levels
54057,Acylcarnitine (18:1) levels,Phenotype,Acylcarnitine (18:1) levels
54060,Acylcarnitine (18:2) levels,Phenotype,Acylcarnitine (18:2) levels
54065,Monohexosylceramide (d16:1/20:0) levels,Phenotype,Monohexosylceramide (d16:1/20:0) levels
54072,Phosphatidylserine (36:2) levels,Phenotype,Phosphatidylserine (36:2) levels
54074,Sphingomyelin (d18:1/20:0) levels/Sphingomyelin (d16:1/22:0) levels,Phenotype,Sphingomyelin (d18:1/20:0) levels/Sphingomyelin (d16:1/22:0) levels
54090,Serum copper levels,Phenotype,Serum copper levels
54093,Serum iron levels,Phenotype,Serum iron levels
54096,Serum magnesium levels,Phenotype,Serum magnesium levels
54097,Serum manganese levels,Phenotype,Serum manganese levels
54100,Serum molybdenum levels,Phenotype,Serum molybdenum levels
54102,Serum nickel levels,Phenotype,Serum nickel levels
54105,Serum cobalt levels,Phenotype,Serum cobalt levels
54107,Serum chromium levels,Phenotype,Serum chromium levels
54110,Cleft lip (with or without cleft palate) or cleft palate,Phenotype,Cleft lip (with or without cleft palate) or cleft palate
54130,Mediator of RNA polymerase II transcription subunit 1 levels,Phenotype,Mediator of RNA polymerase II transcription subunit 1 levels
54140,Carnitine levels,Phenotype,Carnitine levels
54142,Arginine levels,Phenotype,Arginine levels
54144,Acetylcarnitine levels,Phenotype,Acetylcarnitine levels
54145,Venous thromboembolism in pregnancy,Phenotype,Venous thromboembolism in pregnancy
54147,Alkylphosphatidylcholine (O-16:0/16:0) levels,Phenotype,Alkylphosphatidylcholine (O-16:0/16:0) levels
54149,Phosphatidylcholine (40:7) (a) levels,Phenotype,Phosphatidylcholine (40:7) (a) levels
54151,Phosphatidylcholine (38:4) (b) levels,Phenotype,Phosphatidylcholine (38:4) (b) levels
54152,Phosphatidylcholine (38:5) (a) levels,Phenotype,Phosphatidylcholine (38:5) (a) levels
54153,Phosphatidylcholine (38:5) (b) levels,Phenotype,Phosphatidylcholine (38:5) (b) levels
54154,Phosphatidylcholine (38:7) (c) levels,Phenotype,Phosphatidylcholine (38:7) (c) levels
54155,Phosphatidylcholine (18:1_20:3) levels,Phenotype,Phosphatidylcholine (18:1_20:3) levels
54158,Phosphatidylcholine (39:5) (b) levels,Phenotype,Phosphatidylcholine (39:5) (b) levels
54159,Alkenylphosphatidylethanolamine (P-18:0/22:6) levels,Phenotype,Alkenylphosphatidylethanolamine (P-18:0/22:6) levels
54161,Alkenylphosphatidylethanolamine (P-16:0/20:3) (a) levels,Phenotype,Alkenylphosphatidylethanolamine (P-16:0/20:3) (a) levels
54163,Alkenylphosphatidylethanolamine (P-16:0/22:5) (n3) levels,Phenotype,Alkenylphosphatidylethanolamine (P-16:0/22:5) (n3) levels
54165,Alkenylphosphatidylethanolamine (P-16:0/22:6) levels,Phenotype,Alkenylphosphatidylethanolamine (P-16:0/22:6) levels
54167,Alkenylphosphatidylethanolamine (P-18:0/20:3) (b) levels,Phenotype,Alkenylphosphatidylethanolamine (P-18:0/20:3) (b) levels
54168,Diacylglycerol (16:0_22:6) levels,Phenotype,Diacylglycerol (16:0_22:6) levels
54171,Dehydrocholesteryl ester (18:2) levels,Phenotype,Dehydrocholesteryl ester (18:2) levels
54173,Ceramide (d19:1/26:0) levels,Phenotype,Ceramide (d19:1/26:0) levels
54175,Ceramide (d19:1/24:0) levels,Phenotype,Ceramide (d19:1/24:0) levels
54177,Phosphatidylcholine (16:0_20:3) (a) levels,Phenotype,Phosphatidylcholine (16:0_20:3) (a) levels
54180,Phosphatidylcholine (17:0_20:4) levels,Phenotype,Phosphatidylcholine (17:0_20:4) levels
54182,Phosphatidylcholine (16:0_18:2) levels,Phenotype,Phosphatidylcholine (16:0_18:2) levels
54184,Phosphatidylcholine (15:0_20:4) levels,Phenotype,Phosphatidylcholine (15:0_20:4) levels
54185,Phosphatidylcholine (16:0_20:4) levels,Phenotype,Phosphatidylcholine (16:0_20:4) levels
54186,Phosphatidylcholine (16:0_22:6) levels,Phenotype,Phosphatidylcholine (16:0_22:6) levels
54191,Trefoil factor 3 levels,Phenotype,Trefoil factor 3 levels
54194,Neutrophil collagenase levels,Phenotype,Neutrophil collagenase levels
54197,Plasminogen activator inhibitor 1 levels,Phenotype,Plasminogen activator inhibitor 1 levels
54202,Serum strontium levels,Phenotype,Serum strontium levels
54205,Serum lead levels,Phenotype,Serum lead levels
54207,Serum rubidium levels,Phenotype,Serum rubidium levels
54209,Serum selenium levels,Phenotype,Serum selenium levels
54212,Serum titanium levels,Phenotype,Serum titanium levels
54215,Serum vanadium levels,Phenotype,Serum vanadium levels
54220,Cleft lip with or without cleft palate,Phenotype,Cleft lip with or without cleft palate
54225,Phosphatidylcholine (18:0_20:3) levels,Phenotype,Phosphatidylcholine (18:0_20:3) levels
54228,Phosphatidylcholine (18:0_20:4) levels,Phenotype,Phosphatidylcholine (18:0_20:4) levels
54229,Phosphatidylcholine (18:0_22:5) (n3) levels/Phosphatidylcholine (20:1_20:4) levels,Phenotype,Phosphatidylcholine (18:0_22:5) (n3) levels/Phosphatidylcholine (20:1_20:4) levels
54231,Phosphatidylcholine (18:0_22:5) (n6) levels,Phenotype,Phosphatidylcholine (18:0_22:5) (n6) levels
54233,Phosphatidylcholine (18:0_22:6) levels,Phenotype,Phosphatidylcholine (18:0_22:6) levels
54243,Alkylphosphatidylethanolamine (O-16:0/22:6) levels,Phenotype,Alkylphosphatidylethanolamine (O-16:0/22:6) levels
54245,Alkylphosphatidylethanolamine (O-18:0/22:6) levels,Phenotype,Alkylphosphatidylethanolamine (O-18:0/22:6) levels
54246,Alkenylphosphatidylethanolamine (P-15:0/22:6) (a) levels,Phenotype,Alkenylphosphatidylethanolamine (P-15:0/22:6) (a) levels
54248,Alkenylphosphatidylethanolamine (P-16:0/18:1) levels,Phenotype,Alkenylphosphatidylethanolamine (P-16:0/18:1) levels
54250,Phosphatidylethanolamine (18:0_22:5) (n3) levels,Phenotype,Phosphatidylethanolamine (18:0_22:5) (n3) levels
54252,Phosphatidylethanolamine (18:0_20:3) (a) levels,Phenotype,Phosphatidylethanolamine (18:0_20:3) (a) levels
54258,Ceramide (d18:2/16:0) levels,Phenotype,Ceramide (d18:2/16:0) levels
54260,Ceramide (d18:2/22:0) levels,Phenotype,Ceramide (d18:2/22:0) levels
54262,Lysophosphatidylinositol (18:1) [sn1] levels,Phenotype,Lysophosphatidylinositol (18:1) [sn1] levels
54264,Lysophosphatidylcholine (22:5) [sn2] (n3) levels,Phenotype,Lysophosphatidylcholine (22:5) [sn2] (n3) levels
54266,Lysophosphatidylethanolamine (16:0) [sn1] levels,Phenotype,Lysophosphatidylethanolamine (16:0) [sn1] levels
54267,Lysophosphatidylethanolamine (16:0) [sn2] levels,Phenotype,Lysophosphatidylethanolamine (16:0) [sn2] levels
54272,Plasma copper levels,Phenotype,Plasma copper levels
54275,Plasma iron levels,Phenotype,Plasma iron levels
54277,Plasma cadmium levels,Phenotype,Plasma cadmium levels
54279,Plasma calcium levels,Phenotype,Plasma calcium levels
54283,Revision surgery after total hip arthroplasty,Phenotype,Revision surgery after total hip arthroplasty
54284,Revision surgery after total knee arthroplasty,Phenotype,Revision surgery after total knee arthroplasty
54287,Kynurenine levels,Phenotype,Kynurenine levels
54289,Lysine levels,Phenotype,Lysine levels
54292,Ornithine levels,Phenotype,Ornithine levels
54293,Phosphatidylcholine diacyl C32:0 levels,Phenotype,Phosphatidylcholine diacyl C32:0 levels
54294,lysoPhosphatidylcholine acyl C20:3 levels,Phenotype,lysoPhosphatidylcholine acyl C20:3 levels
54295,lysoPhosphatidylcholine acyl C20:4 levels,Phenotype,lysoPhosphatidylcholine acyl C20:4 levels
54296,lysoPhosphatidylcholine acyl C26:0 levels,Phenotype,lysoPhosphatidylcholine acyl C26:0 levels
54297,Hexadecanoylcarnitine levels,Phenotype,Hexadecanoylcarnitine levels
54298,Hexadecenoylcarnitine levels,Phenotype,Hexadecenoylcarnitine levels
54299,Methylglutarylcarnitine levels,Phenotype,Methylglutarylcarnitine levels
54300,Octadecandienylcarnitine levels,Phenotype,Octadecandienylcarnitine levels
54301,Octadecanoylcarnitine levels,Phenotype,Octadecanoylcarnitine levels
54302,Octadecenoylcarnitine levels,Phenotype,Octadecenoylcarnitine levels
54306,Cholesteryl ester (16:0) levels,Phenotype,Cholesteryl ester (16:0) levels
54307,Cholesteryl ester (16:2) levels,Phenotype,Cholesteryl ester (16:2) levels
54309,Cholesteryl ester (18:0) levels,Phenotype,Cholesteryl ester (18:0) levels
54310,Cholesteryl ester (18:3) levels,Phenotype,Cholesteryl ester (18:3) levels
54311,Cholesteryl ester (20:3) levels,Phenotype,Cholesteryl ester (20:3) levels
54313,Cholesteryl ester (20:5) levels,Phenotype,Cholesteryl ester (20:5) levels
54315,Cholesteryl ester (24:5) levels,Phenotype,Cholesteryl ester (24:5) levels
54322,Cholesteryl ester (24:6) levels,Phenotype,Cholesteryl ester (24:6) levels
54323,Lysophosphatidylcholine (15-MHDA) [sn1] levels /Lysophosphatidylcholine (17:0) [sn2] levels,Phenotype,Lysophosphatidylcholine (15-MHDA) [sn1] levels /Lysophosphatidylcholine (17:0) [sn2] levels
54325,Lysophosphatidylcholine (15-MHDA) [sn2] levels,Phenotype,Lysophosphatidylcholine (15-MHDA) [sn2] levels
54327,Lysophosphatidylcholine (18:2) [sn2] levels,Phenotype,Lysophosphatidylcholine (18:2) [sn2] levels
54329,Lysophosphatidylcholine (20:1) [sn1] levels,Phenotype,Lysophosphatidylcholine (20:1) [sn1] levels
54331,Lysophosphatidylcholine (20:2) [sn1] levels,Phenotype,Lysophosphatidylcholine (20:2) [sn1] levels
54332,Lysophosphatidylcholine (22:5) [sn1] (n3) levels/Lysophosphatidylcholine (22:5) [sn2] (n6) levels,Phenotype,Lysophosphatidylcholine (22:5) [sn1] (n3) levels/Lysophosphatidylcholine (22:5) [sn2] (n6) levels
54334,Lysophosphatidylcholine (22:5) [sn1] (n6) levels,Phenotype,Lysophosphatidylcholine (22:5) [sn1] (n6) levels
54336,Lysophosphatidylcholine (20:3) [sn1] levels,Phenotype,Lysophosphatidylcholine (20:3) [sn1] levels
54339,Lysophosphatidylcholine (20:3) [sn2] levels,Phenotype,Lysophosphatidylcholine (20:3) [sn2] levels
54342,Lysophosphatidylcholine (15:0) [sn1] levels,Phenotype,Lysophosphatidylcholine (15:0) [sn1] levels
54344,Lysophosphatidylcholine (15:0) [sn2] levels,Phenotype,Lysophosphatidylcholine (15:0) [sn2] levels
54345,Lysophosphatidylcholine (15-MHDA) [sn1]  [104_sn1] levels,Phenotype,Lysophosphatidylcholine (15-MHDA) [sn1]  [104_sn1] levels
54346,Monohexosylceramide (d18:1/24:1) levels,Phenotype,Monohexosylceramide (d18:1/24:1) levels
54348,Monohexosylceramide (d18:1/22:0) levels,Phenotype,Monohexosylceramide (d18:1/22:0) levels
54350,Triacylglycerol (50:2) [NL-18:2] levels,Phenotype,Triacylglycerol (50:2) [NL-18:2] levels
54353,Triacylglycerol (51:1) [NL-18:1] levels,Phenotype,Triacylglycerol (51:1) [NL-18:1] levels
54355,Triacylglycerol (54:1) [NL-18:1] levels,Phenotype,Triacylglycerol (54:1) [NL-18:1] levels
54356,Triacylglycerol (50:0) [NL-18:0] levels,Phenotype,Triacylglycerol (50:0) [NL-18:0] levels
54357,Triacylglycerol (50:1) [NL-18:1] levels,Phenotype,Triacylglycerol (50:1) [NL-18:1] levels
54359,Total cholesterol to total lipids ratio in medium VLDL,Phenotype,Total cholesterol to total lipids ratio in medium VLDL
54360,Total cholesterol in medium VLDL,Phenotype,Total cholesterol in medium VLDL
54369,Concentration of medium VLDL particles,Phenotype,Concentration of medium VLDL particles
54370,Total lipids in medium VLDL,Phenotype,Total lipids in medium VLDL
54379,Triglycerides in small HDL,Phenotype,Triglycerides in small HDL
54380,Phospholipids in small HDL,Phenotype,Phospholipids in small HDL
54381,Sphingomyelins levels,Phenotype,Sphingomyelins levels
54394,Ratio of 22:6 docosahexaenoic acid to total fatty acids,Phenotype,Ratio of 22:6 docosahexaenoic acid to total fatty acids
54395,Diacylglycerol levels,Phenotype,Diacylglycerol levels
54396,Ratio of diacylglycerol to triglycerides,Phenotype,Ratio of diacylglycerol to triglycerides
54397,Docosahexaenoic acid (22:6) levels,Phenotype,Docosahexaenoic acid (22:6) levels
54404,Pulse pressure (BMI unadjusted),Phenotype,Pulse pressure (BMI unadjusted)
54407,Pulse pressure (BMI adjusted),Phenotype,Pulse pressure (BMI adjusted)
54409,Esterified cholesterol levels,Phenotype,Esterified cholesterol levels
54410,Estimated description of fatty acid chain length not actual carbon number,Phenotype,Estimated description of fatty acid chain length not actual carbon number
54411,Mean arterial pressure (BMI unadjusted),Phenotype,Mean arterial pressure (BMI unadjusted)
54412,Total Phosphatidylserine levels,Phenotype,Total Phosphatidylserine levels
54414,Total Alkyldiacylglycerol levels,Phenotype,Total Alkyldiacylglycerol levels
54416,Alkylphosphatidylcholine (O-34:1) levels,Phenotype,Alkylphosphatidylcholine (O-34:1) levels
54417,Alkenylphosphatidylcholine (P-16:0/22:6) levels,Phenotype,Alkenylphosphatidylcholine (P-16:0/22:6) levels
54423,Glycated haemoglobin HbA1c levels adjusted for BMI,Phenotype,Glycated haemoglobin HbA1c levels adjusted for BMI
54465,White matter fractional anisotropy x age interaction (2df),Phenotype,White matter fractional anisotropy x age interaction (2df)
54471,Enorma massiliensis abundance in stool,Phenotype,Enorma massiliensis abundance in stool
54473,Eubacterium I ramulus A abundance in stool,Phenotype,Eubacterium I ramulus A abundance in stool
54474,Ezakiellaceae abundance in stool,Phenotype,Ezakiellaceae abundance in stool
54476,Faecalicatena glycyrrhizinilyticum abundance in stool,Phenotype,Faecalicatena glycyrrhizinilyticum abundance in stool
54478,Pediatric asthma,Phenotype,Pediatric asthma
54480,Enteroscipio abundance in stool,Phenotype,Enteroscipio abundance in stool
54484,Geobacteraceae abundance in stool,Phenotype,Geobacteraceae abundance in stool
54486,Holdemania sp900120005 abundance in stool,Phenotype,Holdemania sp900120005 abundance in stool
54488,Firmicutes E abundance in stool,Phenotype,Firmicutes E abundance in stool
54494,Klebsiella A abundance in stool,Phenotype,Klebsiella A abundance in stool
54496,Klebsiella pneumoniae abundance in stool,Phenotype,Klebsiella pneumoniae abundance in stool
54498,Klebsiella abundance in stool,Phenotype,Klebsiella abundance in stool
54500,Paraglaciecola abundance in stool,Phenotype,Paraglaciecola abundance in stool
54502,Megamonas funiformis abundance in stool,Phenotype,Megamonas funiformis abundance in stool
54504,Methanobacterium B abundance in stool,Phenotype,Methanobacterium B abundance in stool
54509,Negativibacillus massiliensis abundance in stool,Phenotype,Negativibacillus massiliensis abundance in stool
54511,Sleep apnea syndrome,Phenotype,Sleep apnea syndrome
54518,Skin cancer,Phenotype,Skin cancer
54522,Spinal canal stenosis,Phenotype,Spinal canal stenosis
54524,Venous thromboembolism or factor VIII levels (pleiotropy),Phenotype,Venous thromboembolism or factor VIII levels (pleiotropy)
54525,Venous thromboembolism or von Willebrand factor levels (pleiotropy),Phenotype,Venous thromboembolism or von Willebrand factor levels (pleiotropy)
54528,Venous thromboembolism or factor XI levels (pleiotropy),Phenotype,Venous thromboembolism or factor XI levels (pleiotropy)
54529,Venous thromboembolism or fibrinogen levels (pleiotropy),Phenotype,Venous thromboembolism or fibrinogen levels (pleiotropy)
54530,Venous thromboembolism or tissue plasminogen activator levels (pleiotropy),Phenotype,Venous thromboembolism or tissue plasminogen activator levels (pleiotropy)
54531,Venous thromboembolism or plasminogen activator inhibitor 1 levels (pleiotropy),Phenotype,Venous thromboembolism or plasminogen activator inhibitor 1 levels (pleiotropy)
54550,Triacylglycerol (54:4) [NL-18:0] levels,Phenotype,Triacylglycerol (54:4) [NL-18:0] levels
54552,Triacylglycerol (54:5) [NL-18:1] levels,Phenotype,Triacylglycerol (54:5) [NL-18:1] levels
54553,Triacylglycerol (56:6) [NL-20:4] levels,Phenotype,Triacylglycerol (56:6) [NL-20:4] levels
54555,Total Phosphatidylcholine levels,Phenotype,Total Phosphatidylcholine levels
54557,Alkylphosphatidylcholine (O-32:1) levels,Phenotype,Alkylphosphatidylcholine (O-32:1) levels
54558,Total Phosphatidylinositol levels,Phenotype,Total Phosphatidylinositol levels
54560,Sphingomyelin (d19:1/24:1) levels,Phenotype,Sphingomyelin (d19:1/24:1) levels
54562,Sulfatide (d18:1/16:0) levels,Phenotype,Sulfatide (d18:1/16:0) levels
54564,Total Triacylglycerol levels,Phenotype,Total Triacylglycerol levels
54566,Alkyldiacylglycerol (O-50:1) [NL-16:0] levels,Phenotype,Alkyldiacylglycerol (O-50:1) [NL-16:0] levels
54567,Alkyldiacylglycerol (O-52:0) [NL-16:0] levels,Phenotype,Alkyldiacylglycerol (O-52:0) [NL-16:0] levels
54568,Alkyldiacylglycerol (O-52:2) [NL-16:0] levels,Phenotype,Alkyldiacylglycerol (O-52:2) [NL-16:0] levels
54569,Total Acylcarnitine levels,Phenotype,Total Acylcarnitine levels
54570,Total Cholesteryl ester levels,Phenotype,Total Cholesteryl ester levels
54572,Total Dehydrocholesteryl ester levels,Phenotype,Total Dehydrocholesteryl ester levels
54575,Alkenylphosphatidylcholine (P-16:0/16:0) levels,Phenotype,Alkenylphosphatidylcholine (P-16:0/16:0) levels
54578,Asthma-COPD overlap syndrome,Phenotype,Asthma-COPD overlap syndrome
54592,Vascular endothelial growth factor A level in Chronic kidney disease with hypertension and no diabetes (2597_8),Phenotype,Vascular endothelial growth factor A level in Chronic kidney disease with hypertension and no diabetes (2597_8)
54594,Adhesion G protein-coupled receptor F5 level in Chronic kidney disease with hypertension and no diabetes (6409_57),Phenotype,Adhesion G protein-coupled receptor F5 level in Chronic kidney disease with hypertension and no diabetes (6409_57)
54596,Tenascin-X level in Chronic kidney disease with hypertension and no diabetes (5698_60),Phenotype,Tenascin-X level in Chronic kidney disease with hypertension and no diabetes (5698_60)
54598,Retinoic acid early transcript 1L protein level in Chronic kidney disease with hypertension and no diabetes (20526_3),Phenotype,Retinoic acid early transcript 1L protein level in Chronic kidney disease with hypertension and no diabetes (20526_3)
54600,Izumo sperm-egg fusion protein 4 level in Chronic kidney disease with hypertension and no diabetes (20549_1),Phenotype,Izumo sperm-egg fusion protein 4 level in Chronic kidney disease with hypertension and no diabetes (20549_1)
54601,T-cell surface glycoprotein CD8 alpha chain level in Chronic kidney disease with hypertension and no diabetes (5992_50),Phenotype,T-cell surface glycoprotein CD8 alpha chain level in Chronic kidney disease with hypertension and no diabetes (5992_50)
54603,Protein Mdm4 level in Chronic kidney disease with hypertension and no diabetes (13229_20),Phenotype,Protein Mdm4 level in Chronic kidney disease with hypertension and no diabetes (13229_20)
54606,Interleukin-36 alpha level in Chronic kidney disease with hypertension and no diabetes (14150_7),Phenotype,Interleukin-36 alpha level in Chronic kidney disease with hypertension and no diabetes (14150_7)
54608,Prolyl endopeptidase level in Chronic kidney disease with hypertension and no diabetes (14273_19),Phenotype,Prolyl endopeptidase level in Chronic kidney disease with hypertension and no diabetes (14273_19)
54609,Butyrophilin subfamily 3 member A2 level in Chronic kidney disease with hypertension and no diabetes (21433_3),Phenotype,Butyrophilin subfamily 3 member A2 level in Chronic kidney disease with hypertension and no diabetes (21433_3)
54611,MTSS1-like protein level in Chronic kidney disease with hypertension and no diabetes (25252_29),Phenotype,MTSS1-like protein level in Chronic kidney disease with hypertension and no diabetes (25252_29)
54613,Interleukin-21 level in Chronic kidney disease with hypertension and no diabetes (7124_18),Phenotype,Interleukin-21 level in Chronic kidney disease with hypertension and no diabetes (7124_18)
54615,Uncharacterized metallophosphoesterase CSTP1 level in Chronic kidney disease with hypertension and no diabetes (21108_5),Phenotype,Uncharacterized metallophosphoesterase CSTP1 level in Chronic kidney disease with hypertension and no diabetes (21108_5)
54617,MHC class I polypeptide-related sequence A level in Chronic kidney disease with hypertension and no diabetes (2730_58),Phenotype,MHC class I polypeptide-related sequence A level in Chronic kidney disease with hypertension and no diabetes (2730_58)
54619,Vascular endothelial growth factor A-- isoform 121 level in Chronic kidney disease with hypertension and no diabetes (14032_2),Phenotype,Vascular endothelial growth factor A-- isoform 121 level in Chronic kidney disease with hypertension and no diabetes (14032_2)
54620,Alpha-L-fucoside fucohydrolase level in Chronic kidney disease with hypertension and no diabetes (21384_2),Phenotype,Alpha-L-fucoside fucohydrolase level in Chronic kidney disease with hypertension and no diabetes (21384_2)
54621,Neutrophil collagenase level in Chronic kidney disease with hypertension and no diabetes (2954_56),Phenotype,Neutrophil collagenase level in Chronic kidney disease with hypertension and no diabetes (2954_56)
54622,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 level in Chronic kidney disease with hypertension and no diabetes (6556_5),Phenotype,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 level in Chronic kidney disease with hypertension and no diabetes (6556_5)
54623,Low-density lipoprotein receptor-related protein 11 level in Chronic kidney disease with hypertension and no diabetes (6713_4),Phenotype,Low-density lipoprotein receptor-related protein 11 level in Chronic kidney disease with hypertension and no diabetes (6713_4)
54625,Hemoglobin subunit zeta level in Chronic kidney disease with hypertension and no diabetes (6919_3),Phenotype,Hemoglobin subunit zeta level in Chronic kidney disease with hypertension and no diabetes (6919_3)
54627,Haptoglobin level in Chronic kidney disease with hypertension and no diabetes (3054_3),Phenotype,Haptoglobin level in Chronic kidney disease with hypertension and no diabetes (3054_3)
54628,Sialidase-1 level in Chronic kidney disease with hypertension and no diabetes (15426_5),Phenotype,Sialidase-1 level in Chronic kidney disease with hypertension and no diabetes (15426_5)
54630,N-sulphoglucosamine sulphohydrolase level in Chronic kidney disease with hypertension and no diabetes (21766_50),Phenotype,N-sulphoglucosamine sulphohydrolase level in Chronic kidney disease with hypertension and no diabetes (21766_50)
54632,HLA-C level in Chronic kidney disease with hypertension and no diabetes (21797_4),Phenotype,HLA-C level in Chronic kidney disease with hypertension and no diabetes (21797_4)
54633,Neuregulin-1-- sensory and motor neuron-derived factor isoform level in Chronic kidney disease with hypertension and no diabetes (15446_25),Phenotype,Neuregulin-1-- sensory and motor neuron-derived factor isoform level in Chronic kidney disease with hypertension and no diabetes (15446_25)
54634,5'-Nucleotidase level in Chronic kidney disease with hypertension and no diabetes (15452_5),Phenotype,5'-Nucleotidase level in Chronic kidney disease with hypertension and no diabetes (15452_5)
54636,T-cell surface glycoprotein CD8 alpha chain level in Chronic kidney disease with hypertension and no diabetes (15462_28),Phenotype,T-cell surface glycoprotein CD8 alpha chain level in Chronic kidney disease with hypertension and no diabetes (15462_28)
54638,Low-density lipoprotein receptor-related protein 11 level in Chronic kidney disease with hypertension and no diabetes (15472_16),Phenotype,Low-density lipoprotein receptor-related protein 11 level in Chronic kidney disease with hypertension and no diabetes (15472_16)
54640,Vascular non-inflammatory molecule 2 level in Chronic kidney disease with hypertension and no diabetes (15480_2),Phenotype,Vascular non-inflammatory molecule 2 level in Chronic kidney disease with hypertension and no diabetes (15480_2)
54642,Glutamate receptor 4 level in Chronic kidney disease with hypertension and no diabetes (10760_107),Phenotype,Glutamate receptor 4 level in Chronic kidney disease with hypertension and no diabetes (10760_107)
54644,Cerebellin-2 level in Chronic kidney disease with hypertension and no diabetes (21887_2),Phenotype,Cerebellin-2 level in Chronic kidney disease with hypertension and no diabetes (21887_2)
54646,Apolipoprotein M level in Chronic kidney disease with hypertension and no diabetes (10445_20),Phenotype,Apolipoprotein M level in Chronic kidney disease with hypertension and no diabetes (10445_20)
54648,Tryptase beta-2 level in Chronic kidney disease with hypertension and no diabetes (14696_45),Phenotype,Tryptase beta-2 level in Chronic kidney disease with hypertension and no diabetes (14696_45)
54650,Coiled-coil domain-containing protein 134 level in Chronic kidney disease with hypertension and no diabetes (15300_66),Phenotype,Coiled-coil domain-containing protein 134 level in Chronic kidney disease with hypertension and no diabetes (15300_66)
54651,Thioredoxin-like protein 4B level in Chronic kidney disease with hypertension and no diabetes (15316_262),Phenotype,Thioredoxin-like protein 4B level in Chronic kidney disease with hypertension and no diabetes (15316_262)
54653,Stromal cell-derived factor 2 level in Chronic kidney disease with hypertension and no diabetes (15333_11),Phenotype,Stromal cell-derived factor 2 level in Chronic kidney disease with hypertension and no diabetes (15333_11)
54655,alpha-2-macroglobulin receptor-associated protein level in Chronic kidney disease with hypertension and no diabetes (3640_14),Phenotype,alpha-2-macroglobulin receptor-associated protein level in Chronic kidney disease with hypertension and no diabetes (3640_14)
54656,Cation-independent mannose-6-phosphate receptor level in Chronic kidney disease with hypertension and no diabetes (3676_15),Phenotype,Cation-independent mannose-6-phosphate receptor level in Chronic kidney disease with hypertension and no diabetes (3676_15)
54657,Spermatogenesis-associated protein 20 level in Chronic kidney disease with hypertension and no diabetes (11117_2),Phenotype,Spermatogenesis-associated protein 20 level in Chronic kidney disease with hypertension and no diabetes (11117_2)
54660,CD109 antigen level in Chronic kidney disease with hypertension and no diabetes (3290_50),Phenotype,CD109 antigen level in Chronic kidney disease with hypertension and no diabetes (3290_50)
54662,Heparin cofactor 2 level in Chronic kidney disease with hypertension and no diabetes (3316_58),Phenotype,Heparin cofactor 2 level in Chronic kidney disease with hypertension and no diabetes (3316_58)
54663,Complement C4b level in Chronic kidney disease with hypertension and no diabetes (2182_54),Phenotype,Complement C4b level in Chronic kidney disease with hypertension and no diabetes (2182_54)
54664,Tryptase beta-2 level in Chronic kidney disease with hypertension and no diabetes (3403_1),Phenotype,Tryptase beta-2 level in Chronic kidney disease with hypertension and no diabetes (3403_1)
54666,Calsequestrin-1 level in Chronic kidney disease with hypertension and no diabetes (11263_57),Phenotype,Calsequestrin-1 level in Chronic kidney disease with hypertension and no diabetes (11263_57)
54667,Cyclic AMP-responsive element-binding protein 3-like protein 4 level in Chronic kidney disease with hypertension and no diabetes (11308_8),Phenotype,Cyclic AMP-responsive element-binding protein 3-like protein 4 level in Chronic kidney disease with hypertension and no diabetes (11308_8)
54668,MAM domain-containing glycosylphosphatidylinositol anchor protein 1 level in Chronic kidney disease with hypertension and no diabetes (16900_29),Phenotype,MAM domain-containing glycosylphosphatidylinositol anchor protein 1 level in Chronic kidney disease with hypertension and no diabetes (16900_29)
54670,Alanine--tRNA ligase-- cytoplasmic level in Chronic kidney disease with hypertension and no diabetes (12340_17),Phenotype,Alanine--tRNA ligase-- cytoplasmic level in Chronic kidney disease with hypertension and no diabetes (12340_17)
54672,Aspartate aminotransferase-- mitochondrial level in Chronic kidney disease with hypertension and no diabetes (18233_10),Phenotype,Aspartate aminotransferase-- mitochondrial level in Chronic kidney disease with hypertension and no diabetes (18233_10)
54674,Ermin level in Chronic kidney disease with hypertension and no diabetes (23425_19),Phenotype,Ermin level in Chronic kidney disease with hypertension and no diabetes (23425_19)
54675,Methyltransferase-like protein 2B level in Chronic kidney disease with hypertension and no diabetes (23558_33),Phenotype,Methyltransferase-like protein 2B level in Chronic kidney disease with hypertension and no diabetes (23558_33)
54676,Coiled-coil domain-containing protein 94 level in Chronic kidney disease with hypertension and no diabetes (23571_93),Phenotype,Coiled-coil domain-containing protein 94 level in Chronic kidney disease with hypertension and no diabetes (23571_93)
54677,GATA zinc finger domain-containing protein 1 level in Chronic kidney disease with hypertension and no diabetes (22154_37),Phenotype,GATA zinc finger domain-containing protein 1 level in Chronic kidney disease with hypertension and no diabetes (22154_37)
54678,Complement factor B level in Chronic kidney disease with hypertension and no diabetes (4129_72),Phenotype,Complement factor B level in Chronic kidney disease with hypertension and no diabetes (4129_72)
54680,Butyrophilin subfamily 2 member A2 level in Chronic kidney disease with hypertension and no diabetes (22586_24),Phenotype,Butyrophilin subfamily 2 member A2 level in Chronic kidney disease with hypertension and no diabetes (22586_24)
54681,Collagen alpha-1(X) chain level in Chronic kidney disease with hypertension and no diabetes (15653_9),Phenotype,Collagen alpha-1(X) chain level in Chronic kidney disease with hypertension and no diabetes (15653_9)
54683,Cation-independent mannose-6-phosphate receptor level in Chronic kidney disease with hypertension and no diabetes (16057_6),Phenotype,Cation-independent mannose-6-phosphate receptor level in Chronic kidney disease with hypertension and no diabetes (16057_6)
54684,Triggering receptor expressed on myeloid cells 2 level in Chronic kidney disease with hypertension and no diabetes (16300_4),Phenotype,Triggering receptor expressed on myeloid cells 2 level in Chronic kidney disease with hypertension and no diabetes (16300_4)
54686,Vascular endothelial growth factor A-- isoform 121 level in Chronic kidney disease with hypertension and no diabetes (4867_15),Phenotype,Vascular endothelial growth factor A-- isoform 121 level in Chronic kidney disease with hypertension and no diabetes (4867_15)
54687,Apolipoprotein L1 level in Chronic kidney disease with hypertension and no diabetes (11510_31),Phenotype,Apolipoprotein L1 level in Chronic kidney disease with hypertension and no diabetes (11510_31)
54689,Folate receptor alpha level in Chronic kidney disease with hypertension and no diabetes (17455_42),Phenotype,Folate receptor alpha level in Chronic kidney disease with hypertension and no diabetes (17455_42)
54690,Butyrophilin subfamily 3 member A3 level in Chronic kidney disease with hypertension and no diabetes (17692_2),Phenotype,Butyrophilin subfamily 3 member A3 level in Chronic kidney disease with hypertension and no diabetes (17692_2)
54691,Butyrophilin subfamily 3 member A3 level in Chronic kidney disease with hypertension and no diabetes (22950_6),Phenotype,Butyrophilin subfamily 3 member A3 level in Chronic kidney disease with hypertension and no diabetes (22950_6)
54693,Endophilin-A3 level in Chronic kidney disease with hypertension and no diabetes (23029_3),Phenotype,Endophilin-A3 level in Chronic kidney disease with hypertension and no diabetes (23029_3)
54694,Tapasin level in Chronic kidney disease with hypertension and no diabetes (12378_71),Phenotype,Tapasin level in Chronic kidney disease with hypertension and no diabetes (12378_71)
54696,Dipeptidase 1 level in Chronic kidney disease with hypertension and no diabetes (8794_13),Phenotype,Dipeptidase 1 level in Chronic kidney disease with hypertension and no diabetes (8794_13)
54698,Dipeptidase 2 level in Chronic kidney disease with hypertension and no diabetes (8327_26),Phenotype,Dipeptidase 2 level in Chronic kidney disease with hypertension and no diabetes (8327_26)
54700,Low-density lipoprotein receptor-related protein 11 level in Chronic kidney disease with hypertension and no diabetes (8330_1),Phenotype,Low-density lipoprotein receptor-related protein 11 level in Chronic kidney disease with hypertension and no diabetes (8330_1)
54702,Zymogen granule membrane protein 16 level in Chronic kidney disease with hypertension and no diabetes (8219_14),Phenotype,Zymogen granule membrane protein 16 level in Chronic kidney disease with hypertension and no diabetes (8219_14)
54706,Triggering receptor expressed on myeloid cells 1 level in Chronic kidney disease with hypertension and no diabetes (9266_1),Phenotype,Triggering receptor expressed on myeloid cells 1 level in Chronic kidney disease with hypertension and no diabetes (9266_1)
54708,Cysteine-rich secretory protein 2 level in Chronic kidney disease with hypertension and no diabetes (9282_12),Phenotype,Cysteine-rich secretory protein 2 level in Chronic kidney disease with hypertension and no diabetes (9282_12)
54710,Cerebellin-1 level in Chronic kidney disease with hypertension and no diabetes (9313_27),Phenotype,Cerebellin-1 level in Chronic kidney disease with hypertension and no diabetes (9313_27)
54711,WAP four-disulfide core domain protein 1 level in Chronic kidney disease with hypertension and no diabetes (9316_67),Phenotype,WAP four-disulfide core domain protein 1 level in Chronic kidney disease with hypertension and no diabetes (9316_67)
54712,Trimeric intracellular cation channel type B level in Chronic kidney disease with hypertension and no diabetes (9509_4),Phenotype,Trimeric intracellular cation channel type B level in Chronic kidney disease with hypertension and no diabetes (9509_4)
54713,HLA class II histocompatibility antigen-- DQ alpha 2 chain level in Chronic kidney disease with hypertension and no diabetes (7757_5),Phenotype,HLA class II histocompatibility antigen-- DQ alpha 2 chain level in Chronic kidney disease with hypertension and no diabetes (7757_5)
54714,Haptoglobin isoform 2 level in Chronic kidney disease with hypertension and no diabetes (7905_30),Phenotype,Haptoglobin isoform 2 level in Chronic kidney disease with hypertension and no diabetes (7905_30)
54715,Glycoprotein endo-alpha-1--2-mannosidase level in Chronic kidney disease with hypertension and no diabetes (8014_359),Phenotype,Glycoprotein endo-alpha-1--2-mannosidase level in Chronic kidney disease with hypertension and no diabetes (8014_359)
54717,DnaJ homolog subfamily C member 4 level in Chronic kidney disease with hypertension and no diabetes (8016_19),Phenotype,DnaJ homolog subfamily C member 4 level in Chronic kidney disease with hypertension and no diabetes (8016_19)
54718,Ferritin-- mitochondrial level in Chronic kidney disease with hypertension and no diabetes (8048_9),Phenotype,Ferritin-- mitochondrial level in Chronic kidney disease with hypertension and no diabetes (8048_9)
54719,Cadherin-11 level in Chronic kidney disease with hypertension and no diabetes (9604_14),Phenotype,Cadherin-11 level in Chronic kidney disease with hypertension and no diabetes (9604_14)
54721,T-cell surface protein tactile level in Chronic kidney disease with hypertension and no diabetes (9735_44),Phenotype,T-cell surface protein tactile level in Chronic kidney disease with hypertension and no diabetes (9735_44)
54722,NAD(P)H dehydrogenase [quinone] 1 level in Chronic kidney disease with hypertension and no diabetes (9837_60),Phenotype,NAD(P)H dehydrogenase [quinone] 1 level in Chronic kidney disease with hypertension and no diabetes (9837_60)
54732,Suicide attempts,Phenotype,Suicide attempts
54734,Circulating levels of total-tau,Phenotype,Circulating levels of total-tau
54740,Overall survival in advanced colorectal cancer,Phenotype,Overall survival in advanced colorectal cancer
54753,Fasting insulin adjusted for BMI,Phenotype,Fasting insulin adjusted for BMI
54763,Acute graft-versus-host disease (stage 2 to 4) (donor effect),Phenotype,Acute graft-versus-host disease (stage 2 to 4) (donor effect)
54765,Acute graft-versus-host disease (stage 2b to 4) (donor effect),Phenotype,Acute graft-versus-host disease (stage 2b to 4) (donor effect)
54767,Acute graft-versus-host disease (gut) (donor effect),Phenotype,Acute graft-versus-host disease (gut) (donor effect)
54769,Chronic graft-versus-host disease (recipient effect),Phenotype,Chronic graft-versus-host disease (recipient effect)
54794,Guanylate-binding protein 2 level in Chronic kidney disease with hypertension and no diabetes (18891_98),Phenotype,Guanylate-binding protein 2 level in Chronic kidney disease with hypertension and no diabetes (18891_98)
54795,Katanin p60 ATPase-containing subunit A-like 1 level in Chronic kidney disease with hypertension and no diabetes (24494_67),Phenotype,Katanin p60 ATPase-containing subunit A-like 1 level in Chronic kidney disease with hypertension and no diabetes (24494_67)
54797,MHC class I polypeptide-related sequence B level in Chronic kidney disease with hypertension and no diabetes (5102_55),Phenotype,MHC class I polypeptide-related sequence B level in Chronic kidney disease with hypertension and no diabetes (5102_55)
54798,cAMP-specific 3'--5'-cyclic phosphodiesterase 4D level in Chronic kidney disease with hypertension and no diabetes (5255_22),Phenotype,cAMP-specific 3'--5'-cyclic phosphodiesterase 4D level in Chronic kidney disease with hypertension and no diabetes (5255_22)
54799,Histone deacetylase complex subunit SAP30 level in Chronic kidney disease with hypertension and no diabetes (12888_18),Phenotype,Histone deacetylase complex subunit SAP30 level in Chronic kidney disease with hypertension and no diabetes (12888_18)
54800,Isoform L-VEGF165 level in Chronic kidney disease with hypertension and no diabetes (19437_61),Phenotype,Isoform L-VEGF165 level in Chronic kidney disease with hypertension and no diabetes (19437_61)
54802,Chymotrypsinogen B2 level in Chronic kidney disease with hypertension and no diabetes (5648_28),Phenotype,Chymotrypsinogen B2 level in Chronic kidney disease with hypertension and no diabetes (5648_28)
54818,Glaucoma (low intraocular pressure),Phenotype,Glaucoma (low intraocular pressure)
54819,CD127 on CD28+ CD45RA+ CD8+ T cell,Phenotype,CD127 on CD28+ CD45RA+ CD8+ T cell
54821,CD127 on CD28- CD8+ T cell,Phenotype,CD127 on CD28- CD8+ T cell
54823,CD127 on CD4+ T cell,Phenotype,CD127 on CD4+ T cell
54825,CD45 on CD4+ T cell,Phenotype,CD45 on CD4+ T cell
54827,CD127 on CD45RA+ CD4+ T cell,Phenotype,CD127 on CD45RA+ CD4+ T cell
54829,CD45 on HLA DR+ T cell,Phenotype,CD45 on HLA DR+ T cell
54831,CCR7 on naive CD8+ T cell,Phenotype,CCR7 on naive CD8+ T cell
54834,CD45 on HLA DR+ CD4+ T cell,Phenotype,CD45 on HLA DR+ CD4+ T cell
54836,CD127 on CD28+ CD4+ T cell,Phenotype,CD127 on CD28+ CD4+ T cell
54837,CD127 on CD28+ CD4-CD8- T cell,Phenotype,CD127 on CD28+ CD4-CD8- T cell
54839,CD4 on monocyte,Phenotype,CD4 on monocyte
54840,CD4 on HLA DR+ CD4+ T cell,Phenotype,CD4 on HLA DR+ CD4+ T cell
54842,HippSubfield lh volume subiculum-head,Phenotype,HippSubfield lh volume subiculum-head
54844,CD16-CD56 on Natural Killer T,Phenotype,CD16-CD56 on Natural Killer T
54845,CD28 on CD45RA+ CD4+ T cell,Phenotype,CD28 on CD45RA+ CD4+ T cell
54846,CD34 on Hematopoietic Stem Cell,Phenotype,CD34 on Hematopoietic Stem Cell
54848,HVEM on naive CD8+ T cell,Phenotype,HVEM on naive CD8+ T cell
54850,CD28 on CD28+ CD4+ T cell,Phenotype,CD28 on CD28+ CD4+ T cell
54851,CD28 on CD28+ CD4-CD8- T cell,Phenotype,CD28 on CD28+ CD4-CD8- T cell
54852,CD28 on CD28+ CD45RA+ CD8+ T cell,Phenotype,CD28 on CD28+ CD45RA+ CD8+ T cell
54854,CD28 on CD4+ T cell,Phenotype,CD28 on CD4+ T cell
54855,CD28 on resting CD4 regulatory T cell,Phenotype,CD28 on resting CD4 regulatory T cell
54856,aseg rh volume choroid-plexus,Phenotype,aseg rh volume choroid-plexus
54857,aseg rh volume Lateral-Ventricle,Phenotype,aseg rh volume Lateral-Ventricle
54858,CCR7 on naive CD4+ T cell,Phenotype,CCR7 on naive CD4+ T cell
54859,HLA DR on CD14- CD16+ monocyte,Phenotype,HLA DR on CD14- CD16+ monocyte
54861,HLA DR on plasmacytoid Dendritic Cell,Phenotype,HLA DR on plasmacytoid Dendritic Cell
54862,HLA DR on Dendritic Cell,Phenotype,HLA DR on Dendritic Cell
54865,HLA DR on Hematopoietic Stem Cell,Phenotype,HLA DR on Hematopoietic Stem Cell
54867,HLA DR on CD33+ HLA DR+ CD14-,Phenotype,HLA DR on CD33+ HLA DR+ CD14-
54870,HLA DR on CD33+ HLA DR+ CD14dim,Phenotype,HLA DR on CD33+ HLA DR+ CD14dim
54871,HLA DR on CD33dim HLA DR+ CD11b+,Phenotype,HLA DR on CD33dim HLA DR+ CD11b+
54875,HLA DR on CD33dim HLA DR+ CD11b-,Phenotype,HLA DR on CD33dim HLA DR+ CD11b-
54877,HLA DR on CD33- HLA DR+,Phenotype,HLA DR on CD33- HLA DR+
54878,CD11c on myeloid Dendritic Cell,Phenotype,CD11c on myeloid Dendritic Cell
54882,CD11c on CD62L+ myeloid Dendritic Cell,Phenotype,CD11c on CD62L+ myeloid Dendritic Cell
54884,CD11c on monocyte,Phenotype,CD11c on monocyte
54886,CD11c on granulocyte,Phenotype,CD11c on granulocyte
54888,HLA DR on HLA DR+ T cell,Phenotype,HLA DR on HLA DR+ T cell
54890,HLA DR on HLA DR+ CD4+ T cell,Phenotype,HLA DR on HLA DR+ CD4+ T cell
54891,HLA DR on B cell,Phenotype,HLA DR on B cell
54894,HLA DR on HLA DR+ Natural Killer,Phenotype,HLA DR on HLA DR+ Natural Killer
54897,CD8 on CD28+ CD45RA- CD8+ T cell,Phenotype,CD8 on CD28+ CD45RA- CD8+ T cell
54899,CD8 on CD28+ CD45RA+ CD8+ T cell,Phenotype,CD8 on CD28+ CD45RA+ CD8+ T cell
54901,CD8 on CD28- CD8+ T cell,Phenotype,CD8 on CD28- CD8+ T cell
54902,CD8 on CD39+ CD8+ T cell,Phenotype,CD8 on CD39+ CD8+ T cell
54904,IDP SWI T2star left putamen,Phenotype,IDP SWI T2star left putamen
54905,IDP SWI T2star right putamen,Phenotype,IDP SWI T2star right putamen
54907,HLA DR on myeloid Dendritic Cell,Phenotype,HLA DR on myeloid Dendritic Cell
54916,IDP dMRI ProbtrackX L2 unc r,Phenotype,IDP dMRI ProbtrackX L2 unc r
54917,IDP dMRI ProbtrackX L1 unc r,Phenotype,IDP dMRI ProbtrackX L1 unc r
54918,IDP dMRI ProbtrackX L2 ifo l,Phenotype,IDP dMRI ProbtrackX L2 ifo l
54919,IDP dMRI ProbtrackX L1 unc l,Phenotype,IDP dMRI ProbtrackX L1 unc l
54921,aparc-pial rh area TotalSurface,Phenotype,aparc-pial rh area TotalSurface
54922,aparc-pial rh area caudalmiddlefrontal,Phenotype,aparc-pial rh area caudalmiddlefrontal
54923,aparc-pial rh area cuneus,Phenotype,aparc-pial rh area cuneus
54924,aparc-pial rh area lateraloccipital,Phenotype,aparc-pial rh area lateraloccipital
54925,aparc-pial rh area lateralorbitofrontal,Phenotype,aparc-pial rh area lateralorbitofrontal
54927,aparc-pial lh area caudalmiddlefrontal,Phenotype,aparc-pial lh area caudalmiddlefrontal
54928,aparc-pial lh area lateralorbitofrontal,Phenotype,aparc-pial lh area lateralorbitofrontal
54929,aparc-pial lh area pericalcarine,Phenotype,aparc-pial lh area pericalcarine
54931,aparc-a2009s rh area Pole-occipital,Phenotype,aparc-a2009s rh area Pole-occipital
54933,aparc-a2009s rh area G-cuneus,Phenotype,aparc-a2009s rh area G-cuneus
54934,IDP dMRI TBSS ISOVF Posterior corona radiata L,Phenotype,IDP dMRI TBSS ISOVF Posterior corona radiata L
54935,IDP dMRI TBSS ISOVF Posterior thalamic radiation L,Phenotype,IDP dMRI TBSS ISOVF Posterior thalamic radiation L
54936,IDP dMRI TBSS ISOVF Sagittal stratum R,Phenotype,IDP dMRI TBSS ISOVF Sagittal stratum R
54937,IDP dMRI TBSS ISOVF Sagittal stratum L,Phenotype,IDP dMRI TBSS ISOVF Sagittal stratum L
54938,IDP dMRI TBSS ISOVF External capsule R,Phenotype,IDP dMRI TBSS ISOVF External capsule R
54940,IDP dMRI TBSS ISOVF External capsule L,Phenotype,IDP dMRI TBSS ISOVF External capsule L
54941,IDP dMRI TBSS ISOVF Cingulum cingulate gyrus R,Phenotype,IDP dMRI TBSS ISOVF Cingulum cingulate gyrus R
54942,IDP dMRI TBSS ISOVF Superior longitudinal fasciculus R,Phenotype,IDP dMRI TBSS ISOVF Superior longitudinal fasciculus R
54943,IDP dMRI TBSS ISOVF Superior longitudinal fasciculus L,Phenotype,IDP dMRI TBSS ISOVF Superior longitudinal fasciculus L
54944,IDP dMRI ProbtrackX ISOVF ar r,Phenotype,IDP dMRI ProbtrackX ISOVF ar r
54945,IDP T1 FAST ROIs R mid front gyrus,Phenotype,IDP T1 FAST ROIs R mid front gyrus
54946,IDP dMRI ProbtrackX ISOVF slf l,Phenotype,IDP dMRI ProbtrackX ISOVF slf l
54947,IDP dMRI ProbtrackX ISOVF slf r,Phenotype,IDP dMRI ProbtrackX ISOVF slf r
54949,IDP dMRI ProbtrackX ISOVF str l,Phenotype,IDP dMRI ProbtrackX ISOVF str l
54950,IDP dMRI ProbtrackX ISOVF str r,Phenotype,IDP dMRI ProbtrackX ISOVF str r
54951,IDP dMRI ProbtrackX ISOVF unc l,Phenotype,IDP dMRI ProbtrackX ISOVF unc l
54952,IDP dMRI ProbtrackX ISOVF unc r,Phenotype,IDP dMRI ProbtrackX ISOVF unc r
54953,IDP dMRI ProbtrackX ISOVF cgc l,Phenotype,IDP dMRI ProbtrackX ISOVF cgc l
54954,IDP dMRI ProbtrackX ISOVF cgc r,Phenotype,IDP dMRI ProbtrackX ISOVF cgc r
54955,IDP dMRI ProbtrackX ISOVF fmi,Phenotype,IDP dMRI ProbtrackX ISOVF fmi
54957,IDP dMRI ProbtrackX ISOVF ifo l,Phenotype,IDP dMRI ProbtrackX ISOVF ifo l
54958,IDP dMRI ProbtrackX ISOVF ifo r,Phenotype,IDP dMRI ProbtrackX ISOVF ifo r
54959,IDP dMRI ProbtrackX ISOVF ilf l,Phenotype,IDP dMRI ProbtrackX ISOVF ilf l
54960,IDP dMRI ProbtrackX ISOVF ilf r,Phenotype,IDP dMRI ProbtrackX ISOVF ilf r
54961,IDP T1 SIENAX CSF normalised volume,Phenotype,IDP T1 SIENAX CSF normalised volume
54962,IDP T1 SIENAX CSF unnormalised volume,Phenotype,IDP T1 SIENAX CSF unnormalised volume
54963,aseg lh intensity Cerebellum-Cortex,Phenotype,aseg lh intensity Cerebellum-Cortex
54964,aseg lh intensity Thalamus-Proper,Phenotype,aseg lh intensity Thalamus-Proper
54966,aseg lh intensity Putamen,Phenotype,aseg lh intensity Putamen
54968,wg lh intensity-contrast lateraloccipital,Phenotype,wg lh intensity-contrast lateraloccipital
54970,wg lh intensity-contrast lateralorbitofrontal,Phenotype,wg lh intensity-contrast lateralorbitofrontal
54972,wg lh intensity-contrast medialorbitofrontal,Phenotype,wg lh intensity-contrast medialorbitofrontal
54974,aseg rh intensity Cerebellum-Cortex,Phenotype,aseg rh intensity Cerebellum-Cortex
54975,aseg rh intensity Thalamus-Proper,Phenotype,aseg rh intensity Thalamus-Proper
54976,aseg rh intensity Putamen,Phenotype,aseg rh intensity Putamen
54977,wg lh intensity-contrast fusiform,Phenotype,wg lh intensity-contrast fusiform
54979,wg lh intensity-contrast inferiorparietal,Phenotype,wg lh intensity-contrast inferiorparietal
54980,wg lh intensity-contrast inferiortemporal,Phenotype,wg lh intensity-contrast inferiortemporal
54981,wg lh intensity-contrast isthmuscingulate,Phenotype,wg lh intensity-contrast isthmuscingulate
54982,wg lh intensity-contrast bankssts,Phenotype,wg lh intensity-contrast bankssts
54984,Highest math class taken (MTAG),Phenotype,Highest math class taken (MTAG)
54985,Rotator cuff injury,Phenotype,Rotator cuff injury
54986,Body fat percentage and type 2 diabetes (pairwise),Phenotype,Body fat percentage and type 2 diabetes (pairwise)
54987,Body mass index and HDL-C (pairwise),Phenotype,Body mass index and HDL-C (pairwise)
54988,Body mass index and LDL-C (pairwise),Phenotype,Body mass index and LDL-C (pairwise)
54989,Body mass index and triglycerides (pairwise),Phenotype,Body mass index and triglycerides (pairwise)
54990,Adipsin levels,Phenotype,Adipsin levels
54992,Adipsin levels in overweight individuals,Phenotype,Adipsin levels in overweight individuals
54993,Adipsin levels in type 2 diabetes,Phenotype,Adipsin levels in type 2 diabetes
54997,ghrelin levels in lean individuals,Phenotype,ghrelin levels in lean individuals
54999,ghrelin levels in overweight individuals,Phenotype,ghrelin levels in overweight individuals
55001,Chronic lymphocytic leukemia (time to first treatment),Phenotype,Chronic lymphocytic leukemia (time to first treatment)
55002,Gastrointestinal event in colchicine-treated recent myocardial infarction (time to event),Phenotype,Gastrointestinal event in colchicine-treated recent myocardial infarction (time to event)
55003,Podoconiosis,Phenotype,Podoconiosis
55005,HLA DR++ monocyte %monocyte,Phenotype,HLA DR++ monocyte %monocyte
55007,HLA DR++ monocyte %leukocyte,Phenotype,HLA DR++ monocyte %leukocyte
55008,HLA DR++ monocyte Absolute Count,Phenotype,HLA DR++ monocyte Absolute Count
55010,CD4+/CD8+ T cell,Phenotype,CD4+/CD8+ T cell
55012,CD4+ T cell %T cell,Phenotype,CD4+ T cell %T cell
55013,CD8+ T cell Absolute Count,Phenotype,CD8+ T cell Absolute Count
55015,CD8+ T cell %T cell,Phenotype,CD8+ T cell %T cell
55016,CD8dim T cell Absolute Count,Phenotype,CD8dim T cell Absolute Count
55017,CD8dim T cell %T cell,Phenotype,CD8dim T cell %T cell
55018,CD4-CD8- T cell Absolute Count,Phenotype,CD4-CD8- T cell Absolute Count
55019,CD4-CD8- T cell %T cell,Phenotype,CD4-CD8- T cell %T cell
55020,Lymphocyte Absolute Count,Phenotype,Lymphocyte Absolute Count
55022,T cell Absolute Count,Phenotype,T cell Absolute Count
55023,CD4+ T cell %leukocyte,Phenotype,CD4+ T cell %leukocyte
55024,CD8+ T cell %leukocyte,Phenotype,CD8+ T cell %leukocyte
55025,CD4+ CD8dim T cell Absolute Count,Phenotype,CD4+ CD8dim T cell Absolute Count
55027,CD4+ CD8dim T cell %lymphocyte,Phenotype,CD4+ CD8dim T cell %lymphocyte
55029,CD4+ CD8dim T cell %leukocyte,Phenotype,CD4+ CD8dim T cell %leukocyte
55030,CD8dim T cell %leukocyte,Phenotype,CD8dim T cell %leukocyte
55031,CD4-CD8- T cell %leukocyte,Phenotype,CD4-CD8- T cell %leukocyte
55032,CD8+ and CD8dim T cell %leukocyte,Phenotype,CD8+ and CD8dim T cell %leukocyte
55033,TCRgd T cell Absolute Count,Phenotype,TCRgd T cell Absolute Count
55035,TCRgd T cell %lymphocyte,Phenotype,TCRgd T cell %lymphocyte
55037,HLA DR+ T cell Absolute Count,Phenotype,HLA DR+ T cell Absolute Count
55040,HLA DR+ T cell%T cell,Phenotype,HLA DR+ T cell%T cell
55041,HLA DR+ T cell%lymphocyte,Phenotype,HLA DR+ T cell%lymphocyte
55043,Natural Killer T Absolute Count,Phenotype,Natural Killer T Absolute Count
55044,Natural Killer T %T cell,Phenotype,Natural Killer T %T cell
55045,Natural Killer T %lymphocyte,Phenotype,Natural Killer T %lymphocyte
55046,HLA DR+ CD4+ T cell Absolute Count,Phenotype,HLA DR+ CD4+ T cell Absolute Count
55047,HLA DR+ CD4+ T cell %T cell,Phenotype,HLA DR+ CD4+ T cell %T cell
55049,HLA DR+ CD4+ T cell %lymphocyte,Phenotype,HLA DR+ CD4+ T cell %lymphocyte
55050,HLA DR+ CD8+ T cell Absolute Count,Phenotype,HLA DR+ CD8+ T cell Absolute Count
55051,HLA DR+ CD8+ T cell %T cell,Phenotype,HLA DR+ CD8+ T cell %T cell
55052,HLA DR+ CD8+ T cell %lymphocyte,Phenotype,HLA DR+ CD8+ T cell %lymphocyte
55053,CD8+ Natural Killer T Absolute Count,Phenotype,CD8+ Natural Killer T Absolute Count
55055,CD8dim Natural Killer T Absolute Count,Phenotype,CD8dim Natural Killer T Absolute Count
55056,CD25 on CD28+ CD4+ T cell,Phenotype,CD25 on CD28+ CD4+ T cell
55058,FSC-A on plasmacytoid Dendritic Cell,Phenotype,FSC-A on plasmacytoid Dendritic Cell
55059,FSC-A on CD4+ T cell,Phenotype,FSC-A on CD4+ T cell
55061,IDP dMRI ProbtrackX FA str l,Phenotype,IDP dMRI ProbtrackX FA str l
55063,Brainstem global volume Whole-brainstem,Phenotype,Brainstem global volume Whole-brainstem
55065,aparc-Desikan lh volume caudalmiddlefrontal,Phenotype,aparc-Desikan lh volume caudalmiddlefrontal
55066,aparc-Desikan lh volume pericalcarine,Phenotype,aparc-Desikan lh volume pericalcarine
55067,Brainstem global volume Pons,Phenotype,Brainstem global volume Pons
55069,Brainstem global volume Medulla,Phenotype,Brainstem global volume Medulla
55071,IDP dMRI ProbtrackX MD unc r,Phenotype,IDP dMRI ProbtrackX MD unc r
55072,aparc-Desikan rh area caudalmiddlefrontal,Phenotype,aparc-Desikan rh area caudalmiddlefrontal
55073,aparc-Desikan rh area cuneus,Phenotype,aparc-Desikan rh area cuneus
55074,IDP dMRI ProbtrackX ICVF ar l,Phenotype,IDP dMRI ProbtrackX ICVF ar l
55075,IDP dMRI ProbtrackX ICVF ar r,Phenotype,IDP dMRI ProbtrackX ICVF ar r
55076,IDP dMRI ProbtrackX ICVF ifo r,Phenotype,IDP dMRI ProbtrackX ICVF ifo r
55077,IDP dMRI ProbtrackX ICVF cst r,Phenotype,IDP dMRI ProbtrackX ICVF cst r
55079,IDP dMRI ProbtrackX ICVF ilf r,Phenotype,IDP dMRI ProbtrackX ICVF ilf r
55080,IDP dMRI ProbtrackX ICVF ptr l,Phenotype,IDP dMRI ProbtrackX ICVF ptr l
55081,IDP dMRI ProbtrackX ICVF ptr r,Phenotype,IDP dMRI ProbtrackX ICVF ptr r
55082,IDP dMRI ProbtrackX ICVF slf l,Phenotype,IDP dMRI ProbtrackX ICVF slf l
55083,Keratoconus,Phenotype,Keratoconus
55084,Age-related hearing impairment (MTAG),Phenotype,Age-related hearing impairment (MTAG)
55087,Myeloperoxidase-DNA complexes,Phenotype,Myeloperoxidase-DNA complexes
55088,Odorant perception,Phenotype,Odorant perception
55089,Low hand grip strength (60 years and older) (EWGSOP),Phenotype,Low hand grip strength (60 years and older) (EWGSOP)
55090,Low hand grip strength (60 years and older) (FNIH),Phenotype,Low hand grip strength (60 years and older) (FNIH)
55091,Highest math class taken,Phenotype,Highest math class taken
55092,CD33dim HLA DR+ CD11b- Absolute Count,Phenotype,CD33dim HLA DR+ CD11b- Absolute Count
55094,Monocytic Myeloid-Derived Suppressor Cells Absolute Count,Phenotype,Monocytic Myeloid-Derived Suppressor Cells Absolute Count
55095,CD28- CD4-CD8- T cell %T cell,Phenotype,CD28- CD4-CD8- T cell %T cell
55096,CD20 on IgD- CD38dim B cell,Phenotype,CD20 on IgD- CD38dim B cell
55098,CD20 on memory B cell,Phenotype,CD20 on memory B cell
55101,CD20 on naive-mature B cell,Phenotype,CD20 on naive-mature B cell
55104,CD20 on unswitched memory B cell,Phenotype,CD20 on unswitched memory B cell
55107,CD20 on switched memory B cell,Phenotype,CD20 on switched memory B cell
55109,CD20 on IgD+ B cell,Phenotype,CD20 on IgD+ B cell
55110,CD20 on IgD+ CD38+ B cell,Phenotype,CD20 on IgD+ CD38+ B cell
55113,CD20 on IgD+ CD38dim B cell,Phenotype,CD20 on IgD+ CD38dim B cell
55115,CD20 on IgD- CD24- B cell,Phenotype,CD20 on IgD- CD24- B cell
55117,CD20 on IgD- CD27- B cell,Phenotype,CD20 on IgD- CD27- B cell
55119,CD20 on IgD- CD38- B cell,Phenotype,CD20 on IgD- CD38- B cell
55121,CD19 on switched memory B cell,Phenotype,CD19 on switched memory B cell
55122,CD19 on transitional B cell,Phenotype,CD19 on transitional B cell
55124,CD20 on B cell,Phenotype,CD20 on B cell
55126,CD20 on CD24+ CD27+ B cell,Phenotype,CD20 on CD24+ CD27+ B cell
55127,CD20 on IgD+ CD24+ B cell,Phenotype,CD20 on IgD+ CD24+ B cell
55128,CD20 on IgD+ CD24- B cell,Phenotype,CD20 on IgD+ CD24- B cell
55129,CD20 on IgD+ CD38- B cell,Phenotype,CD20 on IgD+ CD38- B cell
55130,CD19 on IgD+ CD24+ B cell,Phenotype,CD19 on IgD+ CD24+ B cell
55132,CD19 on IgD+ CD24- B cell,Phenotype,CD19 on IgD+ CD24- B cell
55134,CD19 on IgD+ CD38+ B cell,Phenotype,CD19 on IgD+ CD38+ B cell
55135,CD19 on IgD+ CD38dim B cell,Phenotype,CD19 on IgD+ CD38dim B cell
55136,CD19 on IgD- CD27- B cell,Phenotype,CD19 on IgD- CD27- B cell
55137,CD19 on IgD- CD38- B cell,Phenotype,CD19 on IgD- CD38- B cell
55138,CD19 on IgD- CD38dim B cell,Phenotype,CD19 on IgD- CD38dim B cell
55139,CD19 on unswitched memory B cell,Phenotype,CD19 on unswitched memory B cell
55140,CD64 on CD14+ CD16- monocyte,Phenotype,CD64 on CD14+ CD16- monocyte
55142,HLA DR on CD14+ CD16- monocyte,Phenotype,HLA DR on CD14+ CD16- monocyte
55144,CD40 on CD14- CD16+ monocyte,Phenotype,CD40 on CD14- CD16+ monocyte
55146,HLA DR on CD14+ monocyte,Phenotype,HLA DR on CD14+ monocyte
55147,CCR2 on CD14+ CD16+ monocyte,Phenotype,CCR2 on CD14+ CD16+ monocyte
55149,HLA DR on CD14- CD16-,Phenotype,HLA DR on CD14- CD16-
55151,HLA DR on monocyte,Phenotype,HLA DR on monocyte
55152,CD64 on CD14+ CD16+ monocyte,Phenotype,CD64 on CD14+ CD16+ monocyte
55153,CD4 on CD4+ T cell,Phenotype,CD4 on CD4+ T cell
55155,CD4 on Central Memory CD4+ T cell,Phenotype,CD4 on Central Memory CD4+ T cell
55156,CD4 on naive CD4+ T cell,Phenotype,CD4 on naive CD4+ T cell
55158,CD4 on Effector Memory CD4+ T cell,Phenotype,CD4 on Effector Memory CD4+ T cell
55160,CD4 on CD45RA+ CD4+ T cell,Phenotype,CD4 on CD45RA+ CD4+ T cell
55161,CD19 on B cell,Phenotype,CD19 on B cell
55162,CD64 on CD14- CD16-,Phenotype,CD64 on CD14- CD16-
55164,CD64 on monocyte,Phenotype,CD64 on monocyte
55165,HLA DR on CD14+ CD16+ monocyte,Phenotype,HLA DR on CD14+ CD16+ monocyte
55166,ThalamNuclei lh volume L-Sg,Phenotype,ThalamNuclei lh volume L-Sg
55168,wg rh intensity-contrast precuneus,Phenotype,wg rh intensity-contrast precuneus
55169,wg rh intensity-contrast rostralanteriorcingulate,Phenotype,wg rh intensity-contrast rostralanteriorcingulate
55171,wg rh intensity-contrast rostralmiddlefrontal,Phenotype,wg rh intensity-contrast rostralmiddlefrontal
55172,wg rh intensity-contrast superiorfrontal,Phenotype,wg rh intensity-contrast superiorfrontal
55174,IDP dMRI TBSS MD Sagittal stratum R,Phenotype,IDP dMRI TBSS MD Sagittal stratum R
55175,IDP dMRI TBSS MD Sagittal stratum L,Phenotype,IDP dMRI TBSS MD Sagittal stratum L
55176,aparc-DKTatlas rh volume lingual,Phenotype,aparc-DKTatlas rh volume lingual
55177,IDP dMRI TBSS MD Corticospinal tract R,Phenotype,IDP dMRI TBSS MD Corticospinal tract R
55179,aparc-DKTatlas rh volume pericalcarine,Phenotype,aparc-DKTatlas rh volume pericalcarine
55180,IDP dMRI TBSS MD Posterior thalamic radiation R,Phenotype,IDP dMRI TBSS MD Posterior thalamic radiation R
55181,IDP dMRI TBSS ICVF Retrolenticular part of internal capsule R,Phenotype,IDP dMRI TBSS ICVF Retrolenticular part of internal capsule R
55182,aparc-DKTatlas rh area caudalmiddlefrontal,Phenotype,aparc-DKTatlas rh area caudalmiddlefrontal
55183,aparc-DKTatlas rh area cuneus,Phenotype,aparc-DKTatlas rh area cuneus
55184,aparc-DKTatlas lh area pericalcarine,Phenotype,aparc-DKTatlas lh area pericalcarine
55185,IDP dMRI TBSS ICVF Posterior thalamic radiation R,Phenotype,IDP dMRI TBSS ICVF Posterior thalamic radiation R
55186,IDP dMRI TBSS ICVF Posterior thalamic radiation L,Phenotype,IDP dMRI TBSS ICVF Posterior thalamic radiation L
55187,IDP dMRI TBSS ICVF Sagittal stratum R,Phenotype,IDP dMRI TBSS ICVF Sagittal stratum R
55188,BA-exvivo lh area BA6,Phenotype,BA-exvivo lh area BA6
55189,BA-exvivo lh area V1,Phenotype,BA-exvivo lh area V1
55190,BA-exvivo lh area V2,Phenotype,BA-exvivo lh area V2
55191,BA-exvivo rh area V1,Phenotype,BA-exvivo rh area V1
55192,BA-exvivo rh area perirhinal,Phenotype,BA-exvivo rh area perirhinal
55194,BA-exvivo rh area entorhinal,Phenotype,BA-exvivo rh area entorhinal
55195,aparc-DKTatlas lh area caudalmiddlefrontal,Phenotype,aparc-DKTatlas lh area caudalmiddlefrontal
55196,IDP dMRI TBSS ICVF Superior corona radiata R,Phenotype,IDP dMRI TBSS ICVF Superior corona radiata R
55197,IDP dMRI TBSS ICVF Posterior corona radiata L,Phenotype,IDP dMRI TBSS ICVF Posterior corona radiata L
55198,wg rh intensity-contrast parsopercularis,Phenotype,wg rh intensity-contrast parsopercularis
55199,wg rh intensity-contrast parsorbitalis,Phenotype,wg rh intensity-contrast parsorbitalis
55200,wg rh intensity-contrast parstriangularis,Phenotype,wg rh intensity-contrast parstriangularis
55201,IDP T1 FAST ROIs L intracalc cortex,Phenotype,IDP T1 FAST ROIs L intracalc cortex
55202,wg rh intensity-contrast medialorbitofrontal,Phenotype,wg rh intensity-contrast medialorbitofrontal
55204,wg rh intensity-contrast middletemporal,Phenotype,wg rh intensity-contrast middletemporal
55205,wg rh intensity-contrast inferiortemporal,Phenotype,wg rh intensity-contrast inferiortemporal
55206,wg rh intensity-contrast lateraloccipital,Phenotype,wg rh intensity-contrast lateraloccipital
55207,wg rh intensity-contrast lateralorbitofrontal,Phenotype,wg rh intensity-contrast lateralorbitofrontal
55209,IDP T1 FAST ROIs R intracalc cortex,Phenotype,IDP T1 FAST ROIs R intracalc cortex
55210,IDP T1 FAST ROIs R planum temporale,Phenotype,IDP T1 FAST ROIs R planum temporale
55211,IDP T1 FAST ROIs L occ pole,Phenotype,IDP T1 FAST ROIs L occ pole
55213,IDP T1 FAST ROIs R cerebellum crus I,Phenotype,IDP T1 FAST ROIs R cerebellum crus I
55215,IDP T1 FAST ROIs R occ pole,Phenotype,IDP T1 FAST ROIs R occ pole
55216,IDP T1 FAST ROIs L caudate,Phenotype,IDP T1 FAST ROIs L caudate
55217,IDP T1 FAST ROIs L putamen,Phenotype,IDP T1 FAST ROIs L putamen
55218,IDP T1 FAST ROIs R putamen,Phenotype,IDP T1 FAST ROIs R putamen
55219,Left–right brain asymmetry,Phenotype,Left–right brain asymmetry
55222,Chronic pain,Phenotype,Chronic pain
55223,Dilated cardiomyopathy,Phenotype,Dilated cardiomyopathy
55224,Childhood asthma exacerbations in long-acting beta2-agonist treatment,Phenotype,Childhood asthma exacerbations in long-acting beta2-agonist treatment
55225,aparc-a2009s rh volume Pole-occipital,Phenotype,aparc-a2009s rh volume Pole-occipital
55226,aparc-Desikan lh area caudalmiddlefrontal,Phenotype,aparc-Desikan lh area caudalmiddlefrontal
55227,aparc-Desikan lh area pericalcarine,Phenotype,aparc-Desikan lh area pericalcarine
55228,IDP dMRI TBSS L3 Posterior thalamic radiation L,Phenotype,IDP dMRI TBSS L3 Posterior thalamic radiation L
55230,IDP dMRI TBSS L3 Sagittal stratum R,Phenotype,IDP dMRI TBSS L3 Sagittal stratum R
55231,IDP dMRI TBSS ICVF Superior longitudinal fasciculus R,Phenotype,IDP dMRI TBSS ICVF Superior longitudinal fasciculus R
55232,IDP dMRI TBSS ICVF Superior longitudinal fasciculus L,Phenotype,IDP dMRI TBSS ICVF Superior longitudinal fasciculus L
55233,IDP dMRI TBSS ICVF Sagittal stratum L,Phenotype,IDP dMRI TBSS ICVF Sagittal stratum L
55243,Pancreatic ductal adenocarcinoma x smoking interaction,Phenotype,Pancreatic ductal adenocarcinoma x smoking interaction
55244,Sick sinus syndrome,Phenotype,Sick sinus syndrome
55245,Plasma Blast-Plasma Cell %lymphocyte,Phenotype,Plasma Blast-Plasma Cell %lymphocyte
55247,CD8dim Natural Killer T %T cell,Phenotype,CD8dim Natural Killer T %T cell
55248,CD8dim Natural Killer T %lymphocyte,Phenotype,CD8dim Natural Killer T %lymphocyte
55249,CD4-CD8- Natural Killer T Absolute Count,Phenotype,CD4-CD8- Natural Killer T Absolute Count
55250,CD4-CD8- Natural Killer T %T cell,Phenotype,CD4-CD8- Natural Killer T %T cell
55251,CD4-CD8- Natural Killer T %lymphocyte,Phenotype,CD4-CD8- Natural Killer T %lymphocyte
55252,IgD+ CD38- B cell %B cell,Phenotype,IgD+ CD38- B cell %B cell
55254,IgD on unswitched memory B cell,Phenotype,IgD on unswitched memory B cell
55257,IgD on transitional B cell,Phenotype,IgD on transitional B cell
55259,CD3 on naive CD8+ T cell,Phenotype,CD3 on naive CD8+ T cell
55261,IgD on IgD+ CD24+ B cell,Phenotype,IgD on IgD+ CD24+ B cell
55263,IgD on IgD+ CD38+ B cell,Phenotype,IgD on IgD+ CD38+ B cell
55265,CD25 on IgD- CD24- B cell,Phenotype,CD25 on IgD- CD24- B cell
55266,CD20 on transitional B cell,Phenotype,CD20 on transitional B cell
55268,CD24 on CD24+ CD27+ B cell,Phenotype,CD24 on CD24+ CD27+ B cell
55271,CD24 on IgD+ CD24+ B cell,Phenotype,CD24 on IgD+ CD24+ B cell
55275,CD24 on IgD+ CD38- B cell,Phenotype,CD24 on IgD+ CD38- B cell
55276,CD24 on IgD+ CD38+ B cell,Phenotype,CD24 on IgD+ CD38+ B cell
55278,CD24 on IgD- CD38- B cell,Phenotype,CD24 on IgD- CD38- B cell
55279,CD24 on IgD- CD38dim B cell,Phenotype,CD24 on IgD- CD38dim B cell
55280,CD24 on memory B cell,Phenotype,CD24 on memory B cell
55281,CD24 on unswitched memory B cell,Phenotype,CD24 on unswitched memory B cell
55282,CD24 on switched memory B cell,Phenotype,CD24 on switched memory B cell
55283,CD24 on transitional B cell,Phenotype,CD24 on transitional B cell
55285,CD3 on HLA DR+ T cell,Phenotype,CD3 on HLA DR+ T cell
55287,CD3 on Natural Killer T,Phenotype,CD3 on Natural Killer T
55288,CD3 on Naive CD4+ T cell,Phenotype,CD3 on Naive CD4+ T cell
55290,CD3 on CD45RA+ CD4+ T cell,Phenotype,CD3 on CD45RA+ CD4+ T cell
55291,IDP dMRI TBSS MO Retrolenticular part of internal capsule R,Phenotype,IDP dMRI TBSS MO Retrolenticular part of internal capsule R
55292,IDP dMRI TBSS MO Superior corona radiata R,Phenotype,IDP dMRI TBSS MO Superior corona radiata R
55294,IDP dMRI TBSS MO Superior corona radiata L,Phenotype,IDP dMRI TBSS MO Superior corona radiata L
55296,IDP dMRI TBSS MO Posterior corona radiata R,Phenotype,IDP dMRI TBSS MO Posterior corona radiata R
55297,IDP dMRI ProbtrackX MO str l,Phenotype,IDP dMRI ProbtrackX MO str l
55299,IDP dMRI ProbtrackX MO str r,Phenotype,IDP dMRI ProbtrackX MO str r
55301,IDP dMRI TBSS MO Body of corpus callosum,Phenotype,IDP dMRI TBSS MO Body of corpus callosum
55302,IDP dMRI TBSS MO Fornix,Phenotype,IDP dMRI TBSS MO Fornix
55303,aparc-Desikan rh volume lingual,Phenotype,aparc-Desikan rh volume lingual
55304,aparc-DKTatlas lh volume pericalcarine,Phenotype,aparc-DKTatlas lh volume pericalcarine
55305,BA-exvivo rh volume V1,Phenotype,BA-exvivo rh volume V1
55306,BA-exvivo rh volume V2,Phenotype,BA-exvivo rh volume V2
55307,aparc-DKTatlas lh volume caudalanteriorcingulate,Phenotype,aparc-DKTatlas lh volume caudalanteriorcingulate
55308,aparc-DKTatlas lh volume caudalmiddlefrontal,Phenotype,aparc-DKTatlas lh volume caudalmiddlefrontal
55309,aparc-Desikan rh volume pericalcarine,Phenotype,aparc-Desikan rh volume pericalcarine
55310,BA-exvivo lh volume V2,Phenotype,BA-exvivo lh volume V2
55311,IDP dMRI TBSS ICVF Retrolenticular part of internal capsule L,Phenotype,IDP dMRI TBSS ICVF Retrolenticular part of internal capsule L
55313,aparc-pial rh area pericalcarine,Phenotype,aparc-pial rh area pericalcarine
55314,IDP dMRI ProbtrackX L3 unc r,Phenotype,IDP dMRI ProbtrackX L3 unc r
55315,IDP dMRI TBSS ICVF Fornix,Phenotype,IDP dMRI TBSS ICVF Fornix
55316,IDP dMRI TBSS ICVF Cerebral peduncle R,Phenotype,IDP dMRI TBSS ICVF Cerebral peduncle R
55317,IDP dMRI TBSS ICVF Cerebral peduncle L,Phenotype,IDP dMRI TBSS ICVF Cerebral peduncle L
55318,wg lh intensity-contrast posteriorcingulate,Phenotype,wg lh intensity-contrast posteriorcingulate
55320,wg lh intensity-contrast rostralanteriorcingulate,Phenotype,wg lh intensity-contrast rostralanteriorcingulate
55321,wg lh intensity-contrast rostralmiddlefrontal,Phenotype,wg lh intensity-contrast rostralmiddlefrontal
55322,wg lh intensity-contrast superiorfrontal,Phenotype,wg lh intensity-contrast superiorfrontal
55323,wg rh intensity-contrast fusiform,Phenotype,wg rh intensity-contrast fusiform
55324,wg rh intensity-contrast inferiorparietal,Phenotype,wg rh intensity-contrast inferiorparietal
55325,wg lh intensity-contrast frontalpole,Phenotype,wg lh intensity-contrast frontalpole
55326,wg lh intensity-contrast temporalpole,Phenotype,wg lh intensity-contrast temporalpole
55329,wg lh intensity-contrast superiorparietal,Phenotype,wg lh intensity-contrast superiorparietal
55330,wg lh intensity-contrast superiortemporal,Phenotype,wg lh intensity-contrast superiortemporal
55331,wg lh intensity-contrast supramarginal,Phenotype,wg lh intensity-contrast supramarginal
55332,wg lh intensity-contrast middletemporal,Phenotype,wg lh intensity-contrast middletemporal
55334,wg lh intensity-contrast parsopercularis,Phenotype,wg lh intensity-contrast parsopercularis
55335,wg lh intensity-contrast parsorbitalis,Phenotype,wg lh intensity-contrast parsorbitalis
55337,wg lh intensity-contrast parstriangularis,Phenotype,wg lh intensity-contrast parstriangularis
55339,Rapid response to perioperative phenylephrine (change in diastolic blood pressure),Phenotype,Rapid response to perioperative phenylephrine (change in diastolic blood pressure)
55340,Liver fibrogenesis (alpha smooth muscle actin levels),Phenotype,Liver fibrogenesis (alpha smooth muscle actin levels)
55341,Liver fibrosis (total hepatic collagen content),Phenotype,Liver fibrosis (total hepatic collagen content)
55342,Body fat percentage and HDL-C (pairwise),Phenotype,Body fat percentage and HDL-C (pairwise)
55343,Body fat percentage and LDL-C (pairwise),Phenotype,Body fat percentage and LDL-C (pairwise)
55344,Body fat percentage and triglycerides (pairwise),Phenotype,Body fat percentage and triglycerides (pairwise)
55345,Interleukin-6 levels in overweight individuals,Phenotype,Interleukin-6 levels in overweight individuals
55347,Insulin levels in lean individuals,Phenotype,Insulin levels in lean individuals
55351,Glucagon levels,Phenotype,Glucagon levels
55353,Glucagon levels in overweight individuals,Phenotype,Glucagon levels in overweight individuals
55360,CD28- CD25++ CD8+ T cell Absolute Count,Phenotype,CD28- CD25++ CD8+ T cell Absolute Count
55361,CD127- CD8+ T cell Absolute Count,Phenotype,CD127- CD8+ T cell Absolute Count
55362,CD28- CD8+ T cell %T cell,Phenotype,CD28- CD8+ T cell %T cell
55364,CD28- CD8+ T cell %CD8+ T cell,Phenotype,CD28- CD8+ T cell %CD8+ T cell
55366,CD28- CD8+ T cell Absolute Count,Phenotype,CD28- CD8+ T cell Absolute Count
55367,CD28+ CD45RA+ CD8+ T cell %T cell,Phenotype,CD28+ CD45RA+ CD8+ T cell %T cell
55369,CD28+ CD45RA+ CD8+ T cell Absolute Count,Phenotype,CD28+ CD45RA+ CD8+ T cell Absolute Count
55371,CD28+ CD45RA- CD8+ T cell %CD8+ T cell,Phenotype,CD28+ CD45RA- CD8+ T cell %CD8+ T cell
55373,Naive CD4+ T cell Absolute Count,Phenotype,Naive CD4+ T cell Absolute Count
55374,Naive CD4+ T cell %CD4+ T cell,Phenotype,Naive CD4+ T cell %CD4+ T cell
55375,Effector Memory CD4+ T cell %CD4+ T cell,Phenotype,Effector Memory CD4+ T cell %CD4+ T cell
55377,Effector Memory CD4+ T cell %T cell,Phenotype,Effector Memory CD4+ T cell %T cell
55378,Terminally Differentiated CD4+ T cell Absolute Count,Phenotype,Terminally Differentiated CD4+ T cell Absolute Count
55380,Terminally Differentiated CD4+ T cell %CD4+ T cell,Phenotype,Terminally Differentiated CD4+ T cell %CD4+ T cell
55381,Terminally Differentiated CD4+ T cell %T cell,Phenotype,Terminally Differentiated CD4+ T cell %T cell
55382,Naive CD8+ T cell Absolute Count,Phenotype,Naive CD8+ T cell Absolute Count
55384,Naive CD8+ T cell %T cell,Phenotype,Naive CD8+ T cell %T cell
55385,Effector Memory CD8+ T cell Absolute Count,Phenotype,Effector Memory CD8+ T cell Absolute Count
55386,Terminally Differentiated CD4-CD8- T cell %T cell,Phenotype,Terminally Differentiated CD4-CD8- T cell %T cell
55388,CD28- CD4-CD8- T cell Absolute Count,Phenotype,CD28- CD4-CD8- T cell Absolute Count
55390,CD28- CD8dim T cell %T cell,Phenotype,CD28- CD8dim T cell %T cell
55391,CD45RA+ CD8+ T cell Absolute Count,Phenotype,CD45RA+ CD8+ T cell Absolute Count
55392,CD45RA+ CD8+ T cell %T cell,Phenotype,CD45RA+ CD8+ T cell %T cell
55394,Naive CD4-CD8- T cell %T cell,Phenotype,Naive CD4-CD8- T cell %T cell
55395,Effector Memory CD4-CD8- T cell Absolute Count,Phenotype,Effector Memory CD4-CD8- T cell Absolute Count
55396,Effector Memory CD4-CD8- T cell %T cell,Phenotype,Effector Memory CD4-CD8- T cell %T cell
55397,Terminally Differentiated CD4-CD8- T cell Absolute Count,Phenotype,Terminally Differentiated CD4-CD8- T cell Absolute Count
55399,CD28- CD8dim T cell Absolute Count,Phenotype,CD28- CD8dim T cell Absolute Count
55400,CD28+ CD45RA+ CD8dim T cell %T cell,Phenotype,CD28+ CD45RA+ CD8dim T cell %T cell
55402,CD28+ CD45RA+ CD8dim T cell %CD8dim T cell,Phenotype,CD28+ CD45RA+ CD8dim T cell %CD8dim T cell
55403,CD28- CD127- CD25++ CD8+ T cell Absolute Count,Phenotype,CD28- CD127- CD25++ CD8+ T cell Absolute Count
55405,CD25++ CD4+ T cell %T cell,Phenotype,CD25++ CD4+ T cell %T cell
55406,CD25++ CD45RA- CD4 not regulatory T cell Absolute Count,Phenotype,CD25++ CD45RA- CD4 not regulatory T cell Absolute Count
55407,CD25++ CD45RA- CD4 not regulatory T cell %T cell,Phenotype,CD25++ CD45RA- CD4 not regulatory T cell %T cell
55408,CD45RA- CD4+ T cell %T cell,Phenotype,CD45RA- CD4+ T cell %T cell
55409,wg rh intensity-contrast temporalpole,Phenotype,wg rh intensity-contrast temporalpole
55412,IDP T2 FLAIR BIANCA WMH volume,Phenotype,IDP T2 FLAIR BIANCA WMH volume
55413,IDP SWI T2star left thalamus,Phenotype,IDP SWI T2star left thalamus
55414,CD4 on activated CD4 regulatory T cell,Phenotype,CD4 on activated CD4 regulatory T cell
55416,CD4 on CD39+ secreting CD4 regulatory T cell,Phenotype,CD4 on CD39+ secreting CD4 regulatory T cell
55417,CD45 on CD33- HLA DR+,Phenotype,CD45 on CD33- HLA DR+
55419,CD8 on Central Memory CD8+ T cell,Phenotype,CD8 on Central Memory CD8+ T cell
55423,CD8 on naive CD8+ T cell,Phenotype,CD8 on naive CD8+ T cell
55424,CD8 on Effector Memory CD8+ T cell,Phenotype,CD8 on Effector Memory CD8+ T cell
55426,CD8 on CD8+ T cell,Phenotype,CD8 on CD8+ T cell
55427,SSC-A on CD4+ T cell,Phenotype,SSC-A on CD4+ T cell
55428,SSC-A on HLA DR+ T cell,Phenotype,SSC-A on HLA DR+ T cell
55429,CD80 on myeloid Dendritic Cell,Phenotype,CD80 on myeloid Dendritic Cell
55431,CD80 on CD62L+ myeloid Dendritic Cell,Phenotype,CD80 on CD62L+ myeloid Dendritic Cell
55433,CD8 on Natural Killer T,Phenotype,CD8 on Natural Killer T
55434,CD4 on CD28+ CD4+ T cell,Phenotype,CD4 on CD28+ CD4+ T cell
55435,CD4 on CD39+ activated CD4 regulatory T cell,Phenotype,CD4 on CD39+ activated CD4 regulatory T cell
55436,wg rh intensity-contrast superiorparietal,Phenotype,wg rh intensity-contrast superiorparietal
55437,wg rh intensity-contrast supramarginal,Phenotype,wg rh intensity-contrast supramarginal
55438,wg rh intensity-contrast frontalpole,Phenotype,wg rh intensity-contrast frontalpole
55439,IDP SWI T2star left caudate,Phenotype,IDP SWI T2star left caudate
55440,IDP SWI T2star right caudate,Phenotype,IDP SWI T2star right caudate
55441,SSC-A on myeloid Dendritic Cell,Phenotype,SSC-A on myeloid Dendritic Cell
55443,IDP dMRI TBSS L1 Superior longitudinal fasciculus L,Phenotype,IDP dMRI TBSS L1 Superior longitudinal fasciculus L
55444,IDP dMRI TBSS L2 Corticospinal tract R,Phenotype,IDP dMRI TBSS L2 Corticospinal tract R
55446,IDP dMRI TBSS L1 Corticospinal tract R,Phenotype,IDP dMRI TBSS L1 Corticospinal tract R
55447,IDP dMRI TBSS L1 Superior corona radiata L,Phenotype,IDP dMRI TBSS L1 Superior corona radiata L
55449,IDP dMRI TBSS L1 Sagittal stratum R,Phenotype,IDP dMRI TBSS L1 Sagittal stratum R
55450,aparc-a2009s lh area S-orbital-med-olfact,Phenotype,aparc-a2009s lh area S-orbital-med-olfact
55451,IDP dMRI TBSS OD Body of corpus callosum,Phenotype,IDP dMRI TBSS OD Body of corpus callosum
55452,IDP dMRI TBSS OD Superior corona radiata L,Phenotype,IDP dMRI TBSS OD Superior corona radiata L
55453,IDP dMRI TBSS OD Posterior corona radiata R,Phenotype,IDP dMRI TBSS OD Posterior corona radiata R
55454,aparc-DKTatlas rh area insula,Phenotype,aparc-DKTatlas rh area insula
55456,aparc-a2009s lh area G-cuneus,Phenotype,aparc-a2009s lh area G-cuneus
55457,aparc-a2009s lh area S-calcarine,Phenotype,aparc-a2009s lh area S-calcarine
55458,IDP dMRI ProbtrackX OD str l,Phenotype,IDP dMRI ProbtrackX OD str l
55459,IDP dMRI ProbtrackX OD str r,Phenotype,IDP dMRI ProbtrackX OD str r
55460,IDP dMRI TBSS ISOVF Corticospinal tract R,Phenotype,IDP dMRI TBSS ISOVF Corticospinal tract R
55461,IDP dMRI TBSS ISOVF Anterior corona radiata R,Phenotype,IDP dMRI TBSS ISOVF Anterior corona radiata R
55463,IDP dMRI TBSS ISOVF Anterior corona radiata L,Phenotype,IDP dMRI TBSS ISOVF Anterior corona radiata L
55464,IDP dMRI TBSS ISOVF Posterior corona radiata R,Phenotype,IDP dMRI TBSS ISOVF Posterior corona radiata R
55466,QC T2 FLAIR-to-T1 linear alignment discrepancy,Phenotype,QC T2 FLAIR-to-T1 linear alignment discrepancy
55467,aseg lh volume VentralDC,Phenotype,aseg lh volume VentralDC
55468,aseg lh volume choroid-plexus,Phenotype,aseg lh volume choroid-plexus
55469,aseg lh volume CerebralWhiteMatter,Phenotype,aseg lh volume CerebralWhiteMatter
55470,aseg global volume VentricleChoroid,Phenotype,aseg global volume VentricleChoroid
55472,aseg global volume 4th-Ventricle,Phenotype,aseg global volume 4th-Ventricle
55473,aseg global volume WM-hypointensities,Phenotype,aseg global volume WM-hypointensities
55474,IDP T1 FAST ROIs L cerebellum VIIIa,Phenotype,IDP T1 FAST ROIs L cerebellum VIIIa
55476,IDP T1 FAST ROIs V cerebellum VIIIa,Phenotype,IDP T1 FAST ROIs V cerebellum VIIIa
55477,IDP T1 FAST ROIs L cerebellum VIIIb,Phenotype,IDP T1 FAST ROIs L cerebellum VIIIb
55478,IDP T1 FAST ROIs V cerebellum VIIIb,Phenotype,IDP T1 FAST ROIs V cerebellum VIIIb
55480,IDP T1 FAST ROIs V cerebellum IX,Phenotype,IDP T1 FAST ROIs V cerebellum IX
55481,Body mass index and fasting glucose (pairwise),Phenotype,Body mass index and fasting glucose (pairwise)
55482,Body mass index and systole blood pressure (pairwise),Phenotype,Body mass index and systole blood pressure (pairwise)
55483,Body mass index and coronary artery disease (pairwise),Phenotype,Body mass index and coronary artery disease (pairwise)
55484,Waist-hip ratio and HDL-C (pairwise),Phenotype,Waist-hip ratio and HDL-C (pairwise)
55485,Waist-hip ratio and systolic blood pressure (pairwise),Phenotype,Waist-hip ratio and systolic blood pressure (pairwise)
55486,Visfatin levels in type 2 diabetes,Phenotype,Visfatin levels in type 2 diabetes
55488,Glucose-dependent insulinotropic peptide levels,Phenotype,Glucose-dependent insulinotropic peptide levels
55490,Glucagon-like peptide-1 levels in overweight individuals,Phenotype,Glucagon-like peptide-1 levels in overweight individuals
55492,ghrelin levels,Phenotype,ghrelin levels
55495,Glucose-dependent insulinotropic peptide levels in lean individuals,Phenotype,Glucose-dependent insulinotropic peptide levels in lean individuals
55497,Fibrosis-4 index in high alcohol intake,Phenotype,Fibrosis-4 index in high alcohol intake
55500,Aspartate transaminase levels in high alcohol intake,Phenotype,Aspartate transaminase levels in high alcohol intake
55501,Forns index in high alcohol intake,Phenotype,Forns index in high alcohol intake
55504,Hair morphology traits,Phenotype,Hair morphology traits
55505,Depression (broad),Phenotype,Depression (broad)
55509,Nicotine dependence and major depression (severity of comorbidity),Phenotype,Nicotine dependence and major depression (severity of comorbidity)
55510,Lateral ventricular volume in normal aging,Phenotype,Lateral ventricular volume in normal aging
55511,Offspring birth weight,Phenotype,Offspring birth weight
55512,Cholesteryl ester transfer protein levels,Phenotype,Cholesteryl ester transfer protein levels
55513,Response to opioid analgesics in cancer (pain decrease),Phenotype,Response to opioid analgesics in cancer (pain decrease)
55526,Anti-rubella virus IgG levels,Phenotype,Anti-rubella virus IgG levels
55527,Subiculum volume (corrected for total hippocampal volume),Phenotype,Subiculum volume (corrected for total hippocampal volume)
55528,Ewing sarcoma,Phenotype,Ewing sarcoma
55529,Hip bone mineral density and total body fat mass (bivariate analysis),Phenotype,Hip bone mineral density and total body fat mass (bivariate analysis)
55530,Falling risk,Phenotype,Falling risk
55531,Eye color traits,Phenotype,Eye color traits
55532,Anthropometric traits (multi-trait analysis),Phenotype,Anthropometric traits (multi-trait analysis)
55533,Skin pigmentation traits,Phenotype,Skin pigmentation traits
55534,Endometrial cancer (Non-endometrioid histology),Phenotype,Endometrial cancer (Non-endometrioid histology)
55535,Endometrial cancer (endometrioid histology),Phenotype,Endometrial cancer (endometrioid histology)
55536,Extremely high intelligence,Phenotype,Extremely high intelligence
55552,Anorexia nervosa or obsessive-compulsive disorder,Phenotype,Anorexia nervosa or obsessive-compulsive disorder
55553,Postburn scar pliability,Phenotype,Postburn scar pliability
55554,Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count),Phenotype,Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)
55555,Eudaimonic well-being,Phenotype,Eudaimonic well-being
55556,Lung cancer (SNP x SNP interaction),Phenotype,Lung cancer (SNP x SNP interaction)
55557,Relative amplitude of rest-activity cycles,Phenotype,Relative amplitude of rest-activity cycles
55558,Disrupted circadian rhythm (low relative amplitude of rest-activity cycles),Phenotype,Disrupted circadian rhythm (low relative amplitude of rest-activity cycles)
55589,Adrenomedullin levels,Phenotype,Adrenomedullin levels
55591,Growth differentiation factor-15 levels,Phenotype,Growth differentiation factor-15 levels
55593,C-C motif chemokine 20 levels,Phenotype,C-C motif chemokine 20 levels
55594,Ovarian cancer-related tumor marker CA 125 levels,Phenotype,Ovarian cancer-related tumor marker CA 125 levels
55597,Cathepsin L1 levels,Phenotype,Cathepsin L1 levels
55601,CX3CL1 levels,Phenotype,CX3CL1 levels
55604,Estimated glomerular filtration rate (creatinine-- Rapid3),Phenotype,Estimated glomerular filtration rate (creatinine-- Rapid3)
55605,Estimated glomerular filtration rate (creatinine-- CKDi25),Phenotype,Estimated glomerular filtration rate (creatinine-- CKDi25)
55606,Stool frequency,Phenotype,Stool frequency
55608,Body composition traits,Phenotype,Body composition traits
55610,Gut microbiota alpha diversity (Simpson index),Phenotype,Gut microbiota alpha diversity (Simpson index)
55612,Gut microbiota alpha diversity (Inverse Simpson index),Phenotype,Gut microbiota alpha diversity (Inverse Simpson index)
55618,Verbal-numerical reasoning,Phenotype,Verbal-numerical reasoning
55619,Low myopia vs hyperopia,Phenotype,Low myopia vs hyperopia
55620,CD99L2/RARRES2 protein level ratio,Phenotype,CD99L2/RARRES2 protein level ratio
55621,CD84/SDC4 protein level ratio,Phenotype,CD84/SDC4 protein level ratio
55623,CD84/TREML2 protein level ratio,Phenotype,CD84/TREML2 protein level ratio
55624,CD93/CLEC14A protein level ratio,Phenotype,CD93/CLEC14A protein level ratio
55625,GP1BA/SDC4 protein level ratio,Phenotype,GP1BA/SDC4 protein level ratio
55627,CD79B/TNFRSF13B protein level ratio,Phenotype,CD79B/TNFRSF13B protein level ratio
55629,CD79B/TNFRSF4 protein level ratio,Phenotype,CD79B/TNFRSF4 protein level ratio
55631,CD83/HAVCR2 protein level ratio,Phenotype,CD83/HAVCR2 protein level ratio
55633,CD83/IL12A_IL12B protein level ratio,Phenotype,CD83/IL12A_IL12B protein level ratio
55635,CD83/LAMP3 protein level ratio,Phenotype,CD83/LAMP3 protein level ratio
55637,CD83/TNFRSF4 protein level ratio,Phenotype,CD83/TNFRSF4 protein level ratio
55639,CD83/TREM2 protein level ratio,Phenotype,CD83/TREM2 protein level ratio
55640,CD74/JAM2 protein level ratio,Phenotype,CD74/JAM2 protein level ratio
55642,CD74/LILRB4 protein level ratio,Phenotype,CD74/LILRB4 protein level ratio
55643,CD74/NPDC1 protein level ratio,Phenotype,CD74/NPDC1 protein level ratio
55645,CD74/TIMD4 protein level ratio,Phenotype,CD74/TIMD4 protein level ratio
55646,CD74/TNFRSF21 protein level ratio,Phenotype,CD74/TNFRSF21 protein level ratio
55648,CD79B/FCRL1 protein level ratio,Phenotype,CD79B/FCRL1 protein level ratio
55650,CD79B/FCRL2 protein level ratio,Phenotype,CD79B/FCRL2 protein level ratio
55653,CD79B/ICAM3 protein level ratio,Phenotype,CD79B/ICAM3 protein level ratio
55654,CD84/CDKN1A protein level ratio,Phenotype,CD84/CDKN1A protein level ratio
55655,CDC37/SNX9 protein level ratio,Phenotype,CDC37/SNX9 protein level ratio
55656,CDCP1/IL18BP protein level ratio,Phenotype,CDCP1/IL18BP protein level ratio
55658,CDCP1/MSR1 protein level ratio,Phenotype,CDCP1/MSR1 protein level ratio
55659,CDH17/GALNT3 protein level ratio,Phenotype,CDH17/GALNT3 protein level ratio
55660,GOPC/PLXNA4 protein level ratio,Phenotype,GOPC/PLXNA4 protein level ratio
55661,GP1BA/HBEGF protein level ratio,Phenotype,GP1BA/HBEGF protein level ratio
55662,CD69/TXNDC5 protein level ratio,Phenotype,CD69/TXNDC5 protein level ratio
55663,CD74/DLL1 protein level ratio,Phenotype,CD74/DLL1 protein level ratio
55665,CD74/IL18BP protein level ratio,Phenotype,CD74/IL18BP protein level ratio
55667,HSPA1A/MITD1 protein level ratio,Phenotype,HSPA1A/MITD1 protein level ratio
55669,HSPA1A/STIP1 protein level ratio,Phenotype,HSPA1A/STIP1 protein level ratio
55672,HSPA1A/WWP2 protein level ratio,Phenotype,HSPA1A/WWP2 protein level ratio
55675,HSPB1/KYAT1 protein level ratio,Phenotype,HSPB1/KYAT1 protein level ratio
55676,HSPB1/PLIN3 protein level ratio,Phenotype,HSPB1/PLIN3 protein level ratio
55677,HSPB1/QDPR protein level ratio,Phenotype,HSPB1/QDPR protein level ratio
55678,HSPG2/SMOC2 protein level ratio,Phenotype,HSPG2/SMOC2 protein level ratio
55679,HSPG2/VASN protein level ratio,Phenotype,HSPG2/VASN protein level ratio
55680,HYOU1/PTPRF protein level ratio,Phenotype,HYOU1/PTPRF protein level ratio
55681,ICAM2/IL7R protein level ratio,Phenotype,ICAM2/IL7R protein level ratio
55682,ICAM3/LY9 protein level ratio,Phenotype,ICAM3/LY9 protein level ratio
55685,ICAM3/NOTCH1 protein level ratio,Phenotype,ICAM3/NOTCH1 protein level ratio
55686,IDS/SMPDL3A protein level ratio,Phenotype,IDS/SMPDL3A protein level ratio
55687,IFNGR1/LTBR protein level ratio,Phenotype,IFNGR1/LTBR protein level ratio
55689,IGF2R/LGMN protein level ratio,Phenotype,IGF2R/LGMN protein level ratio
55691,IGFBP6/SMOC2 protein level ratio,Phenotype,IGFBP6/SMOC2 protein level ratio
55692,IGSF8/NECTIN2 protein level ratio,Phenotype,IGSF8/NECTIN2 protein level ratio
55693,IL18BP/THBD protein level ratio,Phenotype,IL18BP/THBD protein level ratio
55694,IL1R2/MEGF9 protein level ratio,Phenotype,IL1R2/MEGF9 protein level ratio
55696,IKBKG/TJAP1 protein level ratio,Phenotype,IKBKG/TJAP1 protein level ratio
55698,IL12A_IL12B/LAG3 protein level ratio,Phenotype,IL12A_IL12B/LAG3 protein level ratio
55700,HYOU1/THBD protein level ratio,Phenotype,HYOU1/THBD protein level ratio
55702,HPCAL1/PLA2G4A protein level ratio,Phenotype,HPCAL1/PLA2G4A protein level ratio
55703,HSPA1A/MGLL protein level ratio,Phenotype,HSPA1A/MGLL protein level ratio
55704,CEACAM8/PGLYRP1 protein level ratio,Phenotype,CEACAM8/PGLYRP1 protein level ratio
55706,CELA3A/CPA1 protein level ratio,Phenotype,CELA3A/CPA1 protein level ratio
55708,CELA3A/CPB1 protein level ratio,Phenotype,CELA3A/CPB1 protein level ratio
55710,CELA3A/CTRB1 protein level ratio,Phenotype,CELA3A/CTRB1 protein level ratio
55712,CELA3A/CTRC protein level ratio,Phenotype,CELA3A/CTRC protein level ratio
55713,CELA3A/KIRREL2 protein level ratio,Phenotype,CELA3A/KIRREL2 protein level ratio
55715,CELA3A/PLA2G1B protein level ratio,Phenotype,CELA3A/PLA2G1B protein level ratio
55716,CEP20/LBR protein level ratio,Phenotype,CEP20/LBR protein level ratio
55718,CEP20/MED18 protein level ratio,Phenotype,CEP20/MED18 protein level ratio
55719,CEP20/PRKRA protein level ratio,Phenotype,CEP20/PRKRA protein level ratio
55721,CDKN2D/TBL1X protein level ratio,Phenotype,CDKN2D/TBL1X protein level ratio
55722,CDSN/KLK8 protein level ratio,Phenotype,CDSN/KLK8 protein level ratio
55723,CDSN/LY6D protein level ratio,Phenotype,CDSN/LY6D protein level ratio
55724,CDSN/NECTIN4 protein level ratio,Phenotype,CDSN/NECTIN4 protein level ratio
55725,CEACAM8/MMP9 protein level ratio,Phenotype,CEACAM8/MMP9 protein level ratio
55726,CEP43/MPHOSPH8 protein level ratio,Phenotype,CEP43/MPHOSPH8 protein level ratio
55727,CEP43/PLXNB3 protein level ratio,Phenotype,CEP43/PLXNB3 protein level ratio
55728,IPCEF1/TXLNA protein level ratio,Phenotype,IPCEF1/TXLNA protein level ratio
55730,IRAG2/WASF1 protein level ratio,Phenotype,IRAG2/WASF1 protein level ratio
55732,Type 1 diabetes (age at diagnosis),Phenotype,Type 1 diabetes (age at diagnosis)
55733,Gut microbiota presence (family Pseudomonadaceae id.3718),Phenotype,Gut microbiota presence (family Pseudomonadaceae id.3718)
55735,Gut microbiota abundance (order Gastranaerophilales id.1591),Phenotype,Gut microbiota abundance (order Gastranaerophilales id.1591)
55737,Gut microbiota abundance (unknown family id.1000001214),Phenotype,Gut microbiota abundance (unknown family id.1000001214)
55738,Episodic memory (pairs-matching),Phenotype,Episodic memory (pairs-matching)
55741,Theta electroencephalogram power,Phenotype,Theta electroencephalogram power
55742,Ischemic stroke in hypertension,Phenotype,Ischemic stroke in hypertension
55744,Cardio-cerebrovascular disease in diabetes mellitus,Phenotype,Cardio-cerebrovascular disease in diabetes mellitus
55746,Coronary artery disease in hypertension,Phenotype,Coronary artery disease in hypertension
55748,Cardio-cerebrovascular disease in dyslipidemia,Phenotype,Cardio-cerebrovascular disease in dyslipidemia
55751,Ischemic stroke in diabetes mellitus,Phenotype,Ischemic stroke in diabetes mellitus
55757,CD63/EDAR protein level ratio,Phenotype,CD63/EDAR protein level ratio
55759,CD69/CHMP1A protein level ratio,Phenotype,CD69/CHMP1A protein level ratio
55760,CD69/EDAR protein level ratio,Phenotype,CD69/EDAR protein level ratio
55761,CD69/PLXNA4 protein level ratio,Phenotype,CD69/PLXNA4 protein level ratio
55762,HOMA-B (corrected for HOMA-IR),Phenotype,HOMA-B (corrected for HOMA-IR)
55763,GZMH/KLRD1 protein level ratio,Phenotype,GZMH/KLRD1 protein level ratio
55765,HAGH/HBQ1 protein level ratio,Phenotype,HAGH/HBQ1 protein level ratio
55768,HAGH/HMBS protein level ratio,Phenotype,HAGH/HMBS protein level ratio
55770,HAGH/PKLR protein level ratio,Phenotype,HAGH/PKLR protein level ratio
55771,HAGH/PSMD9 protein level ratio,Phenotype,HAGH/PSMD9 protein level ratio
55772,HAGH/UBAC1 protein level ratio,Phenotype,HAGH/UBAC1 protein level ratio
55773,HARS1/RWDD1 protein level ratio,Phenotype,HARS1/RWDD1 protein level ratio
55775,HARS1/SERPINB1 protein level ratio,Phenotype,HARS1/SERPINB1 protein level ratio
55777,HAVCR2/LRRC25 protein level ratio,Phenotype,HAVCR2/LRRC25 protein level ratio
55778,HAVCR2/PILRA protein level ratio,Phenotype,HAVCR2/PILRA protein level ratio
55779,HAVCR2/TNFRSF1B protein level ratio,Phenotype,HAVCR2/TNFRSF1B protein level ratio
55781,HBEGF/LAT2 protein level ratio,Phenotype,HBEGF/LAT2 protein level ratio
55782,STAMBP/WWP2 protein level ratio,Phenotype,STAMBP/WWP2 protein level ratio
55784,GYS1/USP8 protein level ratio,Phenotype,GYS1/USP8 protein level ratio
55786,GYS1/WASF1 protein level ratio,Phenotype,GYS1/WASF1 protein level ratio
55787,GZMA/GZMB protein level ratio,Phenotype,GZMA/GZMB protein level ratio
55788,GZMA/IL12A_IL12B protein level ratio,Phenotype,GZMA/IL12A_IL12B protein level ratio
55789,GZMA/ITGB7 protein level ratio,Phenotype,GZMA/ITGB7 protein level ratio
55790,GZMA/KIR2DL3 protein level ratio,Phenotype,GZMA/KIR2DL3 protein level ratio
55792,GZMA/LTA protein level ratio,Phenotype,GZMA/LTA protein level ratio
55793,GZMA/TNFRSF4 protein level ratio,Phenotype,GZMA/TNFRSF4 protein level ratio
55795,GZMA/TNFRSF8 protein level ratio,Phenotype,GZMA/TNFRSF8 protein level ratio
55796,GZMB/IL15 protein level ratio,Phenotype,GZMB/IL15 protein level ratio
55797,GP6/MANF protein level ratio,Phenotype,GP6/MANF protein level ratio
55798,GP6/SERPINB1 protein level ratio,Phenotype,GP6/SERPINB1 protein level ratio
55799,GSTA1/PBLD protein level ratio,Phenotype,GSTA1/PBLD protein level ratio
55801,GSTA1/RBP5 protein level ratio,Phenotype,GSTA1/RBP5 protein level ratio
55802,GSTA1/SULT2A1 protein level ratio,Phenotype,GSTA1/SULT2A1 protein level ratio
55803,GSTA3/KRT18 protein level ratio,Phenotype,GSTA3/KRT18 protein level ratio
55804,GYS1/ITGB1BP2 protein level ratio,Phenotype,GYS1/ITGB1BP2 protein level ratio
55805,GYS1/PPP1R2 protein level ratio,Phenotype,GYS1/PPP1R2 protein level ratio
55806,GYS1/STK11 protein level ratio,Phenotype,GYS1/STK11 protein level ratio
55807,GYS1/SUSD1 protein level ratio,Phenotype,GYS1/SUSD1 protein level ratio
55809,GSTA1/KRT18 protein level ratio,Phenotype,GSTA1/KRT18 protein level ratio
55810,AMBP/EFEMP1 protein level ratio,Phenotype,AMBP/EFEMP1 protein level ratio
55812,AMBP/HYOU1 protein level ratio,Phenotype,AMBP/HYOU1 protein level ratio
55813,ALCAM/CDH5 protein level ratio,Phenotype,ALCAM/CDH5 protein level ratio
55816,ALCAM/CNTN1 protein level ratio,Phenotype,ALCAM/CNTN1 protein level ratio
55817,ALCAM/ICAM3 protein level ratio,Phenotype,ALCAM/ICAM3 protein level ratio
55818,ALCAM/LRRC25 protein level ratio,Phenotype,ALCAM/LRRC25 protein level ratio
55820,ALCAM/NOTCH1 protein level ratio,Phenotype,ALCAM/NOTCH1 protein level ratio
55822,ALCAM/SPINT1 protein level ratio,Phenotype,ALCAM/SPINT1 protein level ratio
55823,ALDH1A1/CA2 protein level ratio,Phenotype,ALDH1A1/CA2 protein level ratio
55824,ALDH1A1/PTS protein level ratio,Phenotype,ALDH1A1/PTS protein level ratio
55825,ANPEP/NT5E protein level ratio,Phenotype,ANPEP/NT5E protein level ratio
55827,ANXA11/NT5C3A protein level ratio,Phenotype,ANXA11/NT5C3A protein level ratio
55829,IMPA1/TBCC protein level ratio,Phenotype,IMPA1/TBCC protein level ratio
55831,ANGPT1/CCN2 protein level ratio,Phenotype,ANGPT1/CCN2 protein level ratio
55833,ANGPT1/CPXM1 protein level ratio,Phenotype,ANGPT1/CPXM1 protein level ratio
55835,INPP1/TBCC protein level ratio,Phenotype,INPP1/TBCC protein level ratio
55836,IPCEF1/SMAD1 protein level ratio,Phenotype,IPCEF1/SMAD1 protein level ratio
55837,ANGPT1/PDGFB protein level ratio,Phenotype,ANGPT1/PDGFB protein level ratio
55838,IPCEF1/SPARC protein level ratio,Phenotype,IPCEF1/SPARC protein level ratio
55840,IPCEF1/TBCB protein level ratio,Phenotype,IPCEF1/TBCB protein level ratio
55841,IPCEF1/TBCC protein level ratio,Phenotype,IPCEF1/TBCC protein level ratio
55843,ITGA5/VCAM1 protein level ratio,Phenotype,ITGA5/VCAM1 protein level ratio
55844,ITGA6/THPO protein level ratio,Phenotype,ITGA6/THPO protein level ratio
55845,ITGAM/ITGAV protein level ratio,Phenotype,ITGAM/ITGAV protein level ratio
55847,ITGB1BP2/LAT2 protein level ratio,Phenotype,ITGB1BP2/LAT2 protein level ratio
55848,ITGA5/ITGB7 protein level ratio,Phenotype,ITGA5/ITGB7 protein level ratio
55849,ITGB1BP2/USP8 protein level ratio,Phenotype,ITGB1BP2/USP8 protein level ratio
55850,ITGB1BP2/WASF1 protein level ratio,Phenotype,ITGB1BP2/WASF1 protein level ratio
55851,ITGB1/ITGB2 protein level ratio,Phenotype,ITGB1/ITGB2 protein level ratio
55853,ITGB1/MCAM protein level ratio,Phenotype,ITGB1/MCAM protein level ratio
55855,ITGB1/VASN protein level ratio,Phenotype,ITGB1/VASN protein level ratio
55857,ITGB1BP2/MED18 protein level ratio,Phenotype,ITGB1BP2/MED18 protein level ratio
55858,ITGB1BP2/MITD1 protein level ratio,Phenotype,ITGB1BP2/MITD1 protein level ratio
55859,ITGB1BP2/PDLIM7 protein level ratio,Phenotype,ITGB1BP2/PDLIM7 protein level ratio
55860,ITGB1BP2/PLXNA4 protein level ratio,Phenotype,ITGB1BP2/PLXNA4 protein level ratio
55861,ITGB1BP2/TIA1 protein level ratio,Phenotype,ITGB1BP2/TIA1 protein level ratio
55862,ITGB1BP2/SKAP2 protein level ratio,Phenotype,ITGB1BP2/SKAP2 protein level ratio
55863,ITGB1BP2/STAT5B protein level ratio,Phenotype,ITGB1BP2/STAT5B protein level ratio
55864,ITGB1BP2/STK11 protein level ratio,Phenotype,ITGB1BP2/STK11 protein level ratio
55865,ITGB1BP2/PPP1R12A protein level ratio,Phenotype,ITGB1BP2/PPP1R12A protein level ratio
55866,ITGB1BP2/PTPN6 protein level ratio,Phenotype,ITGB1BP2/PTPN6 protein level ratio
55867,CD40 ligand levels,Phenotype,CD40 ligand levels
55870,Proheparin-binding EGF-like growth factor levels,Phenotype,Proheparin-binding EGF-like growth factor levels
55871,C-C motif chemokine 3 levels,Phenotype,C-C motif chemokine 3 levels
55873,C-X-C motif chemokine 16 levels,Phenotype,C-X-C motif chemokine 16 levels
55875,Receptor for advanced glycosylation end products levels,Phenotype,Receptor for advanced glycosylation end products levels
55879,Matrix metalloproteinase-10 levels,Phenotype,Matrix metalloproteinase-10 levels
55881,Kidney injury molecule 1 levels,Phenotype,Kidney injury molecule 1 levels
55882,Dickkopf-related protein 1 levels,Phenotype,Dickkopf-related protein 1 levels
55883,Galanin peptide levels,Phenotype,Galanin peptide levels
55886,Gut microbiota abundance (unknown genus id.1000001215),Phenotype,Gut microbiota abundance (unknown genus id.1000001215)
55887,Gut microbiota abundance (family Oxalobacteraceae id.2966),Phenotype,Gut microbiota abundance (family Oxalobacteraceae id.2966)
55889,Gut microbiota abundance (class Actinobacteria id.419),Phenotype,Gut microbiota abundance (class Actinobacteria id.419)
55891,Cognitive traits (MTAG),Phenotype,Cognitive traits (MTAG)
55894,Tuberculosis susceptibility in HIV infection,Phenotype,Tuberculosis susceptibility in HIV infection
55895,Coronary artery disease in dyslipidemia,Phenotype,Coronary artery disease in dyslipidemia
55897,Ischemic stroke in dyslipidemia,Phenotype,Ischemic stroke in dyslipidemia
55902,Lacunar stroke,Phenotype,Lacunar stroke
55903,CDKN2D/MANF protein level ratio,Phenotype,CDKN2D/MANF protein level ratio
55905,CDKN2D/ITGB1BP2 protein level ratio,Phenotype,CDKN2D/ITGB1BP2 protein level ratio
55906,CDKN2D/CHMP1A protein level ratio,Phenotype,CDKN2D/CHMP1A protein level ratio
55907,CDKN2D/CNPY4 protein level ratio,Phenotype,CDKN2D/CNPY4 protein level ratio
55910,CDKN2D/TACC3 protein level ratio,Phenotype,CDKN2D/TACC3 protein level ratio
55911,CDKN1A/TBL1X protein level ratio,Phenotype,CDKN1A/TBL1X protein level ratio
55912,CDKN1A/TMSB10 protein level ratio,Phenotype,CDKN1A/TMSB10 protein level ratio
55913,CDKN1A/TXLNA protein level ratio,Phenotype,CDKN1A/TXLNA protein level ratio
55914,CDKN1A/YES1 protein level ratio,Phenotype,CDKN1A/YES1 protein level ratio
55915,Tumor necrosis factor receptor 2 levels,Phenotype,Tumor necrosis factor receptor 2 levels
55916,Resistin levels,Phenotype,Resistin levels
55919,Tumor necrosis factor receptor superfamily member 6 levels,Phenotype,Tumor necrosis factor receptor superfamily member 6 levels
55920,Angiopoietin-1 receptor levels,Phenotype,Angiopoietin-1 receptor levels
55923,Heat shock 27 kDa protein levels,Phenotype,Heat shock 27 kDa protein levels
55925,Myeloperoxidase levels,Phenotype,Myeloperoxidase levels
55926,Lectin-like oxidized LDL receptor 1 levels,Phenotype,Lectin-like oxidized LDL receptor 1 levels
55929,Tissue factor levels,Phenotype,Tissue factor levels
55931,Type 2 diabetes or prostate cancer (pleiotropy),Phenotype,Type 2 diabetes or prostate cancer (pleiotropy)
55932,TNF/TNFRSF1B protein level ratio,Phenotype,TNF/TNFRSF1B protein level ratio
55933,TRAF2/WWP2 protein level ratio,Phenotype,TRAF2/WWP2 protein level ratio
55934,USP8/WASF1 protein level ratio,Phenotype,USP8/WASF1 protein level ratio
55935,HBEGF/PDGFA protein level ratio,Phenotype,HBEGF/PDGFA protein level ratio
55936,TNFRSF1A/TNFRSF1B protein level ratio,Phenotype,TNFRSF1A/TNFRSF1B protein level ratio
55937,TNFRSF4/TNFRSF9 protein level ratio,Phenotype,TNFRSF4/TNFRSF9 protein level ratio
55938,TBCC/TXLNA protein level ratio,Phenotype,TBCC/TXLNA protein level ratio
55939,TBCC/WWP2 protein level ratio,Phenotype,TBCC/WWP2 protein level ratio
55940,TCL1A/TNFRSF13C protein level ratio,Phenotype,TCL1A/TNFRSF13C protein level ratio
55941,TGFBI/VASN protein level ratio,Phenotype,TGFBI/VASN protein level ratio
55942,TGFBR2/THBD protein level ratio,Phenotype,TGFBR2/THBD protein level ratio
55944,STAT5B/WASF1 protein level ratio,Phenotype,STAT5B/WASF1 protein level ratio
55945,STK4/VTA1 protein level ratio,Phenotype,STK4/VTA1 protein level ratio
55946,SUGT1/TBL1X protein level ratio,Phenotype,SUGT1/TBL1X protein level ratio
55947,SULT1A1/VTA1 protein level ratio,Phenotype,SULT1A1/VTA1 protein level ratio
55948,SUSD1/THPO protein level ratio,Phenotype,SUSD1/THPO protein level ratio
55949,TNFRSF13B/TNFRSF9 protein level ratio,Phenotype,TNFRSF13B/TNFRSF9 protein level ratio
55950,TACC3/TBC1D23 protein level ratio,Phenotype,TACC3/TBC1D23 protein level ratio
55951,TACC3/TRIAP1 protein level ratio,Phenotype,TACC3/TRIAP1 protein level ratio
55952,TBCB/TBCC protein level ratio,Phenotype,TBCB/TBCC protein level ratio
55953,CDH5/PTPRM protein level ratio,Phenotype,CDH5/PTPRM protein level ratio
55954,CDH5/TEK protein level ratio,Phenotype,CDH5/TEK protein level ratio
55956,CDKN1A/CDKN2D protein level ratio,Phenotype,CDKN1A/CDKN2D protein level ratio
55957,CDKN1A/DAB2 protein level ratio,Phenotype,CDKN1A/DAB2 protein level ratio
55958,CDH17/SPINT1 protein level ratio,Phenotype,CDH17/SPINT1 protein level ratio
55959,CDH3/NECTIN4 protein level ratio,Phenotype,CDH3/NECTIN4 protein level ratio
55960,CDH3/TNFRSF21 protein level ratio,Phenotype,CDH3/TNFRSF21 protein level ratio
55961,CDH5/ENG protein level ratio,Phenotype,CDH5/ENG protein level ratio
55962,CDH5/NOTCH1 protein level ratio,Phenotype,CDH5/NOTCH1 protein level ratio
55963,ANXA3/EDAR protein level ratio,Phenotype,ANXA3/EDAR protein level ratio
55964,ANXA3/RWDD1 protein level ratio,Phenotype,ANXA3/RWDD1 protein level ratio
55965,ANXA3/SERPINB1 protein level ratio,Phenotype,ANXA3/SERPINB1 protein level ratio
55966,ANXA4/HSPB1 protein level ratio,Phenotype,ANXA4/HSPB1 protein level ratio
55967,CDKN1A/TACC3 protein level ratio,Phenotype,CDKN1A/TACC3 protein level ratio
55968,CDKN1A/TBC1D23 protein level ratio,Phenotype,CDKN1A/TBC1D23 protein level ratio
55969,CDKN1A/FXN protein level ratio,Phenotype,CDKN1A/FXN protein level ratio
55970,CDKN1A/HBEGF protein level ratio,Phenotype,CDKN1A/HBEGF protein level ratio
55971,CDKN1A/NCK2 protein level ratio,Phenotype,CDKN1A/NCK2 protein level ratio
55972,CDKN1A/PLA2G4A protein level ratio,Phenotype,CDKN1A/PLA2G4A protein level ratio
55973,CDKN1A/DNAJB1 protein level ratio,Phenotype,CDKN1A/DNAJB1 protein level ratio
55974,CDKN1A/ENO2 protein level ratio,Phenotype,CDKN1A/ENO2 protein level ratio
55975,CDKN1A/FOXO1 protein level ratio,Phenotype,CDKN1A/FOXO1 protein level ratio
55976,Aspartate aminotransferase platelet ratio index in high alcohol intake,Phenotype,Aspartate aminotransferase platelet ratio index in high alcohol intake
55979,Ondansetron-induced QT prolongation,Phenotype,Ondansetron-induced QT prolongation
55980,Carotid artery stenosis,Phenotype,Carotid artery stenosis
55981,Gut microbiota presence (family Bacteroidales S24 7group id.11173),Phenotype,Gut microbiota presence (family Bacteroidales S24 7group id.11173)
55982,Gut microbiota presence (genus Lachnospiraceae UCG 010 id.11330),Phenotype,Gut microbiota presence (genus Lachnospiraceae UCG 010 id.11330)
55984,Gut microbiota presence (genus Anaerostipes id.1991),Phenotype,Gut microbiota presence (genus Anaerostipes id.1991)
55987,Alzheimer's disease or LDL levels (pleiotropy),Phenotype,Alzheimer's disease or LDL levels (pleiotropy)
55988,Tinnitus,Phenotype,Tinnitus
55989,Low myopia,Phenotype,Low myopia
55990,Mitochondrial heteroplasmy measurement,Phenotype,Mitochondrial heteroplasmy measurement
55991,LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder,Phenotype,LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder
55992,Total cholesterol levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder,Phenotype,Total cholesterol levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder
55993,Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder,Phenotype,Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder
55994,LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder,Phenotype,LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder
55995,HDL levels x fish oil supplementation interaction (2df),Phenotype,HDL levels x fish oil supplementation interaction (2df)
55996,HDL levels x fish oil supplementation interaction (1df),Phenotype,HDL levels x fish oil supplementation interaction (1df)
55997,Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder,Phenotype,Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder
55998,HLAE/LILRB1 protein level ratio,Phenotype,HLAE/LILRB1 protein level ratio
56000,HMBS/PKLR protein level ratio,Phenotype,HMBS/PKLR protein level ratio
56001,HMBS/PSMG3 protein level ratio,Phenotype,HMBS/PSMG3 protein level ratio
56003,HMBS/TGM2 protein level ratio,Phenotype,HMBS/TGM2 protein level ratio
56004,HBEGF/PFKFB2 protein level ratio,Phenotype,HBEGF/PFKFB2 protein level ratio
56005,HBEGF/PLXNA4 protein level ratio,Phenotype,HBEGF/PLXNA4 protein level ratio
56006,HBEGF/SDC4 protein level ratio,Phenotype,HBEGF/SDC4 protein level ratio
56007,HBEGF/WWP2 protein level ratio,Phenotype,HBEGF/WWP2 protein level ratio
56008,HBEGF/YES1 protein level ratio,Phenotype,HBEGF/YES1 protein level ratio
56009,HBQ1/HMBS protein level ratio,Phenotype,HBQ1/HMBS protein level ratio
56012,HBEGF/PDGFB protein level ratio,Phenotype,HBEGF/PDGFB protein level ratio
56013,HEXIM1/IKBKG protein level ratio,Phenotype,HEXIM1/IKBKG protein level ratio
56014,HEXIM1/STK11 protein level ratio,Phenotype,HEXIM1/STK11 protein level ratio
56015,HEXIM1/IPCEF1 protein level ratio,Phenotype,HEXIM1/IPCEF1 protein level ratio
56016,HEXIM1/SRPK2 protein level ratio,Phenotype,HEXIM1/SRPK2 protein level ratio
56017,JAM2/TGFBR2 protein level ratio,Phenotype,JAM2/TGFBR2 protein level ratio
56018,JAM2/TNFRSF21 protein level ratio,Phenotype,JAM2/TNFRSF21 protein level ratio
56020,KIRREL2/PLA2G1B protein level ratio,Phenotype,KIRREL2/PLA2G1B protein level ratio
56022,KLK6/MOG protein level ratio,Phenotype,KLK6/MOG protein level ratio
56023,KLRB1/KLRD1 protein level ratio,Phenotype,KLRB1/KLRD1 protein level ratio
56025,CHMP1A/VASH1 protein level ratio,Phenotype,CHMP1A/VASH1 protein level ratio
56026,CHRDL1/SMOC2 protein level ratio,Phenotype,CHRDL1/SMOC2 protein level ratio
56027,CIAPIN1/MSRA protein level ratio,Phenotype,CIAPIN1/MSRA protein level ratio
56029,CIAPIN1/PARK7 protein level ratio,Phenotype,CIAPIN1/PARK7 protein level ratio
56031,CIAPIN1/PLA2G4A protein level ratio,Phenotype,CIAPIN1/PLA2G4A protein level ratio
56032,CIAPIN1/PLPBP protein level ratio,Phenotype,CIAPIN1/PLPBP protein level ratio
56034,CIAPIN1/SNX9 protein level ratio,Phenotype,CIAPIN1/SNX9 protein level ratio
56035,KIFBP/TACC3 protein level ratio,Phenotype,KIFBP/TACC3 protein level ratio
56036,CHAC2/GMPR protein level ratio,Phenotype,CHAC2/GMPR protein level ratio
56037,Monoclonal gammopathy of undetermined significance,Phenotype,Monoclonal gammopathy of undetermined significance
56051,Energy expenditure,Phenotype,Energy expenditure
56055,Skin reflectance (Melanin index),Phenotype,Skin reflectance (Melanin index)
56056,Pemphigus foliaceus,Phenotype,Pemphigus foliaceus
56060,Iris color (b* coordinate),Phenotype,Iris color (b* coordinate)
56061,Anxiety/tension (special factor of neuroticism),Phenotype,Anxiety/tension (special factor of neuroticism)
56062,3-month functional outcome in ischaemic stroke (modified Rankin score),Phenotype,3-month functional outcome in ischaemic stroke (modified Rankin score)
56063,3-month functional outcome in non-lacunar ischaemic stroke (modified Rankin score),Phenotype,3-month functional outcome in non-lacunar ischaemic stroke (modified Rankin score)
56075,General factor of neuroticism,Phenotype,General factor of neuroticism
56086,Post bronchodilator FEV1/FVC ratio in smoking,Phenotype,Post bronchodilator FEV1/FVC ratio in smoking
56091,Obesity without metabolic disease,Phenotype,Obesity without metabolic disease
56097,Bronchopulmonary dysplasia in preterm infants,Phenotype,Bronchopulmonary dysplasia in preterm infants
56098,Plasma parathyroid hormone levels,Phenotype,Plasma parathyroid hormone levels
56099,Cannabis use,Phenotype,Cannabis use
56100,Abdominal aortic aneurysm,Phenotype,Abdominal aortic aneurysm
56101,Response to antidepressants (symptom improvement),Phenotype,Response to antidepressants (symptom improvement)
56102,Remission after antidepressant treatment in major depression,Phenotype,Remission after antidepressant treatment in major depression
56103,Alpha synuclein levels (MTAG),Phenotype,Alpha synuclein levels (MTAG)
56104,Response to lurasidone in schizophrenia,Phenotype,Response to lurasidone in schizophrenia
56105,Waldenström macroglobulinemia / lymphoplasmacytic lymphoma,Phenotype,Waldenström macroglobulinemia / lymphoplasmacytic lymphoma
56106,High IL-1beta levels in gingival crevicular fluid,Phenotype,High IL-1beta levels in gingival crevicular fluid
56107,Uterine fibroid number (single vs multiple),Phenotype,Uterine fibroid number (single vs multiple)
56108,Uterine fibroid size (maximum dimension),Phenotype,Uterine fibroid size (maximum dimension)
56109,Uterine fibroid size (maximum volume),Phenotype,Uterine fibroid size (maximum volume)
56122,Iris heterochromicity,Phenotype,Iris heterochromicity
56126,Gemcitabine-induced early high-grade neutropenia in pancreatic cancer,Phenotype,Gemcitabine-induced early high-grade neutropenia in pancreatic cancer
56139,MED18/ZBTB16 protein level ratio,Phenotype,MED18/ZBTB16 protein level ratio
56140,COL6A3/SMOC2 protein level ratio,Phenotype,COL6A3/SMOC2 protein level ratio
56141,COLEC12/LAIR1 protein level ratio,Phenotype,COLEC12/LAIR1 protein level ratio
56142,MANF/NCK2 protein level ratio,Phenotype,MANF/NCK2 protein level ratio
56144,MANF/PDGFB protein level ratio,Phenotype,MANF/PDGFB protein level ratio
56146,MANF/PLA2G4A protein level ratio,Phenotype,MANF/PLA2G4A protein level ratio
56147,MANF/PMVK protein level ratio,Phenotype,MANF/PMVK protein level ratio
56148,MCAM/NCAM1 protein level ratio,Phenotype,MCAM/NCAM1 protein level ratio
56149,MCAM/NTRK3 protein level ratio,Phenotype,MCAM/NTRK3 protein level ratio
56150,MCFD2/TXNDC5 protein level ratio,Phenotype,MCFD2/TXNDC5 protein level ratio
56151,MED18/SH2B3 protein level ratio,Phenotype,MED18/SH2B3 protein level ratio
56153,MED18/TACC3 protein level ratio,Phenotype,MED18/TACC3 protein level ratio
56154,MED18/TBL1X protein level ratio,Phenotype,MED18/TBL1X protein level ratio
56155,MAP3K5/ZBTB16 protein level ratio,Phenotype,MAP3K5/ZBTB16 protein level ratio
56157,MAP4K5/TBCC protein level ratio,Phenotype,MAP4K5/TBCC protein level ratio
56158,MANF/PTPN6 protein level ratio,Phenotype,MANF/PTPN6 protein level ratio
56159,MANF/TXNDC5 protein level ratio,Phenotype,MANF/TXNDC5 protein level ratio
56161,MAP3K5/MAVS protein level ratio,Phenotype,MAP3K5/MAVS protein level ratio
56162,Brain shape (segment 117),Phenotype,Brain shape (segment 117)
56164,Brain shape (segment 140),Phenotype,Brain shape (segment 140)
56165,Brain shape (segment 199),Phenotype,Brain shape (segment 199)
56167,Brain shape (segment 204),Phenotype,Brain shape (segment 204)
56169,Brain shape (segment 116),Phenotype,Brain shape (segment 116)
56171,CTSO/IGF2R protein level ratio,Phenotype,CTSO/IGF2R protein level ratio
56172,CTSZ/SMPDL3A protein level ratio,Phenotype,CTSZ/SMPDL3A protein level ratio
56173,CX3CL1/EPHB6 protein level ratio,Phenotype,CX3CL1/EPHB6 protein level ratio
56175,CX3CL1/LAYN protein level ratio,Phenotype,CX3CL1/LAYN protein level ratio
56176,CX3CL1/RGMB protein level ratio,Phenotype,CX3CL1/RGMB protein level ratio
56178,CSF1/SEMA3F protein level ratio,Phenotype,CSF1/SEMA3F protein level ratio
56179,CST3/DEFA1_DEFA1B protein level ratio,Phenotype,CST3/DEFA1_DEFA1B protein level ratio
56181,CST3/RARRES2 protein level ratio,Phenotype,CST3/RARRES2 protein level ratio
56182,CST3/RETN protein level ratio,Phenotype,CST3/RETN protein level ratio
56183,CST3/TFF3 protein level ratio,Phenotype,CST3/TFF3 protein level ratio
56184,CTF1/ITGB1BP2 protein level ratio,Phenotype,CTF1/ITGB1BP2 protein level ratio
56185,CTRB1/KIRREL2 protein level ratio,Phenotype,CTRB1/KIRREL2 protein level ratio
56187,CTRB1/PLA2G1B protein level ratio,Phenotype,CTRB1/PLA2G1B protein level ratio
56188,CTRB1/PRSS2 protein level ratio,Phenotype,CTRB1/PRSS2 protein level ratio
56189,CTRC/KIRREL2 protein level ratio,Phenotype,CTRC/KIRREL2 protein level ratio
56190,CTRC/PLA2G1B protein level ratio,Phenotype,CTRC/PLA2G1B protein level ratio
56191,CTSF/SMPDL3A protein level ratio,Phenotype,CTSF/SMPDL3A protein level ratio
56192,CRTAM/PDCD1 protein level ratio,Phenotype,CRTAM/PDCD1 protein level ratio
56194,CRTAM/TNFRSF9 protein level ratio,Phenotype,CRTAM/TNFRSF9 protein level ratio
56195,CRTAM/VCAM1 protein level ratio,Phenotype,CRTAM/VCAM1 protein level ratio
56196,DAG1/F2R protein level ratio,Phenotype,DAG1/F2R protein level ratio
56198,DAG1/HBEGF protein level ratio,Phenotype,DAG1/HBEGF protein level ratio
56199,DAG1/MGLL protein level ratio,Phenotype,DAG1/MGLL protein level ratio
56200,Thymus and reactivation regulated chemokine levels,Phenotype,Thymus and reactivation regulated chemokine levels
56201,Vascular endothelial growth factor A levels,Phenotype,Vascular endothelial growth factor A levels
56202,PDCD1/TNFRSF4 protein level ratio,Phenotype,PDCD1/TNFRSF4 protein level ratio
56204,PDCD1/TNFRSF8 protein level ratio,Phenotype,PDCD1/TNFRSF8 protein level ratio
56206,PDCD1/TNFRSF9 protein level ratio,Phenotype,PDCD1/TNFRSF9 protein level ratio
56208,PDGFB/SNAP29 protein level ratio,Phenotype,PDGFB/SNAP29 protein level ratio
56209,DEFA1_DEFA1B/LCN2 protein level ratio,Phenotype,DEFA1_DEFA1B/LCN2 protein level ratio
56212,DFFA/SIRT2 protein level ratio,Phenotype,DFFA/SIRT2 protein level ratio
56214,DKK1/VEGFC protein level ratio,Phenotype,DKK1/VEGFC protein level ratio
56215,PKLR/TGM2 protein level ratio,Phenotype,PKLR/TGM2 protein level ratio
56216,PKLR/UBAC1 protein level ratio,Phenotype,PKLR/UBAC1 protein level ratio
56217,PLA2G15/PRCP protein level ratio,Phenotype,PLA2G15/PRCP protein level ratio
56218,DKK1/IPCEF1 protein level ratio,Phenotype,DKK1/IPCEF1 protein level ratio
56219,DKK1/SDC4 protein level ratio,Phenotype,DKK1/SDC4 protein level ratio
56221,DKK1/VEGFA protein level ratio,Phenotype,DKK1/VEGFA protein level ratio
56222,DSG3/DSG4 protein level ratio,Phenotype,DSG3/DSG4 protein level ratio
56224,DNMBP/STX4 protein level ratio,Phenotype,DNMBP/STX4 protein level ratio
56226,DNMBP/TBC1D5 protein level ratio,Phenotype,DNMBP/TBC1D5 protein level ratio
56227,DNMBP/TBCC protein level ratio,Phenotype,DNMBP/TBCC protein level ratio
56228,DNMBP/TJAP1 protein level ratio,Phenotype,DNMBP/TJAP1 protein level ratio
56229,DNMBP/WWP2 protein level ratio,Phenotype,DNMBP/WWP2 protein level ratio
56230,DNPH1/EIF4EBP1 protein level ratio,Phenotype,DNPH1/EIF4EBP1 protein level ratio
56232,DNPH1/GLOD4 protein level ratio,Phenotype,DNPH1/GLOD4 protein level ratio
56233,DNPH1/LHPP protein level ratio,Phenotype,DNPH1/LHPP protein level ratio
56235,DNPH1/NSFL1C protein level ratio,Phenotype,DNPH1/NSFL1C protein level ratio
56236,DLL1/EFEMP1 protein level ratio,Phenotype,DLL1/EFEMP1 protein level ratio
56238,DLL1/IL18BP protein level ratio,Phenotype,DLL1/IL18BP protein level ratio
56240,DLL1/NBL1 protein level ratio,Phenotype,DLL1/NBL1 protein level ratio
56242,DLL1/NECTIN4 protein level ratio,Phenotype,DLL1/NECTIN4 protein level ratio
56243,DLL1/NOTCH1 protein level ratio,Phenotype,DLL1/NOTCH1 protein level ratio
56244,DLL1/TGFBR2 protein level ratio,Phenotype,DLL1/TGFBR2 protein level ratio
56246,DNAJA2/FIS1 protein level ratio,Phenotype,DNAJA2/FIS1 protein level ratio
56247,DNPH1/PKLR protein level ratio,Phenotype,DNPH1/PKLR protein level ratio
56248,DNPH1/PSMG3 protein level ratio,Phenotype,DNPH1/PSMG3 protein level ratio
56250,DRG2/INPP1 protein level ratio,Phenotype,DRG2/INPP1 protein level ratio
56251,DRG2/SEMA4D protein level ratio,Phenotype,DRG2/SEMA4D protein level ratio
56252,DNAJB1/SIRT2 protein level ratio,Phenotype,DNAJB1/SIRT2 protein level ratio
56253,DNMBP/FKBP5 protein level ratio,Phenotype,DNMBP/FKBP5 protein level ratio
56255,DNMBP/PTPN1 protein level ratio,Phenotype,DNMBP/PTPN1 protein level ratio
56256,DPP6/SEZ6L protein level ratio,Phenotype,DPP6/SEZ6L protein level ratio
56257,EIF4G1/HEXIM1 protein level ratio,Phenotype,EIF4G1/HEXIM1 protein level ratio
56258,EFNA1/TNFRSF1A protein level ratio,Phenotype,EFNA1/TNFRSF1A protein level ratio
56260,EFNA4/LAYN protein level ratio,Phenotype,EFNA4/LAYN protein level ratio
56261,EIF4B/RWDD1 protein level ratio,Phenotype,EIF4B/RWDD1 protein level ratio
56262,EIF4B/TBCC protein level ratio,Phenotype,EIF4B/TBCC protein level ratio
56263,EIF4EBP1/GLRX protein level ratio,Phenotype,EIF4EBP1/GLRX protein level ratio
56264,EIF4EBP1/PSMG3 protein level ratio,Phenotype,EIF4EBP1/PSMG3 protein level ratio
56265,EIF4G1/FKBP5 protein level ratio,Phenotype,EIF4G1/FKBP5 protein level ratio
56266,SDC4/SELP protein level ratio,Phenotype,SDC4/SELP protein level ratio
56267,EFNA4/SCARB2 protein level ratio,Phenotype,EFNA4/SCARB2 protein level ratio
56268,EFNA4/TNFRSF10A protein level ratio,Phenotype,EFNA4/TNFRSF10A protein level ratio
56270,EFNA4/TNFRSF10B protein level ratio,Phenotype,EFNA4/TNFRSF10B protein level ratio
56271,EFNA4/TNFRSF9 protein level ratio,Phenotype,EFNA4/TNFRSF9 protein level ratio
56272,EGF/MANF protein level ratio,Phenotype,EGF/MANF protein level ratio
56273,EIF4B/IPCEF1 protein level ratio,Phenotype,EIF4B/IPCEF1 protein level ratio
56274,EIF4B/METAP2 protein level ratio,Phenotype,EIF4B/METAP2 protein level ratio
56275,EGF/MGLL protein level ratio,Phenotype,EGF/MGLL protein level ratio
56277,EGF/PPIB protein level ratio,Phenotype,EGF/PPIB protein level ratio
56278,CC2D1A/CDKN1A protein level ratio,Phenotype,CC2D1A/CDKN1A protein level ratio
56279,CC2D1A/TBCC protein level ratio,Phenotype,CC2D1A/TBCC protein level ratio
56280,CC2D1A/WWP2 protein level ratio,Phenotype,CC2D1A/WWP2 protein level ratio
56282,CCL13/CCL17 protein level ratio,Phenotype,CCL13/CCL17 protein level ratio
56284,CCL17/CCL22 protein level ratio,Phenotype,CCL17/CCL22 protein level ratio
56286,CCL5/CXCL3 protein level ratio,Phenotype,CCL5/CXCL3 protein level ratio
56288,CCL5/CXCL5 protein level ratio,Phenotype,CCL5/CXCL5 protein level ratio
56289,F2R/ITGB1BP2 protein level ratio,Phenotype,F2R/ITGB1BP2 protein level ratio
56290,CASP8/SERPINB1 protein level ratio,Phenotype,CASP8/SERPINB1 protein level ratio
56291,CC2D1A/CD2AP protein level ratio,Phenotype,CC2D1A/CD2AP protein level ratio
56293,CASP3/SULT1A1 protein level ratio,Phenotype,CASP3/SULT1A1 protein level ratio
56294,CASP8/CIAPIN1 protein level ratio,Phenotype,CASP8/CIAPIN1 protein level ratio
56295,CCL17/PDGFB protein level ratio,Phenotype,CCL17/PDGFB protein level ratio
56297,CCL17/THPO protein level ratio,Phenotype,CCL17/THPO protein level ratio
56298,CCL17/CCL5 protein level ratio,Phenotype,CCL17/CCL5 protein level ratio
56300,CCL17/CD69 protein level ratio,Phenotype,CCL17/CD69 protein level ratio
56302,CCL17/CXCL3 protein level ratio,Phenotype,CCL17/CXCL3 protein level ratio
56303,CCL17/F2R protein level ratio,Phenotype,CCL17/F2R protein level ratio
56304,CD46/TIMP1 protein level ratio,Phenotype,CD46/TIMP1 protein level ratio
56306,CD48/CRTAM protein level ratio,Phenotype,CD48/CRTAM protein level ratio
56307,CD48/FCRL6 protein level ratio,Phenotype,CD48/FCRL6 protein level ratio
56309,CD48/ITGB7 protein level ratio,Phenotype,CD48/ITGB7 protein level ratio
56310,CD4/LILRB4 protein level ratio,Phenotype,CD4/LILRB4 protein level ratio
56311,CD58/IFNGR1 protein level ratio,Phenotype,CD58/IFNGR1 protein level ratio
56313,CD58/MCAM protein level ratio,Phenotype,CD58/MCAM protein level ratio
56314,CD5/IL16 protein level ratio,Phenotype,CD5/IL16 protein level ratio
56315,CD5/TNFRSF9 protein level ratio,Phenotype,CD5/TNFRSF9 protein level ratio
56316,CD38/IL12A_IL12B protein level ratio,Phenotype,CD38/IL12A_IL12B protein level ratio
56317,CD40/FIS1 protein level ratio,Phenotype,CD40/FIS1 protein level ratio
56318,CD40/VSIR protein level ratio,Phenotype,CD40/VSIR protein level ratio
56319,Retinal nerve fibre layer (RNFL) thickness,Phenotype,Retinal nerve fibre layer (RNFL) thickness
56320,Abdominal fat cell number,Phenotype,Abdominal fat cell number
56324,Ganglion cell inner plexiform layer (GCIPL) thickness,Phenotype,Ganglion cell inner plexiform layer (GCIPL) thickness
56331,Retinal nerve fibre layer thickness or ganglion cell inner plexiform layer thickness (MTAG),Phenotype,Retinal nerve fibre layer thickness or ganglion cell inner plexiform layer thickness (MTAG)
56332,QT dynamics during exercise,Phenotype,QT dynamics during exercise
56334,Endometriosis or depression (pleiotropy),Phenotype,Endometriosis or depression (pleiotropy)
56342,SSRI response to core syndromal factor measured by HAM-D-21 in major depressive disorder,Phenotype,SSRI response to core syndromal factor measured by HAM-D-21 in major depressive disorder
56343,SSRI response to anorexia syndromal factor measured by HAM-D-21 in major depressive disorder,Phenotype,SSRI response to anorexia syndromal factor measured by HAM-D-21 in major depressive disorder
56345,SSRI response to total HAM-D-21 score in major depressive disorder,Phenotype,SSRI response to total HAM-D-21 score in major depressive disorder
56346,Cardiometabolic multimorbidity,Phenotype,Cardiometabolic multimorbidity
56347,Multisite chronic pain,Phenotype,Multisite chronic pain
56348,Haemorrhoidal disease,Phenotype,Haemorrhoidal disease
56349,Hair curvature (quantitative),Phenotype,Hair curvature (quantitative)
56350,Hair curvature (observational),Phenotype,Hair curvature (observational)
56354,Opioid use disorder vs exposed controls,Phenotype,Opioid use disorder vs exposed controls
56355,Age at natural menopause,Phenotype,Age at natural menopause
56369,Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics,Phenotype,Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics
56370,Biological sex,Phenotype,Biological sex
56374,Congenital heart disease (anomalies of thoracic arteries and veins),Phenotype,Congenital heart disease (anomalies of thoracic arteries and veins)
56381,Vitamin C levels,Phenotype,Vitamin C levels
56382,Phoneme awareness,Phenotype,Phoneme awareness
56383,Word spelling,Phenotype,Word spelling
56384,Reading ability (multivariate),Phenotype,Reading ability (multivariate)
56385,Rapid automised naming of letters,Phenotype,Rapid automised naming of letters
56386,Non-word reading,Phenotype,Non-word reading
56390,Smoking status,Phenotype,Smoking status
56395,Adverse response to chemotherapy (amenorrhea) in breast cancer,Phenotype,Adverse response to chemotherapy (amenorrhea) in breast cancer
56396,Alcohol consumption,Phenotype,Alcohol consumption
56397,Participation in an health questionnaire (not invited vs invited),Phenotype,Participation in an health questionnaire (not invited vs invited)
56398,Glucosuria (moderate to severe),Phenotype,Glucosuria (moderate to severe)
56399,Glucosuria (mild),Phenotype,Glucosuria (mild)
56400,Glucosuria,Phenotype,Glucosuria
56416,Liver fibrosis in non-alcoholic fatty liver disease,Phenotype,Liver fibrosis in non-alcoholic fatty liver disease
56417,Non-alcoholic fatty liver disease activity score in non-alcoholic fatty liver disease,Phenotype,Non-alcoholic fatty liver disease activity score in non-alcoholic fatty liver disease
56418,Neurological blood protein biomarker levels,Phenotype,Neurological blood protein biomarker levels
56422,Annualised percent change of cerebrospinal fluid AB1-42 levels,Phenotype,Annualised percent change of cerebrospinal fluid AB1-42 levels
56423,Cognitive ability-- years of educational attainment or schizophrenia (pleiotropy),Phenotype,Cognitive ability-- years of educational attainment or schizophrenia (pleiotropy)
56424,Anti-anoctamin 2 antibody levels,Phenotype,Anti-anoctamin 2 antibody levels
56425,Airway obstruction (FEV1/FVC<70%) in never smokers,Phenotype,Airway obstruction (FEV1/FVC<70%) in never smokers
56427,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers,Phenotype,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers
56443,Glomerular filtration rate in type 2 diabetes,Phenotype,Glomerular filtration rate in type 2 diabetes
56444,Glomerular filtration rate in diabetes,Phenotype,Glomerular filtration rate in diabetes
56445,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD),Phenotype,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)
56446,Early diabetic kidney disease in type 2 diabetes,Phenotype,Early diabetic kidney disease in type 2 diabetes
56447,Diabetic kidney disease in type 2 diabetes,Phenotype,Diabetic kidney disease in type 2 diabetes
56448,Central cerebrospinal fluid amyloid beta 42 to 40 ratio,Phenotype,Central cerebrospinal fluid amyloid beta 42 to 40 ratio
56450,Contamination dimension in obsessive compulsive disorder,Phenotype,Contamination dimension in obsessive compulsive disorder
56454,Type 2 diabetes nephropathy including microalbuminuria,Phenotype,Type 2 diabetes nephropathy including microalbuminuria
56468,Facial morphology (forehead protrusion 1),Phenotype,Facial morphology (forehead protrusion 1)
56470,Facial morphology (brow ridge protrusion 1),Phenotype,Facial morphology (brow ridge protrusion 1)
56472,Facial morphology (lower lip protrusion),Phenotype,Facial morphology (lower lip protrusion)
56474,Facial morphology (lip protrusion),Phenotype,Facial morphology (lip protrusion)
56475,Facial morphology (brow ridge protrusion 2),Phenotype,Facial morphology (brow ridge protrusion 2)
56476,Facial morphology (upper face flatness),Phenotype,Facial morphology (upper face flatness)
56477,Tuberculosis (SNP x SNP interaction),Phenotype,Tuberculosis (SNP x SNP interaction)
56478,Psychological distress,Phenotype,Psychological distress
56479,Fish intake frequency,Phenotype,Fish intake frequency
56480,LAG3/VCAM1 protein level ratio,Phenotype,LAG3/VCAM1 protein level ratio
56482,LAYN/ULBP2 protein level ratio,Phenotype,LAYN/ULBP2 protein level ratio
56484,LBR/RWDD1 protein level ratio,Phenotype,LBR/RWDD1 protein level ratio
56485,LBR/SERPINB1 protein level ratio,Phenotype,LBR/SERPINB1 protein level ratio
56486,KLRD1/LY9 protein level ratio,Phenotype,KLRD1/LY9 protein level ratio
56487,CEP43/USP8 protein level ratio,Phenotype,CEP43/USP8 protein level ratio
56488,CEP43/WASF1 protein level ratio,Phenotype,CEP43/WASF1 protein level ratio
56489,LAMA4/NID1 protein level ratio,Phenotype,LAMA4/NID1 protein level ratio
56491,LAMP3/MSLN protein level ratio,Phenotype,LAMP3/MSLN protein level ratio
56493,LAT2/MANF protein level ratio,Phenotype,LAT2/MANF protein level ratio
56494,LAT2/SERPINB1 protein level ratio,Phenotype,LAT2/SERPINB1 protein level ratio
56495,LAT2/YES1 protein level ratio,Phenotype,LAT2/YES1 protein level ratio
56496,CHAC2/TPMT protein level ratio,Phenotype,CHAC2/TPMT protein level ratio
56498,CHGB/MOG protein level ratio,Phenotype,CHGB/MOG protein level ratio
56500,CHGB/PTPRN2 protein level ratio,Phenotype,CHGB/PTPRN2 protein level ratio
56501,CHMP1A/CRADD protein level ratio,Phenotype,CHMP1A/CRADD protein level ratio
56502,CHMP1A/DCTN1 protein level ratio,Phenotype,CHMP1A/DCTN1 protein level ratio
56503,CHMP1A/EIF4B protein level ratio,Phenotype,CHMP1A/EIF4B protein level ratio
56504,CHMP1A/EREG protein level ratio,Phenotype,CHMP1A/EREG protein level ratio
56505,CHMP1A/HPCAL1 protein level ratio,Phenotype,CHMP1A/HPCAL1 protein level ratio
56506,CHMP1A/MITD1 protein level ratio,Phenotype,CHMP1A/MITD1 protein level ratio
56507,CHMP1A/PLA2G4A protein level ratio,Phenotype,CHMP1A/PLA2G4A protein level ratio
56508,CHMP1A/PTPN6 protein level ratio,Phenotype,CHMP1A/PTPN6 protein level ratio
56509,CHMP1A/RHOC protein level ratio,Phenotype,CHMP1A/RHOC protein level ratio
56510,CHMP1A/SNAP23 protein level ratio,Phenotype,CHMP1A/SNAP23 protein level ratio
56511,CHMP1A/SNAP29 protein level ratio,Phenotype,CHMP1A/SNAP29 protein level ratio
56512,CHMP1A/STAMBP protein level ratio,Phenotype,CHMP1A/STAMBP protein level ratio
56513,CHMP1A/STK11 protein level ratio,Phenotype,CHMP1A/STK11 protein level ratio
56514,CHMP1A/SUGT1 protein level ratio,Phenotype,CHMP1A/SUGT1 protein level ratio
56515,CHMP1A/TBCB protein level ratio,Phenotype,CHMP1A/TBCB protein level ratio
56516,CHMP1A/USP8 protein level ratio,Phenotype,CHMP1A/USP8 protein level ratio
56517,CLEC1B/EGF protein level ratio,Phenotype,CLEC1B/EGF protein level ratio
56518,CLEC1B/HBEGF protein level ratio,Phenotype,CLEC1B/HBEGF protein level ratio
56519,CLEC1B/HEXIM1 protein level ratio,Phenotype,CLEC1B/HEXIM1 protein level ratio
56520,MPI/SIRT2 protein level ratio,Phenotype,MPI/SIRT2 protein level ratio
56521,MPI/TACC3 protein level ratio,Phenotype,MPI/TACC3 protein level ratio
56522,MPO/PRTN3 protein level ratio,Phenotype,MPO/PRTN3 protein level ratio
56523,MOG/PTPRN2 protein level ratio,Phenotype,MOG/PTPRN2 protein level ratio
56524,MOG/RTBDN protein level ratio,Phenotype,MOG/RTBDN protein level ratio
56525,MOG/SEZ6L protein level ratio,Phenotype,MOG/SEZ6L protein level ratio
56526,CRELD2/SUMF2 protein level ratio,Phenotype,CRELD2/SUMF2 protein level ratio
56528,CRELD2/TXNDC5 protein level ratio,Phenotype,CRELD2/TXNDC5 protein level ratio
56529,CRIM1/NRP2 protein level ratio,Phenotype,CRIM1/NRP2 protein level ratio
56531,CRKL/SERPINB1 protein level ratio,Phenotype,CRKL/SERPINB1 protein level ratio
56532,CRTAM/FCRL6 protein level ratio,Phenotype,CRTAM/FCRL6 protein level ratio
56534,CRTAM/GZMA protein level ratio,Phenotype,CRTAM/GZMA protein level ratio
56535,CRTAM/ICAM3 protein level ratio,Phenotype,CRTAM/ICAM3 protein level ratio
56536,CRTAM/KLRD1 protein level ratio,Phenotype,CRTAM/KLRD1 protein level ratio
56538,CRKL/MANF protein level ratio,Phenotype,CRKL/MANF protein level ratio
56539,CRKL/MGLL protein level ratio,Phenotype,CRKL/MGLL protein level ratio
56540,MPHOSPH8/WASF1 protein level ratio,Phenotype,MPHOSPH8/WASF1 protein level ratio
56541,MPIG6B/PLXNA4 protein level ratio,Phenotype,MPIG6B/PLXNA4 protein level ratio
56543,MSRA/SERPINB1 protein level ratio,Phenotype,MSRA/SERPINB1 protein level ratio
56544,Obstructive sleep apnea,Phenotype,Obstructive sleep apnea
56545,Brain shape (segment 1),Phenotype,Brain shape (segment 1)
56548,NID1/SORT1 protein level ratio,Phenotype,NID1/SORT1 protein level ratio
56550,NOTCH1/TIE1 protein level ratio,Phenotype,NOTCH1/TIE1 protein level ratio
56552,MSRA/SNX9 protein level ratio,Phenotype,MSRA/SNX9 protein level ratio
56553,MSRA/TJAP1 protein level ratio,Phenotype,MSRA/TJAP1 protein level ratio
56554,MVK/SHMT1 protein level ratio,Phenotype,MVK/SHMT1 protein level ratio
56556,NFATC1/TJAP1 protein level ratio,Phenotype,NFATC1/TJAP1 protein level ratio
56557,NSFL1C/PSMG3 protein level ratio,Phenotype,NSFL1C/PSMG3 protein level ratio
56558,NSFL1C/RWDD1 protein level ratio,Phenotype,NSFL1C/RWDD1 protein level ratio
56559,NUCB2/TXNDC5 protein level ratio,Phenotype,NUCB2/TXNDC5 protein level ratio
56560,NUDT5/RWDD1 protein level ratio,Phenotype,NUDT5/RWDD1 protein level ratio
56561,NUDT5/SERPINB1 protein level ratio,Phenotype,NUDT5/SERPINB1 protein level ratio
56562,OLR1/OSM protein level ratio,Phenotype,OLR1/OSM protein level ratio
56564,DAPP1/ITGB1BP2 protein level ratio,Phenotype,DAPP1/ITGB1BP2 protein level ratio
56565,PIK3IP1/TNFRSF1A protein level ratio,Phenotype,PIK3IP1/TNFRSF1A protein level ratio
56566,PIK3IP1/TNFRSF1B protein level ratio,Phenotype,PIK3IP1/TNFRSF1B protein level ratio
56568,APP/HBEGF protein level ratio,Phenotype,APP/HBEGF protein level ratio
56570,PEAR1/TREML2 protein level ratio,Phenotype,PEAR1/TREML2 protein level ratio
56571,PFKFB2/SERPINB1 protein level ratio,Phenotype,PFKFB2/SERPINB1 protein level ratio
56572,PIK3AP1/PSMG3 protein level ratio,Phenotype,PIK3AP1/PSMG3 protein level ratio
56573,Urine 6-hydroxymelatonin sulfate-to-creatinine ratio,Phenotype,Urine 6-hydroxymelatonin sulfate-to-creatinine ratio
56575,PPP1R2/TBL1X protein level ratio,Phenotype,PPP1R2/TBL1X protein level ratio
56576,AXIN1/CALCOCO1 protein level ratio,Phenotype,AXIN1/CALCOCO1 protein level ratio
56578,AXIN1/CDKN1A protein level ratio,Phenotype,AXIN1/CDKN1A protein level ratio
56579,AXIN1/CLIP2 protein level ratio,Phenotype,AXIN1/CLIP2 protein level ratio
56580,AXIN1/DAPP1 protein level ratio,Phenotype,AXIN1/DAPP1 protein level ratio
56581,PPP1R2/TACC3 protein level ratio,Phenotype,PPP1R2/TACC3 protein level ratio
56582,PRKAR1A/SNAP23 protein level ratio,Phenotype,PRKAR1A/SNAP23 protein level ratio
56583,AXIN1/BACH1 protein level ratio,Phenotype,AXIN1/BACH1 protein level ratio
56584,AXIN1/BANK1 protein level ratio,Phenotype,AXIN1/BANK1 protein level ratio
56585,AXIN1/DOK2 protein level ratio,Phenotype,AXIN1/DOK2 protein level ratio
56586,AXIN1/GOPC protein level ratio,Phenotype,AXIN1/GOPC protein level ratio
56587,AXIN1/HEXIM1 protein level ratio,Phenotype,AXIN1/HEXIM1 protein level ratio
56588,ROBO2/SCARF2 protein level ratio,Phenotype,ROBO2/SCARF2 protein level ratio
56589,ROBO2/SFTPD protein level ratio,Phenotype,ROBO2/SFTPD protein level ratio
56591,RWDD1/SERPINB6 protein level ratio,Phenotype,RWDD1/SERPINB6 protein level ratio
56594,RWDD1/STAMBP protein level ratio,Phenotype,RWDD1/STAMBP protein level ratio
56595,RWDD1/SULT1A1 protein level ratio,Phenotype,RWDD1/SULT1A1 protein level ratio
56596,BLVRB/HAGH protein level ratio,Phenotype,BLVRB/HAGH protein level ratio
56597,BLVRB/HBQ1 protein level ratio,Phenotype,BLVRB/HBQ1 protein level ratio
56598,BLVRB/HMBS protein level ratio,Phenotype,BLVRB/HMBS protein level ratio
56599,BCAN/MOG protein level ratio,Phenotype,BCAN/MOG protein level ratio
56601,RWDD1/TXNDC5 protein level ratio,Phenotype,RWDD1/TXNDC5 protein level ratio
56602,RWDD1/VTA1 protein level ratio,Phenotype,RWDD1/VTA1 protein level ratio
56604,S100A4/SNX9 protein level ratio,Phenotype,S100A4/SNX9 protein level ratio
56605,BCR/ITGB1BP2 protein level ratio,Phenotype,BCR/ITGB1BP2 protein level ratio
56606,BCR/PLXNA4 protein level ratio,Phenotype,BCR/PLXNA4 protein level ratio
56607,BIN2/TJAP1 protein level ratio,Phenotype,BIN2/TJAP1 protein level ratio
56608,BLVRB/CA2 protein level ratio,Phenotype,BLVRB/CA2 protein level ratio
56609,BIN2/CORO1A protein level ratio,Phenotype,BIN2/CORO1A protein level ratio
56610,CANT1/GSTA1 protein level ratio,Phenotype,CANT1/GSTA1 protein level ratio
56611,CARHSP1/HMBS protein level ratio,Phenotype,CARHSP1/HMBS protein level ratio
56613,CARHSP1/TBC1D17 protein level ratio,Phenotype,CARHSP1/TBC1D17 protein level ratio
56614,ENG/NCAM2 protein level ratio,Phenotype,ENG/NCAM2 protein level ratio
56615,CA3/HMBS protein level ratio,Phenotype,CA3/HMBS protein level ratio
56616,CA5A/GRPEL1 protein level ratio,Phenotype,CA5A/GRPEL1 protein level ratio
56618,CA5A/GSTA1 protein level ratio,Phenotype,CA5A/GSTA1 protein level ratio
56619,CA5A/KRT18 protein level ratio,Phenotype,CA5A/KRT18 protein level ratio
56620,CA5A/SULT2A1 protein level ratio,Phenotype,CA5A/SULT2A1 protein level ratio
56621,CA9/CBLIF protein level ratio,Phenotype,CA9/CBLIF protein level ratio
56623,ENO1/FIS1 protein level ratio,Phenotype,ENO1/FIS1 protein level ratio
56624,ENO1/RWDD1 protein level ratio,Phenotype,ENO1/RWDD1 protein level ratio
56625,ENO1/SERPINB6 protein level ratio,Phenotype,ENO1/SERPINB6 protein level ratio
56626,ENO1/SULT1A1 protein level ratio,Phenotype,ENO1/SULT1A1 protein level ratio
56627,ENO1/VTA1 protein level ratio,Phenotype,ENO1/VTA1 protein level ratio
56628,CA1/CA2 protein level ratio,Phenotype,CA1/CA2 protein level ratio
56629,CA1/HMBS protein level ratio,Phenotype,CA1/HMBS protein level ratio
56630,CA1/TGM2 protein level ratio,Phenotype,CA1/TGM2 protein level ratio
56631,CA2/CA3 protein level ratio,Phenotype,CA2/CA3 protein level ratio
56632,CA2/DNPH1 protein level ratio,Phenotype,CA2/DNPH1 protein level ratio
56633,CA2/HAGH protein level ratio,Phenotype,CA2/HAGH protein level ratio
56634,CA2/HMBS protein level ratio,Phenotype,CA2/HMBS protein level ratio
56635,CA2/PSMG3 protein level ratio,Phenotype,CA2/PSMG3 protein level ratio
56636,CALCOCO1/MAP3K5 protein level ratio,Phenotype,CALCOCO1/MAP3K5 protein level ratio
56637,CALCOCO1/TJAP1 protein level ratio,Phenotype,CALCOCO1/TJAP1 protein level ratio
56638,CD209/GP2 protein level ratio,Phenotype,CD209/GP2 protein level ratio
56639,CD22/CD79B protein level ratio,Phenotype,CD22/CD79B protein level ratio
56641,CD22/FCER2 protein level ratio,Phenotype,CD22/FCER2 protein level ratio
56643,CD22/FCRL1 protein level ratio,Phenotype,CD22/FCRL1 protein level ratio
56644,CD22/FOLR2 protein level ratio,Phenotype,CD22/FOLR2 protein level ratio
56645,CD22/SEMA7A protein level ratio,Phenotype,CD22/SEMA7A protein level ratio
56646,FCRL5/MZB1 protein level ratio,Phenotype,FCRL5/MZB1 protein level ratio
56647,FCRL6/GZMA protein level ratio,Phenotype,FCRL6/GZMA protein level ratio
56649,FCRL6/KLRD1 protein level ratio,Phenotype,FCRL6/KLRD1 protein level ratio
56651,CD22/TNFRSF13C protein level ratio,Phenotype,CD22/TNFRSF13C protein level ratio
56652,CD244/CRTAM protein level ratio,Phenotype,CD244/CRTAM protein level ratio
56654,CD244/TREML2 protein level ratio,Phenotype,CD244/TREML2 protein level ratio
56656,CD109/CNTN4 protein level ratio,Phenotype,CD109/CNTN4 protein level ratio
56658,CD160/IL15 protein level ratio,Phenotype,CD160/IL15 protein level ratio
56659,CD160/KIR2DL3 protein level ratio,Phenotype,CD160/KIR2DL3 protein level ratio
56660,CD160/KLRB1 protein level ratio,Phenotype,CD160/KLRB1 protein level ratio
56661,CD160/NCR1 protein level ratio,Phenotype,CD160/NCR1 protein level ratio
56663,FIS1/HSPA1A protein level ratio,Phenotype,FIS1/HSPA1A protein level ratio
56664,FIS1/HTRA2 protein level ratio,Phenotype,FIS1/HTRA2 protein level ratio
56665,CD163/MSR1 protein level ratio,Phenotype,CD163/MSR1 protein level ratio
56666,CD163/SIGLEC1 protein level ratio,Phenotype,CD163/SIGLEC1 protein level ratio
56667,CD164/CD99 protein level ratio,Phenotype,CD164/CD99 protein level ratio
56669,CD1C/CD207 protein level ratio,Phenotype,CD1C/CD207 protein level ratio
56670,CD27/ICAM3 protein level ratio,Phenotype,CD27/ICAM3 protein level ratio
56671,CD27/TNFRSF13B protein level ratio,Phenotype,CD27/TNFRSF13B protein level ratio
56673,CD2AP/CD40 protein level ratio,Phenotype,CD2AP/CD40 protein level ratio
56674,CD2AP/EIF4EBP1 protein level ratio,Phenotype,CD2AP/EIF4EBP1 protein level ratio
56675,CD2AP/PLPBP protein level ratio,Phenotype,CD2AP/PLPBP protein level ratio
56676,CD2AP/SNX9 protein level ratio,Phenotype,CD2AP/SNX9 protein level ratio
56678,CD2AP/TRAF2 protein level ratio,Phenotype,CD2AP/TRAF2 protein level ratio
56679,CD2AP/VSIR protein level ratio,Phenotype,CD2AP/VSIR protein level ratio
56680,FCRL2/LY9 protein level ratio,Phenotype,FCRL2/LY9 protein level ratio
56683,FCRL2/SEMA7A protein level ratio,Phenotype,FCRL2/SEMA7A protein level ratio
56684,FCRL2/TNFRSF13B protein level ratio,Phenotype,FCRL2/TNFRSF13B protein level ratio
56686,AHSP/HMBS protein level ratio,Phenotype,AHSP/HMBS protein level ratio
56689,AIF1/TPMT protein level ratio,Phenotype,AIF1/TPMT protein level ratio
56691,AK1/DNPH1 protein level ratio,Phenotype,AK1/DNPH1 protein level ratio
56692,AGXT/CA5A protein level ratio,Phenotype,AGXT/CA5A protein level ratio
56693,AGXT/GSTA1 protein level ratio,Phenotype,AGXT/GSTA1 protein level ratio
56694,AHCY/HSPA1A protein level ratio,Phenotype,AHCY/HSPA1A protein level ratio
56695,AHSP/BLVRB protein level ratio,Phenotype,AHSP/BLVRB protein level ratio
56697,AHSP/CA2 protein level ratio,Phenotype,AHSP/CA2 protein level ratio
56699,AHSP/HBQ1 protein level ratio,Phenotype,AHSP/HBQ1 protein level ratio
56701,AARSD1/PIK3AP1 protein level ratio,Phenotype,AARSD1/PIK3AP1 protein level ratio
56702,AARSD1/PSMG3 protein level ratio,Phenotype,AARSD1/PSMG3 protein level ratio
56703,AARSD1/RWDD1 protein level ratio,Phenotype,AARSD1/RWDD1 protein level ratio
56704,ABHD14B/APRT protein level ratio,Phenotype,ABHD14B/APRT protein level ratio
56706,ABHD14B/CCS protein level ratio,Phenotype,ABHD14B/CCS protein level ratio
56707,ADH4/CA5A protein level ratio,Phenotype,ADH4/CA5A protein level ratio
56708,ADH4/GSTA1 protein level ratio,Phenotype,ADH4/GSTA1 protein level ratio
56709,ADH4/KRT18 protein level ratio,Phenotype,ADH4/KRT18 protein level ratio
56711,AGRN/BTN2A1 protein level ratio,Phenotype,AGRN/BTN2A1 protein level ratio
56713,Longevity (100 years and older),Phenotype,Longevity (100 years and older)
56714,Facial wrinkles (frown lines),Phenotype,Facial wrinkles (frown lines)
56716,LBR/TXNDC5 protein level ratio,Phenotype,LBR/TXNDC5 protein level ratio
56717,LCN2/PGLYRP1 protein level ratio,Phenotype,LCN2/PGLYRP1 protein level ratio
56718,LCN2/RETN protein level ratio,Phenotype,LCN2/RETN protein level ratio
56719,LDLR/MEGF9 protein level ratio,Phenotype,LDLR/MEGF9 protein level ratio
56720,MANF/MESD protein level ratio,Phenotype,MANF/MESD protein level ratio
56721,MANF/MPIG6B protein level ratio,Phenotype,MANF/MPIG6B protein level ratio
56722,LYN/TACC3 protein level ratio,Phenotype,LYN/TACC3 protein level ratio
56723,COL18A1/RETN protein level ratio,Phenotype,COL18A1/RETN protein level ratio
56724,CNPY4/SIRT2 protein level ratio,Phenotype,CNPY4/SIRT2 protein level ratio
56727,CNPY4/TBC1D23 protein level ratio,Phenotype,CNPY4/TBC1D23 protein level ratio
56729,CNST/ITGB1BP2 protein level ratio,Phenotype,CNST/ITGB1BP2 protein level ratio
56730,CNTN1/EGFR protein level ratio,Phenotype,CNTN1/EGFR protein level ratio
56731,CNPY4/INPP1 protein level ratio,Phenotype,CNPY4/INPP1 protein level ratio
56732,CNPY4/KIFBP protein level ratio,Phenotype,CNPY4/KIFBP protein level ratio
56733,CNPY4/MANF protein level ratio,Phenotype,CNPY4/MANF protein level ratio
56734,CNPY4/MESD protein level ratio,Phenotype,CNPY4/MESD protein level ratio
56736,CNPY4/MPI protein level ratio,Phenotype,CNPY4/MPI protein level ratio
56739,CLPS/CTRB1 protein level ratio,Phenotype,CLPS/CTRB1 protein level ratio
56741,CLPS/PLA2G1B protein level ratio,Phenotype,CLPS/PLA2G1B protein level ratio
56742,CLPS/PRSS2 protein level ratio,Phenotype,CLPS/PRSS2 protein level ratio
56743,CNPY4/ERBIN protein level ratio,Phenotype,CNPY4/ERBIN protein level ratio
56745,CLIP2/PDLIM7 protein level ratio,Phenotype,CLIP2/PDLIM7 protein level ratio
56746,CPB1/PRSS2 protein level ratio,Phenotype,CPB1/PRSS2 protein level ratio
56747,CPB1/REG1A protein level ratio,Phenotype,CPB1/REG1A protein level ratio
56748,CPPED1/PPCDC protein level ratio,Phenotype,CPPED1/PPCDC protein level ratio
56750,CPXM1/DKK1 protein level ratio,Phenotype,CPXM1/DKK1 protein level ratio
56751,CPXM1/HBEGF protein level ratio,Phenotype,CPXM1/HBEGF protein level ratio
56753,COLEC12/TGFBR2 protein level ratio,Phenotype,COLEC12/TGFBR2 protein level ratio
56754,CRADD/STAMBP protein level ratio,Phenotype,CRADD/STAMBP protein level ratio
56755,CRADD/TBCC protein level ratio,Phenotype,CRADD/TBCC protein level ratio
56756,CREG1/GUSB protein level ratio,Phenotype,CREG1/GUSB protein level ratio
56757,CPB1/CTRB1 protein level ratio,Phenotype,CPB1/CTRB1 protein level ratio
56758,CPB1/CTRC protein level ratio,Phenotype,CPB1/CTRC protein level ratio
56759,CPB1/KIRREL2 protein level ratio,Phenotype,CPB1/KIRREL2 protein level ratio
56760,CRADD/EDAR protein level ratio,Phenotype,CRADD/EDAR protein level ratio
56761,CRADD/FADD protein level ratio,Phenotype,CRADD/FADD protein level ratio
56762,CRADD/HSPA1A protein level ratio,Phenotype,CRADD/HSPA1A protein level ratio
56763,CRADD/SIRT2 protein level ratio,Phenotype,CRADD/SIRT2 protein level ratio
56764,COMT/ITGB1BP2 protein level ratio,Phenotype,COMT/ITGB1BP2 protein level ratio
56765,CORO1A/SNX9 protein level ratio,Phenotype,CORO1A/SNX9 protein level ratio
56766,CORO1A/TBC1D5 protein level ratio,Phenotype,CORO1A/TBC1D5 protein level ratio
56768,CPXM1/LGMN protein level ratio,Phenotype,CPXM1/LGMN protein level ratio
56769,CPXM1/MDK protein level ratio,Phenotype,CPXM1/MDK protein level ratio
56770,CPXM1/SPARC protein level ratio,Phenotype,CPXM1/SPARC protein level ratio
56771,CPXM1/VEGFC protein level ratio,Phenotype,CPXM1/VEGFC protein level ratio
56772,CR2/TNFRSF13B protein level ratio,Phenotype,CR2/TNFRSF13B protein level ratio
56773,CRACR2A/DNMBP protein level ratio,Phenotype,CRACR2A/DNMBP protein level ratio
56775,CPA1/CTRB1 protein level ratio,Phenotype,CPA1/CTRB1 protein level ratio
56776,CPA1/CTRC protein level ratio,Phenotype,CPA1/CTRC protein level ratio
56777,CRACR2A/MAP3K5 protein level ratio,Phenotype,CRACR2A/MAP3K5 protein level ratio
56778,CRADD/DARS1 protein level ratio,Phenotype,CRADD/DARS1 protein level ratio
56779,Brain shape (segment 3),Phenotype,Brain shape (segment 3)
56780,Brain shape (segment 5),Phenotype,Brain shape (segment 5)
56782,Brain shape (segment 2),Phenotype,Brain shape (segment 2)
56785,APOM/ERBB3 protein level ratio,Phenotype,APOM/ERBB3 protein level ratio
56787,NSFL1C/SERPINB1 protein level ratio,Phenotype,NSFL1C/SERPINB1 protein level ratio
56788,NSFL1C/STIP1 protein level ratio,Phenotype,NSFL1C/STIP1 protein level ratio
56789,NSFL1C/TXNDC5 protein level ratio,Phenotype,NSFL1C/TXNDC5 protein level ratio
56790,NT5C3A/RWDD1 protein level ratio,Phenotype,NT5C3A/RWDD1 protein level ratio
56791,OSCAR/TNFRSF14 protein level ratio,Phenotype,OSCAR/TNFRSF14 protein level ratio
56792,PARK7/S100A4 protein level ratio,Phenotype,PARK7/S100A4 protein level ratio
56794,PARK7/STIP1 protein level ratio,Phenotype,PARK7/STIP1 protein level ratio
56795,PARK7/TXNDC5 protein level ratio,Phenotype,PARK7/TXNDC5 protein level ratio
56796,PCDH17/THBD protein level ratio,Phenotype,PCDH17/THBD protein level ratio
56797,Adiponectin levels (BMI-adjusted),Phenotype,Adiponectin levels (BMI-adjusted)
56799,ARG1/HMBS protein level ratio,Phenotype,ARG1/HMBS protein level ratio
56800,ARG1/PKLR protein level ratio,Phenotype,ARG1/PKLR protein level ratio
56802,ARHGAP1/RAD23B protein level ratio,Phenotype,ARHGAP1/RAD23B protein level ratio
56803,ARHGEF12/AXIN1 protein level ratio,Phenotype,ARHGEF12/AXIN1 protein level ratio
56804,ARHGEF12/BANK1 protein level ratio,Phenotype,ARHGEF12/BANK1 protein level ratio
56805,ART3/RGMA protein level ratio,Phenotype,ART3/RGMA protein level ratio
56806,ART3/RGMB protein level ratio,Phenotype,ART3/RGMB protein level ratio
56807,ARG1/HAGH protein level ratio,Phenotype,ARG1/HAGH protein level ratio
56808,PLAUR/PRSS8 protein level ratio,Phenotype,PLAUR/PRSS8 protein level ratio
56810,PLAUR/TREM2 protein level ratio,Phenotype,PLAUR/TREM2 protein level ratio
56811,PLPBP/RWDD1 protein level ratio,Phenotype,PLPBP/RWDD1 protein level ratio
56812,PLPBP/SERPINB1 protein level ratio,Phenotype,PLPBP/SERPINB1 protein level ratio
56813,PLPBP/SNX9 protein level ratio,Phenotype,PLPBP/SNX9 protein level ratio
56814,PMVK/RHOC protein level ratio,Phenotype,PMVK/RHOC protein level ratio
56816,PPCDC/RWDD1 protein level ratio,Phenotype,PPCDC/RWDD1 protein level ratio
56817,PLA2G15/SMPD1 protein level ratio,Phenotype,PLA2G15/SMPD1 protein level ratio
56819,PLA2G15/SMPDL3A protein level ratio,Phenotype,PLA2G15/SMPDL3A protein level ratio
56820,PLXNA4/VASH1 protein level ratio,Phenotype,PLXNA4/VASH1 protein level ratio
56821,PLA2G4A/SNX9 protein level ratio,Phenotype,PLA2G4A/SNX9 protein level ratio
56822,PLA2G4A/TBL1X protein level ratio,Phenotype,PLA2G4A/TBL1X protein level ratio
56823,PLXNA4/SNAP29 protein level ratio,Phenotype,PLXNA4/SNAP29 protein level ratio
56825,PLXNA4/SRPK2 protein level ratio,Phenotype,PLXNA4/SRPK2 protein level ratio
56827,PLXNA4/USP8 protein level ratio,Phenotype,PLXNA4/USP8 protein level ratio
56828,PPP1R12A/TXNDC5 protein level ratio,Phenotype,PPP1R12A/TXNDC5 protein level ratio
56830,QPCT/RNASET2 protein level ratio,Phenotype,QPCT/RNASET2 protein level ratio
56831,RARRES2/TFPI protein level ratio,Phenotype,RARRES2/TFPI protein level ratio
56833,RHOC/TIA1 protein level ratio,Phenotype,RHOC/TIA1 protein level ratio
56834,RILP/RWDD1 protein level ratio,Phenotype,RILP/RWDD1 protein level ratio
56835,RNF41/WWP2 protein level ratio,Phenotype,RNF41/WWP2 protein level ratio
56836,RGMB/SMOC2 protein level ratio,Phenotype,RGMB/SMOC2 protein level ratio
56837,RGMB/TNFRSF21 protein level ratio,Phenotype,RGMB/TNFRSF21 protein level ratio
56838,RHOC/TBCB protein level ratio,Phenotype,RHOC/TBCB protein level ratio
56839,RHOC/TBCC protein level ratio,Phenotype,RHOC/TBCC protein level ratio
56840,REG1A/TFF3 protein level ratio,Phenotype,REG1A/TFF3 protein level ratio
56841,RETN/RNASET2 protein level ratio,Phenotype,RETN/RNASET2 protein level ratio
56842,EBAG9/FKBP5 protein level ratio,Phenotype,EBAG9/FKBP5 protein level ratio
56843,PSMD9/UBAC1 protein level ratio,Phenotype,PSMD9/UBAC1 protein level ratio
56844,PSME2/PSMG3 protein level ratio,Phenotype,PSME2/PSMG3 protein level ratio
56845,PSME2/RBKS protein level ratio,Phenotype,PSME2/RBKS protein level ratio
56846,PTPN1/WWP2 protein level ratio,Phenotype,PTPN1/WWP2 protein level ratio
56847,PTPN6/SULT1A1 protein level ratio,Phenotype,PTPN6/SULT1A1 protein level ratio
56848,PTPN6/TXNDC5 protein level ratio,Phenotype,PTPN6/TXNDC5 protein level ratio
56849,EPHB6/TNFRSF9 protein level ratio,Phenotype,EPHB6/TNFRSF9 protein level ratio
56850,EPO/TFRC protein level ratio,Phenotype,EPO/TFRC protein level ratio
56851,ESAM/LAMA4 protein level ratio,Phenotype,ESAM/LAMA4 protein level ratio
56853,ESAM/THPO protein level ratio,Phenotype,ESAM/THPO protein level ratio
56854,ENO2/RWDD1 protein level ratio,Phenotype,ENO2/RWDD1 protein level ratio
56855,ENO2/SULT1A1 protein level ratio,Phenotype,ENO2/SULT1A1 protein level ratio
56856,ENO2/TXNDC5 protein level ratio,Phenotype,ENO2/TXNDC5 protein level ratio
56857,ERBB2/PTPRF protein level ratio,Phenotype,ERBB2/PTPRF protein level ratio
56858,ERBB3/IL1R2 protein level ratio,Phenotype,ERBB3/IL1R2 protein level ratio
56859,ERBB4/UMOD protein level ratio,Phenotype,ERBB4/UMOD protein level ratio
56860,ERBIN/LAT2 protein level ratio,Phenotype,ERBIN/LAT2 protein level ratio
56861,EREG/HBEGF protein level ratio,Phenotype,EREG/HBEGF protein level ratio
56863,EREG/ITGB1BP2 protein level ratio,Phenotype,EREG/ITGB1BP2 protein level ratio
56864,ERP44/SUMF2 protein level ratio,Phenotype,ERP44/SUMF2 protein level ratio
56865,ENO2/ITGB1BP2 protein level ratio,Phenotype,ENO2/ITGB1BP2 protein level ratio
56866,ENO2/MGLL protein level ratio,Phenotype,ENO2/MGLL protein level ratio
56867,CASP3/SERPINB1 protein level ratio,Phenotype,CASP3/SERPINB1 protein level ratio
56868,Neck circumference,Phenotype,Neck circumference
56869,FKBP4/RWDD1 protein level ratio,Phenotype,FKBP4/RWDD1 protein level ratio
56870,FKBP4/WWP2 protein level ratio,Phenotype,FKBP4/WWP2 protein level ratio
56871,FKBP5/MAP4K5 protein level ratio,Phenotype,FKBP5/MAP4K5 protein level ratio
56872,FKBP5/MITD1 protein level ratio,Phenotype,FKBP5/MITD1 protein level ratio
56873,FKBP5/MPIG6B protein level ratio,Phenotype,FKBP5/MPIG6B protein level ratio
56874,FKBP5/PTPN1 protein level ratio,Phenotype,FKBP5/PTPN1 protein level ratio
56875,FOLR1/MSLN protein level ratio,Phenotype,FOLR1/MSLN protein level ratio
56876,FOLR2/HAVCR2 protein level ratio,Phenotype,FOLR2/HAVCR2 protein level ratio
56877,FOLR2/MSR1 protein level ratio,Phenotype,FOLR2/MSR1 protein level ratio
56878,FOLR2/THY1 protein level ratio,Phenotype,FOLR2/THY1 protein level ratio
56880,CD300E/CXCL10 protein level ratio,Phenotype,CD300E/CXCL10 protein level ratio
56882,CD300E/LILRA5 protein level ratio,Phenotype,CD300E/LILRA5 protein level ratio
56884,FLI1/TBL1X protein level ratio,Phenotype,FLI1/TBL1X protein level ratio
56885,FLT1/VEGFA protein level ratio,Phenotype,FLT1/VEGFA protein level ratio
56886,FLT4/ICAM2 protein level ratio,Phenotype,FLT4/ICAM2 protein level ratio
56888,CD300C/CLEC14A protein level ratio,Phenotype,CD300C/CLEC14A protein level ratio
56889,CD300C/GOLM2 protein level ratio,Phenotype,CD300C/GOLM2 protein level ratio
56890,CD300C/HAVCR2 protein level ratio,Phenotype,CD300C/HAVCR2 protein level ratio
56891,FIS1/MGLL protein level ratio,Phenotype,FIS1/MGLL protein level ratio
56892,FIS1/MPIG6B protein level ratio,Phenotype,FIS1/MPIG6B protein level ratio
56893,FIS1/SKAP2 protein level ratio,Phenotype,FIS1/SKAP2 protein level ratio
56894,FKBP4/FKBP5 protein level ratio,Phenotype,FKBP4/FKBP5 protein level ratio
56895,FOXO1/MAP3K5 protein level ratio,Phenotype,FOXO1/MAP3K5 protein level ratio
56896,FKBP5/RHOC protein level ratio,Phenotype,FKBP5/RHOC protein level ratio
56897,FKBP5/TBCB protein level ratio,Phenotype,FKBP5/TBCB protein level ratio
56898,FKBP5/TBCC protein level ratio,Phenotype,FKBP5/TBCC protein level ratio
56899,FKBP5/ZBTB16 protein level ratio,Phenotype,FKBP5/ZBTB16 protein level ratio
56900,FLI1/IPCEF1 protein level ratio,Phenotype,FLI1/IPCEF1 protein level ratio
56901,ACE2/GGT1 protein level ratio,Phenotype,ACE2/GGT1 protein level ratio
56902,ACVRL1/EFNA4 protein level ratio,Phenotype,ACVRL1/EFNA4 protein level ratio
56904,ACVRL1/TNFRSF9 protein level ratio,Phenotype,ACVRL1/TNFRSF9 protein level ratio
56905,ACY1/GSTA1 protein level ratio,Phenotype,ACY1/GSTA1 protein level ratio
56906,LTA/LTBR protein level ratio,Phenotype,LTA/LTBR protein level ratio
56907,LTBP2/PDGFRA protein level ratio,Phenotype,LTBP2/PDGFRA protein level ratio
56909,LGMN/SPINT2 protein level ratio,Phenotype,LGMN/SPINT2 protein level ratio
56910,LHPP/PKLR protein level ratio,Phenotype,LHPP/PKLR protein level ratio
56911,LRP11/NECTIN2 protein level ratio,Phenotype,LRP11/NECTIN2 protein level ratio
56913,LRP11/ROR1 protein level ratio,Phenotype,LRP11/ROR1 protein level ratio
56914,CKAP4/IL4R protein level ratio,Phenotype,CKAP4/IL4R protein level ratio
56916,CKAP4/TNFRSF4 protein level ratio,Phenotype,CKAP4/TNFRSF4 protein level ratio
56917,CLEC14A/EPHB4 protein level ratio,Phenotype,CLEC14A/EPHB4 protein level ratio
56918,CLEC14A/PIK3IP1 protein level ratio,Phenotype,CLEC14A/PIK3IP1 protein level ratio
56920,CLEC14A/TNFRSF21 protein level ratio,Phenotype,CLEC14A/TNFRSF21 protein level ratio
56921,CLEC4D/MMP9 protein level ratio,Phenotype,CLEC4D/MMP9 protein level ratio
56922,CLEC4D/OSM protein level ratio,Phenotype,CLEC4D/OSM protein level ratio
56923,CLEC4D/TGFA protein level ratio,Phenotype,CLEC4D/TGFA protein level ratio
56924,LDLR/PCSK9 protein level ratio,Phenotype,LDLR/PCSK9 protein level ratio
56925,LGALS8/RWDD1 protein level ratio,Phenotype,LGALS8/RWDD1 protein level ratio
56926,LGALS8/SERPINB6 protein level ratio,Phenotype,LGALS8/SERPINB6 protein level ratio
56927,LGALS8/TXNDC5 protein level ratio,Phenotype,LGALS8/TXNDC5 protein level ratio
56928,CLEC1B/TXNDC5 protein level ratio,Phenotype,CLEC1B/TXNDC5 protein level ratio
56929,CLEC4G/MERTK protein level ratio,Phenotype,CLEC4G/MERTK protein level ratio
56931,Clostridioides difficle infection in antibiotics-users,Phenotype,Clostridioides difficle infection in antibiotics-users
56932,MITD1/TBCC protein level ratio,Phenotype,MITD1/TBCC protein level ratio
56933,MLN/TNFRSF12A protein level ratio,Phenotype,MLN/TNFRSF12A protein level ratio
56935,MMP8/MMP9 protein level ratio,Phenotype,MMP8/MMP9 protein level ratio
56936,MMP8/PGLYRP1 protein level ratio,Phenotype,MMP8/PGLYRP1 protein level ratio
56938,MMP9/OLR1 protein level ratio,Phenotype,MMP9/OLR1 protein level ratio
56940,MMP9/PGLYRP1 protein level ratio,Phenotype,MMP9/PGLYRP1 protein level ratio
56942,MGLL/PTPN6 protein level ratio,Phenotype,MGLL/PTPN6 protein level ratio
56943,MGLL/SHMT1 protein level ratio,Phenotype,MGLL/SHMT1 protein level ratio
56944,MGLL/STK4 protein level ratio,Phenotype,MGLL/STK4 protein level ratio
56945,MGLL/VTA1 protein level ratio,Phenotype,MGLL/VTA1 protein level ratio
56946,MICB_MICA/TEK protein level ratio,Phenotype,MICB_MICA/TEK protein level ratio
56948,MIF/SERPINB1 protein level ratio,Phenotype,MIF/SERPINB1 protein level ratio
56949,MITD1/SNX9 protein level ratio,Phenotype,MITD1/SNX9 protein level ratio
56950,MGLL/MITD1 protein level ratio,Phenotype,MGLL/MITD1 protein level ratio
56951,MGLL/MPIG6B protein level ratio,Phenotype,MGLL/MPIG6B protein level ratio
56952,MGLL/PLA2G4A protein level ratio,Phenotype,MGLL/PLA2G4A protein level ratio
56953,METAP2/PLPBP protein level ratio,Phenotype,METAP2/PLPBP protein level ratio
56954,CREG1/PLA2G15 protein level ratio,Phenotype,CREG1/PLA2G15 protein level ratio
56955,CREG1/SMPDL3A protein level ratio,Phenotype,CREG1/SMPDL3A protein level ratio
56956,MESD/SERPINB1 protein level ratio,Phenotype,MESD/SERPINB1 protein level ratio
56957,Brain shape (segment 62),Phenotype,Brain shape (segment 62)
56959,Brain shape (segment 81),Phenotype,Brain shape (segment 81)
56961,Brain shape (segment 86),Phenotype,Brain shape (segment 86)
56963,Brain shape (segment 31),Phenotype,Brain shape (segment 31)
56965,Brain shape (segment 20),Phenotype,Brain shape (segment 20)
56966,Brain shape (segment 21),Phenotype,Brain shape (segment 21)
56967,Brain shape (segment 7),Phenotype,Brain shape (segment 7)
56969,CXCL3/CXCL5 protein level ratio,Phenotype,CXCL3/CXCL5 protein level ratio
56970,CXCL3/MGLL protein level ratio,Phenotype,CXCL3/MGLL protein level ratio
56971,CXCL3/PTPN6 protein level ratio,Phenotype,CXCL3/PTPN6 protein level ratio
56972,APP/DKK1 protein level ratio,Phenotype,APP/DKK1 protein level ratio
56973,CXCL10/CXCL9 protein level ratio,Phenotype,CXCL10/CXCL9 protein level ratio
56974,CXCL10/WARS protein level ratio,Phenotype,CXCL10/WARS protein level ratio
56975,CXCL11/CXCL13 protein level ratio,Phenotype,CXCL11/CXCL13 protein level ratio
56976,CXCL11/ITGB1BP2 protein level ratio,Phenotype,CXCL11/ITGB1BP2 protein level ratio
56977,CXCL11/SDC4 protein level ratio,Phenotype,CXCL11/SDC4 protein level ratio
56978,CXCL5/CXCL6 protein level ratio,Phenotype,CXCL5/CXCL6 protein level ratio
56979,CXCL5/EDAR protein level ratio,Phenotype,CXCL5/EDAR protein level ratio
56980,CXCL5/MESD protein level ratio,Phenotype,CXCL5/MESD protein level ratio
56983,Brain shape (segment 276),Phenotype,Brain shape (segment 276)
56985,Brain shape (segment 285),Phenotype,Brain shape (segment 285)
56986,CXCL5/SERPINE1 protein level ratio,Phenotype,CXCL5/SERPINE1 protein level ratio
56987,DAB2/NCK2 protein level ratio,Phenotype,DAB2/NCK2 protein level ratio
56988,DAB2/FKBP5 protein level ratio,Phenotype,DAB2/FKBP5 protein level ratio
56989,DAB2/GRAP2 protein level ratio,Phenotype,DAB2/GRAP2 protein level ratio
56990,CXCL5/PLXNA4 protein level ratio,Phenotype,CXCL5/PLXNA4 protein level ratio
56991,CXCL5/PPIB protein level ratio,Phenotype,CXCL5/PPIB protein level ratio
56992,Brain shape (segment 51),Phenotype,Brain shape (segment 51)
56993,Brain shape (segment 60),Phenotype,Brain shape (segment 60)
56995,ATG4A/TPMT protein level ratio,Phenotype,ATG4A/TPMT protein level ratio
56996,ATOX1/GYS1 protein level ratio,Phenotype,ATOX1/GYS1 protein level ratio
56997,DCTN1/RWDD1 protein level ratio,Phenotype,DCTN1/RWDD1 protein level ratio
56998,DCXR/GSTA1 protein level ratio,Phenotype,DCXR/GSTA1 protein level ratio
56999,DBNL/EDAR protein level ratio,Phenotype,DBNL/EDAR protein level ratio
57000,DBNL/HEXIM1 protein level ratio,Phenotype,DBNL/HEXIM1 protein level ratio
57001,DBNL/HSPA1A protein level ratio,Phenotype,DBNL/HSPA1A protein level ratio
57002,DBNL/RWDD1 protein level ratio,Phenotype,DBNL/RWDD1 protein level ratio
57003,DBI/STIP1 protein level ratio,Phenotype,DBI/STIP1 protein level ratio
57004,DDR1/SFTPD protein level ratio,Phenotype,DDR1/SFTPD protein level ratio
57005,ATP5IF1/HSPA1A protein level ratio,Phenotype,ATP5IF1/HSPA1A protein level ratio
57006,AXL/MSR1 protein level ratio,Phenotype,AXL/MSR1 protein level ratio
57007,BCAM/CDH5 protein level ratio,Phenotype,BCAM/CDH5 protein level ratio
57008,BCAM/EPO protein level ratio,Phenotype,BCAM/EPO protein level ratio
57009,BAG6/WASF1 protein level ratio,Phenotype,BAG6/WASF1 protein level ratio
57010,BANK1/HEXIM1 protein level ratio,Phenotype,BANK1/HEXIM1 protein level ratio
57011,B4GALT1/LRP11 protein level ratio,Phenotype,B4GALT1/LRP11 protein level ratio
57012,B4GALT1/SMOC2 protein level ratio,Phenotype,B4GALT1/SMOC2 protein level ratio
57013,BACH1/CD2AP protein level ratio,Phenotype,BACH1/CD2AP protein level ratio
57014,AXIN1/NFATC1 protein level ratio,Phenotype,AXIN1/NFATC1 protein level ratio
57015,AXIN1/PLXNA4 protein level ratio,Phenotype,AXIN1/PLXNA4 protein level ratio
57016,AXIN1/SRPK2 protein level ratio,Phenotype,AXIN1/SRPK2 protein level ratio
57017,AXL/IL18BP protein level ratio,Phenotype,AXL/IL18BP protein level ratio
57019,AXL/MCAM protein level ratio,Phenotype,AXL/MCAM protein level ratio
57020,AXIN1/ITGB1BP2 protein level ratio,Phenotype,AXIN1/ITGB1BP2 protein level ratio
57021,AXIN1/MAP2K6 protein level ratio,Phenotype,AXIN1/MAP2K6 protein level ratio
57022,AXIN1/MAVS protein level ratio,Phenotype,AXIN1/MAVS protein level ratio
57023,AXIN1/IKBKG protein level ratio,Phenotype,AXIN1/IKBKG protein level ratio
57024,AXIN1/INPPL1 protein level ratio,Phenotype,AXIN1/INPPL1 protein level ratio
57025,AXIN1/IRAK4 protein level ratio,Phenotype,AXIN1/IRAK4 protein level ratio
57026,BACH1/SNX9 protein level ratio,Phenotype,BACH1/SNX9 protein level ratio
57027,BMP6/SPINT2 protein level ratio,Phenotype,BMP6/SPINT2 protein level ratio
57029,BPIFB1/GLRX protein level ratio,Phenotype,BPIFB1/GLRX protein level ratio
57030,BTN2A1/BTN3A2 protein level ratio,Phenotype,BTN2A1/BTN3A2 protein level ratio
57032,BTN2A1/CSF1 protein level ratio,Phenotype,BTN2A1/CSF1 protein level ratio
57035,BTN2A1/EPHA1 protein level ratio,Phenotype,BTN2A1/EPHA1 protein level ratio
57037,BTN2A1/IFNGR1 protein level ratio,Phenotype,BTN2A1/IFNGR1 protein level ratio
57039,BTN2A1/IL10RB protein level ratio,Phenotype,BTN2A1/IL10RB protein level ratio
57040,BTN2A1/IL18BP protein level ratio,Phenotype,BTN2A1/IL18BP protein level ratio
57041,BTN2A1/LILRB4 protein level ratio,Phenotype,BTN2A1/LILRB4 protein level ratio
57042,BTN2A1/PIK3IP1 protein level ratio,Phenotype,BTN2A1/PIK3IP1 protein level ratio
57043,BTN2A1/SMOC2 protein level ratio,Phenotype,BTN2A1/SMOC2 protein level ratio
57044,C2/LILRB4 protein level ratio,Phenotype,C2/LILRB4 protein level ratio
57045,C2/SSC5D protein level ratio,Phenotype,C2/SSC5D protein level ratio
57046,EBAG9/HBEGF protein level ratio,Phenotype,EBAG9/HBEGF protein level ratio
57047,EBAG9/TBCC protein level ratio,Phenotype,EBAG9/TBCC protein level ratio
57048,EDAR/SERPINB1 protein level ratio,Phenotype,EDAR/SERPINB1 protein level ratio
57049,EDAR/SNAP23 protein level ratio,Phenotype,EDAR/SNAP23 protein level ratio
57050,EDAR/TMSB10 protein level ratio,Phenotype,EDAR/TMSB10 protein level ratio
57051,EDAR/TXNDC5 protein level ratio,Phenotype,EDAR/TXNDC5 protein level ratio
57052,EDAR/ENO2 protein level ratio,Phenotype,EDAR/ENO2 protein level ratio
57053,EDAR/F2R protein level ratio,Phenotype,EDAR/F2R protein level ratio
57054,EDAR/PRDX5 protein level ratio,Phenotype,EDAR/PRDX5 protein level ratio
57055,EDAR/SDC4 protein level ratio,Phenotype,EDAR/SDC4 protein level ratio
57056,EDAR/IRAK4 protein level ratio,Phenotype,EDAR/IRAK4 protein level ratio
57057,EDAR/ITGB1BP2 protein level ratio,Phenotype,EDAR/ITGB1BP2 protein level ratio
57058,SRC/SULT1A1 protein level ratio,Phenotype,SRC/SULT1A1 protein level ratio
57059,C4BPB/ENTPD5 protein level ratio,Phenotype,C4BPB/ENTPD5 protein level ratio
57060,SNX9/VTA1 protein level ratio,Phenotype,SNX9/VTA1 protein level ratio
57061,SNX9/WWP2 protein level ratio,Phenotype,SNX9/WWP2 protein level ratio
57062,SORT1/VSIR protein level ratio,Phenotype,SORT1/VSIR protein level ratio
57063,SLAMF7/TXNDC15 protein level ratio,Phenotype,SLAMF7/TXNDC15 protein level ratio
57064,SMAD1/ZBTB16 protein level ratio,Phenotype,SMAD1/ZBTB16 protein level ratio
57065,SEZ6L/SEZ6L2 protein level ratio,Phenotype,SEZ6L/SEZ6L2 protein level ratio
57066,SH2B3/TBL1X protein level ratio,Phenotype,SH2B3/TBL1X protein level ratio
57067,SEMA4D/TREML2 protein level ratio,Phenotype,SEMA4D/TREML2 protein level ratio
57068,SEMA4D/TXNDC5 protein level ratio,Phenotype,SEMA4D/TXNDC5 protein level ratio
57069,SERPINB1/SERPINB6 protein level ratio,Phenotype,SERPINB1/SERPINB6 protein level ratio
57070,SERPINB1/SERPINB9 protein level ratio,Phenotype,SERPINB1/SERPINB9 protein level ratio
57071,SERPINB1/STAT5B protein level ratio,Phenotype,SERPINB1/STAT5B protein level ratio
57072,SERPINB1/STIP1 protein level ratio,Phenotype,SERPINB1/STIP1 protein level ratio
57073,SERPINB1/TMSB10 protein level ratio,Phenotype,SERPINB1/TMSB10 protein level ratio
57074,SERPINB6/SOD1 protein level ratio,Phenotype,SERPINB6/SOD1 protein level ratio
57075,SERPINB6/TXNDC5 protein level ratio,Phenotype,SERPINB6/TXNDC5 protein level ratio
57076,SMPD1/SMPDL3A protein level ratio,Phenotype,SMPD1/SMPDL3A protein level ratio
57077,SNAP23/TBL1X protein level ratio,Phenotype,SNAP23/TBL1X protein level ratio
57078,SNAP23/ZBTB16 protein level ratio,Phenotype,SNAP23/ZBTB16 protein level ratio
57079,SNAP29/SNX9 protein level ratio,Phenotype,SNAP29/SNX9 protein level ratio
57080,SNAP29/TJAP1 protein level ratio,Phenotype,SNAP29/TJAP1 protein level ratio
57081,SNX9/STAMBP protein level ratio,Phenotype,SNX9/STAMBP protein level ratio
57082,SNX9/STIP1 protein level ratio,Phenotype,SNX9/STIP1 protein level ratio
57083,SNX9/STK4 protein level ratio,Phenotype,SNX9/STK4 protein level ratio
57084,SNX9/VASH1 protein level ratio,Phenotype,SNX9/VASH1 protein level ratio
57086,Early-onset schizophrenia,Phenotype,Early-onset schizophrenia
57087,FBP1/GSTA1 protein level ratio,Phenotype,FBP1/GSTA1 protein level ratio
57088,FCER2/FCRL1 protein level ratio,Phenotype,FCER2/FCRL1 protein level ratio
57091,FCER2/TCL1A protein level ratio,Phenotype,FCER2/TCL1A protein level ratio
57092,FCER2/TNFRSF9 protein level ratio,Phenotype,FCER2/TNFRSF9 protein level ratio
57095,FAM3B/GUCA2A protein level ratio,Phenotype,FAM3B/GUCA2A protein level ratio
57096,CCN2/HBEGF protein level ratio,Phenotype,CCN2/HBEGF protein level ratio
57097,FCRL1/TNFRSF13C protein level ratio,Phenotype,FCRL1/TNFRSF13C protein level ratio
57100,FCRL1/TREML2 protein level ratio,Phenotype,FCRL1/TREML2 protein level ratio
57101,CCN2/DKK1 protein level ratio,Phenotype,CCN2/DKK1 protein level ratio
57104,CCN2/SPINT2 protein level ratio,Phenotype,CCN2/SPINT2 protein level ratio
57105,CCN2/TPP1 protein level ratio,Phenotype,CCN2/TPP1 protein level ratio
57106,CCN2/VEGFC protein level ratio,Phenotype,CCN2/VEGFC protein level ratio
57108,CCN3/FAP protein level ratio,Phenotype,CCN3/FAP protein level ratio
57110,FADD/MGLL protein level ratio,Phenotype,FADD/MGLL protein level ratio
57111,F2R/SNX9 protein level ratio,Phenotype,F2R/SNX9 protein level ratio
57112,GFER/RRM2B protein level ratio,Phenotype,GFER/RRM2B protein level ratio
57114,GFER/TRIAP1 protein level ratio,Phenotype,GFER/TRIAP1 protein level ratio
57116,GFRA1/TNFRSF1A protein level ratio,Phenotype,GFRA1/TNFRSF1A protein level ratio
57117,GFRA3/LAYN protein level ratio,Phenotype,GFRA3/LAYN protein level ratio
57118,GLRX/QDPR protein level ratio,Phenotype,GLRX/QDPR protein level ratio
57119,GMPR/NSFL1C protein level ratio,Phenotype,GMPR/NSFL1C protein level ratio
57120,GMPR/PSMG3 protein level ratio,Phenotype,GMPR/PSMG3 protein level ratio
57121,GNLY/GZMA protein level ratio,Phenotype,GNLY/GZMA protein level ratio
57123,GNLY/KIR2DL3 protein level ratio,Phenotype,GNLY/KIR2DL3 protein level ratio
57124,GOLM2/ITGA5 protein level ratio,Phenotype,GOLM2/ITGA5 protein level ratio
57125,ADA2/COMP protein level ratio,Phenotype,ADA2/COMP protein level ratio
57126,ADA2/VCAM1 protein level ratio,Phenotype,ADA2/VCAM1 protein level ratio
57127,GLO1/GLOD4 protein level ratio,Phenotype,GLO1/GLOD4 protein level ratio
57128,GLO1/S100A4 protein level ratio,Phenotype,GLO1/S100A4 protein level ratio
57129,GLOD4/GMPR protein level ratio,Phenotype,GLOD4/GMPR protein level ratio
57130,GLOD4/HSPA1A protein level ratio,Phenotype,GLOD4/HSPA1A protein level ratio
57131,ADGRE5/ITGB2 protein level ratio,Phenotype,ADGRE5/ITGB2 protein level ratio
57132,ADGRE5/VCAM1 protein level ratio,Phenotype,ADGRE5/VCAM1 protein level ratio
57133,ADAM23/BSG protein level ratio,Phenotype,ADAM23/BSG protein level ratio
57134,ADAMTS15/CLMP protein level ratio,Phenotype,ADAMTS15/CLMP protein level ratio
57135,ADGRE2/B4GALT1 protein level ratio,Phenotype,ADGRE2/B4GALT1 protein level ratio
57137,ADGRE2/CRIM1 protein level ratio,Phenotype,ADGRE2/CRIM1 protein level ratio
57138,ADGRE2/IFNGR1 protein level ratio,Phenotype,ADGRE2/IFNGR1 protein level ratio
57139,ADGRE2/SIGLEC1 protein level ratio,Phenotype,ADGRE2/SIGLEC1 protein level ratio
57140,Parkinson's disease progression (cognitive),Phenotype,Parkinson's disease progression (cognitive)
57141,Serum levels of protein APOA1,Phenotype,Serum levels of protein APOA1
57142,Serum levels of protein ADGRE5,Phenotype,Serum levels of protein ADGRE5
57143,Serum levels of protein ADGRF5,Phenotype,Serum levels of protein ADGRF5
57146,Serum levels of protein APOA5,Phenotype,Serum levels of protein APOA5
57147,Serum levels of protein AGER,Phenotype,Serum levels of protein AGER
57148,Serum levels of protein AGRP,Phenotype,Serum levels of protein AGRP
57151,Serum levels of protein AHSA1,Phenotype,Serum levels of protein AHSA1
57152,Serum levels of protein RAB17,Phenotype,Serum levels of protein RAB17
57153,Serum levels of protein PTPN1,Phenotype,Serum levels of protein PTPN1
57154,Serum levels of protein RAB5C,Phenotype,Serum levels of protein RAB5C
57155,Serum levels of protein RACGAP1,Phenotype,Serum levels of protein RACGAP1
57158,Serum levels of protein RAD51,Phenotype,Serum levels of protein RAD51
57159,Serum levels of protein NAALAD2,Phenotype,Serum levels of protein NAALAD2
57160,Serum levels of protein NCR3,Phenotype,Serum levels of protein NCR3
57162,Serum levels of protein NDUFB4,Phenotype,Serum levels of protein NDUFB4
57163,Serum levels of protein EPO,Phenotype,Serum levels of protein EPO
57164,Serum levels of protein ERP29,Phenotype,Serum levels of protein ERP29
57166,Serum levels of protein ENPP5,Phenotype,Serum levels of protein ENPP5
57167,Serum levels of protein ENTPD3,Phenotype,Serum levels of protein ENTPD3
57169,Serum levels of protein NAGPA,Phenotype,Serum levels of protein NAGPA
57171,Serum levels of protein NBL1,Phenotype,Serum levels of protein NBL1
57172,Serum levels of protein NCAM2,Phenotype,Serum levels of protein NCAM2
57174,Serum levels of protein PTN,Phenotype,Serum levels of protein PTN
57176,Bilateral cleft lip,Phenotype,Bilateral cleft lip
57177,Serum levels of protein FAS,Phenotype,Serum levels of protein FAS
57178,Serum levels of protein FCER1A,Phenotype,Serum levels of protein FCER1A
57179,Serum levels of protein PCDHA4,Phenotype,Serum levels of protein PCDHA4
57181,Serum levels of protein PCDHB14,Phenotype,Serum levels of protein PCDHB14
57182,Serum levels of protein PCDHB4,Phenotype,Serum levels of protein PCDHB4
57183,Serum levels of protein PCDHGA11,Phenotype,Serum levels of protein PCDHGA11
57185,Serum levels of protein PCDHGB4,Phenotype,Serum levels of protein PCDHGB4
57186,Serum levels of protein NRXN3,Phenotype,Serum levels of protein NRXN3
57187,Serum levels of protein NPTX1,Phenotype,Serum levels of protein NPTX1
57188,Serum levels of protein NPW,Phenotype,Serum levels of protein NPW
57190,Serum levels of protein NQO1,Phenotype,Serum levels of protein NQO1
57191,Serum levels of protein NQO2,Phenotype,Serum levels of protein NQO2
57193,Bilateral cleft lip and palate,Phenotype,Bilateral cleft lip and palate
57194,Unilateral cleft lip,Phenotype,Unilateral cleft lip
57195,Serum levels of protein ATF6,Phenotype,Serum levels of protein ATF6
57197,Serum levels of protein ATF6B,Phenotype,Serum levels of protein ATF6B
57198,Serum levels of protein IFNAR1,Phenotype,Serum levels of protein IFNAR1
57199,Serum levels of protein PIGA,Phenotype,Serum levels of protein PIGA
57200,Serum levels of protein PIK3CG,Phenotype,Serum levels of protein PIK3CG
57201,Serum levels of protein PILRA,Phenotype,Serum levels of protein PILRA
57202,Serum levels of protein C2,Phenotype,Serum levels of protein C2
57204,Serum levels of protein C2orf40,Phenotype,Serum levels of protein C2orf40
57205,Serum levels of protein C4A;C4B,Phenotype,Serum levels of protein C4A;C4B
57211,Serum levels of protein CBLN1,Phenotype,Serum levels of protein CBLN1
57213,Serum levels of protein C6orf25,Phenotype,Serum levels of protein C6orf25
57215,Serum levels of protein CA4,Phenotype,Serum levels of protein CA4
57216,Serum levels of protein IL15,Phenotype,Serum levels of protein IL15
57218,Serum levels of protein IL21,Phenotype,Serum levels of protein IL21
57219,Serum levels of protein IL34,Phenotype,Serum levels of protein IL34
57221,Serum levels of protein IL36A,Phenotype,Serum levels of protein IL36A
57223,Serum levels of protein IL18R1,Phenotype,Serum levels of protein IL18R1
57224,Serum levels of protein IL18RAP,Phenotype,Serum levels of protein IL18RAP
57226,Serum levels of protein CLPS,Phenotype,Serum levels of protein CLPS
57231,Serum levels of protein CMPK1,Phenotype,Serum levels of protein CMPK1
57232,Noncognitive aspects of educational attainment,Phenotype,Noncognitive aspects of educational attainment
57233,Serum levels of protein CLIC5,Phenotype,Serum levels of protein CLIC5
57234,Serum levels of protein KIR2DS2,Phenotype,Serum levels of protein KIR2DS2
57235,Serum levels of protein KLK12,Phenotype,Serum levels of protein KLK12
57236,Serum levels of protein CLEC12B,Phenotype,Serum levels of protein CLEC12B
57237,Serum levels of protein KCNE2,Phenotype,Serum levels of protein KCNE2
57238,Serum levels of protein LAYN,Phenotype,Serum levels of protein LAYN
57239,Serum levels of protein KLK6,Phenotype,Serum levels of protein KLK6
57240,Serum levels of protein KLRC3,Phenotype,Serum levels of protein KLRC3
57241,Serum levels of protein LDLRAD4,Phenotype,Serum levels of protein LDLRAD4
57242,Serum levels of protein CPB1,Phenotype,Serum levels of protein CPB1
57243,Serum levels of protein CPXM1,Phenotype,Serum levels of protein CPXM1
57245,Serum levels of protein CRABP1,Phenotype,Serum levels of protein CRABP1
57246,Serum levels of protein CREB3L4,Phenotype,Serum levels of protein CREB3L4
57247,Serum levels of protein COL11A2,Phenotype,Serum levels of protein COL11A2
57251,Serum levels of protein CRISP2,Phenotype,Serum levels of protein CRISP2
57256,Serum levels of protein CRISPLD2,Phenotype,Serum levels of protein CRISPLD2
57259,Serum levels of protein CNTN1,Phenotype,Serum levels of protein CNTN1
57260,Serum levels of protein MICA,Phenotype,Serum levels of protein MICA
57263,Serum levels of protein MICB,Phenotype,Serum levels of protein MICB
57267,Serum levels of protein PPIL1,Phenotype,Serum levels of protein PPIL1
57269,Serum levels of protein METTL24,Phenotype,Serum levels of protein METTL24
57272,Serum levels of protein PLXDC2,Phenotype,Serum levels of protein PLXDC2
57273,Serum levels of protein PNLIPRP1,Phenotype,Serum levels of protein PNLIPRP1
57274,Serum levels of protein GPC3,Phenotype,Serum levels of protein GPC3
57276,Serum levels of protein GRAMD1C,Phenotype,Serum levels of protein GRAMD1C
57279,Serum levels of protein MLN,Phenotype,Serum levels of protein MLN
57281,Serum levels of protein POLR1C,Phenotype,Serum levels of protein POLR1C
57282,Serum levels of protein POMC,Phenotype,Serum levels of protein POMC
57283,Serum levels of protein EEF2K,Phenotype,Serum levels of protein EEF2K
57284,Serum levels of protein MOCS3,Phenotype,Serum levels of protein MOCS3
57285,Serum levels of protein MPG,Phenotype,Serum levels of protein MPG
57287,Serum levels of protein PRSS2,Phenotype,Serum levels of protein PRSS2
57288,Serum levels of protein PRSS22,Phenotype,Serum levels of protein PRSS22
57290,Serum levels of protein PRSS57,Phenotype,Serum levels of protein PRSS57
57292,Serum levels of protein PSMB1,Phenotype,Serum levels of protein PSMB1
57294,Serum levels of protein MMP7,Phenotype,Serum levels of protein MMP7
57295,Serum levels of protein MRPL55,Phenotype,Serum levels of protein MRPL55
57296,Serum levels of protein MST1R,Phenotype,Serum levels of protein MST1R
57297,Serum levels of protein PRSS8,Phenotype,Serum levels of protein PRSS8
57299,Serum levels of protein PRTN3,Phenotype,Serum levels of protein PRTN3
57300,Serum levels of protein PSMD11,Phenotype,Serum levels of protein PSMD11
57301,Serum levels of protein HPSE,Phenotype,Serum levels of protein HPSE
57303,Serum levels of protein HSPA1A,Phenotype,Serum levels of protein HSPA1A
57304,Serum levels of protein ANTXR1,Phenotype,Serum levels of protein ANTXR1
57305,Serum levels of protein ANXA10,Phenotype,Serum levels of protein ANXA10
57306,Serum levels of protein HNF4A,Phenotype,Serum levels of protein HNF4A
57307,Serum levels of protein HP,Phenotype,Serum levels of protein HP
57309,Serum levels of protein AIF1,Phenotype,Serum levels of protein AIF1
57311,Serum levels of protein AKT3,Phenotype,Serum levels of protein AKT3
57312,Serum levels of protein ALB,Phenotype,Serum levels of protein ALB
57314,Serum levels of protein RGS8,Phenotype,Serum levels of protein RGS8
57315,Serum levels of protein RBM19,Phenotype,Serum levels of protein RBM19
57316,Serum levels of protein OSM,Phenotype,Serum levels of protein OSM
57317,Serum levels of protein P4HB,Phenotype,Serum levels of protein P4HB
57319,Serum levels of protein F13B,Phenotype,Serum levels of protein F13B
57321,Serum levels of protein PCSK7,Phenotype,Serum levels of protein PCSK7
57323,Serum levels of protein RSPO3,Phenotype,Serum levels of protein RSPO3
57326,Serum levels of protein RNF43,Phenotype,Serum levels of protein RNF43
57327,Serum levels of protein RPL30,Phenotype,Serum levels of protein RPL30
57328,Serum levels of protein RPS10,Phenotype,Serum levels of protein RPS10
57329,Serum levels of protein PDIA3,Phenotype,Serum levels of protein PDIA3
57331,Serum levels of protein PDIA5,Phenotype,Serum levels of protein PDIA5
57333,Serum levels of protein PDILT,Phenotype,Serum levels of protein PDILT
57335,Serum levels of protein APOL1,Phenotype,Serum levels of protein APOL1
57336,Serum levels of protein APOM,Phenotype,Serum levels of protein APOM
57339,Unilateral cleft lip and palate,Phenotype,Unilateral cleft lip and palate
57340,Serum levels of protein BGLAP,Phenotype,Serum levels of protein BGLAP
57341,Serum levels of protein BGN,Phenotype,Serum levels of protein BGN
57344,Serum levels of protein BMP7,Phenotype,Serum levels of protein BMP7
57346,Serum levels of protein IL10RA,Phenotype,Serum levels of protein IL10RA
57347,Serum levels of protein BAGE3,Phenotype,Serum levels of protein BAGE3
57348,Serum levels of protein BCL2L1,Phenotype,Serum levels of protein BCL2L1
57349,Serum levels of protein BCL2L10,Phenotype,Serum levels of protein BCL2L10
57350,Serum levels of protein AZGP1,Phenotype,Serum levels of protein AZGP1
57351,Serum levels of protein B2M,Phenotype,Serum levels of protein B2M
57353,Serum levels of protein IGF2R,Phenotype,Serum levels of protein IGF2R
57357,Serum levels of protein IGFBP6,Phenotype,Serum levels of protein IGFBP6
57358,Serum levels of protein IGFBPL1,Phenotype,Serum levels of protein IGFBPL1
57360,Serum levels of protein IGFL3,Phenotype,Serum levels of protein IGFL3
57361,Serum levels of protein C11orf87,Phenotype,Serum levels of protein C11orf87
57363,Serum levels of protein FN1,Phenotype,Serum levels of protein FN1
57364,Serum levels of protein CCL17,Phenotype,Serum levels of protein CCL17
57366,Serum levels of protein CCL19,Phenotype,Serum levels of protein CCL19
57368,Serum levels of protein CCL22,Phenotype,Serum levels of protein CCL22
57369,Cervical intraepithelial neoplasia grade 3,Phenotype,Cervical intraepithelial neoplasia grade 3
57370,Cervical intraepithelial neoplasia grade 3 and invasive cervical cancer,Phenotype,Cervical intraepithelial neoplasia grade 3 and invasive cervical cancer
57371,Serum levels of protein CCL1,Phenotype,Serum levels of protein CCL1
57372,Serum levels of protein CD109,Phenotype,Serum levels of protein CD109
57376,Serum levels of protein CD8A,Phenotype,Serum levels of protein CD8A
57377,Serum levels of protein CFB,Phenotype,Serum levels of protein CFB
57379,Serum levels of protein ISG15,Phenotype,Serum levels of protein ISG15
57381,Serum levels of protein CDH7,Phenotype,Serum levels of protein CDH7
57382,Serum levels of protein CDK5;CDK5R1,Phenotype,Serum levels of protein CDK5;CDK5R1
57383,Serum levels of protein CFP,Phenotype,Serum levels of protein CFP
57384,Serum levels of protein CFTR,Phenotype,Serum levels of protein CFTR
57385,Serum levels of protein CGA;TSHB,Phenotype,Serum levels of protein CGA;TSHB
57387,Serum levels of protein CDH11,Phenotype,Serum levels of protein CDH11
57390,Serum levels of protein LILRB1,Phenotype,Serum levels of protein LILRB1
57392,Serum levels of protein FRS2,Phenotype,Serum levels of protein FRS2
57394,Serum levels of protein LIPA,Phenotype,Serum levels of protein LIPA
57395,Serum levels of protein LPO,Phenotype,Serum levels of protein LPO
57397,Serum levels of protein LRP11,Phenotype,Serum levels of protein LRP11
57400,Serum levels of protein LRPAP1,Phenotype,Serum levels of protein LRPAP1
57405,Serum levels of protein FRZB,Phenotype,Serum levels of protein FRZB
57406,Serum levels of protein CTGF,Phenotype,Serum levels of protein CTGF
57409,Serum levels of protein CTRB2,Phenotype,Serum levels of protein CTRB2
57411,Serum levels of protein GFRAL,Phenotype,Serum levels of protein GFRAL
57414,Serum levels of protein GIP,Phenotype,Serum levels of protein GIP
57416,Serum levels of protein FTH1;FTL,Phenotype,Serum levels of protein FTH1;FTL
57417,Serum levels of protein FTMT,Phenotype,Serum levels of protein FTMT
57418,Serum levels of protein CX3CL1,Phenotype,Serum levels of protein CX3CL1
57420,Serum levels of protein CXCL2;CXCL3,Phenotype,Serum levels of protein CXCL2;CXCL3
57422,Serum levels of protein GABARAPL2,Phenotype,Serum levels of protein GABARAPL2
57424,Serum levels of protein GBP6,Phenotype,Serum levels of protein GBP6
57425,Serum levels of protein GCNT4,Phenotype,Serum levels of protein GCNT4
57426,Serum levels of protein DES,Phenotype,Serum levels of protein DES
57427,Serum levels of protein DEFB119,Phenotype,Serum levels of protein DEFB119
57429,Serum levels of protein MAPK13,Phenotype,Serum levels of protein MAPK13
57431,Serum levels of protein DCUN1D5,Phenotype,Serum levels of protein DCUN1D5
57432,Serum levels of protein DDR1,Phenotype,Serum levels of protein DDR1
57434,Serum levels of protein GNLY,Phenotype,Serum levels of protein GNLY
57436,Serum levels of protein GNMT,Phenotype,Serum levels of protein GNMT
57438,Serum levels of protein GNPTG,Phenotype,Serum levels of protein GNPTG
57440,Serum levels of protein MANEA,Phenotype,Serum levels of protein MANEA
57442,Serum levels of protein PLG,Phenotype,Serum levels of protein PLG
57447,Serum levels of protein GLO1,Phenotype,Serum levels of protein GLO1
57450,Cognitive aspects of educational attainment,Phenotype,Cognitive aspects of educational attainment
57451,Serum levels of protein DLK2,Phenotype,Serum levels of protein DLK2
57453,Serum levels of protein DNAJB11,Phenotype,Serum levels of protein DNAJB11
57455,Serum levels of protein PREP,Phenotype,Serum levels of protein PREP
57457,Serum levels of protein HBZ,Phenotype,Serum levels of protein HBZ
57459,Serum levels of protein GZMA,Phenotype,Serum levels of protein GZMA
57460,Serum levels of protein GZMB,Phenotype,Serum levels of protein GZMB
57462,Serum levels of protein H6PD,Phenotype,Serum levels of protein H6PD
57463,Serum levels of protein HAVCR2,Phenotype,Serum levels of protein HAVCR2
57467,Serum levels of protein DNAJC10,Phenotype,Serum levels of protein DNAJC10
57469,Serum levels of protein DPEP1,Phenotype,Serum levels of protein DPEP1
57471,Serum levels of protein DSG1,Phenotype,Serum levels of protein DSG1
57472,Serum levels of protein SERPIND1,Phenotype,Serum levels of protein SERPIND1
57473,Serum levels of protein SERPINF2,Phenotype,Serum levels of protein SERPINF2
57474,Serum levels of protein SEMA6C,Phenotype,Serum levels of protein SEMA6C
57475,Serum levels of protein SIGLEC8,Phenotype,Serum levels of protein SIGLEC8
57476,Serum levels of protein SMPDL3A,Phenotype,Serum levels of protein SMPDL3A
57477,Primary central nervous system lymphoma,Phenotype,Primary central nervous system lymphoma
57478,Gallstone disease,Phenotype,Gallstone disease
57479,Arterial stiffness index,Phenotype,Arterial stiffness index
57480,Strabismus,Phenotype,Strabismus
57482,Invasive breast cancer,Phenotype,Invasive breast cancer
57483,Serum levels of protein TDO2,Phenotype,Serum levels of protein TDO2
57484,Serum levels of protein TEK,Phenotype,Serum levels of protein TEK
57485,Serum levels of protein SYT11,Phenotype,Serum levels of protein SYT11
57486,Serum levels of protein TAPBP,Phenotype,Serum levels of protein TAPBP
57488,Serum levels of protein TAPBPL,Phenotype,Serum levels of protein TAPBPL
57490,Serum levels of protein SPARCL1,Phenotype,Serum levels of protein SPARCL1
57491,Serum levels of protein SPAG11B,Phenotype,Serum levels of protein SPAG11B
57493,Serum levels of protein SULT4A1,Phenotype,Serum levels of protein SULT4A1
57494,Serum levels of protein SURF1,Phenotype,Serum levels of protein SURF1
57495,Serum levels of protein SYNCRIP,Phenotype,Serum levels of protein SYNCRIP
57496,Serum levels of protein SRL,Phenotype,Serum levels of protein SRL
57498,Breast cancer (triple negative or BRCA1-positive),Phenotype,Breast cancer (triple negative or BRCA1-positive)
57500,Serum levels of protein TMX3,Phenotype,Serum levels of protein TMX3
57502,Serum levels of protein TF,Phenotype,Serum levels of protein TF
57503,Serum levels of protein TFF3,Phenotype,Serum levels of protein TFF3
57504,Serum levels of protein TGM3,Phenotype,Serum levels of protein TGM3
57505,Serum levels of protein THBS2,Phenotype,Serum levels of protein THBS2
57506,Serum levels of protein TMCC3,Phenotype,Serum levels of protein TMCC3
57507,Serum levels of protein TMEM52B,Phenotype,Serum levels of protein TMEM52B
57508,Serum levels of protein TREM2,Phenotype,Serum levels of protein TREM2
57510,Serum levels of protein TREML1,Phenotype,Serum levels of protein TREML1
57512,Serum levels of protein TRIL,Phenotype,Serum levels of protein TRIL
57513,Serum levels of protein TXNDC15,Phenotype,Serum levels of protein TXNDC15
57514,Serum levels of protein USP25,Phenotype,Serum levels of protein USP25
57515,Serum levels of protein UST,Phenotype,Serum levels of protein UST
57516,Serum levels of protein UTS2,Phenotype,Serum levels of protein UTS2
57517,Serum levels of protein UXS1,Phenotype,Serum levels of protein UXS1
57519,Serum levels of protein VEGFA,Phenotype,Serum levels of protein VEGFA
57520,Serum levels of protein VEGFB,Phenotype,Serum levels of protein VEGFB
57521,Serum levels of protein TXNDC5,Phenotype,Serum levels of protein TXNDC5
57523,Serum levels of protein TYK2,Phenotype,Serum levels of protein TYK2
57524,Serum levels of protein UBC,Phenotype,Serum levels of protein UBC
57525,Serum levels of protein TPM2,Phenotype,Serum levels of protein TPM2
57526,Serum levels of protein TPPP2,Phenotype,Serum levels of protein TPPP2
57528,Serum levels of protein TPSB2,Phenotype,Serum levels of protein TPSB2
57531,Serum levels of protein TNXB,Phenotype,Serum levels of protein TNXB
57532,Serum levels of protein TPSB2;TPSAB1,Phenotype,Serum levels of protein TPSB2;TPSAB1
57538,Serum levels of protein TREM1,Phenotype,Serum levels of protein TREM1
57543,Serum levels of protein VOPP1,Phenotype,Serum levels of protein VOPP1
57544,Serum levels of protein ZAP70,Phenotype,Serum levels of protein ZAP70
57545,Serum levels of protein ZG16B,Phenotype,Serum levels of protein ZG16B
57546,Serum levels of protein WFDC1,Phenotype,Serum levels of protein WFDC1
57547,Serum levels of protein WFIKKN1,Phenotype,Serum levels of protein WFIKKN1
57550,Serum levels of protein WIF1,Phenotype,Serum levels of protein WIF1
57551,Serum levels of protein ZNF276,Phenotype,Serum levels of protein ZNF276
57552,Chronic obstructive pulmonary disease x ever smoker interaction (2df),Phenotype,Chronic obstructive pulmonary disease x ever smoker interaction (2df)
57553,Skin and soft tissue infections,Phenotype,Skin and soft tissue infections
57554,Chronic obstructive pulmonary disease in ever smokers,Phenotype,Chronic obstructive pulmonary disease in ever smokers
57555,Chronic obstructive pulmonary disease in never smokers,Phenotype,Chronic obstructive pulmonary disease in never smokers
57556,Chronic obstructive pulmonary disease x ever smoker interaction (main effect),Phenotype,Chronic obstructive pulmonary disease x ever smoker interaction (main effect)
57557,Chronic obstructive pulmonary disease x current smoker interaction (2df),Phenotype,Chronic obstructive pulmonary disease x current smoker interaction (2df)
57558,Chronic obstructive pulmonary disease x current smoker interaction (main effect),Phenotype,Chronic obstructive pulmonary disease x current smoker interaction (main effect)
57562,Bioavailable testosterone levels,Phenotype,Bioavailable testosterone levels
57563,Spondylosis,Phenotype,Spondylosis
57564,Body size at age 10,Phenotype,Body size at age 10
57565,Coronary artery disease in individuals without type 2 diabetes,Phenotype,Coronary artery disease in individuals without type 2 diabetes
57566,Childhood asthma with severe exacerbations,Phenotype,Childhood asthma with severe exacerbations
57567,Neuropsychiatric disorders,Phenotype,Neuropsychiatric disorders
57569,Esophageal or stomach cancer,Phenotype,Esophageal or stomach cancer
57574,Thyroid cancer,Phenotype,Thyroid cancer
57576,Lymphocytic leukemia,Phenotype,Lymphocytic leukemia
57584,Walking pace,Phenotype,Walking pace
57590,Cancer (pleiotropy)(bidirectional),Phenotype,Cancer (pleiotropy)(bidirectional)
57596,interferon-related traits,Phenotype,interferon-related traits
57614,Non-tuberculous mycobacterial pulmonary disease,Phenotype,Non-tuberculous mycobacterial pulmonary disease
57615,Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect),Phenotype,Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect)
57616,Type 2 diabetes (SNP x SNP interaction-- 2df),Phenotype,Type 2 diabetes (SNP x SNP interaction-- 2df)
57617,Type 2 diabetes (SNP x SNP interaction-- 1df),Phenotype,Type 2 diabetes (SNP x SNP interaction-- 1df)
57618,Fasting blood glucose adjusted for BMI,Phenotype,Fasting blood glucose adjusted for BMI
57619,Benign prostatic hyperplasia,Phenotype,Benign prostatic hyperplasia
57620,Hyperuricemia,Phenotype,Hyperuricemia
57621,Resting-state electroencephalogram vigilance,Phenotype,Resting-state electroencephalogram vigilance
57622,Remission after SSRI treatment in MDD or openness,Phenotype,Remission after SSRI treatment in MDD or openness
57623,Response to SSRI in MDD or openness,Phenotype,Response to SSRI in MDD or openness
57632,Non-Hodgkin's lymphoma,Phenotype,Non-Hodgkin's lymphoma
57637,Thyrotoxic periodic paralysis,Phenotype,Thyrotoxic periodic paralysis
57638,Inflammatory biomarkers (multivariate analysis),Phenotype,Inflammatory biomarkers (multivariate analysis)
57639,Cryptococcosis in HIV infection,Phenotype,Cryptococcosis in HIV infection
57640,Hypertension in type 2 diabetes,Phenotype,Hypertension in type 2 diabetes
57641,Barrett's esophagus or esophageal adenocarcinoma x sex interaction (2df test),Phenotype,Barrett's esophagus or esophageal adenocarcinoma x sex interaction (2df test)
57642,Attention deficit hyperactivity disorder symptom score,Phenotype,Attention deficit hyperactivity disorder symptom score
57643,tricyclic pyrone compound response (IC50),Phenotype,tricyclic pyrone compound response (IC50)
57644,Shoulder impingement,Phenotype,Shoulder impingement
57645,Plasma factor VII activating protease levels,Phenotype,Plasma factor VII activating protease levels
57646,Cigarettes smoked per day (MTAG),Phenotype,Cigarettes smoked per day (MTAG)
57647,Asthma onset (childhood vs adult),Phenotype,Asthma onset (childhood vs adult)
57649,Handedness (Right-handed vs. non-right-handed),Phenotype,Handedness (Right-handed vs. non-right-handed)
57650,Breast cancer specific mortality in breast cancer,Phenotype,Breast cancer specific mortality in breast cancer
57651,Breast cancer specific mortality in estrogen receptor negative breast cancer,Phenotype,Breast cancer specific mortality in estrogen receptor negative breast cancer
57652,Smoking cessation (MTAG),Phenotype,Smoking cessation (MTAG)
57653,Breast cancer specific mortality in estrogen receptor positive breast cancer,Phenotype,Breast cancer specific mortality in estrogen receptor positive breast cancer
57654,Cortical brain region measurements (area-- volume and thickness),Phenotype,Cortical brain region measurements (area-- volume and thickness)
57656,Chronic obstructive pulmonary disease or high blood pressure (pleiotropy),Phenotype,Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)
57657,Chronic obstructive pulmonary disease or coronary artery disease (pleiotropy),Phenotype,Chronic obstructive pulmonary disease or coronary artery disease (pleiotropy)
57658,Spine bone size,Phenotype,Spine bone size
57659,Thyrotoxic hypokalemic periodic paralysis and Graves disease,Phenotype,Thyrotoxic hypokalemic periodic paralysis and Graves disease
57660,Supraventricular ectopy,Phenotype,Supraventricular ectopy
57661,Early chronic obstructive pulmonary disease in never smokers,Phenotype,Early chronic obstructive pulmonary disease in never smokers
57662,Early chronic obstructive pulmonary disease,Phenotype,Early chronic obstructive pulmonary disease
57663,Nocturnal enuresis,Phenotype,Nocturnal enuresis
57664,Idiopathic intracranial hypertension,Phenotype,Idiopathic intracranial hypertension
57665,Global electrical heterogeneity phenotypes,Phenotype,Global electrical heterogeneity phenotypes
57666,Clostridium difficile infection in multiple myeloma,Phenotype,Clostridium difficile infection in multiple myeloma
57667,Lipid traits (pleiotropy) (HIPO component 2),Phenotype,Lipid traits (pleiotropy) (HIPO component 2)
57668,Social science traits (pleiotropy) (HIPO component 1),Phenotype,Social science traits (pleiotropy) (HIPO component 1)
57669,Endometriosis or endometrial cancer (pleiotropy),Phenotype,Endometriosis or endometrial cancer (pleiotropy)
57670,Warfarin-associated bleeding,Phenotype,Warfarin-associated bleeding
57671,Antidepressant treatment resistance (> 2 drugs prescribed),Phenotype,Antidepressant treatment resistance (> 2 drugs prescribed)
57672,DNA methylation variation (age effect),Phenotype,DNA methylation variation (age effect)
57673,Diffusing capacity of carbon monoxide,Phenotype,Diffusing capacity of carbon monoxide
57674,Cortical amyloid beta load,Phenotype,Cortical amyloid beta load
57675,Alzheimer's disease progression score,Phenotype,Alzheimer's disease progression score
57676,Body mass index and waist-hip ratio (pleiotropy),Phenotype,Body mass index and waist-hip ratio (pleiotropy)
57677,Cholesterol efflux capacity,Phenotype,Cholesterol efflux capacity
57678,Cholesterol efflux capacity (cAMP stimulated assay),Phenotype,Cholesterol efflux capacity (cAMP stimulated assay)
57679,Atypical femoral fracture in phosphonate treatment,Phenotype,Atypical femoral fracture in phosphonate treatment
57680,Bisphosphonate-associated atypical femoral fracture,Phenotype,Bisphosphonate-associated atypical femoral fracture
57681,Asthma (age of onset),Phenotype,Asthma (age of onset)
57682,Infliximab-induced mucosal healing in Crohn's disease,Phenotype,Infliximab-induced mucosal healing in Crohn's disease
57683,Low susceptibility to hepatitis C infection,Phenotype,Low susceptibility to hepatitis C infection
57684,Cocaine dependence,Phenotype,Cocaine dependence
57685,Severity of nausea and vomiting of pregnancy,Phenotype,Severity of nausea and vomiting of pregnancy
57724,Verbal learning,Phenotype,Verbal learning
57726,Metabolite peak levels (QI15571),Phenotype,Metabolite peak levels (QI15571)
57728,Metabolite peak levels (QI9645),Phenotype,Metabolite peak levels (QI9645)
57730,Metabolite peak levels (QI7379),Phenotype,Metabolite peak levels (QI7379)
57731,Metabolite peak levels (QI7380),Phenotype,Metabolite peak levels (QI7380)
57732,Metabolite peak levels (QI7389),Phenotype,Metabolite peak levels (QI7389)
57734,Metabolite peak levels (QI7549),Phenotype,Metabolite peak levels (QI7549)
57736,Metabolite peak levels (QI8421),Phenotype,Metabolite peak levels (QI8421)
57739,Metabolite peak levels (QI8422),Phenotype,Metabolite peak levels (QI8422)
57741,Metabolite peak levels (QI843),Phenotype,Metabolite peak levels (QI843)
57742,Metabolite peak levels (QI8774),Phenotype,Metabolite peak levels (QI8774)
57743,Metabolite peak levels (QI8814),Phenotype,Metabolite peak levels (QI8814)
57744,Metabolite peak levels (QI7090),Phenotype,Metabolite peak levels (QI7090)
57745,Metabolite peak levels (QI14245),Phenotype,Metabolite peak levels (QI14245)
57749,Peptidoglycan recognition protein 1 levels,Phenotype,Peptidoglycan recognition protein 1 levels
57758,Cerebrospinal fluid p-tau levels,Phenotype,Cerebrospinal fluid p-tau levels
57773,Sterol ester (27:1/20:3) levels,Phenotype,Sterol ester (27:1/20:3) levels
57774,Phosphatidylcholine (15:0_18:2) levels,Phenotype,Phosphatidylcholine (15:0_18:2) levels
57775,Phosphatidylcholine (16:0_16:0) levels,Phenotype,Phosphatidylcholine (16:0_16:0) levels
57776,Phosphatidylcholine (16:0_18:3) levels,Phenotype,Phosphatidylcholine (16:0_18:3) levels
57777,Sterol ester (27:1/20:4) levels,Phenotype,Sterol ester (27:1/20:4) levels
57779,Sterol ester (27:1/16:0) levels,Phenotype,Sterol ester (27:1/16:0) levels
57780,Sterol ester (27:1/18:0) levels,Phenotype,Sterol ester (27:1/18:0) levels
57781,Sedentary behavior at work,Phenotype,Sedentary behavior at work
57783,Leisure screen time (MTAG),Phenotype,Leisure screen time (MTAG)
57784,Moderate-to-vigorous intensity physical activity during leisure time (MTAG),Phenotype,Moderate-to-vigorous intensity physical activity during leisure time (MTAG)
57785,Phosphatidylinositol (18:0_20:3) levels,Phenotype,Phosphatidylinositol (18:0_20:3) levels
57787,Phosphatidylcholine (18:1_18:1) levels,Phenotype,Phosphatidylcholine (18:1_18:1) levels
57788,Phosphatidylcholine (18:1_18:2) levels,Phenotype,Phosphatidylcholine (18:1_18:2) levels
57789,Phosphatidylinositol (18:1_20:4) levels,Phenotype,Phosphatidylinositol (18:1_20:4) levels
57791,Apolipoprotein L1 levels,Phenotype,Apolipoprotein L1 levels
57793,Heat shock protein beta-1 levels,Phenotype,Heat shock protein beta-1 levels
57795,Triacylglycerol (50:1) levels,Phenotype,Triacylglycerol (50:1) levels
57803,R-spondin-3 levels,Phenotype,R-spondin-3 levels
57806,Apolipoprotein M levels,Phenotype,Apolipoprotein M levels
57869,Complement component 1 Q subcomponent-binding protein-- mitochondrial levels,Phenotype,Complement component 1 Q subcomponent-binding protein-- mitochondrial levels
57870,Endoplasmic reticulum resident protein 29 levels,Phenotype,Endoplasmic reticulum resident protein 29 levels
57900,Gremlin-1 levels,Phenotype,Gremlin-1 levels
57902,Interleukin-22 receptor subunit alpha-2 levels,Phenotype,Interleukin-22 receptor subunit alpha-2 levels
57904,Contactin-1 levels,Phenotype,Contactin-1 levels
57907,Verbal short term memory,Phenotype,Verbal short term memory
57916,Descending aorta maximum area,Phenotype,Descending aorta maximum area
57917,Ascending aorta distensibility,Phenotype,Ascending aorta distensibility
57921,Ascending aorta distensibility (MTAG),Phenotype,Ascending aorta distensibility (MTAG)
57923,Descending aorta distensibility (MTAG),Phenotype,Descending aorta distensibility (MTAG)
57926,Ascending aorta maximum area (MTAG),Phenotype,Ascending aorta maximum area (MTAG)
57928,Facial phenotypes (interpalpebral inferius length),Phenotype,Facial phenotypes (interpalpebral inferius length)
57930,Facial phenotypes (nasion to pogonion),Phenotype,Facial phenotypes (nasion to pogonion)
57933,Facial phenotypes (left palpebral fissure length),Phenotype,Facial phenotypes (left palpebral fissure length)
57935,Facial phenotypes (outercanthal width),Phenotype,Facial phenotypes (outercanthal width)
57937,Facial phenotypes (midendocanthion to pogonion),Phenotype,Facial phenotypes (midendocanthion to pogonion)
57940,Descending aorta maximum area (MTAG),Phenotype,Descending aorta maximum area (MTAG)
57941,Facial phenotypes (right palpebrale fissure height),Phenotype,Facial phenotypes (right palpebrale fissure height)
57943,Facial phenotypes (midendocanthion to subnasale),Phenotype,Facial phenotypes (midendocanthion to subnasale)
57954,Descending aorta minimum area,Phenotype,Descending aorta minimum area
57962,N4-acetylcytidine levels,Phenotype,N4-acetylcytidine levels
57964,Metabolite peak levels (QI11461),Phenotype,Metabolite peak levels (QI11461)
57979,Metabolite peak levels (QI12750),Phenotype,Metabolite peak levels (QI12750)
57980,Metabolite peak levels (QI13644),Phenotype,Metabolite peak levels (QI13644)
57981,Xanthosine levels,Phenotype,Xanthosine levels
57982,Metabolite peak levels (QI4584),Phenotype,Metabolite peak levels (QI4584)
57983,Metabolite peak levels (QI2718),Phenotype,Metabolite peak levels (QI2718)
57985,Metabolite peak levels (QI3783),Phenotype,Metabolite peak levels (QI3783)
58007,Metabolite peak levels (QI12380),Phenotype,Metabolite peak levels (QI12380)
58009,Protein Wnt-7a levels,Phenotype,Protein Wnt-7a levels
58011,C34 gp41 HIV Fragment levels,Phenotype,C34 gp41 HIV Fragment levels
58012,dCTP pyrophosphatase 1 levels,Phenotype,dCTP pyrophosphatase 1 levels
58045,Leisure screen time,Phenotype,Leisure screen time
58048,Moderate-to-vigorous intensity physical activity during leisure time,Phenotype,Moderate-to-vigorous intensity physical activity during leisure time
58054,Phosphatidylcholine (18:0_18:2) levels,Phenotype,Phosphatidylcholine (18:0_18:2) levels
58056,Phosphatidylcholine (O-18:2_18:2) levels,Phenotype,Phosphatidylcholine (O-18:2_18:2) levels
58057,Phosphatidylethanolamine (18:0_18:2) levels,Phenotype,Phosphatidylethanolamine (18:0_18:2) levels
58058,Phosphatidylcholine (O-16:0_16:1) levels,Phenotype,Phosphatidylcholine (O-16:0_16:1) levels
58059,Phosphatidylcholine (O-16:0_18:1) levels,Phenotype,Phosphatidylcholine (O-16:0_18:1) levels
58060,Phosphatidylcholine (O-16:0_18:2) levels,Phenotype,Phosphatidylcholine (O-16:0_18:2) levels
58061,Phosphatidylcholine (O-16:0_20:3) levels,Phenotype,Phosphatidylcholine (O-16:0_20:3) levels
58062,Phosphatidylcholine (O-16:1_18:2) levels,Phenotype,Phosphatidylcholine (O-16:1_18:2) levels
58063,Phosphatidylcholine (O-16:1_20:3) levels,Phenotype,Phosphatidylcholine (O-16:1_20:3) levels
58064,Phosphatidylcholine (O-17:0_17:1) levels,Phenotype,Phosphatidylcholine (O-17:0_17:1) levels
58065,Phosphatidylcholine (O-18:1_16:0) levels,Phenotype,Phosphatidylcholine (O-18:1_16:0) levels
58066,Phosphatidylcholine (O-18:1_20:3) levels,Phenotype,Phosphatidylcholine (O-18:1_20:3) levels
58067,Phosphatidylcholine (O-18:1_20:4) levels,Phenotype,Phosphatidylcholine (O-18:1_20:4) levels
58068,Phosphatidylcholine (O-18:2_16:0) levels,Phenotype,Phosphatidylcholine (O-18:2_16:0) levels
58069,Phosphatidylcholine (16:0_20:3) levels,Phenotype,Phosphatidylcholine (16:0_20:3) levels
58070,Phosphatidylcholine (16:1_18:2) levels,Phenotype,Phosphatidylcholine (16:1_18:2) levels
58071,Interleukin-17F levels,Phenotype,Interleukin-17F levels
58074,Mitogen-activated protein kinase 3 levels,Phenotype,Mitogen-activated protein kinase 3 levels
58077,Fractalkine levels,Phenotype,Fractalkine levels
58078,Tumor necrosis factor receptor superfamily member EDAR levels,Phenotype,Tumor necrosis factor receptor superfamily member EDAR levels
58081,Platelet-activating factor levels,Phenotype,Platelet-activating factor levels
58084,Stem Cell Growth Factor-beta levels,Phenotype,Stem Cell Growth Factor-beta levels
58089,Leukocyte immunoglobulin-like receptor subfamily B member 1 levels,Phenotype,Leukocyte immunoglobulin-like receptor subfamily B member 1 levels
58104,Non-receptor tyrosine-protein kinase TYK2 levels,Phenotype,Non-receptor tyrosine-protein kinase TYK2 levels
58152,Total omega-3 fatty acid levels,Phenotype,Total omega-3 fatty acid levels
58156,Total omega-6 fatty acid levels,Phenotype,Total omega-6 fatty acid levels
58159,Perinatal depression,Phenotype,Perinatal depression
58162,Metabolonic lactone sulfate levels,Phenotype,Metabolonic lactone sulfate levels
58179,Age of onset of depression x felt loved as a child interaction,Phenotype,Age of onset of depression x felt loved as a child interaction
58185,von Willebrand factor levels,Phenotype,von Willebrand factor levels
58188,Large artery stroke (MTAG),Phenotype,Large artery stroke (MTAG)
58189,Small vessel stroke (MTAG),Phenotype,Small vessel stroke (MTAG)
58210,eGFR decline after treatment with platinum based chemotherapy,Phenotype,eGFR decline after treatment with platinum based chemotherapy
58220,Survival in coronary artery disease,Phenotype,Survival in coronary artery disease
58223,Circulating docosahexaenoic acid levels,Phenotype,Circulating docosahexaenoic acid levels
58236,Chronic spontaneous urticaria,Phenotype,Chronic spontaneous urticaria
58249,COVID-19 (hospitalized vs tested-- not hospitalized),Phenotype,COVID-19 (hospitalized vs tested-- not hospitalized)
58251,COVID-19 (hospitalized vs not hospitalized),Phenotype,COVID-19 (hospitalized vs not hospitalized)
58273,Facial morphology (multitrait analysis),Phenotype,Facial morphology (multitrait analysis)
58276,C-reactive protein levels (MTAG),Phenotype,C-reactive protein levels (MTAG)
58278,Drinks per week,Phenotype,Drinks per week
58289,COVID-19 death (death vs tested and survived),Phenotype,COVID-19 death (death vs tested and survived)
58291,COVID-19 death (death vs population),Phenotype,COVID-19 death (death vs population)
58307,COVID-19 (severe vs tested-- not severe),Phenotype,COVID-19 (severe vs tested-- not severe)
58311,COVID-19 (severe vs population),Phenotype,COVID-19 (severe vs population)
58330,Acute tubulointerstitial nephritis,Phenotype,Acute tubulointerstitial nephritis
58338,Episodic memory,Phenotype,Episodic memory
58340,Language performance,Phenotype,Language performance
58349,Visuospatial ability,Phenotype,Visuospatial ability
58355,sarcopenia,Phenotype,sarcopenia
58357,COVID-19 (severe vs non-severe with positive test),Phenotype,COVID-19 (severe vs non-severe with positive test)
58370,School performance E-factor 1 (overall performance),Phenotype,School performance E-factor 1 (overall performance)
58371,School performance E-factor 2 (language performance relative to maths),Phenotype,School performance E-factor 2 (language performance relative to maths)
58372,School performance E-factor 3 (oral performance relative to written),Phenotype,School performance E-factor 3 (oral performance relative to written)
58414,Pulmonary embolism,Phenotype,Pulmonary embolism
58439,Frequency of common cold infection,Phenotype,Frequency of common cold infection
58441,Systemic infections,Phenotype,Systemic infections
58458,COVID-19 hospitalization or rheumatoid arthritis (MTAG),Phenotype,COVID-19 hospitalization or rheumatoid arthritis (MTAG)
58461,Severe COVID-19 or rheumatoid arthritis (MTAG),Phenotype,Severe COVID-19 or rheumatoid arthritis (MTAG)
58492,Antipsychotic-induced metabolic syndrome in schizophrenia,Phenotype,Antipsychotic-induced metabolic syndrome in schizophrenia
58494,Chronic Chagas Cardiomyopathy in Chagas disease,Phenotype,Chronic Chagas Cardiomyopathy in Chagas disease
58498,Free testosterone levels,Phenotype,Free testosterone levels
58515,Nonsyndromic orofacial cleft x sex interaction,Phenotype,Nonsyndromic orofacial cleft x sex interaction
58535,Severe COVID-19 or systemic lupus erythematosus (inverse variance),Phenotype,Severe COVID-19 or systemic lupus erythematosus (inverse variance)
58536,Premature atrial contraction frequency,Phenotype,Premature atrial contraction frequency
58550,Albumin levels,Phenotype,Albumin levels
58570,Risk-taking behavior (multivariate analysis),Phenotype,Risk-taking behavior (multivariate analysis)
58585,Very low density lipoprotein cholesterol levels,Phenotype,Very low density lipoprotein cholesterol levels
58588,Smoking initiation (ever vs never),Phenotype,Smoking initiation (ever vs never)
58590,Smoking cessation (current vs former),Phenotype,Smoking cessation (current vs former)
58592,Nonsyndromic orofacial cleft x sex interaction (2df),Phenotype,Nonsyndromic orofacial cleft x sex interaction (2df)
58595,Serum glutamic-oxaloacetic transaminase levels,Phenotype,Serum glutamic-oxaloacetic transaminase levels
58596,Urinary microalbumin levels,Phenotype,Urinary microalbumin levels
58600,Univariate microbial feature (genus: staphylococcus) at the forehead (sebaceous skin),Phenotype,Univariate microbial feature (genus: staphylococcus) at the forehead (sebaceous skin)
58602,Univariate microbial feature (asv: asv004) at the forehead (sebaceous skin),Phenotype,Univariate microbial feature (asv: asv004) at the forehead (sebaceous skin)
58604,Univariate microbial feature (genus: anaerococcus) at the dorsal forearm (dry skin),Phenotype,Univariate microbial feature (genus: anaerococcus) at the dorsal forearm (dry skin)
58606,Univariate microbial feature (family: clostridiales) at the incertae (moist skin),Phenotype,Univariate microbial feature (family: clostridiales) at the incertae (moist skin)
58610,Blood pressure (pleiotropy model 1 DBP adjusted for estimated causal effects x SBP),Phenotype,Blood pressure (pleiotropy model 1 DBP adjusted for estimated causal effects x SBP)
58617,Change in processing speed in pediatric CNS tumors treated with craniospinal irradiation,Phenotype,Change in processing speed in pediatric CNS tumors treated with craniospinal irradiation
58620,3-carboxy-4-methyl-5-propyl-2-furanpropanoate (cmpf) levels,Phenotype,3-carboxy-4-methyl-5-propyl-2-furanpropanoate (cmpf) levels
58621,21-hydroxypregnenolone disulfate levels,Phenotype,21-hydroxypregnenolone disulfate levels
58622,3-methoxytyrosine levels,Phenotype,3-methoxytyrosine levels
58623,3-phenylpropionate (hydrocinnamate) levels,Phenotype,3-phenylpropionate (hydrocinnamate) levels
58625,4-allylphenol sulfate levels,Phenotype,4-allylphenol sulfate levels
58629,1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) levels,Phenotype,1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) levels
58630,1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3) levels,Phenotype,1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3) levels
58632,4-androsten-3beta--17beta-diol disulfate (2) levels,Phenotype,4-androsten-3beta--17beta-diol disulfate (2) levels
58634,4-androsten-3beta--17beta-diol monosulfate (2) levels,Phenotype,4-androsten-3beta--17beta-diol monosulfate (2) levels
58636,4-ethylphenylsulfate levels,Phenotype,4-ethylphenylsulfate levels
58637,5alpha-androstan-3alpha--17beta-diol monosulfate (1) levels,Phenotype,5alpha-androstan-3alpha--17beta-diol monosulfate (1) levels
58638,5alpha-androstan-3beta--17beta-diol monosulfate (2) levels,Phenotype,5alpha-androstan-3beta--17beta-diol monosulfate (2) levels
58639,5-bromotryptophan levels,Phenotype,5-bromotryptophan levels
58642,Dihomo-linolenate (20:3n3 or n6) levels,Phenotype,Dihomo-linolenate (20:3n3 or n6) levels
58643,Dodecadienoate (12:2) (X-21343) levels,Phenotype,Dodecadienoate (12:2) (X-21343) levels
58645,Ethylmalonate levels,Phenotype,Ethylmalonate levels
58646,Gamma-glutamyl-alpha-lysine levels,Phenotype,Gamma-glutamyl-alpha-lysine levels
58648,Gamma-glutamyltyrosine levels,Phenotype,Gamma-glutamyltyrosine levels
58652,Epiandrosterone sulfate levels,Phenotype,Epiandrosterone sulfate levels
58653,Ergothioneine levels,Phenotype,Ergothioneine levels
58655,Hydroxy-cmpf (X-02269) levels,Phenotype,Hydroxy-cmpf (X-02269) levels
58656,Imidazole lactate levels,Phenotype,Imidazole lactate levels
58659,1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) levels,Phenotype,1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) levels
58661,1-palmitoyl-2-docosahexaenoyl-gpc (16:0/22:6) levels,Phenotype,1-palmitoyl-2-docosahexaenoyl-gpc (16:0/22:6) levels
58662,1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (p-16:0/18:2) levels,Phenotype,1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (p-16:0/18:2) levels
58663,1-(1-enyl-palmitoyl)-2-oleoyl-gpc (p-16:0/18:1) levels,Phenotype,1-(1-enyl-palmitoyl)-2-oleoyl-gpc (p-16:0/18:1) levels
58664,1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) levels,Phenotype,1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) levels
58665,1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) levels,Phenotype,1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) levels
58666,1-(1-enyl-stearoyl)-2-linoleoyl-GPC (p-18:0/18:2) levels,Phenotype,1-(1-enyl-stearoyl)-2-linoleoyl-GPC (p-18:0/18:2) levels
58667,1-dihomo-linolenoyl-GPC (20:3n3 or 6) levels,Phenotype,1-dihomo-linolenoyl-GPC (20:3n3 or 6) levels
58668,1-docosahexaenoyl-GPC (22:6) levels,Phenotype,1-docosahexaenoyl-GPC (22:6) levels
58670,1-docosahexaenoyl-GPE (22:6) levels,Phenotype,1-docosahexaenoyl-GPE (22:6) levels
58672,1-(1-enyl-stearoyl)-2-oleoyl-GPC (p-18:0/18:1) levels,Phenotype,1-(1-enyl-stearoyl)-2-oleoyl-GPC (p-18:0/18:1) levels
58673,1--2-dipalmitoyl-gpc (16:0/16:0) levels,Phenotype,1--2-dipalmitoyl-gpc (16:0/16:0) levels
58674,1--3--7-trimethylurate levels,Phenotype,1--3--7-trimethylurate levels
58676,Xanthurenate levels,Phenotype,Xanthurenate levels
58677,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels,Phenotype,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels
58678,X-23749 levels,Phenotype,X-23749 levels
58682,Waist circumference (aged 40-50 years),Phenotype,Waist circumference (aged 40-50 years)
58683,Migraine or type 2 diabetes,Phenotype,Migraine or type 2 diabetes
58686,Remission after antidepressant treatment in major depressive disorder,Phenotype,Remission after antidepressant treatment in major depressive disorder
58687,Response to antidepressants (symptom improvement) in major depressive disorder,Phenotype,Response to antidepressants (symptom improvement) in major depressive disorder
58690,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Phenotype,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels
58691,1-palmityl-2-palmitoyl-GPC (O-16:0/16:0) levels,Phenotype,1-palmityl-2-palmitoyl-GPC (O-16:0/16:0) levels
58692,1-palmityl-2-stearoyl-GPC (O-16:0/18:0) levels,Phenotype,1-palmityl-2-stearoyl-GPC (O-16:0/18:0) levels
58693,1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) levels,Phenotype,1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) levels
58701,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Phenotype,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels
58702,1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) levels,Phenotype,1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) levels
58705,Estimated glomerular filtration rate in type 2 diabetes,Phenotype,Estimated glomerular filtration rate in type 2 diabetes
58707,Ascorbic acid 3-sulfate (X-12206) levels,Phenotype,Ascorbic acid 3-sulfate (X-12206) levels
58710,Beta-hydroxyisovalerate levels,Phenotype,Beta-hydroxyisovalerate levels
58713,Betaine levels,Phenotype,Betaine levels
58714,Cis-4-decenoyl carnitine levels,Phenotype,Cis-4-decenoyl carnitine levels
58716,Androsterone sulfate levels,Phenotype,Androsterone sulfate levels
58717,Cys-gly-- oxidized levels,Phenotype,Cys-gly-- oxidized levels
58720,Cysteine s-sulfate levels,Phenotype,Cysteine s-sulfate levels
58722,Cysteinylglycine levels,Phenotype,Cysteinylglycine levels
58725,Cystine levels,Phenotype,Cystine levels
58726,Cytidine levels,Phenotype,Cytidine levels
58727,Decadienedioic acid (c10:2-dc) (X-21792) levels,Phenotype,Decadienedioic acid (c10:2-dc) (X-21792) levels
58730,Indolepropionate levels,Phenotype,Indolepropionate levels
58732,Isobutyrylcarnitine levels,Phenotype,Isobutyrylcarnitine levels
58733,Isoleucylleucine/leucylisoleucine levels,Phenotype,Isoleucylleucine/leucylisoleucine levels
58736,Laurylcarnitine levels,Phenotype,Laurylcarnitine levels
58738,Methionine sulfone levels,Phenotype,Methionine sulfone levels
58739,Myristoylcarnitine levels,Phenotype,Myristoylcarnitine levels
58740,N1-methyladenosine levels,Phenotype,N1-methyladenosine levels
58742,N6--n6--n6-trimethyllysine levels,Phenotype,N6--n6--n6-trimethyllysine levels
58753,N-acetylcarnosine levels,Phenotype,N-acetylcarnosine levels
58754,N-acetylphenylalanine levels,Phenotype,N-acetylphenylalanine levels
58755,Linoleoylcarnitine levels,Phenotype,Linoleoylcarnitine levels
58757,N-acetylglucosamine/n-acetylgalactosamine levels,Phenotype,N-acetylglucosamine/n-acetylgalactosamine levels
58759,N-acetylhistidine levels,Phenotype,N-acetylhistidine levels
58760,N-acetyl-isoputreanine (X-12688) levels,Phenotype,N-acetyl-isoputreanine (X-12688) levels
58763,Palmitoylcarnitine levels,Phenotype,Palmitoylcarnitine levels
58764,P-cresol-glucuronide levels,Phenotype,P-cresol-glucuronide levels
58766,Phenyllactate (pla) levels,Phenotype,Phenyllactate (pla) levels
58771,Orotate levels,Phenotype,Orotate levels
58772,Palmitoleoylcarnitine levels,Phenotype,Palmitoleoylcarnitine levels
58773,Oleoylcarnitine levels,Phenotype,Oleoylcarnitine levels
58774,Stearoylcarnitine levels,Phenotype,Stearoylcarnitine levels
58775,Succinylcarnitine levels,Phenotype,Succinylcarnitine levels
58778,Blood pressure (pleiotropy model 2 SBP adjusted for estimated causal effects x DBP),Phenotype,Blood pressure (pleiotropy model 2 SBP adjusted for estimated causal effects x DBP)
58784,X-11470 levels,Phenotype,X-11470 levels
58789,X-11478 levels,Phenotype,X-11478 levels
58791,X-12100 levels,Phenotype,X-12100 levels
58792,X-19141 levels,Phenotype,X-19141 levels
58794,X-21319 levels,Phenotype,X-21319 levels
58797,X-21364 levels,Phenotype,X-21364 levels
58798,X-21410 levels,Phenotype,X-21410 levels
58800,X-12847 levels,Phenotype,X-12847 levels
58802,X-13684 levels,Phenotype,X-13684 levels
58805,X-13866 levels,Phenotype,X-13866 levels
58808,X-15469 levels,Phenotype,X-15469 levels
58810,X-15486 levels,Phenotype,X-15486 levels
58811,X-11261 levels,Phenotype,X-11261 levels
58813,X-11381 levels,Phenotype,X-11381 levels
58815,X-17676 levels,Phenotype,X-17676 levels
58818,X-17690 levels,Phenotype,X-17690 levels
58820,X-18921 levels,Phenotype,X-18921 levels
58847,Posterior urethral valves,Phenotype,Posterior urethral valves
58887,Bone stiffness index,Phenotype,Bone stiffness index
58895,Hip fracture,Phenotype,Hip fracture
58902,Skin autofluorescence,Phenotype,Skin autofluorescence
58903,Skin reflectance,Phenotype,Skin reflectance
58910,Suicide behavior,Phenotype,Suicide behavior
58913,4-acetaminophen sulfate levels,Phenotype,4-acetaminophen sulfate levels
58915,4-acetylphenol sulfate levels,Phenotype,4-acetylphenol sulfate levels
58917,4-androsten-3alpha--17alpha-diol monosulfate (2) levels,Phenotype,4-androsten-3alpha--17alpha-diol monosulfate (2) levels
58920,4-androsten-3beta--17beta-diol disulfate (1) levels,Phenotype,4-androsten-3beta--17beta-diol disulfate (1) levels
58923,4-androsten-3beta--17beta-diol monosulfate (1) levels,Phenotype,4-androsten-3beta--17beta-diol monosulfate (1) levels
58925,Triglyceride levels in type 2 diabetes,Phenotype,Triglyceride levels in type 2 diabetes
58926,Triglyceride levels in non-type 2 diabetes,Phenotype,Triglyceride levels in non-type 2 diabetes
58928,4-guanidinobutanoate levels,Phenotype,4-guanidinobutanoate levels
58929,4-hydroxycoumarin levels,Phenotype,4-hydroxycoumarin levels
58931,4-methylcatechol sulfate levels,Phenotype,4-methylcatechol sulfate levels
58933,4-vinylguaiacol sulfate levels,Phenotype,4-vinylguaiacol sulfate levels
58935,5alpha-androstan-3alpha--17beta-diol monosulfate (2) levels,Phenotype,5alpha-androstan-3alpha--17beta-diol monosulfate (2) levels
58937,5alpha-androstan-3beta--17alpha-diol disulfate levels,Phenotype,5alpha-androstan-3beta--17alpha-diol disulfate levels
58939,5alpha-androstan-3beta--17beta-diol disulfate levels,Phenotype,5alpha-androstan-3beta--17beta-diol disulfate levels
58940,5alpha-pregnan-3beta--20beta-diol monosulfate (1) levels,Phenotype,5alpha-pregnan-3beta--20beta-diol monosulfate (1) levels
58942,4-vinylphenol sulfate levels,Phenotype,4-vinylphenol sulfate levels
58943,5alpha-androstan-3alpha--17beta-diol disulfate levels,Phenotype,5alpha-androstan-3alpha--17beta-diol disulfate levels
58946,5-methyluridine (ribothymidine) levels,Phenotype,5-methyluridine (ribothymidine) levels
58949,6-hydroxyindole sulfate levels,Phenotype,6-hydroxyindole sulfate levels
58951,Asparagine levels,Phenotype,Asparagine levels
58955,Bilirubin (z--z) levels,Phenotype,Bilirubin (z--z) levels
58957,Cholate levels,Phenotype,Cholate levels
58959,Alpha-hydroxyisovalerate levels,Phenotype,Alpha-hydroxyisovalerate levels
58961,Andro steroid monosulfate (1) levels,Phenotype,Andro steroid monosulfate (1) levels
58962,Acisoga levels,Phenotype,Acisoga levels
58964,Adenine levels,Phenotype,Adenine levels
58966,Adipoylcarnitine levels,Phenotype,Adipoylcarnitine levels
58967,Docosahexaenoate (DHA; 22:6n3) levels,Phenotype,Docosahexaenoate (DHA; 22:6n3) levels
58969,Dodecanedioate levels,Phenotype,Dodecanedioate levels
58972,dihydroferulic acid levels,Phenotype,dihydroferulic acid levels
58974,Cysteine-glutathione disulfide levels,Phenotype,Cysteine-glutathione disulfide levels
58975,Dehydroisoandrosterone sulfate (dhea-s) levels,Phenotype,Dehydroisoandrosterone sulfate (dhea-s) levels
58982,Etiocholanolone glucuronide levels,Phenotype,Etiocholanolone glucuronide levels
58983,Ferulic acid 4-sulfate levels,Phenotype,Ferulic acid 4-sulfate levels
58984,Gamma-CEHC levels,Phenotype,Gamma-CEHC levels
58985,Gamma-glutamylleucine levels,Phenotype,Gamma-glutamylleucine levels
58987,Gamma-glutamylmethionine levels,Phenotype,Gamma-glutamylmethionine levels
58988,Gamma-glutamylphenylalanine levels,Phenotype,Gamma-glutamylphenylalanine levels
58991,Glutarylcarnitine (C5) levels,Phenotype,Glutarylcarnitine (C5) levels
58994,Hexanoylcarnitine levels,Phenotype,Hexanoylcarnitine levels
58995,Glycodeoxycholate sulfate levels,Phenotype,Glycodeoxycholate sulfate levels
58997,Glycolithocholate sulfate levels,Phenotype,Glycolithocholate sulfate levels
58999,Gamma-glutamyl-2-aminobutyrate levels,Phenotype,Gamma-glutamyl-2-aminobutyrate levels
59000,Gamma-glutamyl-epsilon-lysine levels,Phenotype,Gamma-glutamyl-epsilon-lysine levels
59002,Gamma-glutamylglutamate levels,Phenotype,Gamma-glutamylglutamate levels
59003,Gamma-glutamylglutamine levels,Phenotype,Gamma-glutamylglutamine levels
59004,Gamma-glutamylhistidine levels,Phenotype,Gamma-glutamylhistidine levels
59008,Glycocholenate sulfate levels,Phenotype,Glycocholenate sulfate levels
59010,Gluconic acid levels,Phenotype,Gluconic acid levels
59012,1-palmitoyl-2-oleoyl-gpc (16:0/18:1) levels,Phenotype,1-palmitoyl-2-oleoyl-gpc (16:0/18:1) levels
59014,1-palmitoyl-2-palmitoleoyl-gpc (16:0/16:1) levels,Phenotype,1-palmitoyl-2-palmitoleoyl-gpc (16:0/16:1) levels
59015,1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4) levels,Phenotype,1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4) levels
59019,1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5) levels,Phenotype,1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5) levels
59021,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,Phenotype,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels
59023,Hydroquinone sulfate levels,Phenotype,Hydroquinone sulfate levels
59026,Hypotaurine levels,Phenotype,Hypotaurine levels
59028,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Phenotype,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels
59030,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,Phenotype,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels
59031,1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) levels,Phenotype,1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) levels
59033,1-stearoyl-2-docosahexaenoyl-gpc (18:0/22:6) levels,Phenotype,1-stearoyl-2-docosahexaenoyl-gpc (18:0/22:6) levels
59036,1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n6) levels,Phenotype,1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n6) levels
59038,1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels,Phenotype,1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels
59039,1-stearoyl-2-linoleoyl-GPI (18:0/18:2) levels,Phenotype,1-stearoyl-2-linoleoyl-GPI (18:0/18:2) levels
59041,1-stearoyl-2-oleoyl-gpc (18:0/18:1) levels,Phenotype,1-stearoyl-2-oleoyl-gpc (18:0/18:1) levels
59043,1-stearoyl-GPE (18:0) levels,Phenotype,1-stearoyl-GPE (18:0) levels
59045,2-aminooctanoate levels,Phenotype,2-aminooctanoate levels
59047,Indolelactate levels,Phenotype,Indolelactate levels
59049,Myo-inositol levels,Phenotype,Myo-inositol levels
59052,N2--N5-diacetylornithine levels,Phenotype,N2--N5-diacetylornithine levels
59054,N6-carbamoylthreonyladenosine levels,Phenotype,N6-carbamoylthreonyladenosine levels
59055,Mannitol/sorbitol levels,Phenotype,Mannitol/sorbitol levels
59058,Lactosyl-N-palmitoyl-sphingosine levels,Phenotype,Lactosyl-N-palmitoyl-sphingosine levels
59059,Indoleacetate levels,Phenotype,Indoleacetate levels
59060,Indoleacetylglutamine levels,Phenotype,Indoleacetylglutamine levels
59062,Indolin-2-one levels,Phenotype,Indolin-2-one levels
59063,Isoeugenol sulfate levels,Phenotype,Isoeugenol sulfate levels
59066,Isovalerylcarnitine levels,Phenotype,Isovalerylcarnitine levels
59067,Kynurenate levels,Phenotype,Kynurenate levels
59070,Interstitial lung diseases in rheumatoid arthritis,Phenotype,Interstitial lung diseases in rheumatoid arthritis
59072,N-acetylarginine levels,Phenotype,N-acetylarginine levels
59073,N-acetyltryptophan levels,Phenotype,N-acetyltryptophan levels
59074,N-delta-acetylornithine levels,Phenotype,N-delta-acetylornithine levels
59076,N-acetylkynurenine (2) levels,Phenotype,N-acetylkynurenine (2) levels
59077,N-acetylleucine levels,Phenotype,N-acetylleucine levels
59079,N-acetylneuraminate levels,Phenotype,N-acetylneuraminate levels
59080,N-acetylcitrulline levels,Phenotype,N-acetylcitrulline levels
59082,N-acetylglycine levels,Phenotype,N-acetylglycine levels
59084,Chronic obstructive pulmonary disease liability (machine learning-based score),Phenotype,Chronic obstructive pulmonary disease liability (machine learning-based score)
59090,Resistance to COVID-19 infection (Exposed negative vs positive),Phenotype,Resistance to COVID-19 infection (Exposed negative vs positive)
59092,Low-density lipoprotein levels (MTAG),Phenotype,Low-density lipoprotein levels (MTAG)
59109,Photoreceptor cell layer thickness phenotypes (MTAG),Phenotype,Photoreceptor cell layer thickness phenotypes (MTAG)
59118,Mitral valve annular diameter (left ventricle systole),Phenotype,Mitral valve annular diameter (left ventricle systole)
59139,Childhood median systolic blood pressure percentile (0-3 years old),Phenotype,Childhood median systolic blood pressure percentile (0-3 years old)
59142,Childhood median systolic blood pressure percentile,Phenotype,Childhood median systolic blood pressure percentile
59145,Childhood median systolic blood pressure percentile (13-18 years old),Phenotype,Childhood median systolic blood pressure percentile (13-18 years old)
59149,Age of onset of childhood onset asthma,Phenotype,Age of onset of childhood onset asthma
59152,Age of onset of adult onset asthma,Phenotype,Age of onset of adult onset asthma
59154,BMI (standard GWA),Phenotype,BMI (standard GWA)
59165,Triglyceride levels (MTAG),Phenotype,Triglyceride levels (MTAG)
59166,Coffee intake (weighted GWA),Phenotype,Coffee intake (weighted GWA)
59167,Depression/anxiety (standard GWA),Phenotype,Depression/anxiety (standard GWA)
59168,Diabetes (standard GWA),Phenotype,Diabetes (standard GWA)
59170,Diabetes (weighted GWA),Phenotype,Diabetes (weighted GWA)
59171,Coffee intake (standard GWA),Phenotype,Coffee intake (standard GWA)
59179,Plasma myo-inositol levels,Phenotype,Plasma myo-inositol levels
59181,Idiopathic knee osteoarthritis,Phenotype,Idiopathic knee osteoarthritis
59186,Age when finished full-time education (standard GWA),Phenotype,Age when finished full-time education (standard GWA)
59205,Age when finished full-time education (weighted GWA),Phenotype,Age when finished full-time education (weighted GWA)
59214,Fruit intake (standard GWA),Phenotype,Fruit intake (standard GWA)
59241,Migraine (MTAG),Phenotype,Migraine (MTAG)
59243,Cervical artery dissection (MTAG),Phenotype,Cervical artery dissection (MTAG)
59244,Migraine without aura (MTAG),Phenotype,Migraine without aura (MTAG)
59257,Height (standard GWA),Phenotype,Height (standard GWA)
59274,Gestational age (fetal effect),Phenotype,Gestational age (fetal effect)
59276,Multisyllabic word repetition,Phenotype,Multisyllabic word repetition
59278,Hearing loss,Phenotype,Hearing loss
59287,Attention deficit hyperactivity disorder or autism spectrum disorder or intelligence (pleiotropy),Phenotype,Attention deficit hyperactivity disorder or autism spectrum disorder or intelligence (pleiotropy)
59317,Impulse control disorders in Parkinson’s disease,Phenotype,Impulse control disorders in Parkinson’s disease
59321,3-hydroxyhexanoate levels,Phenotype,3-hydroxyhexanoate levels
59323,Myristoleoylcarnitine (C14:1) levels,Phenotype,Myristoleoylcarnitine (C14:1) levels
59325,Suberoylcarnitine (C8-DC) levels,Phenotype,Suberoylcarnitine (C8-DC) levels
59326,1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) levels,Phenotype,1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) levels
59327,Adipoylcarnitine (C6-DC) levels,Phenotype,Adipoylcarnitine (C6-DC) levels
59328,Nonanoylcarnitine (C9) levels,Phenotype,Nonanoylcarnitine (C9) levels
59329,1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) levels,Phenotype,1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) levels
59348,N-acetylglucosaminylasparagine levels,Phenotype,N-acetylglucosaminylasparagine levels
59350,Flavin adenine dinucleotide (FAD) levels,Phenotype,Flavin adenine dinucleotide (FAD) levels
59351,Succinylcarnitine (c4-dc) levels,Phenotype,Succinylcarnitine (c4-dc) levels
59353,Palmitoylcarnitine (C16) levels,Phenotype,Palmitoylcarnitine (C16) levels
59355,Propionylcarnitine (c3) levels,Phenotype,Propionylcarnitine (c3) levels
59356,Octanoylcarnitine (c8) levels,Phenotype,Octanoylcarnitine (c8) levels
59357,Decanoylcarnitine (C10) levels,Phenotype,Decanoylcarnitine (C10) levels
59358,Laurylcarnitine (C12) levels,Phenotype,Laurylcarnitine (C12) levels
59359,Oleoylcarnitine (C18:1) levels,Phenotype,Oleoylcarnitine (C18:1) levels
59360,Ascorbic acid 2-sulfate levels,Phenotype,Ascorbic acid 2-sulfate levels
59366,Carotene diol (1) levels,Phenotype,Carotene diol (1) levels
59368,Carotene diol (2) levels,Phenotype,Carotene diol (2) levels
59369,Carotene diol (3) levels,Phenotype,Carotene diol (3) levels
59370,Ascorbic acid 3-sulfate levels,Phenotype,Ascorbic acid 3-sulfate levels
59376,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),Phenotype,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile)
59382,Dietary macronutrient intake (multi-trait analysis),Phenotype,Dietary macronutrient intake (multi-trait analysis)
59383,Widow's peak,Phenotype,Widow's peak
59384,Earlobe attachment,Phenotype,Earlobe attachment
59392,Late-onset Alzheimer's disease in high risk polygenic risk score,Phenotype,Late-onset Alzheimer's disease in high risk polygenic risk score
59394,CFTR mutation F508del heterozygosity in cystic fibrosis,Phenotype,CFTR mutation F508del heterozygosity in cystic fibrosis
59405,Depression-- cognition and memory (multivariate analysis),Phenotype,Depression-- cognition and memory (multivariate analysis)
59408,1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n3) levels,Phenotype,1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n3) levels
59410,Pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels,Phenotype,Pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels
59411,Docosapentaenoylcarnitine (C22:5n3) levels,Phenotype,Docosapentaenoylcarnitine (C22:5n3) levels
59412,N-acetyl-2-aminooctanoate levels,Phenotype,N-acetyl-2-aminooctanoate levels
59414,Dodecadienoate (12:2) levels,Phenotype,Dodecadienoate (12:2) levels
59416,Arachidonoylcarnitine (C20:4) levels,Phenotype,Arachidonoylcarnitine (C20:4) levels
59417,Eicosenoylcarnitine (C20:1) levels,Phenotype,Eicosenoylcarnitine (C20:1) levels
59418,Dihomo-linoleoylcarnitine (C20:2) levels,Phenotype,Dihomo-linoleoylcarnitine (C20:2) levels
59419,Dihomo-linolenoylcarnitine (C20:3n3 or 6) levels,Phenotype,Dihomo-linolenoylcarnitine (C20:3n3 or 6) levels
59420,Linolenoylcarnitine (C18:3) levels,Phenotype,Linolenoylcarnitine (C18:3) levels
59421,Cerotoylcarnitine (C26) levels,Phenotype,Cerotoylcarnitine (C26) levels
59422,Ximenoylcarnitine (C26:1) levels,Phenotype,Ximenoylcarnitine (C26:1) levels
59423,Nisinate (24:6n3) levels,Phenotype,Nisinate (24:6n3) levels
59425,Ceramide [N(26)S(19)] levels,Phenotype,Ceramide [N(26)S(19)] levels
59427,3beta--7alpha-dihydroxy-5-cholestenoate levels,Phenotype,3beta--7alpha-dihydroxy-5-cholestenoate levels
59429,Hexanoylglutamine levels,Phenotype,Hexanoylglutamine levels
59431,Androstenediol (3beta--17beta) disulfate (1) levels,Phenotype,Androstenediol (3beta--17beta) disulfate (1) levels
59432,Androstenediol (3beta--17beta) disulfate (2) levels,Phenotype,Androstenediol (3beta--17beta) disulfate (2) levels
59433,Androstenediol (3alpha-- 17alpha) monosulfate (2) levels,Phenotype,Androstenediol (3alpha-- 17alpha) monosulfate (2) levels
59434,Androstenediol (3beta--17beta) monosulfate (2) levels,Phenotype,Androstenediol (3beta--17beta) monosulfate (2) levels
59450,COVID-19 or hypertension (pleiotropy),Phenotype,COVID-19 or hypertension (pleiotropy)
59451,3-(3-hydroxyphenyl)propionate levels,Phenotype,3-(3-hydroxyphenyl)propionate levels
59452,3--4-methyleneheptanoate levels,Phenotype,3--4-methyleneheptanoate levels
59453,3-formylindole levels,Phenotype,3-formylindole levels
59455,3-indoleglyoxylic acid levels,Phenotype,3-indoleglyoxylic acid levels
59457,Phenylacetate levels,Phenotype,Phenylacetate levels
59461,COVID-19 or obesity (pleiotropy),Phenotype,COVID-19 or obesity (pleiotropy)
59463,Glutarylcarnitine (c5-dc) levels,Phenotype,Glutarylcarnitine (c5-dc) levels
59464,X-26054 levels,Phenotype,X-26054 levels
59466,X-24811 levels,Phenotype,X-24811 levels
59468,X-25371 levels,Phenotype,X-25371 levels
59469,Homoarginine levels,Phenotype,Homoarginine levels
59491,Trigger finger,Phenotype,Trigger finger
59495,Insomnia in migraine with aura,Phenotype,Insomnia in migraine with aura
59499,Alcohol consumption (drinks per month) (UKB data field 1578-- 4424),Phenotype,Alcohol consumption (drinks per month) (UKB data field 1578-- 4424)
59504,Lamb or mutton consumption (UKB data field 1379),Phenotype,Lamb or mutton consumption (UKB data field 1379)
59506,Drink temperature,Phenotype,Drink temperature
59511,Added salt consumption,Phenotype,Added salt consumption
59516,Cheese consumption,Phenotype,Cheese consumption
59523,Opioid use disorder (MTAG),Phenotype,Opioid use disorder (MTAG)
59545,Triglyceride levels in medium HDL,Phenotype,Triglyceride levels in medium HDL
59547,High-density lipoprotein 2 cholesterol levels,Phenotype,High-density lipoprotein 2 cholesterol levels
59563,HDL cholesterol levels adjusted for adiponectin levels,Phenotype,HDL cholesterol levels adjusted for adiponectin levels
59564,Methylmalonate (mma) levels,Phenotype,Methylmalonate (mma) levels
59567,3-decenoylcarnitine levels,Phenotype,3-decenoylcarnitine levels
59568,3-hydroxydecanoylcarnitine levels,Phenotype,3-hydroxydecanoylcarnitine levels
59569,Picolinoylglycine levels,Phenotype,Picolinoylglycine levels
59571,(2 or 3)-decenoate (10:1n7 or n8) levels,Phenotype,(2 or 3)-decenoate (10:1n7 or n8) levels
59573,Decadienedioic acid (C10:2-DC) levels,Phenotype,Decadienedioic acid (C10:2-DC) levels
59574,Gamma-glutamyltryptophan levels,Phenotype,Gamma-glutamyltryptophan levels
59575,Phenylalanylphenylalanine levels,Phenotype,Phenylalanylphenylalanine levels
59577,Isoleucylglycine levels,Phenotype,Isoleucylglycine levels
59578,Hypoxanthine levels,Phenotype,Hypoxanthine levels
59580,Phenylacetylglutamate levels,Phenotype,Phenylacetylglutamate levels
59581,4-hydroxyphenylacetylglutamine levels,Phenotype,4-hydroxyphenylacetylglutamine levels
59584,X-07765 levels,Phenotype,X-07765 levels
59586,X-12216 levels,Phenotype,X-12216 levels
59588,X-12689 levels,Phenotype,X-12689 levels
59589,X-12707 levels,Phenotype,X-12707 levels
59590,X-12822 levels,Phenotype,X-12822 levels
59601,Dried fruit consumption,Phenotype,Dried fruit consumption
59602,Spread type: Butter and margarine spreads vs oil-based spreads (UKB data field 1428),Phenotype,Spread type: Butter and margarine spreads vs oil-based spreads (UKB data field 1428)
59604,Spread type: Flora Pro-Active/Benecol (UKB data field 1428_2),Phenotype,Spread type: Flora Pro-Active/Benecol (UKB data field 1428_2)
59605,Cooked vegetables consumption,Phenotype,Cooked vegetables consumption
59607,Raw vegetable consumption,Phenotype,Raw vegetable consumption
59608,Fresh fruit consumption,Phenotype,Fresh fruit consumption
59609,Healthy aging,Phenotype,Healthy aging
59614,Principal component-derived dietary pattern 1,Phenotype,Principal component-derived dietary pattern 1
59615,Principal component-derived dietary pattern 13,Phenotype,Principal component-derived dietary pattern 13
59618,Principal component-derived dietary pattern 3,Phenotype,Principal component-derived dietary pattern 3
59622,Principal component-derived dietary pattern 5,Phenotype,Principal component-derived dietary pattern 5
59636,Glycerate levels,Phenotype,Glycerate levels
59638,N-acetyl-d-tryptophan levels,Phenotype,N-acetyl-d-tryptophan levels
59640,Right ventricular end systolic volume,Phenotype,Right ventricular end systolic volume
59641,Right ventricular stroke volume,Phenotype,Right ventricular stroke volume
59642,Right ventricular end diastolic volume,Phenotype,Right ventricular end diastolic volume
59644,Uterine leiomyoma or ER positive breast cancer (pleiotropy),Phenotype,Uterine leiomyoma or ER positive breast cancer (pleiotropy)
59647,Uterine leiomyoma or breast cancer (pleiotropy),Phenotype,Uterine leiomyoma or breast cancer (pleiotropy)
59655,Uterine leiomyoma or ER negative breast cancer (pleiotropy),Phenotype,Uterine leiomyoma or ER negative breast cancer (pleiotropy)
59658,X-23787 levels,Phenotype,X-23787 levels
59660,X-24328 levels,Phenotype,X-24328 levels
59662,X-13553 levels,Phenotype,X-13553 levels
59664,X-13729 levels,Phenotype,X-13729 levels
59665,X-13844 levels,Phenotype,X-13844 levels
59668,X-24422 levels,Phenotype,X-24422 levels
59669,X-24556 levels,Phenotype,X-24556 levels
59670,X-16087 levels,Phenotype,X-16087 levels
59671,X-21285 levels,Phenotype,X-21285 levels
59673,X-21470 levels,Phenotype,X-21470 levels
59678,Linoleoylcarnitine (C18:2) levels,Phenotype,Linoleoylcarnitine (C18:2) levels
59679,1-dihomo-linolenoyl-GPE (20:3n3 or 6) levels,Phenotype,1-dihomo-linolenoyl-GPE (20:3n3 or 6) levels
59680,Andro steroid monosulfate C19H28O6S (1) levels,Phenotype,Andro steroid monosulfate C19H28O6S (1) levels
59682,Cis-4-decenoylcarnitine (C10:1) levels,Phenotype,Cis-4-decenoylcarnitine (C10:1) levels
59683,16a-hydroxy DHEA 3-sulfate levels,Phenotype,16a-hydroxy DHEA 3-sulfate levels
59692,Insomnia in chronic migraine,Phenotype,Insomnia in chronic migraine
59695,Never eat wheat vs no wheat restrictions (UKB data field 6144),Phenotype,Never eat wheat vs no wheat restrictions (UKB data field 6144)
59696,Never eat sugar vs no eggs-- dairy-- wheat or sugar restrictions (UKB data field 6144),Phenotype,Never eat sugar vs no eggs-- dairy-- wheat or sugar restrictions (UKB data field 6144)
59697,Never eat sugar vs no sugar restrictions (UKB data field 6144),Phenotype,Never eat sugar vs no sugar restrictions (UKB data field 6144)
59699,Tea intake (UKB data field 1488),Phenotype,Tea intake (UKB data field 1488)
59701,Champagne or white wine consumption (glasses per month) (UKB data field 1578-- 4418),Phenotype,Champagne or white wine consumption (glasses per month) (UKB data field 1578-- 4418)
59703,Red wine consumption (glasses per month) (UKB data field 1578-- 4419),Phenotype,Red wine consumption (glasses per month) (UKB data field 1578-- 4419)
59704,Water consumption (glasses per day) (UKB data field 1528),Phenotype,Water consumption (glasses per day) (UKB data field 1528)
59707,Bread type: White (UKB data field 1448_1),Phenotype,Bread type: White (UKB data field 1448_1)
59709,Cereal type: Other (e.g. Cornflakes-- Frosties) (UKB data field 1468_5),Phenotype,Cereal type: Other (e.g. Cornflakes-- Frosties) (UKB data field 1468_5)
59711,Cereal consumption (bowls per week) (UKB data field 1458),Phenotype,Cereal consumption (bowls per week) (UKB data field 1458)
59712,Bread consumption (slices per week) (UKB data field 1438),Phenotype,Bread consumption (slices per week) (UKB data field 1438)
59717,Principal component-derived dietary pattern 36,Phenotype,Principal component-derived dietary pattern 36
59719,Principal component-derived dietary pattern 43,Phenotype,Principal component-derived dietary pattern 43
59720,Principal component-derived dietary pattern 44,Phenotype,Principal component-derived dietary pattern 44
59722,Principal component-derived dietary pattern 54,Phenotype,Principal component-derived dietary pattern 54
59756,Argininate levels,Phenotype,Argininate levels
59758,2-oxoarginine levels,Phenotype,2-oxoarginine levels
59762,Indoleacetoylcarnitine levels,Phenotype,Indoleacetoylcarnitine levels
59764,2-ketocaprylate levels,Phenotype,2-ketocaprylate levels
59765,Hydroxy-N6--N6--N6-trimethyllysine levels,Phenotype,Hydroxy-N6--N6--N6-trimethyllysine levels
59766,Picolinate levels,Phenotype,Picolinate levels
59767,N--N--N-trimethyl-5-aminovalerate levels,Phenotype,N--N--N-trimethyl-5-aminovalerate levels
59768,6-bromotryptophan levels,Phenotype,6-bromotryptophan levels
59774,Fructosyllysine levels,Phenotype,Fructosyllysine levels
59775,3-methylglutarylcarnitine (2) levels,Phenotype,3-methylglutarylcarnitine (2) levels
59777,Orbital telorism,Phenotype,Orbital telorism
59779,Oral microbiome alpha diversity (Shannon index) in oral squamous cell carcinoma,Phenotype,Oral microbiome alpha diversity (Shannon index) in oral squamous cell carcinoma
59781,Oral microbiome beta diversity (Bray-Curtis) in oral squamous cell carcinoma,Phenotype,Oral microbiome beta diversity (Bray-Curtis) in oral squamous cell carcinoma
59786,P-cresol glucuronide levels,Phenotype,P-cresol glucuronide levels
59788,4-allylcatechol sulfate levels,Phenotype,4-allylcatechol sulfate levels
59790,2-hydroxyfluorene sulfate levels,Phenotype,2-hydroxyfluorene sulfate levels
59792,3-ethylcatechol sulfate (1) levels,Phenotype,3-ethylcatechol sulfate (1) levels
59794,Salicylate levels,Phenotype,Salicylate levels
59798,S-adenosylhomocysteine (SAH) levels,Phenotype,S-adenosylhomocysteine (SAH) levels
59802,5-methylthioadenosine (mta) levels,Phenotype,5-methylthioadenosine (mta) levels
59804,2-hydroxyphenylacetate levels,Phenotype,2-hydroxyphenylacetate levels
59805,Phenylpyruvate levels,Phenotype,Phenylpyruvate levels
59844,Severe COVID-19 infection,Phenotype,Severe COVID-19 infection
59847,High-density lipoprotein levels (MTAG),Phenotype,High-density lipoprotein levels (MTAG)
59876,Minimum measurement of hepatic fat,Phenotype,Minimum measurement of hepatic fat
59878,Maximum measurement of hepatic fat,Phenotype,Maximum measurement of hepatic fat
59881,Medication use for hyperlipidemia (number of purchases),Phenotype,Medication use for hyperlipidemia (number of purchases)
59884,Medication use for T2D (number of purchases),Phenotype,Medication use for T2D (number of purchases)
59886,Years ovulating,Phenotype,Years ovulating
59913,COVID-19 infection or rheumatoid arthritis (MTAG),Phenotype,COVID-19 infection or rheumatoid arthritis (MTAG)
59915,COVID-19 hospitalization or systemic lupus erythematosus (MTAG),Phenotype,COVID-19 hospitalization or systemic lupus erythematosus (MTAG)
59918,Severe COVID-19 or systemic lupus erythematosus (MTAG),Phenotype,Severe COVID-19 or systemic lupus erythematosus (MTAG)
59926,Suicidal thoughts and behaviors,Phenotype,Suicidal thoughts and behaviors
59932,Body composition (MOSTest),Phenotype,Body composition (MOSTest)
59934,Bone mineral density at right trochanter (model 2),Phenotype,Bone mineral density at right trochanter (model 2)
59936,Bone mineral density at left trochanter (model 2),Phenotype,Bone mineral density at left trochanter (model 2)
59954,COVID-19 infection or systemic lupus erythematosus (MTAG),Phenotype,COVID-19 infection or systemic lupus erythematosus (MTAG)
60018,Systolic blood pressure x low social support interaction (2df test),Phenotype,Systolic blood pressure x low social support interaction (2df test)
60024,Systolic blood pressure x depressive symptoms interaction (2df test),Phenotype,Systolic blood pressure x depressive symptoms interaction (2df test)
60025,Diastolic blood pressure x depressive symptoms interaction (2df test),Phenotype,Diastolic blood pressure x depressive symptoms interaction (2df test)
60027,Pulse pressure x anxiety symptoms interaction (2df test),Phenotype,Pulse pressure x anxiety symptoms interaction (2df test)
60029,Pulse pressure x low social support interaction (2df test),Phenotype,Pulse pressure x low social support interaction (2df test)
60030,Pulse pressure x anxiety symptoms interaction (1df test),Phenotype,Pulse pressure x anxiety symptoms interaction (1df test)
60039,Heart failure (multivariate analysis),Phenotype,Heart failure (multivariate analysis)
60044,MSLN plasma levels,Phenotype,MSLN plasma levels
60046,Haptoglobin plasma levels,Phenotype,Haptoglobin plasma levels
60047,Lp a plasma levels,Phenotype,Lp a plasma levels
60049,Early onset colorectal cancer,Phenotype,Early onset colorectal cancer
60050,Colorectal cancer (age of onset),Phenotype,Colorectal cancer (age of onset)
60052,VEGF plasma levels,Phenotype,VEGF plasma levels
60054,Irritable bowel syndrome (MTAG),Phenotype,Irritable bowel syndrome (MTAG)
60057,Half-life of apixaban,Phenotype,Half-life of apixaban
60059,Time to peak concentration of apixaban,Phenotype,Time to peak concentration of apixaban
60061,anti-Xa activity of apixaban,Phenotype,anti-Xa activity of apixaban
60064,Concentration of apixaban (at 12h),Phenotype,Concentration of apixaban (at 12h)
60102,Interleukin-12 subunit beta levels,Phenotype,Interleukin-12 subunit beta levels
60104,TNF-beta levels,Phenotype,TNF-beta levels
60106,CUB domain-containing protein 1 levels,Phenotype,CUB domain-containing protein 1 levels
60118,THP plasma levels,Phenotype,THP plasma levels
60119,TN X plasma levels,Phenotype,TN X plasma levels
60121,Change in working memory in pediatric CNS tumors treated with craniospinal irradiation,Phenotype,Change in working memory in pediatric CNS tumors treated with craniospinal irradiation
60124,Change in intelligence quotient in pediatric CNS tumors treated with craniospinal irradiation,Phenotype,Change in intelligence quotient in pediatric CNS tumors treated with craniospinal irradiation
60135,High grade prostate cancer x metformin use interaction (simple model),Phenotype,High grade prostate cancer x metformin use interaction (simple model)
60146,Nap duration in severe depression,Phenotype,Nap duration in severe depression
60149,Response to antidepressants in major depressive disorder,Phenotype,Response to antidepressants in major depressive disorder
60151,1--2-dilinoleoyl-GPC (18:2/18:2) levels,Phenotype,1--2-dilinoleoyl-GPC (18:2/18:2) levels
60154,1-(1-enyl-stearoyl)-2-arachidonoyl-GPC (p-18:0/20:4) levels,Phenotype,1-(1-enyl-stearoyl)-2-arachidonoyl-GPC (p-18:0/20:4) levels
60155,1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPC (p-18:0/22:6) levels,Phenotype,1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPC (p-18:0/22:6) levels
60156,1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPE (p-18:0/22:6) levels,Phenotype,1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPE (p-18:0/22:6) levels
60157,Phenol sulfate levels,Phenotype,Phenol sulfate levels
60158,1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (p-16:0/20:4) levels,Phenotype,1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (p-16:0/20:4) levels
60159,1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (p-16:0/22:6) levels,Phenotype,1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (p-16:0/22:6) levels
60160,1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPE (p-16:0/22:6) levels,Phenotype,1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPE (p-16:0/22:6) levels
60161,1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (p-16:0/18:2) levels,Phenotype,1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (p-16:0/18:2) levels
60163,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,Phenotype,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels
60164,Pantothenate levels,Phenotype,Pantothenate levels
60165,P-cresol sulfate levels,Phenotype,P-cresol sulfate levels
60168,Body surface area,Phenotype,Body surface area
60177,Sphingomyelin (d18:1/20:1-- d18:2/20:0) levels,Phenotype,Sphingomyelin (d18:1/20:1-- d18:2/20:0) levels
60178,Suberate (octanedioate) levels,Phenotype,Suberate (octanedioate) levels
60181,Sarcosine (N-Methylglycine) levels,Phenotype,Sarcosine (N-Methylglycine) levels
60183,Spermidine levels,Phenotype,Spermidine levels
60185,Sphingomyelin (d18:1/20:0-- d16:1/22:0) levels,Phenotype,Sphingomyelin (d18:1/20:0-- d16:1/22:0) levels
60186,Sphingosine 1-phosphate levels,Phenotype,Sphingosine 1-phosphate levels
60188,Sphingomyelin (d18:2/24:1-- d18:1/24:2) levels,Phenotype,Sphingomyelin (d18:2/24:1-- d18:1/24:2) levels
60196,Theophylline levels,Phenotype,Theophylline levels
60198,Threonate levels,Phenotype,Threonate levels
60200,X-11429 levels,Phenotype,X-11429 levels
60202,X-11440 levels,Phenotype,X-11440 levels
60203,Vanillylmandelate (VMA) levels,Phenotype,Vanillylmandelate (VMA) levels
60204,X-02249 levels,Phenotype,X-02249 levels
60206,X-02269 levels,Phenotype,X-02269 levels
60207,X-09789 levels,Phenotype,X-09789 levels
60209,X-11308 levels,Phenotype,X-11308 levels
60211,X-11334 levels,Phenotype,X-11334 levels
60212,X-22379 levels,Phenotype,X-22379 levels
60214,X-21736 levels,Phenotype,X-21736 levels
60216,X-21792 levels,Phenotype,X-21792 levels
60217,Alcohol dependence (codominant genetic model),Phenotype,Alcohol dependence (codominant genetic model)
60252,IgG antibody levels in response to SARS-CoV-2 vaccination,Phenotype,IgG antibody levels in response to SARS-CoV-2 vaccination
60254,Total antibody levels in response to SARS-CoV-2 vaccination,Phenotype,Total antibody levels in response to SARS-CoV-2 vaccination
60256,Neutral antibody levels in response to SARS-CoV-2 vaccination,Phenotype,Neutral antibody levels in response to SARS-CoV-2 vaccination
60258,Maximum habitual alcohol consumption (MTAG),Phenotype,Maximum habitual alcohol consumption (MTAG)
60260,Opioid addiction,Phenotype,Opioid addiction
60270,Medication use for hypertension (number of purchases),Phenotype,Medication use for hypertension (number of purchases)
60276,Abdominal subcutaneous adipose tissue normalized,Phenotype,Abdominal subcutaneous adipose tissue normalized
60277,Posterior thigh muscle volume,Phenotype,Posterior thigh muscle volume
60278,Anterior thigh muscle fat infiltration percentage,Phenotype,Anterior thigh muscle fat infiltration percentage
60280,Abdominal subcutaneous adipose tissue,Phenotype,Abdominal subcutaneous adipose tissue
60281,Anterior thigh muscle volume,Phenotype,Anterior thigh muscle volume
60283,Posterior thigh muscle fat infiltration percentage,Phenotype,Posterior thigh muscle fat infiltration percentage
60317,Weight-to-muscle ratio,Phenotype,Weight-to-muscle ratio
60318,Abdominal fat ratio,Phenotype,Abdominal fat ratio
60337,Early-onset anorexia nervosa,Phenotype,Early-onset anorexia nervosa
60341,LDL (standard GWA),Phenotype,LDL (standard GWA)
60344,BMI (weighted GWA),Phenotype,BMI (weighted GWA)
60347,Cancer (standard GWA),Phenotype,Cancer (standard GWA)
60353,Brain arteriolosclerosis,Phenotype,Brain arteriolosclerosis
60355,LDL (weighted GWA),Phenotype,LDL (weighted GWA)
60364,Sleep health score,Phenotype,Sleep health score
60367,Male infertility (Sertoli cell-only),Phenotype,Male infertility (Sertoli cell-only)
60384,Early neurological instability after acute ischemic stroke,Phenotype,Early neurological instability after acute ischemic stroke
60415,Body shape (principal component analysis),Phenotype,Body shape (principal component analysis)
60417,Anti-beta-casein IgG levels,Phenotype,Anti-beta-casein IgG levels
60419,Anti-feline herpes IgG levels,Phenotype,Anti-feline herpes IgG levels
60420,Fibromuscular dysplasia,Phenotype,Fibromuscular dysplasia
60427,Opioid analgesic dose requirement in cancer pain treatment,Phenotype,Opioid analgesic dose requirement in cancer pain treatment
60501,Red blood cell distribution width coefficient of variation,Phenotype,Red blood cell distribution width coefficient of variation
60502,Disruptive behavior (multivariate analysis),Phenotype,Disruptive behavior (multivariate analysis)
60512,Common executive function,Phenotype,Common executive function
60551,Nodal modulator 1 levels,Phenotype,Nodal modulator 1 levels
60554,Low-density lipoprotein receptor-related protein 11 levels,Phenotype,Low-density lipoprotein receptor-related protein 11 levels
60558,Matrix metalloproteinase-2 levels,Phenotype,Matrix metalloproteinase-2 levels
60561,Serpin B6 levels,Phenotype,Serpin B6 levels
60564,Interleukin-4 receptor subunit alpha levels,Phenotype,Interleukin-4 receptor subunit alpha levels
60566,Serine protease 27 levels,Phenotype,Serine protease 27 levels
60570,Pulmonary surfactant-associated protein D levels,Phenotype,Pulmonary surfactant-associated protein D levels
60593,Early-onset ischemic stroke,Phenotype,Early-onset ischemic stroke
60603,Pulse rate,Phenotype,Pulse rate
60635,AFP levels,Phenotype,AFP levels
60641,Sialomucin core protein 24 levels,Phenotype,Sialomucin core protein 24 levels
60643,Cadherin-5 levels,Phenotype,Cadherin-5 levels
60645,Carbonic anhydrase 5A--mitochondrial levels,Phenotype,Carbonic anhydrase 5A--mitochondrial levels
60648,Carboxypeptidase A1 levels,Phenotype,Carboxypeptidase A1 levels
60649,Carboxypeptidase B levels,Phenotype,Carboxypeptidase B levels
60650,Cathepsin O levels,Phenotype,Cathepsin O levels
60654,Periodic limb movement in sleep,Phenotype,Periodic limb movement in sleep
60655,Periodic limb movement index,Phenotype,Periodic limb movement index
60656,Early childhood caries,Phenotype,Early childhood caries
60658,Hand Osteoarthritis,Phenotype,Hand Osteoarthritis
60686,Dental development,Phenotype,Dental development
60688,Oral cancer,Phenotype,Oral cancer
60698,Pediatric steroid sensitive nephrotic syndrome,Phenotype,Pediatric steroid sensitive nephrotic syndrome
60708,Personality traits or cognitive traits (multivariate analysis),Phenotype,Personality traits or cognitive traits (multivariate analysis)
60714,Multi-trait sex score,Phenotype,Multi-trait sex score
60728,Mood disorder,Phenotype,Mood disorder
60733,Noninflammatory bullous pemphigoid in response to dipeptidyl peptidase-4 inhibitors,Phenotype,Noninflammatory bullous pemphigoid in response to dipeptidyl peptidase-4 inhibitors
60735,Conventional bullous pemphigoid,Phenotype,Conventional bullous pemphigoid
60737,Bullous pemphigoid (except dipeptidyl peptidase-4 inhibitor-induced noninflammatory),Phenotype,Bullous pemphigoid (except dipeptidyl peptidase-4 inhibitor-induced noninflammatory)
60743,Total cholesterol levels (MTAG),Phenotype,Total cholesterol levels (MTAG)
60758,Neutrophil perturbation response (side fluorescence standard deviation of neutrophil 4 in response to colchicine perturbation measured by WDF dye),Phenotype,Neutrophil perturbation response (side fluorescence standard deviation of neutrophil 4 in response to colchicine perturbation measured by WDF dye)
60760,Breast area percent density,Phenotype,Breast area percent density
60775,Irritable bowel syndrome or major depressive disorder (pleiotropy),Phenotype,Irritable bowel syndrome or major depressive disorder (pleiotropy)
60778,AGRP levels,Phenotype,AGRP levels
60793,Aging (eyeAgeAcceleration),Phenotype,Aging (eyeAgeAcceleration)
60798,Multi-trait sum score,Phenotype,Multi-trait sum score
60801,COVID-19 with respiratory failure,Phenotype,COVID-19 with respiratory failure
60803,COVID-19 with respiratory failure requiring mechanical ventilation,Phenotype,COVID-19 with respiratory failure requiring mechanical ventilation
60833,ICD10 M54: Dorsalgia,Phenotype,ICD10 M54: Dorsalgia
60834,ICD10 M51: Intervertebral disc disorder,Phenotype,ICD10 M51: Intervertebral disc disorder
60861,Time to osteonecrosis in systemic lupus erythematosus,Phenotype,Time to osteonecrosis in systemic lupus erythematosus
60866,Persistence with methotrexate treatment at three years in early rheumatoid arthritis,Phenotype,Persistence with methotrexate treatment at three years in early rheumatoid arthritis
60869,ICD10 C22: Malignant neoplasm of liver and intrahepatic bile ducts,Phenotype,ICD10 C22: Malignant neoplasm of liver and intrahepatic bile ducts
60871,ICD10 C34: Malignant neoplasm of bronchus and lung,Phenotype,ICD10 C34: Malignant neoplasm of bronchus and lung
60873,Non-insulin-dependent diabetes mellitus (Union E11),Phenotype,Non-insulin-dependent diabetes mellitus (Union E11)
60874,ICD10 E14: Unspecified diabetes mellitus,Phenotype,ICD10 E14: Unspecified diabetes mellitus
60875,ICD10 H40: Glaucoma,Phenotype,ICD10 H40: Glaucoma
60877,ICD10 K74: Fibrosis and cirrhosis of liver,Phenotype,ICD10 K74: Fibrosis and cirrhosis of liver
60879,ICD10 K81: Cholecystitis,Phenotype,ICD10 K81: Cholecystitis
60881,Treatment effectiveness of angiotensin II receptor blocker in hypertension,Phenotype,Treatment effectiveness of angiotensin II receptor blocker in hypertension
60884,Treatment effectiveness of beta blocker in hypertension,Phenotype,Treatment effectiveness of beta blocker in hypertension
60886,Treatment effectiveness of angiotensin converting enzyme inhibitor in hypertension,Phenotype,Treatment effectiveness of angiotensin converting enzyme inhibitor in hypertension
60889,Treatment effectiveness of alpha blocker in hypertension,Phenotype,Treatment effectiveness of alpha blocker in hypertension
60891,Treatment effectiveness of alpha-beta blocker in hypertension,Phenotype,Treatment effectiveness of alpha-beta blocker in hypertension
60893,Treatment effectiveness of calcium channel blocker-dihydropyridine in hypertension,Phenotype,Treatment effectiveness of calcium channel blocker-dihydropyridine in hypertension
60896,Treatment effectiveness of calcium channel blocker in hypertension,Phenotype,Treatment effectiveness of calcium channel blocker in hypertension
60899,Treatment effectiveness of calcium channel blocker-benzothiazepine in hypertension,Phenotype,Treatment effectiveness of calcium channel blocker-benzothiazepine in hypertension
60918,Periodontitis / loose teeth (MTAG),Phenotype,Periodontitis / loose teeth (MTAG)
60934,Osteonecrosis in systemic lupus erythematosus,Phenotype,Osteonecrosis in systemic lupus erythematosus
60940,Raynauds phenomenon disease,Phenotype,Raynauds phenomenon disease
60941,Breast dense area,Phenotype,Breast dense area
60968,Brain age gap,Phenotype,Brain age gap
60975,Hearing problems,Phenotype,Hearing problems
60979,Treatment effectiveness of anti-hypertensive diuretic in hypertension,Phenotype,Treatment effectiveness of anti-hypertensive diuretic in hypertension
60982,Resistance to antihypertensive treatment in hypertension,Phenotype,Resistance to antihypertensive treatment in hypertension
60984,CSF1 levels,Phenotype,CSF1 levels
60986,CXCL9 levels,Phenotype,CXCL9 levels
60988,Breast area,Phenotype,Breast area
60998,Pierre Robin Sequence endophenotypic score,Phenotype,Pierre Robin Sequence endophenotypic score
61006,Inflammatory bowel disease or bipolar disorder (pleiotropy),Phenotype,Inflammatory bowel disease or bipolar disorder (pleiotropy)
61012,MIC-A levels,Phenotype,MIC-A levels
61019,TIE2 levels,Phenotype,TIE2 levels
61024,Gestational duration,Phenotype,Gestational duration
61040,Annual healthcare cost,Phenotype,Annual healthcare cost
61046,Male puberty timing (late vs. average onset facial hair),Phenotype,Male puberty timing (late vs. average onset facial hair)
61048,Male puberty timing (early vs. average onset voice breaking),Phenotype,Male puberty timing (early vs. average onset voice breaking)
61049,Male puberty timing (late vs. average onset voice breaking),Phenotype,Male puberty timing (late vs. average onset voice breaking)
61051,Male puberty timing (age at voice breaking MTAG),Phenotype,Male puberty timing (age at voice breaking MTAG)
61063,Spontaneous dizygotic twinning,Phenotype,Spontaneous dizygotic twinning
61086,Early onset non-small cell lung cancer,Phenotype,Early onset non-small cell lung cancer
61088,Migraine or glucose levels,Phenotype,Migraine or glucose levels
61089,Migraine or fasting glucose levels,Phenotype,Migraine or fasting glucose levels
61091,Headache or fasting glucose levels,Phenotype,Headache or fasting glucose levels
61093,Migraine or fasting insulin levels,Phenotype,Migraine or fasting insulin levels
61096,Headache or fasting insulin levels,Phenotype,Headache or fasting insulin levels
61097,Headache or HbA1c levels,Phenotype,Headache or HbA1c levels
61106,Cannabis use disorder,Phenotype,Cannabis use disorder
61109,Fracture of forearm,Phenotype,Fracture of forearm
61112,Thromboembolic events in Sickle cell disease,Phenotype,Thromboembolic events in Sickle cell disease
61122,Pain,Phenotype,Pain
61138,Gastroesophageal reflux disease or bipolar disorder (pleiotropy),Phenotype,Gastroesophageal reflux disease or bipolar disorder (pleiotropy)
61139,COVID-19 severity,Phenotype,COVID-19 severity
61149,Serum sclerostin levels,Phenotype,Serum sclerostin levels
61154,Male puberty timing (early vs. average onset facial hair),Phenotype,Male puberty timing (early vs. average onset facial hair)
61178,Childhood wheezing (pre-school remitting),Phenotype,Childhood wheezing (pre-school remitting)
61180,Childhood wheezing (late-onset),Phenotype,Childhood wheezing (late-onset)
61183,S-6-hydroxywarfarin levels,Phenotype,S-6-hydroxywarfarin levels
61191,R-6-hydroxywarfarin levels,Phenotype,R-6-hydroxywarfarin levels
61234,Morbidity in COVID-19 (deceased vs asymptomatic),Phenotype,Morbidity in COVID-19 (deceased vs asymptomatic)
61236,COVID-19 (severe vs population) x cardiometabolic health status interaction (joint test),Phenotype,COVID-19 (severe vs population) x cardiometabolic health status interaction (joint test)
61238,COVID-19 (severe vs population) x cardiometabolic health status interaction,Phenotype,COVID-19 (severe vs population) x cardiometabolic health status interaction
61240,COVID-19 (severe vs population) x sex interaction (joint test),Phenotype,COVID-19 (severe vs population) x sex interaction (joint test)
61242,COVID-19 (severe vs population) x sex interaction,Phenotype,COVID-19 (severe vs population) x sex interaction
61243,S-6-hydroxywarfarin to S-warfarin ratio,Phenotype,S-6-hydroxywarfarin to S-warfarin ratio
61245,S-warfarin to R-warfarin ratio,Phenotype,S-warfarin to R-warfarin ratio
61249,R-6-hydroxywarfarin to R-warfarin ratio,Phenotype,R-6-hydroxywarfarin to R-warfarin ratio
61256,DHEA-S-to-4-androsten-3beta--17beta-diol disulfate 2 ratio,Phenotype,DHEA-S-to-4-androsten-3beta--17beta-diol disulfate 2 ratio
61257,Docosapentaenoate n3 DPA; 22:5n3-to-X-12627 ratio,Phenotype,Docosapentaenoate n3 DPA; 22:5n3-to-X-12627 ratio
61258,Hexanoylcarnitine-to-octanoylcarnitine ratio,Phenotype,Hexanoylcarnitine-to-octanoylcarnitine ratio
61259,Linoleate 18:2n6-to-dihomo-linolenate 20:3n3 or n6 ratio,Phenotype,Linoleate 18:2n6-to-dihomo-linolenate 20:3n3 or n6 ratio
61260,Lysine-to-glutaroyl carnitine ratio,Phenotype,Lysine-to-glutaroyl carnitine ratio
61261,Phenyllactate-to-phenylalanine ratio,Phenotype,Phenyllactate-to-phenylalanine ratio
61263,X-11444-to-X-11470 ratio,Phenotype,X-11444-to-X-11470 ratio
61264,X-12798-to-phenylalanine ratio,Phenotype,X-12798-to-phenylalanine ratio
61265,4-androsten-3beta--17beta-diol disulfate 2 levels,Phenotype,4-androsten-3beta--17beta-diol disulfate 2 levels
61267,Cigarettes smoked per day,Phenotype,Cigarettes smoked per day
61280,Age of smoking initiation,Phenotype,Age of smoking initiation
61281,Visceral adipose tissue volumes,Phenotype,Visceral adipose tissue volumes
61282,Abdominal adipose tissue volumes,Phenotype,Abdominal adipose tissue volumes
61284,Gluteofemoral adipose tissue volumes,Phenotype,Gluteofemoral adipose tissue volumes
61288,Visceral adipose tissue volumes (adjusted for BMI and height),Phenotype,Visceral adipose tissue volumes (adjusted for BMI and height)
61291,Visceral adipose tissue volumes to gluteofemoral adipose tissue volumes ratio,Phenotype,Visceral adipose tissue volumes to gluteofemoral adipose tissue volumes ratio
61293,Abdominal adipose tissue volumes to gluteofemoral adipose tissue volumes ratio,Phenotype,Abdominal adipose tissue volumes to gluteofemoral adipose tissue volumes ratio
61295,Gluteofemoral adipose tissue volumes (adjusted for BMI and height),Phenotype,Gluteofemoral adipose tissue volumes (adjusted for BMI and height)
61296,Visceral adipose tissue volumes to abdominal adipose tissue volumes ratio,Phenotype,Visceral adipose tissue volumes to abdominal adipose tissue volumes ratio
61302,Abdominal adipose tissue volumes (adjusted for BMI and height),Phenotype,Abdominal adipose tissue volumes (adjusted for BMI and height)
61303,Colorectal cancer x menopausal hormone therapy interaction,Phenotype,Colorectal cancer x menopausal hormone therapy interaction
61306,Colorectal cancer x menopausal hormone therapy interaction (2df test),Phenotype,Colorectal cancer x menopausal hormone therapy interaction (2df test)
61308,Colorectal cancer x menopausal hormone therapy interaction (3df test),Phenotype,Colorectal cancer x menopausal hormone therapy interaction (3df test)
61309,Colorectal cancer x estrogen-progesterone hormone therapy interaction,Phenotype,Colorectal cancer x estrogen-progesterone hormone therapy interaction
61311,R-warfarin levels,Phenotype,R-warfarin levels
61322,RS-10-hydroxywarfarin to RS-warfarin ratio,Phenotype,RS-10-hydroxywarfarin to RS-warfarin ratio
61324,S-7-hydroxywarfarin to S-warfarin ratio,Phenotype,S-7-hydroxywarfarin to S-warfarin ratio
61328,Platelet factor 4/heparin antibody levels in heparin treatment,Phenotype,Platelet factor 4/heparin antibody levels in heparin treatment
61336,Opioid use disorder (broad),Phenotype,Opioid use disorder (broad)
61338,RS-warfarin levels,Phenotype,RS-warfarin levels
61340,Octadecadienylcarnitine levels,Phenotype,Octadecadienylcarnitine levels
61362,X-11550 levels,Phenotype,X-11550 levels
61363,X-12038 levels,Phenotype,X-12038 levels
61364,X-12244--N-acetylcarnosine levels,Phenotype,X-12244--N-acetylcarnosine levels
61365,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Phenotype,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels
61367,Glutaroyl carnitine levels,Phenotype,Glutaroyl carnitine levels
61368,Dihomo-linolenate 20:3n3 or n6 levels,Phenotype,Dihomo-linolenate 20:3n3 or n6 levels
61369,X-12556 levels,Phenotype,X-12556 levels
61371,X-12627 levels,Phenotype,X-12627 levels
61377,COVID-19,Phenotype,COVID-19
61380,Alanine aminotransferase level after methotrexate initiation in rheumatoid arthritis,Phenotype,Alanine aminotransferase level after methotrexate initiation in rheumatoid arthritis
61383,Alanine aminotransferase elevation after methotrexate initiation in rheumatoid arthritis (>1.5 × ULN),Phenotype,Alanine aminotransferase elevation after methotrexate initiation in rheumatoid arthritis (>1.5 × ULN)
61398,RS-6-hydroxywarfarin levels,Phenotype,RS-6-hydroxywarfarin levels
61405,S-7-hydroxywarfarin levels,Phenotype,S-7-hydroxywarfarin levels
61417,3-phenylpropionate hydrocinnamate levels,Phenotype,3-phenylpropionate hydrocinnamate levels
61420,Scyllo-inositol levels,Phenotype,Scyllo-inositol levels
61477,COVID-19 (severe vs mild),Phenotype,COVID-19 (severe vs mild)
61489,Adverse response to chemotherapy in breast cancer (grade 3/4 neutropenic or leukopenic events),Phenotype,Adverse response to chemotherapy in breast cancer (grade 3/4 neutropenic or leukopenic events)
61491,Alzheimer's disease in non-APOE e4 carriers,Phenotype,Alzheimer's disease in non-APOE e4 carriers
61507,Lifelong premature ejaculation,Phenotype,Lifelong premature ejaculation
61511,Dementia in APOE e4+ carriers,Phenotype,Dementia in APOE e4+ carriers
61512,Dementia in non-APOE e4 carriers,Phenotype,Dementia in non-APOE e4 carriers
61526,Colorectal cancer x estrogen hormone therapy interaction,Phenotype,Colorectal cancer x estrogen hormone therapy interaction
61529,Colorectal cancer x estrogen-progesterone hormone therapy interaction (3df test),Phenotype,Colorectal cancer x estrogen-progesterone hormone therapy interaction (3df test)
61540,HLA risk haplotype in IgA deficiency (homozygous HLA-DRB1*07:01 HLA-DQB1*02:02),Phenotype,HLA risk haplotype in IgA deficiency (homozygous HLA-DRB1*07:01 HLA-DQB1*02:02)
61542,Colorectal cancer x estrogen-progesterone hormone therapy interaction (2df test),Phenotype,Colorectal cancer x estrogen-progesterone hormone therapy interaction (2df test)
61543,S-warfarin levels,Phenotype,S-warfarin levels
61551,RS-10-hydroxywarfarin levels,Phenotype,RS-10-hydroxywarfarin levels
61618,Age-related macular degeneration or COVID-19 infection (MTAG),Phenotype,Age-related macular degeneration or COVID-19 infection (MTAG)
61620,COVID-19 critical illness or age-related macular degeneration (MTAG),Phenotype,COVID-19 critical illness or age-related macular degeneration (MTAG)
61621,COVID-19 hospitalization or age-related macular degeneration (MTAG),Phenotype,COVID-19 hospitalization or age-related macular degeneration (MTAG)
61645,Asthma or chronic obstructive pulmonary disease (pleiotropy),Phenotype,Asthma or chronic obstructive pulmonary disease (pleiotropy)
61662,Age-related macular degeneration or COVID-19 hospitalization (MTAG),Phenotype,Age-related macular degeneration or COVID-19 hospitalization (MTAG)
61663,Age-related macular degeneration or COVID-19 critical illness (MTAG),Phenotype,Age-related macular degeneration or COVID-19 critical illness (MTAG)
61678,Geographic atrophy within a central 5 mm circle (model 1),Phenotype,Geographic atrophy within a central 5 mm circle (model 1)
61680,Drusen area within a central 5 mm circle (model 1),Phenotype,Drusen area within a central 5 mm circle (model 1)
61684,Drusen volume within a central 5 mm circle (model 1),Phenotype,Drusen volume within a central 5 mm circle (model 1)
61687,Drusen area within a central 3 mm circle (model 1),Phenotype,Drusen area within a central 3 mm circle (model 1)
61688,Drusen area within a central 5 mm circle (model 2),Phenotype,Drusen area within a central 5 mm circle (model 2)
61697,Uterine leiomyomata,Phenotype,Uterine leiomyomata
61706,Juvenile dermatomyositis,Phenotype,Juvenile dermatomyositis
61722,Crohn's disease x smoking status (never vs ever smoking) interaction,Phenotype,Crohn's disease x smoking status (never vs ever smoking) interaction
61724,Ulcerative colitis x smoking status (never vs ever smoking) interaction,Phenotype,Ulcerative colitis x smoking status (never vs ever smoking) interaction
61725,Inflammatory bowel disease x smoking status (never vs ever smoking) interaction,Phenotype,Inflammatory bowel disease x smoking status (never vs ever smoking) interaction
61726,Crohn's disease x smoking status (never vs current smoking) interaction,Phenotype,Crohn's disease x smoking status (never vs current smoking) interaction
61729,Inflammatory bowel disease x smoking status (never vs current smoking) interaction,Phenotype,Inflammatory bowel disease x smoking status (never vs current smoking) interaction
61730,Crohn's disease x smoking status (never vs former smoking) interaction,Phenotype,Crohn's disease x smoking status (never vs former smoking) interaction
61732,Inflammatory bowel disease x smoking status (never vs former smoking) interaction,Phenotype,Inflammatory bowel disease x smoking status (never vs former smoking) interaction
61738,Bone mineral density mean,Phenotype,Bone mineral density mean
61746,Whole body fat mass (UKB data field 23100),Phenotype,Whole body fat mass (UKB data field 23100)
61779,Baseline memory in normal cognition,Phenotype,Baseline memory in normal cognition
61782,Whole body fat free mass (UKB data field 23101),Phenotype,Whole body fat free mass (UKB data field 23101)
61787,Baseline memory in normal cognition x sex interaction,Phenotype,Baseline memory in normal cognition x sex interaction
61790,Memory decline in impaired cognition,Phenotype,Memory decline in impaired cognition
61793,Memory decline in normal cognition,Phenotype,Memory decline in normal cognition
61835,Bone mineral density variability,Phenotype,Bone mineral density variability
61845,Memory decline,Phenotype,Memory decline
61849,Memory decline in impaired cognition x sex interaction,Phenotype,Memory decline in impaired cognition x sex interaction
61856,Memory decline in normal cognition x sex interaction,Phenotype,Memory decline in normal cognition x sex interaction
61912,Memory decline x sex interaction,Phenotype,Memory decline x sex interaction
61941,Gastroesophageal reflux disease (UKB data field 20002_1138),Phenotype,Gastroesophageal reflux disease (UKB data field 20002_1138)
61942,Gastritis and duodenitis (UKB data field 20002_1143),Phenotype,Gastritis and duodenitis (UKB data field 20002_1143)
61944,ICD10 K31.7: Polyp of stomach and duodenum,Phenotype,ICD10 K31.7: Polyp of stomach and duodenum
61946,ICD10 K70: Liver fibrosis and cirrhosis,Phenotype,ICD10 K70: Liver fibrosis and cirrhosis
61956,Diffuse gastric cancer in H. pylori positive individuals,Phenotype,Diffuse gastric cancer in H. pylori positive individuals
61961,Posterior brain arterial diameters,Phenotype,Posterior brain arterial diameters
61967,ICD10 K50-- K51: inflammatory bowel disease,Phenotype,ICD10 K50-- K51: inflammatory bowel disease
61968,Colorectal polyp (UKB data field 20002_1460),Phenotype,Colorectal polyp (UKB data field 20002_1460)
61974,Cancer code-- self-reported: small intestinal cancer (UKB data field 20001_1019),Phenotype,Cancer code-- self-reported: small intestinal cancer (UKB data field 20001_1019)
61975,Cholelithiasis (UKB data field 20002_1162),Phenotype,Cholelithiasis (UKB data field 20002_1162)
61978,alpha-Fetoprotein levels,Phenotype,alpha-Fetoprotein levels
62001,Bone density T-score,Phenotype,Bone density T-score
62010,Body fat rate,Phenotype,Body fat rate
62017,Ischemic heart disease (PheCode 411),Phenotype,Ischemic heart disease (PheCode 411)
62020,Bone density Z-score,Phenotype,Bone density Z-score
62049,Baseline memory x sex interaction,Phenotype,Baseline memory x sex interaction
62052,Baseline memory in impaired cognition x sex interaction,Phenotype,Baseline memory in impaired cognition x sex interaction
62063,Telomere length (principal component 1),Phenotype,Telomere length (principal component 1)
62078,Estimated glomerular filtration rate (creatinine-- cystatin c),Phenotype,Estimated glomerular filtration rate (creatinine-- cystatin c)
62085,Baseline memory in impaired cognition,Phenotype,Baseline memory in impaired cognition
62099,Baseline memory,Phenotype,Baseline memory
62105,Hip shape mode 1,Phenotype,Hip shape mode 1
62108,Hip shape mode 2,Phenotype,Hip shape mode 2
62184,Ease of skin tanning,Phenotype,Ease of skin tanning
62188,Ease of sunburn,Phenotype,Ease of sunburn
62190,Extensive white matter perivascular space burden,Phenotype,Extensive white matter perivascular space burden
62193,Underweight,Phenotype,Underweight
62196,Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase-- mitochondrial levels,Phenotype,Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase-- mitochondrial levels
62197,Statherin levels,Phenotype,Statherin levels
62199,Stromal interaction molecule 1 levels,Phenotype,Stromal interaction molecule 1 levels
62201,Serine/threonine-protein kinase 16 levels,Phenotype,Serine/threonine-protein kinase 16 levels
62203,Adenylyltransferase and sulfurtransferase MOCS3 levels,Phenotype,Adenylyltransferase and sulfurtransferase MOCS3 levels
62204,Matrix-remodeling-associated protein 8 levels,Phenotype,Matrix-remodeling-associated protein 8 levels
62205,Myeloblastin levels,Phenotype,Myeloblastin levels
62207,Myosin light chain 6B levels,Phenotype,Myosin light chain 6B levels
62208,Myelin protein zero-like protein 1 levels,Phenotype,Myelin protein zero-like protein 1 levels
62209,Melanoregulin levels,Phenotype,Melanoregulin levels
62210,Methenyltetrahydrofolate synthase domain-containing protein levels,Phenotype,Methenyltetrahydrofolate synthase domain-containing protein levels
62212,Serine/threonine-protein kinase PAK 3 levels,Phenotype,Serine/threonine-protein kinase PAK 3 levels
62214,Serine/threonine-protein kinase PAK 5 levels,Phenotype,Serine/threonine-protein kinase PAK 5 levels
62216,Mucin-16 levels,Phenotype,Mucin-16 levels
62219,Mitochondrial ubiquitin ligase activator of NFKB 1 levels,Phenotype,Mitochondrial ubiquitin ligase activator of NFKB 1 levels
62220,Neuroendocrine protein 7B2 levels,Phenotype,Neuroendocrine protein 7B2 levels
62223,E3 ubiquitin-protein ligase NEURL1 levels,Phenotype,E3 ubiquitin-protein ligase NEURL1 levels
62226,Magnesium transporter NIPA4 levels,Phenotype,Magnesium transporter NIPA4 levels
62227,Neutrophil elastase levels,Phenotype,Neutrophil elastase levels
62229,NEDD8-activating enzyme E1 regulatory subunit levels,Phenotype,NEDD8-activating enzyme E1 regulatory subunit levels
62231,Fc receptor-like protein 1 levels,Phenotype,Fc receptor-like protein 1 levels
62232,Zona pellucida-binding protein 1 levels,Phenotype,Zona pellucida-binding protein 1 levels
62233,Protein zwilch homolog levels,Phenotype,Protein zwilch homolog levels
62234,Inhibin beta B chain (mixed) levels,Phenotype,Inhibin beta B chain (mixed) levels
62240,Fatty acid-binding protein 9 levels,Phenotype,Fatty acid-binding protein 9 levels
62242,Iron-sulfur cluster co-chaperone protein HscB-- mitochondrial levels,Phenotype,Iron-sulfur cluster co-chaperone protein HscB-- mitochondrial levels
62243,Fibroblast growth factor 8 isoform B levels,Phenotype,Fibroblast growth factor 8 isoform B levels
62246,Poly(A) RNA polymerase-- mitochondrial levels,Phenotype,Poly(A) RNA polymerase-- mitochondrial levels
62247,Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 levels,Phenotype,Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 levels
62248,Guanylate-binding protein 6 levels,Phenotype,Guanylate-binding protein 6 levels
62249,GTP cyclohydrolase 1 levels,Phenotype,GTP cyclohydrolase 1 levels
62250,Melanocyte protein PMEL levels,Phenotype,Melanocyte protein PMEL levels
62253,Insomnia (standard GWA),Phenotype,Insomnia (standard GWA)
62255,Number of non-cancer illnesses (standard GWA),Phenotype,Number of non-cancer illnesses (standard GWA)
62257,Height (weighted GWA),Phenotype,Height (weighted GWA)
62260,Body mass index (MTAG),Phenotype,Body mass index (MTAG)
62274,TNF receptor-associated factor 1 levels,Phenotype,TNF receptor-associated factor 1 levels
62277,Triggering receptor expressed on myeloid cells 2 levels,Phenotype,Triggering receptor expressed on myeloid cells 2 levels
62279,Tryptophan 2--3-dioxygenase levels,Phenotype,Tryptophan 2--3-dioxygenase levels
62280,Thiopurine S-methyltransferase levels,Phenotype,Thiopurine S-methyltransferase levels
62281,Transferrin receptor protein 1 levels,Phenotype,Transferrin receptor protein 1 levels
62282,Trypsin-1 levels,Phenotype,Trypsin-1 levels
62284,Trypsin-2 levels,Phenotype,Trypsin-2 levels
62285,Tubulin polymerization-promoting protein family member 2 levels,Phenotype,Tubulin polymerization-promoting protein family member 2 levels
62290,Tapasin-related protein levels,Phenotype,Tapasin-related protein levels
62292,Troponin T-- fast skeletal muscle levels,Phenotype,Troponin T-- fast skeletal muscle levels
62293,TOM1-like protein 2 levels,Phenotype,TOM1-like protein 2 levels
62294,TOMM20-like protein 1 levels,Phenotype,TOMM20-like protein 1 levels
62295,Thioredoxin-related transmembrane protein 2 levels,Phenotype,Thioredoxin-related transmembrane protein 2 levels
62296,Protein disulfide-isomerase TMX3 levels,Phenotype,Protein disulfide-isomerase TMX3 levels
62298,Mitochondrial import inner membrane translocase subunit TIM14 levels,Phenotype,Mitochondrial import inner membrane translocase subunit TIM14 levels
62300,T-cell immunoglobulin and mucin domain-containing protein 4 levels,Phenotype,T-cell immunoglobulin and mucin domain-containing protein 4 levels
62302,Transcription factor AP-1 levels,Phenotype,Transcription factor AP-1 levels
62303,Tumor necrosis factor alpha-induced protein 3 levels,Phenotype,Tumor necrosis factor alpha-induced protein 3 levels
62305,Tumor necrosis factor receptor superfamily member 21 levels,Phenotype,Tumor necrosis factor receptor superfamily member 21 levels
62307,Tumor necrosis factor receptor superfamily member 3 levels,Phenotype,Tumor necrosis factor receptor superfamily member 3 levels
62308,Tumor necrosis factor receptor superfamily member 8 levels,Phenotype,Tumor necrosis factor receptor superfamily member 8 levels
62310,Tumor necrosis factor ligand superfamily member 14 levels,Phenotype,Tumor necrosis factor ligand superfamily member 14 levels
62311,Tumor necrosis factor ligand superfamily member 18 levels,Phenotype,Tumor necrosis factor ligand superfamily member 18 levels
62313,Trimeric intracellular cation channel type B levels,Phenotype,Trimeric intracellular cation channel type B levels
62314,Tumor necrosis factor receptor superfamily member 17 levels,Phenotype,Tumor necrosis factor receptor superfamily member 17 levels
62315,Chronotype x daytime light exposure interaction,Phenotype,Chronotype x daytime light exposure interaction
62317,Alanine--tRNA ligase-- cytoplasmic levels,Phenotype,Alanine--tRNA ligase-- cytoplasmic levels
62319,Paralemmin-1 levels,Phenotype,Paralemmin-1 levels
62320,Peptide chain release factor 1-like-- mitochondrial levels,Phenotype,Peptide chain release factor 1-like-- mitochondrial levels
62323,Proprotein convertase subtilisin/kexin type 7 levels,Phenotype,Proprotein convertase subtilisin/kexin type 7 levels
62325,Protein canopy homolog 3 levels,Phenotype,Protein canopy homolog 3 levels
62327,Phosphoenolpyruvate carboxykinase-- cytosolic [GTP] levels,Phenotype,Phosphoenolpyruvate carboxykinase-- cytosolic [GTP] levels
62328,RBC levels of 15-HETE,Phenotype,RBC levels of 15-HETE
62331,Beta-defensin 113 levels,Phenotype,Beta-defensin 113 levels
62333,Beta-defensin 116 levels,Phenotype,Beta-defensin 116 levels
62334,Beta-defensin 132 levels,Phenotype,Beta-defensin 132 levels
62335,Biglycan levels,Phenotype,Biglycan levels
62337,RBC levels of 9--10-diHOME,Phenotype,RBC levels of 9--10-diHOME
62339,RBC levels of acetyl-carnitine,Phenotype,RBC levels of acetyl-carnitine
62340,RBC levels of ADP,Phenotype,RBC levels of ADP
62342,RBC levels of 2-Oxoglutaramate,Phenotype,RBC levels of 2-Oxoglutaramate
62344,RBC levels of 5-6-Dihydrothymine,Phenotype,RBC levels of 5-6-Dihydrothymine
62346,RBC levels of 8-HETE.1,Phenotype,RBC levels of 8-HETE.1
62348,RBC levels of 11-HETE.1,Phenotype,RBC levels of 11-HETE.1
62352,Left ventricular end diastolic mass,Phenotype,Left ventricular end diastolic mass
62354,Left ventricular end-diastolic volume,Phenotype,Left ventricular end-diastolic volume
62355,Left ventricular ejection fraction,Phenotype,Left ventricular ejection fraction
62358,Right ventricular peak ejection rate,Phenotype,Right ventricular peak ejection rate
62367,Left ventricular end diastolic mass end diastolic volume ratio,Phenotype,Left ventricular end diastolic mass end diastolic volume ratio
62370,Systolic blood pressure (standard GWA),Phenotype,Systolic blood pressure (standard GWA)
62374,Smoking status (standard GWA),Phenotype,Smoking status (standard GWA)
62376,Nuclear distribution protein nudE homolog 1 levels,Phenotype,Nuclear distribution protein nudE homolog 1 levels
62378,Nucleoside diphosphate kinase-- mitochondrial levels,Phenotype,Nucleoside diphosphate kinase-- mitochondrial levels
62381,Protein NDRG4 levels,Phenotype,Protein NDRG4 levels
62385,NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11-- mitochondrial levels,Phenotype,NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11-- mitochondrial levels
62386,Tight junction protein ZO-1 levels,Phenotype,Tight junction protein ZO-1 levels
62389,U6 snRNA-associated Sm-like protein LSm4 levels,Phenotype,U6 snRNA-associated Sm-like protein LSm4 levels
62390,Neural cell adhesion molecule 2 levels,Phenotype,Neural cell adhesion molecule 2 levels
62392,Gamma-aminobutyric acid receptor-associated protein-like 2 levels,Phenotype,Gamma-aminobutyric acid receptor-associated protein-like 2 levels
62394,Nuclear pore membrane glycoprotein 210-like levels,Phenotype,Nuclear pore membrane glycoprotein 210-like levels
62396,Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha levels,Phenotype,Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha levels
62397,Receptor-type tyrosine-protein kinase FLT3 levels,Phenotype,Receptor-type tyrosine-protein kinase FLT3 levels
62398,G2/mitotic-specific cyclin-B2 levels,Phenotype,G2/mitotic-specific cyclin-B2 levels
62399,Galactose-3-O-sulfotransferase 2 levels,Phenotype,Galactose-3-O-sulfotransferase 2 levels
62401,Glycerol-3-phosphate dehydrogenase 1-like protein levels,Phenotype,Glycerol-3-phosphate dehydrogenase 1-like protein levels
62404,Frizzled-10 levels,Phenotype,Frizzled-10 levels
62405,Phospholipase A2 levels,Phenotype,Phospholipase A2 levels
62406,Prolyl 4-hydroxylase subunit alpha-2 levels,Phenotype,Prolyl 4-hydroxylase subunit alpha-2 levels
62408,Ferritin light chain levels,Phenotype,Ferritin light chain levels
62409,Pancreatic triacylglycerol lipase levels,Phenotype,Pancreatic triacylglycerol lipase levels
62412,Proto-oncogene tyrosine-protein kinase ROS levels,Phenotype,Proto-oncogene tyrosine-protein kinase ROS levels
62413,Peroxisome proliferator-activated receptor alpha levels,Phenotype,Peroxisome proliferator-activated receptor alpha levels
62415,PH and SEC7 domain-containing protein 1 levels,Phenotype,PH and SEC7 domain-containing protein 1 levels
62416,Pre-mRNA-processing factor 6 levels,Phenotype,Pre-mRNA-processing factor 6 levels
62417,PR domain zinc finger protein 1 levels,Phenotype,PR domain zinc finger protein 1 levels
62418,Prion-like protein doppel levels,Phenotype,Prion-like protein doppel levels
62420,Proteasome subunit alpha type-2 levels,Phenotype,Proteasome subunit alpha type-2 levels
62421,Proteasome subunit alpha type-5 levels,Phenotype,Proteasome subunit alpha type-5 levels
62423,Proteasome subunit alpha type-7 levels,Phenotype,Proteasome subunit alpha type-7 levels
62426,Proteasome subunit beta type-2 levels,Phenotype,Proteasome subunit beta type-2 levels
62430,Pro-opiomelanocortin levels,Phenotype,Pro-opiomelanocortin levels
62432,Prostasin levels,Phenotype,Prostasin levels
62443,Reaction time (standard GWA),Phenotype,Reaction time (standard GWA)
62444,Reaction time (weighted GWA),Phenotype,Reaction time (weighted GWA)
62445,Risk taking (standard GWA),Phenotype,Risk taking (standard GWA)
62447,Risk taking (weighted GWA),Phenotype,Risk taking (weighted GWA)
62448,Alcohol frequency weekly (standard GWA),Phenotype,Alcohol frequency weekly (standard GWA)
62460,Soluble CD163 levels,Phenotype,Soluble CD163 levels
62463,Neuronal pentraxin-1 levels,Phenotype,Neuronal pentraxin-1 levels
62465,Neurexophilin-1 levels,Phenotype,Neurexophilin-1 levels
62466,OCIA domain-containing protein 1 levels,Phenotype,OCIA domain-containing protein 1 levels
62467,Opticin levels,Phenotype,Opticin levels
62468,Oral cancer-overexpressed protein 1 levels,Phenotype,Oral cancer-overexpressed protein 1 levels
62469,Oncostatin-M levels,Phenotype,Oncostatin-M levels
62470,Arsenite methyltransferase levels,Phenotype,Arsenite methyltransferase levels
62471,Histone chaperone ASF1A levels,Phenotype,Histone chaperone ASF1A levels
62473,ATPase family AAA domain-containing protein 1 levels,Phenotype,ATPase family AAA domain-containing protein 1 levels
62474,Cyclic AMP-dependent transcription factor ATF-6 alpha levels,Phenotype,Cyclic AMP-dependent transcription factor ATF-6 alpha levels
62475,Armadillo repeat-containing protein 5 levels,Phenotype,Armadillo repeat-containing protein 5 levels
62478,ATP synthase subunit beta-- mitochondrial levels,Phenotype,ATP synthase subunit beta-- mitochondrial levels
62479,ATP-dependent RNA helicase A levels,Phenotype,ATP-dependent RNA helicase A levels
62480,Extracellular tyrosine-protein kinase PKDCC levels,Phenotype,Extracellular tyrosine-protein kinase PKDCC levels
62481,Plasmin levels,Phenotype,Plasmin levels
62484,1-phosphatidylinositol 4--5-bisphosphate phosphodiesterase gamma-1 levels,Phenotype,1-phosphatidylinositol 4--5-bisphosphate phosphodiesterase gamma-1 levels
62485,1-phosphatidylinositol 4--5-bisphosphate phosphodiesterase gamma-2 levels,Phenotype,1-phosphatidylinositol 4--5-bisphosphate phosphodiesterase gamma-2 levels
62487,Augurin levels,Phenotype,Augurin levels
62488,Aurora kinase B levels,Phenotype,Aurora kinase B levels
62499,Skin phototype score,Phenotype,Skin phototype score
62512,Skin color (Fitzpatrick scale),Phenotype,Skin color (Fitzpatrick scale)
62515,Primary focal segmental glomerulosclerosis in chronic kidney disease,Phenotype,Primary focal segmental glomerulosclerosis in chronic kidney disease
62523,Extrapulmonary tuberculosis,Phenotype,Extrapulmonary tuberculosis
62525,Transcription initiation factor TFIID subunit 10 levels,Phenotype,Transcription initiation factor TFIID subunit 10 levels
62526,Tropomyosin beta chain levels,Phenotype,Tropomyosin beta chain levels
62527,Histone-lysine N-methyltransferase SUV420H2 levels,Phenotype,Histone-lysine N-methyltransferase SUV420H2 levels
62528,T-cell surface glycoprotein CD1a levels,Phenotype,T-cell surface glycoprotein CD1a levels
62529,Sulfatase-modifying factor 2 levels,Phenotype,Sulfatase-modifying factor 2 levels
62531,Synaptotagmin-11 levels,Phenotype,Synaptotagmin-11 levels
62533,Syntaxin-7 levels,Phenotype,Syntaxin-7 levels
62535,Suppressor of fused homolog levels,Phenotype,Suppressor of fused homolog levels
62536,TLR4 interactor with leucine rich repeats levels,Phenotype,TLR4 interactor with leucine rich repeats levels
62538,Thymidine kinase-- cytosolic levels,Phenotype,Thymidine kinase-- cytosolic levels
62539,Thymidine kinase 2-- mitochondrial levels,Phenotype,Thymidine kinase 2-- mitochondrial levels
62541,Tachykinin-4 levels,Phenotype,Tachykinin-4 levels
62542,Transmembrane protein 9 levels,Phenotype,Transmembrane protein 9 levels
62543,Thyroid peroxidase levels,Phenotype,Thyroid peroxidase levels
62544,Transmembrane protein C1orf162 levels,Phenotype,Transmembrane protein C1orf162 levels
62545,Transmembrane protein 185A levels,Phenotype,Transmembrane protein 185A levels
62547,Ubiquitin D levels,Phenotype,Ubiquitin D levels
62548,Malignant lymphoma (Non-Hodgkin lymphoma-- multiple myeloma-- or Hodgkin lymphoma),Phenotype,Malignant lymphoma (Non-Hodgkin lymphoma-- multiple myeloma-- or Hodgkin lymphoma)
62551,Alanine aminotransferase 1 levels,Phenotype,Alanine aminotransferase 1 levels
62552,Anthrax toxin receptor 1 levels,Phenotype,Anthrax toxin receptor 1 levels
62553,Angiopoietin-1 receptor-- soluble levels,Phenotype,Angiopoietin-1 receptor-- soluble levels
62558,Cryptic phenotype that captures Alport syndrome severity,Phenotype,Cryptic phenotype that captures Alport syndrome severity
62559,Cryptic phenotype that captures autosomal dominant polycystic kidney disease severity,Phenotype,Cryptic phenotype that captures autosomal dominant polycystic kidney disease severity
62560,Systolic blood pressure (weighted GWA),Phenotype,Systolic blood pressure (weighted GWA)
62572,Alpha-1--3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A levels,Phenotype,Alpha-1--3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A levels
62573,Myc-associated zinc finger protein levels,Phenotype,Myc-associated zinc finger protein levels
62575,Mast cell-expressed membrane protein 1 levels,Phenotype,Mast cell-expressed membrane protein 1 levels
62576,Malonyl-CoA decarboxylase-- mitochondrial levels,Phenotype,Malonyl-CoA decarboxylase-- mitochondrial levels
62578,Homeobox protein MOX-2 levels,Phenotype,Homeobox protein MOX-2 levels
62580,MICAL-like protein 2 levels,Phenotype,MICAL-like protein 2 levels
62586,Matrix metalloproteinase-9 levels,Phenotype,Matrix metalloproteinase-9 levels
62588,UDP-glucuronic acid decarboxylase 1 levels,Phenotype,UDP-glucuronic acid decarboxylase 1 levels
62591,Valine--tRNA ligase levels,Phenotype,Valine--tRNA ligase levels
62592,Vesicle-associated membrane protein 8 levels,Phenotype,Vesicle-associated membrane protein 8 levels
62593,Urotensin-2 levels,Phenotype,Urotensin-2 levels
62596,Vascular endothelial growth factor B levels,Phenotype,Vascular endothelial growth factor B levels
62597,Vascular endothelial growth factor receptor 1 levels,Phenotype,Vascular endothelial growth factor receptor 1 levels
62598,Uncharacterized protein C3orf18 levels,Phenotype,Uncharacterized protein C3orf18 levels
62599,Uncharacterized protein C4orf32 levels,Phenotype,Uncharacterized protein C4orf32 levels
62600,Sleep apnea (MTAG),Phenotype,Sleep apnea (MTAG)
62602,Protein disulfide-isomerase A4 levels,Phenotype,Protein disulfide-isomerase A4 levels
62603,Apolipoprotein A-V levels,Phenotype,Apolipoprotein A-V levels
62604,Protein delta homolog 1 levels,Phenotype,Protein delta homolog 1 levels
62605,Protein delta homolog 2 levels,Phenotype,Protein delta homolog 2 levels
62606,Apolipoprotein C-III levels,Phenotype,Apolipoprotein C-III levels
62612,ER membrane protein complex subunit 4 levels,Phenotype,ER membrane protein complex subunit 4 levels
62613,Chymotrypsin-like elastase family member 2A levels,Phenotype,Chymotrypsin-like elastase family member 2A levels
62615,Histone-lysine N-methyltransferase EHMT2 levels,Phenotype,Histone-lysine N-methyltransferase EHMT2 levels
62616,Erythropoietin levels,Phenotype,Erythropoietin levels
62617,Epididymal-specific lipocalin-10 levels,Phenotype,Epididymal-specific lipocalin-10 levels
62618,Electron transfer flavoprotein subunit alpha-- mitochondrial levels,Phenotype,Electron transfer flavoprotein subunit alpha-- mitochondrial levels
62619,DNA excision repair protein ERCC-1 levels,Phenotype,DNA excision repair protein ERCC-1 levels
62621,Protein FAM177A1 levels,Phenotype,Protein FAM177A1 levels
62623,Ectonucleotide pyrophosphatase/phosphodiesterase family member 6 levels,Phenotype,Ectonucleotide pyrophosphatase/phosphodiesterase family member 6 levels
62625,Ectonucleoside triphosphate diphosphohydrolase 1 levels,Phenotype,Ectonucleoside triphosphate diphosphohydrolase 1 levels
62626,Ectonucleoside triphosphate diphosphohydrolase 3 levels,Phenotype,Ectonucleoside triphosphate diphosphohydrolase 3 levels
62627,Endothelin-2 levels,Phenotype,Endothelin-2 levels
62630,OTU domain-containing protein 5 levels,Phenotype,OTU domain-containing protein 5 levels
62631,Activin receptor type-2A levels,Phenotype,Activin receptor type-2A levels
62632,Aspartoacylase levels,Phenotype,Aspartoacylase levels
62633,Acyl-coenzyme A thioesterase 13 levels,Phenotype,Acyl-coenzyme A thioesterase 13 levels
62635,Oxygen-dependent coproporphyrinogen-III oxidase-- mitochondrial levels,Phenotype,Oxygen-dependent coproporphyrinogen-III oxidase-- mitochondrial levels
62636,14-3-3 protein family levels,Phenotype,14-3-3 protein family levels
62638,5-Nucleotidase levels,Phenotype,5-Nucleotidase levels
62641,Amiloride-sensitive amine oxidase [copper-containing] levels,Phenotype,Amiloride-sensitive amine oxidase [copper-containing] levels
62643,Prorelaxin H2 levels,Phenotype,Prorelaxin H2 levels
62644,Prefoldin subunit 3 levels,Phenotype,Prefoldin subunit 3 levels
62645,Platelet endothelial cell adhesion molecule levels,Phenotype,Platelet endothelial cell adhesion molecule levels
62646,Prolyl endopeptidase FAP levels,Phenotype,Prolyl endopeptidase FAP levels
62647,Peptidyl-prolyl cis-trans isomerase G levels,Phenotype,Peptidyl-prolyl cis-trans isomerase G levels
62649,Peroxisomal 2--4-dienoyl-CoA reductase levels,Phenotype,Peroxisomal 2--4-dienoyl-CoA reductase levels
62668,Left ventricle sphericity index,Phenotype,Left ventricle sphericity index
62670,Left ventricle short axis,Phenotype,Left ventricle short axis
62673,Skin color,Phenotype,Skin color
62675,Overweight,Phenotype,Overweight
62677,Epstein-Barr virus seropositivity,Phenotype,Epstein-Barr virus seropositivity
62679,Colorectal cancer x cigarettes per day interaction (1df),Phenotype,Colorectal cancer x cigarettes per day interaction (1df)
62680,Colorectal cancer x cigarettes per day interaction (3df),Phenotype,Colorectal cancer x cigarettes per day interaction (3df)
62681,Pro-FMRFamide-related neuropeptide FF levels,Phenotype,Pro-FMRFamide-related neuropeptide FF levels
62682,NKG2-E type II integral membrane protein levels,Phenotype,NKG2-E type II integral membrane protein levels
62683,NmrA-like family domain-containing protein 1 levels,Phenotype,NmrA-like family domain-containing protein 1 levels
62686,Vitamin K-dependent protein S levels,Phenotype,Vitamin K-dependent protein S levels
62688,Noggin levels,Phenotype,Noggin levels
62689,B-cell lymphoma 6 protein levels,Phenotype,B-cell lymphoma 6 protein levels
62690,Breast cancer anti-estrogen resistance protein 3 levels,Phenotype,Breast cancer anti-estrogen resistance protein 3 levels
62693,Left ventricular stroke volume,Phenotype,Left ventricular stroke volume
62701,Inclusion body myositis,Phenotype,Inclusion body myositis
62702,Idiopathic inflammatory myopathy with anti-Jo1 positive,Phenotype,Idiopathic inflammatory myopathy with anti-Jo1 positive
62703,Thioredoxin domain-containing protein 15 levels,Phenotype,Thioredoxin domain-containing protein 15 levels
62705,Thioredoxin-interacting protein levels,Phenotype,Thioredoxin-interacting protein levels
62706,Trypsin-3 levels,Phenotype,Trypsin-3 levels
62711,Thrombospondin-type laminin G domain and EAR repeat-containing protein levels,Phenotype,Thrombospondin-type laminin G domain and EAR repeat-containing protein levels
62714,Tyrosine-protein kinase receptor Tie-1-- soluble levels,Phenotype,Tyrosine-protein kinase receptor Tie-1-- soluble levels
62716,Tyrosine-protein kinase ZAP-70 levels,Phenotype,Tyrosine-protein kinase ZAP-70 levels
62717,Alpha angle,Phenotype,Alpha angle
62719,Zinc finger protein 276 levels,Phenotype,Zinc finger protein 276 levels
62720,V-set and transmembrane domain-containing protein 4 levels,Phenotype,V-set and transmembrane domain-containing protein 4 levels
62721,Protein Wnt-11 levels,Phenotype,Protein Wnt-11 levels
62724,WAP four-disulfide core domain protein 5 levels,Phenotype,WAP four-disulfide core domain protein 5 levels
62725,Protein Wnt-5a levels,Phenotype,Protein Wnt-5a levels
62726,WW domain-containing oxidoreductase levels,Phenotype,WW domain-containing oxidoreductase levels
62729,Very low-density lipoprotein receptor levels,Phenotype,Very low-density lipoprotein receptor levels
62730,Vascular non-inflammatory molecule 2 levels,Phenotype,Vascular non-inflammatory molecule 2 levels
62735,Vesicular-- overexpressed in cancer-- prosurvival protein 1 levels,Phenotype,Vesicular-- overexpressed in cancer-- prosurvival protein 1 levels
62736,Vacuolar protein sorting-associated protein 28 homolog levels,Phenotype,Vacuolar protein sorting-associated protein 28 homolog levels
62738,Zinc fingers and homeoboxes protein 3 levels,Phenotype,Zinc fingers and homeoboxes protein 3 levels
62739,Afamin levels,Phenotype,Afamin levels
62747,25-hydroxyvitamin D levels (skin colour stratified),Phenotype,25-hydroxyvitamin D levels (skin colour stratified)
62748,25-Hydroxyvitamin D levels,Phenotype,25-Hydroxyvitamin D levels
62766,Soluble transferrin receptor concentration,Phenotype,Soluble transferrin receptor concentration
62770,Hepcidin concentration,Phenotype,Hepcidin concentration
62789,Hip shape mode 4,Phenotype,Hip shape mode 4
62794,Hip shape mode 3,Phenotype,Hip shape mode 3
62796,Hip shape mode 6,Phenotype,Hip shape mode 6
62806,Serum O-methylascorbate levels  x sex interaction,Phenotype,Serum O-methylascorbate levels  x sex interaction
62809,Serum ascorbic acid 2-sulfate levels x sex interaction,Phenotype,Serum ascorbic acid 2-sulfate levels x sex interaction
62826,Lactate levels in blood donors,Phenotype,Lactate levels in blood donors
62827,Phosphoenolpyruvate levels in blood donors,Phenotype,Phosphoenolpyruvate levels in blood donors
62862,FVC,Phenotype,FVC
62923,Pain intensity in opioid-treated advanced cancer,Phenotype,Pain intensity in opioid-treated advanced cancer
62964,Hip shape mode 8,Phenotype,Hip shape mode 8
62966,Hip shape mode 9,Phenotype,Hip shape mode 9
62975,Hip shape mode 10,Phenotype,Hip shape mode 10
62979,Fluid intelligence,Phenotype,Fluid intelligence
62996,2--3-Phospho-D-glycerate levels in blood donors,Phenotype,2--3-Phospho-D-glycerate levels in blood donors
62998,ATP levels in blood donors,Phenotype,ATP levels in blood donors
62999,D-Hexose-phosphate levels in blood donors,Phenotype,D-Hexose-phosphate levels in blood donors
63000,Serum 25-Hydroxyvitamin D levels (conditioned on BMI),Phenotype,Serum 25-Hydroxyvitamin D levels (conditioned on BMI)
63002,Adhesion G protein-coupled receptor B3 levels,Phenotype,Adhesion G protein-coupled receptor B3 levels
63004,Cadherin-15 levels,Phenotype,Cadherin-15 levels
63010,Epithelial discoidin domain-containing receptor 1 levels,Phenotype,Epithelial discoidin domain-containing receptor 1 levels
63012,Dipeptidase 1 levels,Phenotype,Dipeptidase 1 levels
63014,Dipeptidase 2 levels,Phenotype,Dipeptidase 2 levels
63061,Achondroplasia-like facial shape score,Phenotype,Achondroplasia-like facial shape score
63101,25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction,Phenotype,25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction
63102,Microalbumin urine,Phenotype,Microalbumin urine
63107,Telomere length (principal component 2),Phenotype,Telomere length (principal component 2)
63134,NKG2D ligand 2 levels,Phenotype,NKG2D ligand 2 levels
63140,SPARC-related modular calcium-binding protein 2 levels,Phenotype,SPARC-related modular calcium-binding protein 2 levels
63143,Interleukin-32 levels,Phenotype,Interleukin-32 levels
63146,Group 10 secretory phospholipase A2 levels,Phenotype,Group 10 secretory phospholipase A2 levels
63148,Tubulin polymerization-promoting protein family member 3 levels,Phenotype,Tubulin polymerization-promoting protein family member 3 levels
63154,Dihomo-gamma-linolenic acid; eicosatrienoic acid levels (305.2485_0.386),Phenotype,Dihomo-gamma-linolenic acid; eicosatrienoic acid levels (305.2485_0.386)
63155,Dihomo-gamma-linolenic acid; eicosatrienoic acid levels (305.2485_0.386) x waist circumference interaction (2df),Phenotype,Dihomo-gamma-linolenic acid; eicosatrienoic acid levels (305.2485_0.386) x waist circumference interaction (2df)
63172,Corpus callosum fractional anisotropy (body),Phenotype,Corpus callosum fractional anisotropy (body)
63176,Corpus callosum fractional anisotropy (MOSTest),Phenotype,Corpus callosum fractional anisotropy (MOSTest)
63180,Allergen component sensitization (Hevea brasiliensis 8),Phenotype,Allergen component sensitization (Hevea brasiliensis 8)
63204,Smoking initiation (MTAG),Phenotype,Smoking initiation (MTAG)
63209,Color vision defects (Tritan),Phenotype,Color vision defects (Tritan)
63221,Major depressive disorder or hospitalized COVID-19 (pleiotropy),Phenotype,Major depressive disorder or hospitalized COVID-19 (pleiotropy)
63222,Major depressive disorder or COVID-19 infection (pleiotropy),Phenotype,Major depressive disorder or COVID-19 infection (pleiotropy)
63226,Arthritis,Phenotype,Arthritis
63227,Cholesterol levels,Phenotype,Cholesterol levels
63233,Biliary atresia,Phenotype,Biliary atresia
63235,Metabolite levels (gamma-glutamyllysine; gamma-glutamyl-epsilon-lysine),Phenotype,Metabolite levels (gamma-glutamyllysine; gamma-glutamyl-epsilon-lysine)
63236,Metabolite levels (propyl 4-hydroxybenzoate sulfate),Phenotype,Metabolite levels (propyl 4-hydroxybenzoate sulfate)
63242,Metabolite levels (methyl-4-hydroxybenzoate sulfate),Phenotype,Metabolite levels (methyl-4-hydroxybenzoate sulfate)
63244,Metabolite levels (indoleacetoylcarnitine),Phenotype,Metabolite levels (indoleacetoylcarnitine)
63246,Metabolite levels (1-dihomo-linolenylglycerol (alpha-- gamma); 1-dihomo-linolenylglycerol (20:3)),Phenotype,Metabolite levels (1-dihomo-linolenylglycerol (alpha-- gamma); 1-dihomo-linolenylglycerol (20:3))
63247,Metabolite levels (N-acetylcarnosine),Phenotype,Metabolite levels (N-acetylcarnosine)
63249,Metabolite levels (butyrylcarnitine; butyrylcarnitine (C4); C4 carnitine; C4_carnitine),Phenotype,Metabolite levels (butyrylcarnitine; butyrylcarnitine (C4); C4 carnitine; C4_carnitine)
63250,Metabolite levels (cys-gly-- oxidized),Phenotype,Metabolite levels (cys-gly-- oxidized)
63253,Metabolite levels (linolenoylcarnitine (C18:3)),Phenotype,Metabolite levels (linolenoylcarnitine (C18:3))
63255,Metabolite levels (tyrosine),Phenotype,Metabolite levels (tyrosine)
63257,Metabolite levels (4-androsten-3beta--17beta-diol disulfate (2); androstenediol (3beta--17beta) disulfate (2)),Phenotype,Metabolite levels (4-androsten-3beta--17beta-diol disulfate (2); androstenediol (3beta--17beta) disulfate (2))
63278,Monocyte side fluorescence,Phenotype,Monocyte side fluorescence
63279,Basophil forward scatter distribution width,Phenotype,Basophil forward scatter distribution width
63280,Monocyte side scatter,Phenotype,Monocyte side scatter
63287,Pain (pleiotropy),Phenotype,Pain (pleiotropy)
63360,Metabolite levels (isobutyrylcarnitine; isobutyrylcarnitine (C4)),Phenotype,Metabolite levels (isobutyrylcarnitine; isobutyrylcarnitine (C4))
63361,Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Phenotype,Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine)
63362,Metabolite levels (1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6); C38:6 PC; C38_6_PC),Phenotype,Metabolite levels (1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6); C38:6 PC; C38_6_PC)
63363,Metabolite levels (ornithine),Phenotype,Metabolite levels (ornithine)
63364,Metabolite levels (arachidonoylcarnitine (C20:4)),Phenotype,Metabolite levels (arachidonoylcarnitine (C20:4))
63365,Metabolite levels (azelaoyltaurine),Phenotype,Metabolite levels (azelaoyltaurine)
63368,Metabolite levels (phenylacetate),Phenotype,Metabolite levels (phenylacetate)
63370,Metabolite levels (dihomo-linolenoylcarnitine (C20:3n3 or 6)),Phenotype,Metabolite levels (dihomo-linolenoylcarnitine (C20:3n3 or 6))
63371,Metabolite levels (dihomo-linoleoylcarnitine (C20:2)),Phenotype,Metabolite levels (dihomo-linoleoylcarnitine (C20:2))
63372,Metabolite levels (lysine),Phenotype,Metabolite levels (lysine)
63373,Metabolite levels (serotonin (5HT); serotonin),Phenotype,Metabolite levels (serotonin (5HT); serotonin)
63374,Metabolite levels (succinylcarnitine; succinylcarnitine (C4-DC)),Phenotype,Metabolite levels (succinylcarnitine; succinylcarnitine (C4-DC))
63375,Metabolite levels (cysteinylglycine disulfide),Phenotype,Metabolite levels (cysteinylglycine disulfide)
63377,Metabolite levels (guanosine),Phenotype,Metabolite levels (guanosine)
63380,Metabolite levels (o-cresol sulfate),Phenotype,Metabolite levels (o-cresol sulfate)
63381,Metabolite levels (oleoylcarnitine; oleoylcarnitine (C18:1); C18:1 carnitine; C18_1_carnitine),Phenotype,Metabolite levels (oleoylcarnitine; oleoylcarnitine (C18:1); C18:1 carnitine; C18_1_carnitine)
63382,Metabolite levels (21-hydroxypregnenolone disulfate),Phenotype,Metabolite levels (21-hydroxypregnenolone disulfate)
63383,Metabolite levels (indolepropionate; indole-3-propionate; cmh_indole_pro; Indole_3_propanoate),Phenotype,Metabolite levels (indolepropionate; indole-3-propionate; cmh_indole_pro; Indole_3_propanoate)
63384,Metabolite levels (inosine; cmh_inosine; Inosine),Phenotype,Metabolite levels (inosine; cmh_inosine; Inosine)
63387,Metabolite levels (phenyllactate (PLA); phenyllactate),Phenotype,Metabolite levels (phenyllactate (PLA); phenyllactate)
63389,Metabolite levels (3-phenylpropionate (hydrocinnamate); hydrocinnamate),Phenotype,Metabolite levels (3-phenylpropionate (hydrocinnamate); hydrocinnamate)
63390,Metabolite levels (propionylcarnitine; propionylcarnitine (C3); C3 carnitine; C3_carnitine),Phenotype,Metabolite levels (propionylcarnitine; propionylcarnitine (C3); C3 carnitine; C3_carnitine)
63391,ICD10 L50: Urticaria,Phenotype,ICD10 L50: Urticaria
63398,Common variable immunodeficiency,Phenotype,Common variable immunodeficiency
63413,Anterior uveitis,Phenotype,Anterior uveitis
63415,Crohn's disease x sex interaction (2df),Phenotype,Crohn's disease x sex interaction (2df)
63421,Erythema nodosum in Behcet's disease,Phenotype,Erythema nodosum in Behcet's disease
63422,Neurological involvement in Behcet's disease,Phenotype,Neurological involvement in Behcet's disease
63424,Absolute neutrophil count,Phenotype,Absolute neutrophil count
63452,Antipsychotic-induced triglycerides change in schizophrenia (6-week),Phenotype,Antipsychotic-induced triglycerides change in schizophrenia (6-week)
63454,Triglycerides level in antipsychotic-treated schizophrenia (6-week),Phenotype,Triglycerides level in antipsychotic-treated schizophrenia (6-week)
63464,Genetic generalized epilepsy,Phenotype,Genetic generalized epilepsy
63466,Red blood cell haemoglobin equivalent,Phenotype,Red blood cell haemoglobin equivalent
63468,Red cell distribution width - standard deviation,Phenotype,Red cell distribution width - standard deviation
63484,Reticulocyte haemoglobin equivalent,Phenotype,Reticulocyte haemoglobin equivalent
63486,Reticulocyte production index,Phenotype,Reticulocyte production index
63488,Low fluorescent percentage of reticulocytes,Phenotype,Low fluorescent percentage of reticulocytes
63489,Immature granulocyte percentage of white cells,Phenotype,Immature granulocyte percentage of white cells
63491,Neutrophil forward scatter distribution width,Phenotype,Neutrophil forward scatter distribution width
63493,Immature granulocyte count,Phenotype,Immature granulocyte count
63494,Neutrophil side scatter distribution width,Phenotype,Neutrophil side scatter distribution width
63495,Neutrophil forward scatter,Phenotype,Neutrophil forward scatter
63498,Neutrophil side fluorescence,Phenotype,Neutrophil side fluorescence
63501,Corpus callosum volume (MOSTest),Phenotype,Corpus callosum volume (MOSTest)
63509,Response to high-intensity interval training in physically inactive (maximal oxygen uptake),Phenotype,Response to high-intensity interval training in physically inactive (maximal oxygen uptake)
63514,Metabolite levels (1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)),Phenotype,Metabolite levels (1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0))
63515,Metabolite levels (gamma-glutamyl-alpha-lysine),Phenotype,Metabolite levels (gamma-glutamyl-alpha-lysine)
63517,Metabolite levels (pterin),Phenotype,Metabolite levels (pterin)
63520,Metabolite levels (N-acetylglucosamine/N-acetylgalactosamine),Phenotype,Metabolite levels (N-acetylglucosamine/N-acetylgalactosamine)
63521,Metabolite levels (N-acetylglucosaminylasparagine),Phenotype,Metabolite levels (N-acetylglucosaminylasparagine)
63525,Metabolite levels (12-HETE),Phenotype,Metabolite levels (12-HETE)
63526,Metabolite levels (hexanoylglutamine),Phenotype,Metabolite levels (hexanoylglutamine)
63527,Metabolite levels (3-hydroxyhexanoate),Phenotype,Metabolite levels (3-hydroxyhexanoate)
63529,Metabolite levels (beta-hydroxyisovalerate),Phenotype,Metabolite levels (beta-hydroxyisovalerate)
63531,Metabolite levels (carnitine),Phenotype,Metabolite levels (carnitine)
63532,Metabolite levels (arginine),Phenotype,Metabolite levels (arginine)
63533,Metabolite levels (picolinate),Phenotype,Metabolite levels (picolinate)
63536,Metabolite levels (pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC)),Phenotype,Metabolite levels (pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC))
63537,Metabolite levels (S-1-pyrroline-5-carboxylate),Phenotype,Metabolite levels (S-1-pyrroline-5-carboxylate)
63539,Liver thiopurine methyltransferase levels,Phenotype,Liver thiopurine methyltransferase levels
63550,Iron deficiency anaemia,Phenotype,Iron deficiency anaemia
63555,End-diastolic bi-ventricular shape (principal component 5),Phenotype,End-diastolic bi-ventricular shape (principal component 5)
63556,End-diastolic bi-ventricular shape (principal component 9),Phenotype,End-diastolic bi-ventricular shape (principal component 9)
63558,End-diastolic bi-ventricular shape (principal component 1),Phenotype,End-diastolic bi-ventricular shape (principal component 1)
63560,End-diastolic bi-ventricular shape (principal component 3),Phenotype,End-diastolic bi-ventricular shape (principal component 3)
63561,End-diastolic bi-ventricular shape (principal component 4),Phenotype,End-diastolic bi-ventricular shape (principal component 4)
63564,Alcohol use frequency in adolescence,Phenotype,Alcohol use frequency in adolescence
63571,Platelet forward scatter distribution width,Phenotype,Platelet forward scatter distribution width
63572,High fluorescence immature platelet fraction,Phenotype,High fluorescence immature platelet fraction
63573,Platelet side fluorescence distribution width,Phenotype,Platelet side fluorescence distribution width
63576,Platelet side scatter distribution width,Phenotype,Platelet side scatter distribution width
63579,Reticulocyte forward scatter,Phenotype,Reticulocyte forward scatter
63581,Reticulocyte side fluorescence,Phenotype,Reticulocyte side fluorescence
63585,Medium fluorescent percentage of reticulocytes,Phenotype,Medium fluorescent percentage of reticulocytes
63586,High fluorescent percentage of reticulocytes,Phenotype,High fluorescent percentage of reticulocytes
63588,Neutrophil side scatter,Phenotype,Neutrophil side scatter
63589,Immature reticulocyte forward scatter,Phenotype,Immature reticulocyte forward scatter
63613,Reactive lymphocyte percentage of white cells,Phenotype,Reactive lymphocyte percentage of white cells
63615,Lymphocyte side scatter distribution width,Phenotype,Lymphocyte side scatter distribution width
63617,Lymphocyte side fluorescence distribution width,Phenotype,Lymphocyte side fluorescence distribution width
63619,Reactive lymphocyte count,Phenotype,Reactive lymphocyte count
63621,Reactive percentage of lymphocytes,Phenotype,Reactive percentage of lymphocytes
63623,Monocyte side fluorescence distribution width,Phenotype,Monocyte side fluorescence distribution width
63624,Lymphocyte side scatter,Phenotype,Lymphocyte side scatter
63627,Lymphocyte forward scatter,Phenotype,Lymphocyte forward scatter
63631,Lymphocyte side fluorescence,Phenotype,Lymphocyte side fluorescence
63639,Cannabis use disorder (MTAG),Phenotype,Cannabis use disorder (MTAG)
63688,Alcohol use disorder (MTAG),Phenotype,Alcohol use disorder (MTAG)
63691,Allergen component sensitization (Mercurialis annua 1),Phenotype,Allergen component sensitization (Mercurialis annua 1)
63692,Allergen component sensitization (Phleum pratense 1),Phenotype,Allergen component sensitization (Phleum pratense 1)
63702,Breast cancer or critical COVID-19 (pleiotropy),Phenotype,Breast cancer or critical COVID-19 (pleiotropy)
63704,Metabolite levels (xanthosine; Xanthosine),Phenotype,Metabolite levels (xanthosine; Xanthosine)
63705,Metabolite levels (carotene diol (1)),Phenotype,Metabolite levels (carotene diol (1))
63707,Metabolite levels (carotene diol (2)),Phenotype,Metabolite levels (carotene diol (2))
63708,Metabolite levels (cysteinylglycine),Phenotype,Metabolite levels (cysteinylglycine)
63709,Metabolite levels (imidazole lactate; imidazolelactate),Phenotype,Metabolite levels (imidazole lactate; imidazolelactate)
63711,Metabolite levels (prolylglycine; pro-gly),Phenotype,Metabolite levels (prolylglycine; pro-gly)
63713,Metabolite levels (S-adenosylhomocysteine (SAH); ___adenosylhomocysteine; S_Ado_homocysteine),Phenotype,Metabolite levels (S-adenosylhomocysteine (SAH); ___adenosylhomocysteine; S_Ado_homocysteine)
63715,Metabolite levels (indoleacetylglutamine),Phenotype,Metabolite levels (indoleacetylglutamine)
63716,Metabolite levels (indolebutyrate),Phenotype,Metabolite levels (indolebutyrate)
63718,Metabolite levels (linoleoylcarnitine; linoleoylcarnitine (C18:2); C18:2 carnitine; C18_2_carnitine),Phenotype,Metabolite levels (linoleoylcarnitine; linoleoylcarnitine (C18:2); C18:2 carnitine; C18_2_carnitine)
63719,Metabolite levels (3-methylglutarylcarnitine (2)),Phenotype,Metabolite levels (3-methylglutarylcarnitine (2))
63720,Metabolite levels (N-6-trimethyllysine; N6--N6--N6-trimethyllysine; N6.N6.N6-trimethyllysine),Phenotype,Metabolite levels (N-6-trimethyllysine; N6--N6--N6-trimethyllysine; N6.N6.N6-trimethyllysine)
63721,Metabolite levels (N-acetyltryptophan),Phenotype,Metabolite levels (N-acetyltryptophan)
63723,Metabolite levels (N-palmitoyltaurine),Phenotype,Metabolite levels (N-palmitoyltaurine)
63727,Basophil side fluorescence,Phenotype,Basophil side fluorescence
63731,Basophil side fluorescence distribution width,Phenotype,Basophil side fluorescence distribution width
63732,Eosinophil forward scatter distribution width,Phenotype,Eosinophil forward scatter distribution width
63735,Eosinophil side scatter,Phenotype,Eosinophil side scatter
63736,Eosinophil side fluorescence,Phenotype,Eosinophil side fluorescence
63737,Eosinophil forward scatter,Phenotype,Eosinophil forward scatter
63739,Eosinophil side scatter distribution width,Phenotype,Eosinophil side scatter distribution width
63743,Corpus callosum fractional anisotropy (splenium),Phenotype,Corpus callosum fractional anisotropy (splenium)
63745,Corpus callosum posterior volume,Phenotype,Corpus callosum posterior volume
63747,Corpus callosum volume,Phenotype,Corpus callosum volume
63753,Metabolite levels (glycine),Phenotype,Metabolite levels (glycine)
63755,Metabolite levels (dihomo-linolenate (20:3n3 or n6); eicosatrienoate),Phenotype,Metabolite levels (dihomo-linolenate (20:3n3 or n6); eicosatrienoate)
63756,Metabolite levels (glutarylcarnitine (C5); glutarylcarnitine (C5-DC); C5-DC carnitine; C5_DC_carnitine),Phenotype,Metabolite levels (glutarylcarnitine (C5); glutarylcarnitine (C5-DC); C5-DC carnitine; C5_DC_carnitine)
63757,Metabolite levels (docosapentaenoate (n3 DPA; 22:5n3)),Phenotype,Metabolite levels (docosapentaenoate (n3 DPA; 22:5n3))
63758,IL-6 response to bacterial stimulus (Fla),Phenotype,IL-6 response to bacterial stimulus (Fla)
63760,IL-6 response to bacterial stimulus (LPA),Phenotype,IL-6 response to bacterial stimulus (LPA)
63919,Asthma in any disease,Phenotype,Asthma in any disease
63923,Asthma in gastrointestinal disease,Phenotype,Asthma in gastrointestinal disease
63924,Asthma in muscoskeletal disease,Phenotype,Asthma in muscoskeletal disease
63925,Asthma in cardiovascular disease,Phenotype,Asthma in cardiovascular disease
63929,Triamcinolone acetonide-induced ocular hypertension,Phenotype,Triamcinolone acetonide-induced ocular hypertension
63932,Dyslexia,Phenotype,Dyslexia
63945,Opioid addiction (multi-trait analysis),Phenotype,Opioid addiction (multi-trait analysis)
63948,General pain factor,Phenotype,General pain factor
63956,Type 2 diabetes or schizophrenia (pleiotropy),Phenotype,Type 2 diabetes or schizophrenia (pleiotropy)
63967,Hoarding symptoms,Phenotype,Hoarding symptoms
63970,Congenital solitary functioning kidney,Phenotype,Congenital solitary functioning kidney
63974,Serum neurofilament light levels,Phenotype,Serum neurofilament light levels
63980,Hippocampal subfield left CA3 volume (body),Phenotype,Hippocampal subfield left CA3 volume (body)
63982,Hippocampal subfield left CA1 volume (head),Phenotype,Hippocampal subfield left CA1 volume (head)
63984,Hippocampal subfield left CA4 volume (body),Phenotype,Hippocampal subfield left CA4 volume (body)
63986,Hippocampal left GC-ML-DG volume (body),Phenotype,Hippocampal left GC-ML-DG volume (body)
63988,Hippocampal subfield left CA4 volume (head),Phenotype,Hippocampal subfield left CA4 volume (head)
63992,Orbitofrontal area (unadjusted for global measures),Phenotype,Orbitofrontal area (unadjusted for global measures)
63994,Occipital area (unadjusted for global measures),Phenotype,Occipital area (unadjusted for global measures)
63998,Hippocampal subfield right CA1 volume (head),Phenotype,Hippocampal subfield right CA1 volume (head)
64000,Right molecular layer hippocampal volume (head),Phenotype,Right molecular layer hippocampal volume (head)
64002,Right presubiculum volume (body),Phenotype,Right presubiculum volume (body)
64004,Right presubiculum volume (head),Phenotype,Right presubiculum volume (head)
64007,Right subiculum volume (body),Phenotype,Right subiculum volume (body)
64009,Right subiculum volume (head),Phenotype,Right subiculum volume (head)
64019,Occipital thickness (unadjusted for global measures),Phenotype,Occipital thickness (unadjusted for global measures)
64022,Superior parietal thickness (unadjusted for global measures),Phenotype,Superior parietal thickness (unadjusted for global measures)
64024,Perisylvian thickness (unadjusted for global measures),Phenotype,Perisylvian thickness (unadjusted for global measures)
64025,Right hippocampal volume (body),Phenotype,Right hippocampal volume (body)
64058,Triacylglycerol (52:4) levels,Phenotype,Triacylglycerol (52:4) levels
64060,Triacylglycerol (58:8) levels,Phenotype,Triacylglycerol (58:8) levels
64062,Inferior parietal area (unadjusted for global measures),Phenotype,Inferior parietal area (unadjusted for global measures)
64067,Motor premotor area (unadjusted for global measures),Phenotype,Motor premotor area (unadjusted for global measures)
64072,Dorsomedial frontal area (unadjusted for global measures),Phenotype,Dorsomedial frontal area (unadjusted for global measures)
64073,Hippocampal subfield right CA4 volume (head),Phenotype,Hippocampal subfield right CA4 volume (head)
64075,Hippocampal right GC-ML-DG volume (body),Phenotype,Hippocampal right GC-ML-DG volume (body)
64077,Hippocampal right GC-ML-DG volume (head),Phenotype,Hippocampal right GC-ML-DG volume (head)
64079,Hippocampal subfield right CA4 volume (body),Phenotype,Hippocampal subfield right CA4 volume (body)
64082,Right hippocampal volume (fissure),Phenotype,Right hippocampal volume (fissure)
64083,Right hippocampal volume (head),Phenotype,Right hippocampal volume (head)
64085,Inferior parietal thickness (unadjusted for global measures),Phenotype,Inferior parietal thickness (unadjusted for global measures)
64089,Post-traumatic stress disorder in combat exposure,Phenotype,Post-traumatic stress disorder in combat exposure
64091,Post-traumatic stress disorder symptom severity (total),Phenotype,Post-traumatic stress disorder symptom severity (total)
64101,O-methylcatechol sulfate levels,Phenotype,O-methylcatechol sulfate levels
64102,Palmitoyl dihydrosphingomyelin (d18:0/16:0) levels,Phenotype,Palmitoyl dihydrosphingomyelin (d18:0/16:0) levels
64103,Palmitoyl sphingomyelin (d18:1/16:0) levels,Phenotype,Palmitoyl sphingomyelin (d18:1/16:0) levels
64104,2-oleoylglycerol (18:1) levels,Phenotype,2-oleoylglycerol (18:1) levels
64106,3-(3-hydroxyphenyl)propionate sulfate levels,Phenotype,3-(3-hydroxyphenyl)propionate sulfate levels
64107,3-(4-hydroxyphenyl)lactate levels,Phenotype,3-(4-hydroxyphenyl)lactate levels
64111,3--7-dimethylurate levels,Phenotype,3--7-dimethylurate levels
64112,3-hydroxyoctanoate levels,Phenotype,3-hydroxyoctanoate levels
64114,3-indoxyl sulfate levels,Phenotype,3-indoxyl sulfate levels
64116,3-methyl catechol sulfate (1) levels,Phenotype,3-methyl catechol sulfate (1) levels
64117,X-23297 levels,Phenotype,X-23297 levels
64119,Orotidine levels,Phenotype,Orotidine levels
64121,Oxalate (ethanedioate) levels,Phenotype,Oxalate (ethanedioate) levels
64132,Phosphatidylcholine (16:0/22:5n3-- 18:1/20:4) levels,Phenotype,Phosphatidylcholine (16:0/22:5n3-- 18:1/20:4) levels
64133,1-methylnicotinamide levels,Phenotype,1-methylnicotinamide levels
64134,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Phenotype,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels
64135,Pregnenolone sulfate levels,Phenotype,Pregnenolone sulfate levels
64136,Proline levels,Phenotype,Proline levels
64138,Pipecolate levels,Phenotype,Pipecolate levels
64140,Pregn steroid monosulfate levels,Phenotype,Pregn steroid monosulfate levels
64142,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Phenotype,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels
64143,Pregnanediol-3-glucuronide levels,Phenotype,Pregnanediol-3-glucuronide levels
64145,Pregnen-diol disulfate levels,Phenotype,Pregnen-diol disulfate levels
64146,Pyridoxate levels,Phenotype,Pyridoxate levels
64148,Quinate levels,Phenotype,Quinate levels
64151,X-11564 levels,Phenotype,X-11564 levels
64152,X-11593 levels,Phenotype,X-11593 levels
64154,X-12681 levels,Phenotype,X-12681 levels
64156,X-12688 levels,Phenotype,X-12688 levels
64158,X-12714 levels,Phenotype,X-12714 levels
64160,X-12715 levels,Phenotype,X-12715 levels
64162,X-12170 levels,Phenotype,X-12170 levels
64164,X-12206 levels,Phenotype,X-12206 levels
64168,X-12221 levels,Phenotype,X-12221 levels
64169,X-12231 levels,Phenotype,X-12231 levels
64170,X-12339 levels,Phenotype,X-12339 levels
64172,X-12462 levels,Phenotype,X-12462 levels
64173,X-12511 levels,Phenotype,X-12511 levels
64176,X-12007 levels,Phenotype,X-12007 levels
64178,X-12117 levels,Phenotype,X-12117 levels
64179,X-12824 levels,Phenotype,X-12824 levels
64180,X-11452 levels,Phenotype,X-11452 levels
64182,Alcohol dependence (allelic genetic model),Phenotype,Alcohol dependence (allelic genetic model)
64184,Spielberger Trait Anxiety Inventory in alcohol dependence (allelic genetic model),Phenotype,Spielberger Trait Anxiety Inventory in alcohol dependence (allelic genetic model)
64185,Otosclerosis,Phenotype,Otosclerosis
64199,X-23369 levels,Phenotype,X-23369 levels
64201,X-23593 levels,Phenotype,X-23593 levels
64203,X-23997 levels,Phenotype,X-23997 levels
64205,X-24240 levels,Phenotype,X-24240 levels
64206,X-24452 levels,Phenotype,X-24452 levels
64207,X-24542 levels,Phenotype,X-24542 levels
64211,X-24544 levels,Phenotype,X-24544 levels
64213,X-24449 levels,Phenotype,X-24449 levels
64214,Refractive error (autorefraction measured),Phenotype,Refractive error (autorefraction measured)
64216,1-dihomo-linoleoyl-GPC (20:2) levels,Phenotype,1-dihomo-linoleoyl-GPC (20:2) levels
64217,1-linoleoyl-GPE (18:2) levels,Phenotype,1-linoleoyl-GPE (18:2) levels
64218,1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,Phenotype,1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels
64220,1-methylimidazoleacetate levels,Phenotype,1-methylimidazoleacetate levels
64222,1-linolenoyl-GPC (18:3) levels,Phenotype,1-linolenoyl-GPC (18:3) levels
64224,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Phenotype,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels
64226,1-linoleoyl-gpc (18:2) levels,Phenotype,1-linoleoyl-gpc (18:2) levels
64227,1-arachidonoyl-GPA (20:4) levels,Phenotype,1-arachidonoyl-GPA (20:4) levels
64229,1-arachidonoyl-gpc (20:4n6) levels,Phenotype,1-arachidonoyl-gpc (20:4n6) levels
64230,1-docosapentaenoyl-GPC (22:5n3) levels,Phenotype,1-docosapentaenoyl-GPC (22:5n3) levels
64231,1-docosapentaenoyl-GPC (22:5n6) levels,Phenotype,1-docosapentaenoyl-GPC (22:5n6) levels
64233,1-eicosapentaenoyl-GPC (20:5) levels,Phenotype,1-eicosapentaenoyl-GPC (20:5) levels
64235,1-eicosapentaenoyl-GPE (20:5) levels,Phenotype,1-eicosapentaenoyl-GPE (20:5) levels
64237,1--5-anhydroglucitol (1--5-ag) levels,Phenotype,1--5-anhydroglucitol (1--5-ag) levels
64242,X-16071 levels,Phenotype,X-16071 levels
64244,X-16570 levels,Phenotype,X-16570 levels
64246,X-16649 levels,Phenotype,X-16649 levels
64249,X-14056 levels,Phenotype,X-14056 levels
64251,X-16944 levels,Phenotype,X-16944 levels
64252,X-17337 levels,Phenotype,X-17337 levels
64254,X-12846 levels,Phenotype,X-12846 levels
64256,X-13431 levels,Phenotype,X-13431 levels
64257,X-14939 levels,Phenotype,X-14939 levels
64258,X-15503 levels,Phenotype,X-15503 levels
64261,X-17677 levels,Phenotype,X-17677 levels
64262,X-18922 levels,Phenotype,X-18922 levels
64265,X-21258 levels,Phenotype,X-21258 levels
64266,X-21286 levels,Phenotype,X-21286 levels
64267,X-21312 levels,Phenotype,X-21312 levels
64268,X-21339 levels,Phenotype,X-21339 levels
64269,X-21343 levels,Phenotype,X-21343 levels
64274,X-21365 levels,Phenotype,X-21365 levels
64277,X-21467 levels,Phenotype,X-21467 levels
64279,X-21411 levels,Phenotype,X-21411 levels
64281,X-21441 levels,Phenotype,X-21441 levels
64283,Basal cell carcinoma (MTAG),Phenotype,Basal cell carcinoma (MTAG)
64287,Squamous cell carcinoma (MTAG),Phenotype,Squamous cell carcinoma (MTAG)
64289,Hiatus hernia,Phenotype,Hiatus hernia
64291,Hernia (two or more subtypes),Phenotype,Hernia (two or more subtypes)
64292,Back pain,Phenotype,Back pain
64294,Hernia (any subtypes),Phenotype,Hernia (any subtypes)
64295,Hernia,Phenotype,Hernia
64313,Dietary Approaches to Stop Hypertension (DASH) diet,Phenotype,Dietary Approaches to Stop Hypertension (DASH) diet
64327,Anteromedial temporal area (unadjusted for global measures),Phenotype,Anteromedial temporal area (unadjusted for global measures)
64328,Dorsolateral prefrontal area (unadjusted for global measures),Phenotype,Dorsolateral prefrontal area (unadjusted for global measures)
64330,Hippocampal left GC-ML-DG volume (head),Phenotype,Hippocampal left GC-ML-DG volume (head)
64332,Left hippocampal volume (body),Phenotype,Left hippocampal volume (body)
64333,Left hippocampal volume (tail),Phenotype,Left hippocampal volume (tail)
64336,Left hippocampal volume (head),Phenotype,Left hippocampal volume (head)
64339,Posterolateral temporal area (unadjusted for global measures),Phenotype,Posterolateral temporal area (unadjusted for global measures)
64342,Parsopercularis area (unadjusted for global measures),Phenotype,Parsopercularis area (unadjusted for global measures)
64343,Superior temporal area (unadjusted for global measures),Phenotype,Superior temporal area (unadjusted for global measures)
64346,Superior parietal area (unadjusted for global measures),Phenotype,Superior parietal area (unadjusted for global measures)
64347,Dorsolateral prefrontal thickness (unadjusted for global measures),Phenotype,Dorsolateral prefrontal thickness (unadjusted for global measures)
64349,Primary aldosteronism,Phenotype,Primary aldosteronism
64351,Ventromedial occipital thickness (unadjusted for global measures),Phenotype,Ventromedial occipital thickness (unadjusted for global measures)
64352,Temporal pole thickness (unadjusted for global measures),Phenotype,Temporal pole thickness (unadjusted for global measures)
64355,Ventral frontal thickness (unadjusted for global measures),Phenotype,Ventral frontal thickness (unadjusted for global measures)
64357,Vasculitis (pleiotropy),Phenotype,Vasculitis (pleiotropy)
64362,Phosphatidylinositol (16:0_18:1) levels,Phenotype,Phosphatidylinositol (16:0_18:1) levels
64397,Developmental dysplasia of the hip,Phenotype,Developmental dysplasia of the hip
64399,Left subiculum volume (body),Phenotype,Left subiculum volume (body)
64400,Left subiculum volume (head),Phenotype,Left subiculum volume (head)
64401,Precuneus area (unadjusted for global measures),Phenotype,Precuneus area (unadjusted for global measures)
64404,Left molecular layer hippocampal volume (head),Phenotype,Left molecular layer hippocampal volume (head)
64405,Left parasubiculum volume,Phenotype,Left parasubiculum volume
64408,Left presubiculum volume (body),Phenotype,Left presubiculum volume (body)
64410,Left presubiculum volume (head),Phenotype,Left presubiculum volume (head)
64414,Right hippocampal volume,Phenotype,Right hippocampal volume
64415,Right hippocampal volume (tail),Phenotype,Right hippocampal volume (tail)
64416,Medial prefrontal thickness (unadjusted for global measures),Phenotype,Medial prefrontal thickness (unadjusted for global measures)
64419,Middle temporal thickness (unadjusted for global measures),Phenotype,Middle temporal thickness (unadjusted for global measures)
64420,Motor premotor thickness (unadjusted for global measures),Phenotype,Motor premotor thickness (unadjusted for global measures)
64422,Right molecular layer hippocampal volume (body),Phenotype,Right molecular layer hippocampal volume (body)
64424,Cognitive performance (memory) (longitudinal),Phenotype,Cognitive performance (memory) (longitudinal)
64427,Cognitive performance (language) (longitudinal),Phenotype,Cognitive performance (language) (longitudinal)
64433,Cognitive performance (visuospatial function) (longitudinal),Phenotype,Cognitive performance (visuospatial function) (longitudinal)
64435,Post-traumatic stress disorder symptom severity (avoidance),Phenotype,Post-traumatic stress disorder symptom severity (avoidance)
64441,Genetically independent pain phenotypes (GIP2),Phenotype,Genetically independent pain phenotypes (GIP2)
64452,Tuberculosis x mycobacterium tuberculosis lineage interaction,Phenotype,Tuberculosis x mycobacterium tuberculosis lineage interaction
64454,Tuberculosis (main host cluster) x mycobacterium tuberculosis lineage interaction,Phenotype,Tuberculosis (main host cluster) x mycobacterium tuberculosis lineage interaction
64455,Diffuse idiopathic skeletal hyperostosis flow score,Phenotype,Diffuse idiopathic skeletal hyperostosis flow score
64462,Endometriosis (stage 3 or 4),Phenotype,Endometriosis (stage 3 or 4)
64463,Endometriosis (MTAG),Phenotype,Endometriosis (MTAG)
64485,Preterm delivery,Phenotype,Preterm delivery
64487,Nonalcoholic fatty liver disease in lean individuals (BMI <25),Phenotype,Nonalcoholic fatty liver disease in lean individuals (BMI <25)
64492,Docosanoid osbond acid-- all-cis-4--7--10--13--16-DPA-- FFA Docosapentaenoic Acid levels,Phenotype,Docosanoid osbond acid-- all-cis-4--7--10--13--16-DPA-- FFA Docosapentaenoic Acid levels
64493,Docosanoid 14S-HDHA-- Docosanoid 17R-HDHA levels,Phenotype,Docosanoid 14S-HDHA-- Docosanoid 17R-HDHA levels
64495,Eicosanoid 13-HpODE-- Eicosanoid 9-HpODE b levels,Phenotype,Eicosanoid 13-HpODE-- Eicosanoid 9-HpODE b levels
64497,FFA Adrenic Acid a levels,Phenotype,FFA Adrenic Acid a levels
64499,FFA Docosahexaenoic Acid levels,Phenotype,FFA Docosahexaenoic Acid levels
64500,FFA Eicosapentaenoic Acid c levels,Phenotype,FFA Eicosapentaenoic Acid c levels
64502,Sarcopenia in chronic obstructive pulmonary disease (fat-free mass index defined),Phenotype,Sarcopenia in chronic obstructive pulmonary disease (fat-free mass index defined)
64503,Fat-free mass index in chronic obstructive pulmonary disease,Phenotype,Fat-free mass index in chronic obstructive pulmonary disease
64504,Appendicular skeletal muscle index in chronic obstructive pulmonary disease,Phenotype,Appendicular skeletal muscle index in chronic obstructive pulmonary disease
64505,Hand grip strength in chronic obstructive pulmonary disease,Phenotype,Hand grip strength in chronic obstructive pulmonary disease
64507,Basal metabolic rate in chronic obstructive pulmonary disease,Phenotype,Basal metabolic rate in chronic obstructive pulmonary disease
64530,Body mass index or knee osteoarthritis (pleiotropy),Phenotype,Body mass index or knee osteoarthritis (pleiotropy)
64534,Body mass index or osteoarthritis (pleiotropy),Phenotype,Body mass index or osteoarthritis (pleiotropy)
64539,Body mass index or hip osteoarthritis (pleiotropy),Phenotype,Body mass index or hip osteoarthritis (pleiotropy)
64545,Lung disease severity in cystic fibrosis with pancreatic insufficiency,Phenotype,Lung disease severity in cystic fibrosis with pancreatic insufficiency
64554,Problematic tobacco use,Phenotype,Problematic tobacco use
64557,Substance use disorder (pleiotropy),Phenotype,Substance use disorder (pleiotropy)
64559,Addiction risk factors,Phenotype,Addiction risk factors
64601,Erosive hand osteoarthritis,Phenotype,Erosive hand osteoarthritis
64603,Cerebrospinal fluid amyloid beta 42 levels (12 month visit),Phenotype,Cerebrospinal fluid amyloid beta 42 levels (12 month visit)
64605,Amyloid (PET imaging) (24 month visit),Phenotype,Amyloid (PET imaging) (24 month visit)
64606,Cerebrospinal fluid p-tau levels (24 month visit),Phenotype,Cerebrospinal fluid p-tau levels (24 month visit)
64608,Functional activities questionnaire (baseline),Phenotype,Functional activities questionnaire (baseline)
64760,Butyrophilin-like protein 9 levels,Phenotype,Butyrophilin-like protein 9 levels
64762,S-methylmethionine--homocysteine S-methyltransferase BHMT2 levels,Phenotype,S-methylmethionine--homocysteine S-methyltransferase BHMT2 levels
64763,Baculoviral IAP repeat-containing protein 5 levels,Phenotype,Baculoviral IAP repeat-containing protein 5 levels
64764,Bone morphogenetic protein 3 levels,Phenotype,Bone morphogenetic protein 3 levels
64765,Bone morphogenetic protein 7 levels,Phenotype,Bone morphogenetic protein 7 levels
64766,RBC levels of D-Rhamnose,Phenotype,RBC levels of D-Rhamnose
64769,RBC levels of L-Carnitine.1,Phenotype,RBC levels of L-Carnitine.1
64770,RBC levels of LPC18:2,Phenotype,RBC levels of LPC18:2
64772,RBC levels of Fumarate,Phenotype,RBC levels of Fumarate
64774,RBC levels of L-Carnitine,Phenotype,RBC levels of L-Carnitine
64775,RBC levels of Diphosphate,Phenotype,RBC levels of Diphosphate
64777,RBC levels of Dopamine,Phenotype,RBC levels of Dopamine
64781,RBC levels of Pyruvate (uM),Phenotype,RBC levels of Pyruvate (uM)
64787,DNA-directed RNA polymerases I and III subunit RPAC1 levels,Phenotype,DNA-directed RNA polymerases I and III subunit RPAC1 levels
64788,DNA-directed RNA polymerase III subunit RPC9 levels,Phenotype,DNA-directed RNA polymerase III subunit RPC9 levels
64789,Rap guanine nucleotide exchange factor 5 levels,Phenotype,Rap guanine nucleotide exchange factor 5 levels
64794,Spatial QRS-T angle,Phenotype,Spatial QRS-T angle
64798,Kallikrein-6 levels,Phenotype,Kallikrein-6 levels
64800,Junctophilin-4 levels,Phenotype,Junctophilin-4 levels
64802,Killer cell immunoglobulin-like receptor 2DL1 levels,Phenotype,Killer cell immunoglobulin-like receptor 2DL1 levels
64803,Killer cell immunoglobulin-like receptor 2DL2 levels,Phenotype,Killer cell immunoglobulin-like receptor 2DL2 levels
64805,Integral membrane protein 2B levels,Phenotype,Integral membrane protein 2B levels
64806,Inactive tyrosine-protein kinase 7 levels,Phenotype,Inactive tyrosine-protein kinase 7 levels
64808,Adenylate kinase 4-- mitochondrial levels,Phenotype,Adenylate kinase 4-- mitochondrial levels
64809,Kallikrein-12 levels,Phenotype,Kallikrein-12 levels
64810,Frontal QRS-T angle,Phenotype,Frontal QRS-T angle
64817,Leucine-rich repeat-containing protein 74A levels,Phenotype,Leucine-rich repeat-containing protein 74A levels
64818,Leucine-rich repeat and fibronectin type III domain-containing protein 1 levels,Phenotype,Leucine-rich repeat and fibronectin type III domain-containing protein 1 levels
64819,Leucine-rich repeat-containing protein 25 levels,Phenotype,Leucine-rich repeat-containing protein 25 levels
64820,Leucine-rich repeat and transmembrane domain-containing protein 2 levels,Phenotype,Leucine-rich repeat and transmembrane domain-containing protein 2 levels
64821,Cadherin-11 levels,Phenotype,Cadherin-11 levels
64822,Cadherin-17 levels,Phenotype,Cadherin-17 levels
64837,Cytochrome c oxidase subunit 4 isoform 2-- mitochondrial levels,Phenotype,Cytochrome c oxidase subunit 4 isoform 2-- mitochondrial levels
64838,Collectin-10 levels,Phenotype,Collectin-10 levels
64843,Coagulation factor Xa levels,Phenotype,Coagulation factor Xa levels
64850,Glutathione S-transferase A1 levels,Phenotype,Glutathione S-transferase A1 levels
64851,Glutathione S-transferase A4 levels,Phenotype,Glutathione S-transferase A4 levels
64852,General transcription factor II-I levels,Phenotype,General transcription factor II-I levels
64854,Glycine N-methyltransferase levels,Phenotype,Glycine N-methyltransferase levels
64856,GMP reductase 2 levels,Phenotype,GMP reductase 2 levels
64859,BPI fold-containing family B member 1 levels,Phenotype,BPI fold-containing family B member 1 levels
64861,Growth factor receptor-bound protein 7 levels,Phenotype,Growth factor receptor-bound protein 7 levels
64862,Glutamate receptor 4 levels,Phenotype,Glutamate receptor 4 levels
64865,Granzyme B levels,Phenotype,Granzyme B levels
64867,Granzyme K levels,Phenotype,Granzyme K levels
64868,Scavenger receptor class A member 3 levels,Phenotype,Scavenger receptor class A member 3 levels
64869,Small conductance calcium-activated potassium channel protein 1 levels,Phenotype,Small conductance calcium-activated potassium channel protein 1 levels
64870,Secretogranin-1 levels,Phenotype,Secretogranin-1 levels
64872,DNA-binding protein SATB2 levels,Phenotype,DNA-binding protein SATB2 levels
64873,Soluble calcium-activated nucleotidase 1 levels,Phenotype,Soluble calcium-activated nucleotidase 1 levels
64874,Sperm acrosome membrane-associated protein 3 levels,Phenotype,Sperm acrosome membrane-associated protein 3 levels
64876,Interleukin-20 receptor subunit alpha levels,Phenotype,Interleukin-20 receptor subunit alpha levels
64877,Interleukin-20 receptor subunit beta levels,Phenotype,Interleukin-20 receptor subunit beta levels
64880,Interleukin-23 levels,Phenotype,Interleukin-23 levels
64881,Interleukin-36 receptor antagonist protein levels,Phenotype,Interleukin-36 receptor antagonist protein levels
64882,Interleukin-37 levels,Phenotype,Interleukin-37 levels
64883,Interleukin-5 receptor subunit alpha levels,Phenotype,Interleukin-5 receptor subunit alpha levels
64884,Vasomotor rhinitis or allergic rhinitis (MTAG),Phenotype,Vasomotor rhinitis or allergic rhinitis (MTAG)
64885,Chronic rhinosinusitis (MTAG),Phenotype,Chronic rhinosinusitis (MTAG)
64887,Nasal polyposis (MTAG),Phenotype,Nasal polyposis (MTAG)
64888,Nasal septal deviation (MTAG),Phenotype,Nasal septal deviation (MTAG)
64889,Chronic inflammatory sinonasal disease,Phenotype,Chronic inflammatory sinonasal disease
64891,ICD10 K04: Diseases of pulp and periapical tissues,Phenotype,ICD10 K04: Diseases of pulp and periapical tissues
64895,SWI/SNF complex subunit SMARCC1 levels,Phenotype,SWI/SNF complex subunit SMARCC1 levels
64904,CD9 antigen levels,Phenotype,CD9 antigen levels
64905,Cadherin-related family member 5 levels,Phenotype,Cadherin-related family member 5 levels
64906,Leukocyte antigen CD37 levels,Phenotype,Leukocyte antigen CD37 levels
64907,Cyclin-dependent kinase 4 inhibitor C levels,Phenotype,Cyclin-dependent kinase 4 inhibitor C levels
64912,C-C motif chemokine 28 levels,Phenotype,C-C motif chemokine 28 levels
64913,C-C motif chemokine 3-like 1 levels,Phenotype,C-C motif chemokine 3-like 1 levels
64914,CD166 antigen levels,Phenotype,CD166 antigen levels
64918,C-C motif chemokine 24 levels,Phenotype,C-C motif chemokine 24 levels
64919,Cervical dysplasia,Phenotype,Cervical dysplasia
64923,Potassium voltage-gated channel subfamily F member 1 levels,Phenotype,Potassium voltage-gated channel subfamily F member 1 levels
64924,Potassium voltage-gated channel subfamily G member 4 levels,Phenotype,Potassium voltage-gated channel subfamily G member 4 levels
64925,Ras-related protein Rab-35 levels,Phenotype,Ras-related protein Rab-35 levels
64926,Rab9 effector protein with kelch motifs levels,Phenotype,Rab9 effector protein with kelch motifs levels
64927,rRNA 2-O-methyltransferase fibrillarin levels,Phenotype,rRNA 2-O-methyltransferase fibrillarin levels
64928,Reticulon-4-interacting protein 1-- mitochondrial levels,Phenotype,Reticulon-4-interacting protein 1-- mitochondrial levels
64930,Protein PET117 homolog-- mitochondrial levels,Phenotype,Protein PET117 homolog-- mitochondrial levels
64932,Ras-related protein Rab-17 levels,Phenotype,Ras-related protein Rab-17 levels
64933,Ras-related protein Rab-26 levels,Phenotype,Ras-related protein Rab-26 levels
64935,Polycomb protein SCMH1 levels,Phenotype,Polycomb protein SCMH1 levels
64936,Sodium-coupled monocarboxylate transporter 1 levels,Phenotype,Sodium-coupled monocarboxylate transporter 1 levels
64937,Secreted and transmembrane protein 1 levels,Phenotype,Secreted and transmembrane protein 1 levels
64939,Stromal cell-derived factor 2 levels,Phenotype,Stromal cell-derived factor 2 levels
64940,Protein sel-1 homolog 2 levels,Phenotype,Protein sel-1 homolog 2 levels
64941,Advanced metachronous adenoma,Phenotype,Advanced metachronous adenoma
64946,Multiple metachronous adenoma,Phenotype,Multiple metachronous adenoma
64947,Sarcalumenin levels,Phenotype,Sarcalumenin levels
64949,ICD10 K05.30-31: Chronic periodontitis,Phenotype,ICD10 K05.30-31: Chronic periodontitis
64951,Spindlin-1 levels,Phenotype,Spindlin-1 levels
64952,Serine protease inhibitor Kazal-type 14 levels,Phenotype,Serine protease inhibitor Kazal-type 14 levels
64953,SPARC-like protein 1 levels,Phenotype,SPARC-like protein 1 levels
64954,Sodium/potassium-transporting ATPase subunit beta-1 levels,Phenotype,Sodium/potassium-transporting ATPase subunit beta-1 levels
64962,Spermatogenesis-associated protein 9 levels,Phenotype,Spermatogenesis-associated protein 9 levels
64964,Sorting nexin-7 levels,Phenotype,Sorting nexin-7 levels
64965,SAM pointed domain-containing Ets transcription factor levels,Phenotype,SAM pointed domain-containing Ets transcription factor levels
64967,Serine protease 57 levels,Phenotype,Serine protease 57 levels
64971,Low affinity immunoglobulin epsilon Fc receptor levels,Phenotype,Low affinity immunoglobulin epsilon Fc receptor levels
64973,Leukocyte-associated immunoglobulin-like receptor 1 levels,Phenotype,Leukocyte-associated immunoglobulin-like receptor 1 levels
64977,Layilin levels,Phenotype,Layilin levels
64978,Kv channel-interacting protein 1 levels,Phenotype,Kv channel-interacting protein 1 levels
64979,Left-right determination factor 2 levels,Phenotype,Left-right determination factor 2 levels
64981,Sulfotransferase 1A3 levels,Phenotype,Sulfotransferase 1A3 levels
64985,Sulfotransferase family cytosolic 2B member 1 levels,Phenotype,Sulfotransferase family cytosolic 2B member 1 levels
64986,Signal transducer and activator of transcription 5B levels,Phenotype,Signal transducer and activator of transcription 5B levels
64987,Stabilin-2 levels,Phenotype,Stabilin-2 levels
64997,Microtubule-associated proteins 1A/1B light chain 3B levels,Phenotype,Microtubule-associated proteins 1A/1B light chain 3B levels
64999,O-acetyl-ADP-ribose deacetylase MACROD1 levels,Phenotype,O-acetyl-ADP-ribose deacetylase MACROD1 levels
65000,Macrophage-stimulating protein receptor levels,Phenotype,Macrophage-stimulating protein receptor levels
65001,Endothelial differentiation-related factor 1 levels,Phenotype,Endothelial differentiation-related factor 1 levels
65002,Lymphokine-activated killer T-cell-originated protein kinase levels,Phenotype,Lymphokine-activated killer T-cell-originated protein kinase levels
65003,Isoform L-VEGF165 levels,Phenotype,Isoform L-VEGF165 levels
65004,Radiation-inducible immediate-early gene IEX-1 levels,Phenotype,Radiation-inducible immediate-early gene IEX-1 levels
65008,Heparan-sulfate 6-O-sulfotransferase 1 levels,Phenotype,Heparan-sulfate 6-O-sulfotransferase 1 levels
65009,Regulator of G-protein signaling 19 levels,Phenotype,Regulator of G-protein signaling 19 levels
65010,Regulator of G-protein signaling 8 levels,Phenotype,Regulator of G-protein signaling 8 levels
65011,Rhophilin-2 levels,Phenotype,Rhophilin-2 levels
65012,Hephaestin-like protein 1 levels,Phenotype,Hephaestin-like protein 1 levels
65013,Hexokinase-3 levels,Phenotype,Hexokinase-3 levels
65015,Sialate O-acetylesterase levels,Phenotype,Sialate O-acetylesterase levels
65017,SH3 and multiple ankyrin repeat domains protein 3 levels,Phenotype,SH3 and multiple ankyrin repeat domains protein 3 levels
65018,Methotrexate-induced liver injury in rheumatoid arthritis,Phenotype,Methotrexate-induced liver injury in rheumatoid arthritis
65020,C-C motif chemokine 1 levels,Phenotype,C-C motif chemokine 1 levels
65022,Chromobox protein homolog 5 levels,Phenotype,Chromobox protein homolog 5 levels
65023,Cytochrome b-c1 complex subunit 7 levels,Phenotype,Cytochrome b-c1 complex subunit 7 levels
65024,Cerebellin-1 levels,Phenotype,Cerebellin-1 levels
65029,Carboxypeptidase E levels,Phenotype,Carboxypeptidase E levels
65030,Carboxypeptidase M levels,Phenotype,Carboxypeptidase M levels
65031,17-beta-hydroxysteroid dehydrogenase 14 levels,Phenotype,17-beta-hydroxysteroid dehydrogenase 14 levels
65032,ATP-dependent RNA helicase DHX8 levels,Phenotype,ATP-dependent RNA helicase DHX8 levels
65033,Disks large homolog 3 levels,Phenotype,Disks large homolog 3 levels
65034,Delta-like protein 1 levels,Phenotype,Delta-like protein 1 levels
65036,Desmin levels,Phenotype,Desmin levels
65037,Desmoglein-1 levels,Phenotype,Desmoglein-1 levels
65038,Desmoglein-2 levels,Phenotype,Desmoglein-2 levels
65039,Differentially expressed in FDCP 6 homolog levels,Phenotype,Differentially expressed in FDCP 6 homolog levels
65041,Alzheimer disease (MTAG),Phenotype,Alzheimer disease (MTAG)
65050,Complement C3d fragment levels,Phenotype,Complement C3d fragment levels
65053,Complement component C8 levels,Phenotype,Complement component C8 levels
65054,Glutaredoxin-like protein C5orf63 levels,Phenotype,Glutaredoxin-like protein C5orf63 levels
65055,RBC levels of Sphingosine 1-phosphate,Phenotype,RBC levels of Sphingosine 1-phosphate
65058,RBC levels of Threonine,Phenotype,RBC levels of Threonine
65060,RBC levels of Urate (uM),Phenotype,RBC levels of Urate (uM)
65062,RBC levels of LPS20:4,Phenotype,RBC levels of LPS20:4
65063,RBC levels of S-Adenosyl-L-homocysteine,Phenotype,RBC levels of S-Adenosyl-L-homocysteine
65069,Relative index of whole blood hyposectomy,Phenotype,Relative index of whole blood hyposectomy
65077,Whole blood low cut reduction viscosity,Phenotype,Whole blood low cut reduction viscosity
65079,Plasma viscosity,Phenotype,Plasma viscosity
65081,Pharyngeal disease,Phenotype,Pharyngeal disease
65082,Sinonasal disease,Phenotype,Sinonasal disease
65084,3-ketodihydrosphingosine reductase levels,Phenotype,3-ketodihydrosphingosine reductase levels
65085,Keratin-- type II cytoskeletal 7 levels,Phenotype,Keratin-- type II cytoskeletal 7 levels
65091,Calcineurin subunit B type 2 levels,Phenotype,Calcineurin subunit B type 2 levels
65092,Calcium/calmodulin-dependent protein kinase type 1D levels,Phenotype,Calcium/calmodulin-dependent protein kinase type 1D levels
65093,Caspase-8 levels,Phenotype,Caspase-8 levels
65094,Catenin beta-1 levels,Phenotype,Catenin beta-1 levels
65099,Cullin-9 levels,Phenotype,Cullin-9 levels
65100,Cytochrome c oxidase subunit 7A1-- mitochondrial levels,Phenotype,Cytochrome c oxidase subunit 7A1-- mitochondrial levels
65102,C-X-C motif chemokine 10 levels,Phenotype,C-X-C motif chemokine 10 levels
65103,Cysteine and glycine-rich protein 2 levels,Phenotype,Cysteine and glycine-rich protein 2 levels
65105,D-dopachrome decarboxylase levels,Phenotype,D-dopachrome decarboxylase levels
65107,ATP-dependent RNA helicase DDX19A levels,Phenotype,ATP-dependent RNA helicase DDX19A levels
65108,ATP-dependent RNA helicase DDX19B levels,Phenotype,ATP-dependent RNA helicase DDX19B levels
65109,Probable ATP-dependent RNA helicase DDX46 levels,Phenotype,Probable ATP-dependent RNA helicase DDX46 levels
65110,C-X-C motif chemokine 17 levels,Phenotype,C-X-C motif chemokine 17 levels
65111,C-X-C motif chemokine 5 levels,Phenotype,C-X-C motif chemokine 5 levels
65112,Cystatin-8 levels,Phenotype,Cystatin-8 levels
65121,Cellular retinoic acid-binding protein 1 levels,Phenotype,Cellular retinoic acid-binding protein 1 levels
65122,DNA repair protein RAD51 homolog 1 levels,Phenotype,DNA repair protein RAD51 homolog 1 levels
65124,Ribosome biogenesis protein TSR3 homolog levels,Phenotype,Ribosome biogenesis protein TSR3 homolog levels
65125,RAC-beta serine/threonine-protein kinase levels,Phenotype,RAC-beta serine/threonine-protein kinase levels
65127,2-deoxynucleoside 5-phosphate N-hydrolase 1 levels,Phenotype,2-deoxynucleoside 5-phosphate N-hydrolase 1 levels
65129,Ribonucleoside-diphosphate reductase subunit M2 levels,Phenotype,Ribonucleoside-diphosphate reductase subunit M2 levels
65131,Retinoic acid early transcript 1G protein levels,Phenotype,Retinoic acid early transcript 1G protein levels
65132,Retinoblastoma-associated protein levels,Phenotype,Retinoblastoma-associated protein levels
65133,High affinity immunoglobulin epsilon receptor subunit alpha levels,Phenotype,High affinity immunoglobulin epsilon receptor subunit alpha levels
65135,Regenerating islet-derived protein 3-alpha levels,Phenotype,Regenerating islet-derived protein 3-alpha levels
65137,Ras-related protein Rab-27B levels,Phenotype,Ras-related protein Rab-27B levels
65139,RNA-binding protein 24 levels,Phenotype,RNA-binding protein 24 levels
65140,Surgical knee osteoarthritis,Phenotype,Surgical knee osteoarthritis
65143,Non-surgical knee osteoarthritis,Phenotype,Non-surgical knee osteoarthritis
65144,Serotransferrin levels,Phenotype,Serotransferrin levels
65145,Protein SET levels,Phenotype,Protein SET levels
65148,Surgical hip osteoarthritis,Phenotype,Surgical hip osteoarthritis
65150,Sperm-associated antigen 11B levels,Phenotype,Sperm-associated antigen 11B levels
65151,SH3 domain-binding glutamic acid-rich-like protein 2 levels,Phenotype,SH3 domain-binding glutamic acid-rich-like protein 2 levels
65152,Secreted frizzled-related protein 3 levels,Phenotype,Secreted frizzled-related protein 3 levels
65153,Non-surgical hip osteoarthritis,Phenotype,Non-surgical hip osteoarthritis
65154,Liver carboxylesterase 1 levels,Phenotype,Liver carboxylesterase 1 levels
65155,Leukotriene B4 receptor 1 levels,Phenotype,Leukotriene B4 receptor 1 levels
65163,Leukocyte immunoglobulin-like receptor subfamily B member 2 levels,Phenotype,Leukocyte immunoglobulin-like receptor subfamily B member 2 levels
65175,Complement receptor type 2 levels,Phenotype,Complement receptor type 2 levels
65180,Cysteine-rich PDZ-binding protein levels,Phenotype,Cysteine-rich PDZ-binding protein levels
65185,Age at adiposity rebound x sex interaction,Phenotype,Age at adiposity rebound x sex interaction
65187,BMI at adiposity rebound x sex interaction,Phenotype,BMI at adiposity rebound x sex interaction
65189,BMI at 1.5 -2.5 years old interval,Phenotype,BMI at 1.5 -2.5 years old interval
65193,Apnea hypopnea index,Phenotype,Apnea hypopnea index
65195,Apnea hypopnea index during non-REM sleep,Phenotype,Apnea hypopnea index during non-REM sleep
65196,Obstructive sleep apnea trait (percentage of blood oxygen below 90% of total sleep time),Phenotype,Obstructive sleep apnea trait (percentage of blood oxygen below 90% of total sleep time)
65197,Obstructive sleep apnea trait (oxygen desaturation index),Phenotype,Obstructive sleep apnea trait (oxygen desaturation index)
65198,Obstructive sleep apnea trait (percentage of wake time during sleep period time),Phenotype,Obstructive sleep apnea trait (percentage of wake time during sleep period time)
65206,Heterogeneous nuclear ribonucleoprotein Q levels,Phenotype,Heterogeneous nuclear ribonucleoprotein Q levels
65207,Glycoprotein hormone alpha-2 levels,Phenotype,Glycoprotein hormone alpha-2 levels
65209,Heme oxygenase 1 levels,Phenotype,Heme oxygenase 1 levels
65210,HEPACAM family member 2 levels,Phenotype,HEPACAM family member 2 levels
65212,Hematological and neurological expressed 1 protein levels,Phenotype,Hematological and neurological expressed 1 protein levels
65217,Kin of IRRE-like protein 2 levels,Phenotype,Kin of IRRE-like protein 2 levels
65219,Insulin receptor levels,Phenotype,Insulin receptor levels
65225,Cytochrome c oxidase assembly factor 3 homolog-- mitochondrial levels,Phenotype,Cytochrome c oxidase assembly factor 3 homolog-- mitochondrial levels
65226,Coagulation Factor X levels,Phenotype,Coagulation Factor X levels
65228,C-type lectin domain family 4 member D levels,Phenotype,C-type lectin domain family 4 member D levels
65229,Calcium-activated potassium channel subunit beta-3 levels,Phenotype,Calcium-activated potassium channel subunit beta-3 levels
65230,C-type lectin domain family 4 member A levels,Phenotype,C-type lectin domain family 4 member A levels
65231,Collagen alpha-1(IX) chain levels,Phenotype,Collagen alpha-1(IX) chain levels
65233,Collagen alpha-1(X) chain levels,Phenotype,Collagen alpha-1(X) chain levels
65239,Endothelin-converting enzyme 1 levels,Phenotype,Endothelin-converting enzyme 1 levels
65241,Enoyl-CoA delta isomerase 2-- mitochondrial levels,Phenotype,Enoyl-CoA delta isomerase 2-- mitochondrial levels
65243,Histone-lysine N-methyltransferase-- H3 lysine-79 specific levels,Phenotype,Histone-lysine N-methyltransferase-- H3 lysine-79 specific levels
65245,Disintegrin and metalloproteinase domain-containing protein 10 levels,Phenotype,Disintegrin and metalloproteinase domain-containing protein 10 levels
65246,Dipeptidyl peptidase 4 levels,Phenotype,Dipeptidyl peptidase 4 levels
65247,Diphosphomevalonate decarboxylase levels,Phenotype,Diphosphomevalonate decarboxylase levels
65250,DnaJ homolog subfamily B member 9 levels,Phenotype,DnaJ homolog subfamily B member 9 levels
65255,Dipeptidyl peptidase 1 levels,Phenotype,Dipeptidyl peptidase 1 levels
65260,Non-alcoholic fatty liver disease or type 2 diabetes,Phenotype,Non-alcoholic fatty liver disease or type 2 diabetes
65270,Preeclampsia or other maternal hypertension (maternal genotype effect),Phenotype,Preeclampsia or other maternal hypertension (maternal genotype effect)
65274,Aortic stenosis,Phenotype,Aortic stenosis
65276,Cholesteryl esters to total lipids in medium VLDL percentage (UKB data field 23596),Phenotype,Cholesteryl esters to total lipids in medium VLDL percentage (UKB data field 23596)
65277,Triglycerides to total lipids in medium VLDL percentage (UKB data field 23598),Phenotype,Triglycerides to total lipids in medium VLDL percentage (UKB data field 23598)
65278,Free cholesterol to total lipids in medium VLDL percentage (UKB data field 23597),Phenotype,Free cholesterol to total lipids in medium VLDL percentage (UKB data field 23597)
65280,Phospholipids to total lipids in small VLDL percentage (UKB data field 23599),Phenotype,Phospholipids to total lipids in small VLDL percentage (UKB data field 23599)
65281,Cholesteryl esters to total lipids in IDL percentage (UKB data field 23611),Phenotype,Cholesteryl esters to total lipids in IDL percentage (UKB data field 23611)
65282,Free cholesterol to total lipids in IDL percentage (UKB data field 23612),Phenotype,Free cholesterol to total lipids in IDL percentage (UKB data field 23612)
65283,Cholesterol to total lipids in IDL percentage (UKB data field 23610),Phenotype,Cholesterol to total lipids in IDL percentage (UKB data field 23610)
65284,Phospholipids to total lipids in IDL percentage (UKB data field 23609),Phenotype,Phospholipids to total lipids in IDL percentage (UKB data field 23609)
65289,Cholesterol to total lipids in small LDL percentage (UKB data field 23625),Phenotype,Cholesterol to total lipids in small LDL percentage (UKB data field 23625)
65290,Cholesteryl esters to total lipids in small LDL percentage (UKB data field 23626),Phenotype,Cholesteryl esters to total lipids in small LDL percentage (UKB data field 23626)
65292,Free cholesterol to total lipids in small LDL percentage (UKB data field 23627),Phenotype,Free cholesterol to total lipids in small LDL percentage (UKB data field 23627)
65293,Triglycerides to total lipids in small LDL percentage (UKB data field 23628),Phenotype,Triglycerides to total lipids in small LDL percentage (UKB data field 23628)
65294,Margaroylcarnitine (C17) levels,Phenotype,Margaroylcarnitine (C17) levels
65296,Phenylacetylcarnitine levels,Phenotype,Phenylacetylcarnitine levels
65297,Carnitine C18:2 levels,Phenotype,Carnitine C18:2 levels
65298,Carboxyethyl-gaba levels,Phenotype,Carboxyethyl-gaba levels
65299,Prolylglycine levels,Phenotype,Prolylglycine levels
65301,Cholesterol to total lipids in large HDL percentage (UKB data field 23635),Phenotype,Cholesterol to total lipids in large HDL percentage (UKB data field 23635)
65302,Cholesteryl esters to total lipids in large HDL percentage (UKB data field 23636),Phenotype,Cholesteryl esters to total lipids in large HDL percentage (UKB data field 23636)
65304,Phospholipids to total lipids in large HDL percentage (UKB data field 23634),Phenotype,Phospholipids to total lipids in large HDL percentage (UKB data field 23634)
65305,Gamma-glutamylcitrulline levels,Phenotype,Gamma-glutamylcitrulline levels
65307,3-amino-2-piperidone levels,Phenotype,3-amino-2-piperidone levels
65310,Cis 3--4-methyleneheptanoate levels,Phenotype,Cis 3--4-methyleneheptanoate levels
65311,Vanillic acid glycine levels,Phenotype,Vanillic acid glycine levels
65312,N-succinyl-phenylalanine levels,Phenotype,N-succinyl-phenylalanine levels
65314,Cis-3--4-methyleneheptanoylcarnitine levels,Phenotype,Cis-3--4-methyleneheptanoylcarnitine levels
65317,Free cholesterol to total lipids in medium HDL percentage (UKB data field 23642),Phenotype,Free cholesterol to total lipids in medium HDL percentage (UKB data field 23642)
65318,Cholesteryl esters to total lipids in medium HDL percentage (UKB data field 23641),Phenotype,Cholesteryl esters to total lipids in medium HDL percentage (UKB data field 23641)
65321,Microscopic colitis,Phenotype,Microscopic colitis
65322,Creatinine levels (UKB data field 23478),Phenotype,Creatinine levels (UKB data field 23478)
65325,Concentration of chylomicrons and extremely large VLDL particles (UKB data field 23481),Phenotype,Concentration of chylomicrons and extremely large VLDL particles (UKB data field 23481)
65327,3-hydroxybutyrate levels (UKB data field 23474),Phenotype,3-hydroxybutyrate levels (UKB data field 23474)
65328,Acetoacetate levels (UKB data field 23476),Phenotype,Acetoacetate levels (UKB data field 23476)
65330,Glycoprotein acetyls levels (UKB data field 23480),Phenotype,Glycoprotein acetyls levels (UKB data field 23480)
65334,Phospholipids in very large VLDL (UKB data field 23490),Phenotype,Phospholipids in very large VLDL (UKB data field 23490)
65336,Cholesteryl esters in very large VLDL (UKB data field 23492),Phenotype,Cholesteryl esters in very large VLDL (UKB data field 23492)
65337,Free cholesterol in very large VLDL (UKB data field 23493),Phenotype,Free cholesterol in very large VLDL (UKB data field 23493)
65338,Total lipids in very large VLDL (UKB data field 23489),Phenotype,Total lipids in very large VLDL (UKB data field 23489)
65339,Cholesterol in very large VLDL (UKB data field 23491),Phenotype,Cholesterol in very large VLDL (UKB data field 23491)
65340,Glycine levels (UKB data field 23462),Phenotype,Glycine levels (UKB data field 23462)
65342,Tyrosine levels (UKB data field 23469),Phenotype,Tyrosine levels (UKB data field 23469)
65344,Glucose levels (UKB data field 23470),Phenotype,Glucose levels (UKB data field 23470)
65346,Lactate levels (UKB data field 23471),Phenotype,Lactate levels (UKB data field 23471)
65347,Total concentration of branched-chain amino acids (leucine + isoleucine + valine) (UKB data field 23464),Phenotype,Total concentration of branched-chain amino acids (leucine + isoleucine + valine) (UKB data field 23464)
65348,Isoleucine levels (UKB data field 23465),Phenotype,Isoleucine levels (UKB data field 23465)
65349,Leucine levels (UKB data field 23466),Phenotype,Leucine levels (UKB data field 23466)
65350,Valine levels (UKB data field 23467),Phenotype,Valine levels (UKB data field 23467)
65353,Alanine levels (UKB data field 23460),Phenotype,Alanine levels (UKB data field 23460)
65354,Pyruvate levels (UKB data field 23472),Phenotype,Pyruvate levels (UKB data field 23472)
65355,Citrate levels (UKB data field 23473),Phenotype,Citrate levels (UKB data field 23473)
65358,Glutamine levels (UKB data field 23461),Phenotype,Glutamine levels (UKB data field 23461)
65359,Triglycerides in chylomicrons and extremely large VLDL (UKB data field 23487),Phenotype,Triglycerides in chylomicrons and extremely large VLDL (UKB data field 23487)
65361,Concentration of very large VLDL particles (UKB data field 23488),Phenotype,Concentration of very large VLDL particles (UKB data field 23488)
65362,Free cholesterol in chylomicrons and extremely large VLDL (UKB data field 23486),Phenotype,Free cholesterol in chylomicrons and extremely large VLDL (UKB data field 23486)
65363,Phospholipids in large VLDL (UKB data field 23497),Phenotype,Phospholipids in large VLDL (UKB data field 23497)
65364,Cholesteryl esters in large VLDL (UKB data field 23499),Phenotype,Cholesteryl esters in large VLDL (UKB data field 23499)
65365,Cholesterol in large VLDL (UKB data field 23498),Phenotype,Cholesterol in large VLDL (UKB data field 23498)
65366,Concentration of very small VLDL particles (UKB data field 23516),Phenotype,Concentration of very small VLDL particles (UKB data field 23516)
65367,Triglycerides in small VLDL (UKB data field 23515),Phenotype,Triglycerides in small VLDL (UKB data field 23515)
65368,Total lipids in very small VLDL (UKB data field 23517),Phenotype,Total lipids in very small VLDL (UKB data field 23517)
65369,Cholesterol in very small VLDL (UKB data field 23519),Phenotype,Cholesterol in very small VLDL (UKB data field 23519)
65370,Phospholipids in very small VLDL (UKB data field 23518),Phenotype,Phospholipids in very small VLDL (UKB data field 23518)
65371,Concentration of large LDL particles (UKB data field 23530),Phenotype,Concentration of large LDL particles (UKB data field 23530)
65372,Cholesterol in large LDL (UKB data field 23533),Phenotype,Cholesterol in large LDL (UKB data field 23533)
65373,Phospholipids in large LDL (UKB data field 23532),Phenotype,Phospholipids in large LDL (UKB data field 23532)
65375,Cholesteryl esters in large LDL (UKB data field 23534),Phenotype,Cholesteryl esters in large LDL (UKB data field 23534)
65376,Total lipids in large LDL (UKB data field 23531),Phenotype,Total lipids in large LDL (UKB data field 23531)
65377,Triglycerides in IDL (UKB data field 23529),Phenotype,Triglycerides in IDL (UKB data field 23529)
65379,Concentration of very large HDL particles (UKB data field 23551),Phenotype,Concentration of very large HDL particles (UKB data field 23551)
65381,Total lipids in very large HDL (UKB data field 23552),Phenotype,Total lipids in very large HDL (UKB data field 23552)
65382,Phospholipids in very large HDL (UKB data field 23553),Phenotype,Phospholipids in very large HDL (UKB data field 23553)
65384,Triglycerides in small LDL (UKB data field 23550),Phenotype,Triglycerides in small LDL (UKB data field 23550)
65388,Cholesterol in large HDL (UKB data field 23561),Phenotype,Cholesterol in large HDL (UKB data field 23561)
65389,Cholesteryl esters in large HDL (UKB data field 23562),Phenotype,Cholesteryl esters in large HDL (UKB data field 23562)
65391,Total lipids in medium HDL (UKB data field 23566),Phenotype,Total lipids in medium HDL (UKB data field 23566)
65392,Cholesterol in medium HDL (UKB data field 23568),Phenotype,Cholesterol in medium HDL (UKB data field 23568)
65393,Cholesteryl esters in medium HDL (UKB data field 23569),Phenotype,Cholesteryl esters in medium HDL (UKB data field 23569)
65394,Phospholipids in medium HDL (UKB data field 23567),Phenotype,Phospholipids in medium HDL (UKB data field 23567)
65395,Cholesteryl esters to total lipids in large VLDL percentage (UKB data field 23591),Phenotype,Cholesteryl esters to total lipids in large VLDL percentage (UKB data field 23591)
65396,Triglycerides to total lipids in very large VLDL percentage (UKB data field 23588),Phenotype,Triglycerides to total lipids in very large VLDL percentage (UKB data field 23588)
65397,Cholesterol to total lipids in large VLDL percentage (UKB data field 23590),Phenotype,Cholesterol to total lipids in large VLDL percentage (UKB data field 23590)
65398,Phospholipids to total lipids in large VLDL percentage (UKB data field 23589),Phenotype,Phospholipids to total lipids in large VLDL percentage (UKB data field 23589)
65399,Phospholipids to total lipids in very large VLDL percentage (UKB data field 23584),Phenotype,Phospholipids to total lipids in very large VLDL percentage (UKB data field 23584)
65400,Cholesterol to total lipids in very large VLDL percentage (UKB data field 23585),Phenotype,Cholesterol to total lipids in very large VLDL percentage (UKB data field 23585)
65401,Cholesteryl esters to total lipids in very large VLDL percentage (UKB data field 23586),Phenotype,Cholesteryl esters to total lipids in very large VLDL percentage (UKB data field 23586)
65402,Mitochondrial DNA copy number (raw),Phenotype,Mitochondrial DNA copy number (raw)
65409,Triglycerides to total lipids in small VLDL percentage (UKB data field 23603),Phenotype,Triglycerides to total lipids in small VLDL percentage (UKB data field 23603)
65410,Free cholesterol to total lipids in small VLDL percentage (UKB data field 23602),Phenotype,Free cholesterol to total lipids in small VLDL percentage (UKB data field 23602)
65411,Cholesterol to total lipids in very small VLDL percentage (UKB data field 23605),Phenotype,Cholesterol to total lipids in very small VLDL percentage (UKB data field 23605)
65412,Phospholipids to total lipids in very small VLDL percentage (UKB data field 23604),Phenotype,Phospholipids to total lipids in very small VLDL percentage (UKB data field 23604)
65414,Phospholipids to total lipids in medium LDL percentage (UKB data field 23619),Phenotype,Phospholipids to total lipids in medium LDL percentage (UKB data field 23619)
65415,Cholesteryl esters to total lipids in medium LDL percentage (UKB data field 23621),Phenotype,Cholesteryl esters to total lipids in medium LDL percentage (UKB data field 23621)
65416,Cholesterol to total lipids in medium LDL percentage (UKB data field 23620),Phenotype,Cholesterol to total lipids in medium LDL percentage (UKB data field 23620)
65418,X-24241 levels,Phenotype,X-24241 levels
65419,Triglycerides to total lipids in large LDL percentage (UKB data field 23618),Phenotype,Triglycerides to total lipids in large LDL percentage (UKB data field 23618)
65421,X-25109 levels,Phenotype,X-25109 levels
65423,X-24947 levels,Phenotype,X-24947 levels
65424,X-24949 levels,Phenotype,X-24949 levels
65425,X-24518 levels,Phenotype,X-24518 levels
65426,X-24531 levels,Phenotype,X-24531 levels
65429,Thymol sulfate levels,Phenotype,Thymol sulfate levels
65430,Free cholesterol to total lipids in very large HDL percentage (UKB data field 23632),Phenotype,Free cholesterol to total lipids in very large HDL percentage (UKB data field 23632)
65431,Cholesteryl esters to total lipids in very large HDL percentage (UKB data field 23631),Phenotype,Cholesteryl esters to total lipids in very large HDL percentage (UKB data field 23631)
65432,Cholesterol to total lipids in very large HDL percentage (UKB data field 23630),Phenotype,Cholesterol to total lipids in very large HDL percentage (UKB data field 23630)
65436,Free cholesterol to total lipids in large HDL percentage (UKB data field 23637),Phenotype,Free cholesterol to total lipids in large HDL percentage (UKB data field 23637)
65441,3-hydroxyoctanoylcarnitine (1) levels,Phenotype,3-hydroxyoctanoylcarnitine (1) levels
65442,3-hydroxyoctanoylcarnitine (2) levels,Phenotype,3-hydroxyoctanoylcarnitine (2) levels
65447,Triglycerides to total lipids in medium HDL percentage (UKB data field 23643),Phenotype,Triglycerides to total lipids in medium HDL percentage (UKB data field 23643)
65448,Phospholipids to total lipids in small HDL percentage (UKB data field 23644),Phenotype,Phospholipids to total lipids in small HDL percentage (UKB data field 23644)
65451,Cholesterol to total lipids in small VLDL percentage (UKB data field 23600),Phenotype,Cholesterol to total lipids in small VLDL percentage (UKB data field 23600)
65452,Cholesteryl esters to total lipids in small VLDL percentage (UKB data field 23601),Phenotype,Cholesteryl esters to total lipids in small VLDL percentage (UKB data field 23601)
65455,Cholesteryl esters to total lipids in large LDL percentage (UKB data field 23616),Phenotype,Cholesteryl esters to total lipids in large LDL percentage (UKB data field 23616)
65456,Cholesterol to total lipids in large LDL percentage (UKB data field 23615),Phenotype,Cholesterol to total lipids in large LDL percentage (UKB data field 23615)
65458,Triglycerides to total lipids in IDL percentage (UKB data field 23613),Phenotype,Triglycerides to total lipids in IDL percentage (UKB data field 23613)
65459,Phospholipids to total lipids in large LDL percentage (UKB data field 23614),Phenotype,Phospholipids to total lipids in large LDL percentage (UKB data field 23614)
65460,Free cholesterol to total lipids in large LDL percentage (UKB data field 23617),Phenotype,Free cholesterol to total lipids in large LDL percentage (UKB data field 23617)
65466,X-12839 levels,Phenotype,X-12839 levels
65471,X-21829 levels,Phenotype,X-21829 levels
65472,Phospholipids to total lipids in very large HDL percentage (UKB data field 23629),Phenotype,Phospholipids to total lipids in very large HDL percentage (UKB data field 23629)
65473,Stearoylcarnitine (C18) levels,Phenotype,Stearoylcarnitine (C18) levels
65475,Indolebutyrate levels,Phenotype,Indolebutyrate levels
65479,Hydroxy-cmpf levels,Phenotype,Hydroxy-cmpf levels
65481,Glycine conjugate of C10H12O2 levels,Phenotype,Glycine conjugate of C10H12O2 levels
65483,Cholesterol to total lipids in medium HDL percentage (UKB data field 23640),Phenotype,Cholesterol to total lipids in medium HDL percentage (UKB data field 23640)
65484,Response to BNT162b2 vaccine (anti-SARS-CoV-2 Spike antibody levels at two months after first dose),Phenotype,Response to BNT162b2 vaccine (anti-SARS-CoV-2 Spike antibody levels at two months after first dose)
65486,Response to BNT162b2 vaccine (anti-SARS-CoV-2 Spike antibody levels at four months after first dose),Phenotype,Response to BNT162b2 vaccine (anti-SARS-CoV-2 Spike antibody levels at four months after first dose)
65489,Response to BNT162b2 vaccine (percentage decrease of anti-SARS-CoV-2 Spike antibody levels from two to four months after first dose),Phenotype,Response to BNT162b2 vaccine (percentage decrease of anti-SARS-CoV-2 Spike antibody levels from two to four months after first dose)
65492,Free cholesterol to total lipids in large VLDL percentage (UKB data field 23592),Phenotype,Free cholesterol to total lipids in large VLDL percentage (UKB data field 23592)
65495,Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595),Phenotype,Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595)
65496,Triglycerides to total lipids in large VLDL percentage (UKB data field 23593),Phenotype,Triglycerides to total lipids in large VLDL percentage (UKB data field 23593)
65498,Phospholipids to total lipids in medium VLDL percentage (UKB data field 23594),Phenotype,Phospholipids to total lipids in medium VLDL percentage (UKB data field 23594)
65499,Free cholesterol to total lipids in very small VLDL percentage (UKB data field 23607),Phenotype,Free cholesterol to total lipids in very small VLDL percentage (UKB data field 23607)
65501,Cholesteryl esters to total lipids in very small VLDL percentage (UKB data field 23606),Phenotype,Cholesteryl esters to total lipids in very small VLDL percentage (UKB data field 23606)
65502,Triglycerides to total lipids in very small VLDL percentage (UKB data field 23608),Phenotype,Triglycerides to total lipids in very small VLDL percentage (UKB data field 23608)
65503,Phospholipids to total lipids in small LDL percentage (UKB data field 23624),Phenotype,Phospholipids to total lipids in small LDL percentage (UKB data field 23624)
65504,Triglycerides to total lipids in medium LDL percentage (UKB data field 23623),Phenotype,Triglycerides to total lipids in medium LDL percentage (UKB data field 23623)
65505,1-palmitoyl-2-arachidonoyl-gpc (16:0/20:4n6) levels,Phenotype,1-palmitoyl-2-arachidonoyl-gpc (16:0/20:4n6) levels
65506,Butyrylcarnitine (C4) levels,Phenotype,Butyrylcarnitine (C4) levels
65507,Free cholesterol to total lipids in medium LDL percentage (UKB data field 23622),Phenotype,Free cholesterol to total lipids in medium LDL percentage (UKB data field 23622)
65509,Cysteinylglycine disulfide levels,Phenotype,Cysteinylglycine disulfide levels
65510,Succinylcarnitine (C4DC) levels,Phenotype,Succinylcarnitine (C4DC) levels
65511,5alpha-androstan-3alpha--17alpha-diol monosulfate levels,Phenotype,5alpha-androstan-3alpha--17alpha-diol monosulfate levels
65512,Triglycerides to total lipids in very large HDL percentage (UKB data field 23633),Phenotype,Triglycerides to total lipids in very large HDL percentage (UKB data field 23633)
65515,Methylsuccinoylcarnitine levels,Phenotype,Methylsuccinoylcarnitine levels
65516,Furaneol sulfate levels,Phenotype,Furaneol sulfate levels
65517,Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) levels,Phenotype,Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) levels
65518,Phospholipids to total lipids in medium HDL percentage (UKB data field 23639),Phenotype,Phospholipids to total lipids in medium HDL percentage (UKB data field 23639)
65519,Triglycerides to total lipids in large HDL percentage (UKB data field 23638),Phenotype,Triglycerides to total lipids in large HDL percentage (UKB data field 23638)
65522,Cholesteryl esters to total lipids in small HDL percentage (UKB data field 23646),Phenotype,Cholesteryl esters to total lipids in small HDL percentage (UKB data field 23646)
65524,Free cholesterol to total lipids in small HDL percentage (UKB data field 23647),Phenotype,Free cholesterol to total lipids in small HDL percentage (UKB data field 23647)
65525,Triglycerides to total lipids in small HDL percentage (UKB data field 23648),Phenotype,Triglycerides to total lipids in small HDL percentage (UKB data field 23648)
65526,Cholesterol to total lipids in small HDL percentage (UKB data field 23645),Phenotype,Cholesterol to total lipids in small HDL percentage (UKB data field 23645)
65538,Color vision defects (Deutan-Protan),Phenotype,Color vision defects (Deutan-Protan)
65571,Immature platelet fraction,Phenotype,Immature platelet fraction
65573,Immature platelet count,Phenotype,Immature platelet count
65581,Hearing difficulty,Phenotype,Hearing difficulty
65582,Hearing difficulty with background noise,Phenotype,Hearing difficulty with background noise
65583,Hearing difficulty and hearing difficulty with background noise,Phenotype,Hearing difficulty and hearing difficulty with background noise
65584,Fornix white matter microstructure (isotropic or free water volume fraction),Phenotype,Fornix white matter microstructure (isotropic or free water volume fraction)
65612,HDL-cholesterol level in antipsychotic-treated schizophrenia (4-week),Phenotype,HDL-cholesterol level in antipsychotic-treated schizophrenia (4-week)
65614,Antipsychotic-induced HDL-cholesterol change in schizophrenia (6-week),Phenotype,Antipsychotic-induced HDL-cholesterol change in schizophrenia (6-week)
65617,HDL-cholesterol level in antipsychotic-treated schizophrenia (6-week),Phenotype,HDL-cholesterol level in antipsychotic-treated schizophrenia (6-week)
65624,Alcohol use frequency,Phenotype,Alcohol use frequency
65680,Platelet side scatter,Phenotype,Platelet side scatter
65682,Left ventricular end systole anterolateral wall thickness,Phenotype,Left ventricular end systole anterolateral wall thickness
65683,Left ventricular end systole inferoseptal wall thickness,Phenotype,Left ventricular end systole inferoseptal wall thickness
65684,Left ventricular end systole inferolateral wall thickness,Phenotype,Left ventricular end systole inferolateral wall thickness
65685,Left ventricular end diastole inferior wall thickness,Phenotype,Left ventricular end diastole inferior wall thickness
65686,Left ventricular end diastole anterolateral wall thickness,Phenotype,Left ventricular end diastole anterolateral wall thickness
65688,Platelet side fluorescence,Phenotype,Platelet side fluorescence
65689,Facial morphology (D497),Phenotype,Facial morphology (D497)
65691,Facial morphology (D99),Phenotype,Facial morphology (D99)
65693,Gastroparesis,Phenotype,Gastroparesis
65695,Plasma oxylipin levels (PC2),Phenotype,Plasma oxylipin levels (PC2)
65697,Plasma oxylipin levels (PC1),Phenotype,Plasma oxylipin levels (PC1)
65707,Phenotypic age acceleration,Phenotype,Phenotypic age acceleration
65711,Alcohol use frequency in adulthood,Phenotype,Alcohol use frequency in adulthood
65718,Alcohol use frequency in early adulthood,Phenotype,Alcohol use frequency in early adulthood
65732,Red blood cell side fluorescence,Phenotype,Red blood cell side fluorescence
65736,Red blood cell side scatter,Phenotype,Red blood cell side scatter
65739,Red blood cell forward scatter,Phenotype,Red blood cell forward scatter
65740,Platelet large cell ratio,Phenotype,Platelet large cell ratio
65743,Peptic ulcer disease,Phenotype,Peptic ulcer disease
65746,Duodenal ulcer,Phenotype,Duodenal ulcer
65773,Facial morphology (D10),Phenotype,Facial morphology (D10)
65775,Facial morphology (D120),Phenotype,Facial morphology (D120)
65777,Platelet forward scatter,Phenotype,Platelet forward scatter
65783,Red blood cell forward scatter distribution width,Phenotype,Red blood cell forward scatter distribution width
65785,Hyper-haemoglobinised percentage of red cells,Phenotype,Hyper-haemoglobinised percentage of red cells
65787,Macrocytic percentage of red cells,Phenotype,Macrocytic percentage of red cells
65791,Microcytic percentage of red cells,Phenotype,Microcytic percentage of red cells
65792,Red blood cell side fluorescence distribution width,Phenotype,Red blood cell side fluorescence distribution width
65798,Fornix white matter microstructure (intra-cellular volume fraction),Phenotype,Fornix white matter microstructure (intra-cellular volume fraction)
65799,Fornix white matter microstructure (diffusion tensor mode),Phenotype,Fornix white matter microstructure (diffusion tensor mode)
65800,Hearing aid use,Phenotype,Hearing aid use
65802,Neonatal circulating Complement Component 3 (C3) protein concentration,Phenotype,Neonatal circulating Complement Component 3 (C3) protein concentration
65804,Neonatal circulating Complement Component 4 (C4) protein concentration,Phenotype,Neonatal circulating Complement Component 4 (C4) protein concentration
65815,Cranial vault shape (segment 1),Phenotype,Cranial vault shape (segment 1)
65817,Cranial vault shape (segment 3),Phenotype,Cranial vault shape (segment 3)
65826,Cranial vault shape (segment 11),Phenotype,Cranial vault shape (segment 11)
65831,Ulcerative colitis x sex interaction (2df),Phenotype,Ulcerative colitis x sex interaction (2df)
65835,Inflammatory bowel disease x sex interaction (2df),Phenotype,Inflammatory bowel disease x sex interaction (2df)
65836,Solar lentigines (non-facial),Phenotype,Solar lentigines (non-facial)
65850,Mercury levels in pregnancy,Phenotype,Mercury levels in pregnancy
65864,Lymphatic filariasis,Phenotype,Lymphatic filariasis
65867,Lymphatic filariasis with lymphedema,Phenotype,Lymphatic filariasis with lymphedema
65869,Delta of the haemoglobin equivalents,Phenotype,Delta of the haemoglobin equivalents
65871,Delta of the red cell haemoglobins,Phenotype,Delta of the red cell haemoglobins
65890,Chemoradiation-induced hearing loss in nasopharyngeal carcinoma,Phenotype,Chemoradiation-induced hearing loss in nasopharyngeal carcinoma
65928,Systemic lupus erythematosus (MTAG),Phenotype,Systemic lupus erythematosus (MTAG)
65936,Anxiety x Caesarean-section interaction,Phenotype,Anxiety x Caesarean-section interaction
65938,Self-harm x Caesarean-section interaction,Phenotype,Self-harm x Caesarean-section interaction
65940,Free androgen index,Phenotype,Free androgen index
65978,Neurocognitive measure (immediate recall) in obsessive-compulsive disorder,Phenotype,Neurocognitive measure (immediate recall) in obsessive-compulsive disorder
65980,Neurocognitive measure (delayed recall) in obsessive-compulsive disorder,Phenotype,Neurocognitive measure (delayed recall) in obsessive-compulsive disorder
65982,Neurocognitive measure (copy organization) in obsessive-compulsive disorder,Phenotype,Neurocognitive measure (copy organization) in obsessive-compulsive disorder
66007,Interventricular septum cross-sectional area,Phenotype,Interventricular septum cross-sectional area
66025,Median relapse-independent longitudinal age-related multiple sclerosis severity score in relapse-onset multiple sclerosis,Phenotype,Median relapse-independent longitudinal age-related multiple sclerosis severity score in relapse-onset multiple sclerosis
66027,Median relapse-independent longitudinal Multiple Sclerosis Severity Scale score in relapse-onset multiple sclerosis,Phenotype,Median relapse-independent longitudinal Multiple Sclerosis Severity Scale score in relapse-onset multiple sclerosis
66029,Multiple sclerosis (age of onset),Phenotype,Multiple sclerosis (age of onset)
66047,Alcohol withdrawal factor score,Phenotype,Alcohol withdrawal factor score
66083,Hip width to body height ratio,Phenotype,Hip width to body height ratio
66085,Shoulder width to body height ratio,Phenotype,Shoulder width to body height ratio
66089,Torso length to body height ratio,Phenotype,Torso length to body height ratio
66091,Tibiofemoral angle,Phenotype,Tibiofemoral angle
66095,Femur length to body height ratio,Phenotype,Femur length to body height ratio
66097,ICD10 127.0 pulmonary arterial hypertension,Phenotype,ICD10 127.0 pulmonary arterial hypertension
66112,Vitamin D levels or COVID-19 (MTAG),Phenotype,Vitamin D levels or COVID-19 (MTAG)
66139,Pelvic organ prolapse x maximum birth weight interaction,Phenotype,Pelvic organ prolapse x maximum birth weight interaction
66144,Pelvic organ prolapse x age interaction,Phenotype,Pelvic organ prolapse x age interaction
66147,Red meat related metabolomic signature,Phenotype,Red meat related metabolomic signature
66155,Preeclampsia or eclampsia,Phenotype,Preeclampsia or eclampsia
66203,Forearm length to body height ratio,Phenotype,Forearm length to body height ratio
66239,BolA-like protein 2 levels,Phenotype,BolA-like protein 2 levels
66241,Complement C1q tumor necrosis factor-related protein 5 levels,Phenotype,Complement C1q tumor necrosis factor-related protein 5 levels
66242,Complement C1q and tumor necrosis factor-related protein 9A levels,Phenotype,Complement C1q and tumor necrosis factor-related protein 9A levels
66244,Butyrophilin subfamily 3 member A3 levels,Phenotype,Butyrophilin subfamily 3 member A3 levels
66249,Protein BTG2 levels,Phenotype,Protein BTG2 levels
66251,Glypican-3 levels,Phenotype,Glypican-3 levels
66256,Insulin growth factor-like family member 3 levels,Phenotype,Insulin growth factor-like family member 3 levels
66257,Interferon alpha-5 levels,Phenotype,Interferon alpha-5 levels
66259,ICOS ligand levels,Phenotype,ICOS ligand levels
66260,Insulin-like growth factor I levels,Phenotype,Insulin-like growth factor I levels
66262,Insulin-like growth factor-binding protein complex acid labile subunit levels,Phenotype,Insulin-like growth factor-binding protein complex acid labile subunit levels
66264,Insulin-like growth factor-binding protein 3 levels,Phenotype,Insulin-like growth factor-binding protein 3 levels
66265,Interleukin-10 receptor subunit beta levels,Phenotype,Interleukin-10 receptor subunit beta levels
66266,Immunoglobulin lambda-like polypeptide 1 levels,Phenotype,Immunoglobulin lambda-like polypeptide 1 levels
66268,Immunoglobulin M levels,Phenotype,Immunoglobulin M levels
66270,ICD10 J33: nasal polyps,Phenotype,ICD10 J33: nasal polyps
66271,ICD10 J35: Chronic diseases of tonsils and adenoids,Phenotype,ICD10 J35: Chronic diseases of tonsils and adenoids
66272,Somatoliberin levels,Phenotype,Somatoliberin levels
66273,S-methyl-5-thioadenosine phosphorylase levels,Phenotype,S-methyl-5-thioadenosine phosphorylase levels
66277,Stromal membrane-associated protein 1 levels,Phenotype,Stromal membrane-associated protein 1 levels
66284,Casein kinase II subunit alpha levels,Phenotype,Casein kinase II subunit alpha levels
66285,Ceruloplasmin levels,Phenotype,Ceruloplasmin levels
66286,Chitinase-3-like protein 2 levels,Phenotype,Chitinase-3-like protein 2 levels
66287,Chordin levels,Phenotype,Chordin levels
66288,Carcinoembryonic antigen-related cell adhesion molecule 19 levels,Phenotype,Carcinoembryonic antigen-related cell adhesion molecule 19 levels
66289,CCAAT/enhancer-binding protein beta levels,Phenotype,CCAAT/enhancer-binding protein beta levels
66290,Carbohydrate sulfotransferase 4 levels,Phenotype,Carbohydrate sulfotransferase 4 levels
66292,Chymotrypsinogen B levels,Phenotype,Chymotrypsinogen B levels
66298,Mitogen-activated protein kinase 13 levels,Phenotype,Mitogen-activated protein kinase 13 levels
66301,Melanoma-associated antigen 5 levels,Phenotype,Melanoma-associated antigen 5 levels
66302,Mast/stem cell growth factor receptor Kit levels,Phenotype,Mast/stem cell growth factor receptor Kit levels
66303,Left ventricular mass indexed by body surface area,Phenotype,Left ventricular mass indexed by body surface area
66305,Left ventricular mass,Phenotype,Left ventricular mass
66325,Triglycerides in large VLDL (UKB data field 23501),Phenotype,Triglycerides in large VLDL (UKB data field 23501)
66326,Concentration of medium VLDL particles (UKB data field 23502),Phenotype,Concentration of medium VLDL particles (UKB data field 23502)
66329,Breast cancer (luminal A),Phenotype,Breast cancer (luminal A)
66332,Total lipids in medium VLDL (UKB data field 23503),Phenotype,Total lipids in medium VLDL (UKB data field 23503)
66333,Cholesterol in medium VLDL (UKB data field 23505),Phenotype,Cholesterol in medium VLDL (UKB data field 23505)
66334,Phospholipids in medium VLDL (UKB data field 23504),Phenotype,Phospholipids in medium VLDL (UKB data field 23504)
66335,Cholesterol in small VLDL (UKB data field 23512),Phenotype,Cholesterol in small VLDL (UKB data field 23512)
66336,Cholesteryl esters in small VLDL (UKB data field 23513),Phenotype,Cholesteryl esters in small VLDL (UKB data field 23513)
66337,Free cholesterol in small VLDL (UKB data field 23514),Phenotype,Free cholesterol in small VLDL (UKB data field 23514)
66338,Total lipids in small VLDL (UKB data field 23510),Phenotype,Total lipids in small VLDL (UKB data field 23510)
66339,Phospholipids in small VLDL (UKB data field 23511),Phenotype,Phospholipids in small VLDL (UKB data field 23511)
66340,Cholesteryl esters in IDL (UKB data field 23527),Phenotype,Cholesteryl esters in IDL (UKB data field 23527)
66341,Cholesterol in IDL (UKB data field 23526),Phenotype,Cholesterol in IDL (UKB data field 23526)
66342,Free cholesterol in IDL (UKB data field 23528),Phenotype,Free cholesterol in IDL (UKB data field 23528)
66343,Phospholipids in IDL (UKB data field 23525),Phenotype,Phospholipids in IDL (UKB data field 23525)
66344,Total lipids in IDL (UKB data field 23524),Phenotype,Total lipids in IDL (UKB data field 23524)
66345,Total lipids in medium LDL (UKB data field 23538),Phenotype,Total lipids in medium LDL (UKB data field 23538)
66347,Triglycerides in large LDL (UKB data field 23536),Phenotype,Triglycerides in large LDL (UKB data field 23536)
66348,Free cholesterol in large LDL (UKB data field 23535),Phenotype,Free cholesterol in large LDL (UKB data field 23535)
66349,Cholesterol in medium LDL (UKB data field 23540),Phenotype,Cholesterol in medium LDL (UKB data field 23540)
66350,Phospholipids in medium LDL (UKB data field 23539),Phenotype,Phospholipids in medium LDL (UKB data field 23539)
66351,Concentration of medium LDL particles (UKB data field 23537),Phenotype,Concentration of medium LDL particles (UKB data field 23537)
66352,Total lipids in small LDL (UKB data field 23545),Phenotype,Total lipids in small LDL (UKB data field 23545)
66353,Free cholesterol in small LDL (UKB data field 23549),Phenotype,Free cholesterol in small LDL (UKB data field 23549)
66354,Cholesterol in small LDL (UKB data field 23547),Phenotype,Cholesterol in small LDL (UKB data field 23547)
66355,Phospholipids in small LDL (UKB data field 23546),Phenotype,Phospholipids in small LDL (UKB data field 23546)
66357,Cholesteryl esters in small LDL (UKB data field 23548),Phenotype,Cholesteryl esters in small LDL (UKB data field 23548)
66358,Concentration of large HDL particles (UKB data field 23558),Phenotype,Concentration of large HDL particles (UKB data field 23558)
66359,Phospholipids in large HDL (UKB data field 23560),Phenotype,Phospholipids in large HDL (UKB data field 23560)
66360,Total lipids in large HDL (UKB data field 23559),Phenotype,Total lipids in large HDL (UKB data field 23559)
66361,Free cholesterol in large HDL (UKB data field 23563),Phenotype,Free cholesterol in large HDL (UKB data field 23563)
66362,Concentration of medium HDL particles (UKB data field 23565),Phenotype,Concentration of medium HDL particles (UKB data field 23565)
66363,Movement related adverse drug reaction to aripiprazole in schizophrenia,Phenotype,Movement related adverse drug reaction to aripiprazole in schizophrenia
66365,Cholesteryl esters to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23581),Phenotype,Cholesteryl esters to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23581)
66366,Free cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23582),Phenotype,Free cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23582)
66367,Phospholipids to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23579),Phenotype,Phospholipids to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23579)
66368,Cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23580),Phenotype,Cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23580)
66369,Cholesterol in small HDL (UKB data field 23575),Phenotype,Cholesterol in small HDL (UKB data field 23575)
66370,Phospholipids in small HDL (UKB data field 23574),Phenotype,Phospholipids in small HDL (UKB data field 23574)
66371,Cholesteryl esters in small HDL (UKB data field 23576),Phenotype,Cholesteryl esters in small HDL (UKB data field 23576)
66372,Free cholesterol in small HDL (UKB data field 23577),Phenotype,Free cholesterol in small HDL (UKB data field 23577)
66374,Triglycerides in small HDL (UKB data field 23578),Phenotype,Triglycerides in small HDL (UKB data field 23578)
66375,Descending aorta strain,Phenotype,Descending aorta strain
66378,Vascular endothelial function,Phenotype,Vascular endothelial function
66400,Phospholipids in LDL (UKB data field 23413),Phenotype,Phospholipids in LDL (UKB data field 23413)
66402,Phospholipids in VLDL (UKB data field 23412),Phenotype,Phospholipids in VLDL (UKB data field 23412)
66403,Phospholipids in HDL (UKB data field 23414),Phenotype,Phospholipids in HDL (UKB data field 23414)
66404,Average diameter for HDL particles (UKB data field 23433),Phenotype,Average diameter for HDL particles (UKB data field 23433)
66405,Phosphoglycerides levels (UKB data field 23434),Phenotype,Phosphoglycerides levels (UKB data field 23434)
66406,Triglycerides to phosphoglycerides ratio (UKB data field 23435),Phenotype,Triglycerides to phosphoglycerides ratio (UKB data field 23435)
66407,Monounsaturated fatty acids levels (UKB data field 23447),Phenotype,Monounsaturated fatty acids levels (UKB data field 23447)
66408,Saturated fatty acids levels (UKB data field 23448),Phenotype,Saturated fatty acids levels (UKB data field 23448)
66409,Linoleic acid levels (UKB data field 23449),Phenotype,Linoleic acid levels (UKB data field 23449)
66410,Docosahexaenoic acid levels (UKB data field 23450),Phenotype,Docosahexaenoic acid levels (UKB data field 23450)
66424,Descending aorta diameter,Phenotype,Descending aorta diameter
66425,Headache or migraine,Phenotype,Headache or migraine
66451,Total lipids in lipoprotein particles (UKB data field 23423),Phenotype,Total lipids in lipoprotein particles (UKB data field 23423)
66452,Free cholesterol in LDL (UKB data field 23421),Phenotype,Free cholesterol in LDL (UKB data field 23421)
66453,Free cholesterol in VLDL (UKB data field 23420),Phenotype,Free cholesterol in VLDL (UKB data field 23420)
66454,Free cholesterol in HDL (UKB data field 23422),Phenotype,Free cholesterol in HDL (UKB data field 23422)
66455,Total lipids in VLDL (UKB data field 23424),Phenotype,Total lipids in VLDL (UKB data field 23424)
66456,Total lipids in LDL (UKB data field 23425),Phenotype,Total lipids in LDL (UKB data field 23425)
66457,Total lipids in HDL (UKB data field 23426),Phenotype,Total lipids in HDL (UKB data field 23426)
66458,Omega-3 fatty acids to total fatty acids percentage (UKB data field 23451),Phenotype,Omega-3 fatty acids to total fatty acids percentage (UKB data field 23451)
66459,Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453),Phenotype,Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453)
66460,Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452),Phenotype,Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452)
66461,Saturated fatty acids to total fatty acids percentage (UKB data field 23455),Phenotype,Saturated fatty acids to total fatty acids percentage (UKB data field 23455)
66462,Linoleic acid to total fatty acids percentage (UKB data field 23456),Phenotype,Linoleic acid to total fatty acids percentage (UKB data field 23456)
66463,Occupational creativity,Phenotype,Occupational creativity
66464,Total lipids in chylomicrons and extremely large VLDL (UKB data field 23482),Phenotype,Total lipids in chylomicrons and extremely large VLDL (UKB data field 23482)
66465,Cholesterol in chylomicrons and extremely large VLDL (UKB data field 23484),Phenotype,Cholesterol in chylomicrons and extremely large VLDL (UKB data field 23484)
66466,Cholesteryl esters in chylomicrons and extremely large VLDL (UKB data field 23485),Phenotype,Cholesteryl esters in chylomicrons and extremely large VLDL (UKB data field 23485)
66467,Phospholipids in chylomicrons and extremely large VLDL (UKB data field 23483),Phenotype,Phospholipids in chylomicrons and extremely large VLDL (UKB data field 23483)
66472,Concentration of large VLDL particles (UKB data field 23495),Phenotype,Concentration of large VLDL particles (UKB data field 23495)
66473,Triglycerides in very large VLDL (UKB data field 23494),Phenotype,Triglycerides in very large VLDL (UKB data field 23494)
66474,Total lipids in large VLDL (UKB data field 23496),Phenotype,Total lipids in large VLDL (UKB data field 23496)
66475,Free cholesterol in large VLDL (UKB data field 23500),Phenotype,Free cholesterol in large VLDL (UKB data field 23500)
66476,Free cholesterol in medium VLDL (UKB data field 23507),Phenotype,Free cholesterol in medium VLDL (UKB data field 23507)
66477,Concentration of small VLDL particles (UKB data field 23509),Phenotype,Concentration of small VLDL particles (UKB data field 23509)
66478,Triglycerides in medium VLDL (UKB data field 23508),Phenotype,Triglycerides in medium VLDL (UKB data field 23508)
66479,Cholesteryl esters in medium VLDL (UKB data field 23506),Phenotype,Cholesteryl esters in medium VLDL (UKB data field 23506)
66480,Free cholesterol in very small VLDL (UKB data field 23521),Phenotype,Free cholesterol in very small VLDL (UKB data field 23521)
66481,Concentration of IDL particles (UKB data field 23523),Phenotype,Concentration of IDL particles (UKB data field 23523)
66482,Triglycerides in very small VLDL (UKB data field 23522),Phenotype,Triglycerides in very small VLDL (UKB data field 23522)
66483,Cholesteryl esters in very small VLDL (UKB data field 23520),Phenotype,Cholesteryl esters in very small VLDL (UKB data field 23520)
66484,Triglycerides in medium LDL (UKB data field 23543),Phenotype,Triglycerides in medium LDL (UKB data field 23543)
66485,Cholesteryl esters in medium LDL (UKB data field 23541),Phenotype,Cholesteryl esters in medium LDL (UKB data field 23541)
66486,Free cholesterol in medium LDL (UKB data field 23542),Phenotype,Free cholesterol in medium LDL (UKB data field 23542)
66487,Concentration of small LDL particles (UKB data field 23544),Phenotype,Concentration of small LDL particles (UKB data field 23544)
66491,Systemic sclerosis complicated with interstitial lung disease,Phenotype,Systemic sclerosis complicated with interstitial lung disease
66492,Triglycerides in very large HDL (UKB data field 23557),Phenotype,Triglycerides in very large HDL (UKB data field 23557)
66493,Cholesteryl esters in very large HDL (UKB data field 23555),Phenotype,Cholesteryl esters in very large HDL (UKB data field 23555)
66494,Cholesterol in very large HDL (UKB data field 23554),Phenotype,Cholesterol in very large HDL (UKB data field 23554)
66495,Free cholesterol in very large HDL (UKB data field 23556),Phenotype,Free cholesterol in very large HDL (UKB data field 23556)
66496,Triglycerides in medium HDL (UKB data field 23571),Phenotype,Triglycerides in medium HDL (UKB data field 23571)
66497,Concentration of small HDL particles (UKB data field 23572),Phenotype,Concentration of small HDL particles (UKB data field 23572)
66498,Total lipids in small HDL (UKB data field 23573),Phenotype,Total lipids in small HDL (UKB data field 23573)
66501,Free cholesterol in medium HDL (UKB data field 23570),Phenotype,Free cholesterol in medium HDL (UKB data field 23570)
66502,Triglycerides to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23583),Phenotype,Triglycerides to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23583)
66503,Free cholesterol to total lipids in very large VLDL percentage (UKB data field 23587),Phenotype,Free cholesterol to total lipids in very large VLDL percentage (UKB data field 23587)
66505,Gall stone disease or coronary artery disease,Phenotype,Gall stone disease or coronary artery disease
66516,Adverse response to chemotherapy in colorectal cancer (FOLFOX) (Stomatitis),Phenotype,Adverse response to chemotherapy in colorectal cancer (FOLFOX) (Stomatitis)
66518,Adverse response to chemotherapy in colorectal cancer (FOLFOX) (Neutropenia),Phenotype,Adverse response to chemotherapy in colorectal cancer (FOLFOX) (Neutropenia)
66520,Time to levodopa-induced-dyskinesia onset in Parkinson's disease,Phenotype,Time to levodopa-induced-dyskinesia onset in Parkinson's disease
66522,Age at menarche or uterine leiomyomata (pleiotropy),Phenotype,Age at menarche or uterine leiomyomata (pleiotropy)
66523,Age at natural menopause or uterine leiomyomata (pleiotropy),Phenotype,Age at natural menopause or uterine leiomyomata (pleiotropy)
66524,Age at first birth or uterine leiomyomata (pleiotropy),Phenotype,Age at first birth or uterine leiomyomata (pleiotropy)
66525,Hypothyroidism or rheumatoid arthritis (pleiotropy),Phenotype,Hypothyroidism or rheumatoid arthritis (pleiotropy)
66637,Postmenopausal breast cancer,Phenotype,Postmenopausal breast cancer
66671,Skull bone mineral density,Phenotype,Skull bone mineral density
66690,Mono-(2-ethyl-5-carboxypentyl) phthalate levels (MTAG),Phenotype,Mono-(2-ethyl-5-carboxypentyl) phthalate levels (MTAG)
66725,Nonsyndromic biliary atresia,Phenotype,Nonsyndromic biliary atresia
66730,Hospitalized COVID-19 or BMI (pleiotropy),Phenotype,Hospitalized COVID-19 or BMI (pleiotropy)
66836,Skin luminance,Phenotype,Skin luminance
66840,Skin yellow/blue component,Phenotype,Skin yellow/blue component
66842,Femoral neck width,Phenotype,Femoral neck width
66843,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 60),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 60)
66844,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 62),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 62)
66845,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 71),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 71)
66846,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 80),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 80)
66848,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 4),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 4)
66849,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 42),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 42)
66851,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 44),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 44)
66852,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 10),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 10)
66854,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 22),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 22)
66855,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 28),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 28)
66857,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 39),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 39)
66858,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 7),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 7)
66860,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 11),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 11)
66862,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 16),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 16)
66864,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 24),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 24)
66866,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 117),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 117)
66869,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 121),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 121)
66870,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 125),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 125)
66871,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 2),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 2)
66872,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 8),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 8)
66873,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 114),Phenotype,T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 114)
66875,PCSK9 levels in statin-naive individuals,Phenotype,PCSK9 levels in statin-naive individuals
66992,Vegetarianism,Phenotype,Vegetarianism
66998,Uterine cancer,Phenotype,Uterine cancer
67012,PMA induced IL5 level without BCG vaccination,Phenotype,PMA induced IL5 level without BCG vaccination
67014,PMA induced TNFa level without BCG vaccination,Phenotype,PMA induced TNFa level without BCG vaccination
67016,Preeclampsia in pregnancy,Phenotype,Preeclampsia in pregnancy
67046,Facial trait (Forehead height),Phenotype,Facial trait (Forehead height)
67049,Clonal hematopoiesis (overall),Phenotype,Clonal hematopoiesis (overall)
67050,Clonal hematopoiesis (DNMT3A mutation),Phenotype,Clonal hematopoiesis (DNMT3A mutation)
67052,Steroid-dependent/frequent relapse nephrotic syndrome,Phenotype,Steroid-dependent/frequent relapse nephrotic syndrome
67059,DTI TBSS MD Fornix,Phenotype,DTI TBSS MD Fornix
67063,Body fat percentage (adjusted for testosterone and SHBG),Phenotype,Body fat percentage (adjusted for testosterone and SHBG)
67069,T1 FreeSurfer DK rh cuneus volume,Phenotype,T1 FreeSurfer DK rh cuneus volume
67070,T1 FreeSurfer pial lh pericalcarine area,Phenotype,T1 FreeSurfer pial lh pericalcarine area
67072,T1 FreeSurfer pial rh cuneus area,Phenotype,T1 FreeSurfer pial rh cuneus area
67073,T1 FIRST volume BrStem,Phenotype,T1 FIRST volume BrStem
67074,T1 FreeSurfer DK lh cuneus volume,Phenotype,T1 FreeSurfer DK lh cuneus volume
67075,T1 FreeSurfer DK rh cuneus area,Phenotype,T1 FreeSurfer DK rh cuneus area
67076,T1 FreeSurfer DK rh lateraloccipital area,Phenotype,T1 FreeSurfer DK rh lateraloccipital area
67077,T1 FreeSurfer DK rh lingual area,Phenotype,T1 FreeSurfer DK rh lingual area
67078,T1 FreeSurfer DK rh pericalcarine area,Phenotype,T1 FreeSurfer DK rh pericalcarine area
67079,T1 CAT volume R PostcentralGyrus,Phenotype,T1 CAT volume R PostcentralGyrus
67081,T1 CAT volume R SupramarginalGyrusanteriordivision,Phenotype,T1 CAT volume R SupramarginalGyrusanteriordivision
67082,T1 CAT volume L X,Phenotype,T1 CAT volume L X
67086,Short sleep duration (<5 hours),Phenotype,Short sleep duration (<5 hours)
67115,Left-hemisphere visual network to left-hemisphere limbic network white-matter structural connectivity,Phenotype,Left-hemisphere visual network to left-hemisphere limbic network white-matter structural connectivity
67220,T1 FreeSurfer DK lh pericalcarine area,Phenotype,T1 FreeSurfer DK lh pericalcarine area
67221,T1 CAT volume L MiddleTemporalGyrusanteriordivision,Phenotype,T1 CAT volume L MiddleTemporalGyrusanteriordivision
67222,T1 FreeSurfer BA rh V1 exvivo area,Phenotype,T1 FreeSurfer BA rh V1 exvivo area
67223,T1 FreeSurfer BA rh V2 exvivo area,Phenotype,T1 FreeSurfer BA rh V2 exvivo area
67224,T1 FreeSurfer BA lh V1 exvivo area,Phenotype,T1 FreeSurfer BA lh V1 exvivo area
67225,DTI autoptx MD ilf l tract,Phenotype,DTI autoptx MD ilf l tract
67227,Long sleep duration (>=10 hours),Phenotype,Long sleep duration (>=10 hours)
67230,T1 FreeSurfer DKT rh rostralanteriorcingulate thickness,Phenotype,T1 FreeSurfer DKT rh rostralanteriorcingulate thickness
67232,T1 FreeSurfer DKT rh cuneus volume,Phenotype,T1 FreeSurfer DKT rh cuneus volume
67233,REST UKBBICA NET100 0810,Phenotype,REST UKBBICA NET100 0810
67235,DTI TBSS L2 Fornix,Phenotype,DTI TBSS L2 Fornix
67236,DTI TBSS L2 Corticospinal tract R,Phenotype,DTI TBSS L2 Corticospinal tract R
67238,DTI TBSS FA Posterior thalamic radiation L,Phenotype,DTI TBSS FA Posterior thalamic radiation L
67240,DTI TBSS L1 Fornix,Phenotype,DTI TBSS L1 Fornix
67241,DTI TBSS L1 Superior corona radiata L,Phenotype,DTI TBSS L1 Superior corona radiata L
67325,DTI TBSS L3 Fornix,Phenotype,DTI TBSS L3 Fornix
67326,DTI TBSS L3 Superior corona radiata R,Phenotype,DTI TBSS L3 Superior corona radiata R
67414,Right-hemisphere visual network to right-hemisphere salience/ventral attention network white-matter structural connectivity,Phenotype,Right-hemisphere visual network to right-hemisphere salience/ventral attention network white-matter structural connectivity
67416,Right-hemisphere visual network to right-hemisphere control network white-matter structural connectivity,Phenotype,Right-hemisphere visual network to right-hemisphere control network white-matter structural connectivity
67417,Right-hemisphere visual network to pallidum white-matter structural connectivity,Phenotype,Right-hemisphere visual network to pallidum white-matter structural connectivity
67419,Left-hemisphere control network to accumbens white-matter structural connectivity,Phenotype,Left-hemisphere control network to accumbens white-matter structural connectivity
67421,Left-hemisphere default mode network to right-hemisphere visual network white-matter structural connectivity,Phenotype,Left-hemisphere default mode network to right-hemisphere visual network white-matter structural connectivity
67422,Left-hemisphere control network to right-hemisphere visual network white-matter structural connectivity,Phenotype,Left-hemisphere control network to right-hemisphere visual network white-matter structural connectivity
67424,Right-hemisphere visual network to right-hemisphere visual network white-matter structural connectivity,Phenotype,Right-hemisphere visual network to right-hemisphere visual network white-matter structural connectivity
67425,Left-hemisphere limbic network to thalamus white-matter structural connectivity,Phenotype,Left-hemisphere limbic network to thalamus white-matter structural connectivity
67427,Left-hemisphere limbic network to putamen white-matter structural connectivity,Phenotype,Left-hemisphere limbic network to putamen white-matter structural connectivity
67428,Left-hemisphere control network to thalamus white-matter structural connectivity,Phenotype,Left-hemisphere control network to thalamus white-matter structural connectivity
67429,Left-hemisphere control network to putamen white-matter structural connectivity,Phenotype,Left-hemisphere control network to putamen white-matter structural connectivity
67431,Left-hemisphere visual network to right-hemisphere control network white-matter structural connectivity,Phenotype,Left-hemisphere visual network to right-hemisphere control network white-matter structural connectivity
67445,Right-hemisphere somatomotor network to amygdala white-matter structural connectivity,Phenotype,Right-hemisphere somatomotor network to amygdala white-matter structural connectivity
67447,Right-hemisphere dorsal attention network to hippocampus white-matter structural connectivity,Phenotype,Right-hemisphere dorsal attention network to hippocampus white-matter structural connectivity
67449,Right-hemisphere limbic network to thalamus white-matter structural connectivity,Phenotype,Right-hemisphere limbic network to thalamus white-matter structural connectivity
67450,Right-hemisphere limbic network to caudate white-matter structural connectivity,Phenotype,Right-hemisphere limbic network to caudate white-matter structural connectivity
67451,Right-hemisphere limbic network to putamen white-matter structural connectivity,Phenotype,Right-hemisphere limbic network to putamen white-matter structural connectivity
67452,Right-hemisphere control network to right-hemisphere control network white-matter structural connectivity,Phenotype,Right-hemisphere control network to right-hemisphere control network white-matter structural connectivity
67454,Right-hemisphere control network to thalamus white-matter structural connectivity,Phenotype,Right-hemisphere control network to thalamus white-matter structural connectivity
67455,Right-hemisphere control network to putamen white-matter structural connectivity,Phenotype,Right-hemisphere control network to putamen white-matter structural connectivity
67457,Right-hemisphere control network to hippocampus white-matter structural connectivity,Phenotype,Right-hemisphere control network to hippocampus white-matter structural connectivity
67458,Right-hemisphere default mode network to hippocampus white-matter structural connectivity,Phenotype,Right-hemisphere default mode network to hippocampus white-matter structural connectivity
67530,T1 FreeSurfer a2009s rh S calcarine area,Phenotype,T1 FreeSurfer a2009s rh S calcarine area
67531,T1 FreeSurfer a2009s rh S circular insula ant area,Phenotype,T1 FreeSurfer a2009s rh S circular insula ant area
67532,T1 FreeSurfer a2009s rh G cuneus volume,Phenotype,T1 FreeSurfer a2009s rh G cuneus volume
67533,T1 FreeSurfer a2009s rh G pariet inf-Supramar volume,Phenotype,T1 FreeSurfer a2009s rh G pariet inf-Supramar volume
67537,T1 FreeSurfer a2009s rh S calcarine volume,Phenotype,T1 FreeSurfer a2009s rh S calcarine volume
67538,T1 FreeSurfer a2009s lh G cuneus volume,Phenotype,T1 FreeSurfer a2009s lh G cuneus volume
67539,T1 FreeSurfer a2009s lh G parietal sup volume,Phenotype,T1 FreeSurfer a2009s lh G parietal sup volume
67540,T1 FreeSurfer a2009s rh G cuneus area,Phenotype,T1 FreeSurfer a2009s rh G cuneus area
67541,T1 FreeSurfer a2009s lh G cuneus area,Phenotype,T1 FreeSurfer a2009s lh G cuneus area
67543,T1 FreeSurfer pial rh pericalcarine area,Phenotype,T1 FreeSurfer pial rh pericalcarine area
67544,T1 FreeSurfer aseg 4th-Ventricle,Phenotype,T1 FreeSurfer aseg 4th-Ventricle
67545,T1 FreeSurfer DKT lh pericalcarine area,Phenotype,T1 FreeSurfer DKT lh pericalcarine area
67546,T1 FreeSurfer pial rh supramarginal area,Phenotype,T1 FreeSurfer pial rh supramarginal area
67547,T1 FreeSurfer DKT lh cuneus volume,Phenotype,T1 FreeSurfer DKT lh cuneus volume
67548,T1 FreeSurfer DKT rh cuneus area,Phenotype,T1 FreeSurfer DKT rh cuneus area
67549,T1 FreeSurfer DKT rh lateraloccipital area,Phenotype,T1 FreeSurfer DKT rh lateraloccipital area
67550,T1 FreeSurfer DKT rh lingual area,Phenotype,T1 FreeSurfer DKT rh lingual area
67551,T1 FreeSurfer DKT rh pericalcarine area,Phenotype,T1 FreeSurfer DKT rh pericalcarine area
67602,Drug-induced liver injury (Japanese traditional medicines),Phenotype,Drug-induced liver injury (Japanese traditional medicines)
67628,(Z)-4-hydroxytamoxifen to tamoxifen ratio in tamoxifen-treated hormone-receptor-positive breast cancer,Phenotype,(Z)-4-hydroxytamoxifen to tamoxifen ratio in tamoxifen-treated hormone-receptor-positive breast cancer
67630,Ascending aorta strain,Phenotype,Ascending aorta strain
67632,Tinnitus-related distress,Phenotype,Tinnitus-related distress
67642,Response to metfomin (Fasting glucose levels adjusted for baseline glucose levels),Phenotype,Response to metfomin (Fasting glucose levels adjusted for baseline glucose levels)
67644,Total phospholipids in lipoprotein particles (UKB data field 23411),Phenotype,Total phospholipids in lipoprotein particles (UKB data field 23411)
67645,Triglycerides in HDL (UKB data field 23410),Phenotype,Triglycerides in HDL (UKB data field 23410)
67646,Triglycerides in VLDL (UKB data field 23408),Phenotype,Triglycerides in VLDL (UKB data field 23408)
67647,Triglycerides in LDL (UKB data field 23409),Phenotype,Triglycerides in LDL (UKB data field 23409)
67648,Average diameter for LDL particles (UKB data field 23432),Phenotype,Average diameter for LDL particles (UKB data field 23432)
67649,Average diameter for VLDL particles (UKB data field 23431),Phenotype,Average diameter for VLDL particles (UKB data field 23431)
67650,Infliximab persistence in Crohn's disease,Phenotype,Infliximab persistence in Crohn's disease
67652,Omega-3 fatty acids levels (UKB data field 23444),Phenotype,Omega-3 fatty acids levels (UKB data field 23444)
67653,Degree of unsaturation (UKB data field 23443),Phenotype,Degree of unsaturation (UKB data field 23443)
67655,Polyunsaturated fatty acids levels (UKB data field 23446),Phenotype,Polyunsaturated fatty acids levels (UKB data field 23446)
67656,Omega-6 fatty acids levels (UKB data field 23445),Phenotype,Omega-6 fatty acids levels (UKB data field 23445)
67657,Heart rate variability (corrected root mean square of successive differences),Phenotype,Heart rate variability (corrected root mean square of successive differences)
67658,Heart rate variability (root mean square of successive differences),Phenotype,Heart rate variability (root mean square of successive differences)
67659,Heart rate variability (corrected standard deviation of normal-to-normal intervals),Phenotype,Heart rate variability (corrected standard deviation of normal-to-normal intervals)
67660,Heart rate variability (standard deviation of normal-to-normal intervals),Phenotype,Heart rate variability (standard deviation of normal-to-normal intervals)
67670,Alzheimer's disease or related dementias (adjusted for APOE E4 dosage),Phenotype,Alzheimer's disease or related dementias (adjusted for APOE E4 dosage)
67672,Alzheimer's disease-- proxy Alzheimer's disease or related dementias,Phenotype,Alzheimer's disease-- proxy Alzheimer's disease or related dementias
67678,Alzheimer's disease-- proxy Alzheimer's disease or related dementias (adjusted for APOE E4 dosage),Phenotype,Alzheimer's disease-- proxy Alzheimer's disease or related dementias (adjusted for APOE E4 dosage)
67687,Insulin resistance,Phenotype,Insulin resistance
67689,Clinical LDL cholesterol levels (UKB data field 23404),Phenotype,Clinical LDL cholesterol levels (UKB data field 23404)
67690,LDL cholesterol levels (UKB data field 23405),Phenotype,LDL cholesterol levels (UKB data field 23405)
67691,HDL cholesterol levels (UKB data field 23406),Phenotype,HDL cholesterol levels (UKB data field 23406)
67692,Total triglycerides levels (UKB data field 23407),Phenotype,Total triglycerides levels (UKB data field 23407)
67693,Total esterified cholesterol levels (UKB data field 23415),Phenotype,Total esterified cholesterol levels (UKB data field 23415)
67694,Cholesteryl esters in HDL (UKB data field 23418),Phenotype,Cholesteryl esters in HDL (UKB data field 23418)
67695,Cholesteryl esters in LDL (UKB data field 23417),Phenotype,Cholesteryl esters in LDL (UKB data field 23417)
67696,Cholesteryl esters in VLDL (UKB data field 23416),Phenotype,Cholesteryl esters in VLDL (UKB data field 23416)
67697,Total free cholesterol levels (UKB data field 23419),Phenotype,Total free cholesterol levels (UKB data field 23419)
67698,Apolipoprotein A1 levels (UKB data field 23440),Phenotype,Apolipoprotein A1 levels (UKB data field 23440)
67699,Apolipoprotein B to apolipoprotein A1 ratio (UKB data field 23441),Phenotype,Apolipoprotein B to apolipoprotein A1 ratio (UKB data field 23441)
67701,Apolipoprotein B levels (UKB data field 23439),Phenotype,Apolipoprotein B levels (UKB data field 23439)
67702,Total fatty acids levels (UKB data field 23442),Phenotype,Total fatty acids levels (UKB data field 23442)
67707,Primary sclerosing cholangitis (MTAG),Phenotype,Primary sclerosing cholangitis (MTAG)
67724,Concentration of LDL particles (UKB data field 23429),Phenotype,Concentration of LDL particles (UKB data field 23429)
67725,Concentration of VLDL particles (UKB data field 23428),Phenotype,Concentration of VLDL particles (UKB data field 23428)
67726,Total concentration of lipoprotein particles (UKB data field 23427),Phenotype,Total concentration of lipoprotein particles (UKB data field 23427)
67727,Concentration of HDL particles (UKB data field 23430),Phenotype,Concentration of HDL particles (UKB data field 23430)
67738,Total cholesterol levels (UKB data field 23400),Phenotype,Total cholesterol levels (UKB data field 23400)
67739,VLDL cholesterol levels (UKB data field 23403),Phenotype,VLDL cholesterol levels (UKB data field 23403)
67740,Total cholesterol minus HDL-C levels (UKB data field 23401),Phenotype,Total cholesterol minus HDL-C levels (UKB data field 23401)
67741,Remnant cholesterol (non-HDL-- non-LDL -cholesterol) levels (UKB data field 23402),Phenotype,Remnant cholesterol (non-HDL-- non-LDL -cholesterol) levels (UKB data field 23402)
67749,Phosphatidylcholines levels (UKB data field 23437),Phenotype,Phosphatidylcholines levels (UKB data field 23437)
67750,Sphingomyelins levels (UKB data field 23438),Phenotype,Sphingomyelins levels (UKB data field 23438)
67751,Total cholines levels (UKB data field 23436),Phenotype,Total cholines levels (UKB data field 23436)
67752,Docosahexaenoic acid to total fatty acids percentage (UKB data field 23457),Phenotype,Docosahexaenoic acid to total fatty acids percentage (UKB data field 23457)
67753,Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458),Phenotype,Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458)
67754,Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454),Phenotype,Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454)
67756,Omega-6 fatty acids to omega-3 fatty acids ratio (UKB data field 23459),Phenotype,Omega-6 fatty acids to omega-3 fatty acids ratio (UKB data field 23459)
67757,Age at dementia onset in PSEN1 E280A mutation carriers,Phenotype,Age at dementia onset in PSEN1 E280A mutation carriers
67764,Serum levels of protein IGF1,Phenotype,Serum levels of protein IGF1
67765,Serum levels of protein IGFBP3,Phenotype,Serum levels of protein IGFBP3
67766,IGF-1 and IGFBP-3 levels (bivariate analysis),Phenotype,IGF-1 and IGFBP-3 levels (bivariate analysis)
67770,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 76),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 76)
67771,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 79),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 79)
67773,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 81),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 81)
67774,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 82),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 82)
67775,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 85),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 85)
67776,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 105),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 105)
67777,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 108),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 108)
67778,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 109),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 109)
67780,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 112),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 112)
67782,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 52),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 52)
67784,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 100),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 100)
67785,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 101),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 101)
67786,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 122),Phenotype,T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 122)
67790,Response to BNT162b2 vaccine (anti-SARS-CoV-2 Spike antibody levels after second dose),Phenotype,Response to BNT162b2 vaccine (anti-SARS-CoV-2 Spike antibody levels after second dose)
67934,Speech-in-noise perception,Phenotype,Speech-in-noise perception
68055,IL6 expression at 6 weeks in PBMC upon Bbmix 10-5 stimulation in Lyme borreliosis,Phenotype,IL6 expression at 6 weeks in PBMC upon Bbmix 10-5 stimulation in Lyme borreliosis
68057,IL6 expression at 6 weeks in whole blood upon Bbmix moi30 stimulation in Lyme borreliosis,Phenotype,IL6 expression at 6 weeks in whole blood upon Bbmix moi30 stimulation in Lyme borreliosis
68082,High-density lipoprotein levels,Phenotype,High-density lipoprotein levels
68090,Anti-N-methyl-D-aspartate receptor encephalitis,Phenotype,Anti-N-methyl-D-aspartate receptor encephalitis
68093,B-cell lymphoblastic leukemia or hypothyroidism (pleiotropy),Phenotype,B-cell lymphoblastic leukemia or hypothyroidism (pleiotropy)
68095,B-cell lymphoblastic leukemia or primary biliary cholangitis (pleiotropy),Phenotype,B-cell lymphoblastic leukemia or primary biliary cholangitis (pleiotropy)
68096,B-cell lymphoblastic leukemia or inflammatory bowel disease (pleiotropy),Phenotype,B-cell lymphoblastic leukemia or inflammatory bowel disease (pleiotropy)
68098,B-cell lymphoblastic leukemia or Crohn's disease (pleiotropy),Phenotype,B-cell lymphoblastic leukemia or Crohn's disease (pleiotropy)
68109,B-cell lymphoblastic leukemia or rheumatoid arthritis (pleiotropy),Phenotype,B-cell lymphoblastic leukemia or rheumatoid arthritis (pleiotropy)
68110,B-cell lymphoblastic leukemia or multiple sclerosis (pleiotropy),Phenotype,B-cell lymphoblastic leukemia or multiple sclerosis (pleiotropy)
68112,Pancreatic cancer x smoking interaction,Phenotype,Pancreatic cancer x smoking interaction
68116,Attention deficit hyperactivity disorder or risk-taking behavior (pleiotropy),Phenotype,Attention deficit hyperactivity disorder or risk-taking behavior (pleiotropy)
68123,Obsessive-compulsive symptoms,Phenotype,Obsessive-compulsive symptoms
68126,Current medication use (UKB data field 20003),Phenotype,Current medication use (UKB data field 20003)
68130,Age at first sexual intercourse or uterine leiomyoma (pleiotropy),Phenotype,Age at first sexual intercourse or uterine leiomyoma (pleiotropy)
68131,Lifetime number of sexual partners or uterine leiomyoma (pleiotropy),Phenotype,Lifetime number of sexual partners or uterine leiomyoma (pleiotropy)
68134,Left atrial maximum volume,Phenotype,Left atrial maximum volume
68137,Left atrial minimum volume,Phenotype,Left atrial minimum volume
68139,Left atrial stroke volume,Phenotype,Left atrial stroke volume
68141,Left atrial maximum volume BSA indexed,Phenotype,Left atrial maximum volume BSA indexed
68143,Knee extension strength,Phenotype,Knee extension strength
68152,Left atrial minimum volume BSA indexed,Phenotype,Left atrial minimum volume BSA indexed
68153,Left atrial stroke volume BSA indexed,Phenotype,Left atrial stroke volume BSA indexed
68181,Neuroticism general factor,Phenotype,Neuroticism general factor
68193,Neuroticism group factors (worry),Phenotype,Neuroticism group factors (worry)
68197,Kidney stone disease,Phenotype,Kidney stone disease
68209,Pregnancy loss in nulliparas,Phenotype,Pregnancy loss in nulliparas
68229,Gestational length in nulliparas,Phenotype,Gestational length in nulliparas
68236,Progression-free survival in glioma,Phenotype,Progression-free survival in glioma
68238,Apo-CIII0c levels,Phenotype,Apo-CIII0c levels
68240,Apo-CIII1 levels,Phenotype,Apo-CIII1 levels
68242,Apo-CIII1/apo-CIII2 ratio,Phenotype,Apo-CIII1/apo-CIII2 ratio
68244,ECG cardiac MRI latent space,Phenotype,ECG cardiac MRI latent space
68250,ECG latent space,Phenotype,ECG latent space
68270,Late-onset Alzheimer's disease (adjusted for APOE),Phenotype,Late-onset Alzheimer's disease (adjusted for APOE)
68308,Oral lichen planus,Phenotype,Oral lichen planus
68311,Non-oral lichen planus,Phenotype,Non-oral lichen planus
68320,T-cell receptor clonality in colorectal cancer,Phenotype,T-cell receptor clonality in colorectal cancer
68322,Preeclampsia in nulliparas,Phenotype,Preeclampsia in nulliparas
68325,Gestational diabetes in nulliparas,Phenotype,Gestational diabetes in nulliparas
68340,Cardiac MRI latent space,Phenotype,Cardiac MRI latent space
68358,Leukocyte telomere length or COVID-19 infection (MTAG),Phenotype,Leukocyte telomere length or COVID-19 infection (MTAG)
68361,Leukocyte telomere length or COVID-19 hospitalization (MTAG),Phenotype,Leukocyte telomere length or COVID-19 hospitalization (MTAG)
68364,Leukocyte telomere length or severe COVID-19 infection (MTAG),Phenotype,Leukocyte telomere length or severe COVID-19 infection (MTAG)
68382,ICD10 L43: Lichen planus,Phenotype,ICD10 L43: Lichen planus
68383,Dry skin (generalised),Phenotype,Dry skin (generalised)
68517,Hepatitis B virus antibody levels,Phenotype,Hepatitis B virus antibody levels
68523,Urine red blood cell levels,Phenotype,Urine red blood cell levels
68527,Number of sexual partners in opposite-sex sexual behavior,Phenotype,Number of sexual partners in opposite-sex sexual behavior
68531,IL6 expression at 6 weeks in whole blood upon LPS stimulation in Lyme borreliosis,Phenotype,IL6 expression at 6 weeks in whole blood upon LPS stimulation in Lyme borreliosis
68536,Myeloproliferative neoplasms (MTAG),Phenotype,Myeloproliferative neoplasms (MTAG)
68868,Total_GRS,Phenotype,Total_GRS
69131,Lipodystrophy1,Phenotype,Lipodystrophy1
69132,ALPNeg,Phenotype,ALPNeg
69133,SHBG_LpA,Phenotype,SHBG_LpA
69134,Lipodystrophy2,Phenotype,Lipodystrophy2
69135,HyperInsulin,Phenotype,HyperInsulin
69136,BetaCell_2,Phenotype,BetaCell_2
69137,Liver_Lipid,Phenotype,Liver_Lipid
69138,Bilirubin,Phenotype,Bilirubin
69139,BetaCell_1,Phenotype,BetaCell_1
69140,Proinsulin,Phenotype,Proinsulin
